During O
the O
COVID O
- O
19 O
epidemic O
, O
fewer O
patients O
presented O
to O
the O
ED O
requiring O
acute O
surgical O
care O
. O

The O
CAT O
is O
a O
useful O
tool O
to O
assess O
symptoms O
of O
COVID O
- O
19 O
recovery O
. O

This O
discussion O
also O
serves O
as O
a O
succinct O
primer O
on O
some O
of O
the O
pivotal O
epidemiological O
analyses O
( O
and O
their O
communication O
) O
during O
the O
early O
phases O
of O
the O
COVID O
- O
19 O
outbreak O
, O
as O
seen O
through O
the O
lens O
of O
a O
Twitter O
feed O
. O

The O
critical O
role O
of O
futility O
analysis O
in O
the O
pursuit O
of O
effective O
treatments O
for O
COVID O
- O
19 O
. O

Ineffectual O
AEC1 O
differentiation O
from O
KRT8 O
hi O
transitional O
state O
without O
fibrosis O
is O
associated O
with O
fatal O
COVID O
- O
19 O
ARDS O
. O

Mental O
Health O
Care O
Providers O
Dealing O
With O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
: O
What O
Is O
the O
Definition O
of O
a O
Case O
, O
How O
Is O
That O
Changing O
, O
and O
What O
Kinds O
of O
Tests O
Are O
Available O
? O

Ethical O
reflections O
on O
the O
COVID O
- O
19 O
pandemic O
: O
The O
epidemiology O
of O
panic O
. O

Cross O
sectional O
chest O
CT O
images O
( O
N O
= O
12744 O
) O
from O
well O
- O
evaluated O
cases O
of O
pneumonias O
induced O
by O
COVID O
- O
19 O
or O
H1N1 O
Influenza O
viruses O
, O
and O
normal O
individuals O
were O
collected O
. O

Can O
Students O
Safely O
Return O
to O
School O
in O
the O
Age O
of O
COVID O
- O
19 O
? O

Here O
we O
discuss O
the O
potential O
of O
cross O
- O
reactive O
immunity O
to O
drive O
the O
immunopathogenesis O
of O
COVID O
- O
19 O
and O
its O
implications O
for O
current O
efforts O
to O
develop O
immune O
- O
based O
therapies O
and O
vaccines O
. O

The O
morbidity O
and O
mortality O
of O
COVID O
- O
19 O
are O
associated O
with O
ABO O
and O
Rh O
blood O
groups O
. O

Limited O
research O
has O
been O
published O
on O
the O
use O
of O
TCM O
for O
COVID O
- O
19 O
. O

The O
epidemiological O
situation O
of O
COVID O
- O
19 O
in O
West O
Africa O
is O
marked O
by O
a O
continuous O
increase O
in O
the O
numbers O
of O
confirmed O
cases O
. O

Since O
there O
is O
no O
specific O
drug O
for O
COVID O
- O
19 O
, O
the O
treatment O
is O
mainly O
symptomatic O
supportive O
therapy O
. O

The O
objective O
of O
this O
study O
was O
to O
perform O
a O
linguistic O
validation O
and O
cross O
- O
cultural O
adaptation O
of O
the O
Post O
- O
COVID O
- O
19 O
Functional O
Status O
scale O
for O
people O
infected O
with O
COVID O
- O
19 O
for O
the O
Chilean O
population O
. O

Alongside O
the O
investigational O
COVID O
- O
19 O
drugs O
, O
the O
patients O
may O
also O
be O
on O
therapeutics O
for O
comorbidities O
; O
especially O
epidemiological O
studies O
have O
indicated O
that O
individuals O
with O
hypertension O
, O
hyperglycemia O
, O
and O
obesity O
are O
more O
vulnerable O
to O
COVID O
- O
19 O
than O
the O
average O
population O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
association O
between O
OHSD O
and O
SARS O
- O
CoV O
- O
2 O
epidemiologic O
burden O
during O
the O
first O
COVID O
- O
19 O
pandemic O
across O
the O
highly O
diverse O
neighborhoods O
of O
NYC O
. O

High O
MPR O
level O
is O
an O
independent O
risk O
factor O
for O
severe O
pneumonia O
in O
patients O
with O
COVID O
- O
19 O
. O

This O
paper O
, O
therefore O
, O
aims O
to O
highlight O
the O
current O
guidance O
and O
evidence O
regarding O
breast O
cancer O
management O
in O
the O
era O
of O
COVID O
- O
19 O
, O
and O
also O
aims O
to O
look O
at O
future O
management O
strategies O
in O
this O
period O
of O
uncertainty O
. O

Time O
series O
forecasting O
of O
COVID O
- O
19 O
transmission O
in O
Asia O
Pacific O
countries O
using O
deep O
neural O
networks O
. O

While O
respondents O
considered O
that O
all O
races O
were O
susceptible O
to O
the O
signs O
and O
symptoms O
of O
infection O
as O
well O
as O
death O
from O
COVID O
- O
19 O
, O
they O
considered O
mortality O
would O
be O
highest O
among O
white O
people O
from O
Europe O
and O
the O
USA O
. O

Thus O
, O
we O
aimed O
to O
determine O
whether O
use O
of O
PPIs O
increases O
the O
odds O
for O
acquiring O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
among O
community O
- O
dwelling O
Americans O
. O

Participant O
samples O
with O
negative O
or O
equivocal O
results O
but O
with O
analytical O
signals O
above O
the O
limit O
of O
detection O
and O
/ O
or O
previously O
confirmed O
COVID O
- O
19 O
diagnosis O
were O
also O
tested O
for O
IgG O
anti O
- O
Nucleocapsid O
. O

Letter O
to O
' O
Clinical O
update O
on O
COVID O
- O
19 O
in O
pregnancy O
: O
A O
review O
article O
' O
: O
Obstetric O
or O
Gynecologic O
papers O
on O
COVID O
- O
19 O
should O
have O
an O
informative O
title O
. O

It O
is O
easily O
transportable O
and O
compared O
to O
a O
traditional O
oxygen O
concentrator O
with O
its O
dedicated O
compressor O
, O
the O
Snap O
- O
on O
concentrator O
is O
particularly O
relevant O
for O
the O
oxygen O
therapy O
needs O
of O
a O
larger O
number O
of O
patients O
in O
situations O
such O
as O
COVID O
- O
19 O
. O

As O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
ravages O
the O
world O
, O
we O
have O
seen O
many O
perish O
in O
a O
short O
time O
. O

However O
, O
due O
to O
the O
novel O
nature O
of O
the O
COVID O
- O
19 O
, O
there O
is O
a O
lack O
of O
evidence O
about O
the O
specific O
risks O
of O
the O
disease O
in O
this O
patient O
group O
. O

Current O
observations O
suggest O
that O
the O
risk O
of O
CVST O
may O
be O
profoundly O
impacted O
by O
this O
novel O
COVID O
- O
19 O
pandemic O
, O
thus O
prompting O
increased O
attention O
to O
disease O
presentation O
, O
pathogenesis O
, O
and O
management O
. O

Strategies O
for O
Disseminating O
and O
Implementing O
COVID O
- O
19 O
Public O
Health O
Prevention O
Practices O
in O
Rural O
Areas O
. O

This O
study O
is O
a O
first O
comprehensive O
, O
high O
- O
resolution O
investigation O
of O
spatiotemporal O
heterogeneities O
on O
the O
effect O
of O
the O
Wuhan O
lockdown O
on O
the O
risk O
of O
COVID O
- O
19 O
symptom O
onset O
in O
all O
347 O
Chinese O
cities O
. O

COVID O
- O
19 O
and O
cancer O
: O
A O
clear O
change O
not O
only O
in O
daily O
clinical O
practice O
but O
also O
in O
clinical O
research O
management O
. O

This O
study O
compares O
the O
mental O
health O
and O
psychological O
response O
of O
students O
with O
or O
without O
hearing O
loss O
during O
the O
recurrence O
of O
the O
COVID O
- O
19 O
pandemic O
in O
Beijing O
, O
the O
capital O
of O
China O
. O

Background O
: O
Disruptions O
due O
to O
the O
COVID O
- O
19 O
pandemic O
have O
forced O
medical O
schools O
around O
the O
world O
to O
adapt O
. O

COVID O
- O
19 O
has O
impacted O
the O
world O
in O
many O
ways O
, O
including O
loss O
of O
lives O
, O
economic O
downturn O
and O
social O
isolation O
. O

Further O
, O
a O
significant O
proportion O
of O
those O
with O
recent O
suicidal O
ideation O
explicitly O
link O
their O
suicidal O
thoughts O
to O
COVID O
- O
19 O
. O

Patients O
with O
COVID O
- O
19 O
demonstrated O
improved O
mobility O
at O
hospital O
discharge O
and O
higher O
probability O
of O
discharging O
home O
with O
increased O
frequency O
and O
longer O
mean O
duration O
of O
physical O
therapy O
visits O
. O

A O
number O
of O
useful O
online O
resources O
are O
presented O
, O
as O
access O
to O
public O
allied O
health O
services O
may O
be O
limited O
because O
of O
the O
COVID O
- O
19 O
pandemic O
. O

A O
survey O
on O
5115 O
beekeepers O
and O
121 O
patients O
treated O
with O
bee O
venom O
by O
an O
apitherapy O
clinic O
in O
the O
Hubei O
province O
, O
the O
epicenter O
of O
COVID O
- O
19 O
in O
China O
, O
reported O
that O
none O
of O
the O
beekeepers O
developed O
symptoms O
associated O
with O
COVID O
- O
19 O
, O
the O
new O
and O
devastating O
pandemic O
. O

A O
brief O
guidance O
for O
cardiologists O
for O
resource O
containment O
measures O
to O
mitigate O
anticipated O
shortages O
of O
n O
- O
95 O
filtering O
facepiece O
respirators O
during O
COVID O
- O
19 O
pandemic O
. O

To O
maintain O
antimicrobial O
stewardship O
principles O
, O
further O
prospective O
studies O
are O
necessary O
to O
better O
characterize O
risk O
factors O
and O
prediction O
modeling O
to O
better O
understand O
when O
to O
suspect O
and O
empirically O
treat O
for O
sBSI O
in O
severe O
COVID O
- O
19 O
. O

The O
aim O
of O
this O
study O
is O
to O
examine O
the O
CRP O
response O
in O
patients O
hospitalized O
with O
COVID O
- O
19 O
and O
to O
determine O
the O
utility O
of O
CRP O
on O
admission O
for O
predicting O
inpatient O
mortality O
. O

Understanding O
novel O
COVID O
- O
19 O
: O
Its O
impact O
on O
organ O
failure O
and O
risk O
assessment O
for O
diabetic O
and O
cancer O
patients O
. O

The O
cause O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
known O
as O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
, O
formerly O
designated O
2019 O
- O
nCoV O
) O
was O
first O
discovered O
in O
December O
2019 O
in O
Wuhan O
, O
China O
. O

We O
also O
incorporated O
experiences O
, O
standard O
operating O
procedures O
and O
approaches O
across O
several O
HEMS O
services O
internationally O
. O
As O
a O
result O
of O
this O
collaboration O
, O
we O
outline O
an O
approach O
to O
the O
safe O
aeromedical O
retrieval O
of O
a O
COVID O
- O
19 O
patient O
, O
and O
describe O
how O
this O
framework O
can O
be O
used O
to O
develop O
a O
local O
standard O
operating O
procedure O
. O

Critically O
ill O
COVID O
- O
19 O
patients O
have O
relatively O
well O
- O
preserved O
lung O
mechanics O
despite O
severe O
gas O
exchange O
abnormalities O
, O
a O
feature O
not O
consistent O
with O
classical O
ARDS O
but O
more O
consistent O
with O
pulmonary O
vascular O
disease O
. O

The O
article O
illustrates O
the O
general O
principles O
for O
the O
triage O
and O
evaluation O
of O
trauma O
patients O
during O
the O
outbreak O
of O
COVID O
- O
19 O
, O
indications O
for O
emergency O
surgery O
, O
and O
infection O
prevention O
and O
control O
for O
medical O
personnel O
, O
providing O
a O
practical O
algorithm O
for O
trauma O
care O
providers O
during O
the O
outbreak O
period O
. O

The O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
poses O
a O
grave O
threat O
to O
refugees O
and O
internally O
displaced O
persons O
( O
IDPs O
) O
. O

The O
paper O
continues O
by O
discussing O
the O
major O
impacts O
, O
behaviours O
and O
experiences O
that O
three O
major O
tourism O
stakeholders O
( O
namely O
tourism O
demand O
, O
supply O
and O
destination O
management O
organisations O
and O
policy O
makers O
) O
are O
experiencing O
during O
three O
COVID O
- O
19 O
stages O
( O
response O
, O
recovery O
and O
reset O
) O
. O

Public O
health O
policy O
needs O
improved O
methods O
to O
encourage O
people O
to O
adhere O
to O
COVID O
- O
19 O
- O
preventive O
behaviors O
. O

This O
study O
retrospectively O
reviewed O
the O
medical O
records O
of O
421 O
patients O
with O
COVID O
- O
19 O
admitted O
to O
a O
mobile O
cabin O
hospital O
in O
Wuhan O
from O
February O
9 O
, O
2020 O
, O
to O
March O
5 O
, O
2020 O
. O

In O
this O
study O
, O
we O
carried O
out O
a O
virtual O
screening O
for O
almost O
all O
members O
of O
ARBs O
( O
nine O
) O
against O
COVID O
- O
19 O
main O
protease O
. O

Lung O
ultrasound O
score O
predicts O
outcomes O
in O
COVID O
- O
19 O
patients O
admitted O
to O
the O
emergency O
department O
. O

Type O
2 O
diabetes O
and O
obesity O
may O
have O
contributed O
to O
disease O
severity O
and O
mortality O
in O
COVID O
- O
19 O
critically O
ill O
patients O
in O
Greece O
. O

[ O
COVID O
- O
19 O
: O
Intensive O
care O
management O
] O
. O

Of O
1099 O
unique O
records O
, O
6 O
studies O
were O
eligible O
, O
and O
none O
of O
these O
included O
patients O
with O
COVID O
- O
19 O
. O

Clinical O
data O
on O
COVID O
- O
19 O
- O
infected O
patients O
with O
psoriasis O
or O
psoriatic O
arthritis O
are O
still O
scarce O
. O

Maternal O
and O
Neonatal O
Outcomes O
of O
COVID O
- O
19 O
in O
Pregnancy O
: O
A O
Single O
- O
Centre O
Observational O
Study O
. O

Significantly O
higher O
total O
CTP O
hypoperfused O
volume O
( O
83 O
. O
3 O
vs O
18 O
. O
5 O
ml O
, O
p O
= O
0 O
. O
003 O
) O
, O
core O
volume O
( O
27 O
. O
8 O
vs O
1 O
. O
0 O
ml O
, O
p O
< O
0 O
. O
001 O
) O
, O
and O
unfavorable O
mismatch O
( O
0 O
. O
51 O
vs O
0 O
. O
91 O
, O
p O
< O
0 O
. O
001 O
) O
were O
found O
during O
the O
COVID O
- O
19 O
period O
compared O
to O
no O
- O
COVID O
- O
19 O
one O
. O

Chest O
Radiograph O
Findings O
in O
Asymptomatic O
and O
Minimally O
Symptomatic O
Quarantined O
Patients O
in O
Codogno O
, O
Italy O
during O
COVID O
- O
19 O
Pandemic O
. O

Np O
is O
one O
of O
the O
most O
abundant O
structural O
proteins O
and O
it O
serves O
as O
a O
diagnostic O
marker O
for O
the O
accurate O
and O
sensitive O
detection O
of O
COVID O
- O
19 O
. O

The O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
is O
spreading O
between O
human O
populations O
mainly O
through O
nasal O
droplets O
. O

Autopsy O
studies O
have O
provided O
new O
insights O
into O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
treatments O
like O
anti O
- O
coagulative O
therapy O
. O

Severe O
COVID O
- O
19 O
patients O
may O
experience O
cytokine O
release O
syndrome O
( O
CRS O
) O
, O
leading O
to O
alveolar O
damage O
, O
pulmonary O
fibrinolysis O
, O
dysregulated O
coagulation O
, O
and O
pulmonary O
injury O
. O

Managing O
an O
IBD O
Infusion O
Unit O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
Service O
Modifications O
and O
the O
Patient O
Perspective O
. O

The O
vast O
majority O
of O
nurses O
were O
willing O
to O
participate O
in O
care O
of O
patients O
with O
COVID O
- O
19 O
in O
China O
. O

COVID O
- O
19 O
Nonessential O
Surgery O
Restrictions O
and O
Spine O
Surgery O
: O
A O
German O
Experience O
. O

The O
existence O
of O
this O
autocrine O
loop O
rationalizes O
post O
- O
damage O
repair O
with O
perispinal O
etanercept O
and O
proposes O
a O
treatment O
for O
cerebral O
aspects O
of O
COVID O
- O
19 O
chronicity O
. O

During O
the O
current O
COVID O
- O
19 O
pandemic O
, O
the O
triage O
, O
assessment O
, O
and O
management O
of O
patients O
presenting O
to O
the O
emergency O
department O
with O
critical O
conditions O
has O
become O
- O
challenging O
. O

Acute O
kidney O
injury O
is O
an O
independent O
risk O
factor O
for O
mortality O
in O
COVID O
- O
19 O
patients O
. O

Five O
patients O
presenting O
with O
DKA O
complicating O
a O
concurrent O
COVID O
- O
19 O
infection O
were O
reported O
. O

Autopsies O
revealed O
all O
COVID O
- O
19 O
patients O
to O
have O
a O
fatal O
( O
broncho O
) O
pneumonia O
and O
signs O
of O
relevant O
pre O
- O
existing O
cardiac O
, O
renal O
and O
pulmonary O
conditions O
in O
all O
cases O
. O

In O
our O
increasingly O
stressed O
world O
, O
especially O
with O
the O
COVID O
- O
19 O
pandemic O
, O
the O
activation O
of O
the O
threat O
network O
in O
everyday O
situations O
can O
adversely O
affect O
our O
mental O
and O
physical O
health O
. O

The O
literature O
is O
full O
of O
descriptive O
statistics O
showing O
the O
higher O
incidence O
and O
mortality O
experienced O
by O
the O
Black O
population O
for O
health O
conditions O
ranging O
from O
infant O
mortality O
to O
infectious O
disease O
, O
including O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Thus O
, O
it O
is O
essential O
to O
investigate O
if O
the O
novel O
COVID O
- O
19 O
hampers O
female O
fertility O
, O
given O
that O
there O
is O
no O
systematic O
and O
comprehensive O
evidence O
on O
the O
association O
of O
COVID O
- O
19 O
with O
female O
fertility O
. O

The O
association O
between O
moderate O
- O
severe O
liver O
injury O
and O
more O
severe O
clinical O
course O
of O
COVID O
- O
19 O
has O
suggested O
that O
liver O
injury O
is O
prevalent O
in O
severe O
than O
in O
mild O
cases O
of O
COVID O
- O
19 O
, O
while O
no O
difference O
in O
liver O
involvement O
has O
been O
reported O
between O
survivors O
and O
non O
- O
survivors O
. O

Psychological O
impact O
on O
women O
health O
workers O
involved O
in O
COVID O
- O
19 O
outbreak O
in O
Wuhan O
: O
a O
cross O
- O
sectional O
study O
. O

Managing O
Lung O
Nodules O
Using O
Telemedicine O
and O
Molecular O
Biomarkers O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

The O
cohort O
is O
younger O
and O
had O
less O
severe O
symptoms O
than O
in O
many O
previosly O
published O
studies O
of O
COVID O
- O
19 O
. O

The O
hidden O
disaster O
of O
COVID O
- O
19 O
: O
Intimate O
partner O
violence O
. O

Public O
Health O
Strategies O
for O
the O
Gradual O
Lifting O
of O
the O
Public O
Sector O
Lockdown O
in O
Jordan O
and O
the O
United O
Arab O
Emirates O
During O
the O
COVID O
- O
19 O
Crisis O
. O

The O
novel O
corona O
virus O
COVID O
- O
19 O
has O
become O
a O
worldwide O
public O
health O
pandemic O
that O
has O
induced O
anomic O
conditions O
impacting O
daily O
routines O
. O

Of O
the O
173 O
, O
942 O
hospitalized O
COVID O
- O
19 O
patients O
, O
the O
median O
age O
was O
63 O
years O
, O
51 O
. O
0 O
% O
were O
male O
, O
and O
48 O
. O
5 O
% O
were O
covered O
by O
Medicare O
. O

An O
artificial O
intelligence O
- O
based O
first O
- O
line O
defence O
against O
COVID O
- O
19 O
: O
digitally O
screening O
citizens O
for O
risks O
via O
a O
chatbot O
. O

Because O
of O
fear O
caused O
by O
the O
COVID O
- O
19 O
virus O
, O
it O
is O
thought O
that O
depression O
, O
stress O
, O
and O
anxiety O
levels O
have O
increased O
. O

Six O
nurses O
were O
transferred O
to O
COVID O
- O
19 O
units O
( O
out O
of O
a O
total O
of O
33 O
nurses O
) O
while O
1 O
of O
the O
7 O
residents O
was O
transferred O
to O
an O
intensive O
care O
unit O
and O
1 O
senior O
surgeon O
was O
put O
on O
prophylactic O
leave O
. O

Evidence O
- O
based O
interventions O
are O
required O
to O
enhance O
the O
health O
- O
related O
quality O
of O
life O
of O
community O
pharmacists O
involved O
in O
the O
first O
line O
of O
the O
COVID O
- O
19 O
pandemic O
. O

[ O
The O
use O
of O
antiplatelet O
agents O
for O
arterial O
thromboprophylaxis O
in O
COVID O
- O
19 O
] O
. O

In O
late O
2019 O
, O
a O
novel O
coronavirus O
strain O
, O
SARS O
- O
CoV O
- O
2 O
( O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
) O
, O
also O
known O
as O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
triggered O
a O
global O
pandemic O
as O
the O
virus O
spread O
from O
the O
Wuhan O
Province O
, O
China O
, O
across O
all O
continents O
. O

Studies O
have O
shown O
that O
structurally O
modified O
lopinavir O
, O
favipiravir O
, O
and O
other O
similar O
compounds O
can O
inhibit O
COVID O
- O
19 O
main O
protease O
( O
Mpro O
) O
and O
RNA O
- O
dependent O
RNA O
polymerase O
( O
RdRp O
) O
. O

In O
the O
COVID O
- O
19 O
pandemic O
in O
Brazil O
, O
do O
brown O
lives O
matter O
? O

Arachidonic O
acid O
- O
derived O
epoxyeicosatrienoic O
acids O
could O
alleviate O
the O
systemic O
hyperinflammatory O
response O
in O
COVID O
- O
19 O
infection O
by O
modulating O
endoplasmic O
reticulum O
stress O
and O
stimulating O
the O
resolution O
of O
inflammation O
. O

We O
investigated O
the O
status O
of O
113 O
pediatric O
hematological O
patients O
in O
Wuhan O
union O
hospital O
during O
the O
COVID O
- O
19 O
pandemic O
from O
January O
23 O
to O
March O
10 O
, O
2020 O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
can O
reportedly O
cause O
gastrointestinal O
symptoms O
. O

Most O
hematological O
and O
biochemical O
indexes O
of O
patients O
with O
COVID O
- O
19 O
were O
significantly O
different O
from O
patients O
with O
CAP O
. O

A O
pooled O
analysis O
of O
recently O
published O
studies O
suggests O
no O
additional O
benefit O
for O
reducing O
mortality O
in O
COVID O
- O
19 O
patients O
when O
Hydroxychloroquine O
is O
given O
as O
add O
- O
on O
to O
the O
standard O
care O
. O

The O
first O
case O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
was O
declared O
in O
December O
in O
Wuhan O
, O
before O
becoming O
a O
global O
pandemic O
in O
a O
few O
weeks O
. O

Physical O
Activity O
, O
Health O
- O
Related O
Quality O
of O
Life O
, O
and O
Stress O
among O
the O
Chinese O
Adult O
Population O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

We O
summarized O
all O
registered O
clinical O
trials O
examining O
treatment O
and O
prevention O
options O
for O
COVID O
- O
19 O
. O

We O
retrospectively O
included O
COVID O
- O
19 O
patients O
between O
24 O
/ O
01 O
/ O
2020 O
and O
31 O
/ O
03 O
/ O
2020 O
as O
case O
group O
and O
patients O
with O
pulmonary O
GGOs O
between O
04 O
/ O
02 O
/ O
2012 O
and O
31 O
/ O
03 O
/ O
2020 O
as O
a O
control O
group O
. O

This O
systematic O
review O
and O
meta O
- O
analysis O
aims O
to O
identify O
studies O
assessing O
long O
- O
term O
effects O
of O
COVID O
- O
19 O
and O
estimates O
the O
prevalence O
of O
each O
symptom O
, O
sign O
, O
or O
laboratory O
parameter O
of O
patients O
at O
a O
post O
- O
COVID O
- O
19 O
stage O
. O

In O
this O
retrospective O
cohort O
analysis O
of O
all O
adult O
patients O
discharged O
from O
the O
Johns O
hopkins O
hospital O
between O
Mar O
1 O
and O
May O
12 O
, O
2020 O
, O
we O
compared O
demographic O
, O
clinical O
characteristics O
, O
VTE O
outcomes O
, O
prescription O
and O
administration O
of O
VTE O
prophylaxis O
between O
COVID O
- O
19 O
positive O
, O
negative O
, O
and O
not O
tested O
groups O
. O

Chest O
CT O
of O
patients O
with O
COVID O
- O
19 O
contains O
valuable O
information O
that O
can O
be O
accessed O
using O
automated O
image O
analysis O
. O

Detection O
and O
Recognition O
of O
Fearful O
Facial O
Expressions O
During O
the O
Coronavirus O
Disease O
( O
COVID O
- O
19 O
) O
Pandemic O
in O
an O
Italian O
Sample O
: O
An O
Online O
Experiment O
. O

With O
increased O
testing O
capacity O
, O
detecting O
more O
COVID O
- O
19 O
positive O
patients O
in O
the O
community O
will O
also O
enable O
the O
reduction O
of O
secondary O
cases O
with O
stricter O
quarantine O
rules O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
was O
reported O
in O
Europe O
in O
the O
beginning O
of O
February O
2020 O
. O

For O
these O
reasons O
, O
these O
three O
cases O
were O
considered O
typical O
examples O
of O
erythema O
in O
patients O
with O
COVID O
- O
19 O
. O

Eosinopenia O
was O
often O
noticed O
in O
patients O
with O
COVID O
- O
19 O
pneumonia O
, O
but O
its O
role O
is O
poorly O
investigated O
. O

We O
aimed O
to O
determine O
publication O
trends O
in O
leading O
clinical O
research O
journals O
( O
impact O
factor O
> O
20 O
) O
during O
the O
rise O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
and O
to O
check O
for O
an O
increase O
in O
publication O
times O
of O
non O
- O
COVID O
- O
19 O
original O
research O
articles O
. O

This O
was O
in O
reaction O
to O
the O
COVID O
- O
19 O
pandemic O
. O

Acute O
normovolemic O
hemodilution O
for O
major O
cancer O
surgeries O
during O
the O
COVID O
- O
19 O
pandemic O
: O
A O
beacon O
of O
hope O
. O

It O
is O
reasonable O
to O
speculate O
that O
COVID O
- O
19 O
may O
increase O
disease O
activity O
in O
patients O
with O
HAE O
and O
vice O
versa O
. O

The O
COVID O
- O
19 O
Pandemic O
: O
Public O
Health O
and O
Epidemiology O
. O

Dynamic O
analysis O
of O
pulmonary O
computed O
tomography O
( O
CT O
) O
characteristics O
in O
cured O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
patients O
. O

To O
determine O
the O
incidence O
of O
and O
risk O
factors O
for O
the O
development O
of O
acute O
kidney O
injury O
( O
AKI O
) O
and O
investigate O
the O
association O
between O
AKI O
and O
mortality O
in O
patients O
hospitalized O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
infection O
. O

COVID O
- O
19 O
can O
lead O
to O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
. O

Short O
- O
term O
effects O
of O
specific O
humidity O
and O
temperature O
on O
COVID O
- O
19 O
morbidity O
in O
select O
US O
cities O
. O

The O
overall O
rate O
of O
COVID O
- O
19 O
was O
2 O
. O
23 O
% O
, O
suggesting O
an O
increased O
rate O
of O
COVID O
- O
19 O
infection O
. O

Stroke O
and O
mechanical O
thrombectomy O
in O
patients O
with O
COVID O
- O
19 O
: O
technical O
observations O
and O
patient O
characteristics O
. O

A O
number O
of O
contiguous O
small O
- O
areas O
appear O
to O
be O
at O
a O
significant O
elevated O
risk O
of O
high O
COVID O
- O
19 O
transmission O
, O
many O
of O
which O
are O
also O
at O
increased O
risk O
for O
higher O
mortality O
rates O
. O

Health O
departments O
can O
adapt O
workplace O
guidance O
to O
each O
industry O
sector O
affected O
by O
COVID O
- O
19 O
to O
account O
for O
different O
production O
processes O
and O
working O
conditions O
. O

Overall O
, O
the O
potential O
role O
of O
BPA O
on O
the O
risk O
and O
severity O
of O
COVID O
- O
19 O
merits O
further O
investigation O
. O

The O
exact O
prevalence O
and O
impact O
of O
cardiac O
injury O
in O
hospitalized O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
still O
controversial O
. O

Safety O
and O
immunogenicity O
of O
S O
- O
Trimer O
( O
SCB O
- O
2019 O
) O
, O
a O
protein O
subunit O
vaccine O
candidate O
for O
COVID O
- O
19 O
in O
healthy O
adults O
: O
a O
phase O
1 O
, O
randomised O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O

Estimating O
the O
case O
- O
fatality O
rate O
and O
clinical O
outcomes O
for O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
crucial O
because O
health O
care O
systems O
must O
adequately O
prepare O
for O
outbreaks O
and O
design O
appropriate O
policies O
. O

The O
questionnaire O
consisted O
of O
queries O
based O
on O
following O
domains O
: O
demographic O
details O
, O
awareness O
of O
COVID O
- O
19 O
pandemic O
, O
analysis O
of O
mental O
health O
of O
participants O
during O
lockdown O
, O
estimate O
of O
physical O
load O
for O
work O
from O
home O
, O
physical O
load O
due O
to O
house O
hold O
chores O
and O
overall O
effect O
on O
health O
. O

Coping O
With O
the O
COVID O
- O
19 O
Crisis O
: O
A O
Call O
for O
Youth O
Engagement O
and O
the O
Inclusion O
of O
Young O
People O
in O
Matters O
That O
Affect O
Their O
Lives O
. O

It O
is O
unclear O
why O
some O
SARS O
- O
CoV O
- O
2 O
- O
positive O
individuals O
develop O
severe O
COVID O
- O
19 O
symptoms O
, O
which O
can O
be O
fatal O
, O
while O
others O
only O
develop O
mild O
symptoms O
. O

Cardiovascular O
complications O
with O
myocarditis O
and O
embolism O
due O
to O
COVID O
- O
19 O
have O
been O
reported O
. O

According O
to O
Professor O
Vana O
Papaevangelou O
, O
Professor O
of O
Paediatrics O
at O
the O
University O
of O
Athens O
School O
of O
Medicine O
, O
children O
comprise O
only O
2 O
- O
6 O
% O
of O
COVID O
- O
19 O
cases O
, O
worldwide O
, O
and O
they O
are O
not O
considered O
as O
super O
- O
spreaders O
of O
this O
infection O
. O

Perspectives O
on O
monoclonal O
antibody O
therapy O
as O
potential O
therapeutic O
intervention O
for O
Coronavirus O
disease O
- O
19 O
( O
COVID O
- O
19 O
) O
. O

Increased O
risk O
for O
severe O
COVID O
- O
19 O
in O
patients O
with O
inflammatory O
rheumatic O
diseases O
treated O
with O
rituximab O
. O

A O
Video O
- O
based O
Debriefing O
Program O
to O
Support O
Emergency O
Medicine O
Clinician O
Well O
- O
being O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

This O
study O
aims O
to O
review O
the O
current O
literature O
on O
COVID O
- O
19 O
related O
chatbots O
in O
healthcare O
, O
identify O
and O
characterize O
these O
emerging O
technologies O
and O
their O
applications O
for O
combating O
COVID O
- O
19 O
, O
and O
describe O
related O
challenges O
. O

The O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
the O
provision O
of O
surgical O
care O
. O

Thresholds O
of O
Glycemia O
and O
the O
Outcomes O
of O
COVID O
- O
19 O
Complicated O
With O
Diabetes O
: O
A O
Retrospective O
Exploratory O
Study O
Using O
Continuous O
Glucose O
Monitoring O
. O

The O
spread O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
across O
the O
United O
States O
confirms O
that O
not O
all O
Americans O
are O
equally O
at O
risk O
of O
infection O
, O
severe O
disease O
, O
or O
mortality O
. O

This O
study O
aims O
to O
discuss O
the O
available O
evidence O
for O
the O
use O
of O
chloroquine O
( O
CQ O
) O
and O
hydroxychloroquine O
( O
HCQ O
) O
against O
COVID O
- O
19 O
. O

COVID O
- O
19 O
is O
caused O
by O
a O
novel O
coronavirus O
SARS O
- O
CoV O
- O
2 O
, O
which O
enters O
human O
target O
cells O
via O
angiotensin O
converting O
enzyme O
2 O
( O
ACE2 O
) O
. O

In O
general O
, O
seasonal O
respiratory O
pathogens O
are O
more O
prevalent O
than O
SARS O
- O
CoV O
- O
2 O
in O
symptomatic O
patients O
in O
non O
- O
COVID O
- O
19 O
endemic O
area O
during O
the O
flu O
season O
. O

The O
outbreak O
of O
COVID O
- O
19 O
in O
2020 O
has O
led O
to O
a O
surge O
in O
interest O
in O
the O
research O
of O
the O
mathematical O
modeling O
of O
epidemics O
. O

We O
present O
the O
use O
of O
telemedicine O
to O
aid O
in O
the O
diagnosis O
of O
Lyme O
disease O
and O
to O
provide O
prompt O
access O
to O
diagnosis O
and O
care O
during O
the O
ongoing O
COVID O
- O
19 O
pandemic O
and O
in O
the O
future O
. O

Unique O
needs O
of O
childhood O
cancer O
survivors O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
population O
includes O
all O
hospitalized O
patients O
in O
the O
Department O
of O
Pediatrics O
, O
with O
clinical O
and O
surgical O
diagnoses O
associated O
with O
COVID O
- O
19 O
. O

The O
coronavirus O
- O
19 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
resulted O
in O
renewed O
attention O
to O
CCT O
as O
a O
safe O
alternative O
or O
adjunct O
to O
TEE O
in O
selected O
patients O
. O

: O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
so O
far O
affected O
over O
41 O
million O
people O
globally O
. O

We O
included O
347 O
patients O
: O
326 O
without O
COVID O
- O
19 O
and O
21 O
with O
COVID O
- O
19 O
. O

Without O
modern O
medical O
management O
and O
vaccines O
, O
the O
severity O
of O
the O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
caused O
by O
severe O
acute O
respiratory O
syndrome O
( O
SARS O
) O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
might O
approach O
the O
magnitude O
of O
1894 O
- O
plague O
( O
12 O
million O
deaths O
) O
and O
1918 O
- O
A O
( O
H1N1 O
) O
influenza O
( O
50 O
million O
deaths O
) O
pandemics O
. O

Autoimmune O
diseases O
are O
independently O
associated O
with O
COVID O
- O
19 O
severity O
: O
Evidence O
based O
on O
adjusted O
effect O
estimates O
. O

Neurological O
complications O
of O
coronavirus O
and O
COVID O
- O
19 O
. O

These O
phenomena O
required O
further O
investigation O
and O
analysis O
that O
may O
possibly O
be O
unrelated O
with O
the O
COVID O
- O
19 O
, O
but O
due O
to O
the O
change O
of O
the O
government O
policy O
and O
its O
impact O
, O
such O
as O
the O
more O
quiet O
road O
after O
national O
social O
distancing O
. O

Impact O
of O
COVID O
- O
19 O
on O
maintenance O
haemodialysis O
patients O
: O
The O
Indian O
scenario O
. O

Data O
are O
emerging O
that O
highlight O
the O
extent O
of O
cardiovascular O
involvement O
in O
COVID O
- O
19 O
patients O
, O
including O
evidence O
that O
SARS O
- O
CoV O
- O
2 O
causes O
myocarditis O
and O
increases O
cardiac O
risk O
. O

Worry O
about O
COVID O
- O
19 O
is O
a O
central O
topic O
of O
research O
into O
the O
social O
and O
economic O
consequences O
of O
the O
COVID O
- O
19 O
pandemic O
. O

In O
this O
review O
, O
we O
compare O
and O
contrast O
the O
use O
of O
intravenous O
immunoglobulin O
and O
hyperimmune O
globulin O
in O
the O
treatment O
of O
COVID O
- O
19 O
infection O
. O

Mean O
interleukin O
- O
6 O
concentrations O
were O
nearly O
100 O
times O
higher O
in O
patients O
with O
cytokine O
release O
syndrome O
( O
3110 O
· O
5 O
pg O
/ O
mL O
, O
632 O
· O
3 O
- O
15 O
302 O
· O
9 O
pg O
/ O
mL O
; O
p O
< O
0 O
· O
0001 O
) O
, O
27 O
times O
higher O
in O
patients O
with O
sepsis O
( O
983 O
· O
6 O
pg O
/ O
mL O
, O
550 O
· O
1 O
- O
1758 O
· O
4 O
pg O
/ O
mL O
; O
p O
< O
0 O
· O
0001 O
) O
, O
and O
12 O
times O
higher O
in O
patients O
with O
acute O
respiratory O
distress O
syndrome O
unrelated O
to O
COVID O
- O
19 O
( O
460 O
pg O
/ O
mL O
, O
216 O
· O
3 O
- O

978 O
· O
7 O
pg O
/ O
mL O
; O
p O
< O
0 O
· O
0001 O
) O
. O

The O
higher O
neutrophil O
- O
lymphocyte O
- O
ratio O
in O
older O
males O
diagnosed O
with O
COVID O
- O
19 O
could O
be O
a O
causative O
reason O
for O
the O
higher O
mortality O
rates O
in O
men O
. O

The O
Practice O
of O
Gastrointestinal O
Motility O
Laboratory O
During O
COVID O
- O
19 O
Pandemic O
: O
Position O
Statements O
of O
the O
Asian O
Neurogastroenterolog O
and O
Motility O
Association O
( O
ANMA O
- O
GML O
- O
COVID O
- O
19 O
Position O
Statements O
) O
. O

As O
community O
- O
based O
ambulatory O
endoscopy O
centers O
( O
AECs O
) O
across O
the O
nation O
are O
trying O
to O
reopen O
and O
safely O
resume O
outpatient O
endoscopic O
procedures O
after O
the O
unprecedented O
lockdown O
related O
to O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
guidelines O
recommend O
pretesting O
and O
screening O
for O
COVID O
- O
19 O
along O
with O
other O
mitigation O
measures O
for O
the O
safety O
of O
patients O
and O
staff O
. O

The O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
fellowship O
training O
: O
A O
national O
survey O
of O
pediatric O
otolaryngology O
fellowship O
directors O
. O

Hypertension O
in O
Patients O
Hospitalized O
with O
COVID O
- O
19 O
in O
Wuhan O
, O
China O
. O

Two O
distinct O
headache O
phenotypes O
were O
observed O
in O
relation O
with O
COVID O
- O
19 O
status O
. O

Surgical O
treatment O
of O
thoracolumbar O
fracture O
with O
incomplete O
lower O
limb O
paralysis O
in O
a O
patient O
with O
COVID O
- O
19 O
. O

While O
there O
are O
a O
number O
of O
early O
publications O
relating O
to O
risk O
factors O
for O
COVID O
- O
19 O
infection O
, O
low O
sample O
size O
and O
heterogeneity O
in O
study O
design O
impacted O
consolidation O
of O
early O
findings O
. O

The O
column O
addresses O
the O
following O
questions O
: O
( O
1 O
) O
What O
are O
the O
3 O
aspects O
of O
the O
race O
to O
minimize O
the O
damage O
caused O
by O
COVID O
- O
19 O
? O

The O
sharing O
of O
individual O
participant O
- O
level O
data O
from O
COVID O
- O
19 O
trials O
would O
allow O
re O
- O
use O
and O
secondary O
analysis O
that O
can O
help O
accelerate O
the O
identification O
of O
effective O
treatments O
. O

Hazard O
Pay O
for O
COVID O
- O
19 O
? O
Yes O
, O
But O
It O
' O
s O
Not O
a O
Substitute O
for O
a O
Living O
Wage O
and O
Enforceable O
Worker O
Protections O
. O

Laparoscopy O
during O
the O
COVID O
- O
19 O
Pandemic O
: O
Absence O
of O
Evidence O
is O
not O
Evidence O
of O
Absence O
. O

COVINet O
: O
a O
convolutional O
neural O
network O
approach O
for O
predicting O
COVID O
- O
19 O
from O
chest O
X O
- O
ray O
images O
. O

Our O
work O
offers O
a O
useful O
support O
to O
identify O
the O
individual O
susceptibility O
to O
COVID O
- O
19 O
and O
illustrates O
a O
mechanism O
underlying O
variations O
in O
the O
immune O
response O
to O
SARS O
- O
CoV O
- O
2 O
. O

Patients O
hospitalised O
with O
COVID O
- O
19 O
infection O
were O
divided O
into O
two O
groups O
: O
those O
with O
and O
without O
musculoskeletal O
symptoms O
. O

Government O
and O
sporting O
federations O
must O
support O
athletes O
and O
develop O
and O
implement O
guidelines O
to O
reduce O
the O
risk O
in O
a O
COVID O
- O
19 O
environment O
. O

These O
findings O
are O
well O
consistent O
with O
the O
results O
from O
clinical O
investigations O
showing O
broad O
endotheliitis O
and O
organ O
injury O
in O
severe O
COVID O
- O
19 O
patients O
. O

[ O
Position O
paper O
of O
the O
Austrian O
Alzheimer O
Association O
( O
Ö O
sterreichische O
Alzheimer O
Gesellschaft O
, O
Ö O
AG O
) O
: O
Effects O
of O
the O
COVID O
- O
19 O
pandemic O
in O
Austria O
on O
people O
with O
dementia O
and O
their O
care O
environment O
- O
problem O
areas O
, O
recommendations O
, O
and O
strategies O
] O
. O

As O
these O
measures O
are O
exhausted O
, O
non O
- O
COVID O
- O
19 O
related O
issues O
such O
as O
those O
associated O
with O
the O
mental O
and O
physical O
well O
- O
being O
of O
people O
under O
lockdowns O
became O
an O
emerging O
concern O
. O

Nasopharyngeal O
viral O
load O
predicts O
hypoxemia O
and O
disease O
outcome O
in O
admitted O
COVID O
- O
19 O
patients O
. O

Have O
COVID O
- O
19 O
affected O
ALL O
epidemiology O
? O

Only O
urgent O
treatment O
of O
dental O
diseases O
can O
be O
performed O
during O
the O
COVID O
- O
19 O
outbreak O
taking O
into O
consideration O
pharmacological O
management O
as O
the O
first O
line O
and O
contagion O
- O
reduced O
minimally O
invasive O
emergency O
treatment O
as O
the O
secondary O
and O
final O
management O
. O

Currently O
, O
many O
people O
have O
been O
infected O
by O
the O
Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
and O
presented O
cardiorespiratory O
symptoms O
caused O
mainly O
by O
the O
host O
immune O
system O
response O
and O
respiratory O
tract O
inflammation O
. O

The O
purpose O
of O
this O
review O
is O
primarily O
reviewing O
the O
COVID O
- O
19 O
disease O
, O
including O
pathogen O
, O
clinical O
features O
, O
diagnosis O
, O
and O
treatment O
with O
particular O
attention O
to O
cardiovascular O
involvement O
based O
on O
the O
current O
evidence O
. O

We O
set O
out O
to O
understand O
how O
the O
COVID O
- O
19 O
pandemic O
has O
impacted O
the O
lives O
of O
these O
patients O
in O
the O
United O
States O
. O

COVID O
- O
19 O
- O
Related O
Changes O
in O
Perceived O
Household O
Food O
Waste O
in O
the O
United O
States O
: O
A O
Cross O
- O
Sectional O
Descriptive O
Study O
. O

Renin O
- O
angiotensin O
- O
aldosterone O
system O
inhibitors O
and O
COVID O
- O
19 O
. O

Hospital O
emergency O
departments O
play O
a O
crucial O
role O
in O
the O
initial O
assessment O
and O
management O
of O
suspected O
COVID O
- O
19 O
infection O
. O

To O
analyse O
the O
effects O
of O
confinement O
among O
people O
with O
type O
1 O
diabetes O
( O
T1D O
) O
and O
their O
caregivers O
over O
the O
course O
of O
the O
COVID O
- O
19 O
crisis O
and O
to O
evaluate O
contemporary O
changes O
in O
medical O
assistance O
and O
patient O
preferences O
. O

We O
observed O
a O
significant O
decline O
in O
monthly O
admissions O
in O
March O
( O
157 O
) O
, O
April O
( O
128 O
) O
and O
May O
( O
135 O
) O
compared O
with O
the O
pre O
- O
COVID O
- O
19 O
6 O
- O
month O
average O
( O
229 O
) O
( O
p O
= O
0 O
. O
024 O
) O
. O

Adapting O
harm O
reduction O
services O
during O
COVID O
- O
19 O
: O
lessons O
from O
the O
supervised O
injecting O
facilities O
in O
Australia O
. O

Commentary O
: O
Could O
iron O
chelators O
prove O
to O
be O
useful O
as O
an O
adjunct O
to O
COVID O
- O
19 O
Treatment O
Regimens O
? O

Qualitative O
data O
shows O
that O
patients O
while O
emphasizing O
the O
importance O
of O
the O
relationship O
with O
the O
healthcare O
team O
, O
had O
increased O
concerns O
about O
safety O
as O
a O
result O
of O
COVID O
- O
19 O
. O

From O
May O
4 O
to O
May O
17 O
, O
2020 O
, O
a O
web O
- O
based O
questionnaire O
focused O
on O
the O
COVID O
- O
19 O
pandemic O
was O
completed O
by O
1 O
, O
272 O
people O
( O
aged O
64 O
and O
older O
) O
who O
were O
part O
of O
an O
ongoing O
research O
panel O
in O
New O
Jersey O
recruited O
in O
2006 O
. O

COVID O
- O
19 O
: O
test O
, O
trace O
and O
isolate O
- O
new O
epidemiological O
data O
. O

Our O
experimental O
results O
and O
observations O
demonstrate O
the O
impact O
of O
the O
proposed O
medical O
, O
prevention O
, O
detection O
, O
prediction O
, O
and O
social O
methods O
for O
facing O
the O
spread O
of O
COVID O
- O
19 O
from O
December O
2019 O
to O
July O
2020 O
. O

We O
describe O
a O
patient O
, O
60 O
- O
year O
old O
Korean O
woman O
, O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
who O
had O
been O
taking O
hydroxychloroquine O
for O
6 O
months O
. O

In O
this O
Perspective O
, O
we O
discuss O
the O
utility O
and O
challenges O
of O
current O
diagnostics O
for O
COVID O
- O
19 O
. O

A O
protocol O
was O
developed O
after O
performing O
a O
literature O
review O
of O
tracheostomy O
in O
COVID O
- O
19 O
patients O
. O

Perinatal O
COVID O
- O
19 O
: O
review O
of O
current O
evidence O
and O
practical O
approach O
towards O
prevention O
and O
management O
. O

Different O
countries O
took O
different O
approaches O
for O
the O
diagnosis O
of O
COVID O
- O
19 O
. O

This O
has O
resulted O
in O
a O
missed O
opportunity O
to O
deploy O
mobile O
clinics O
during O
national O
emergencies O
such O
as O
the O
COVID O
- O
19 O
pandemic O
, O
as O
well O
as O
using O
these O
already O
existing O
, O
and O
trusted O
programs O
to O
overcome O
barriers O
to O
access O
that O
are O
experienced O
by O
under O
- O
resourced O
communities O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
already O
became O
a O
public O
health O
emergency O
of O
international O
concern O
. O

Evidence O
relating O
to O
the O
impact O
of O
COVID O
- O
19 O
in O
people O
with O
diabetes O
( O
PWD O
) O
is O
limited O
but O
continuing O
to O
emerge O
. O

In O
the O
case O
of O
a O
COVID O
- O
19 O
confirmed O
or O
suspected O
patient O
, O
attention O
must O
be O
made O
to O
preserve O
operating O
room O
and O
team O
integrity O
. O

In O
response O
to O
the O
economic O
requirement O
of O
the O
nation O
and O
meet O
the O
need O
of O
patient O
' O
s O
, O
a O
momentous O
event O
was O
going O
back O
to O
work O
step O
by O
step O
as O
fighting O
against O
COVID O
- O
19 O
. O

The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
anxiety O
, O
stress O
, O
and O
depression O
of O
patients O
with O
COVID O
- O
19 O
. O

As O
a O
result O
of O
the O
pandemic O
, O
family O
physicians O
face O
the O
additional O
challenge O
of O
navigating O
COVID O
- O
19 O
. O

Patients O
with O
stroke O
hospitalized O
with O
severe O
COVID O
- O
19 O
are O
characterized O
by O
higher O
inflammatory O
, O
coagulopathy O
, O
and O
tissue O
- O
damage O
biomarkers O
, O
supporting O
proposed O
pathogenic O
mechanisms O
of O
hyperinflammation O
activating O
a O
prothrombotic O
state O
. O

Operationalizing O
these O
phases O
relied O
upon O
the O
widespread O
use O
of O
telehealth O
, O
systematic O
COVID O
- O
19 O
testing O
, O
and O
real O
- O
time O
monitoring O
of O
hospital O
and O
personal O
protective O
equipment O
resources O
. O

Fifty O
- O
nine O
of O
these O
patients O
were O
diagnosed O
with O
COVID O
- O
19 O
based O
on O
viral O
RNA O
testing O
( O
N O
= O
41 O
) O
or O
typical O
radiologic O
signs O
: O
37 O
/ O
59 O
( O
63 O
% O
) O
COVID O
- O
19 O
patients O
were O
treated O
for O
metastatic O
breast O
cancer O
, O
and O
13 O
/ O
59 O
( O
22 O
% O
) O
of O
them O
were O
taking O
corticosteroids O
daily O
. O

With O
limited O
resources O
, O
it O
is O
possible O
to O
set O
up O
dedicated O
maternity O
services O
, O
aligned O
to O
international O
guidelines O
, O
for O
safe O
pregnancy O
outcomes O
in O
COVID O
- O
19 O
settings O
. O

In O
the O
management O
of O
head O
and O
neck O
pathologies O
, O
as O
the O
airway O
is O
a O
direct O
source O
of O
infection O
, O
the O
impact O
of O
COVID O
- O
19 O
holds O
special O
significance O
. O

New O
data O
specific O
to O
COVID O
- O
19 O
are O
emerging O
quickly O
on O
key O
issues O
of O
immunity O
and O
prevention O
, O
but O
past O
research O
in O
coronavirology O
and O
for O
other O
human O
pathogens O
( O
e O
. O
g O
. O
, O
Mycoplasma O
pneumoniae O
) O
has O
been O
available O
and O
of O
great O
relevance O
. O

Patients O
with O
autoimmune O
disorders O
, O
multiple O
comorbidities O
, O
poor O
performance O
status O
, O
advanced O
age O
, O
and O
infection O
with O
SARS O
- O
CoV O
- O
2 O
( O
COVID O
- O
19 O
) O
each O
represent O
unique O
subgroups O
of O
patients O
with O
cancer O
to O
whom O
little O
is O
known O
of O
the O
effects O
, O
benefits O
, O
and O
complications O
of O
checkpoint O
inhibitor O
( O
CPI O
) O
therapy O
. O

The O
COVID O
- O
19 O
pandemic O
restricted O
usual O
healthcare O
management O
for O
movement O
- O
disorders O
patients O
, O
with O
a O
consequent O
upsurge O
in O
telemedicine O
to O
bridge O
the O
gap O
. O

Role O
of O
eosinophils O
in O
the O
diagnosis O
and O
prognostic O
evaluation O
of O
COVID O
- O
19 O
. O

Overweight O
and O
obesity O
are O
possible O
risk O
factors O
of O
COVID O
- O
19 O
. O

The O
global O
pandemic O
of O
COVID O
- O
19 O
, O
caused O
by O
the O
SARS O
- O
CoV O
- O
2 O
virus O
, O
highlights O
the O
urgency O
of O
vaccine O
development O
against O
this O
and O
other O
constant O
threats O
of O
zoonotic O
infection O
. O

We O
searched O
the O
World O
Health O
Organization O
( O
WHO O
) O
COVID O
- O
19 O
Global O
Research O
Database O
, O
MEDLINE O
, O
Embase O
, O
Cochrane O
COVID O
- O
19 O
Study O
Register O
, O
Centers O
for O
Disease O
Control O
and O
Prevention O
COVID O
- O
19 O
Research O
Article O
Database O
and O
trial O
registries O
to O
identify O
completed O
and O
ongoing O
studies O
on O
19 O
August O
2020 O
. O

Tracheostomy O
Management O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

Following O
the O
COVID O
- O
19 O
lockdown O
, O
the O
BSc O
in O
Human O
Biology O
Program O
of O
the O
University O
of O
Nicosia O
switched O
from O
face O
- O
to O
- O
face O
to O
online O
delivery O
mode O
. O

Social O
rituals O
, O
spirituality O
, O
hope O
, O
and O
acceptance O
of O
" O
gender O
dissonance O
" O
emerged O
as O
the O
main O
coping O
factors O
, O
whereas O
their O
unmet O
needs O
were O
social O
inclusion O
, O
awareness O
related O
to O
COVID O
- O
19 O
, O
mental O
health O
care O
, O
and O
audience O
to O
their O
distress O
. O

Age O
cohorts O
stratified O
according O
to O
age O
- O
distributions O
of O
COVID O
- O
19 O
morbidity O
statistics O
identify O
uniquely O
age O
- O
dependent O
CD3 O
+ O
CD8 O
+ O
T O
- O
cell O
lymphocytopenia O
in O
COVID O
- O
19 O
patients O
without O
comorbidities O
on O
admission O
. O

Numerous O
immunomodulating O
agents O
are O
currently O
being O
studied O
in O
clinical O
trials O
for O
the O
treatment O
of O
COVID O
- O
19 O
, O
including O
interferon O
therapies O
. O

The O
VitaPCR O
™ O
SARS O
- O
CoV O
- O
2 O
Assay O
is O
an O
accurate O
rapid O
point O
- O
of O
- O
care O
NAAT O
, O
suitable O
for O
clinical O
practice O
for O
the O
rapid O
diagnosis O
of O
COVID O
- O
19 O
, O
especially O
in O
patients O
with O
COVID O
- O
19 O
- O
suspected O
symptoms O
. O

We O
provide O
a O
comprehensive O
look O
at O
COVID O
- O
19 O
epidemiology O
across O
the O
state O
of O
Georgia O
, O
which O
includes O
vast O
rural O
communities O
that O
may O
be O
disproportionately O
impacted O
by O
the O
spread O
of O
this O
infectious O
disease O
. O

To O
monitor O
the O
COVID O
- O
19 O
pandemic O
we O
need O
better O
quality O
primary O
care O
data O
. O

This O
retrospective O
case O
series O
included O
10 O
patients O
with O
a O
clinically O
and O
laboratory O
confirmed O
diagnosis O
of O
severe O
COVID O
- O
19 O
pneumonia O
who O
had O
received O
RDV O
for O
5 O
days O
( O
n O
= O
5 O
) O
or O
10 O
days O
( O
n O
= O
5 O
) O
in O
the O
Phase O
III O
clinical O
trial O
of O
RDV O
( O
GS O
- O
US O
- O
540 O
- O
5773 O
) O
conducted O
by O
Gilead O
Sciences O
. O

The O
practice O
of O
dentistry O
has O
been O
dramatically O
altered O
by O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

COVID O
- O
19 O
Outcomes O
in O
Patients O
With O
Uncontrolled O
HIV O
- O
1 O
Infection O
. O

During O
August O
22 O
- O
September O
5 O
, O
university O
A O
- O
associated O
COVID O
- O
19 O
cases O
were O
reported O
to O
the O
Arkansas O
Department O
of O
Health O
( O
ADH O
) O
. O

Patients O
with O
confirmed O
COVID O
- O
19 O
showed O
a O
higher O
incidence O
of O
anosmia O
( O
21 O
/ O
54 O
[ O
38 O
. O
9 O
% O
] O
vs O
28 O
/ O
45 O
[ O
62 O
. O
2 O
% O
] O
, O
P O
= O
. O
021 O
) O
and O
pneumonia O
( O
10 O
/ O
54 O
[ O
18 O
. O
5 O
% O
] O
vs O
18 O
/ O
45 O
[ O
40 O
% O
] O
, O
P O
= O
. O
018 O
) O
, O
headache O
at O
onset O
( O
32 O
/ O
54 O
[ O
59 O
. O
3 O
% O
] O
vs O
39 O
/ O
45 O
[ O
86 O
. O
7 O
% O
] O
, O
P O
= O
. O
002 O
) O
, O
and O
hospital O
admission O
( O
0 O
/ O
54 O
[ O
0 O
% O
] O
vs O
2 O
/ O
45 O
[ O
11 O
. O
1 O
% O
] O
, O
P O

= O
. O
017 O
) O
. O

This O
systemic O
review O
and O
meta O
- O
analysis O
aimed O
to O
study O
in O
- O
hospital O
mortality O
in O
COVID O
- O
19 O
patients O
who O
were O
on O
ACEI O
/ O
ARB O
as O
compared O
to O
those O
not O
on O
ACEI O
/ O
ARB O
. O

A O
review O
on O
possible O
mechanistic O
insights O
of O
Nitazoxanide O
for O
repurposing O
in O
COVID O
- O
19 O
. O

The O
intervention O
group O
members O
( O
50 O
/ O
99 O
, O
51 O
% O
) O
were O
required O
to O
complete O
Ajivar O
activities O
in O
addition O
to O
routine O
mental O
wellness O
instruction O
during O
the O
semester O
, O
which O
coincided O
with O
the O
onset O
of O
the O
COVID O
- O
19 O
pandemic O
. O

LUS O
may O
help O
in O
early O
diagnosis O
, O
therapeutic O
decisions O
and O
follow O
- O
up O
monitoring O
of O
COVID O
- O
19 O
pneumonia O
, O
particularly O
in O
the O
critical O
care O
setting O
and O
in O
pregnant O
women O
, O
children O
and O
patients O
in O
areas O
with O
high O
rates O
of O
community O
transmission O
. O

CT O
Features O
of O
COVID O
- O
19 O
Pneumonia O
Differ O
Depending O
on O
the O
Severity O
and O
Duration O
of O
Disease O
. O

Promising O
inhibitors O
of O
main O
protease O
of O
novel O
corona O
virus O
to O
prevent O
the O
spread O
of O
COVID O
- O
19 O
using O
docking O
and O
molecular O
dynamics O
simulation O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV2 O
) O
is O
the O
reason O
for O
this O
ongoing O
pandemic O
infection O
diseases O
termed O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
that O
has O
emerged O
since O
early O
December O
2019 O
in O
Wuhan O
City O
, O
Hubei O
Province O
, O
China O
. O

Multiplexed O
bead O
- O
based O
assays O
that O
use O
Luminex O
® O
xMAP O
® O
technology O
have O
become O
popular O
for O
measuring O
antibodies O
against O
proteins O
of O
interest O
in O
many O
fields O
, O
including O
malaria O
and O
more O
recently O
SARS O
- O
CoV O
- O
2 O
/ O
COVID O
- O
19 O
. O

The O
present O
evidence O
shows O
no O
benefit O
of O
hydroxychloroquine O
in O
patients O
affected O
by O
mild O
to O
moderate O
COVID O
- O
19 O
disease O
. O

Bariatric O
Surgical O
Practice O
During O
the O
Initial O
Phase O
of O
COVID O
- O
19 O
Outbreak O
. O

The O
risk O
of O
dying O
from O
COVID O
- O
19 O
increases O
with O
age O
and O
is O
often O
associated O
with O
pre O
- O
existing O
health O
conditions O
. O

Rapid O
Validation O
of O
Telepathology O
by O
an O
Academic O
Neuropathology O
Practice O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

COVID O
- O
19 O
and O
Headache O
Medicine O
: O
A O
Narrative O
Review O
of O
Non O
- O
Steroidal O
Anti O
- O
Inflammatory O
Drug O
( O
NSAID O
) O
and O
Corticosteroid O
Use O
. O

For O
example O
, O
as O
seen O
with O
the O
recent O
COVID O
- O
19 O
pandemic O
, O
the O
forced O
closure O
of O
business O
functions O
and O
the O
move O
to O
remote O
operations O
creates O
additional O
challenges O
for O
leadership O
. O

COVID O
- O
19 O
transient O
snoring O
( O
CVTS O
) O
: O
Clinical O
and O
laboratory O
description O
. O

Afamin O
levels O
were O
higher O
in O
the O
COVID O
- O
19 O
group O
for O
the O
all O
trimesters O
without O
reaching O
statistical O
significance O
( O
p O
> O
. O
05 O
) O
. O

Based O
on O
the O
analysis O
of O
serum O
or O
plasma O
from O
COVID O
- O
19 O
patients O
and O
healthy O
people O
, O
the O
sensitivity O
and O
specificity O
of O
the O
immunochromatographi O
assay O
were O
calculated O
as O
98 O
. O
72 O
% O
and O
100 O
% O
( O
IgG O
) O
, O
and O
98 O
. O
68 O
% O
and O
93 O
. O
10 O
% O
( O
IgM O
) O
, O
respectively O
. O

Optimising O
triage O
procedures O
for O
patients O
with O
cancer O
needing O
active O
anticancer O
treatment O
in O
the O
COVID O
- O
19 O
era O
. O

ST O
Elevations O
in O
the O
Era O
of O
COVID O
- O
19 O
. O

Conclusions O
: O
Due O
to O
the O
infrequency O
of O
viremia O
, O
ACE2 O
- O
mediated O
viral O
hepatitis O
does O
not O
seem O
to O
account O
for O
the O
commonly O
observed O
liver O
disorders O
in O
COVID O
- O
19 O
patients O
. O

COVID O
- O
19 O
has O
spread O
throughout O
the O
world O
; O
various O
forecast O
models O
have O
been O
used O
to O
predict O
the O
development O
of O
the O
pandemic O
. O

Conclusions O
: O
Critically O
ill O
patients O
with O
COVID O
- O
19 O
suffered O
earlier O
occurrence O
, O
greater O
injury O
severity O
, O
and O
slower O
recovery O
from O
liver O
injury O
than O
non O
- O
critically O
ill O
patients O
. O

Respiratory O
co O
- O
infections O
with O
COVID O
- O
19 O
in O
the O
Veterans O
Health O
Administration O
, O
2020 O
. O

In O
December O
2019 O
, O
Wuhan O
, O
China O
, O
experienced O
an O
outbreak O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

COVID O
- O
19 O
PANDEMIC O
AND O
SOCIAL O
DISTANCING O
IN O
PRISONS O
. O

Though O
its O
still O
not O
verified O
in O
any O
way O
whether O
the O
BCG O
vaccination O
can O
actually O
prevent O
COVID O
- O
19 O
or O
not O
but O
we O
believe O
a O
thorough O
analytical O
research O
in O
this O
regard O
is O
indeed O
worth O
a O
shot O
. O

Using O
a O
nationally O
representative O
cross O
- O
sectional O
study O
of O
UK O
households O
and O
individuals O
and O
applying O
principal O
components O
analysis O
, O
we O
derived O
summary O
measures O
representing O
different O
dimensions O
of O
household O
vulnerabilities O
critical O
during O
the O
COVID O
- O
19 O
epidemic O
: O
health O
, O
employment O
, O
housing O
, O
financial O
and O
digital O
. O

Proton O
Therapy O
in O
a O
Pandemic O
: O
An O
Operational O
Response O
to O
the O
COVID O
- O
19 O
Crisis O
. O

Inadvertent O
subcutaneous O
injection O
of O
COVID O
- O
19 O
vaccine O
. O

We O
then O
reported O
some O
remarks O
on O
what O
we O
think O
is O
the O
state O
of O
maturity O
of O
robotics O
in O
dealing O
with O
situations O
like O
COVID O
- O
19 O
. O

Five O
Hundred O
and O
Eleven O
individuals O
completed O
General O
Health O
Questionnaire O
, O
Emotion O
Regulation O
Questionnaire O
, O
Davos O
Assessment O
of O
Cognitive O
Biases O
Scale O
( O
DACOBS O
) O
as O
well O
as O
scales O
measuring O
COVID O
- O
19 O
risk O
perception O
and O
affective O
response O
during O
the O
initial O
days O
of O
the O
epidemic O
in O
Poland O
. O

Complete O
awareness O
of O
the O
effects O
of O
COVID O
- O
19 O
on O
maternal O
and O
fetal O
/ O
infant O
health O
, O
as O
well O
as O
prevention O
and O
management O
guidelines O
for O
pregnant O
HCPs O
, O
will O
allow O
for O
a O
safer O
work O
environment O
. O

Digital O
technology O
has O
served O
people O
for O
educative O
purposes O
and O
formation O
of O
virtual O
social O
connections O
for O
the O
co O
- O
existence O
of O
human O
relationships O
amid O
the O
COVID O
- O
19 O
pandemic O
. O

There O
were O
5556 O
COVID O
- O
19 O
- O
positive O
patients O
included O
, O
421 O
( O
7 O
. O
6 O
% O
) O
with O
cancer O
( O
325 O
solid O
, O
96 O
nonsolid O
) O
. O

Decompressive O
craniectomy O
is O
a O
life O
- O
saving O
procedure O
indicated O
in O
patients O
who O
suffer O
a O
malignant O
cerebral O
stroke O
; O
however O
, O
it O
is O
unclear O
whether O
the O
same O
eligibility O
criteria O
should O
be O
used O
for O
patients O
with O
COVID O
- O
19 O
. O

Mental O
health O
of O
Italian O
adults O
during O
COVID O
- O
19 O
pandemic O
. O

The O
province O
of O
L O
' O
Aquila O
( O
Central O
Italy O
) O
was O
marginally O
affected O
by O
COVID O
- O
19 O
pandemic O
, O
but O
changes O
in O
health O
care O
seeking O
behaviors O
were O
noticed O
. O

The O
SIR O
was O
29 O
% O
( O
n O
= O
55 O
/ O
188 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
23 O
- O
36 O
% O
) O
overall O
, O
42 O
% O
among O
children O
( O
< O
18 O
years O
) O
of O
the O
COVID O
- O
19 O
patient O
and O
33 O
% O
among O
spouses O
/ O
partners O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
continues O
to O
be O
a O
threat O
to O
the O
health O
of O
many O
humans O
across O
the O
world O
as O
they O
confront O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

As O
more O
studies O
become O
available O
, O
this O
trend O
should O
be O
checked O
to O
obtain O
conclusive O
results O
and O
to O
explore O
, O
where O
appropriate O
, O
the O
underlying O
mechanism O
of O
the O
severe O
progression O
and O
adverse O
outcomes O
of O
COVID O
- O
19 O
. O

The O
role O
of O
essential O
organ O
- O
based O
comorbidities O
in O
the O
prognosis O
of O
COVID O
- O
19 O
infection O
patients O
. O

During O
the O
early O
months O
of O
2020 O
, O
in O
addition O
to O
the O
environmental O
crisis O
, O
COVID O
- O
19 O
escalated O
to O
a O
pandemic O
resulting O
in O
the O
alteration O
of O
working O
practices O
across O
the O
UK O
( O
and O
the O
rest O
of O
the O
world O
) O
. O

There O
is O
a O
pressing O
need O
for O
evidence O
- O
based O
interventions O
to O
address O
the O
devastating O
clinical O
and O
public O
health O
effects O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Early O
Observations O
During O
the O
COVID O
- O
19 O
Pandemic O
in O
Cardiac O
Catheterization O
Procedures O
for O
ST O
- O
Elevation O
Myocardial O
Infarction O
Across O
Ontario O
. O

BCG O
Vaccination O
Policy O
and O
Protection O
Against O
COVID O
- O
19 O
. O

Most O
human O
populations O
spend O
the O
majority O
of O
their O
time O
indoors O
and O
the O
COVID O
- O
19 O
pandemic O
has O
likely O
exacerbated O
this O
behavior O
. O

I O
Never O
Thought O
I O
Had O
" O
Moral O
Courage O
, O
" O
until O
COVID O
- O
19 O
Happened O
. O

Importance O
of O
Inclusion O
of O
Pregnant O
and O
Breastfeeding O
Women O
in O
COVID O
- O
19 O
Therapeutic O
Trials O
. O

MSOA O
with O
higher O
proportions O
of O
elderly O
( O
70 O
+ O
years O
of O
age O
) O
and O
elderly O
living O
in O
deprivation O
, O
both O
with O
very O
distinct O
geographic O
distributions O
, O
have O
a O
significantly O
elevated O
COVID O
- O
19 O
mortality O
rates O
. O

The O
association O
of O
heart O
failure O
with O
COVID O
- O
19 O
pneumonia O
is O
discussed O
. O

Case O
rates O
for O
COVID O
- O
19 O
in O
hospitalised O
subjects O
with O
haematological O
cancers O
was O
10 O
% O
( O
95 O
% O
Confidence O
Interval O
[ O
CI O
] O
, O
6 O
, O
17 O
% O
) O
compared O
with O
7 O
% O
( O
4 O
, O
12 O
% O
; O
P O
= O
0 O
. O
322 O
) O
in O
health O
care O
providers O
. O

Our O
study O
highlights O
the O
common O
efforts O
of O
GCT O
experts O
in O
Europe O
and O
Canada O
to O
maintain O
high O
standards O
of O
treatment O
for O
patients O
with O
GCT O
with O
few O
changes O
in O
their O
management O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Of O
the O
7969 O
patients O
diagnosed O
with O
acute O
ischemic O
stroke O
during O
the O
study O
period O
, O
933 O
( O
12 O
% O
) O
presented O
in O
the O
COVID O
- O
19 O
period O
while O
1319 O
( O
17 O
% O
) O
presented O
in O
the O
seasonal O
pre O
- O
COVID O
- O
19 O
period O
. O

Here O
, O
by O
employing O
single O
- O
cell O
analysis O
of O
the O
immune O
cell O
composition O
of O
two O
severe O
- O
stage O
COVID O
- O
19 O
patients O
prior O
to O
and O
following O
tocilizumab O
- O
induced O
remission O
, O
we O
identify O
a O
monocyte O
subpopulation O
that O
contributes O
to O
the O
inflammatory O
cytokine O
storms O
. O

Summary O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
update O
from O
the O
2020 O
Conference O
on O
Retroviruses O
and O
Opportunistic O
Infections O
, O
8 O
- O
11 O
March O
2020 O
, O
Boston O
, O
USA O
. O

Conclusions O
Early O
gestational O
age O
at O
infection O
, O
maternal O
ventilatory O
supports O
and O
low O
birthweight O
are O
the O
main O
determinants O
of O
adverse O
perinatal O
outcomes O
in O
fetuses O
with O
maternal O
COVID O
- O
19 O
infection O
. O

Low O
rate O
of O
bacterial O
co O
- O
infection O
in O
patients O
with O
COVID O
- O
19 O
. O

Her O
initial O
admission O
was O
with O
COVID O
- O
19 O
pneumonitis O
during O
the O
first O
surge O
of O
cases O
in O
early O
2020 O
, O
and O
was O
complicated O
by O
multiple O
bilateral O
segmental O
pulmonary O
emboli O
, O
a O
28 O
- O
day O
stay O
in O
intensive O
care O
, O
16 O
days O
of O
mechanical O
ventilation O
and O
finally O
, O
a O
tracheostomy O
with O
subsequent O
weaning O
of O
respiratory O
support O
and O
rehabilitation O
. O

Strangely O
, O
ample O
evidences O
have O
been O
shown O
that O
the O
severity O
of O
COVID O
- O
19 O
infections O
varies O
widely O
from O
children O
( O
asymptomatic O
) O
, O
adults O
( O
mild O
infection O
) O
, O
as O
well O
as O
elderly O
adults O
( O
deadly O
critical O
) O
. O

In O
this O
study O
, O
we O
evaluated O
the O
effect O
of O
the O
first O
COVID O
- O
19 O
lockdown O
on O
quality O
of O
life O
and O
emotional O
functioning O
of O
patients O
with O
stage O
IV O
cancer O
treated O
for O
painful O
bone O
metastases O
in O
the O
UMC O
Utrecht O
, O
the O
Netherlands O
. O

On O
March O
11 O
, O
2020 O
, O
the O
World O
Health O
Organization O
declared O
a O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

Reports O
that O
the O
over O
- O
the O
- O
counter O
histamine O
H2 O
receptor O
antagonist O
famotidine O
could O
help O
treat O
the O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
appeared O
from O
April O
2020 O
. O

However O
, O
electrocardiograhic O
( O
ECG O
) O
manifestations O
of O
patients O
with O
COVID O
- O
19 O
have O
not O
been O
fully O
described O
. O

Medical O
records O
of O
patients O
referred O
to O
an O
Italian O
COVID O
- O
19 O
Rehabilitation O
Unit O
from O
March O
10th O
, O
2020 O
to O
April O
30th O
, O
2020 O
were O
collected O
. O

In O
patients O
with O
COVID O
- O
19 O
who O
received O
ECMO O
, O
both O
estimated O
mortality O
90 O
days O
after O
ECMO O
and O
mortality O
in O
those O
with O
a O
final O
disposition O
of O
death O
or O
discharge O
were O
less O
than O
40 O
% O
. O

SARS O
- O
CoV O
- O
2 O
positive O
decedents O
were O
also O
more O
likely O
to O
be O
older O
and O
to O
have O
died O
of O
natural O
causes O
, O
including O
of O
COVID O
- O
19 O
disease O
. O

The O
effects O
of O
COVID O
- O
19 O
for O
this O
population O
are O
inextricably O
linked O
to O
areas O
of O
systemic O
oppression O
and O
disenfranchisement O
, O
which O
are O
further O
exacerbated O
by O
COVID O
- O
19 O
: O
( O
1 O
) O
healthcare O
inequality O
; O
( O
2 O
) O
segregation O
, O
overall O
health O
, O
and O
food O
insecurity O
; O
( O
3 O
) O
underrepresentation O
in O
government O
and O
the O
medical O
profession O
; O
and O
( O
4 O
) O
inequalities O
in O
participatory O
democracy O
and O
public O
engagement O
. O

During O
the O
COVID O
- O
19 O
crisis O
, O
nurses O
experience O
a O
greater O
psychological O
burden O
than O
other O
health O
care O
workers O
. O

COVID O
- O
19 O
needs O
to O
be O
considered O
in O
the O
clinic O
set O
- O
up O
along O
with O
the O
planning O
, O
treatment O
and O
post O
- O
treatment O
care O
of O
patients O
utilising O
EBD O
procedures O
. O

Drug O
repurposing O
has O
been O
used O
to O
rapidly O
identify O
potential O
treatments O
for O
COVID O
- O
19 O
, O
which O
could O
move O
quickly O
to O
phase O
III O
. O

Motivated O
by O
historical O
and O
present O
clinical O
observations O
, O
we O
discuss O
the O
possible O
unfavorable O
evolution O
of O
the O
immunity O
( O
similar O
to O
documented O
antibody O
- O
dependent O
enhancement O
scenarios O
) O
after O
a O
first O
infection O
with O
COVID O
- O
19 O
. O

A O
mechanism O
- O
based O
parameterisation O
scheme O
was O
developed O
to O
investigate O
the O
association O
between O
the O
scaled O
transmission O
rate O
( O
STR O
) O
of O
COVID O
- O
19 O
and O
the O
meteorological O
parameters O
in O
20 O
provinces O
/ O
municipalities O
located O
on O
the O
plains O
in O
China O
. O

Amelioration O
of O
COVID O
- O
19 O
- O
related O
cytokine O
storm O
syndrome O
: O
parallels O
to O
chimeric O
antigen O
receptor O
- O
T O
cell O
cytokine O
release O
syndrome O
. O

This O
work O
investigates O
the O
drone O
- O
based O
systems O
, O
COVID O
- O
19 O
pandemic O
situations O
, O
and O
proposes O
an O
architecture O
for O
handling O
pandemic O
situations O
in O
different O
scenarios O
using O
real O
- O
time O
and O
simulation O
- O
based O
scenarios O
. O

The O
novel O
COVID O
- O
19 O
infection O
, O
caused O
by O
a O
beta O
coronavirus O
called O
SARS O
- O
CoV O
- O
2 O
, O
is O
a O
new O
outbreak O
that O
has O
been O
emerged O
in O
Wuhan O
, O
China O
in O
December O
2019 O
. O

The O
policy O
enforcing O
visiting O
restriction O
during O
the O
COVID O
- O
19 O
pandemic O
may O
cause O
feelings O
of O
social O
isolation O
among O
residents O
in O
long O
- O
term O
care O
facilities O
. O

Likewise O
, O
the O
factors O
of O
vaccination O
and O
obedience O
in O
implementing O
health O
protocols O
have O
the O
same O
effect O
in O
slowing O
or O
stopping O
the O
transmission O
of O
COVID O
- O
19 O
in O
Indonesia O
. O

Introduction O
: O
Hospital O
response O
to O
the O
COVID O
- O
19 O
outbreak O
has O
involved O
the O
cancellation O
of O
elective O
, O
deferrable O
surgeries O
throughout O
Europe O
in O
order O
to O
ensure O
capacity O
for O
emergent O
surgery O
and O
a O
selection O
of O
elective O
but O
non O
- O
deferrable O
surgeries O
. O

The O
widespread O
death O
and O
disruption O
caused O
by O
the O
COVID O
- O
19 O
pandemic O
has O
revealed O
deficiencies O
of O
existing O
institutions O
regarding O
the O
protection O
of O
human O
health O
and O
well O
- O
being O
. O

We O
conducted O
a O
comprehensive O
search O
of O
PubMed O
, O
Google O
Scholar O
and O
Cochrane O
Database O
of O
Systematic O
Review O
between O
November O
2019 O
and O
June O
2020 O
and O
screened O
articles O
related O
to O
perinatal O
COVID O
- O
19 O
. O

Adaptation O
of O
the O
Bangla O
Version O
of O
the O
COVID O
- O
19 O
Anxiety O
Scale O
. O

Close O
monitoring O
and O
an O
optimized O
screening O
strategy O
for O
COVID O
- O
19 O
could O
help O
deter O
spread O
of O
the O
virus O
. O

The O
COVID O
- O
19 O
pandemic O
significantly O
increased O
the O
use O
of O
telemedicine O
worldwide O
which O
has O
demonstrated O
to O
be O
useful O
in O
promoting O
social O
distancing O
and O
in O
avoiding O
the O
overload O
of O
the O
healthcare O
system O
. O

Use O
of O
Telehealth O
for O
Domiciliary O
Follow O
- O
up O
After O
Hematopoietic O
Cell O
Transplantation O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
Prospective O
Pilot O
Study O
. O

For O
imaging O
features O
, O
both O
groups O
had O
ground O
- O
glass O
opacity O
and O
thickening O
of O
interlobular O
septum O
, O
but O
the O
ratio O
of O
central O
and O
gradient O
distribution O
was O
higher O
in O
patients O
with O
heart O
failure O
than O
that O
in O
patients O
with O
COVID O
- O
19 O
( O
4 O
/ O
7 O
vs O
. O
1 O
/ O
12 O
, O
P O
= O
0 O
. O
04 O
) O
. O

Essential O
elements O
that O
process O
SARS O
- O
CoV2 O
cell O
entry O
and O
specific O
characteristics O
that O
allow O
SARS O
- O
CoV2 O
to O
escape O
the O
immune O
system O
have O
the O
potential O
as O
targets O
for O
COVID O
- O
19 O
therapy O
. O

The O
COVID O
- O
19 O
outbreak O
is O
becoming O
a O
public O
health O
emergency O
. O

Specifically O
, O
the O
daily O
contact O
rate O
required O
to O
suppress O
the O
epidemic O
and O
prevent O
a O
resurgence O
of O
COVID O
- O
19 O
cases O
, O
and O
the O
daily O
contact O
rate O
required O
to O
stay O
within O
the O
acute O
bed O
capacity O
of O
the O
NEL O
system O
without O
any O
additional O
intervention O
measures O
after O
July O
2020 O
, O
were O
determined O
across O
the O
nine O
different O
scenarios O
. O

The O
COVID O
- O
19 O
pandemic O
and O
the O
fast O
global O
spread O
of O
the O
disease O
resulted O
in O
unprecedented O
decline O
in O
world O
trade O
and O
travel O
. O

COVID O
- O
19 O
has O
exacerbated O
pre O
- O
existing O
difficulties O
children O
and O
adults O
with O
disability O
face O
accessing O
quality O
health O
care O
. O

Affording O
health O
during O
the O
COVID O
- O
19 O
pandemic O
and O
associated O
economic O
downturn O
. O

[ O
Convalescent O
plasma O
therapy O
in O
COVID O
- O
19 O
patients O
, O
in O
the O
Province O
of O
Buenos O
Aires O
] O
. O

Virtual O
Visits O
for O
Care O
of O
Patients O
with O
Heart O
Failure O
in O
the O
Era O
of O
COVID O
- O
19 O
: O
A O
Statement O
from O
the O
Heart O
Failure O
Society O
of O
America O
. O

Clinical O
characteristics O
of O
deceased O
hemodialysis O
patients O
affected O
by O
COVID O
- O
19 O
. O

A O
total O
of O
502 O
COVID O
- O
19 O
adult O
patients O
( O
72 O
asthma O
and O
430 O
non O
- O
asthma O
cohorts O
) O
with O
mean O
age O
of O
60 O
. O
7 O
years O
were O
included O
in O
the O
study O
. O

The O
detailed O
investigations O
were O
performed O
for O
14 O
major O
hotspot O
places O
where O
the O
COVID O
- O
19 O
cases O
were O
> O
1000 O
( O
as O
of O
1st O
June O
2020 O
) O
and O
represents O
more O
than O
70 O
% O
associated O
mortality O
in O
India O
. O

One O
- O
sample O
, O
one O
- O
tailed O
t O
- O
tests O
( O
α O
= O
0 O
. O
05 O
, O
df O
= O
49 O
) O
were O
used O
to O
see O
if O
the O
websites O
with O
information O
on O
COVID O
- O
19 O
testing O
are O
being O
written O
at O
appropriate O
reading O
levels O
. O

It O
can O
completely O
change O
the O
working O
layout O
of O
the O
healthcare O
facilities O
while O
treating O
orthopaedic O
patients O
with O
a O
superior O
level O
of O
care O
and O
more O
satisfaction O
, O
especially O
during O
this O
pandemic O
COVID O
- O
19 O
lockdown O
. O

Response O
to O
: O
' O
Correspondence O
on O
' O
Lung O
involvement O
in O
macrophage O
activation O
syndrome O
and O
severe O
COVID O
- O
19 O
: O
results O
from O
a O
cross O
- O
sectional O
study O
to O
assess O
clinical O
, O
laboratory O
and O
artificial O
intelligence O
- O
radiological O
differences O
' O
by O
Ruscitti O
et O
al O
' O
by O
Chen O
et O
al O
. O

A O
second O
wave O
of O
COVID O
- O
19 O
began O
in O
late O
June O
in O
Victoria O
, O
Australia O
. O

Associations O
Between O
Angiotensin O
- O
Converting O
Enzyme O
Inhibitors O
and O
Angiotensin O
II O
Receptor O
Blocker O
Use O
, O
Gastrointestinal O
Symptoms O
, O
and O
Mortality O
Among O
Patients O
With O
COVID O
- O
19 O
. O

A O
Meta O
- O
analysis O
of O
the O
Relationship O
Between O
Renin O
- O
Angiotensin O
- O
Aldosterone O
System O
Inhibitors O
and O
COVID O
- O
19 O
. O

Beyond O
transmission O
: O
Dire O
need O
for O
integration O
of O
nutrition O
interventions O
in O
COVID O
- O
19 O
pandemic O
- O
response O
strategies O
in O
Developing O
Countries O
like O
Pakistan O
. O

Bacterial O
co O
- O
infections O
and O
antibiotic O
resistance O
in O
patients O
with O
COVID O
- O
19 O
. O

Looking O
at O
intra O
- O
hospital O
non O
COVID O
- O
19 O
mortality O
among O
elderly O
patients O
during O
COVID O
- O
19 O
pandemic O
. O

Despite O
having O
CLL O
, O
he O
developed O
a O
moderate O
COVID O
- O
19 O
infection O
and O
recovered O
in O
a O
few O
days O
. O

We O
also O
found O
that O
fever O
and O
total O
bilirubin O
measurements O
could O
be O
useful O
for O
the O
diagnosis O
of O
COVID O
- O
19 O
in O
this O
population O
. O

The O
critical O
importance O
of O
community O
health O
workers O
as O
first O
responders O
to O
COVID O
- O
19 O
in O
USA O
. O

Finally O
, O
we O
look O
ahead O
and O
address O
the O
lessons O
we O
can O
incorporate O
into O
post O
- O
COVID O
- O
19 O
rheumatology O
. O

Analysis O
and O
Evaluation O
of O
COVID O
- O
19 O
Web O
Applications O
for O
Health O
Professionals O
: O
Challenges O
and O
Opportunities O
. O

How O
are O
family O
doctors O
serving O
the O
Hong O
Kong O
community O
during O
the O
COVID O
- O
19 O
outbreak O
? O
A O
survey O
of O
HKCFP O
members O
. O

It O
has O
been O
challenging O
for O
this O
population O
to O
access O
public O
information O
regarding O
COVID O
- O
19 O
testing O
, O
treatment O
, O
and O
assistance O
programs O
because O
this O
information O
has O
seldom O
been O
disseminated O
in O
Spanish O
and O
even O
less O
frequently O
in O
Portuguese O
. O

During O
the O
COVID O
- O
19 O
pandemic O
urological O
cancer O
care O
has O
been O
severely O
impaired O
. O

The O
2019 O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
: O
A O
review O
of O
the O
current O
evidence O
. O

In O
this O
case O
, O
we O
described O
one O
unique O
COVID O
- O
19 O
patient O
, O
the O
symptoms O
were O
: O
dry O
cough O
, O
fatigue O
, O
poor O
appetite O
and O
subjective O
fever O
, O
moreover O
, O
the O
patient O
was O
a O
non O
- O
smoker O
, O
had O
no O
pulmonary O
bullous O
, O
no O
history O
of O
tuberculosis O
, O
and O
also O
no O
hypertension O
or O
diabetes O
. O

Evaluation O
of O
the O
BioFire O
® O
COVID O
- O
19 O
test O
and O
Respiratory O
Panel O
2 O
. O
1 O
for O
rapid O
identification O
of O
SARS O
- O
CoV O
- O
2 O
in O
nasopharyngeal O
swab O
samples O
. O

Core O
experiences O
of O
parents O
of O
children O
with O
autism O
during O
the O
COVID O
- O
19 O
pandemic O
lockdown O
. O

COVID O
- O
19 O
: O
quelle O
place O
, O
aujourd O
’ O
hui O
, O
pour O
les O
tests O
s O
é O
rologiques O
? O

A O
word O
for O
the O
nephrologist O
: O
what O
we O
changed O
in O
our O
habits O
during O
the O
COVID O
- O
19 O
pandemic O
? O

Increased O
risk O
of O
mental O
health O
disorders O
in O
patients O
with O
RA O
during O
the O
COVID O
- O
19 O
pandemic O
: O
a O
possible O
surge O
and O
solutions O
. O

The O
coronavirus O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
potential O
to O
disproportionately O
and O
severely O
affect O
patients O
with O
neuromuscular O
disorders O
. O

In O
the O
face O
of O
this O
new O
reality O
, O
and O
in O
order O
to O
limit O
the O
impact O
of O
the O
current O
COVID O
- O
19 O
pandemic O
, O
multiple O
programs O
have O
implemented O
physical O
distancing O
to O
reduce O
in O
- O
person O
interactions O
. O

Usefulness O
and O
safety O
of O
self O
- O
electrocardiographic O
monitoring O
during O
treatment O
with O
hydroxychloroquine O
and O
azithromycin O
in O
COVID O
- O
19 O
patients O
. O

COVID O
- O
19 O
infections O
are O
seen O
across O
all O
age O
groups O
, O
but O
they O
have O
shown O
to O
have O
a O
predisposition O
for O
the O
elderly O
and O
those O
with O
underlying O
comorbidities O
. O

There O
are O
currently O
over O
400 O
clinical O
trials O
( O
phase O
2 O
and O
3 O
) O
of O
treatments O
for O
COVID O
- O
19 O
registered O
on O
clinicaltrials O
. O
gov O
. O

[ O
Epilepsy O
and O
COVID O
- O
19 O
: O
patient O
management O
and O
optimization O
of O
antiepileptic O
therapy O
during O
pandemic O
] O
. O

A O
reno O
- O
vascular O
pathogenesis O
of O
COVID O
- O
19 O
AKI O
seems O
likely O
. O

As O
health O
systems O
worldwide O
grapple O
with O
the O
coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
patients O
with O
durable O
LVAD O
support O
represent O
a O
unique O
population O
at O
risk O
for O
the O
disease O
. O

COVID O
- O
19 O
and O
ESKD O
, O
A O
Rapid O
Review O
. O

As O
PGs O
play O
diverse O
biological O
roles O
in O
homeostasis O
and O
inflammatory O
responses O
, O
inhibiting O
PG O
production O
with O
NSAIDs O
could O
affect O
COVID O
- O
19 O
pathogenesis O
in O
multiple O
ways O
, O
including O
: O
( O
1 O
) O
altering O
susceptibility O
to O
infection O
by O
modifying O
expression O
of O
angiotensin O
- O
converting O
enzyme O
2 O
( O
ACE2 O
) O
, O
the O
cell O
entry O
receptor O
for O
SARS O
- O
CoV O
- O
2 O
; O
( O
2 O
) O
regulating O
replication O
of O
SARS O
- O
CoV O
- O
2 O
in O
host O
cells O
; O
and O
( O
3 O
) O
modulating O
the O
immune O
response O
to O
SARS O
- O
CoV O
- O
2 O
. O

We O
hope O
that O
these O
unified O
criteria O
and O
recommendations O
will O
guide O
health O
professionals O
in O
implementing O
SI O
sampling O
and O
processing O
procedures O
as O
safely O
as O
possible O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Conclusions O
This O
case O
series O
highlights O
the O
possible O
benefits O
of O
inhaled O
steroids O
in O
treatment O
of O
COVID O
- O
19 O
patients O
with O
hypoxia O
. O

Because O
of O
the O
latent O
existing O
risk O
of O
facing O
another O
pandemic O
like O
the O
one O
we O
are O
living O
through O
due O
to O
COVID O
- O
19 O
, O
researchers O
are O
constantly O
looking O
forward O
to O
developing O
new O
technologies O
for O
diagnosis O
and O
treatment O
of O
infections O
caused O
by O
different O
bacteria O
and O
viruses O
. O

Evolution O
of O
computed O
tomography O
manifestations O
of O
eleven O
patients O
with O
severe O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pneumonia O
. O

Fourteen O
observational O
studies O
offer O
evidence O
that O
serum O
25 O
- O
hydroxyvitamin O
D O
concentrations O
are O
inversely O
correlated O
with O
the O
incidence O
or O
severity O
of O
COVID O
- O
19 O
. O

Healthy O
pregnant O
women O
are O
more O
susceptible O
to O
developing O
COVID O
- O
19 O
. O

This O
study O
bridges O
structural O
findings O
with O
an O
analysis O
of O
publicly O
available O
clinical O
data O
from O
Wuhan O
and O
suggests O
that O
an O
adjustment O
of O
the O
dexamethasone O
regimen O
should O
be O
further O
investigated O
as O
a O
strategy O
for O
patients O
affected O
by O
two O
major O
COVID O
- O
19 O
risk O
factors O
: O
low O
albumin O
levels O
and O
diabetes O
. O

The O
Lombardy O
region O
, O
in O
Northern O
Italy O
, O
suffered O
a O
major O
outbreak O
of O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
at O
the O
end O
of O
February O
2020 O
. O

Brain O
and O
nerves O
affected O
before O
the O
lungs O
in O
COVID O
- O
19 O
. O

In O
patients O
visiting O
the O
emergency O
department O
( O
ED O
) O
, O
a O
potential O
association O
between O
electrolytes O
disturbance O
and O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
not O
been O
well O
studied O
. O

Why O
are O
more O
BAME O
people O
dying O
from O
COVID O
- O
19 O
? O

SARS O
- O
CoV O
- O
2 O
was O
first O
identified O
as O
an O
etiological O
pathogen O
of O
COVID O
- O
19 O
, O
belonging O
to O
the O
species O
of O
severe O
acute O
respiratory O
syndrome O
- O
related O
coronaviruses O
( O
SARSr O
- O
CoV O
) O
. O

Health O
Care O
Organizations O
: O
Soft O
Target O
during O
COVID O
- O
19 O
Pandemic O
. O

Worldwide O
Survey O
of O
COVID O
- O
19 O
- O
Associated O
Arrhythmias O
. O

COVID O
- O
19 O
pandemics O
required O
a O
reorganisation O
of O
social O
spaces O
to O
prevent O
the O
spread O
of O
the O
virus O
. O

DAH O
and O
COVID O
- O
19 O
might O
share O
common O
clinical O
and O
radiological O
findings O
during O
examination O
. O

As O
for O
many O
respiratory O
viruses O
- O
caused O
diseases O
, O
diagnosis O
of O
COVID O
- O
19 O
relies O
on O
two O
main O
compartments O
: O
clinical O
and O
paraclinical O
diagnostic O
criteria O
. O

COVID O
- O
19 O
pandemic O
impact O
on O
clinical O
outcomes O
of O
patients O
with O
obstructive O
pyelonephritis O
. O

To O
develop O
a O
sensitive O
risk O
score O
predicting O
the O
risk O
of O
mortality O
in O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
using O
complete O
blood O
count O
( O
CBC O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
cases O
and O
deaths O
across O
Italian O
regions O
and O
provinces O
in O
March O
2020 O
were O
linked O
to O
past O
exposure O
to O
fine O
and O
coarse O
particulate O
matter O
( O
namely O
, O
PM2 O
. O
5 O
and O
PM10 O
, O
respectively O
) O
. O

COVID O
- O
19 O
and O
inflammatory O
bowel O
disease O
: O
A O
pathophysiological O
assessment O
. O

Histopathology O
and O
genetic O
susceptibility O
in O
COVID O
- O
19 O
pneumonia O
. O

Impact O
of O
COVID O
- O
19 O
geographic O
distribution O
on O
advanced O
age O
plastic O
surgeons O
: O
A O
cross O
- O
sectional O
analysis O
. O

A O
subsample O
also O
completed O
a O
survey O
about O
their O
experience O
at O
home O
during O
COVID O
- O
19 O
. O

This O
case O
shows O
that O
IPT O
- O
based O
therapy O
can O
reduce O
COVID O
- O
19 O
patient O
depression O
and O
anxiety O
and O
the O
advantage O
of O
IPT O
- O
based O
therapy O
. O

Out O
of O
the O
frying O
pan O
and O
into O
the O
fire O
? O
Due O
diligence O
warranted O
for O
ADE O
in O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
profoundly O
affected O
health O
care O
delivery O
worldwide O
. O

Recommendations O
for O
Surgery O
During O
the O
Novel O
Coronavirus O
( O
COVID O
- O
19 O
) O
Epidemic O
. O

The O
time O
from O
symptom O
onset O
to O
diagnosis O
and O
treatment O
was O
recorded O
for O
each O
patient O
, O
and O
on O
the O
basis O
of O
this O
information O
, O
patients O
with O
COVID O
- O
19 O
were O
divided O
into O
group O
1 O
( O
patients O
for O
whom O
this O
interval O
was O
≤ O
3 O
days O
) O
and O
group O
2 O
( O
those O
for O
whom O
this O
interval O
was O
> O
3 O
days O
) O
. O

The O
prevention O
and O
control O
of O
COVID O
- O
19 O
remains O
extremely O
urgent O
. O

Findings O
suggest O
that O
existing O
disparities O
exacerbate O
COVID O
- O
19 O
outcomes O
for O
Black O
people O
. O

This O
study O
aims O
to O
evaluate O
the O
prevalence O
of O
symptoms O
suggestive O
of O
mental O
disorders O
and O
burnout O
syndrome O
and O
determine O
the O
risk O
factors O
for O
burnout O
among O
postgraduate O
students O
in O
medical O
and O
multidisciplinary O
residencies O
in O
Brazil O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
rapid O
spread O
of O
COVID O
- O
19 O
forced O
many O
hospitality O
managers O
to O
use O
digital O
technologies O
to O
perform O
work O
from O
home O
, O
termed O
digital O
work O
connectivity O
. O

COVID O
- O
19 O
infection O
in O
patients O
with O
sickle O
cell O
disease O
. O

These O
increases O
are O
more O
likely O
to O
occur O
in O
those O
with O
chronic O
cardiovascular O
conditions O
and O
in O
those O
with O
severe O
COVID O
- O
19 O
presentations O
. O

Outcomes O
included O
daily O
cumulative O
COVID O
- O
19 O
cases O
and O
deaths O
for O
each O
state O
. O

A O
case O
- O
control O
study O
was O
conducted O
comparing O
percentage O
of O
total O
weight O
loss O
( O
% O
TWL O
) O
, O
excess O
weight O
lost O
( O
% O
EWL O
) O
, O
and O
the O
remission O
rate O
of O
obesity O
- O
related O
comorbidities O
at O
the O
first O
postoperative O
year O
between O
patients O
who O
underwent O
primary O
SG O
between O
June O
2019 O
and O
October O
2019 O
( O
1 O
- O
year O
postoperative O
period O
affected O
by O
COVID O
- O
19 O
lockdown O
; O
COV O
- O
group O
) O
, O
and O
a O
control O
group O
operated O
between O
June O
2018 O
and O
October O
2018 O
( O
1 O
- O
year O
postoperative O
period O
not O
affected O
by O
COVID O
- O
19 O
lockdown O
; O
CONTROL O
- O
group O
) O
. O

[ O
Influenza O
Vaccination O
in O
Patients O
with O
Cardiovascular O
Disease O
Under O
65 O
in O
the O
COVID O
- O
19 O
Era O
] O
. O

However O
, O
with O
the O
recent O
COVID O
- O
19 O
pandemic O
, O
organizations O
suddenly O
have O
to O
navigate O
the O
unprecedented O
and O
thereby O
find O
new O
solutions O
to O
challenges O
arising O
across O
many O
areas O
of O
their O
operations O
. O

Therefore O
, O
baicalein O
might O
be O
a O
promising O
therapeutic O
drug O
for O
the O
treatment O
of O
COVID O
- O
19 O
. O

Investigating O
Virological O
, O
Immunological O
, O
and O
Pathological O
Avenues O
to O
Identify O
Potential O
Targets O
for O
Developing O
COVID O
- O
19 O
Treatment O
and O
Prevention O
Strategies O
. O

The O
impact O
of O
COVID O
- O
19 O
on O
IC O
fellow O
training O
in O
the O
United O
States O
has O
not O
been O
assessed O
. O

Trust O
in O
Public O
Health O
Is O
Essential O
Amid O
the O
COVID O
- O
19 O
Pandemic O
. O

We O
hypothesize O
that O
IL O
- O
6 O
- O
STAT3 O
signaling O
is O
a O
promising O
therapeutic O
target O
for O
the O
cytokine O
storm O
in O
COVID O
- O
19 O
, O
because O
IL O
- O
6 O
is O
a O
major O
STAT3 O
stimulator O
, O
particularly O
during O
inflammation O
. O

A O
novel O
variant O
, O
SARS O
- O
CoV O
- O
2 O
, O
is O
responsible O
for O
COVID O
- O
19 O
pandemic O
. O

In O
the O
context O
of O
the O
current O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
we O
conducted O
a O
meta O
- O
analysis O
on O
the O
effects O
of O
chloroquine O
derivatives O
in O
patients O
, O
based O
on O
unpublished O
and O
published O
reports O
available O
publicly O
on O
the O
internet O
as O
of O
27 O
May O
2020 O
. O

A O
retrospective O
cohort O
study O
conducted O
at O
a O
university O
- O
affiliated O
fertility O
center O
in O
Montreal O
, O
Quebec O
, O
since O
the O
COVID O
- O
19 O
shut O
down O
, O
March O
13 O
until O
May O
6 O
, O
2020 O
. O

Implementing O
malaria O
control O
in O
South O
Africa O
, O
Eswatini O
and O
southern O
Mozambique O
during O
the O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
is O
an O
infectious O
disease O
caused O
by O
the O
virus O
named O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
and O
declared O
a O
pandemic O
on O
March O
11 O
, O
2020 O
, O
by O
the O
world O
health O
organization O
. O

It O
remains O
unknown O
how O
Coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
prevention O
measures O
implemented O
on O
March O
12 O
, O
2020 O
, O
have O
affected O
the O
rate O
of O
pediatric O
infection O
- O
related O
hospitalizations O
in O
Denmark O
. O

Paired O
samples O
t O
- O
tests O
and O
X2 O
- O
tests O
showed O
that O
the O
mean O
hour O
of O
weekly O
social O
support O
service O
usage O
and O
the O
number O
of O
people O
having O
accessed O
various O
services O
was O
significantly O
reduced O
post O
COVID O
- O
19 O
. O

The O
type O
of O
pneumonia O
( O
coronavirus O
disease O
2019 O
, O
COVID O
- O
19 O
) O
that O
is O
caused O
by O
the O
new O
coronavirus O
( O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
, O
SARS O
- O
CoV O
- O
2 O
) O
is O
now O
spreading O
across O
the O
world O
in O
a O
pandemic O
. O

To O
assess O
detection O
rate O
of O
COVID O
- O
19 O
on O
CT O
and O
its O
correlation O
with O
RT O
- O
PCR O
swab O
results O
. O

Severe O
thrombocytopenia O
in O
a O
patient O
with O
otherwise O
asymptomatic O
COVID O
- O
19 O
. O

Combined O
analysis O
included O
the O
no O
. O
of O
cases O
from O
start O
of O
COVID O
- O
19 O
to O
the O
predicted O
end O
of O
cases O
all O
over O
India O
. O

Re O
" O
Management O
and O
outcomes O
of O
mammalian O
bite O
injuries O
during O
COVID O
- O
19 O
and O
implications O
for O
future O
practice O
" O
. O

Considered O
a O
relative O
of O
severe O
acute O
respiratory O
syndrome O
( O
SARS O
) O
and O
Middle O
East O
respiratory O
syndrome O
( O
MERS O
) O
, O
COVID O
- O
19 O
is O
caused O
by O
a O
betacoronavirus O
named O
SARS O
- O
CoV O
- O
2 O
that O
affects O
the O
lower O
respiratory O
tract O
and O
manifests O
as O
pneumonia O
in O
humans O
. O

In O
this O
report O
, O
for O
the O
first O
time O
, O
we O
have O
identified O
potential O
candidate O
genes O
that O
might O
be O
regulated O
via O
SARS O
- O
CoV O
- O
2 O
induced O
DNA O
methylation O
changes O
in O
COVID O
- O
19 O
infection O
. O

Our O
aim O
was O
to O
investigate O
the O
value O
of O
additional O
chest O
CT O
for O
detection O
of O
coronavirus O
19 O
( O
COVID O
- O
19 O
) O
in O
patients O
who O
undergo O
head O
CT O
for O
suspected O
stroke O
or O
head O
trauma O
in O
a O
COVID O
- O
19 O
- O
endemic O
region O
. O

Persons O
infected O
with O
SARS O
- O
CoV O
- O
2 O
who O
do O
not O
have O
symptoms O
of O
COVID O
- O
19 O
may O
transmit O
the O
virus O
to O
others O
and O
may O
have O
subclinical O
lung O
abnormalities O
. O

The O
majority O
of O
participants O
( O
99 O
% O
) O
reported O
having O
heard O
of O
COVID O
- O
19 O
; O
23 O
% O
reported O
no O
longer O
being O
able O
to O
go O
outside O
, O
17 O
% O
reported O
that O
they O
could O
no O
longer O
go O
to O
their O
regular O
clinic O
for O
medical O
care O
, O
and O
3 O
% O
reported O
that O
they O
could O
no O
longer O
get O
medication O
refills O
. O

A O
model O
using O
age O
and O
BV5 O
% O
had O
an O
area O
under O
the O
receiver O
operating O
characteristic O
curve O
0 O
. O
85 O
to O
predict O
the O
composite O
of O
intubation O
or O
death O
in O
COVID O
- O
19 O
patients O
. O

The O
host O
gene O
classifier O
built O
on O
such O
a O
signature O
exhibited O
potential O
for O
diagnosing O
COVID O
- O
19 O
( O
AUC O
of O
0 O
. O
75 O
- O
0 O
. O
89 O
) O
and O
indicating O
disease O
severity O
. O

Plasma O
tissue O
plasminogen O
activator O
and O
plasminogen O
activator O
inhibitor O
- O
1 O
in O
hospitalized O
COVID O
- O
19 O
patients O
. O

Non O
- O
linear O
link O
between O
temperature O
difference O
and O
COVID O
- O
19 O
: O
Excluding O
the O
effect O
of O
population O
density O
. O

Containment O
of O
future O
waves O
of O
COVID O
- O
19 O
: O
simulating O
the O
impact O
of O
different O
policies O
and O
testing O
capacities O
for O
contact O
tracing O
, O
testing O
, O
and O
isolation O
. O

Until O
now O
, O
few O
cases O
of O
stroke O
in O
COVID O
- O
19 O
have O
been O
described O
, O
mainly O
in O
severe O
forms O
. O

Natural O
Language O
Processing O
for O
Rapid O
Response O
to O
Emergent O
Diseases O
: O
Case O
Study O
of O
Calcium O
Channel O
Blockers O
and O
Hypertension O
in O
the O
COVID O
- O
19 O
Pandemic O
. O

COVID O
- O
19 O
safety O
measures O
and O
possibly O
SARS O
- O
CoV O
- O
2 O
antibody O
testing O
may O
alter O
blood O
donor O
demography O
, O
which O
has O
the O
potential O
to O
alter O
blood O
safety O
. O

Digital O
Disinformation O
About O
COVID O
- O
19 O
and O
the O
Third O
- O
Person O
Effect O
: O
Examining O
the O
Channel O
Differences O
and O
Negative O
Emotional O
Outcomes O
. O

In O
our O
cohort O
, O
compared O
to O
patients O
without O
anemia O
, O
patients O
with O
anemia O
were O
more O
likely O
to O
have O
one O
or O
more O
comorbidities O
and O
severe O
COVID O
- O
19 O
illness O
. O

The O
results O
of O
this O
study O
showed O
that O
Male O
gender O
, O
older O
age O
and O
having O
comorbidities O
were O
significantly O
associated O
with O
the O
risk O
of O
death O
among O
COVID O
- O
19 O
patients O
. O

The O
COVID O
- O
19 O
quarantine O
resulted O
in O
a O
significant O
increase O
in O
LBP O
intensity O
, O
point O
prevalence O
, O
and O
most O
associated O
risk O
factors O
. O

This O
study O
aimed O
to O
assess O
anxiety O
, O
depression O
, O
and O
knowledge O
level O
in O
postpartum O
women O
during O
the O
COVID O
- O
19 O
pandemic O
. O

( O
1 O
) O
Background O
: O
Time O
- O
consuming O
SARS O
- O
CoV O
- O
2 O
RT O
- O
PCR O
suffers O
from O
limited O
sensitivity O
in O
early O
infection O
stages O
whereas O
fast O
available O
chest O
CT O
can O
already O
raise O
COVID O
- O
19 O
suspicion O
. O

Newly O
Discovered O
Cellular O
Pathway O
Blocks O
Ebola O
, O
COVID O
- O
19 O
Viruses O
. O

We O
focused O
on O
the O
spread O
of O
COVID O
- O
19 O
and O
influenza O
infections O
based O
on O
reported O
COVID O
- O
19 O
cases O
and O
influenza O
surveillance O
data O
, O
and O
investigated O
the O
changes O
in O
human O
behaviour O
due O
to O
COVID O
- O
19 O
based O
on O
mass O
transit O
railway O
data O
and O
the O
data O
from O
a O
telephone O
survey O
. O

Therefore O
, O
the O
objective O
of O
this O
research O
was O
to O
estimate O
the O
individual O
' O
s O
willingness O
to O
pay O
( O
WTP O
) O
for O
a O
hypothetical O
COVID O
- O
19 O
vaccine O
and O
, O
at O
the O
same O
time O
, O
find O
the O
main O
factors O
that O
determine O
this O
valuation O
. O

During O
the O
first O
wave O
of O
the O
COVID O
- O
19 O
pandemic O
, O
social O
distancing O
and O
hand O
hygiene O
have O
been O
the O
primary O
means O
of O
reducing O
transmission O
in O
the O
absence O
of O
effective O
treatments O
or O
vaccines O
, O
but O
understanding O
of O
their O
determinants O
is O
limited O
. O

TBI O
incidence O
remained O
increasing O
despite O
entering O
the O
COVID O
- O
19 O
era O
. O

Overall O
, O
these O
results O
demonstrate O
for O
the O
first O
time O
the O
involvement O
of O
the O
PPAR O
γ O
complex O
in O
severe O
COVID O
- O
19 O
lung O
disease O
and O
suggest O
strongly O
its O
role O
in O
the O
major O
monocyte O
/ O
macrophage O
- O
mediated O
inflammatory O
storm O
. O

The O
authors O
are O
from O
different O
countries O
with O
the O
COVID O
- O
19 O
pandemic O
in O
different O
stages O
. O

A O
dedicated O
machine O
for O
COVID O
- O
19 O
suspected O
/ O
confirmed O
cases O
is O
recommended O
. O

COVID O
- O
19 O
pandemic O
had O
changed O
spine O
surgeons O
' O
clinical O
practices O
and O
their O
concerns O
toward O
personal O
and O
family O
risk O
of O
infection O
. O

Also O
, O
in O
view O
of O
the O
vulnerable O
nature O
of O
healthcare O
professionals O
for O
developing O
mental O
health O
concerns O
in O
the O
course O
of O
providing O
services O
for O
COVID O
- O
19 O
- O
affected O
individuals O
, O
future O
psychometric O
research O
needs O
to O
concentrate O
on O
the O
development O
of O
measures O
specific O
for O
these O
professionals O
. O

We O
coupled O
these O
data O
with O
symptom O
reports O
and O
COVID O
- O
19 O
diagnosis O
data O
. O

Materials O
and O
Methods O
Single O
- O
center O
, O
retrospective O
cohort O
study O
of O
21 O
ICU O
patients O
with O
severe O
COVID O
- O
19 O
respiratory O
disease O
treated O
with O
apixaban O
for O
atrial O
fibrillation O
( O
AFib O
) O
, O
venous O
thromboembolism O
( O
VTE O
) O
, O
catheter O
- O
induced O
thrombosis O
, O
and O
/ O
or O
COVID O
- O
19 O
- O
induced O
coagulopathy O
. O

In O
the O
COVID O
- O
19 O
regional O
reference O
hospital O
, O
only O
3 O
out O
of O
20 O
samples O
were O
positive O
for O
SARS O
- O
CoV O
- O
2 O
RNA O
. O

An O
electronic O
survey O
( O
NCT04395755 O
) O
was O
e O
- O
mailed O
between O
April O
and O
June O
2020 O
to O
couples O
whose O
IVF O
treatments O
have O
been O
interrupted O
or O
postponed O
due O
to O
the O
COVID O
- O
19 O
pandemic O
. O

In O
- O
Frame O
12 O
- O
Nucleotide O
Deletion O
within O
Open O
Reading O
Frame O
3a O
in O
a O
SARS O
- O
CoV O
- O
2 O
Strain O
Isolated O
from O
a O
Patient O
Hospitalized O
with O
COVID O
- O
19 O
. O

Approximately O
43 O
% O
of O
patients O
had O
severe O
COVID O
- O
19 O
infection O
, O
and O
approximately O
11 O
% O
died O
. O

To O
evaluate O
the O
prevalence O
and O
the O
clinical O
association O
of O
aPL O
in O
a O
large O
cohort O
of O
COVID O
- O
19 O
patients O
, O
and O
to O
characterize O
the O
epitope O
specificity O
of O
anti O
- O
β O
2 O
GPI O
antibodies O
. O

COVID O
- O
19 O
Pandemic O
& O
Skin O
Care O
Guidelines O
for O
Health O
Care O
Professionals O
. O

These O
results O
highlight O
the O
uncertainties O
around O
the O
perception O
of O
a O
potential O
interference O
between O
ICIs O
and O
COVID O
- O
19 O
, O
supporting O
the O
need O
of O
focused O
studies O
on O
this O
topic O
. O

We O
propose O
that O
medications O
which O
inhibit O
the O
RAS O
ACE O
- O
dependent O
pathway O
may O
be O
beneficial O
in O
treating O
COVID O
- O
19 O
and O
should O
be O
explored O
in O
animal O
models O
and O
clinical O
trials O
. O

It O
could O
be O
prescribed O
for O
the O
treatment O
of O
MERS O
and O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
caused O
a O
nationwide O
disruption O
of O
APPE O
pharmacy O
education O
. O

Impact O
of O
COVID O
- O
19 O
Pandemic O
on O
Ovarian O
Cancer O
Management O
: O
Adjusting O
to O
the O
New O
Normal O
. O

In O
the O
current O
review O
, O
we O
focused O
on O
the O
neurological O
complications O
associated O
with O
COVID O
- O
19 O
. O

Serum O
IL O
- O
26 O
, O
a O
cytokine O
involved O
in O
IL O
- O
17 O
pathway O
, O
TSLP O
and O
adiponectin O
were O
measured O
and O
correlated O
to O
lipid O
COVID O
- O
19 O
patient O
profiles O
. O

During O
this O
first O
half O
of O
2020 O
, O
the O
COVID O
- O
19 O
pandemic O
has O
emerged O
as O
a O
poverty O
- O
related O
neglected O
disease O
on O
at O
least O
two O
fronts O
. O

Although O
crypto O
- O
azoospermia O
was O
found O
in O
a O
high O
percentage O
of O
men O
who O
had O
recovered O
from O
COVID O
- O
19 O
, O
clearly O
exceeding O
the O
percentage O
found O
in O
the O
general O
population O
, O
the O
previous O
semen O
quality O
of O
these O
men O
was O
unknown O
, O
nor O
is O
it O
known O
whether O
a O
recovery O
of O
testicular O
function O
was O
occurring O
. O

Innovations O
in O
practice O
: O
Adaptation O
of O
developmental O
and O
behavioral O
pediatric O
service O
in O
a O
tertiary O
center O
in O
Singapore O
during O
the O
COVID O
- O
19 O
pandemic O
. O

CMR O
is O
useful O
in O
assessing O
the O
prevalence O
, O
mechanism O
, O
and O
extent O
of O
myocardial O
injury O
in O
COVID O
- O
19 O
patients O
. O

The O
most O
recent O
theme O
added O
is O
that O
of O
Global O
crises O
, O
currently O
focusing O
on O
COVID O
- O
19 O
- O
related O
projects O
. O

However O
, O
knowledge O
of O
symptoms O
that O
are O
prognostic O
of O
COVID O
- O
19 O
severity O
is O
lacking O
. O

Fifty O
- O
four O
PLWH O
developed O
COVID O
- O
19 O
with O
14 O
severe O
( O
25 O
. O
9 O
% O
) O
and O
five O
critical O
cases O
( O
9 O
. O
3 O
% O
) O
, O
respectively O
. O

The O
cumulative O
occurrence O
rate O
of O
COVID O
- O
19 O
patients O
was O
0 O
. O
48 O
per O
0 O
. O
1 O
million O
person O
. O

Impact O
of O
ophthalmic O
webinars O
on O
the O
resident O
' O
s O
learning O
experience O
during O
COVID O
- O
19 O
pandemic O
: O
An O
insight O
into O
its O
present O
and O
future O
prospects O
. O

Comprehensive O
review O
of O
guidelines O
to O
practice O
prosthodontic O
and O
implant O
procedures O
during O
COVID O
- O
19 O
pandemic O
. O

On O
the O
other O
hand O
, O
new O
onset O
diabetes O
and O
severe O
metabolic O
complications O
of O
pre O
- O
existing O
diabetes O
, O
including O
diabetic O
ketoacidosis O
( O
DKA O
) O
have O
been O
observed O
in O
patients O
with O
COVID O
- O
19 O
. O

COVID O
- O
19 O
will O
only O
be O
suppressible O
when O
herd O
immunity O
develops O
, O
either O
because O
of O
an O
effective O
vaccine O
or O
if O
the O
population O
has O
been O
infected O
and O
is O
resistant O
to O
reinfection O
. O

Staying O
home O
during O
" O
COVID O
- O
19 O
" O
decreased O
fractures O
, O
but O
trauma O
did O
not O
quarantine O
in O
one O
hundred O
and O
twelve O
adults O
and O
twenty O
eight O
children O
and O
the O
" O
tsunami O
of O
recommendations O
" O
could O
not O
lockdown O
twelve O
elective O
operations O
. O

COVID O
- O
19 O
research O
in O
Africa O
. O

Management O
of O
patients O
with O
autoimmune O
liver O
disease O
during O
COVID O
- O
19 O
pandemic O
. O

Countermeasures O
adopted O
to O
prevent O
the O
spread O
of O
COVID O
- O
19 O
are O
analyzed O
in O
terms O
of O
external O
and O
internal O
categories O
, O
which O
were O
classified O
into O
six O
groups O
: O
passenger O
service O
, O
case O
care O
, O
information O
, O
staff O
, O
equipment O
and O
operation O
management O
. O

Invited O
commentary O
on O
" O
acute O
care O
surgery O
during O
the O
COVID O
- O
19 O
pandemic O
in O
Spain O
: O
Changes O
in O
volume O
, O
causes O
and O
complications O
. O
A O
multicenter O
retrospective O
cohort O
study O
" O
. O

Bioactive O
Lipids O
as O
Mediators O
of O
the O
Beneficial O
Action O
( O
s O
) O
of O
Mesenchymal O
Stem O
Cells O
in O
COVID O
- O
19 O
. O

Till O
to O
date O
, O
no O
epidemiological O
data O
on O
mental O
health O
problems O
due O
to O
outbreak O
of O
the O
COVID O
- O
19 O
and O
mass O
isolation O
were O
not O
available O
. O

Using O
daily O
time O
series O
of O
COVID O
- O
19 O
incidence O
, O
we O
illustrate O
how O
epidemic O
curves O
of O
reported O
cases O
may O
not O
always O
reflect O
the O
true O
epidemic O
growth O
rate O
due O
to O
changes O
in O
testing O
rates O
, O
which O
could O
be O
influenced O
by O
limited O
diagnostic O
testing O
capacity O
during O
the O
early O
epidemic O
phase O
. O

Increase O
in O
reported O
domestic O
abuse O
in O
Integrated O
Sexual O
Health O
( O
ISH O
) O
services O
in O
London O
and O
Surrey O
during O
COVID O
- O
19 O
' O
lockdown O
' O
: O
successful O
application O
of O
national O
guidance O
on O
routine O
enquiry O
during O
rapid O
transition O
to O
remote O
telephone O
consultation O
( O
telemedicine O
) O
. O

Among O
hotspot O
counties O
, O
those O
with O
greater O
social O
vulnerability O
had O
higher O
COVID O
- O
19 O
incidence O
during O
the O
14 O
days O
after O
detection O
( O
212 O
- O
234 O
cases O
per O
100 O
, O
000 O
persons O
for O
highest O
SVI O
quartile O
versus O
35 O
- O
131 O
cases O
per O
100 O
, O
000 O
persons O
for O
other O
quartiles O
) O
. O

Information O
Typology O
in O
Coronavirus O
( O
COVID O
- O
19 O
) O
Crisis O
; O
a O
Commentary O
. O

COVID O
- O
19 O
Mitigation O
: O
Individual O
Freedom O
Should O
Not O
Impede O
Public O
Health O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
resulted O
in O
a O
significant O
decrease O
in O
volume O
of O
electrophysiology O
( O
EP O
) O
procedures O
. O

We O
conducted O
a O
cross O
- O
sectional O
survey O
to O
assess O
the O
extent O
and O
to O
identify O
the O
determinants O
of O
food O
insecurity O
and O
coping O
strategies O
in O
urban O
and O
rural O
households O
of O
Bangladesh O
during O
the O
month O
- O
long O
, O
COVID O
- O
19 O
lockdown O
period O
. O

Effect O
- O
size O
estimates O
are O
summarized O
as O
odds O
ratio O
( O
OR O
) O
and O
95 O
% O
confidence O
interval O
( O
CI O
) O
. O
326 O
patients O
were O
diagnosed O
with O
mild O
or O
ordinary O
COVID O
- O
19 O
, O
and O
44 O
with O
severe O
or O
critical O
COVID O
- O
19 O
. O

This O
systemic O
review O
and O
meta O
- O
analysis O
summaries O
the O
latest O
evidence O
from O
available O
data O
and O
determine O
the O
hematological O
abnormality O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
and O
potential O
efficacy O
on O
the O
outcomes O
in O
patients O
with O
COVID O
- O
19 O
. O

Analyzing O
the O
survival O
of O
older O
people O
hospitalized O
due O
to O
COVID O
- O
19 O
in O
Brazil O
and O
identifying O
its O
main O
predictive O
factors O
for O
death O
. O

Coronavirus O
( O
COVID O
- O
19 O
) O
pandemic O
has O
created O
an O
unprecedented O
loss O
and O
disruptions O
over O
all O
across O
the O
world O
. O

We O
describe O
the O
first O
confirmed O
case O
of O
COVID O
- O
19 O
disease O
in O
C O
ó O
rdoba O
( O
Argentina O
) O
, O
which O
presented O
in O
a O
patient O
without O
comorbidities O
in O
good O
clinical O
condition O
, O
and O
therefore O
ambulatory O
management O
using O
telemedicine O
was O
decided O
, O
which O
was O
satisfactory O
. O

We O
measured O
COVID O
- O
19 O
fear O
, O
along O
with O
anxiety O
, O
stress O
, O
and O
depression O
levels O
( O
DASS21 O
) O
and O
demographics O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
causes O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
a O
newly O
emerging O
human O
infectious O
disease O
. O

To O
uncover O
the O
sources O
of O
SARS O
- O
CoV O
- O
2 O
introductions O
and O
patterns O
of O
spread O
within O
the O
U O
. O
S O
. O
, O
we O
sequenced O
nine O
viral O
genomes O
from O
early O
reported O
COVID O
- O
19 O
patients O
in O
Connecticut O
. O

We O
explored O
the O
impact O
of O
the O
COVID O
- O
19 O
- O
related O
first O
lockdown O
and O
resulting O
school O
closure O
by O
surveying O
parents O
whose O
children O
attended O
three O
special O
schools O
in O
Bedford O
, O
UK O
. O

Using O
prospectively O
collected O
multicentric O
data O
, O
we O
showed O
that O
the O
ICU O
- O
BSI O
risk O
was O
higher O
for O
COVID O
- O
19 O
than O
non O
- O
COVID O
- O
19 O
critically O
ill O
patients O
after O
seven O
days O
of O
ICU O
stay O
. O

Department O
of O
Homeland O
Security O
( O
DHS O
) O
, O
CDC O
instituted O
an O
enhanced O
entry O
risk O
assessment O
and O
management O
( O
screening O
) O
program O
for O
air O
passengers O
arriving O
from O
certain O
countries O
with O
widespread O
, O
sustained O
transmission O
of O
SARS O
- O
CoV O
- O
2 O
, O
the O
virus O
that O
causes O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Prospective O
observational O
study O
of O
PCR O
- O
confirmed O
COVID O
- O
19 O
adults O
with O
symptoms O
of O
lower O
respiratory O
tract O
infection O
in O
the O
emergency O
department O
( O
ED O
) O
of O
Lausanne O
University O
Hospital O
. O

COVID O
- O
19 O
and O
treating O
incarcerated O
populations O
for O
opioid O
use O
disorder O
. O

To O
compare O
the O
anxiety O
of O
internal O
medicine O
residents O
treating O
COVID O
- O
19 O
patients O
at O
a O
level O
- O
3 O
hospital O
with O
a O
level O
- O
2 O
hospital O
. O

This O
study O
highlights O
that O
large O
scale O
prospective O
and O
randomized O
studies O
should O
be O
conducted O
in O
order O
to O
investigate O
the O
role O
of O
TKIs O
in O
the O
treatment O
of O
COVID O
- O
19 O
. O

Some O
( O
83 O
. O
2 O
% O
) O
of O
nurses O
reported O
significant O
prevention O
knowledge O
and O
treatment O
skills O
about O
COVID O
- O
19 O
, O
while O
7 O
. O
6 O
% O
had O
little O
knowledge O
about O
prevention O
. O

An O
unprecedented O
number O
of O
consumer O
problems O
has O
been O
caused O
by O
the O
COVID O
- O
19 O
pandemic O
, O
not O
least O
with O
regard O
to O
refunds O
of O
prepayments O
and O
the O
ability O
of O
consumers O
to O
keep O
up O
their O
monthly O
payments O
under O
loan O
and O
rental O
agreements O
. O

We O
then O
examined O
and O
compared O
two O
data O
sets O
to O
expand O
our O
landscape O
of O
risk O
factors O
and O
symptoms O
related O
to O
COVID O
- O
19 O
. O

To O
determine O
the O
characteristics O
of O
patients O
transported O
for O
confirmed O
or O
suspected O
COVID O
- O
19 O
, O
we O
included O
patient O
data O
from O
February O
2 O
, O
2020 O
, O
to O
May O
6 O
, O
2020 O
. O

A O
Review O
of O
Treatment O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
: O
Therapeutic O
Repurposing O
and O
Unmet O
Clinical O
Needs O
. O

The O
rate O
of O
vertical O
transmission O
is O
5 O
. O
3 O
% O
( O
1 O
. O
3 O
- O
16 O
) O
, O
and O
the O
rate O
of O
positive O
SARS O
- O
CoV O
- O
2 O
test O
for O
neonates O
born O
to O
mothers O
with O
COVID O
- O
19 O
is O
8 O
% O
( O
4 O
- O
16 O
) O
. O

Concerns O
and O
strategies O
for O
wastewater O
treatment O
during O
COVID O
- O
19 O
pandemic O
to O
stop O
plausible O
transmission O
. O

A O
year O
without O
touch O
: O
a O
reflection O
on O
physician O
- O
patient O
interaction O
during O
COVID O
- O
19 O
. O

Musculoskeletal O
Physical O
Therapy O
After O
COVID O
- O
19 O
: O
Time O
for O
a O
New O
" O
Normal O
" O
. O

The O
ongoing O
COVID O
- O
19 O
pandemic O
has O
caused O
rapid O
changes O
in O
the O
healthcare O
system O
. O

Of O
97 O
respondents O
( O
39 O
% O
) O
, O
95 O
( O
98 O
% O
) O
reported O
concern O
about O
the O
impact O
of O
COVID O
- O
19 O
on O
their O
health O
, O
and O
43 O
% O
felt O
their O
risk O
of O
contracting O
COVID O
- O
19 O
was O
above O
average O
; O
62 O
% O
reported O
concern O
about O
medication O
- O
induced O
COVID O
- O
19 O
risk O
, O
and O
11 O
% O
stopped O
medications O
because O
of O
COVID O
- O
19 O
. O

Will O
cases O
of O
leprosy O
reaction O
increase O
with O
COVID O
- O
19 O
infection O
? O

Determination O
of O
disease O
severity O
in O
COVID O
- O
19 O
patients O
using O
deep O
learning O
in O
chest O
X O
- O
ray O
images O
. O

We O
aimed O
to O
evaluate O
the O
diagnostic O
performance O
of O
serological O
testing O
in O
COVID O
- O
19 O
by O
providing O
summary O
sensitivity O
and O
specificity O
estimates O
with O
time O
from O
symptom O
onset O
. O

We O
also O
found O
that O
96 O
. O
1 O
% O
of O
IBD O
units O
advised O
their O
patients O
to O
maintain O
treatment O
if O
they O
were O
asymptomatic O
for O
COVID O
- O
19 O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
a O
novel O
infectious O
disease O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
, O
and O
responsible O
for O
a O
global O
pandemic O
. O

The O
medical O
, O
occupational O
, O
and O
COVID O
- O
19 O
exposure O
histories O
of O
participants O
were O
recorded O
via O
questionnaires O
. O

COVID O
- O
19 O
in O
pregnancy O
and O
the O
puerperium O
: O
A O
review O
for O
emergency O
physicians O
. O

We O
propose O
that O
every O
hospitalized O
patient O
with O
COVID O
- O
19 O
infection O
undergo O
a O
paired O
capillary O
BG O
assessment O
( O
pre O
- O
meal O
and O
2 O
- O
h O
post O
- O
meal O
) O
. O

Staff O
Morale O
and O
Well O
- O
Being O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

The O
purpose O
of O
this O
meta O
- O
analysis O
was O
to O
summarize O
the O
evidence O
on O
the O
association O
between O
hyperglycemia O
at O
admission O
and O
the O
development O
of O
COVID O
- O
19 O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
outbreak O
is O
proving O
to O
be O
an O
unprecedented O
disaster O
that O
lays O
its O
dark O
shadow O
on O
global O
health O
, O
economics O
and O
personal O
freedom O
. O

Our O
findings O
do O
not O
support O
the O
use O
of O
antimalarials O
as O
a O
prophylactic O
treatment O
of O
COVID O
- O
19 O
. O

In O
a O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
world O
, O
such O
time O
- O
lags O
feel O
intolerable O
. O

Robust O
serological O
assays O
are O
essential O
for O
long O
- O
term O
control O
of O
the O
COVID O
- O
19 O
pandemic O
. O

There O
is O
an O
urgent O
need O
for O
vaccines O
and O
antiviral O
drugs O
to O
combat O
the O
COVID O
- O
19 O
pandemic O
. O

Post O
Abortion O
Care O
and O
Management O
After O
Induced O
Abortion O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
A O
Chinese O
Expert O
Consensus O
. O

Given O
the O
status O
of O
adolescent O
mental O
health O
prior O
to O
COVID O
- O
19 O
and O
the O
impact O
of O
COVID O
- O
19 O
, O
health O
professionals O
and O
schools O
must O
partner O
together O
now O
to O
mitigate O
potentially O
deleterious O
health O
, O
mental O
health O
and O
education O
impacts O
for O
children O
and O
adolescents O
. O

The O
COVID O
- O
19 O
pandemic O
, O
which O
broke O
out O
in O
Wuhan O
in O
2019 O
, O
has O
become O
the O
global O
health O
crisis O
of O
our O
time O
. O

In O
this O
study O
, O
we O
found O
genetic O
evidence O
to O
support O
higher O
BMI O
as O
a O
causal O
risk O
factor O
for O
COVID O
- O
19 O
susceptibility O
and O
severity O
. O

Validation O
of O
visual O
acuity O
applications O
for O
teleophthalmology O
during O
COVID O
- O
19 O
. O

Currently O
, O
there O
is O
no O
definite O
treatment O
for O
COVID O
- O
19 O
patients O
. O

Due O
to O
the O
great O
demand O
for O
effective O
COVID O
- O
19 O
testing O
programmes O
to O
control O
the O
spread O
of O
the O
disease O
, O
we O
have O
suggested O
such O
a O
testing O
programme O
that O
includes O
a O
rapid O
RT O
- O
qPCR O
approach O
without O
RNA O
extraction O
. O

Most O
models O
developed O
to O
predict O
the O
spread O
of O
COVID O
- O
19 O
in O
the O
U O
. O
S O
. O
do O
not O
include O
population O
density O
explicitly O
. O

For O
example O
, O
a O
permanent O
unit O
increase O
of O
UVI O
is O
associated O
with O
a O
decrease O
of O
growth O
rates O
of O
COVID O
- O
19 O
deaths O
by O
33 O
% O
( O
= O
- O
1 O
. O
2 O
percentage O
points O
) O
However O
, O
the O
monsoon O
season O
, O
mitigates O
the O
protective O
role O
of O
UVI O
by O
77 O
% O
( O
0 O
. O
92 O
percentage O
points O
) O
. O

Our O
aim O
was O
to O
assess O
the O
immediate O
effects O
of O
national O
lockdown O
orders O
due O
to O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
on O
pediatric O
emergency O
room O
( O
ER O
) O
visits O
and O
respiratory O
tract O
infections O
in O
hospitals O
and O
nationwide O
in O
Finland O
. O

A O
retrospective O
study O
including O
548 O
patients O
with O
COVID O
- O
19 O
with O
clarified O
outcome O
( O
discharged O
or O
deceased O
) O
from O
a O
national O
cohort O
in O
China O
was O
performed O
. O

During O
the O
spread O
of O
the O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
internet O
hospitals O
in O
China O
were O
engaged O
with O
epidemic O
prevention O
and O
control O
, O
offering O
epidemic O
- O
related O
online O
services O
and O
medical O
support O
to O
the O
public O
. O

As O
of O
1st O
June O
2020 O
, O
the O
US O
Centres O
for O
Disease O
Control O
and O
Prevention O
reported O
104 O
, O
232 O
confirmed O
or O
probable O
COVID O
- O
19 O
- O
related O
deaths O
in O
the O
US O
. O

SOT O
recipients O
may O
be O
at O
high O
risk O
from O
COVID O
- O
19 O
disease O
due O
to O
chronic O
immunosuppressive O
treatment O
and O
other O
medical O
comorbidities O
. O

We O
hypothesize O
that O
low O
sodium O
status O
makes O
kidney O
involvement O
during O
the O
course O
of O
COVID O
- O
19 O
infection O
more O
likely O
due O
to O
upregulation O
of O
membrane O
bound O
ACE2 O
in O
the O
kidneys O
. O

The O
median O
Ct O
value O
of O
29 O
. O
0 O
among O
outpatients O
with O
COVID O
- O
19 O
did O
not O
significantly O
differ O
from O
HCW O
. O

Intermediate O
dose O
thromboprophylaxis O
more O
effectively O
inhibited O
TG O
in O
severe O
COVID O
- O
19 O
patients O
by O
increasing O
ETP O
inhibition O
via O
ETP O
with O
TM O
reduction O
vs O
. O
standard O
dose O
. O

Freely O
available O
data O
on O
ECMO O
in O
COVID O
- O
19 O
patients O
reported O
by O
the O
European O
Extracorporeal O
Life O
Support O
Organization O
( O
EuroELSO O
) O
were O
extracted O
and O
analyzed O
after O
conversion O
into O
long O
format O
. O

The O
ongoing O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
, O
represents O
a O
potentially O
major O
challenge O
to O
patients O
with O
immune O
- O
mediated O
inflammatory O
diseases O
who O
are O
treated O
with O
immunomodulatory O
therapies O
. O

In O
response O
to O
urgent O
needs O
for O
updated O
evidence O
for O
decision O
- O
making O
on O
various O
aspects O
related O
to O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
the O
Norwegian O
Institute O
of O
Public O
Health O
established O
a O
rapid O
review O
team O
. O

Two O
scenarios O
were O
identified O
: O
( O
a O
) O
patients O
who O
were O
admitted O
to O
a O
hospital O
for O
an O
acute O
surgical O
condition O
with O
a O
concomitant O
diagnosis O
of O
COVID O
- O
19 O
, O
and O
( O
b O
) O
patients O
with O
severe O
COVID O
- O
19 O
developing O
acute O
abdominal O
pathologies O
during O
their O
hospital O
stay O
. O

Data O
analysis O
found O
a O
correlation O
between O
clinical O
admission O
parameters O
and O
in O
- O
hospital O
mortality O
for O
COVID O
- O
19 O
patients O
. O

The O
benefits O
of O
Tocilizumab O
for O
severely O
infected O
COVID O
- O
19 O
patients O
and O
the O
methodologies O
of O
ongoing O
clinical O
trials O
are O
explored O
. O

This O
study O
may O
help O
in O
predicting O
disease O
progression O
and O
designing O
immunotherapy O
for O
COVID O
- O
19 O
. O

COVID O
- O
19 O
infection O
also O
aggravates O
sarcopenia O
because O
of O
the O
increased O
muscle O
wasting O
caused O
by O
systematic O
inflammation O
and O
the O
reduced O
physical O
activity O
and O
inadequate O
nutrient O
intake O
caused O
by O
social O
isolation O
. O

Parenting O
in O
the O
time O
of O
COVID O
- O
19 O
. O

At O
the O
same O
time O
, O
exploring O
the O
relationship O
between O
covariates O
and O
the O
network O
of O
PTSD O
symptoms O
, O
by O
taking O
sex O
, O
anxiety O
, O
depression O
, O
suicidal O
ideation O
, O
quality O
of O
life O
, O
and O
social O
support O
as O
covariates O
, O
may O
help O
us O
to O
know O
the O
arise O
and O
maintenance O
of O
PTSD O
symptoms O
and O
give O
specified O
suggestions O
to O
people O
under O
the O
shadow O
of O
COVID O
- O
19 O
. O

Therefore O
, O
this O
study O
aimed O
: O
( O
i O
) O
to O
reiterate O
the O
importance O
of O
the O
autoptic O
examination O
, O
the O
only O
method O
able O
to O
precisely O
define O
the O
cause O
of O
death O
; O
( O
ii O
) O
to O
provide O
a O
complete O
post O
- O
mortem O
histological O
and O
immunohistochemical O
investigation O
pattern O
capable O
of O
diagnosing O
death O
from O
COVID O
- O
19 O
infection O
. O
( O
2 O
) O
Methods O
: O
In O
this O
paper O
, O
the O
lung O
examination O
of O
two O
subjects O
who O
died O
from O
COVID O
- O
19 O
are O
discussed O
, O
comparing O
the O
obtained O
data O
with O
those O
of O
the O
control O
, O
a O
newborn O
who O
died O
from O
pneumonia O
in O
the O
same O
pandemic O
period O
. O
( O
3 O
) O

Results O
: O
The O
results O
of O
the O
present O
study O

It O
was O
found O
that O
this O
type O
of O
newly O
revolving O
pandemic O
infection O
mainly O
infects O
the O
human O
respiratory O
tract O
causing O
mild O
to O
moderate O
symptoms O
, O
however O
, O
the O
hidden O
door O
side O
of O
COVID O
- O
19 O
is O
via O
penetrating O
the O
brain O
, O
revealing O
a O
huge O
threat O
especially O
to O
elderly O
people O
who O
are O
more O
susceptible O
to O
its O
severe O
side O
effects O
and O
even O
death O
to O
more O
extent O
. O

The O
COVID O
- O
19 O
pandemic O
has O
had O
serious O
health O
, O
economic O
and O
psychosocial O
consequences O
. O

Infection O
with O
SARS O
- O
CoV O
- O
2 O
, O
which O
caused O
the O
world O
- O
wide O
COVID O
- O
19 O
pandemic O
, O
involves O
airway O
smooth O
muscles O
and O
their O
surrounding O
inflammatory O
environment O
. O

Forty O
- O
one O
of O
305 O
hospitalized O
COVID O
- O
19 O
patients O
( O
13 O
. O
4 O
% O
) O
received O
transfusions O
with O
11 O
. O
1 O
% O
receiving O
red O
blood O
cells O
( O
RBCs O
) O
, O
1 O
. O
6 O
% O
platelets O
( O
PLTs O
) O
, O
1 O
. O
0 O
% O
plasma O
, O
and O
1 O
. O
0 O
% O
cryoprecipitate O
( O
cryo O
) O
. O

The O
readily O
availability O
of O
TLR9 O
modulating O
drug O
candidates O
that O
have O
reached O
clinical O
testing O
for O
other O
disorders O
could O
favor O
a O
fast O
track O
development O
scenario O
, O
an O
important O
advantage O
under O
the O
current O
high O
unmet O
medical O
need O
circumstances O
regarding O
COVID O
- O
19 O
. O

While O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
multiple O
devastating O
public O
health O
and O
socio O
- O
economic O
effects O
across O
the O
world O
, O
Nigeria O
along O
with O
other O
West O
African O
countries O
is O
simultaneously O
faced O
with O
a O
recurrent O
Lassa O
fever O
epidemic O
. O

Epidemiological O
pattern O
of O
orthopaedic O
fracture O
during O
the O
COVID O
- O
19 O
pandemic O
: O
A O
systematic O
review O
and O
meta O
- O
analysis O
. O

Nine O
did O
not O
have O
fever O
and O
were O
diagnosed O
with O
COVID O
- O
19 O
upon O
admission O
for O
stroke O
. O

COVID O
- O
19 O
patients O
were O
additionally O
compared O
to O
an O
historical O
group O
of O
hospitalised O
influenza O
patients O
. O

Evidence O
suggests O
lungs O
as O
the O
organ O
most O
affected O
by O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

An O
89 O
- O
Year O
- O
Old O
Man O
with O
COVID O
- O
19 O
- O
Associated O
Coagulopathy O
Presenting O
with O
a O
Prolonged O
Partial O
Thromboplastin O
Time O
, O
Lupus O
Anticoagulant O
, O
and O
a O
High O
Titer O
of O
Factor O
VIII O
Inhibitor O
. O

This O
study O
adapted O
an O
8 O
- O
item O
COVID O
- O
19 O
Perceived O
Risk O
Scale O
( O
CPRS O
) O
to O
assess O
COVID O
- O
19 O
related O
personal O
risk O
. O

In O
the O
wake O
of O
the O
COVID O
- O
19 O
which O
has O
forced O
many O
countries O
and O
educational O
sectors O
to O
adopt O
online O
learning O
, O
there O
is O
a O
need O
to O
discuss O
the O
effectiveness O
of O
online O
learning O
and O
barriers O
to O
online O
learning O
in O
the O
developing O
contexts O
, O
and O
how O
to O
successfully O
integrate O
ICT O
in O
schools O
for O
online O
learning O
, O
especially O
rural O
schools O
where O
students O
' O
educational O
careers O
are O
in O
jeopardy O
because O
they O
benefit O
less O
from O
online O
learning O
. O

Multiple O
linear O
regression O
analysis O
showed O
that O
the O
knowledge O
, O
attitude O
and O
behavior O
on O
COVID O
- O
19 O
were O
mostly O
influenced O
by O
education O
background O
( O
all O
P O
< O
0 O
. O
05 O
) O
, O
and O
the O
independent O
factors O
affecting O
behavior O
included O
knowledge O
and O
attitude O
, O
gender O
, O
permanent O
residence O
, O
education O
background O
( O
all O
P O
< O
0 O
. O
05 O
) O
. O

Global O
data O
correlates O
severe O
VDD O
with O
COVID O
- O
19 O
associated O
coagulopathy O
, O
disrupted O
immune O
response O
and O
mortality O
, O
reduced O
platelet O
count O
, O
and O
prolonged O
prothrombin O
time O
, O
together O
suggesting O
benefits O
from O
supplementation O
. O

Specifically O
, O
the O
use O
of O
informatics O
to O
mitigate O
the O
spread O
of O
SARS O
- O
CoV O
- O
2 O
, O
support O
COVID O
- O
19 O
care O
delivery O
, O
and O
accelerate O
knowledge O
discovery O
bring O
to O
the O
forefront O
issues O
of O
privacy O
, O
surveillance O
, O
limits O
of O
state O
powers O
, O
and O
interoperability O
between O
public O
health O
and O
clinical O
information O
systems O
. O

Background O
: O
Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
has O
affected O
people O
' O
s O
lives O
globally O
. O

Acetyl O
- O
l O
- O
Carnitine O
and O
New O
- O
Onset O
Psychosis O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

A O
novel O
coronavirus O
, O
which O
has O
been O
designated O
as O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
was O
first O
detected O
in O
December O
2019 O
in O
Wuhan O
China O
and O
causes O
the O
highly O
infectious O
disease O
referred O
to O
as O
COVID O
- O
19 O
. O

Eighty O
- O
seven O
percent O
of O
the O
participating O
hospitals O
had O
to O
reduce O
their O
total O
surgical O
caseload O
and O
34 O
% O
their O
surgical O
volume O
for O
oncological O
colorectal O
patients O
during O
COVID O
- O
19 O
pandemic O
. O

Preventive O
behavior O
of O
Vietnamese O
people O
in O
response O
to O
the O
COVID O
- O
19 O
pandemic O
. O

Inspection O
of O
COVID O
- O
19 O
disease O
severity O
outcomes O
reveal O
nominally O
significant O
risk O
associations O
with O
A O
* O
11 O
: O
01 O
( O
FET O
p O
= O
0 O
. O
0078 O
) O
, O
C O
* O
04 O
: O
01 O
( O
FET O
p O
= O
0 O
. O
0087 O
) O
and O
DQA1 O
* O
01 O
: O
02 O
( O
FET O
p O
= O
0 O
. O
0121 O
) O
. O

Unusual O
prolonged O
dermatological O
symptoms O
from O
recovered O
COVID O
- O
19 O
patients O
have O
rarely O
been O
recorded O
. O

Early O
effects O
of O
the O
COVID O
- O
19 O
pandemic O
on O
physical O
activity O
locations O
and O
behaviors O
in O
adults O
living O
in O
the O
United O
States O
. O

Therefore O
, O
mechanisms O
underlying O
immune O
abnormalities O
in O
patients O
with O
COVID O
- O
19 O
must O
be O
elucidated O
to O
guide O
clinical O
management O
of O
the O
disease O
. O

[ O
Analysis O
of O
medication O
characteristics O
of O
traditional O
Chinese O
medicine O
in O
treating O
COVID O
- O
19 O
based O
on O
data O
mining O
] O
. O

Design O
of O
COVID O
- O
19 O
Staged O
Alert O
Systems O
to O
Ensure O
Healthcare O
Capacity O
with O
Minimal O
Closures O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
led O
to O
a O
policy O
of O
severe O
restrictions O
in O
almost O
all O
countries O
strongly O
involved O
by O
the O
pandemic O
. O

We O
present O
a O
young O
woman O
with O
COVID O
- O
19 O
infection O
with O
haemodynamic O
instability O
caused O
by O
acute O
perimyocarditis O
and O
cardiac O
tamponade O
. O

COVID O
- O
19 O
has O
posed O
a O
real O
pandemic O
risk O
management O
challenge O
in O
terms O
of O
impact O
, O
preparedness O
, O
response O
, O
and O
mitigation O
by O
governments O
, O
health O
organizations O
, O
non O
- O
governmental O
organizations O
( O
NGOs O
) O
, O
mass O
media O
, O
and O
stakeholders O
. O

COVID O
- O
19 O
has O
led O
to O
the O
closure O
of O
various O
schools O
in O
Japan O
to O
cope O
with O
the O
pandemic O
. O

Some O
strategies O
are O
recommended O
that O
have O
been O
used O
by O
professionals O
who O
have O
previously O
been O
under O
pressure O
from O
COVID O
- O
19 O
and O
have O
been O
helpful O
to O
them O
. O

Less O
social O
emergency O
departments O
: O
implementation O
of O
workplace O
contact O
reduction O
during O
COVID O
- O
19 O
. O

Divide O
and O
Conquer O
: O
Strategies O
in O
Singapore O
to O
Manage O
a O
Nuclear O
Medicine O
Department O
During O
COVID O
- O
19 O
. O

The O
Consequences O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
Non O
- O
COVID O
- O
19 O
Clinical O
Trials O
. O

Pulmonary O
Embolism O
in O
Patients O
Hospitalized O
With O
COVID O
- O
19 O
( O
From O
a O
New O
York O
Health O
System O
) O
. O

Chest O
CT O
imaging O
is O
a O
quite O
valuable O
tool O
in O
patients O
with O
longer O
than O
2 O
days O
' O
duration O
of O
symptoms O
, O
in O
whom O
clinical O
and O
epidemiological O
data O
support O
the O
diagnosis O
of O
COVID O
- O
19 O
infection O
. O

Thrombosis O
and O
COVID O
- O
19 O
pneumonia O
: O
the O
clot O
thickens O
! O

Adverse O
mental O
health O
effects O
of O
COVID O
- O
19 O
are O
evident O
after O
discharge O
from O
the O
hospital O
, O
with O
sleep O
difficulties O
highlighted O
as O
a O
central O
issue O
. O

With O
the O
new O
process O
, O
the O
percentage O
of O
patients O
with O
COVID O
- O
19 O
testing O
results O
returned O
before O
surgery O
increased O
from O
10 O
% O
to O
100 O
% O
. O

We O
argue O
that O
one O
of O
the O
greatest O
problems O
with O
regard O
to O
the O
COVID O
- O
19 O
pandemic O
in O
the O
context O
of O
slums O
in O
the O
Global O
South O
is O
the O
lack O
of O
data O
on O
the O
number O
of O
people O
, O
their O
living O
conditions O
, O
and O
their O
health O
status O
. O

Ethical O
and O
legal O
aspects O
pertinent O
to O
triage O
of O
this O
resource O
- O
intensive O
, O
but O
potentially O
life O
- O
saving O
, O
therapy O
in O
the O
setting O
of O
the O
COVID O
- O
19 O
pandemic O
are O
reviewed O
here O
. O

Currently O
, O
no O
potent O
medicine O
is O
available O
to O
treat O
COVID O
- O
19 O
. O

Letter O
to O
the O
Editor O
: O
Possible O
Drug O
- O
Drug O
Interactions O
Between O
Cannabinoids O
and O
Candidate O
COVID O
- O
19 O
Drugs O
. O

Furthermore O
, O
these O
precautions O
may O
help O
control O
the O
spread O
of O
COVID O
- O
19 O
within O
the O
healthcare O
facility O
. O

Prolonged O
Critical O
Illness O
and O
Demoralization O
: O
Curative O
Factors O
in O
Hospice O
Care O
in O
the O
Age O
of O
COVID O
- O
19 O
. O

The O
morbidity O
rate O
, O
severity O
rate O
, O
case O
- O
fatality O
rate O
, O
and O
spread O
ratio O
of O
COVID O
- O
19 O
were O
calculated O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
a O
novel O
infectious O
disease O
and O
became O
a O
global O
issue O
. O

Silent O
hypoxemia O
might O
be O
considered O
as O
an O
early O
sign O
of O
deterioration O
of O
COVID O
- O
19 O
patients O
, O
thus O
, O
physician O
may O
be O
able O
to O
intervene O
early O
and O
decrease O
its O
morbidity O
and O
mortality O
. O

Answering O
to O
the O
Call O
of O
Critically O
Ill O
Patients O
: O
Limiting O
Sonographer O
Exposure O
to O
COVID O
- O
19 O
with O
Focused O
Protocols O
. O

Many O
U O
. O
S O
. O
states O
and O
cities O
have O
imposed O
water O
disconnection O
moratoriums O
during O
the O
COVID O
- O
19 O
pandemic O
. O

[ O
COVID O
- O
19 O
- O
Response O
- O
Strategies O
of O
the O
Task O
- O
Force O
Coronavirus O
and O
experiences O
upon O
implementation O
in O
the O
management O
of O
115 O
cases O
at O
the O
University O
Medical O
Center O
Freiburg O
] O
. O

The O
epidemiological O
characteristics O
and O
early O
clinical O
features O
of O
the O
28 O
patients O
from O
Korea O
with O
confirmed O
COVID O
- O
19 O
were O
analyzed O
using O
COVID O
- O
19 O
reporting O
and O
surveillance O
data O
and O
the O
epidemiological O
investigation O
reports O
prepared O
by O
the O
rapid O
response O
team O
. O

All O
the O
patients O
were O
symptomatic O
for O
COVID O
- O
19 O
, O
with O
cough O
and O
fever O
as O
the O
most O
frequently O
reported O
symptoms O
. O

Outbreaks O
of O
an O
epidemic O
, O
such O
as O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
always O
brings O
about O
far O
- O
ranging O
discrimination O
and O
stigmatization O
to O
the O
epicenter O
. O

This O
model O
for O
tonsillectomy O
is O
a O
simple O
, O
inexpensive O
model O
for O
training O
postgraduate O
residents O
during O
and O
after O
the O
COVID O
- O
19 O
pandemic O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
infection O
has O
now O
reached O
a O
pandemic O
state O
, O
affecting O
more O
than O
a O
million O
patients O
worldwide O
. O

Encephalopathy O
in O
patients O
with O
COVID O
- O
19 O
: O
A O
review O
. O

Mapping O
COVID O
- O
19 O
related O
research O
from O
Saudi O
Arabia O
, O
a O
scoping O
review O
. O
Between O
reality O
and O
dreams O
. O

La O
COVID O
- O
19 O
et O
les O
priorit O
é O
s O
de O
recherche O
sur O
le O
vieillissement O
. O

Information O
about O
the O
respondents O
' O
socioeconomic O
characteristics O
, O
knowledge O
of O
and O
attitudes O
towards O
COVID O
- O
19 O
, O
perceived O
uncertainty O
stress O
, O
social O
capital O
, O
anxiety O
, O
and O
depressive O
symptoms O
was O
collected O
and O
analysed O
. O

During O
the O
COVID O
- O
19 O
pandemic O
, O
between O
February O
and O
March O
2020 O
, O
159 O
endoscopic O
examinations O
and O
treatments O
were O
performed O
, O
including O
emergency O
endoscopy O
for O
17 O
patients O
. O

The O
survey O
collected O
quantitative O
data O
regarding O
life O
changes O
due O
to O
COVID O
- O
19 O
, O
health O
/ O
exposure O
status O
, O
and O
the O
impact O
on O
their O
cessation O
attempt O
( O
e O
. O
g O
. O
, O
motivation O
to O
quit O
, O
change O
in O
triggers O
) O
. O

Coronavirus O
disease O
- O
19 O
( O
COVID O
- O
19 O
) O
is O
associated O
with O
acute O
kidney O
injury O
( O
AKI O
) O
and O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
with O
high O
mortality O
rates O
. O

A O
number O
of O
mechanisms O
of O
action O
have O
been O
proposed O
for O
convalescent O
plasma O
, O
including O
direct O
neutralization O
and O
suppression O
of O
viremia O
, O
anti O
- O
inflammatory O
and O
immunomodulation O
effects O
and O
mitigation O
of O
the O
COVID O
- O
19 O
- O
associated O
hypercoagulable O
state O
. O

Understanding O
women O
' O
s O
risk O
for O
suicide O
during O
the O
COVID O
- O
19 O
pandemic O
: O
A O
call O
to O
action O
. O

To O
report O
on O
the O
gastrointestinal O
manifestations O
and O
pathological O
findings O
of O
patients O
with O
COVID O
- O
19 O
, O
and O
to O
discuss O
the O
possibility O
of O
faecal O
transmission O
. O

Extensive O
fibrin O
deposition O
in O
the O
lungs O
and O
altered O
levels O
of O
circulating O
blood O
coagulation O
proteins O
in O
COVID O
- O
19 O
patients O
imply O
local O
derangement O
of O
pathways O
that O
limit O
fibrin O
formation O
and O
/ O
or O
promote O
its O
clearance O
. O

The O
current O
COVID O
- O
19 O
pandemic O
further O
threatens O
to O
impact O
global O
TB O
control O
by O
diverting O
resources O
, O
reducing O
notifications O
and O
hence O
significantly O
increasing O
deaths O
attributable O
to O
TB O
( O
World O
Health O
Organization O
, O
2020 O
) O
. O

There O
is O
a O
wide O
spectrum O
of O
cardiac O
involvement O
in O
COVID O
- O
19 O
patients O
, O
and O
hence O
a O
Triage O
Risk O
Stratification O
Tool O
can O
serve O
as O
a O
guide O
for O
the O
timely O
recognition O
of O
the O
high O
- O
risk O
patients O
and O
mechanism O
- O
targeted O
therapy O
. O

Tobacco O
Quit O
Intentions O
and O
Behaviors O
among O
Cigar O
Smokers O
in O
the O
United O
States O
in O
Response O
to O
COVID O
- O
19 O
. O

Hence O
, O
we O
proposed O
to O
evaluate O
responses O
about O
COVID O
- O
19 O
among O
the O
health O
care O
workers O
( O
HCWs O
) O
as O
well O
as O
general O
public O
participants O
( O
GPPs O
) O
. O

With O
this O
model O
, O
we O
revealed O
insight O
into O
how O
COVID O
- O
19 O
was O
spread O
from O
the O
epicentre O
Wuhan O
to O
other O
regions O
in O
Mainland O
China O
based O
on O
the O
large O
population O
flow O
network O
data O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
associated O
with O
immune O
dysregulation O
and O
cytokine O
storm O
. O

[ O
Impact O
of O
the O
COVID O
- O
19 O
epidemic O
in O
Friuli O
Venezia O
Giulia O
Region O
( O
Northern O
Italy O
) O
: O
assessment O
of O
factors O
associated O
with O
the O
risk O
of O
death O
by O
competing O
risks O
analysis O
] O
. O

Optimal O
Dynamic O
Prioritization O
of O
Scarce O
COVID O
- O
19 O
Vaccines O
. O

Negative O
Impact O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
Admissions O
for O
Intracranial O
Hemorrhage O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
created O
an O
urgent O
need O
for O
therapeutics O
that O
inhibit O
the O
SARS O
- O
CoV O
- O
2 O
virus O
and O
suppress O
the O
fulminant O
inflammation O
characteristic O
of O
advanced O
illness O
. O

The O
COVID O
- O
19 O
pandemic O
remains O
a O
pressing O
concern O
to O
patients O
with O
cancer O
as O
countries O
enter O
the O
second O
peak O
of O
the O
pandemic O
and O
beyond O
. O

We O
published O
rapid O
advice O
guidelines O
and O
updated O
guidelines O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
management O
on O
February O
6 O
, O
2020 O
, O
and O
September O
4 O
, O
2020 O
, O
respectively O
. O

The O
impact O
of O
COVID O
- O
19 O
on O
the O
practice O
of O
dermatology O
in O
sub O
- O
Saharan O
Africa O
. O

Comments O
on O
psychological O
impact O
of O
COVID O
- O
19 O
lockdown O
: O
An O
online O
survey O
from O
India O
. O

The O
potential O
role O
of O
plasma O
exchange O
in O
COVID O
- O
19 O
patients O
without O
a O
positive O
diagnosis O
of O
TTP O
( O
the O
so O
- O
called O
' O
TTP O
resembling O
presentation O
' O
) O
is O
an O
area O
of O
further O
research O
. O

The O
symptom O
of O
" O
loss O
of O
smell O
" O
( O
OR O
: O
14 O
. O
7 O
, O
CI O
: O
8 O
. O
9 O
- O
24 O
. O
3 O
) O
was O
significantly O
higher O
in O
the O
COVID O
- O
19 O
group O
when O
compared O
to O
the O
control O
group O
. O

We O
show O
that O
self O
- O
reported O
surveys O
can O
be O
used O
to O
build O
predictive O
models O
to O
identify O
likely O
COVID O
- O
19 O
- O
positive O
individuals O
. O

Descriptive O
analysis O
of O
a O
comparison O
between O
lung O
ultrasound O
and O
chest O
radiography O
in O
patients O
suspected O
of O
COVID O
- O
19 O
. O

In O
6 O
months O
, O
more O
than O
25 O
million O
cases O
of O
infected O
people O
and O
more O
than O
890 O
, O
000 O
deaths O
by O
COVID O
- O
19 O
had O
been O
reported O
worldwide O
. O

Forty O
- O
six O
percent O
of O
respondents O
reported O
initially O
unrecognized O
non O
- O
COVID O
- O
19 O
diagnoses O
in O
patients O
admitted O
for O
COVID O
- O
19 O
evaluation O
; O
a O
similar O
number O
reported O
delayed O
identification O
of O
COVID O
- O
19 O
in O
patients O
admitted O
for O
other O
reasons O
. O

We O
also O
provide O
practical O
tips O
for O
qualitative O
researchers O
, O
including O
an O
exemplar O
of O
conducting O
qualitative O
research O
among O
vulnerable O
nurses O
in O
light O
of O
COVID O
- O
19 O
. O

Respondents O
who O
had O
at O
least O
one O
relative O
affected O
by O
COVID O
- O
19 O
had O
a O
significantly O
higher O
IES O
- O
R O
score O
and O
anxiety O
VAS O
, O
but O
not O
higher O
STAI O
scores O
, O
than O
patients O
belonging O
to O
unaffected O
families O
. O

During O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
the O
use O
of O
telemedicine O
changed O
from O
being O
an O
optional O
way O
to O
see O
patients O
to O
becoming O
a O
necessity O
. O

A O
comprehensive O
review O
of O
urology O
practice O
during O
the O
COVID O
- O
19 O
pandemic O
revealed O
changes O
in O
every O
aspect O
of O
practice O
. O

COVID O
- O
19 O
et O
continuit O
é O
des O
soins O
. O
Communiqu O
é O
de O
l O
’ O
Acad O
é O
mie O
nationale O
de O
m O
é O
decine O
et O
de O
l O
’ O
Acad O
é O
mie O
nationale O
de O
chirurgie O
. O

Accounting O
for O
population O
changes O
substantially O
reduced O
the O
excess O
non O
- O
COVID O
- O
19 O
death O
estimates O
, O
providing O
important O
information O
for O
guiding O
future O
clinical O
and O
public O
health O
interventions O
. O

The O
role O
of O
pharmacists O
and O
pharmacovigilance O
after O
the O
advent O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Critically O
ill O
COVID O
- O
19 O
patients O
showed O
hypercoagulability O
in O
ClotPro O
assays O
. O

We O
describe O
5 O
patients O
with O
DKA O
and O
concomitant O
COVID O
- O
19 O
admitted O
to O
the O
intensive O
care O
unit O
of O
an O
academic O
medical O
center O
. O

Application O
of O
artificial O
neural O
networks O
to O
predict O
the O
COVID O
- O
19 O
outbreak O
. O

The O
Weathering O
Framework O
is O
applied O
to O
demonstrate O
the O
dynamic O
interrelationships O
between O
these O
factors O
and O
to O
conceptualize O
COVID O
- O
19 O
as O
a O
stressful O
life O
event O
that O
will O
have O
profound O
health O
implications O
over O
the O
life O
course O
for O
African O
Americans O
. O

Angiotensin O
- O
Converting O
- O
Enzyme O
2 O
and O
Renin O
- O
Angiotensin O
System O
Inhibitors O
in O
COVID O
- O
19 O
: O
An O
Update O
. O

Neonate O
Born O
to O
a O
Mother O
with O
a O
Diagnosis O
of O
Suspected O
Intra O
- O
Amniotic O
Infection O
versus O
COVID O
- O
19 O
or O
Both O
. O

Owing O
to O
the O
limited O
admission O
capacity O
and O
medical O
resources O
, O
increasing O
numbers O
of O
suspected O
cases O
of O
COVID O
- O
19 O
infection O
were O
difficult O
to O
confirm O
or O
treat O
. O

We O
found O
no O
consensus O
regarding O
the O
best O
diagnostic O
criteria O
for O
identifying O
a O
suspected O
case O
of O
COVID O
- O
19 O
. O

Fifty O
, O
24 O
- O
h O
small O
animal O
emergency O
veterinary O
hospital O
representatives O
were O
recruited O
to O
participate O
in O
weekly O
surveys O
in O
April O
2020 O
to O
catalog O
changes O
due O
to O
COVID O
- O
19 O
pandemic O
. O

Nine O
( O
18 O
% O
) O
patients O
with O
STEMI O
were O
diagnosed O
as O
having O
typical O
/ O
indeterminate O
features O
indicating O
COVID O
- O
19 O
involvement O
. O

Randomized O
controlled O
studies O
are O
necessary O
to O
further O
investigate O
the O
efficacy O
, O
safety O
and O
patient O
selection O
criteria O
for O
tocilizumab O
treatment O
in O
COVID O
- O
19 O
. O

[ O
Recommendations O
for O
the O
Treatment O
of O
Elderly O
Patients O
with O
COVID O
- O
19 O
from O
the O
Taskforce O
for O
Gerontopneumology O
] O
. O

Furthermore O
, O
in O
Western O
countries O
with O
positive O
rates O
of O
the O
PCR O
test O
of O
less O
than O
7 O
. O
0 O
% O
, O
the O
increase O
in O
NPDP O
was O
slowing O
- O
down O
two O
weeks O
after O
BPI O
, O
and O
subsequent O
NPDD O
was O
only O
15 O
% O
compared O
with O
those O
with O
higher O
positive O
rates O
, O
which O
suggested O
that O
the O
situation O
of O
testing O
might O
have O
affected O
the O
velocity O
of O
COVID O
- O
19 O
spread O
. O

The O
COVID O
- O
19 O
outbreak O
in O
Israel O
severely O
impacted O
compliance O
with O
anti O
- O
VEGF O
treatments O
. O

There O
is O
limited O
information O
on O
the O
clinical O
characteristics O
of O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
who O
are O
asymptomatic O
or O
have O
mild O
symptoms O
. O

There O
are O
no O
specific O
treatments O
for O
COVID O
- O
19 O
as O
yet O
, O
though O
a O
number O
are O
under O
evaluation O
, O
including O
experimental O
antivirals O
. O

This O
article O
evaluates O
the O
possible O
mechanism O
of O
actions O
of O
SARS O
- O
CoV O
- O
2 O
and O
present O
Nigeria O
based O
medicinal O
plants O
which O
have O
pharmacological O
and O
biological O
activities O
that O
can O
mitigate O
the O
hallmarks O
of O
the O
pathogenesis O
of O
COVID O
- O
19 O
. O

We O
conducted O
a O
retrospective O
observational O
cohort O
study O
of O
critically O
ill O
intubated O
patients O
with O
COVID O
- O
19 O
who O
were O
placed O
in O
the O
prone O
position O
between O
March O
18 O
, O
2020 O
and O
March O
31 O
, O
2020 O
. O

COVID O
- O
19 O
pandemic O
: O
Coroner O
' O
s O
database O
of O
death O
inquiries O
with O
clinical O
epidemiology O
and O
total O
and O
excess O
mortality O
analyses O
in O
the O
District O
of O
Kildare O
March O
to O
June O
2020 O
. O

Reply O
to O
: O
A O
key O
role O
for O
vitamin O
D O
binding O
protein O
in O
COVID O
- O
19 O
? O

A O
total O
of O
106 O
patients O
were O
treated O
in O
two O
COVID O
- O
19 O
healthcare O
centers O
in O
Russia O
. O
22 O
patients O
with O
SARS O
( O
+ O
) O
pneumonia O
at O
the O
stage O
of O
resolving O
the O
pathological O
lesion O
were O
admitted O
to O
rehabilitation O
using O
pulsed O
IR O
laser O
. O
14 O
patients O
with O
acute O
forms O
of O
COVID O
- O
19 O
were O
treated O
using O
LASMIK O
device O
: O
wavelength O
904 O
nm O
, O
pulsed O
mode O
, O
externally O
and O
ILBI O
- O
525 O
( O
intravenous O
laser O
blood O
illumination O
) O
+ O
LUVBI O
( O
ultraviolet O
laser O
blood O
illumination O
) O
. O
70 O
persons O
underwent O
preventive O
courses O
of O
noninvasive O
LLLT O
. O

During O
the O
rapid O
shift O
to O
substantial O
online O
learning O
for O
the O
COVID O
- O
19 O
pandemic O
, O
virtual O
collaboration O
tools O
like O
PIVOT O
may O
help O
health O
professions O
teachers O
to O
better O
support O
groups O
working O
virtually O
on O
scaffolded O
therapeutic O
reasoning O
tasks O
. O

The O
present O
study O
included O
patients O
treated O
in O
a O
university O
hospital O
with O
cardiac O
troponin O
I O
measurements O
and O
with O
suspected O
COVID O
- O
19 O
infection O
, O
confirmed O
or O
ruled O
out O
by O
polymerase O
chain O
reaction O
analysis O
. O

Conclusion O
: O
PVIG O
appears O
to O
be O
a O
potential O
and O
safe O
anti O
- O
inflammatory O
agent O
and O
can O
be O
recommended O
as O
a O
candidate O
medication O
for O
studies O
in O
COVID O
- O
19 O
patients O
. O

We O
draw O
on O
a O
subset O
of O
older O
adults O
from O
Global O
Behaviors O
and O
Perceptions O
in O
the O
COVID O
- O
19 O
Pandemic O
, O
a O
unique O
global O
online O
survey O
of O
13 O
, O
660 O
participants O
from O
62 O
countries O
. O

This O
was O
a O
complicated O
triplet O
pregnancy O
, O
in O
which O
, O
after O
maternal O
infection O
with O
COVID O
- O
19 O
, O
despite O
mild O
maternal O
symptoms O
, O
exacerbated O
placental O
insufficiency O
occurred O
in O
two O
of O
the O
fetuses O
, O
and O
the O
third O
fetus O
had O
a O
positive O
COVID O
- O
19 O
test O
after O
birth O
. O

A O
reduction O
was O
observed O
in O
the O
number O
of O
HAIs O
after O
the O
COVID O
- O
19 O
outbreak O
, O
and O
we O
assume O
that O
the O
dip O
in O
HAIs O
is O
associated O
with O
the O
improvement O
in O
hand O
hygiene O
practices O
in O
the O
recent O
months O
. O

COVID O
- O
19 O
patients O
with O
hypertension O
group O
were O
more O
likely O
to O
receive O
antibiotics O
( O
P O
= O
0 O
. O
035 O
) O
and O
corticosteroid O
therapies O
( O
P O
= O
0 O
. O
035 O
) O
. O

Our O
retrospective O
study O
aimed O
to O
report O
the O
prevalence O
of O
PE O
in O
patients O
with O
COVID O
- O
19 O
and O
severe O
respiratory O
failure O
( O
SRF O
) O
treated O
with O
intermediate O
- O
to O
full O
- O
dose O
enoxaparin O
. O

The O
COVID O
- O
19 O
pandemic O
has O
had O
a O
significant O
impact O
on O
many O
aspects O
of O
head O
and O
neck O
cancer O
( O
HNC O
) O
care O
. O

Global O
Evidence O
on O
the O
Determinants O
of O
Public O
Trust O
in O
Governments O
during O
the O
COVID O
- O
19 O
. O

A O
predictive O
score O
for O
COVID O
- O
19 O
diagnosis O
using O
clinical O
, O
laboratory O
and O
chest O
image O
data O
. O

2 O
· O
5 O
million O
more O
child O
marriages O
due O
to O
COVID O
- O
19 O
pandemic O
. O

The O
challenges O
faced O
by O
the O
Global O
South O
during O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
are O
compounded O
by O
the O
presence O
of O
informal O
settlements O
, O
which O
are O
typically O
densely O
populated O
and O
lacking O
in O
formalized O
sanitation O
infrastructure O
. O

This O
was O
a O
retrospective O
review O
using O
electronic O
records O
and O
laboratory O
data O
of O
adult O
patients O
admitted O
to O
the O
four O
Manchester O
University O
Foundation O
Trust O
Hospitals O
between O
March O
10 O
and O
April O
30 O
2020 O
with O
a O
diagnosis O
of O
COVID O
- O
19 O
. O

Finally O
, O
clinical O
studies O
showed O
that O
the O
level O
of O
IL6 O
was O
elevated O
in O
COVID O
- O
19 O
patients O
, O
and O
DYY O
can O
reduce O
its O
levels O
. O

The O
COVID O
- O
19 O
pandemic O
is O
among O
the O
deadliest O
infectious O
diseases O
to O
have O
emerged O
in O
recent O
history O
. O

In O
addition O
, O
the O
situation O
has O
also O
greatly O
influenced O
usual O
care O
in O
patients O
not O
infected O
with O
COVID O
- O
19 O
. O

Medical O
students O
seem O
to O
be O
aware O
of O
the O
COVID O
- O
19 O
pandemic O
and O
its O
consequences O
for O
academic O
and O
healthcare O
contexts O
. O

COVID O
- O
19 O
restrictions O
had O
a O
negative O
impact O
on O
the O
types O
of O
and O
overall O
PA O
levels O
MET O
- O
min O
/ O
week O
( O
p O
< O
0 O
. O
001 O
) O
. O

SARS O
- O
CoV O
- O
2 O
, O
the O
virus O
responsible O
for O
the O
current O
COVID O
- O
19 O
pandemic O
, O
displays O
a O
corona O
- O
shaped O
layer O
of O
spikes O
which O
play O
a O
fundamental O
role O
in O
the O
infection O
process O
. O

We O
find O
that O
the O
development O
of O
stress O
due O
to O
COVID O
- O
19 O
- O
induced O
lockdown O
is O
particularly O
because O
of O
mood O
swings O
. O

The O
History O
of O
Methylprednisolone O
, O
Ascorbic O
Acid O
, O
Thiamine O
, O
and O
Heparin O
Protocol O
and O
I O
- O
MASK O
+ O
Ivermectin O
Protocol O
for O
COVID O
- O
19 O
. O

This O
has O
caused O
interruptions O
in O
care O
, O
complication O
management O
, O
drug O
pick O
- O
up O
alongside O
the O
almost O
neglected O
silent O
NCD O
epidemic O
, O
with O
major O
consequences O
for O
the O
health O
system O
post O
the O
COVID O
- O
19 O
era O
. O

This O
multinational O
task O
force O
recommends O
early O
, O
bedside O
rehabilitation O
for O
patients O
affected O
by O
severe O
COVID O
- O
19 O
. O

This O
case O
report O
emphasizes O
the O
need O
for O
a O
cautious O
and O
close O
follow O
- O
up O
period O
for O
asymptomatic O
neonates O
born O
to O
mothers O
with O
COVID O
- O
19 O
infection O
. O

Experimental O
Pharmacotherapy O
for O
COVID O
- O
19 O
: O
The O
Latest O
Advances O
. O

The O
COVID O
- O
19 O
pandemic O
, O
caused O
by O
the O
SARS O
- O
CoV O
- O
2 O
virus O
, O
has O
been O
growing O
at O
an O
accelerating O
rate O
, O
and O
has O
become O
a O
public O
health O
emergency O
. O

From O
the O
experimental O
results O
and O
statistical O
validation O
, O
it O
can O
be O
said O
that O
the O
proposed O
models O
use O
simple O
linkage O
functions O
and O
provide O
highly O
reliable O
results O
for O
time O
series O
prediction O
of O
COVID O
- O
19 O
in O
these O
countries O
. O

The O
aim O
of O
this O
study O
was O
to O
analyze O
the O
clinical O
data O
, O
discharge O
rate O
, O
and O
fatality O
rate O
of O
COVID O
- O
19 O
patients O
for O
clinical O
help O
. O

However O
, O
this O
relies O
upon O
adequate O
safety O
measures O
being O
taken O
with O
regards O
to O
screening O
for O
COVID O
- O
19 O
antigen O
positivity O
in O
patients O
preoperatively O
. O

Preparedness O
for O
the O
ongoing O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
its O
spread O
in O
India O
calls O
for O
setting O
up O
of O
adequately O
equipped O
and O
dedicated O
health O
facilities O
to O
manage O
sick O
patients O
while O
protecting O
healthcare O
workers O
and O
the O
environment O
. O

Here O
, O
we O
hypothesize O
that O
the O
measles O
, O
mumps O
, O
and O
rubella O
( O
MMR O
) O
vaccine O
could O
provide O
a O
broad O
neutralizing O
antibody O
against O
numbers O
of O
diseases O
, O
including O
COVID O
- O
19 O
. O

Modified O
management O
mode O
for O
colorectal O
cancer O
during O
COVID O
- O
19 O
outbreak O
- O
a O
single O
- O
center O
experience O
. O

Effects O
of O
COVID O
- O
19 O
on O
Plastic O
Surgery O
Practices O
and O
Medi O
- O
Spas O
in O
Different O
Countries O
. O

The O
ratio O
of O
COVID O
- O
19 O
out O
- O
of O
- O
hospital O
deaths O
to O
in O
- O
hospital O
deaths O
was O
12 O
. O
4 O
% O
, O
and O
so O
the O
national O
statistics O
underestimated O
the O
death O
rate O
. O

COVID O
- O
19 O
: O
guidance O
for O
infection O
prevention O
and O
control O
in O
nuclear O
medicine O
. O

This O
study O
protocol O
aims O
to O
describe O
a O
self O
- O
administered O
web O
- O
based O
intervention O
( O
Mental O
Health O
COVID O
- O
19 O
) O
based O
on O
the O
principles O
of O
positive O
psychology O
supported O
by O
elements O
of O
cognitive O
behavioral O
therapy O
and O
behavioral O
activation O
therapy O
to O
reduce O
the O
symptoms O
of O
anxiety O
and O
depression O
and O
increase O
positive O
emotions O
and O
sleep O
quality O
during O
and O
after O
the O
COVID O
- O
19 O
outbreak O
through O
a O
telepsychology O
system O
. O

The O
pharmacological O
burden O
may O
be O
further O
aggravated O
by O
the O
addition O
of O
treatments O
for O
COVID O
- O
19 O
. O

Since O
the O
emergence O
of O
the O
severe O
acute O
respiratory O
syndrome O
- O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
pandemic O
, O
an O
increasing O
number O
of O
reports O
and O
studies O
have O
tried O
to O
warn O
the O
medical O
community O
about O
the O
thrombotic O
complications O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

The O
need O
for O
innovative O
approaches O
in O
health O
care O
during O
the O
COVID O
- O
19 O
pandemic O
further O
highlights O
the O
relevance O
of O
this O
training O
. O

Further O
studies O
are O
necessary O
to O
more O
accurately O
identify O
and O
address O
health O
disparities O
in O
Hispanics O
and O
other O
vulnerable O
populations O
amidst O
COVID O
- O
19 O
and O
future O
pandemics O
. O

The O
management O
of O
pregnant O
women O
with O
COVID O
- O
19 O
was O
implemented O
as O
per O
international O
( O
WHO O
, O
RCOG O
, O
ACOG O
) O
and O
national O
( O
Indian O
Council O
of O
Medical O
Research O
) O
recommendations O
and O
guidelines O
at O
an O
academic O
, O
tertiary O
care O
, O
COVID O
- O
19 O
hospital O
in O
India O
. O

The O
study O
is O
based O
on O
a O
cross O
- O
organisational O
and O
descriptive O
quantitative O
study O
conducted O
in O
spring O
2013 O
( O
n O
= O
556 O
) O
and O
spring O
2020 O
at O
the O
peak O
of O
the O
pandemic O
in O
Eastern O
Europe O
( O
n O
= O
781 O
) O
to O
identify O
the O
relationships O
and O
the O
changes O
in O
the O
satisfaction O
and O
burnout O
levels O
of O
healthcare O
professionals O
working O
in O
Slovenian O
nursing O
homes O
in O
rural O
areas O
, O
and O
on O
a O
qualitative O
study O
conducted O
in O
2020 O
, O
to O
identify O
in O
- O
depth O
relationships O
and O
changes O
in O
both O
studies O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
proportion O
of O
the O
population O
that O
travelled O
from O
Wuhan O
to O
each O
city O
from O
10 O
January O
2020 O
to O
24 O
January O
2020 O
, O
was O
positively O
correlated O
with O
and O
had O
a O
significant O
linear O
relationship O
with O
the O
cumulative O
number O
of O
confirmed O
cases O
of O
COVID O
- O
19 O
in O
each O
city O
after O
24 O
January O
( O
all O
P O
< O
0 O
. O
01 O
) O
. O

Sixty O
- O
four O
post O
- O
COVID O
- O
19 O
patients O
and O
fifty O
control O
were O
recruited O
. O

Third O
, O
VA O
deficiency O
may O
develop O
during O
COVID O
- O
19 O
due O
to O
specific O
effects O
on O
lung O
and O
liver O
stores O
caused O
by O
inflammation O
and O
impaired O
kidney O
function O
, O
suggesting O
that O
supplements O
may O
be O
needed O
to O
restore O
adequate O
status O
. O

The O
prevalence O
of O
IPA O
in O
this O
cohort O
of O
COVID O
- O
19 O
patients O
( O
3 O
. O
7 O
% O
) O
is O
not O
higher O
than O
what O
is O
described O
in O
the O
other O
ARDS O
populations O
in O
the O
literature O
. O

The O
CT O
lung O
disease O
severity O
score O
may O
be O
predictive O
of O
acute O
abnormalities O
on O
neuroimaging O
in O
patients O
with O
COVID O
- O
19 O
with O
neurologic O
manifestations O
. O

The O
COVID O
- O
19 O
outbreak O
has O
quickly O
spread O
globally O
and O
now O
is O
having O
remarkable O
effects O
on O
public O
health O
and O
national O
economies O
. O

The O
goal O
of O
these O
changes O
must O
be O
both O
to O
improve O
care O
while O
shielding O
patients O
from O
more O
severe O
involvement O
in O
concomitant O
acute O
illnesses O
such O
COVID O
- O
19 O
. O

The O
identified O
SARS O
- O
CoV O
- O
2 O
cross O
- O
neutralizing O
camel O
antibodies O
are O
not O
proposed O
as O
a O
potential O
treatment O
for O
COVID O
- O
19 O
. O

We O
hypothesize O
that O
CB2R O
agonists O
, O
due O
to O
immunomodulatory O
, O
antiinflammatory O
, O
and O
antiviral O
properties O
may O
show O
activity O
against O
COVID O
- O
19 O
. O

Three O
hundred O
and O
thirty O
- O
three O
children O
with O
COVID O
- O
19 O
were O
included O
in O
EPICO O
- O
AEP O
. O

Social O
isolation O
due O
to O
the O
COVID O
- O
19 O
pandemic O
has O
led O
to O
worse O
outcomes O
in O
females O
with O
inflammatory O
arthritis O
. O

Discussion O
: O
The O
results O
of O
the O
study O
will O
add O
to O
the O
evidence O
- O
based O
guidelines O
for O
management O
of O
COVID O
- O
19 O
. O

Using O
the O
PEI O
and O
current O
COVID O
- O
19 O
- O
related O
mortality O
, O
we O
determined O
that O
so O
far O
Germany O
demonstrates O
the O
highest O
PEI O
( O
5 O
. O
1 O
) O
among O
countries O
with O
more O
than O
5 O
, O
000 O
recorded O
cases O
of O
the O
infection O
, O
indicating O
high O
quality O
measures O
instituted O
by O
the O
country O
to O
avert O
death O
during O
the O
pandemic O
. O

Headache O
is O
a O
very O
prevalent O
COVID O
- O
19 O
symptom O
among O
patients O
presenting O
to O
the O
emergency O
room O
, O
most O
frequently O
presenting O
as O
holocranial O
or O
bifrontal O
moderate O
to O
severe O
, O
and O
pressing O
quality O
headache O
. O

COVID O
- O
19 O
- O
associated O
diffuse O
leukoencephalopathy O
and O
cerebral O
microbleeds O
during O
puerperium O
. O

Conclusion O
and O
Relevance O
: O
COVID O
- O
19 O
can O
be O
divided O
into O
three O
distinct O
stages O
, O
beginning O
at O
the O
time O
of O
infection O
( O
Stage O
I O
) O
, O
sometimes O
progressing O
to O
pulmonary O
involvement O
( O
Stage O
II O
, O
with O
or O
without O
hypoxemia O
) O
, O
and O
less O
frequently O
to O
systemic O
inflammation O
( O
Stage O
III O
) O
. O

COVID O
- O
19 O
: O
an O
opportunity O
to O
improve O
infection O
prevention O
and O
control O
in O
LMICs O
. O

Comment O
on O
: O
COVID O
- O
19 O
: O
a O
recommendation O
to O
examine O
the O
effect O
of O
hydroxychloroquine O
in O
preventing O
infection O
and O
progression O
. O

COVID O
- O
19 O
- O
Recent O
advancements O
in O
identifying O
novel O
vaccine O
candidates O
and O
current O
status O
of O
upcoming O
SARS O
- O
CoV O
- O
2 O
vaccines O
. O

Antibody O
responses O
to O
SARS O
- O
CoV2 O
are O
distinct O
in O
children O
with O
MIS O
- O
C O
compared O
to O
adults O
with O
COVID O
- O
19 O
. O

Ischaemic O
stroke O
as O
an O
initial O
presentation O
in O
patients O
with O
COVID O
- O
19 O
: O
evaluation O
of O
a O
case O
series O
in O
an O
emergency O
in O
Brazil O
. O

The O
Impact O
of O
Compassionate O
Connected O
Care O
on O
Safety O
, O
Quality O
, O
and O
Experience O
in O
the O
Age O
of O
COVID O
- O
19 O
. O

Physiological O
high O
- O
altitude O
characteristics O
and O
symptoms O
of O
altitude O
illnesses O
furthermore O
seem O
similar O
to O
several O
pathologies O
associated O
with O
COVID O
- O
19 O
. O

After O
a O
COVID O
- O
19 O
diagnosis O
, O
vulnerable O
populations O
face O
considerable O
logistical O
and O
financial O
challenges O
to O
isolate O
and O
quarantine O
. O

This O
is O
a O
retrospective O
observational O
study O
of O
severe O
COVID O
- O
19 O
cases O
treated O
with O
TCZ O
and O
glucocorticoids O
. O

Seroprevalence O
rates O
are O
important O
indicators O
to O
the O
epidemiology O
of O
COVID O
- O
19 O
and O
the O
extent O
of O
the O
pandemic O
given O
the O
existence O
of O
asymptomatic O
cases O
. O

We O
also O
find O
some O
evidence O
that O
COVID O
- O
19 O
incidence O
had O
a O
positive O
effect O
on O
voters O
' O
mobilization O
, O
helping O
Biden O
win O
the O
presidency O
. O

The O
removal O
of O
pro O
- O
inflammatory O
cytokines O
and O
the O
shutdown O
of O
the O
cytokine O
storm O
could O
ameliorate O
the O
clinical O
outcome O
in O
severe O
COVID O
- O
19 O
cases O
. O

The O
aim O
of O
the O
study O
was O
to O
document O
the O
prevalence O
of O
anosmia O
in O
COVID O
- O
19 O
positive O
patients O
and O
analyze O
the O
effect O
of O
various O
factors O
on O
the O
occurrence O
of O
these O
chemosensory O
dysfunction O
in O
the O
local O
population O
. O

COVID O
- O
19 O
infected O
patient O
data O
has O
extracted O
from O
the O
Italian O
Health O
Ministry O
website O
includes O
registered O
and O
recovered O
cases O
from O
mid O
February O
to O
end O
March O
. O

Cancer O
survivors O
are O
reporting O
mental O
health O
symptoms O
during O
the O
COVID O
- O
19 O
pandemic O
, O
particularly O
young O
adults O
, O
adults O
without O
a O
high O
school O
degree O
, O
women O
, O
and O
survivors O
with O
limited O
social O
support O
. O

COVID O
- O
19 O
Pandemic O
: O
from O
Molecular O
Biology O
, O
Pathogenesis O
, O
Detection O
, O
and O
Treatment O
to O
Global O
Societal O
Impact O
. O

We O
also O
assemble O
data O
on O
government O
policy O
announcements O
and O
daily O
COVID O
- O
19 O
cases O
for O
all O
countries O
. O

In O
this O
study O
serum O
samples O
obtained O
from O
309 O
persons O
infected O
by O
SARS O
- O
CoV O
- O
2 O
and O
324 O
of O
healthy O
, O
uninfected O
individuals O
as O
well O
as O
serum O
from O
7 O
COVID O
- O
19 O
patients O
with O
4 O
- O
7 O
samples O
each O
ranging O
between O
1 O
- O
92 O
days O
post O
first O
positive O
PCR O
were O
tested O
by O
an O
" O
in O
house O
" O
ELISA O
which O
detects O
IgM O
, O
IgA O
and O
IgG O
antibodies O
against O
the O
receptor O
binding O
domain O
( O
RBD O
) O
of O
SARS O
- O
CoV O
- O
2 O
. O

To O
initiate O
case O
management O
, O
COVID O
- O
19 O
should O
be O
suspected O
based O
on O
patient O
symptoms O
and O
/ O
or O
high O
- O
risk O
history O
and O
then O
should O
be O
confirmed O
by O
viral O
testing O
, O
such O
as O
reverse O
transcription O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
analysis O
. O

But O
, O
doing O
so O
during O
a O
pandemic O
can O
help O
in O
the O
spread O
of O
the O
COVID O
- O
19 O
. O

These O
findings O
could O
be O
of O
great O
utility O
to O
differentiate O
influenza O
and O
COVID O
- O
19 O
and O
to O
predict O
poor O
prognosis O
specially O
at O
settings O
of O
high O
incidence O
of O
pandemic O
A O
( O
H1N1 O
) O
. O

The O
combination O
of O
TCM O
treatment O
and O
modern O
medical O
approaches O
will O
benefit O
patients O
with O
COVID O
- O
19 O
and O
help O
to O
overcome O
the O
current O
epidemic O
. O

Effect O
of O
asthma O
and O
asthma O
medication O
on O
the O
prognosis O
of O
patients O
with O
COVID O
- O
19 O
. O

Additional O
studies O
evaluating O
ABO O
blood O
groups O
and O
antibody O
titres O
that O
incorporate O
COVID O
- O
19 O
severity O
are O
needed O
. O

Most O
participants O
( O
88 O
. O
3 O
% O
) O
reported O
sex O
with O
other O
men O
during O
the O
6 O
months O
before O
COVID O
- O
19 O
. O

We O
used O
autoML O
to O
develop O
high O
- O
performing O
models O
that O
predicted O
the O
survival O
of O
patients O
with O
COVID O
- O
19 O
. O

Various O
models O
have O
been O
applied O
to O
predict O
the O
trend O
of O
the O
epidemic O
since O
the O
outbreak O
of O
COVID O
- O
19 O
. O

Besides O
, O
it O
delineates O
the O
treatment O
measures O
and O
drugs O
that O
can O
be O
used O
to O
manage O
mild O
, O
moderate O
, O
and O
severe O
symptoms O
of O
COVID O
- O
19 O
in O
asthmatic O
patients O
, O
thus O
preventing O
any O
exacerbation O
. O

Myocardial O
injury O
and O
COVID O
- O
19 O
: O
Serum O
hs O
- O
cTnI O
level O
in O
risk O
stratification O
and O
the O
prediction O
of O
30 O
- O
day O
fatality O
in O
COVID O
- O
19 O
patients O
with O
no O
prior O
cardiovascular O
disease O
. O

In O
February O
2020 O
, O
the O
World O
Health O
Organization O
( O
WHO O
) O
designated O
the O
disease O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Perceived O
Stress O
and O
Stigma O
Among O
Doctors O
Working O
in O
COVID O
- O
19 O
- O
Designated O
Hospitals O
in O
India O
. O

Multivariable O
logistic O
regression O
analysis O
was O
explored O
to O
evaluate O
the O
independent O
effect O
of O
hospital O
location O
, O
race O
, O
age O
, O
medical O
comorbidities O
, O
cancer O
status O
and O
COVID O
- O
19 O
status O
on O
treatment O
modifications O
. O

In O
the O
current O
analysis O
of O
Harris O
County O
, O
Texas O
, O
we O
used O
custom O
interpolation O
tools O
in O
GIS O
to O
disaggregate O
COVID O
- O
19 O
incidence O
estimates O
from O
the O
zip O
code O
to O
census O
tract O
estimates O
- O
a O
better O
representation O
of O
neighborhood O
- O
level O
estimates O
. O

This O
paper O
identifies O
comorbidities O
associated O
with O
high O
morbidity O
and O
fatalities O
of O
COVID O
- O
19 O
across O
countries O
and O
vulnerable O
groups O
in O
Nigeria O
. O

Treatment O
of O
patients O
with O
glioma O
during O
the O
COVID O
- O
19 O
pandemic O
: O
what O
we O
learned O
and O
what O
we O
take O
home O
for O
the O
future O
. O

COVID O
- O
19 O
and O
the O
ANZ O
Journal O
of O
Surgery O
. O

To O
summarize O
the O
clinical O
features O
and O
effective O
therapy O
of O
severe O
COVID O
- O
19 O
patients O
. O

In O
this O
retrospective O
study O
, O
patients O
with O
RT O
- O
PCR O
confirmed O
COVID O
- O
19 O
( O
N O
= O
213 O
) O
were O
divided O
in O
different O
clinical O
and O
management O
scenarios O
: O
home O
- O
discharge O
, O
ward O
hospitalization O
and O
ICU O
admission O
. O

The O
COVID O
- O
19 O
pandemic O
in O
late O
2019 O
quickly O
stretched O
health O
care O
system O
across O
the O
globe O
. O

COVID O
- O
19 O
- O
Associated O
Guillain O
- O
Barre O
Syndrome O
: O
Atypical O
Para O
- O
infectious O
Profile O
, O
Symptom O
Overlap O
, O
and O
Increased O
Risk O
of O
Severe O
Neurological O
Complications O
. O

In O
this O
study O
, O
we O
estimated O
the O
association O
between O
the O
infection O
probability O
and O
ventilation O
rates O
with O
the O
Wells O
- O
Riley O
equation O
, O
where O
the O
quantum O
generation O
rate O
( O
q O
) O
by O
a O
COVID O
- O
19 O
infector O
was O
obtained O
using O
a O
reproductive O
number O
- O
based O
fitting O
approach O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
affected O
millions O
of O
people O
worldwide O
resulting O
in O
significant O
morbidity O
and O
mortality O
. O

The O
ongoing O
Corona O
Virus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
has O
emphasized O
the O
urgent O
need O
for O
antiviral O
therapeutics O
. O

We O
screened O
resulting O
campaigns O
for O
those O
making O
statements O
about O
the O
ability O
of O
these O
searched O
- O
for O
or O
related O
terms O
to O
prevent O
or O
treat O
COVID O
- O
19 O
. O
Results O
. O

Six O
well O
- O
known O
corticosteroids O
( O
cortisone O
, O
hydrocortisone O
, O
prednisolone O
, O
methylprednisolone O
, O
betamethasone O
and O
dexamethasone O
) O
and O
two O
repurposed O
drugs O
( O
darunavir O
and O
lopinavir O
) O
against O
COVID O
- O
19 O
were O
subjected O
for O
molecular O
docking O
studies O
. O

SARS O
- O
CoV O
- O
2 O
is O
a O
recently O
emerged O
, O
novel O
human O
coronavirus O
responsible O
for O
the O
currently O
ongoing O
COVID O
- O
19 O
pandemic O
. O

Current O
COVID O
- O
19 O
surveillance O
systems O
do O
not O
capture O
information O
about O
sexual O
orientation O
. O

The O
COVID O
- O
19 O
pandemic O
has O
seen O
unprecedented O
restrictions O
on O
face O
- O
to O
- O
face O
healthcare O
encounters O
. O

This O
commentary O
( O
i O
) O
focuses O
on O
Ramazzini O
' O
s O
xiii O
oration O
describing O
that O
event O
, O
( O
ii O
) O
analyses O
the O
approach O
suggested O
to O
fight O
the O
cattle O
epidemic O
and O
economic O
threats O
, O
( O
iii O
) O
highlights O
some O
similar O
aspects O
between O
the O
1711 O
rinderpest O
epidemic O
and O
the O
current O
COVID O
- O
19 O
pandemic O
( O
team O
expertise O
, O
contagion O
transmissibility O
, O
drug O
treatment O
, O
preventive O
measures O
, O
decision O
timeliness O
) O
. O

The O
criterion O
used O
for O
review O
includes O
their O
relevance O
to O
the O
defined O
review O
question O
, O
which O
is O
the O
pathophysiological O
mechanism O
of O
COVID O
- O
19 O
among O
cancer O
patients O
and O
the O
relevant O
therapeutic O
interventions O
therewith O
. O

As O
COVID O
- O
19 O
spans O
multiple O
organ O
systems O
linked O
to O
the O
cardiovascular O
system O
, O
it O
is O
imperative O
to O
understand O
clearly O
how O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
may O
affect O
the O
multifaceted O
RAS O
. O

Manifold O
CNS O
involvement O
is O
increasingly O
reported O
in O
COVID O
- O
19 O
patients O
. O

COVID O
- O
19 O
: O
A O
Concern O
for O
Cardiovascular O
Disease O
Patients O
. O

Multiple O
off O
- O
label O
and O
investigational O
drugs O
, O
such O
as O
chloroquine O
and O
hydroxychloroquine O
, O
have O
gained O
broad O
interest O
due O
to O
positive O
pre O
- O
clinical O
data O
and O
are O
currently O
used O
for O
treatment O
of O
COVID O
- O
19 O
. O

The O
objective O
of O
the O
present O
study O
was O
to O
examine O
the O
willingness O
of O
adult O
residents O
in O
Greece O
to O
receive O
a O
COVID O
- O
19 O
vaccine O
. O

" O
The O
Biden O
- O
Harris O
plan O
to O
beat O
COVID O
- O
19 O
" O
represents O
a O
practicable O
, O
technically O
competent O
, O
plan O
to O
contain O
the O
pandemic O
, O
one O
that O
will O
serve O
the O
country O
well O
in O
the O
months O
ahead O
. O

A O
positive O
test O
result O
for O
COVID O
- O
19 O
was O
not O
significantly O
associated O
with O
vitamin O
D O
levels O
in O
White O
individuals O
but O
was O
associated O
with O
vitamin O
D O
levels O
in O
Black O
individuals O
( O
compared O
with O
≥ O
40 O
ng O
/ O
mL O
: O
< O
20 O
ng O
/ O
mL O
incidence O
rate O
ratio O
[ O
IRR O
] O
, O
2 O
. O
55 O
[ O
95 O
% O
CI O
, O
1 O
. O
26 O
- O
5 O
. O
15 O
] O
; O
P O
= O
. O
009 O
; O
20 O
to O
< O
30 O
ng O
/ O
mL O
IRR O
, O
1 O
. O
69 O
[ O
95 O
% O
CI O
, O
0 O
. O
75 O
- O
3 O
. O
84 O
] O
; O
P O
= O
. O
21 O
; O
30 O
to O
< O
40 O
ng O
/ O
mL O
IRR O

, O
2 O
. O
64 O
[ O
95 O
% O
CI O
, O
1 O
. O
24 O
- O
5 O
. O
66 O
] O
; O
P O
= O
. O

Endoscopists O
and O
endoscopic O
assistants O
are O
easily O
exposed O
to O
germs O
, O
including O
COVID O
- O
19 O
, O
during O
aerosol O
- O
generating O
procedures O
such O
as O
gastrointestinal O
endoscopy O
. O

This O
cohort O
study O
enrolled O
all O
inpatients O
with O
COVID O
- O
19 O
in O
Suizhou O
Zengdu O
Hospital O
, O
Suizhou O
, O
China O
, O
a O
designated O
hospital O
for O
COVID O
- O
19 O
treatment O
in O
the O
area O
, O
from O
January O
27 O
to O
March O
13 O
, O
2020 O
. O

The O
COVID O
- O
19 O
refers O
to O
the O
disease O
while O
the O
SARS O
- O
CoV O
- O
2 O
refers O
to O
the O
virus O
and O
is O
characterized O
by O
a O
rapid O
contagious O
capacity O
able O
to O
spread O
worldwide O
in O
a O
very O
short O
time O
. O

The O
results O
showed O
that O
COVID O
- O
19 O
and O
influenza O
had O
many O
differences O
in O
clinical O
manifestations O
and O
radiographic O
findings O
. O

As O
a O
network O
of O
early O
career O
professionals O
working O
in O
the O
area O
of O
addiction O
medicine O
, O
we O
provide O
our O
views O
with O
regards O
to O
national O
actions O
related O
to O
reducing O
alcohol O
- O
related O
harm O
and O
providing O
care O
for O
people O
with O
alcohol O
use O
disorder O
during O
COVID O
- O
19 O
. O

Overall O
, O
the O
pooled O
prevalence O
of O
headache O
in O
COVID O
- O
19 O
patients O
was O
10 O
. O
1 O
% O
[ O
95 O
% O
CI O
: O
8 O
. O
76 O
- O
11 O
. O
49 O
] O
. O

COVID O
- O
19 O
test O
results O
( O
England O
) O
were O
available O
for O
16 O
/ O
03 O
/ O
2020 O
- O
01 O
/ O
06 O
/ O
2020 O
, O
mostly O
taken O
in O
hospital O
settings O
. O

Neuropathological O
explanation O
of O
minimal O
COVID O
- O
19 O
infection O
rate O
in O
newborns O
, O
infants O
and O
children O
- O
a O
mystery O
so O
far O
. O
New O
insight O
into O
the O
role O
of O
Substance O
P O
. O

Using O
the O
method O
, O
we O
estimate O
that O
risks O
for O
a O
90 O
- O
day O
period O
at O
the O
median O
daily O
summertime O
U O
. O
S O
. O
county O
confirmed O
COVID O
- O
19 O
case O
incidence O
of O
10 O
. O
8 O
per O
100 O
, O
000 O
and O
pre O
- O
pandemic O
contact O
rates O
range O
from O
0 O
. O
4 O
to O
8 O
. O
9 O
per O
100 O
, O
000 O
for O
the O
four O
deciles O
of O
age O
between O
20 O
and O
60 O
years O
. O

Recent O
studies O
have O
reported O
interactions O
between O
statin O
treatment O
and O
COVID O
- O
19 O
- O
related O
outcomes O
. O

We O
hereby O
review O
the O
available O
literature O
and O
emerging O
guidelines O
about O
cardiovascular O
implications O
related O
to O
COVID O
- O
19 O
which O
will O
have O
a O
bearing O
on O
the O
patient O
care O
, O
health O
care O
professionals O
and O
cardiac O
centres O
. O

This O
work O
was O
supported O
by O
a O
King O
' O
s O
Together O
Rapid O
COVID O
- O
19 O
Call O
grant O
from O
King O
' O
s O
College O
London O
. O

In O
the O
present O
short O
report O
, O
we O
have O
presented O
our O
experiences O
as O
a O
cardiovascular O
tertiary O
center O
during O
the O
COVID O
- O
19 O
outbreak O
. O

The O
pathogenic O
and O
highly O
transmissible O
etiological O
agent O
, O
SARS O
- O
CoV O
- O
2 O
, O
has O
caused O
a O
serious O
threat O
COVID O
- O
19 O
pandemic O
. O

Successful O
physician O
workforce O
staffing O
for O
medical O
disasters O
, O
such O
as O
the O
COVID O
- O
19 O
pandemic O
, O
requires O
consideration O
of O
personal O
risk O
, O
as O
well O
as O
medicolegal O
, O
financial O
, O
and O
clinical O
competency O
issues O
. O

From O
the O
Editor O
of O
Sexuality O
and O
Disability O
: O
The O
Impact O
of O
COVID O
- O
19 O
on O
Sexuality O
and O
Disability O
- O
Are O
We O
Closer O
or O
More O
Isolated O
? O

Resumption O
of O
BoNT O
- O
A O
injections O
during O
the O
time O
of O
COVID O
- O
19 O
requires O
a O
systematic O
approach O
based O
on O
risks O
and O
potential O
benefits O
. O

The O
SV O
of O
COVID O
- O
19 O
in O
Hubei O
province O
was O
significantly O
correlated O
with O
the O
number O
of O
newly O
confirmed O
/ O
suspected O
cases O
( O
r O
confirmed O
= O
0 O
. O
723 O
, O
r O
suspected O
= O
0 O
. O
863 O
, O
both O
p O
< O
0 O
. O
001 O
) O
. O

Our O
results O
highlight O
the O
importance O
of O
facilitating O
the O
performance O
of O
preventive O
behaviours O
in O
individuals O
with O
mental O
health O
problems O
to O
prevent O
the O
spread O
of O
COVID O
- O
19 O
in O
this O
population O
. O

Microfluidic O
detection O
of O
human O
diseases O
: O
From O
liquid O
biopsy O
to O
COVID O
- O
19 O
diagnosis O
. O

Purpose O
: O
To O
identify O
the O
impact O
the O
COVID O
- O
19 O
lockdown O
had O
on O
the O
presentation O
and O
management O
of O
sight O
- O
threatening O
ocular O
trauma O
. O

In O
this O
paper O
, O
we O
document O
our O
perception O
of O
the O
national O
response O
to O
COVID O
- O
19 O
in O
Nigeria O
. O

Efforts O
were O
made O
at O
local O
, O
regional O
and O
national O
levels O
to O
lockdown O
the O
movement O
of O
people O
and O
to O
keep O
infected O
one O
in O
quarantine O
or O
isolation O
to O
stop O
the O
spread O
of O
COVID O
- O
19 O
. O

The O
scientific O
literature O
of O
coronavirus O
- O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
rapidly O
expanding O
. O

So O
far O
, O
China O
has O
successfully O
controlled O
transmission O
of O
COVID O
- O
19 O
through O
implementing O
stringent O
preventive O
measures O
. O

The O
overall O
prognosis O
of O
pediatric O
COVID O
- O
19 O
was O
benign O
with O
a O
decent O
recovery O
. O

To O
determine O
the O
effect O
of O
COVID O
- O
19 O
convalescent O
plasma O
on O
mortality O
, O
we O
aggregated O
patient O
outcome O
data O
from O
randomized O
clinical O
trials O
( O
RCT O
) O
, O
matched O
- O
control O
, O
case O
series O
, O
and O
case O
report O
studies O
. O

We O
appreciate O
Gao O
et O
al O
. O
for O
their O
interest O
in O
our O
recent O
manuscript O
on O
the O
association O
between O
elevated O
liver O
biochemistries O
and O
severe O
COVID O
- O
19 O
infection O
. O

Increased O
interest O
in O
remote O
neuropsychological O
assessment O
techniques O
in O
the O
face O
of O
the O
coronavirus O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
warrants O
an O
updated O
review O
of O
relevant O
remote O
assessment O
literature O
. O

In O
certain O
group O
of O
COVID O
- O
19 O
( O
e O
. O
g O
. O
, O
mild O
to O
moderate O
cases O
, O
young O
patients O
without O
comorbidities O
) O
, O
a O
reduction O
instead O
of O
an O
overall O
withdrawal O
of O
immunosuppressant O
in O
kidney O
transplant O
recipients O
is O
feasible O
. O

We O
also O
discuss O
the O
management O
of O
airway O
diseases O
, O
including O
asthma O
, O
COPD O
, O
allergic O
rhinitis O
, O
and O
rhinosinusitis O
in O
the O
era O
of O
COVID O
- O
19 O
. O

The O
average O
weekly O
figure O
of O
all O
myocardial O
infarction O
in O
2020 O
, O
prior O
to O
the O
COVID O
- O
19 O
social O
distancing O
restrictions O
/ O
awareness O
in O
the O
UK O
( O
beginning O
of O
January O
to O
third O
week O
of O
February O
) O
, O
did O
not O
differ O
when O
compared O
with O
corresponding O
weeks O
in O
2019 O
( O
23 O
. O
3 O
± O
5 O
. O
4 O
in O
2019 O
versus O
21 O
. O
13 O
± O
3 O
. O
5 O
, O
p O
= O
0 O
. O
411 O
) O
. O
With O
increased O
media O
reporting O
and O
associated O
public O
awareness O
of O
the O
threat O
of O
COVID O
- O
19 O
( O
last O
week O
of O
February O
) O
, O
there O
was O
a O
significant O
reduction O
in O
all O
myocardial O
infarction O
( O
27 O
. O
1 O
± O
4 O

. O
7 O
in O
2019 O
versus O
15 O
. O
9 O

Despite O
high O
rates O
of O
COVID O
- O
19 O
infection O
and O
increased O
related O
mortality O
have O
been O
reported O
among O
older O
adults O
admitted O
in O
long O
- O
term O
care O
facilities O
, O
a O
limited O
amount O
of O
information O
is O
available O
about O
the O
natural O
course O
of O
this O
pandemic O
and O
prognostic O
factors O
in O
such O
population O
. O

Although O
severe O
, O
COVID O
- O
19 O
accounted O
for O
a O
minority O
of O
overall O
lung O
cancer O
deaths O
during O
the O
pandemic O
( O
11 O
% O
overall O
) O
. O

The O
COVID O
- O
19 O
pandemic O
does O
not O
fit O
into O
prevailing O
Post O
- O
traumatic O
Stress O
Disorder O
( O
PTSD O
) O
models O
, O
or O
diagnostic O
criteria O
, O
yet O
emerging O
research O
shows O
traumatic O
stress O
symptoms O
as O
a O
result O
of O
this O
ongoing O
global O
stressor O
. O

During O
follow O
- O
up O
, O
only O
6 O
/ O
124 O
( O
4 O
. O
8 O
% O
) O
residents O
had O
their O
DNH O
order O
reversed O
, O
2 O
/ O
124 O
( O
1 O
. O
6 O
% O
) O
residents O
were O
hospitalized O
with O
illnesses O
unrelated O
to O
COVID O
- O
19 O
, O
and O
29 O
/ O
124 O
( O
23 O
% O
) O
died O
. O

EDs O
in O
Singapore O
faced O
a O
surge O
of O
confirmed O
cases O
of O
COVID O
- O
19 O
patients O
, O
which O
stretched O
their O
resources O
. O

The O
Impact O
of O
COVID O
- O
19 O
Response O
on O
Central O
Line O
Associated O
Bloodstream O
Infections O
and O
Blood O
Culture O
Contamination O
Rates O
at O
a O
Tertiary O
Care O
Center O
in O
Greater O
Detroit O
Area O
. O

COVID O
- O
19 O
: O
a O
heavy O
toll O
on O
health O
- O
care O
workers O
. O

We O
will O
use O
multilevel O
modelling O
to O
determine O
the O
relationship O
between O
COVID O
- O
19 O
and O
condomless O
sex O
, O
intimate O
partner O
violence O
, O
access O
to O
reproductive O
health O
services O
, O
HIV O
testing O
and O
other O
key O
items O
. O

While O
the O
United O
States O
has O
acted O
to O
improve O
access O
to O
treatment O
for O
mental O
health O
and O
opioid O
use O
, O
research O
will O
be O
needed O
to O
understand O
the O
effectiveness O
of O
new O
policies O
in O
the O
context O
of O
COVID O
- O
19 O
. O
( O
PsycInfo O
Database O
Record O
( O
c O
) O
2020 O
APA O
, O
all O
rights O
reserved O
) O
. O

The O
pandemic O
involving O
COVID O
- O
19 O
caused O
by O
the O
SARS O
- O
CoV O
- O
2 O
coronavirus O
, O
due O
to O
its O
severe O
symptoms O
and O
high O
transmission O
rate O
, O
has O
gone O
on O
to O
pose O
a O
control O
challenge O
for O
healthcare O
systems O
all O
around O
the O
world O
. O

COVID O
- O
19 O
causes O
lung O
parenchymal O
and O
endothelial O
damage O
that O
lead O
to O
hypoxic O
acute O
respiratory O
failure O
( O
hARF O
) O
. O

In O
not O
- O
COVID O
- O
19 O
related O
GBS O
, O
main O
problem O
was O
diagnostic O
delay O
. O

The O
goal O
of O
this O
review O
is O
to O
provide O
evidence O
- O
based O
recommendations O
or O
, O
when O
evidence O
is O
limited O
, O
expert O
opinion O
for O
anesthesiologists O
caring O
for O
pregnant O
women O
during O
the O
COVID O
- O
19 O
pandemic O
with O
a O
focus O
on O
preparedness O
and O
best O
clinical O
obstetric O
anesthesia O
practice O
. O

There O
is O
also O
support O
for O
glucocorticoid O
treatment O
of O
the O
COVID O
- O
19 O
respiratory O
distress O
syndrome O
. O

Although O
the O
recently O
announced O
vaccines O
against O
COVID O
- O
19 O
has O
rekindled O
hope O
, O
there O
is O
still O
a O
major O
challenge O
to O
urgently O
meet O
the O
global O
need O
for O
rapid O
treatment O
of O
the O
pandemic O
. O

Prolonged O
delays O
in O
cancer O
screening O
will O
increase O
cancer O
in O
the O
overall O
population O
from O
pre O
- O
COVID O
- O
19 O
trajectories O
, O
and O
elevate O
the O
cancer O
disparity O
in O
minority O
populations O
. O

The O
numbers O
of O
COVID O
- O
19 O
cases O
and O
deaths O
in O
the O
European O
region O
were O
obtained O
from O
the O
World O
Health O
Organization O
database O
. O

Moreover O
, O
we O
uncover O
that O
populations O
of O
Oceania O
and O
Africa O
react O
significantly O
more O
intensively O
to O
SARS O
- O
CoV O
- O
2 O
infection O
than O
those O
of O
Europe O
and O
Asia O
, O
which O
may O
explain O
why O
African O
Americans O
were O
shown O
to O
be O
at O
increased O
risk O
of O
dying O
from O
COVID O
- O
19 O
, O
in O
addition O
to O
their O
high O
risk O
of O
COVID O
- O
19 O
infection O
caused O
by O
systemic O
health O
and O
social O
inequities O
. O

How O
to O
objectively O
and O
quantitatively O
differentiate O
pneumonia O
patients O
with O
and O
without O
COVID O
- O
19 O
virus O
remains O
clinical O
challenge O
. O

This O
observation O
study O
included O
132 O
patients O
diagnosed O
with O
COVID O
- O
19 O
in O
the O
infectious O
disease O
areas O
of O
the O
East O
Section O
of O
Renmin O
Hospital O
of O
Wuhan O
University O
from O
2020 O
. O
1 O
. O
31 O
to O
2020 O
. O
2 O
. O
29 O
. O

Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
has O
resulted O
in O
considerable O
morbidity O
and O
mortality O
worldwide O
. O

The O
population O
for O
this O
descriptive O
study O
comprised O
clinicians O
working O
in O
a O
variety O
of O
healthcare O
organizations O
in O
Turkey O
who O
provide O
monitoring O
and O
treatment O
within O
the O
intensive O
care O
process O
for O
COVID O
- O
19 O
patients O
. O

Mobile O
health O
( O
mHealth O
) O
apps O
have O
played O
an O
important O
role O
in O
mitigating O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
response O
. O

The O
COVID O
- O
19 O
outbreak O
is O
putting O
tremendous O
strain O
on O
the O
US O
healthcare O
system O
, O
with O
a O
direct O
impact O
on O
medical O
professionals O
, O
hospital O
systems O
, O
and O
physical O
resources O
. O

Impacts O
of O
Social O
and O
Economic O
Factors O
on O
the O
Transmission O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
China O
. O

Does O
COVID O
- O
19 O
Involve O
the O
Retina O
? O

We O
generalized O
this O
strategy O
to O
design O
vaccines O
against O
COVID O
- O
19 O
and O
SARS O
, O
achieving O
10 O
- O
to O
100 O
- O
fold O
enhancement O
of O
NAb O
titers O
. O

The O
best O
model O
was O
used O
to O
forecast O
confirmed O
, O
discharged O
and O
death O
COVID O
- O
19 O
cases O
for O
October O
2020 O
to O
February O
2021 O
. O

In O
this O
case O
report O
, O
we O
describe O
a O
patient O
with O
severe O
COVID O
- O
19 O
pneumonia O
who O
was O
managed O
with O
high O
- O
flow O
nasal O
oxygen O
for O
40 O
days O
, O
with O
an O
eventual O
successful O
outcome O
. O

Otherwise O
, O
failed O
efforts O
to O
dedicate O
resources O
and O
targeted O
behavioral O
interventions O
for O
this O
respective O
population O
will O
inhibit O
survival O
- O
especially O
considering O
the O
recent O
and O
evolving O
COVID O
- O
19 O
pandemic O
. O

Finally O
, O
in O
survival O
COVID O
- O
19 O
patients O
whose O
humoral O
immunity O
was O
re O
- O
examined O
, O
C3 O
levels O
tended O
to O
increase O
, O
while O
in O
non O
- O
survivors O
it O
decreased O
. O

Published O
data O
about O
the O
possible O
role O
of O
2 O
- O
[ O
18F O
] O
FDG O
PET O
/ O
CT O
in O
patients O
with O
COVID O
- O
19 O
are O
increasing O
, O
but O
larger O
studies O
are O
warranted O
. O

Thus O
, O
COVID O
- O
19 O
, O
due O
to O
its O
regular O
flu O
- O
like O
symptoms O
, O
is O
also O
expected O
to O
show O
similar O
seasonality O
and O
subside O
as O
the O
global O
temperatures O
rise O
in O
the O
northern O
hemisphere O
with O
the O
onset O
of O
spring O
. O

The O
surveillance O
system O
has O
been O
successfully O
initiated O
and O
provides O
a O
robust O
set O
of O
data O
for O
Switzerland O
by O
including O
about O
80 O
% O
( O
compared O
with O
official O
statistics O
) O
of O
SARS O
- O
CoV O
- O
2 O
/ O
COVID O
- O
19 O
hospitalised O
patients O
, O
with O
similar O
age O
and O
comorbidity O
distributions O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
had O
unprecedented O
impact O
on O
the O
provision O
of O
medical O
care O
for O
genetic O
disorders O
. O

This O
study O
aims O
to O
investigate O
the O
associations O
between O
COVID O
- O
19 O
caseload O
and O
the O
burden O
of O
dementia O
. O

Several O
treatment O
options O
for O
COVID O
- O
19 O
are O
emerging O
, O
with O
immunotherapies O
, O
peptide O
therapies O
, O
and O
nucleic O
acid O
vaccines O
showing O
promise O
. O

Vaccine O
platforms O
have O
been O
critical O
for O
accelerating O
the O
timeline O
of O
COVID O
- O
19 O
vaccine O
development O
. O

We O
aim O
to O
estimate O
the O
number O
of O
COVID O
- O
19 O
cases O
imported O
from O
12 O
major O
epicentres O
in O
Europe O
and O
America O
to O
each O
African O
country O
, O
as O
well O
as O
the O
probability O
of O
reaching O
10 O
, O
000 O
cases O
in O
total O
by O
the O
end O
of O
March O
, O
April O
, O
May O
, O
and O
June O
following O
viral O
introduction O
. O

Staff O
were O
tested O
for O
COVID O
- O
19 O
by O
obtaining O
oropharyngeal O
/ O
nasopharyngeal O
specimens O
, O
with O
RT O
- O
PCR O
testing O
to O
detect O
SARS O
- O
CoV O
- O
2 O
. O

Emergency O
Food O
Provision O
for O
Children O
and O
Families O
during O
the O
COVID O
- O
19 O
Pandemic O
: O
Examples O
from O
Five O
U O
. O
S O
. O
Cities O
. O

Structured O
interviews O
were O
conducted O
to O
document O
symptoms O
for O
all O
HCP O
with O
confirmed O
COVID O
- O
19 O
. O

A O
study O
of O
physiological O
expressions O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
host O
cell O
entry O
- O
related O
factors O
in O
immune O
system O
components O
may O
help O
explain O
molecular O
mechanisms O
involved O
in O
COVID O
- O
19 O
immunopathology O
. O

The O
increase O
in O
30 O
- O
day O
mortality O
for O
SARS O
- O
CoV O
- O
2 O
positive O
patients O
presenting O
with O
femoral O
neck O
fractures O
is O
multifactorial O
, O
resulting O
from O
a O
combination O
of O
the O
direct O
effects O
of O
COVID O
- O
19 O
pneumonia O
as O
well O
as O
changes O
to O
the O
delivery O
of O
orthopaedic O
services O
. O

Run O
- O
up O
methodology O
, O
procedures O
and O
working O
process O
organization O
are O
detailed O
. O
354 O
COVID O
- O
19 O
patients O
were O
treated O
from O
13 O
. O
04 O
. O
2020 O
to O
10 O
. O
06 O
. O
2020 O
[ O
age O
59 O
( O
470 O
) O
years O
, O
56 O
% O
women O
, O
body O
mass O
index O
28 O
. O
5 O
( O
24 O
. O
932 O
. O
2 O
) O
kg O
/ O
m2 O
] O
. O

To O
assess O
the O
characteristics O
and O
risk O
factors O
for O
mortality O
in O
patients O
with O
severe O
coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
treated O
with O
tocilizumab O
( O
TCZ O
) O
, O
alone O
or O
in O
combination O
with O
corticosteroids O
( O
CS O
) O
. O

ECMO O
is O
a O
supportive O
intervention O
for O
COVID O
- O
19 O
associated O
pneumonia O
that O
could O
be O
considered O
if O
the O
optimum O
mechanical O
ventilation O
is O
deemed O
ineffective O
. O

COVID O
- O
19 O
: O
Poor O
outcomes O
in O
patients O
with O
zinc O
deficiency O
. O

A O
global O
outbreak O
of O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
severe O
acute O
respiratory O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
has O
emerged O
since O
December O
2019 O
, O
in O
Wuhan O
, O
China O
. O

To O
assess O
the O
prevalence O
of O
persistent O
functional O
impairment O
after O
COVID O
- O
19 O
, O
we O
assessed O
118 O
individuals O
3 O
- O
4 O
months O
after O
their O
initial O
COVID O
- O
19 O
diagnosis O
with O
a O
symptom O
survey O
, O
work O
productivity O
and O
activity O
index O
questionnaire O
, O
and O
6 O
- O
minute O
walk O
test O
. O

We O
investigated O
personal O
protective O
equipment O
( O
PPE O
) O
use O
and O
its O
shortage O
, O
training O
, O
and O
adverse O
events O
among O
healthcare O
workers O
( O
HCWs O
) O
in O
the O
intensive O
care O
unit O
( O
ICU O
) O
during O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
in O
Japan O
and O
compared O
the O
results O
with O
an O
international O
survey O
that O
used O
the O
same O
methodology O
. O

Clinical O
benefits O
of O
Tocilizumab O
in O
COVID O
- O
19 O
- O
related O
cytokine O
release O
syndrome O
in O
a O
patient O
with O
end O
- O
stage O
kidney O
disease O
on O
haemodialysis O
in O
Australia O
. O

While O
the O
RT O
- O
PCR O
is O
the O
silver O
bullet O
test O
for O
confirming O
the O
COVID O
- O
19 O
infection O
, O
it O
is O
limited O
by O
the O
lack O
of O
reagents O
, O
time O
- O
consuming O
, O
and O
the O
need O
for O
specialized O
labs O
. O

estimates O
of O
excess O
COVID O
- O
19 O
mortality O
rates O
for O
50 O
US O
states O
and O
Puerto O
Rico O
. O

The O
impact O
of O
laryngopharyngeal O
reflux O
disease O
on O
95 O
hospitalized O
patients O
with O
COVID O
- O
19 O
in O
Wuhan O
, O
China O
: O
A O
retrospective O
study O
. O

Also O
, O
hemodialysis O
patients O
with O
COVID O
- O
19 O
were O
compared O
to O
211 O
nonhemodialysis O
COVID O
- O
19 O
patients O
. O

Our O
study O
investigates O
several O
antecedents O
and O
consequences O
of O
negative O
emotional O
reactions O
to O
the O
COVID O
- O
19 O
pandemic O
in O
a O
cross O
- O
national O
sample O
of O
737 O
participants O
. O

Patients O
with O
older O
age O
and O
higher O
severity O
of O
COVID O
- O
19 O
disease O
had O
more O
widespread O
and O
sever O
oral O
lesions O
. O

Interventional O
cardiologists O
are O
frontline O
workers O
who O
deal O
with O
many O
cardiovascular O
emergencies O
, O
either O
in O
patients O
with O
proven O
COVID O
- O
19 O
or O
in O
suspected O
cases O
. O

However O
, O
there O
is O
limited O
evidence O
on O
the O
effectiveness O
of O
social O
distancing O
on O
COVID O
- O
19 O
incidence O
and O
mortality O
. O

Our O
university O
hospital O
was O
confronted O
to O
the O
very O
need O
of O
specific O
reorganizations O
guided O
by O
the O
implementation O
of O
the O
Hospital O
Emergency O
Plan O
. O
This O
article O
aims O
to O
describe O
the O
experience O
of O
the O
University O
Hospital O
of O
Li O
è O
ge O
( O
CHU O
Li O
è O
ge O
) O
during O
the O
COVID O
- O
19 O
outbreak O
and O
demonstrates O
the O
efficiency O
of O
advanced O
triage O
centers O
to O
regulate O
hospital O
admissions O
from O
the O
emergency O
department O
( O
ED O
) O
. O
since O
the O
beginning O
of O
March O
2020 O
, O
the O
CHU O
of O
Li O
è O
ge O
has O
implemented O
specific O
advanced O
triage O
centers O
to O
manage O
patients O
with O
SARS O
- O
CoV O
- O
2 O
suspected O
symptoms O
. O

This O
study O
relied O
on O
self O
- O
reported O
cross O
- O
sectional O
data O
and O
focused O
on O
extreme O
forms O
of O
disregard O
for O
social O
distancing O
guidelines O
, O
CONCLUSION O
: O
: O
It O
is O
important O
to O
understand O
under O
- O
responses O
to O
COVID O
- O
19 O
and O
how O
these O
relate O
to O
distress O
, O
excessive O
avoidance O
, O
and O
nonadherence O
to O
social O
distancing O
. O

Even O
trials O
that O
continue O
as O
normal O
may O
experience O
external O
changes O
as O
other O
aspects O
of O
the O
healthcare O
service O
may O
not O
be O
available O
to O
the O
patients O
in O
the O
trial O
, O
or O
the O
patients O
themselves O
may O
contract O
COVID O
- O
19 O
. O

Currently O
governments O
across O
the O
world O
have O
instituted O
the O
mandatory O
use O
of O
masks O
and O
other O
face O
coverings O
so O
that O
face O
masks O
now O
find O
much O
broader O
usage O
in O
situations O
where O
close O
contact O
of O
people O
is O
frequent O
and O
inevitable O
, O
particularly O
inside O
public O
transport O
facilities O
, O
shopping O
malls O
and O
workplaces O
in O
response O
to O
the O
COVID O
- O
19 O
. O

Dyspnoea O
was O
the O
only O
symptom O
predictive O
for O
severe O
COVID O
- O
19 O
and O
ICU O
admission O
. O

A O
training O
programme O
on O
basic O
mechanical O
ventilation O
for O
novel O
trainees O
during O
the O
COVID O
- O
19 O
outbreak O
. O

Delirium O
- O
Onset O
COVID O
- O
19 O
( O
DOC O
) O
was O
observed O
in O
21 O
/ O
57 O
( O
36 O
⋅ O
8 O
% O
) O
subjects O
who O
were O
chiefly O
older O
( O
mean O
age O
: O
85 O
⋅ O
4 O
y O
/ O
o O
) O
and O
with O
multiple O
comorbidities O
. O

Julian O
Savulescu O
and O
James O
Cameron O
argue O
that O
mandatory O
isolation O
of O
the O
elderly O
is O
justified O
under O
these O
circumstances O
, O
as O
they O
are O
at O
increased O
risk O
of O
becoming O
severely O
ill O
from O
COVID O
- O
19 O
, O
and O
are O
thus O
likely O
to O
put O
disproportionate O
strain O
on O
limited O
healthcare O
resources O
. O

In O
patients O
with O
STEMI O
, O
fibrinolysis O
achieved O
a O
comparable O
in O
- O
hospital O
and O
30 O
- O
day O
primary O
composite O
end O
point O
, O
as O
compared O
with O
those O
who O
received O
PPCI O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Four O
theme O
categories O
emerged O
from O
the O
data O
analysis O
: O
( O
a O
) O
" O
Facing O
tremendous O
new O
challenges O
and O
danger O
" O
; O
( O
b O
) O
" O
Strong O
pressure O
because O
of O
fear O
of O
infection O
, O
exhaustion O
by O
heavy O
workloads O
and O
stress O
of O
nursing O
seriously O
ill O
COVID O
- O
19 O
patients O
" O
; O
( O
c O
) O
" O
Strong O
sense O
of O
duty O
and O
identity O
as O
a O
healthcare O
provider O
" O
; O
( O
d O
) O
" O
Rational O
understanding O
of O
the O
epidemic O
- O
the O
nurses O
believed O
that O
the O
epidemic O
would O
soon O
be O
overcome O
and O
would O
like O
to O
receive O
disaster O
rescue O
training O
. O
" O
Although O
the O
intensive O
rescue O
work O
drained O
front O
- O
line O
nurses O
, O
both O
physically O
and O
emotionally O
, O
they O
showed O
a O
spirit O

While O
subunit O
vaccines O
are O
one O
of O
the O
prominent O
options O
for O
combating O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
the O
immunogenicity O
of O
spike O
protein O
- O
based O
antigens O
remains O
unknown O
. O

COVID O
- O
19 O
, O
which O
was O
first O
detected O
in O
the O
Hubei O
province O
of O
China O
, O
has O
become O
a O
global O
phenomenon O
. O

COVID O
- O
19 O
is O
well O
established O
as O
a O
respiratory O
tract O
pathogen O
; O
however O
, O
recent O
studies O
have O
shown O
an O
increasing O
number O
of O
patients O
reporting O
gastrointestinal O
manifestations O
such O
as O
diarrhea O
, O
nausea O
, O
vomiting O
, O
and O
abdominal O
pain O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
infection O
has O
been O
deemed O
as O
a O
global O
pandemic O
by O
the O
World O
Health O
Organisation O
. O

Guillain O
- O
Barre O
Syndrome O
Associated O
With O
COVID O
- O
19 O
Infection O
: O
A O
Case O
Report O
With O
Review O
of O
Literature O
. O

Surveillance O
study O
of O
asymptomatic O
and O
presymptomatic O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
care O
homes O
in O
Northern O
Ireland O
. O

Serum O
IL O
- O
18 O
levels O
were O
remarkably O
higher O
in O
COVID O
- O
19 O
patients O
compared O
to O
healthy O
subjects O
with O
being O
highest O
in O
severe O
pneumonia O
group O
( O
p O
< O
0 O
. O
001 O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
develop O
, O
validate O
and O
perform O
the O
reliability O
of O
the O
questionnaire O
" O
Physical O
exercise O
( O
PE O
) O
level O
before O
and O
during O
social O
isolation O
( O
PEF O
- O
COVID19 O
) O
" O
to O
evaluate O
the O
level O
of O
PE O
during O
the O
social O
distancing O
due O
to O
the O
COVID O
- O
19 O
pandemic O
and O
to O
try O
to O
identify O
changes O
in O
the O
daily O
life O
of O
the O
individuals O
. O

COVID O
- O
19 O
reinforces O
the O
need O
to O
improve O
sepsis O
care O
resources O
in O
Africa O
. O

The O
objectives O
were O
to O
investigate O
and O
compare O
the O
risks O
and O
incidences O
of O
venous O
thromboembolism O
( O
VTE O
) O
between O
the O
2 O
groups O
of O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pneumonia O
and O
community O
- O
acquired O
pneumonia O
( O
CAP O
) O
. O

COVID O
- O
19 O
pandemic O
and O
impact O
on O
cancer O
clinical O
trials O
: O
An O
academic O
medical O
center O
perspective O
. O

Traditional O
Chinese O
Medicine O
treatment O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
- O
Associated O
Acute O
Disseminated O
Encephalomyelitis O
- O
Like O
Disease O
. O

The O
Efficacy O
of O
the O
Mineralcorticoid O
Receptor O
Antagonist O
Canrenone O
in O
COVID O
- O
19 O
Patients O
. O

Here O
, O
we O
review O
the O
recent O
findings O
of O
characteristics O
of O
COVID O
- O
19 O
in O
CKD O
patients O
and O
highlight O
the O
possible O
mechanisms O
of O
kidney O
injury O
caused O
by O
SARS O
- O
CoV O
- O
2 O
infection O
. O

What O
Are O
the O
Newest O
Effects O
of O
COVID O
- O
19 O
in O
Children O
? O

Lactate O
dehydrogenase O
was O
a O
reliable O
predictor O
associated O
with O
COVID O
- O
19 O
severity O
and O
mortality O
in O
patients O
with O
different O
medical O
conditions O
. O

The O
dual O
- O
process O
model O
of O
clinical O
reasoning O
is O
used O
to O
analyse O
the O
thought O
processes O
used O
to O
make O
a O
diagnosis O
of O
COVID O
- O
19 O
, O
including O
consideration O
of O
the O
variety O
of O
differential O
diagnoses O
. O
While O
SARS O
- O
CoV O
- O
2 O
is O
likely O
to O
remain O
on O
the O
differential O
diagnostic O
list O
for O
a O
plethora O
of O
presentations O
for O
the O
foreseeable O
future O
, O
clinicians O
should O
be O
cautious O
of O
ignoring O
other O
potential O
diagnoses O
due O
to O
availability O
bias O
. O

The O
diagnostic O
accuracy O
of O
the O
chest O
CT O
suggesting O
COVID O
- O
19 O
was O
71 O
% O
( O
95 O
% O
CI O
: O
65 O
- O
77 O
% O
) O
. O

The O
novel O
coronavirus O
disease O
- O
19 O
( O
COVID O
- O
19 O
) O
, O
a O
global O
pandemic O
that O
emerged O
from O
Wuhan O
, O
China O
has O
today O
travelled O
all O
around O
the O
world O
, O
so O
far O
216 O
countries O
or O
territories O
with O
21 O
, O
732 O
, O
472 O
people O
infected O
and O
770 O
, O
866 O
deaths O
globally O
( O
as O
per O
WHO O
COVID O
- O
19 O
update O
dated O
August O
18 O
, O
2020 O
) O
. O

The O
affordability O
of O
these O
robotic O
pets O
appeared O
to O
influence O
the O
practicalities O
of O
real O
- O
world O
use O
, O
such O
as O
intervention O
delivery O
and O
infection O
control O
, O
which O
are O
especially O
relevant O
in O
light O
of O
COVID O
- O
19 O
. O

We O
aimed O
to O
investigate O
the O
management O
of O
urgent O
dental O
care O
, O
the O
perception O
of O
risk O
and O
workplace O
preparedness O
among O
dental O
staff O
in O
Norway O
during O
the O
COVID O
- O
19 O
pandemic O
. O

This O
meta O
- O
analysis O
provides O
evidence O
for O
the O
differentiation O
of O
severe O
cases O
of O
COVID O
- O
19 O
based O
on O
laboratory O
test O
results O
at O
the O
time O
of O
ICU O
admission O
. O

Because O
most O
patients O
infected O
with O
COVID O
- O
19 O
had O
pneumonia O
and O
characteristic O
CT O
imaging O
patterns O
, O
radiologic O
examinations O
have O
become O
vital O
in O
early O
diagnosis O
and O
the O
assessment O
of O
disease O
course O
. O

By O
using O
quality O
improvement O
methodology O
, O
we O
were O
able O
to O
safely O
and O
rapidly O
implement O
a O
new O
care O
pathway O
for O
women O
at O
high O
risk O
of O
PTB O
which O
was O
acceptable O
to O
patients O
and O
staff O
, O
and O
effective O
in O
reducing O
exposure O
of O
COVID O
- O
19 O
. O

Serum O
Interleukin O
- O
6 O
Concentrations O
and O
the O
Severity O
of O
COVID O
- O
19 O
Pneumonia O
: O
A O
Retrospective O
Study O
at O
a O
Single O
Center O
in O
Bengbu O
City O
, O
Anhui O
Province O
, O
China O
, O
in O
January O
and O
February O
2020 O
. O

To O
examine O
the O
literature O
on O
Traditional O
Chinese O
Medicine O
( O
TCM O
) O
used O
in O
the O
treatment O
, O
prevention O
and O
supportive O
care O
in O
patients O
with O
COVID O
- O
19 O
. O

Furthermore O
, O
to O
ensure O
safety O
, O
especially O
during O
the O
current O
COVID O
- O
19 O
pandemic O
, O
the O
use O
of O
the O
closed O
device O
eliminates O
the O
potential O
samples O
' O
contamination O
during O
vitrification O
and O
storage O
. O

COVID O
- O
19 O
as O
a O
pandemic O
calls O
for O
rapid O
development O
of O
vaccines O
. O

We O
described O
and O
analyzed O
current O
COVID O
- O
19 O
research O
from O
the O
perspectives O
of O
international O
cooperation O
, O
interdisciplinary O
cooperation O
, O
and O
research O
hotspots O
using O
a O
bibliometric O
clustering O
algorithm O
. O

Understanding O
the O
role O
of O
the O
Warburg O
effect O
in O
COVID O
- O
19 O
can O
be O
essential O
to O
developing O
molecules O
reducing O
infectivity O
, O
arresting O
endothelial O
cells O
activation O
and O
the O
pro O
- O
inflammatory O
cascade O
. O

Differences O
observed O
between O
African O
American O
and O
White O
patients O
should O
be O
considered O
in O
the O
context O
of O
the O
complex O
factors O
underlying O
racial O
disparities O
in O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
reemphasized O
the O
indispensable O
role O
of O
plastics O
in O
our O
daily O
life O
. O

Approach O
to O
acute O
febrile O
illness O
during O
the O
COVID O
- O
19 O
pandemic O
. O

In O
response O
to O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
several O
national O
governments O
have O
applied O
lockdown O
restrictions O
to O
reduce O
the O
infection O
rate O
. O

This O
trial O
will O
either O
provide O
support O
or O
discourage O
the O
use O
of O
convalescent O
plasma O
as O
an O
early O
intervention O
for O
the O
treatment O
of O
hospitalized O
patients O
with O
COVID O
- O
19 O
infection O
. O

Automated O
diagnosis O
of O
COVID O
- O
19 O
from O
the O
CT O
scan O
pictures O
can O
be O
used O
by O
the O
doctors O
as O
a O
quick O
and O
efficient O
method O
for O
COVID O
- O
19 O
screening O
. O

Letter O
: O
An O
International O
Investigation O
Into O
the O
COVID O
- O
19 O
Pandemic O
and O
Workforce O
Depletion O
in O
Highly O
Specialized O
Neurointerventional O
Units O
- O
Insights O
From O
Stroke O
Thrombectomy O
and O
Aneurysm O
Registry O
and O
Endovascular O
Neurosurgery O
Research O
Group O
. O

The O
global O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
deranged O
the O
recent O
history O
of O
humankind O
, O
afflicting O
more O
than O
27 O
million O
individuals O
to O
date O
. O

Hence O
, O
we O
propose O
a O
restructuring O
of O
the O
health O
services O
and O
approach O
to O
COVID O
- O
19 O
. O

Effects O
of O
Probiotics O
in O
Conditions O
or O
Infections O
Similar O
to O
COVID O
- O
19 O
on O
Health O
Outcomes O
: O
An O
Evidence O
Analysis O
Center O
Scoping O
Review O
. O

The O
COVID O
- O
19 O
( O
SARS O
- O
CoV O
- O
2 O
) O
outbreak O
has O
disrupted O
residency O
programmes O
due O
to O
university O
and O
hospitals O
' O
priorities O
to O
face O
this O
emergency O
at O
all O
cost O
. O

In O
the O
context O
of O
social O
distancing O
during O
the O
current O
corona O
virus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
nondisabling O
symptoms O
such O
as O
isolated O
dysarthria O
can O
delay O
a O
patient O
' O
s O
perception O
to O
seek O
immediate O
medical O
care O
. O

In O
this O
article O
, O
we O
review O
the O
details O
of O
our O
program O
' O
s O
transition O
in O
the O
face O
of O
COVID O
- O
19 O
and O
highlight O
the O
programmatic O
changes O
that O
will O
endure O
. O

General O
considerations O
include O
workforce O
arrangements O
and O
contingency O
plans O
, O
patient O
risk O
assessment O
for O
COVID O
- O
19 O
and O
level O
of O
care O
( O
personal O
protective O
equipment O
) O
for O
staff O
. O

The O
combined O
use O
of O
thiopurines O
with O
steroids O
and O
/ O
or O
tumor O
necrosis O
factor O
( O
TNF O
) O
monoclonal O
antibodies O
should O
also O
be O
avoided O
because O
those O
combinations O
can O
increase O
the O
risk O
for O
infections O
, O
including O
COVID O
- O
19 O
. O

[ O
Assessment O
of O
the O
psychological O
status O
of O
urologists O
during O
the O
COVID O
- O
19 O
pandemic O
] O
. O

Keywords O
: O
COVID O
- O
19 O
, O
coronavirus O
, O
distress O
syndrome O
, O
lopinavir O
/ O
ritonavir O
, O
ribavirin O
, O
chloroquine O
, O
interferons O
. O

Studying O
prevalence O
in O
an O
asymptomatic O
population O
revealed O
estimates O
of O
unreported O
COVID O
- O
19 O
cases O
. O

In O
COVID O
- O
19 O
this O
was O
associated O
with O
disease O
severity O
. O

The O
extended O
autonomic O
system O
, O
dyshomeostasis O
, O
and O
COVID O
- O
19 O
. O

Globally O
and O
as O
of O
April O
23rd O
2020 O
, O
COVID O
- O
19 O
has O
affected O
2 O
, O
544 O
, O
792 O
individuals O
in O
over O
200 O
countries O
, O
causing O
175 O
, O
694 O
fatalities O
. O

To O
investigate O
the O
results O
of O
LU O
in O
severe O
and O
critical O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
we O
performed O
a O
single O
- O
institution O
study O
to O
evaluate O
the O
related O
lung O
lesions O
and O
variations O
, O
and O
prophylactic O
strategies O
, O
in O
a O
large O
referral O
and O
treatment O
center O
. O

So O
far O
, O
there O
is O
no O
specific O
antiviral O
treatment O
for O
patients O
with O
COVID O
- O
19 O
, O
and O
neither O
are O
there O
results O
of O
controlled O
trials O
supporting O
the O
use O
of O
any O
. O

Global O
scenario O
, O
public O
health O
concerns O
and O
mitigation O
strategies O
to O
counter O
current O
ongoing O
SARS O
- O
CoV O
- O
2 O
/ O
COVID O
- O
19 O
pandemic O
. O

Clinical O
characteristics O
of O
10 O
children O
with O
a O
pediatric O
inflammatory O
multisystem O
syndrome O
associated O
with O
COVID O
- O
19 O
in O
Iran O
. O

We O
conclude O
that O
the O
actors O
in O
this O
urban O
struggle O
have O
limited O
power O
over O
the O
changes O
they O
initiate O
, O
or O
make O
an O
effort O
to O
inflict O
, O
if O
they O
are O
not O
involved O
in O
a O
concerted O
and O
politically O
integrated O
action O
, O
not O
least O
because O
the O
achievements O
they O
obtain O
are O
temporary O
and O
exceptional O
, O
like O
the O
state O
of O
emergency O
imposed O
by O
COVID O
- O
19 O
. O

A O
retrospective O
analysis O
of O
the O
clinical O
manifestation O
and O
auxiliary O
examination O
of O
19 O
patients O
with O
COVID O
- O
19 O
from O
the O
Liyuan O
Hospital O
intensive O
care O
unit O
( O
ICU O
) O
between O
January O
16 O
, O
2020 O
and O
February O
20 O
, O
2020 O
was O
undertaken O
. O

The O
aim O
of O
this O
study O
was O
to O
describe O
similarities O
and O
differences O
in O
COVID O
- O
19 O
symptoms O
, O
knowledge O
, O
and O
beliefs O
by O
race O
and O
ethnicity O
among O
adults O
in O
the O
United O
States O
. O

In O
this O
retrospective O
observational O
study O
, O
hospitalized O
COVID O
- O
19 O
patients O
were O
identified O
and O
divided O
into O
two O
groups O
based O
on O
the O
antiviral O
agents O
during O
their O
hospitalization O
. O

Diagnostic O
testing O
for O
SARS O
- O
CoV O
- O
2 O
was O
suggested O
in O
patients O
with O
OGA O
during O
the O
COVID O
- O
19 O
pandemic O
to O
ensure O
timely O
diagnosis O
and O
appropriate O
quarantine O
. O

Considering O
that O
higher O
D O
- O
dimer O
level O
and O
white O
blood O
cell O
count O
were O
independently O
associated O
with O
ALT O
elevation O
, O
liver O
dysfunction O
in O
COVID O
- O
19 O
patients O
might O
be O
induced O
by O
microvascular O
thrombosis O
in O
addition O
to O
systemic O
inflammation O
. O

Of O
HCP O
with O
COVID O
- O
19 O
, O
641 O
died O
. O

During O
the O
2009 O
H1N1 O
pandemic O
, O
containment O
strategies O
aimed O
at O
limiting O
the O
spread O
of O
the O
virus O
were O
implemented O
but O
not O
to O
the O
extent O
as O
the O
current O
COVID O
- O
19 O
pandemic O
. O

Transitioning O
to O
virtual O
care O
models O
does O
not O
limit O
the O
glycemic O
outcomes O
of O
inpatient O
diabetes O
care O
and O
should O
be O
employed O
to O
reduce O
patient O
and O
provider O
exposure O
in O
the O
setting O
of O
COVID O
- O
19 O
. O

Our O
MDT O
has O
cumulatively O
treated O
77 O
severe O
/ O
critical O
COVID O
- O
19 O
cases O
, O
including O
62 O
( O
80 O
. O
5 O
% O
) O
severe O
cases O
and O
15 O
( O
19 O
. O
5 O
% O
) O
critical O
cases O
, O
with O
an O
average O
age O
of O
63 O
. O
8 O
years O
. O

A O
large O
number O
of O
inbound O
travelers O
from O
other O
regions O
could O
lead O
to O
a O
renewed O
outbreak O
of O
COVID O
- O
19 O
in O
the O
local O
regions O
. O

Why O
Severe O
COVID O
- O
19 O
Patients O
Are O
at O
Greater O
Risk O
of O
Developing O
Depression O
: O
A O
Molecular O
Perspective O
. O

Our O
findings O
suggest O
obesity O
is O
not O
linked O
to O
an O
increased O
risk O
of O
SARS O
- O
CoV O
- O
2 O
infection O
; O
that O
symptom O
phenotype O
is O
strongly O
influenced O
by O
obesity O
; O
and O
that O
despite O
evidence O
of O
obesity O
- O
associated O
immune O
dysregulation O
in O
severe O
COVID O
- O
19 O
, O
there O
is O
no O
evidence O
of O
a O
muted O
or O
suppressed O
immune O
response O
across O
multiple O
immune O
measures O
among O
non O
- O
severe O
infections O
. O

COVID O
- O
19 O
has O
inspired O
some O
promising O
recent O
advancements O
within O
medicine O
worth O
noting O
, O
including O
improvements O
in O
telemedicine O
, O
3 O
- O
D O
printed O
personal O
protective O
equipment O
( O
PPE O
) O
and O
ventilators O
, O
drug O
and O
vaccine O
development O
, O
sterilization O
of O
PPE O
allowing O
for O
reuse O
, O
and O
point O
of O
care O
testing O
; O
they O
highlight O
a O
broader O
lesson O
for O
how O
we O
might O
innovate O
better O
within O
medicine O
, O
even O
after O
the O
crisis O
has O
passed O
. O

Chest O
computed O
tomography O
scans O
before O
the O
antiviral O
therapy O
showed O
bilateral O
multiple O
patchy O
ground O
- O
glass O
opacities O
( O
GGO O
) O
consistent O
with O
COVID O
- O
19 O
pneumonia O
. O

The O
world O
will O
never O
be O
the O
same O
after O
the O
current O
COVID O
- O
19 O
pandemic O
. O

To O
evaluate O
the O
discrimination O
of O
parenchymal O
lesions O
between O
COVID O
- O
19 O
and O
other O
atypical O
pneumonia O
( O
AP O
) O
by O
using O
only O
radiomics O
features O
. O

On O
day O
4 O
of O
hospitalization O
, O
she O
developed O
fever O
, O
cough O
and O
myalgia O
, O
and O
her O
COVID O
- O
19 O
test O
was O
positive O
. O

Background O
: O
The O
dawn O
of O
the O
year O
2020 O
witnessed O
the O
spread O
of O
the O
highly O
infectious O
and O
communicable O
disease O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
globally O
since O
it O
was O
ﬁ O
rst O
reported O
in O
2019 O
. O

Real O
- O
life O
experience O
of O
tocilizumab O
use O
in O
COVID O
- O
19 O
patients O
. O

This O
analysis O
provides O
a O
set O
of O
practical O
implications O
that O
can O
guide O
conceptual O
and O
empirical O
work O
in O
health O
crisis O
management O
with O
an O
alternative O
approach O
, O
especially O
useful O
for O
decision O
- O
making O
processes O
facing O
emergency O
responses O
and O
health O
crises O
, O
even O
in O
an O
unprecedented O
global O
health O
crisis O
such O
as O
the O
traumatic O
events O
caused O
by O
the O
COVID O
- O
19 O
disease O
. O

Widespread O
testing O
for O
severe O
acute O
respiratory O
coronavirus O
virus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
necessary O
to O
curb O
the O
spread O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
but O
testing O
is O
undermined O
when O
the O
only O
option O
is O
a O
nasopharyngeal O
swab O
. O

We O
focused O
on O
the O
impact O
of O
DPP4i O
treatment O
on O
COVID O
- O
19 O
- O
related O
outcomes O
in O
people O
with O
DM O
. O

During O
the O
unprecedented O
COVID O
- O
19 O
pandemic O
in O
2020 O
, O
the O
whole O
world O
faced O
an O
unusual O
health O
emergency O
. O

Understanding O
the O
Mosaic O
of O
COVID O
- O
19 O
: O
A O
Review O
of O
the O
Ongoing O
Crisis O
. O

The O
purpose O
of O
this O
study O
is O
to O
examine O
teachers O
' O
risk O
perception O
, O
self O
- O
efficacy O
, O
response O
efficacy O
, O
and O
approach O
to O
disease O
prevention O
during O
the O
COVID O
- O
19 O
outbreak O
in O
Taiwan O
. O

Determinants O
of O
COVID O
- O
19 O
Vaccine O
Acceptance O
in O
Saudi O
Arabia O
: O
A O
Web O
- O
Based O
National O
Survey O
. O

The O
impact O
of O
COVID O
- O
19 O
on O
patients O
with O
pre O
- O
existing O
kidney O
impairment O
, O
including O
those O
with O
chronic O
kidney O
disease O
, O
kidney O
transplant O
recipients O
, O
and O
individuals O
on O
hemodialysis O
( O
HD O
) O
has O
not O
yet O
been O
clearly O
established O
. O

[ O
Recommendations O
for O
Performing O
Bronchoscopy O
in O
Times O
of O
the O
COVID O
- O
19 O
Pandemic O
] O
. O

Although O
still O
exploratory O
and O
limited O
by O
small O
sample O
size O
, O
the O
present O
study O
suggests O
that O
a O
substantial O
proportion O
of O
KT O
recipients O
exhibited O
detectable O
SARS O
- O
CoV O
- O
2 O
- O
CMI O
after O
6 O
months O
from O
COVID O
- O
19 O
diagnosis O
. O

This O
study O
aimed O
to O
clarify O
the O
current O
global O
surgical O
practice O
including O
COVID O
- O
19 O
screening O
, O
preventive O
measures O
and O
in O
- O
hospital O
infection O
under O
the O
COVID O
- O
19 O
pandemic O
, O
and O
to O
clarify O
the O
international O
gaps O
on O
infection O
control O
policies O
among O
countries O
worldwide O
. O

We O
incorporated O
the O
governments O
' O
interventions O
( O
stay O
- O
at O
- O
home O
advises O
/ O
orders O
, O
lockdowns O
, O
quarantines O
and O
social O
distancing O
) O
against O
COVID O
- O
19 O
into O
consideration O
. O

Past O
as O
Prologue O
: O
The O
Effects O
of O
the O
COVID O
- O
19 O
Economic O
Downturn O
on O
Medicaid O
Coverage O
for O
Podiatry O
Services O
. O

American O
Society O
for O
Gastrointestinal O
Endoscopy O
: O
guidance O
for O
trainees O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Deployment O
of O
these O
innovative O
practice O
strategies O
has O
led O
to O
a O
decline O
in O
health O
care O
- O
associated O
infections O
and O
instituted O
a O
new O
care O
standard O
for O
the O
COVID O
- O
19 O
patients O
. O

Thus O
, O
to O
bridge O
this O
gap O
, O
we O
aim O
to O
identify O
technology O
- O
based O
interventions O
designed O
for O
cancer O
caregivers O
and O
report O
the O
characteristics O
and O
effects O
of O
these O
interventions O
concerning O
the O
distinctive O
challenges O
cancer O
caregivers O
face O
amid O
COVID O
- O
19 O
. O

Early O
clinical O
and O
sociodemographic O
experience O
with O
patients O
hospitalized O
with O
COVID O
- O
19 O
at O
a O
large O
American O
healthcare O
system O
. O

COVID O
- O
19 O
has O
hit O
the O
most O
vulnerable O
first O
in O
terms O
of O
biological O
inequality O
, O
such O
as O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
patients O
. O

COVID O
- O
19 O
patients O
are O
found O
to O
have O
increased O
thrombotic O
risk O
. O

The O
threat O
associated O
with O
physical O
interaction O
in O
teaching O
and O
learning O
timed O
with O
the O
COVID O
- O
19 O
pandemic O
has O
rendered O
faculty O
in O
a O
situation O
that O
they O
were O
not O
entirely O
prepared O
for O
. O

As O
an O
extreme O
event O
, O
the O
outbreak O
of O
COVID O
- O
19 O
has O
greatly O
damaged O
the O
global O
economic O
growth O
and O
caused O
a O
certain O
impact O
on O
the O
environment O
. O

The O
COVID O
- O
19 O
pandemic O
has O
instilled O
fear O
and O
stress O
among O
healthcare O
workers O
. O

The O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
pandemic O
, O
[ O
. O
. O
. O
] O
. O

Here O
, O
we O
hypothesize O
for O
the O
first O
time O
, O
that O
SCG O
and O
/ O
or O
PEA O
suppress O
MC O
activation O
and O
pro O
- O
inflammatory O
mediators O
release O
, O
playing O
an O
anti O
- O
inflammatory O
therapeutic O
role O
in O
the O
inflamed O
lung O
of O
patients O
with O
COVID O
- O
19 O
. O

From O
1619 O
to O
COVID O
- O
19 O
: O
A O
Double O
Pandemic O
. O

With O
the O
outbreak O
of O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
caused O
by O
novel O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
world O
has O
been O
facing O
an O
unprecedented O
challenge O
. O

Caring O
of O
cancer O
patients O
during O
COVID O
- O
19 O
: O
A O
real O
- O
life O
challenge O
. O

Our O
objective O
was O
to O
compare O
the O
management O
of O
appendicitis O
and O
post O
- O
operative O
outcomes O
between O
pre O
- O
and O
post O
- O
COVID O
- O
19 O
. O

Fear O
associated O
with O
medical O
vulnerability O
should O
be O
considered O
when O
assessing O
mental O
health O
among O
individuals O
with O
chronic O
medical O
conditions O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Network O
pharmacology O
and O
RNA O
- O
sequencing O
reveal O
the O
molecular O
mechanism O
of O
Xuebijing O
injection O
on O
COVID O
- O
19 O
- O
induced O
cardiac O
dysfunction O
. O

This O
outcome O
reveals O
that O
the O
nucleotide O
substitution O
distance O
of O
SARS O
- O
CoV O
- O
2 O
may O
be O
used O
to O
infer O
the O
origin O
of O
COVID O
- O
19 O
. O

Numerous O
recent O
studies O
have O
shown O
that O
patients O
with O
underlying O
cardiovascular O
disease O
( O
CVD O
) O
are O
at O
increased O
risk O
of O
more O
severe O
clinical O
course O
as O
well O
as O
mortality O
of O
COVID O
- O
19 O
. O

Food O
and O
Drug O
Administration O
( O
FDA O
) O
has O
granted O
Emergency O
Use O
Authorization O
( O
EUA O
) O
for O
remdesivir O
to O
treat O
COVID O
- O
19 O
patients O
. O

Use O
of O
hydroxychloroquine O
and O
chloroquine O
in O
patients O
with O
COVID O
- O
19 O
: O
a O
meta O
- O
analysis O
of O
randomized O
clinical O
trials O
. O

However O
, O
considering O
the O
outbreak O
of O
COVID O
- O
19 O
and O
the O
consequent O
difficulty O
of O
undergoing O
oral O
examinations O
, O
the O
oral O
manifestations O
might O
be O
misdiagnosed O
; O
then O
, O
we O
would O
encourage O
oral O
professionals O
to O
perform O
other O
studies O
about O
this O
topic O
. O

Thus O
, O
COVID O
- O
19 O
could O
represent O
the O
ultimate O
cause O
of O
AECOPD O
. O

24th O
Collegium O
Ramazzini O
Statement O
: O
Prevention O
of O
Work O
- O
Related O
Infection O
in O
the O
COVID O
- O
19 O
Pandemic O
. O

This O
inflammation O
is O
supposed O
to O
be O
the O
main O
driver O
in O
the O
pathogenesis O
of O
lung O
failure O
( O
Acute O
Respiratory O
Distress O
Syndrome O
) O
in O
COVID O
- O
19 O
. O

The O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
that O
is O
responsible O
for O
the O
global O
corona O
virus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
enters O
host O
cells O
via O
a O
mechanism O
that O
includes O
binding O
to O
angiotensin O
converting O
enzyme O
( O
ACE O
) O
2 O
( O
ACE2 O
) O
. O

Largely O
, O
the O
subjects O
got O
the O
information O
from O
social O
media O
, O
instead O
of O
the O
official O
government O
site O
for O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
spiked O
stress O
- O
related O
symptoms O
worldwide O
. O

Healthcare O
worker O
are O
at O
high O
risk O
for O
COIVD O
- O
19 O
and O
many O
have O
been O
infected O
or O
even O
died O
in O
countries O
severely O
affected O
by O
COVID O
- O
19 O
like O
China O
or O
Italy O
. O

COVID O
- O
19 O
is O
caused O
by O
SARS O
- O
CoV O
- O
2 O
, O
a O
variant O
of O
the O
coronavirus O
. O

Loneliness O
and O
negative O
effects O
on O
mental O
health O
as O
trade O
- O
offs O
of O
the O
policy O
response O
to O
COVID O
- O
19 O
. O

Given O
the O
rapidly O
growing O
pandemic O
and O
the O
overwhelmed O
medical O
system O
, O
there O
is O
an O
urgent O
need O
of O
alternative O
medicine O
to O
help O
children O
relieve O
symptoms O
during O
self O
- O
quarantine O
, O
and O
possibly O
to O
help O
increase O
their O
chances O
of O
survival O
and O
recovery O
from O
COVID O
- O
19 O
. O

Reaching O
Out O
to O
the O
Millions O
: O
A O
5 O
Key O
Messages O
Rapid O
IEC O
Campaign O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Objective O
To O
summarize O
the O
clinical O
characteristics O
and O
chest O
CT O
findings O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
patients O
in O
Peking O
Union O
Medical O
College O
Hospital O
( O
PUMCH O
) O
. O

Dissemination O
of O
extreme O
levels O
of O
extracellular O
vesicles O
: O
tissue O
factor O
activity O
in O
patients O
with O
severe O
COVID O
- O
19 O
. O

COVID O
- O
19 O
, O
previously O
known O
as O
2019 O
novel O
coronavirus O
, O
caused O
by O
SARS O
- O
CoV O
- O
2 O
, O
was O
first O
reported O
in O
Wuhan O
, O
China O
, O
in O
late O
2019 O
, O
and O
quickly O
resulted O
in O
a O
major O
epidemic O
across O
the O
world O
. O

The O
data O
from O
these O
participants O
were O
analyzed O
to O
determine O
sexual O
functioning O
in O
terms O
of O
sexual O
intercourse O
frequency O
and O
sexual O
desire O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
COVID O
- O
19 O
pandemic O
has O
claimed O
the O
lives O
of O
over O
one O
million O
people O
worldwide O
, O
and O
has O
affected O
all O
aspects O
of O
healthcare O
worldwide O
, O
including O
the O
delivery O
of O
care O
to O
patients O
with O
fertility O
- O
related O
diagnoses O
. O

Sputnik O
V O
COVID O
- O
19 O
vaccine O
candidate O
appears O
safe O
and O
effective O
. O

Conclusions O
: O
The O
clustering O
of O
COVID O
- O
19 O
cases O
was O
observed O
in O
this O
workplace O
in O
Tianjin O
, O
which O
affected O
4 O
families O
. O

A O
total O
of O
100 O
severe O
COVID O
- O
19 O
patients O
were O
finally O
collected O
. O

Indeed O
, O
B O
- O
1a O
cells O
have O
been O
shown O
to O
ameliorate O
influenza O
virus O
infection O
, O
sepsis O
, O
and O
pneumonia O
, O
all O
of O
which O
are O
similar O
to O
COVID O
- O
19 O
. O

COVID O
- O
19 O
Management O
and O
Arrhythmia O
: O
Risks O
and O
Challenges O
for O
Clinicians O
Treating O
Patients O
Affected O
by O
SARS O
- O
CoV O
- O
2 O
. O

COVID O
- O
19 O
and O
HIV O
spotlight O
the O
U O
. O
S O
. O
imperative O
for O
permanent O
affordable O
housing O
. O

How O
infodemic O
during O
the O
COVID O
- O
19 O
outbreak O
influenced O
common O
clinical O
practice O
in O
an O
Outpatient O
Service O
of O
Severe O
Psoriasis O
. O

The O
C O
- O
19ASS O
perseveration O
factor O
was O
found O
to O
explain O
an O
additional O
9 O
. O
3 O
% O
variance O
in O
COVID O
- O
19 O
anxiety O
, O
and O
additional O
2 O
. O
2 O
% O
variance O
in O
work O
and O
social O
adjustment O
( O
functional O
impairment O
) O
, O
over O
and O
above O
all O
other O
variables O
. O

Social O
media O
exposure O
to O
COVID O
- O
19 O
information O
influences O
the O
adoption O
of O
preventive O
attitudes O
and O
behaviors O
through O
shaping O
risk O
perception O
. O

We O
aimed O
to O
identify O
the O
effects O
of O
Nano O
- O
curcumin O
on O
the O
modulation O
of O
inflammatory O
cytokines O
in O
COVID O
- O
19 O
patients O
. O

Due O
to O
the O
therapeutic O
importance O
of O
IVIG O
in O
virus O
infections O
, O
in O
the O
current O
study O
, O
we O
reviewed O
the O
possible O
effect O
of O
IVIG O
in O
viral O
infections O
and O
potential O
evidence O
of O
IVIG O
therapy O
in O
patients O
with O
COVID O
- O
19 O
virus O
. O

Elderly O
male O
patients O
of O
COVID O
- O
19 O
with O
CAD O
and O
multiple O
comorbidities O
are O
at O
a O
high O
risk O
of O
mortality O
. O

The O
present O
study O
examined O
whether O
individuals O
who O
were O
experiencing O
high O
levels O
of O
loneliness O
during O
the O
forced O
isolation O
for O
COVID O
- O
19 O
pandemic O
were O
more O
prone O
to O
feel O
anxious O
, O
and O
whether O
their O
sense O
of O
loneliness O
prompted O
excessive O
social O
media O
use O
. O

COVID O
- O
19 O
and O
surgical O
practice O
. O

From O
an O
environmental O
viewpoint O
, O
the O
COVID O
- O
19 O
impacts O
point O
to O
a O
modest O
reduction O
of O
direct O
greenhouse O
gases O
from O
agriculture O
of O
about O
1 O
% O
or O
50 O
million O
tonnes O
of O
carbon O
dioxide O
equivalents O
in O
2020 O
and O
2021 O
. O

With O
the O
experience O
of O
improved O
and O
discharged O
COVID O
- O
19 O
patients O
, O
timely O
respiratory O
rehabilitation O
intervention O
may O
improve O
prognosis O
, O
maximize O
functional O
preservation O
and O
improve O
quality O
of O
life O
( O
QoL O
) O
, O
but O
there O
lacks O
of O
studies O
worldwide O
exploring O
the O
outcome O
of O
this O
intervention O
. O

Coronavirus O
causes O
some O
illnesses O
to O
include O
cold O
, O
COVID O
- O
19 O
, O
MERS O
, O
and O
SARS O
. O

The O
novel O
respiratory O
virus O
SARS O
- O
CoV O
- O
2 O
, O
responsible O
for O
over O
380 O
, O
000 O
COVID O
- O
19 O
related O
deaths O
, O
has O
caused O
significant O
strain O
on O
healthcare O
infrastructure O
and O
clinical O
laboratories O
globally O
. O

r O
= O
- O
0 O
. O
151 O
, O
P O
= O
. O
032 O
) O
, O
negative O
coping O
( O
r O
= O
0 O
. O
154 O
, O
P O
= O
. O
029 O
) O
. O
Nurses O
exposed O
to O
COVID O
- O
19 O
from O
HuBei O
China O
with O
job O
satisfaction O
, O
male O
and O
positive O
coping O
had O
low O
PCL O
- O
C O
scores O
which O
necessitate O
reducing O
the O
PTSD O
level O
by O
ways O
of O
improving O
job O
satisfaction O
, O
positive O
response O
, O
and O
strengthening O
the O
psychological O
counseling O
of O
female O
nurses O
in O
order O
to O
reduce O
the O
risk O
of O
psychological O
impairment O
. O

Recent O
work O
has O
shown O
that O
mTOR O
pathways O
in O
conjunction O
with O
AMPK O
may O
offer O
valuable O
targets O
to O
control O
cell O
injury O
, O
oxidative O
stress O
, O
mitochondrial O
dysfunction O
, O
and O
the O
onset O
of O
hyperinflammation O
, O
a O
significant O
disability O
associated O
with O
COVID O
- O
19 O
. O

Most O
of O
the O
respondents O
had O
sufficient O
knowledge O
about O
COVID O
- O
19 O
pandemic O
. O

The O
role O
of O
remdesivir O
in O
South O
Africa O
: O
preventing O
COVID O
- O
19 O
deaths O
through O
increasing O
ICU O
capacity O
. O

Complement O
C3 O
vs O
C5 O
inhibition O
in O
severe O
COVID O
- O
19 O
: O
Early O
clinical O
findings O
reveal O
differential O
biological O
efficacy O
. O

COVID O
- O
19 O
: O
Review O
and O
hematologic O
impact O
. O

This O
study O
will O
provide O
high O
- O
quality O
comprehensive O
evidence O
for O
the O
effectiveness O
and O
safety O
of O
human O
coronavirus O
immuno O
CP O
in O
the O
treatment O
of O
COVID O
- O
19 O
in O
children O
CONCLUSIONS O
: O
: O
The O
results O
of O
this O
study O
will O
provide O
the O
basis O
for O
the O
effectiveness O
and O
safety O
of O
human O
coronavirus O
immuno O
CP O
treatment O
of O
COVID O
- O
19 O
in O
children O
. O

Only O
3 O
. O
5 O
% O
of O
patients O
with O
COVID O
- O
19 O
had O
normal O
levels O
of O
β O
2GPI O
( O
> O
85 O
mg O
/ O
l O
) O
. O

Since O
in O
vitro O
studies O
and O
a O
preliminary O
clinical O
report O
suggested O
the O
efficacy O
of O
chloroquine O
for O
COVID O
- O
19 O
- O
associated O
pneumonia O
, O
there O
is O
increasing O
interest O
in O
this O
old O
antimalarial O
drug O
. O

The O
Impact O
of O
COVID O
- O
19 O
Disease O
on O
Platelets O
and O
Coagulation O
. O

In O
this O
work O
we O
discuss O
some O
of O
the O
challenges O
with O
fake O
or O
falsified O
product O
distribution O
in O
the O
context O
of O
COVID O
- O
19 O
and O
proposed O
strategies O
to O
best O
manage O
this O
problem O
. O

Statistical O
analyses O
showed O
that O
CRP O
and O
D O
- O
dimer O
serum O
levels O
were O
elevated O
by O
six O
- O
folds O
in O
the O
severe O
cases O
of O
COVID O
- O
19 O
patients O
. O

These O
are O
used O
to O
assess O
the O
level O
of O
population O
immunity O
in O
various O
categories O
of O
people O
, O
as O
well O
as O
for O
retrospective O
diagnosis O
of O
asymptomatic O
and O
mild O
COVID O
- O
19 O
in O
patients O
. O

COVID O
- O
19 O
is O
an O
infectious O
disease O
that O
has O
led O
to O
a O
worldwide O
public O
health O
emergency O
. O

Olfactory O
( O
Â O
± O
gustatory O
) O
dysfunction O
is O
indicative O
of O
COVID O
- O
19 O
infection O
and O
thus O
has O
important O
implications O
in O
the O
context O
of O
healthcare O
workers O
, O
or O
key O
workers O
in O
general O
, O
who O
work O
in O
close O
contact O
with O
others O
if O
not O
recognised O
as O
suffering O
from O
COVID O
. O

The O
28 O
- O
day O
mortality O
rate O
did O
not O
significantly O
differ O
between O
COVID O
- O
19 O
( O
43 O
. O
3 O
% O
) O
and O
influenza O
patients O
( O
50 O
% O
, O
p O
= O
0 O
. O
63 O
) O
. O

Texture O
analysis O
can O
provide O
reliable O
and O
objective O
information O
for O
differential O
diagnosis O
of O
COVID O
- O
19 O
. O
• O
CT O
texture O
analysis O
can O
well O
differentiate O
common O
and O
severe O
COVID O
- O
19 O
patients O
. O
• O
Some O
textural O
features O
showed O
above O
- O
moderate O
correlations O
with O
clinical O
factors O
. O
• O
CT O
texture O
analysis O
can O
provide O
useful O
information O
to O
judge O
the O
severity O
of O
COVID O
- O
19 O
. O

α O
- O
Satellite O
: O
An O
AI O
- O
Driven O
System O
and O
Benchmark O
Datasets O
for O
Dynamic O
COVID O
- O
19 O
Risk O
Assessment O
in O
the O
United O
States O
. O

One O
novel O
virus O
, O
different O
beliefs O
as O
playmakers O
towards O
disease O
spread O
in O
Africa O
: O
looking O
at O
COVID O
- O
19 O
from O
a O
religious O
lens O
. O

To O
explore O
the O
significance O
of O
SAA O
in O
evaluating O
the O
severity O
and O
prognosis O
of O
COVID O
- O
19 O
. O

Primary O
care O
of O
children O
and O
young O
people O
with O
asthma O
during O
the O
COVID O
- O
19 O
era O
. O

The O
short O
- O
term O
effects O
of O
the O
COVID O
- O
19 O
pandemic O
are O
magnifying O
existing O
disparities O
and O
disproportionately O
affecting O
low O
- O
income O
, O
food O
- O
insecure O
households O
that O
already O
struggle O
to O
meet O
basic O
needs O
. O

Preexisting O
cardiovascular O
disease O
( O
CVD O
) O
is O
among O
the O
most O
common O
risk O
factors O
for O
hospitalization O
and O
death O
in O
COVID O
- O
19 O
patients O
, O
and O
the O
pathogenic O
mechanisms O
of O
COVID O
- O
19 O
disease O
progression O
itself O
may O
promote O
the O
development O
of O
cardiovascular O
injury O
, O
increasing O
risk O
of O
in O
- O
hospital O
death O
. O

PCT O
results O
were O
evaluated O
according O
to O
the O
ability O
to O
accurately O
predict O
bacterial O
co O
- O
infections O
and O
death O
in O
comparison O
with O
other O
known O
biomarkers O
of O
infection O
and O
with O
major O
laboratory O
predictors O
of O
COVID O
- O
19 O
severity O
. O

Our O
analysis O
suggests O
that O
prophylactic O
corticosteroids O
given O
in O
the O
24 O
- O
48 O
hours O
prior O
to O
elective O
extubation O
in O
female O
COVID O
- O
19 O
patients O
who O
were O
intubated O
for O
more O
than O
six O
days O
with O
consecutive O
days O
of O
intermittent O
prone O
ventilation O
may O
be O
helpful O
in O
reducing O
the O
incidence O
of O
post O
- O
extubation O
stridor O
in O
this O
population O
. O

We O
collected O
the O
data O
of O
type O
2 O
diabetics O
with O
COVID O
- O
19 O
treated O
in O
our O
hospital O
from O
January O
28 O
to O
March O
15 O
, O
2020 O
and O
performed O
a O
retrospective O
analysis O
. O

Recently O
, O
anti O
- O
inflammatory O
, O
angiogenic O
, O
immune O
- O
modular O
, O
and O
healing O
properties O
of O
intravenous O
injections O
of O
culture O
derived O
stem O
cells O
have O
been O
proposed O
and O
shown O
to O
benefits O
in O
a O
small O
number O
of O
patients O
with O
severe O
COVID O
- O
19 O
infections O
. O

There O
is O
also O
expected O
to O
be O
an O
increase O
in O
mental O
health O
problems O
in O
the O
wake O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Cross O
- O
sectional O
study O
including O
healthcare O
professionals O
in O
the O
emergency O
department O
and O
other O
units O
serving O
patients O
with O
COVID O
- O
19 O
, O
of O
a O
training O
and O
research O
hospital O
in O
Turkey O
. O
210 O
volunteers O
, O
including O
105 O
healthcare O
professionals O
in O
the O
emergency O
department O
and O
105 O
healthcare O
professionals O
working O
in O
other O
departments O
rendering O
services O
for O
COVID O
- O
19 O
patients O
, O
were O
included O
in O
this O
study O
. O

Time O
series O
models O
are O
significant O
in O
predicting O
the O
impact O
of O
the O
COVID O
- O
19 O
outbreak O
and O
taking O
the O
necessary O
measures O
to O
respond O
to O
this O
crisis O
. O

Vaccination O
with O
MMR O
in O
immunocompetent O
individuals O
has O
no O
contraindications O
and O
may O
be O
especially O
effective O
for O
health O
care O
workers O
who O
can O
easily O
be O
exposed O
to O
COVID O
- O
19 O
. O

Patients O
with O
RT O
- O
PCR O
- O
confirmed O
COVID O
- O
19 O
and O
Normal O
Chest O
CT O
. O

COVID O
- O
19 O
outbreak O
results O
in O
considerable O
psychological O
effects O
among O
the O
Mexican O
sample O
. O

Data O
were O
retrospectively O
merged O
into O
a O
combined O
dataset O
covering O
the O
nine O
weeks O
of O
the O
Italian O
COVID O
- O
19 O
pandemic O
phase O
1 O
( O
8 O
March O
2020 O
to O
3 O
May O
2020 O
) O
. O

The O
effects O
of O
preventive O
measures O
such O
as O
social O
distancing O
by O
time O
period O
were O
analyzed O
, O
and O
the O
size O
and O
trends O
of O
future O
COVID O
- O
19 O
outbreaks O
were O
estimated O
. O

The O
coronavirus O
COVID O
- O
19 O
has O
had O
very O
serious O
impacts O
on O
many O
aspects O
of O
people O
' O
s O
lives O
worldwide O
, O
including O
the O
negative O
effect O
on O
the O
educational O
system O
that O
disturbed O
the O
normal O
functions O
of O
medical O
faculties O
. O

This O
meta O
- O
analysis O
is O
to O
evaluate O
the O
prevalence O
of O
disseminated O
intravascular O
coagulation O
( O
DIC O
) O
in O
COVID O
- O
19 O
patients O
and O
to O
determine O
the O
association O
of O
DIC O
with O
the O
severity O
and O
prognosis O
of O
COVID O
- O
19 O
. O

There O
remains O
no O
clear O
understanding O
of O
the O
mechanisms O
that O
underlie O
neurological O
symptoms O
in O
COVID O
- O
19 O
and O
whether O
SARS O
- O
CoV O
- O
2 O
has O
the O
potential O
for O
neuroinvasion O
in O
humans O
. O

It O
should O
be O
considered O
as O
a O
form O
of O
maternal O
medical O
care O
to O
prevent O
the O
spread O
of O
COVID O
- O
19 O
. O

Early O
hospitalization O
and O
medical O
treatment O
can O
alleviate O
symptoms O
, O
improve O
the O
clinical O
course O
and O
reduce O
the O
need O
for O
ICU O
in O
symptomatic O
pregnant O
patients O
with O
suspected O
or O
confirmed O
COVID O
- O
19 O
. O

Respiratory O
SARS O
- O
CoV O
- O
2 O
RNA O
was O
detectable O
in O
58 O
. O
0 O
% O
( O
58 O
/ O
100 O
) O
COVID O
- O
19 O
patients O
upon O
admission O
and O
lasted O
for O
a O
median O
of O
13 O
days O
post O
- O
onset O
. O

We O
aimed O
to O
assess O
the O
efficiency O
of O
a O
primary O
- O
care O
high O
- O
resolution O
radiology O
service O
( O
pcHRRS O
) O
for O
ppCOVID O
- O
19 O
in O
terms O
of O
time O
at O
hospital O
and O
decision O
' O
s O
reliability O
. O

From O
the O
current O
study O
we O
observed O
that O
three O
antiviral O
and O
three O
phyto O
- O
chemicals O
have O
minimum O
binding O
energy O
with O
the O
target O
protein O
which O
were O
further O
evaluated O
in O
molecular O
dynamics O
studies O
and O
could O
specifically O
bind O
to O
RdRp O
protein O
of O
COVID O
- O
19 O
. O

Health O
Problems O
and O
Skin O
Damages O
Caused O
by O
Personal O
Protective O
Equipment O
: O
Experience O
of O
Frontline O
Nurses O
Caring O
for O
Critical O
COVID O
- O
19 O
Patients O
in O
Intensive O
Care O
Units O
. O

Herein O
, O
we O
demonstrated O
serial O
LUS O
changes O
in O
a O
75 O
- O
year O
- O
old O
woman O
recovering O
from O
COVID O
- O
19 O
with O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
in O
need O
of O
veno O
- O
venous O
extracorporeal O
membrane O
oxygenation O
support O
. O

The O
intervention O
began O
in O
February O
2020 O
but O
was O
halted O
due O
to O
the O
COVID O
- O
19 O
pandemic O
. O

Evidence O
of O
COVID O
- O
19 O
Impacts O
on O
Occupations O
During O
the O
First O
Vietnamese O
National O
Lockdown O
. O

This O
study O
attests O
the O
effectiveness O
of O
HBT O
constructs O
in O
predicting O
people O
' O
s O
intention O
to O
receive O
a O
COVID O
- O
19 O
vaccine O
. O

First O
, O
although O
COVID O
- O
19 O
- O
related O
health O
risks O
are O
concentrated O
in O
retirement O
- O
age O
households O
, O
a O
substantial O
proportion O
of O
working O
- O
age O
households O
also O
face O
these O
risks O
. O

An O
analytical O
cross O
- O
sectional O
study O
was O
performed O
in O
a O
single O
- O
center O
tertiary O
care O
institution O
and O
included O
consecutive O
inpatients O
and O
outpatients O
with O
confirmed O
COVID O
- O
19 O
. O

This O
study O
aimed O
to O
analyze O
the O
mortality O
risk O
factors O
of O
diabetic O
patients O
with O
COVID O
- O
19 O
. O

A O
prospective O
study O
was O
conducted O
among O
201 O
patients O
with O
COVID O
- O
19 O
in O
the O
Pakistan O
Military O
Hospital O
from O
April O
1 O
to O
August O
31 O
, O
2020 O
, O
including O
non O
- O
critical O
cases O
and O
critical O
cases O
. O

Stalking O
behaviour O
has O
not O
ceased O
as O
a O
result O
of O
the O
COVID O
- O
19 O
restrictions O
and O
the O
risk O
of O
harm O
to O
victims O
remains O
significant O
. O

SARS O
- O
CoV O
- O
2 O
RNA O
in O
Wastewater O
Settled O
Solids O
Is O
Associated O
with O
COVID O
- O
19 O
Cases O
in O
a O
Large O
Urban O
Sewershed O
. O

This O
work O
provides O
basic O
clinical O
pharmacology O
information O
relevant O
for O
planning O
and O
initiating O
COVID O
- O
19 O
clinical O
studies O
with O
chloroquine O
or O
hydroxychloroquine O
, O
summarizes O
safety O
data O
from O
healthy O
volunteer O
studies O
, O
and O
summarizes O
safety O
data O
from O
phase O
II O
and O
phase O
II O
/ O
III O
clinical O
studies O
in O
patients O
with O
uncomplicated O
malaria O
, O
including O
a O
phase O
II O
/ O
III O
study O
in O
pediatric O
patients O
following O
administration O
of O
azithromycin O
and O
chloroquine O
in O
combination O
. O

Nurse O
- O
led O
triage O
, O
to O
identify O
patients O
with O
possible O
COVID O
- O
19 O
, O
at O
the O
entrances O
of O
hospital O
and O
skin O
clinics O
directs O
patients O
with O
a O
cough O
or O
fever O
to O
a O
specific O
COVID O
- O
19 O
area O
and O
a O
dermatologist O
is O
consulted O
if O
the O
fever O
might O
be O
related O
to O
skin O
disease O
. O

The O
ongoing O
pandemic O
of O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
challenging O
the O
global O
public O
health O
system O
. O

An O
Epidemic O
in O
the O
Midst O
of O
a O
Pandemic O
: O
Opioid O
Use O
Disorder O
and O
COVID O
- O
19 O
. O

However O
, O
the O
ordering O
between O
lymphopenia O
and O
apoptosis O
appears O
different O
between O
SARS O
and O
COVID O
- O
19 O
patients O
, O
ie O
, O
lymphopenia O
is O
prior O
to O
apoptosis O
in O
SARS O
patients O
whereas O
apoptosis O
is O
prior O
to O
lymphopenia O
in O
COVID O
- O
19 O
patients O
. O

We O
found O
the O
prevalence O
of O
anxiety O
( O
defined O
as O
Generalized O
Anxiety O
Disorder O
- O
7 O
score O
≥ O
5 O
) O
was O
37 O
. O
7 O
% O
, O
and O
anxiety O
was O
significantly O
and O
moderately O
correlated O
with O
worry O
about O
COVID O
- O
19 O
. O

Telehealth O
Policies O
Impacting O
Federally O
Qualified O
Health O
Centers O
in O
Face O
of O
COVID O
- O
19 O
. O

In O
this O
article O
, O
we O
describe O
how O
dental O
practice O
has O
been O
impacted O
by O
COVID O
- O
19 O
, O
identify O
the O
public O
health O
response O
to O
COVID O
- O
19 O
, O
and O
explain O
the O
gradual O
resumption O
of O
dental O
care O
after O
the O
initial O
disruption O
due O
to O
the O
pandemic O
. O

Why O
are O
pregnant O
women O
susceptible O
to O
COVID O
- O
19 O
? O
An O
immunological O
viewpoint O
. O

The O
aim O
of O
this O
paper O
is O
to O
study O
the O
effects O
of O
the O
spread O
of O
the O
COVID O
- O
19 O
virus O
in O
different O
regions O
and O
its O
impact O
on O
the O
economy O
and O
regional O
tourist O
flows O
. O

This O
report O
highlights O
the O
need O
for O
further O
research O
into O
the O
underlying O
mechanisms O
and O
optimal O
management O
of O
thrombotic O
complications O
in O
COVID O
- O
19 O
. O

2019 O
Corona O
Virus O
Disease O
( O
COVID O
- O
19 O
) O
caused O
by O
SARS O
- O
CoV O
- O
2 O
is O
still O
pandemic O
now O
. O

We O
performed O
large O
scale O
comparisons O
of O
whole O
transcriptome O
data O
and O
immune O
factor O
transcript O
data O
in O
peripheral O
blood O
mononuclear O
cells O
( O
PBMC O
) O
from O
COVID O
- O
19 O
patients O
and O
patients O
with O
psychiatric O
disorders O
. O

The O
lack O
of O
awareness O
of O
previous O
and O
new O
gym O
members O
regarding O
safety O
precautions O
during O
indoor O
exercise O
should O
be O
overcome O
by O
more O
future O
educational O
intervention O
and O
emphasizing O
on O
following O
the O
Ministry O
of O
Sports O
in O
Saudi O
Arabia O
, O
even O
after O
the O
complete O
clearance O
of O
COVID O
- O
19 O
pandemic O
. O

Recently O
, O
these O
differences O
in O
protection O
against O
hypoxic O
injury O
have O
become O
evident O
in O
the O
systemic O
, O
multi O
- O
organ O
physiological O
failure O
during O
COVID O
- O
19 O
infection O
in O
humans O
. O

The O
relationship O
of O
health O
disparities O
and O
comorbidities O
in O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
related O
outcomes O
are O
an O
ongoing O
area O
of O
interest O
. O

Cardiovascular O
disease O
has O
been O
recognized O
as O
a O
major O
determinant O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
vulnerability O
and O
severity O
. O

It O
is O
our O
hope O
is O
that O
the O
collaborations O
and O
lessons O
learned O
that O
went O
into O
creating O
these O
guidelines O
and O
protocols O
can O
serve O
as O
a O
useful O
template O
for O
other O
systems O
to O
adapt O
to O
their O
fight O
against O
COVID O
- O
19 O
. O

We O
also O
present O
original O
data O
from O
a O
32 O
- O
country O
survey O
( O
n O
= O
26 O
758 O
) O
on O
potential O
acceptance O
of O
COVID O
- O
19 O
vaccines O
, O
conducted O
from O
October O
to O
December O
, O
2020 O
. O

Dental O
professionals O
had O
adequate O
knowledge O
about O
COVID O
- O
19 O
, O
but O
a O
few O
of O
them O
were O
comfortable O
in O
treating O
patients O
during O
the O
pandemic O
. O

Can O
We O
Reduce O
Mortality O
of O
COVID O
- O
19 O
if O
We O
do O
Better O
in O
Glucose O
Control O
? O

COVID O
- O
19 O
has O
literally O
ravaged O
the O
entire O
world O
. O

We O
observed O
higher O
proportion O
of O
plasmablasts O
in O
the O
COVID O
- O
19 O
( O
+ O
) O
and O
COVID O
- O
19 O
( O
- O
) O
virus O
groups O
than O
HC O
( O
8 O
. O
8 O
vs O
. O
11 O
. O
1 O
vs O
. O
2 O
. O
7 O
, O
p O
< O
0 O
. O
05 O
) O
. O

Neurologic O
Syndromes O
Predict O
Higher O
In O
- O
Hospital O
Mortality O
in O
COVID O
- O
19 O
. O

The O
coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
caused O
by O
the O
pathogen O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
started O
in O
China O
during O
late O
2019 O
and O
swiftly O
spread O
worldwide O
. O

Since O
this O
model O
is O
suitable O
to O
describe O
the O
COVID O
- O
19 O
pandemic O
, O
especial O
attention O
is O
devoted O
to O
this O
case O
. O

Since O
cytokine O
release O
syndrome O
with O
elevation O
of O
interleukin O
- O
6 O
( O
IL O
- O
6 O
) O
is O
considered O
to O
be O
associated O
with O
severe O
cases O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
; O
IL O
- O
6 O
inhibitors O
, O
such O
as O
tocilizumab O
, O
are O
expected O
to O
be O
effective O
for O
its O
treatment O
. O

Prognostic O
Factors O
of O
COVID O
- O
19 O
Infection O
in O
Elderly O
Patients O
: O
A O
Multicenter O
Study O
. O

Background O
: O
In O
the O
face O
of O
the O
COVID O
- O
19 O
, O
as O
a O
public O
health O
emergency O
, O
the O
restaurant O
industry O
is O
struggling O
to O
organize O
itself O
. O

Development O
of O
Case O
Numbers O
during O
the O
COVID O
- O
19 O
Pandemic O
in O
a O
Center O
of O
Maximum O
- O
Care O
for O
Traumatology O
and O
Orthopedic O
Oncology O
. O

The O
World O
Health O
Organization O
declared O
COVID O
- O
19 O
in O
China O
as O
a O
Public O
Health O
Emergency O
of O
International O
Concern O
. O

She O
rapidly O
worsened O
after O
COVID O
- O
19 O
diagnosis O
on O
9th O
postoperative O
day O
. O

Data O
of O
patients O
with O
both O
COVID O
- O
19 O
episodes O
were O
recruited O
from O
March O
22 O
to O
December O
27 O
, O
2020 O
. O

Also O
, O
it O
is O
well O
documented O
that O
viral O
infections O
are O
an O
environmental O
factor O
that O
contributes O
to O
the O
development O
of O
autoimmunity O
; O
however O
, O
COVID O
- O
19 O
is O
a O
new O
entity O
, O
and O
it O
is O
not O
known O
if O
it O
could O
trigger O
autoimmune O
conditions O
. O

Active O
IBD O
, O
old O
age O
and O
comorbidities O
were O
associated O
with O
a O
negative O
COVID O
- O
19 O
outcome O
, O
whereas O
IBD O
treatments O
were O
not O
. O

Reporting O
of O
notifiable O
infectious O
diseases O
during O
the O
COVID O
- O
19 O
response O
. O

COV19 O
- O
CNNet O
and O
COV19 O
- O
ResNet O
: O
Diagnostic O
Inference O
Engines O
for O
Early O
Detection O
of O
COVID O
- O
19 O
. O

Patients O
aged O
≥ O
70 O
years O
, O
those O
with O
fever O
on O
admission O
, O
and O
patients O
with O
an O
underlying O
malignancy O
or O
diabetes O
were O
found O
to O
be O
more O
likely O
to O
succumb O
to O
COVID O
- O
19 O
. O

In O
the O
COVID O
- O
19 O
' O
s O
crisis O
, O
elective O
surgery O
and O
non O
- O
emergent O
cases O
were O
postponed O
; O
all O
other O
procedures O
have O
to O
be O
minimized O
. O

A O
total O
of O
333 O
unique O
, O
non O
- O
duplicated O
serum O
samples O
obtained O
from O
COVID O
- O
19 O
patients O
( O
n O
= O
170 O
) O
and O
negative O
controls O
( O
n O
= O
163 O
) O
obtained O
pre O
- O
December O
2019 O
were O
used O
in O
the O
study O
. O

This O
retrospective O
analysis O
suggests O
that O
metformin O
may O
offer O
benefits O
in O
patients O
with O
COVID O
- O
19 O
and O
that O
further O
study O
is O
indicated O
. O

In O
response O
to O
COVID O
- O
19 O
, O
public O
health O
and O
occupational O
safety O
concerns O
have O
rapidly O
transformed O
some O
drug O
policies O
, O
along O
with O
their O
enforcement O
. O

Psychological O
impact O
of O
COVID O
- O
19 O
on O
ophthalmologists O
- O
in O
- O
training O
and O
practising O
ophthalmologists O
in O
India O
. O

In O
the O
17 O
days O
following O
the O
launch O
of O
the O
web O
application O
, O
there O
were O
82 O
, O
347 O
emergency O
calls O
and O
6009 O
new O
hospitalizations O
for O
COVID O
- O
19 O
, O
a O
ratio O
of O
13 O
. O
7 O
calls O
to O
1 O
hospitalization O
( O
chi O
- O
square O
test O
: O
P O
< O
. O
001 O
) O
. O

It O
is O
worth O
noting O
that O
many O
infected O
COVID O
- O
19 O
patients O
have O
malignant O
tumors O
, O
and O
their O
prognosis O
is O
poor O
. O

The O
anti O
- O
epidemic O
measures O
of O
self O
- O
quarantine O
and O
social O
- O
distancing O
were O
deployed O
to O
contain O
the O
spread O
of O
COVID O
- O
19 O
, O
but O
inevitably O
caused O
a O
certain O
extent O
of O
side O
effect O
: O
frustration O
and O
anxiety O
in O
the O
general O
public O
. O

Our O
guidelines O
review O
level O
one O
evidence O
of O
various O
hypofractionated O
regimens O
, O
and O
recommend O
a O
multidisciplinary O
approach O
while O
balancing O
the O
risk O
of O
morbidity O
and O
mortality O
among O
individuals O
at O
high O
risk O
for O
severe O
illness O
from O
COVID O
- O
19 O
infection O
. O

COVID O
- O
19 O
in O
Brazil O
: O
150 O
, O
000 O
deaths O
and O
the O
Brazilian O
underreporting O
. O

Until O
an O
effective O
vaccine O
against O
SARS O
- O
CoV O
- O
2 O
is O
available O
on O
a O
widespread O
scale O
, O
the O
control O
of O
the O
COVID O
- O
19 O
pandemic O
is O
reliant O
upon O
effective O
pandemic O
control O
measures O
. O

This O
case O
series O
shows O
middle O
- O
aged O
patients O
with O
comorbid O
diseases O
present O
with O
severe O
COVID O
- O
19 O
disease O
and O
have O
poor O
outcome O
. O

We O
aimed O
to O
investigate O
the O
potential O
use O
of O
saliva O
samples O
as O
a O
non O
- O
invasive O
tool O
for O
the O
diagnosis O
of O
COVID O
- O
19 O
. O

Mosaic O
RBD O
nanoparticles O
elicited O
antibodies O
with O
superior O
cross O
- O
reactive O
recognition O
of O
heterologous O
RBDs O
relative O
to O
sera O
from O
immunizations O
with O
homotypic O
SARS O
- O
CoV O
- O
2 O
- O
RBD O
nanoparticles O
or O
COVID O
- O
19 O
convalescent O
human O
plasmas O
. O

Significant O
increases O
in O
workload O
were O
observed O
in O
the O
send O
- O
out O
laboratory O
section O
and O
for O
COVID O
- O
19 O
diagnosis O
( O
PCR O
) O
and O
management O
- O
related O
testing O
. O

company O
from O
17 O
March O
to O
17 O
April O
2020 O
by O
their O
GPs O
or O
FP O
and O
subsequently O
classified O
into O
: O
redundant O
reports O
( O
people O
already O
known O
to O
the O
healthcare O
company O
as O
confirmed O
or O
probable O
case O
COVID O
- O
19 O
) O
; O
reports O
inconsistent O
with O
ILI O
criteria O
( O
patients O
not O
known O
to O
APSS O
as O
probable O
/ O
confirmed O
case O
; O
without O
ILI O
criteria O
) O
; O
appropriate O
reports O
( O
patients O
not O
known O
to O
APSS O
as O
probable O
/ O
confirmed O
case O
; O
with O
ILI O
criteria O
) O
. O
proportion O
of O
GPs O
and O
FPs O
who O
participated O
to O
report O
system O
reporting O
at O
least O
one O
patient O
, O
out O
of O
the O
total O
number O
of O
GPs O
and O
FPs O
; O
frequency O
of O
patients O
reported O
as O

A O
panel O
of O
experts O
who O
are O
actively O
engaged O
in O
treating O
and O
managing O
COVID O
- O
19 O
at O
a O
rural O
academic O
center O
was O
convened O
to O
address O
this O
topic O
. O

COVID O
- O
19 O
pandemic O
and O
challenges O
for O
socio O
- O
economic O
issues O
, O
healthcare O
and O
National O
Health O
Programs O
in O
India O
. O

Early O
diagnosis O
and O
treatment O
of O
these O
patients O
are O
crucial O
, O
as O
COVID O
- O
19 O
pneumonia O
shows O
a O
rapid O
progression O
in O
most O
cases O
. O

COVID O
- O
19 O
in O
school O
settings O
: O
webinar O
aimed O
at O
both O
teachers O
and O
educators O
. O

Association O
between O
Participation O
in O
Government O
Subsidy O
Program O
for O
Domestic O
Travel O
and O
Symptoms O
Indicative O
of O
COVID O
- O
19 O
Infection O
. O

Therefore O
, O
an O
effective O
educational O
training O
program O
should O
be O
implemented O
to O
ensure O
maintenance O
of O
appropriate O
practices O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Depression O
, O
Anxiety O
, O
and O
Coping O
During O
the O
COVID O
- O
19 O
Pandemic O
Among O
Indian O
Expats O
in O
the O
Middle O
East O
: O
A O
Survey O
Study O
. O

Obesity O
as O
a O
risk O
factor O
for O
hospitalization O
in O
COronaVirus O
Disease O
- O
19 O
( O
COVID O
- O
19 O
) O
patients O
: O
Analysis O
of O
the O
Tuscany O
regional O
database O
. O

Bronchoscopy O
use O
in O
the O
COVID O
- O
19 O
era O
. O

Concerns O
arose O
about O
the O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
blood O
donations O
and O
potential O
significant O
blood O
transfusion O
needs O
in O
severely O
ill O
COVID O
- O
19 O
patients O
. O

Early O
antiviral O
treatment O
in O
outpatients O
with O
COVID O
- O
19 O
( O
FLARE O
) O
: O
a O
structured O
summary O
of O
a O
study O
protocol O
for O
a O
randomised O
controlled O
trial O
. O

Few O
studies O
have O
evaluated O
COVID O
- O
19 O
- O
related O
racial O
and O
/ O
or O
ethnic O
disparities O
in O
radiology O
. O

A O
large O
part O
of O
the O
world O
is O
presently O
in O
the O
grip O
of O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
virus O
) O
, O
declared O
a O
pandemic O
in O
March O
2020 O
. O

There O
is O
limited O
knowledge O
on O
the O
neurologic O
manifestations O
of O
COVID O
- O
19 O
at O
present O
, O
with O
a O
wide O
array O
of O
neurological O
complications O
reported O
, O
ranging O
from O
ischemic O
stroke O
to O
acute O
demyelination O
and O
encephalitis O
. O

We O
suggest O
against O
using O
diagnostic O
imaging O
to O
improve O
triage O
of O
reverse O
transcriptase O
( O
RT O
) O
- O
PCR O
- O
confirmed O
COVID O
- O
19 O
patients O
, O
unless O
a O
patient O
has O
worsening O
respiratory O
status O
. O

The O
aim O
of O
our O
study O
was O
to O
establish O
best O
- O
evidence O
to O
inform O
pediatric O
CHQ O
doses O
for O
children O
infected O
with O
COVID O
- O
19 O
. O

Moving O
forward O
, O
it O
will O
be O
important O
for O
RDNs O
to O
participate O
fully O
in O
health O
care O
delivered O
by O
telehealth O
and O
telehealth O
research O
both O
during O
and O
after O
the O
COVID O
- O
19 O
public O
health O
emergency O
. O

Noninvasive O
ventilation O
for O
acute O
hypoxemic O
respiratory O
failure O
in O
patients O
with O
COVID O
- O
19 O
. O

Six O
" O
COVID O
- O
19 O
maternity O
centres O
" O
were O
identified O
, O
the O
architecture O
and O
activity O
of O
obstetric O
and O
neonatal O
wards O
of O
each O
centre O
was O
reorganised O
, O
and O
common O
assistance O
protocols O
for O
the O
management O
of O
suspected O
and O
proven O
cases O
were O
formulated O
. O

We O
are O
of O
the O
view O
that O
deployment O
of O
USWD O
in O
patients O
with O
COVID O
- O
19 O
must O
be O
prudent O
and O
supported O
by O
a O
logical O
scientific O
basis O
. O

Along O
the O
same O
line O
, O
anecdotal O
information O
from O
Wuhan O
, O
China O
, O
mentioned O
a O
severe O
course O
of O
COVID O
- O
19 O
in O
a O
child O
treated O
for O
leukaemia O
. O

We O
concluded O
that O
COVID O
- O
19 O
affected O
the O
formation O
of O
the O
lung O
bulla O
and O
induced O
the O
complication O
of O
pneumothorax O
. O

More O
importantly O
, O
we O
find O
a O
bilateral O
contagion O
effect O
of O
bubbles O
in O
oil O
and O
gold O
markets O
during O
the O
recent O
COVID O
- O
19 O
outbreak O
. O

During O
the O
coronavirus O
pandemic O
( O
COVID O
- O
19 O
) O
, O
health O
care O
workers O
are O
innovating O
patient O
care O
and O
safety O
measures O
. O

Reducing O
the O
COVID O
- O
19 O
incidence O
among O
communities O
that O
suffer O
disproportionately O
from O
COVID O
- O
19 O
requires O
strengthening O
the O
coordination O
of O
public O
health O
, O
health O
care O
, O
and O
community O
stakeholders O
to O
provide O
culturally O
and O
linguistically O
tailored O
public O
health O
education O
, O
community O
- O
based O
prevention O
activities O
, O
case O
management O
, O
care O
navigation O
, O
and O
service O
linkage O
. O

The O
development O
of O
dermatologic O
diseases O
in O
patients O
recovered O
from O
COVID O
- O
19 O
. O

Despite O
significant O
changes O
in O
procedures O
that O
included O
COVID O
- O
19 O
screening O
of O
all O
admitted O
patients O
, O
social O
distancing O
and O
use O
of O
personal O
protective O
equipment O
, O
as O
well O
as O
changes O
in O
patient O
and O
provider O
behaviour O
, O
the O
overall O
impact O
of O
the O
pandemic O
on O
the O
emergency O
department O
and O
acute O
care O
service O
delivery O
was O
minimal O
. O

We O
abstracted O
medical O
history O
, O
physical O
examination O
findings O
, O
and O
the O
clinical O
probability O
of O
COVID O
- O
19 O
( O
low O
, O
moderate O
, O
and O
high O
) O
rated O
by O
emergency O
physicians O
, O
depending O
on O
their O
clinical O
judgment O
. O

[ O
Deaths O
by O
COVID O
- O
19 O
: O
Not O
all O
were O
registered O
and O
others O
should O
not O
be O
accounted O
for O
] O
. O

We O
can O
conclude O
, O
on O
the O
diagnostic O
level O
, O
that O
ABO O
blood O
groups O
can O
be O
potentially O
used O
for O
risk O
stratification O
of O
affected O
COVID O
- O
19 O
patients O
, O
to O
anticipate O
the O
deterioration O
of O
patients O
at O
higher O
risk O
for O
complications O
. O

The O
current O
state O
of O
COVID O
- O
19 O
ODT O
recommendations O
is O
limited O
to O
expert O
opinion O
. O

Otolaryngology O
- O
Head O
and O
Neck O
Surgery O
and O
COVID O
- O
19 O
. O

The O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
has O
affected O
nearly O
all O
nations O
globally O
. O

Phone O
interviews O
were O
conducted O
with O
103 O
patients O
with O
mild O
COVID O
- O
19 O
in O
Israel O
over O
a O
6 O
- O
month O
period O
( O
April O
2020 O
to O
October O
2020 O
) O
. O

[ O
COVID O
- O
19 O
associated O
pneumonia O
despite O
repeatedly O
negative O
PCR O
- O
analysis O
from O
oropharyngeal O
swabs O
] O
. O

Tracking O
and O
predicting O
the O
African O
COVID O
- O
19 O
pandemic O
. O

A O
40 O
- O
year O
- O
old O
man O
developed O
acute O
brainstem O
dysfunction O
3 O
days O
after O
hospital O
admission O
with O
symptoms O
of O
the O
novel O
SARS O
- O
CoV O
- O
2 O
infection O
( O
COVID O
- O
19 O
) O
. O

Ambulatory O
care O
pharmacy O
practice O
continued O
to O
advance O
through O
provision O
of O
services O
to O
vulnerable O
patient O
populations O
with O
chronic O
conditions O
that O
were O
anticipated O
to O
experience O
gaps O
in O
care O
management O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Hence O
, O
the O
protection O
and O
control O
measures O
for O
patients O
with O
BD O
against O
the O
COVID O
- O
19 O
are O
of O
the O
utmost O
significance O
. O

A O
risk O
assessment O
of O
drug O
- O
induced O
long O
QT O
syndrome O
( O
LQTS O
) O
associated O
with O
COVID O
- O
19 O
repurposed O
drugs O
was O
performed O
and O
compared O
with O
23 O
well O
- O
known O
torsadogenic O
and O
10 O
low O
torsadogenic O
risk O
compounds O
. O

The O
Effects O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
the O
Lived O
Experience O
of O
Diverse O
Older O
Adults O
Living O
Alone O
With O
Cognitive O
Impairment O
. O

The O
COVID O
- O
19 O
pandemic O
reached O
Europe O
in O
early O
2020 O
. O

The O
storm O
- O
like O
nature O
of O
the O
health O
crises O
caused O
by O
COVID O
- O
19 O
has O
led O
to O
unconventional O
clinical O
trial O
practices O
such O
as O
the O
relaxation O
of O
exclusion O
criteria O
. O

Editorial O
. O
COVID O
- O
19 O
and O
academic O
neurosurgery O
. O

COVID O
- O
19 O
Outbreak O
and O
Turkey O
. O

This O
study O
examined O
whether O
implementation O
of O
statewide O
mask O
mandates O
was O
associated O
with O
COVID O
- O
19 O
- O
associated O
hospitalization O
growth O
rates O
among O
different O
age O
groups O
in O
10 O
sites O
participating O
in O
the O
COVID O
- O
19 O
- O
Associated O
Hospitalization O
Surveillance O
Network O
( O
COVID O
- O
NET O
) O
in O
states O
that O
issued O
statewide O
mask O
mandates O
during O
March O
1 O
- O
October O
17 O
, O
2020 O
. O

Since O
January O
23 O
, O
2020 O
, O
we O
enrolled O
a O
cluster O
of O
eight O
youngsters O
with O
COVID O
- O
19 O
( O
median O
age O
[ O
range O
] O
, O
22 O
[ O
16 O
- O
23 O
] O
years O
; O
six O
males O
) O
originating O
from O
Patient O
- O
Index O
returning O
from O
Wuhan O
to O
Hefei O
on O
January O
19 O
. O

Our O
results O
demonstrated O
that O
the O
pulmonary O
function O
of O
patients O
with O
COVID O
- O
19 O
- O
induced O
pneumonia O
predominantly O
manifested O
as O
restrictive O
ventilation O
disorder O
and O
small O
airway O
obstruction O
, O
which O
was O
increased O
in O
critically O
ill O
patients O
. O

In O
December O
2019 O
, O
a O
coronavirus O
, O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
began O
infecting O
humans O
, O
causing O
a O
novel O
disease O
, O
coronavirus O
disease O
19 O
( O
COVID O
- O
19 O
) O
. O

Of O
the O
251 O
neonates O
delivered O
, O
96 O
. O
8 O
% O
had O
negative O
RT O
- O
PCR O
and O
/ O
or O
IgG O
antibody O
testing O
for O
COVID O
- O
19 O
. O

The O
objective O
of O
this O
study O
is O
to O
discuss O
the O
difference O
of O
spatial O
transmission O
characteristics O
of O
COVID O
- O
19 O
in O
China O
at O
the O
early O
outbreak O
stage O
with O
resolute O
efforts O
. O

Rheumatologists O
' O
practice O
during O
the O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
: O
a O
survey O
in O
Egypt O
. O

Lock O
- O
down O
in O
the O
COVID O
- O
19 O
outbreak O
has O
profoundly O
changed O
daily O
routines O
, O
and O
similarly O
caused O
the O
suspension O
of O
spasticity O
treatment O
plans O
. O

The O
world O
is O
experiencing O
an O
unprecedented O
global O
pandemic O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
caused O
by O
a O
novel O
coronavirus O
, O
Severe O
Acute O
Respiratory O
Syndrome O
- O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

It O
is O
important O
to O
assess O
the O
extent O
to O
which O
observed O
US O
COVID O
- O
19 O
racial O
and O
ethnic O
disparities O
can O
be O
explained O
by O
these O
factors O
. O

Restrictions O
on O
outdoor O
activities O
, O
tips O
for O
hygiene O
, O
and O
tips O
for O
mental O
health O
are O
among O
the O
most O
common O
initiatives O
to O
counter O
the O
COVID O
- O
19 O
pandemic O
. O

Between O
March O
2nd O
and O
April O
14th O
2020 O
, O
telemedicine O
visits O
increased O
from O
102 O
. O
4 O
daily O
to O
801 O
. O
6 O
daily O
. O
( O
683 O
% O
increase O
) O
in O
urgent O
care O
after O
the O
system O
- O
wide O
expansion O
of O
virtual O
urgent O
care O
staff O
in O
response O
to O
COVID O
- O
19 O
. O

Italy O
was O
the O
first O
Western O
country O
to O
be O
seriously O
affected O
by O
COVID O
- O
19 O
, O
and O
the O
first O
to O
implement O
drastic O
measures O
, O
which O
successfully O
curtailed O
the O
first O
wave O
of O
the O
epidemic O
. O

COVID O
- O
19 O
is O
forcing O
many O
around O
the O
world O
to O
re O
- O
evaluate O
existing O
processes O
and O
organizations O
and O
adapt O
to O
carry O
out O
business O
, O
of O
which O
medicine O
and O
education O
are O
not O
immune O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
assess O
the O
impact O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
on O
orthopaedic O
and O
trauma O
surgery O
departments O
in O
university O
hospitals O
in O
Germany O
in O
order O
to O
clarify O
current O
challenges O
. O

Very O
significantly O
lower O
number O
of O
eosinophils O
was O
characterized O
in O
patients O
with O
COVID O
- O
19 O
as O
compared O
with O
that O
of O
nucleic O
acid O
negative O
patients O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
caused O
by O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
has O
become O
a O
global O
pandemic O
and O
a O
burden O
to O
global O
health O
at O
the O
turn O
of O
2019 O
and O
2020 O
. O

2020 O
COVID O
- O
19 O
American O
Academy O
of O
Clinical O
Neuropsychology O
( O
AACN O
) O
Student O
Affairs O
Committee O
survey O
of O
neuropsychology O
trainees O
. O

Short O
- O
term O
impact O
of O
COVID O
- O
19 O
lockdown O
on O
metabolic O
control O
of O
patients O
with O
well O
- O
controlled O
type O
2 O
diabetes O
: O
a O
single O
- O
centre O
observational O
study O
. O

New O
York O
City O
was O
the O
international O
epicenter O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
Coronavirus O
Anxiety O
Scale O
( O
CAS O
) O
and O
Fear O
of O
COVID O
- O
19 O
Scale O
( O
FCV O
- O
19S O
) O
were O
validated O
for O
the O
Portuguese O
population O
and O
correlations O
with O
issues O
related O
to O
travel O
, O
tourism O
and O
hospitality O
were O
established O
. O

Of O
the O
total O
encounters O
, O
790 O
( O
12 O
. O
6 O
% O
) O
were O
via O
telemedicine O
, O
which O
were O
initiated O
on O
03 O
/ O
11 O
/ O
2020 O
after O
the O
World O
Health O
Organization O
' O
s O
( O
WHO O
) O
declaration O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
brief O
intervention O
to O
support O
implementation O
of O
telerehabilitation O
during O
COVID O
- O
19 O
achieved O
clinical O
practice O
change O
, O
but O
barriers O
remain O
. O

We O
performed O
an O
additional O
systematic O
search O
for O
cases O
series O
of O
stroke O
in O
patients O
with O
COVID O
- O
19 O
( O
n O
= O
125 O
) O
, O
and O
we O
pooled O
these O
data O
with O
35 O
unpublished O
cases O
from O
Canada O
, O
the O
United O
States O
, O
and O
Iran O
. O

The O
survivors O
of O
Bhopal O
gas O
tragedy O
are O
at O
higher O
risk O
of O
developing O
COVID O
- O
19 O
related O
adverse O
outcome O
. O

Iran O
has O
faced O
one O
of O
the O
worst O
COVID O
- O
19 O
outbreaks O
in O
the O
world O
, O
and O
no O
studies O
to O
date O
have O
examined O
COVID O
- O
19 O
- O
related O
stress O
in O
the O
general O
Iranian O
population O
. O

Since O
the O
first O
infected O
case O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
was O
reported O
in O
Wuhan O
, O
China O
in O
December O
2019 O
, O
the O
virus O
has O
spread O
swiftly O
, O
inflicting O
upon O
millions O
of O
people O
around O
the O
globe O
. O

Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
the O
infection O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
was O
first O
reported O
on O
December O
31 O
, O
2019 O
. O

Anxiety O
and O
depression O
symptoms O
in O
the O
same O
pregnant O
women O
before O
and O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Loneliness O
in O
the O
UK O
during O
the O
COVID O
- O
19 O
pandemic O
: O
Cross O
- O
sectional O
results O
from O
the O
COVID O
- O
19 O
Psychological O
Wellbeing O
Study O
. O

Conclusions O
: O
The O
results O
of O
this O
study O
indicate O
that O
increased O
social O
vulnerability O
is O
linked O
with O
COVID O
- O
19 O
incidence O
. O

This O
study O
is O
aimed O
at O
forecasting O
the O
needs O
for O
healthcare O
resources O
following O
the O
expansion O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
outbreak O
in O
the O
Republic O
of O
Kazakhstan O
, O
focusing O
on O
hospital O
beds O
, O
equipment O
, O
and O
the O
professional O
workforce O
in O
light O
of O
the O
developing O
epidemiological O
situation O
and O
the O
data O
on O
resources O
currently O
available O
. O

Anticoagulation O
in O
COVID O
- O
19 O
: O
Effect O
of O
Enoxaparin O
, O
Heparin O
, O
and O
Apixaban O
on O
Mortality O
. O

In O
December O
2019 O
a O
respiratory O
illness O
known O
as O
Coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
, O
COVID O
- O
19 O
) O
broke O
out O
in O
a O
region O
in O
China O
and O
rapidly O
spread O
to O
become O
a O
pandemic O
affecting O
all O
sporting O
events O
worldwide O
. O

Behavioral O
biases O
concerning O
the O
comprehension O
of O
disease O
data O
are O
quantitatively O
important O
, O
and O
act O
as O
severe O
impediments O
to O
effective O
policy O
action O
against O
the O
spread O
of O
COVID O
- O
19 O
. O

With O
respect O
to O
the O
risk O
factors O
for O
rumination O
about O
the O
pandemic O
emerged O
concerns O
about O
catching O
COVID O
- O
19 O
( O
OR O
1 O
. O
74 O
, O
[ O
95 O
% O
CI O
= O
1 O
. O
12 O
- O
2 O
. O
71 O
] O
P O
< O
. O
05 O
) O
, O
perceived O
impact O
on O
job O
role O
( O
OR O
= O
1 O
. O
68 O
[ O
95 O
% O
CI O
= O
1 O
. O
12 O
- O
2 O
. O
52 O
] O
P O
< O
. O
05 O
) O
, O
and O
impact O
on O
personal O
life O
( O
OR O
= O
2 O
. O
04 O
[ O
95 O
% O
CI O
= O
1 O
. O
08 O
- O
3 O
. O
86 O
] O
P O
< O
. O
05 O
) O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
Cov O
- O
2 O
) O
is O
the O
pathogen O
that O
causes O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

One O
patient O
tested O
positive O
for O
COVID O
- O
19 O
but O
experienced O
only O
mild O
symptoms O
. O

With O
the O
recent O
escalation O
in O
the O
prevalence O
of O
mental O
health O
disorders O
, O
and O
the O
possible O
negative O
impacts O
of O
the O
COVID O
- O
19 O
pandemic O
on O
public O
mental O
health O
, O
our O
findings O
have O
major O
implications O
for O
policy O
, O
suggesting O
that O
urban O
nature O
has O
great O
potential O
to O
be O
used O
as O
a O
" O
nature O
- O
based O
solution O
" O
for O
improved O
public O
health O
. O

We O
report O
a O
case O
of O
a O
75 O
- O
year O
- O
old O
woman O
diagnosed O
with O
severe O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
complicated O
by O
acute O
cerebral O
infarction O
. O

The O
COVID O
- O
19 O
pandemic O
has O
brought O
about O
an O
urgent O
need O
for O
effective O
treatment O
, O
while O
conserving O
vital O
resources O
such O
as O
intensive O
care O
unit O
beds O
and O
ventilators O
. O

Acute O
Symptomatic O
Seizures O
in O
Critically O
Ill O
Patients O
with O
COVID O
- O
19 O
: O
Is O
There O
an O
Association O
? O

The O
results O
of O
the O
study O
show O
that O
the O
effect O
of O
COVID O
- O
19 O
fear O
on O
OCD O
is O
mediated O
by O
emotional O
reactivity O
, O
experiential O
avoidance O
and O
depression O
- O
anxiety O
. O

Changes O
in O
the O
Profile O
of O
Emergency O
Room O
Patients O
during O
the O
COVID O
- O
19 O
Outbreak O
in O
a O
General O
Hospital O
Specialized O
in O
Cardiovascular O
Care O
in O
Brazil O
. O

Neurological O
and O
psychiatric O
presentations O
associated O
with O
COVID O
- O
19 O
. O

Authorities O
should O
optimize O
online O
education O
systems O
and O
implement O
effective O
interventions O
to O
cope O
with O
the O
psychological O
effects O
of O
COVID O
- O
19 O
on O
children O
, O
as O
it O
is O
affecting O
the O
global O
population O
and O
remains O
uncertain O
when O
it O
will O
end O
. O

The O
current O
disruption O
in O
sports O
activities O
caused O
by O
COVID O
- O
19 O
presents O
a O
challenge O
to O
physicians O
, O
coaches O
, O
and O
trainers O
in O
discerning O
best O
practices O
for O
a O
safe O
return O
to O
sport O
. O

The O
aim O
was O
to O
investigate O
the O
impact O
of O
COVID O
- O
19 O
pandemic O
on O
the O
psychological O
status O
of O
patients O
with O
relapsing O
- O
remitting O
multiple O
sclerosis O
( O
RRMS O
) O
. O

Is O
emergency O
endoscopic O
retrograde O
cholangiopancreatogr O
safe O
in O
COVID O
- O
19 O
pandemic O
? O

A O
total O
of O
45 O
COVID O
- O
19 O
patients O
were O
included O
, O
consisting O
of O
22 O
severe O
cases O
( O
Group O
S O
) O
and O
23 O
mild O
cases O
( O
Group O
M O
) O
. O

Individuals O
infected O
by O
the O
novel O
coronavirus O
( O
SARS O
- O
CoV O
- O
2 O
) O
have O
experienced O
different O
psychiatric O
manifestations O
during O
the O
period O
of O
infectivity O
and O
post O
- O
COVID O
- O
19 O
infection O
. O

The O
global O
sanitary O
crisis O
caused O
by O
the O
emergence O
of O
the O
respiratory O
virus O
SARS O
- O
CoV O
- O
2 O
and O
the O
COVID O
- O
19 O
outbreak O
has O
revealed O
the O
urgent O
need O
for O
rapid O
, O
accurate O
, O
and O
affordable O
diagnostic O
tests O
to O
broadly O
and O
massively O
monitor O
the O
population O
in O
order O
to O
properly O
manage O
and O
control O
the O
spread O
of O
the O
pandemic O
. O

Driving O
Access O
to O
Care O
: O
Use O
of O
Mobile O
Units O
for O
Urine O
Specimen O
Collection O
During O
the O
Coronavirus O
Disease O
- O
19 O
( O
COVID O
- O
19 O
) O
Pandemic O
. O

Association O
Between O
ABO O
and O
Rh O
Blood O
Groups O
and O
SARS O
- O
CoV O
- O
2 O
Infection O
or O
Severe O
COVID O
- O
19 O
Illness O
: O
A O
Population O
- O
Based O
Cohort O
Study O
. O

Access O
to O
Information O
and O
Degree O
of O
Community O
Awareness O
of O
Preventive O
Health O
Measures O
in O
the O
Face O
of O
COVID O
- O
19 O
in O
Spain O
. O

At O
90 O
days O
, O
there O
is O
an O
open O
label O
extension O
wherein O
all O
participants O
are O
offered O
a O
one O
- O
month O
course O
of O
HCQ O
400mg O
once O
daily O
for O
PrEP O
of O
COVID O
- O
19 O
. O

Recently O
, O
the O
number O
of O
Corona O
Virus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
cases O
has O
increased O
remarkably O
in O
South O
Korea O
, O
so O
the O
triage O
clinics O
and O
emergency O
departments O
( O
ED O
) O
are O
expected O
to O
be O
overcrowded O
with O
patients O
with O
presumed O
infection O
. O

Medical O
records O
of O
167 O
confirmed O
cases O
of O
critically O
ill O
COVID O
- O
19 O
from O
February O
16 O
to O
March O
21 O
, O
2020 O
were O
collected O
in O
this O
two O
- O
center O
retrospective O
study O
. O
180 O
- O
day O
' O
s O
outcome O
and O
clinical O
organ O
development O
in O
patients O
with O
thrombocytopenia O
and O
non O
- O
thrombocytopenia O
were O
analyzed O
. O

Not O
long O
after O
COVID O
- O
19 O
hit O
Texas O
last O
March O
, O
pediatricians O
at O
Austin O
Regional O
Clinic O
( O
ARC O
) O
began O
screening O
patients O
for O
food O
insecurity O
. O

In O
this O
position O
statement O
, O
the O
IFSO O
Endoscopy O
Committee O
offers O
guidance O
on O
navigating O
bariatric O
endoscopic O
procedures O
in O
patients O
with O
obesity O
during O
the O
COVID O
- O
19 O
pandemic O
, O
in O
the O
hope O
of O
mitigating O
the O
risk O
of O
SARS O
- O
CoV O
- O
2 O
transmission O
to O
vulnerable O
patients O
and O
healthcare O
workers O
. O

With O
the O
global O
epidemic O
of O
the O
COVID O
- O
19 O
virus O
, O
extensive O
and O
rapid O
research O
on O
drug O
therapy O
is O
underway O
around O
the O
world O
. O

A O
Rare O
Axonal O
Variant O
of O
Guillain O
- O
Barr O
é O
Syndrome O
as O
a O
Neurological O
Complication O
of O
COVID O
- O
19 O
Infection O
. O

RVLS O
is O
a O
powerful O
predictor O
of O
higher O
mortality O
in O
patients O
with O
COVID O
- O
19 O
. O

A O
modern O
iteration O
of O
Occam O
' O
s O
Razor O
posits O
that O
" O
the O
simplest O
explanation O
is O
usually O
correct O
. O
" O
Coronavirus O
Disease O
2019 O
involves O
widespread O
organ O
damage O
and O
uneven O
mortality O
demographics O
, O
deemed O
unexpected O
from O
what O
was O
originally O
thought O
to O
be O
" O
a O
straightforward O
respiratory O
virus O
. O
" O
The O
simplest O
explanation O
is O
that O
both O
the O
expected O
and O
unexpected O
aspects O
of O
COVID O
- O
19 O
share O
a O
common O
mechanism O
. O

Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
became O
a O
pandemic O
in O
March O
2020 O
, O
affecting O
millions O
of O
people O
worldwide O
. O

Is O
it O
possible O
to O
use O
Proton O
Pump O
Inhibitors O
in O
COVID O
- O
19 O
treatment O
and O
prophylaxis O
? O

COVID O
- O
19 O
has O
rapidly O
evolved O
since O
it O
was O
first O
reported O
and O
has O
proven O
to O
be O
a O
fatal O
infective O
process O
. O

A O
dataset O
for O
the O
perceived O
vulnerability O
to O
disease O
scale O
in O
Japan O
before O
the O
spread O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
, O
a O
novel O
severe O
acute O
respiratory O
syndrome O
( O
SARS O
) O
emerging O
in O
China O
' O
s O
Hubei O
province O
in O
late O
2019 O
, O
due O
to O
a O
new O
coronavirus O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
is O
causing O
a O
global O
pandemic O
involving O
many O
areas O
of O
the O
world O
, O
which O
so O
far O
counts O
more O
than O
43 O
million O
cases O
and O
more O
than O
1 O
, O
155 O
, O
000 O
deaths O
worldwide O
[ O
. O
. O
. O
] O
. O

Nitrite O
, O
nitrate O
( O
the O
metabolites O
of O
NO O
) O
, O
methemoglobin O
, O
and O
prooxidant O
- O
antioxidant O
- O
balance O
levels O
were O
measured O
in O
25 O
ICU O
COVID O
- O
19 O
patients O
and O
25 O
healthy O
individuals O
. O

COVID O
- O
19 O
pandemic O
and O
the O
Olympic O
Games O
. O

Visualizing O
an O
unseen O
enemy O
; O
mobilizing O
structural O
biology O
to O
counter O
COVID O
- O
19 O
. O

Emergency O
Surgery O
in O
Suspected O
COVID O
- O
19 O
Patients O
With O
Acute O
Abdomen O
: O
Case O
Series O
and O
Perspectives O
. O

Disruptions O
to O
routine O
care O
, O
high O
volumes O
of O
patient O
and O
caregiver O
calls O
, O
and O
our O
patients O
' O
risk O
of O
infection O
and O
complications O
inspired O
a O
proactive O
COVID O
- O
19 O
outreach O
program O
. O

Short O
- O
Term O
Impact O
of O
Staying O
Home O
on O
Bone O
Health O
in O
Patients O
With O
Osteoporosis O
During O
a O
State O
of O
Emergency O
Declaration O
Due O
to O
COVID O
- O
19 O
in O
Kanagawa O
, O
Japan O
. O

Maternal O
and O
fetal O
effects O
of O
COVID O
- O
19 O
virus O
on O
a O
complicated O
triplet O
pregnancy O
: O
a O
case O
report O
. O

The O
authors O
believe O
that O
based O
on O
current O
knowledge O
, O
KD O
treatment O
delays O
may O
carry O
deleterious O
effects O
in O
the O
near O
future O
for O
children O
with O
COVID O
- O
19 O
- O
related O
Kawasaki O
disease O
. O

We O
administered O
measures O
of O
concern O
about O
the O
spread O
of O
COVID O
- O
19 O
( O
Coronavirus O
Threat O
Scale O
; O
CTS O
) O
, O
health O
anxiety O
, O
and O
OCD O
symptoms O
to O
a O
large O
sample O
of O
community O
adults O
in O
the O
United O
States O
( O
n O
= O
738 O
) O
recruited O
through O
Amazon O
MTurk O
. O

Aerosol O
transmission O
of O
SARS O
- O
CoV O
- O
2 O
by O
children O
and O
adults O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Thrombotic O
complications O
seem O
to O
emerge O
as O
an O
important O
issue O
in O
patients O
infected O
with O
COVID O
- O
19 O
. O

Clinical O
characteristics O
of O
COVID O
- O
19 O
complicated O
with O
pleural O
effusion O
. O

Elections O
occurring O
during O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
have O
been O
affected O
by O
notable O
changes O
in O
the O
methods O
of O
voting O
, O
the O
number O
and O
type O
of O
polling O
locations O
, O
and O
in O
- O
person O
voting O
procedures O
( O
1 O
) O
. O

The O
plausible O
mechanisms O
of O
tramadol O
for O
treatment O
of O
COVID O
- O
19 O
. O

Multivariate O
analyses O
adjusting O
for O
demographics O
and O
comorbidities O
showed O
that O
an O
AI O
system O
- O
based O
score O
≥ O
30 O
on O
the O
initial O
CXR O
was O
an O
independent O
predictor O
both O
for O
mortality O
( O
HR O
2 O
. O
60 O
( O
95 O
% O
CI O
1 O
. O
69 O
- O
3 O
. O
99 O
; O
p O
< O
0 O
. O
001 O
) O
) O
and O
critical O
COVID O
- O
19 O
( O
HR O
3 O
. O
40 O
( O
95 O
% O
CI O
2 O
. O
35 O
- O
4 O
. O
94 O
; O
p O
< O
0 O
. O
001 O
) O
) O
. O

North O
American O
Neuroendocrine O
Tumor O
Society O
Guide O
for O
Neuroendocrine O
Tumor O
Patient O
Health O
Care O
Providers O
During O
COVID O
- O
19 O
. O

SIGNIFICANCE O
OF O
THE O
STUDY O
: O
This O
review O
summarized O
current O
information O
on O
COVID O
- O
19 O
( O
epidemiology O
, O
pathophysiology O
, O
clinical O
, O
laboratory O
, O
cardiovascular O
diseases O
, O
ACE2 O
and O
pharmacological O
agents O
) O
for O
researchers O
and O
reveals O
guiding O
data O
for O
researchers O
, O
especially O
in O
the O
field O
of O
cardiovascular O
system O
, O
pharmacology O
, O
dysregulation O
of O
cellular O
function O
in O
disease O
, O
molecular O
and O
cell O
biology O
and O
physiology O
in O
the O
regulation O
of O
tissue O
function O
in O
health O
and O
disease O
. O

Thus O
, O
these O
findings O
suggest O
that O
the O
population O
density O
and O
the O
lack O
of O
medical O
equipment O
are O
key O
factors O
explaining O
the O
morbidity O
and O
mortality O
of O
COVID O
- O
19 O
in O
Italy O
. O

Based O
on O
these O
premises O
, O
this O
review O
aims O
to O
discuss O
the O
most O
updated O
pharmacological O
treatments O
to O
effectively O
act O
against O
the O
SARS O
- O
CoV O
- O
2 O
infection O
and O
support O
researchers O
and O
clinicians O
in O
relation O
to O
any O
current O
and O
future O
developments O
in O
curing O
COVID O
- O
19 O
patients O
. O

We O
describe O
a O
possible O
pathophysiological O
link O
between O
COVID O
- O
19 O
and O
AF O
, O
and O
therapeutic O
considerations O
for O
AF O
patients O
during O
this O
pandemic O
. O

Potential O
Therapeutic O
Options O
for O
COVID O
- O
19 O
: O
Current O
Status O
, O
Challenges O
, O
and O
Future O
Perspectives O
. O

People O
infected O
with O
COVID O
- O
19 O
shows O
varying O
manifestations O
, O
depending O
on O
their O
health O
and O
age O
. O

The O
levels O
of O
TAT O
, O
PIC O
, O
TM O
, O
t O
- O
PAIC O
, O
PT O
, O
INR O
, O
FIB O
, O
and O
DD O
in O
COVID O
- O
19 O
patients O
were O
higher O
than O
health O
controls O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
also O
higher O
in O
the O
patients O
with O
thrombotic O
disease O
than O
without O
thrombotic O
disease O
( O
p O
< O
0 O
. O
05 O
) O
. O

We O
aimed O
to O
describe O
the O
epidemiology O
and O
clinical O
characteristics O
of O
hospitalized O
COVID O
- O
19 O
patients O
, O
and O
to O
investigate O
the O
potential O
risk O
factors O
for O
COVID O
- O
19 O
severity O
. O
1663 O
hospitalized O
patients O
with O
laboratory O
- O
confirmed O
diagnosed O
COVID O
- O
19 O
from O
Tongji O
Hospital O
between O
January O
14 O
, O
2020 O
, O
and O
February O
28 O
, O
2020 O
were O
included O
in O
the O
present O
study O
. O

We O
documented O
505 O
patients O
with O
dermatologic O
manifestations O
associated O
with O
COVID O
- O
19 O
, O
including O
318 O
( O
63 O
% O
) O
with O
pernio O
- O
like O
lesions O
. O

Media O
Analysis O
of O
News O
Articles O
During O
COVID O
- O
19 O
: O
Renewal O
, O
Continuity O
and O
Cultural O
Dimensions O
of O
Creative O
Action O
. O

Benign O
course O
of O
COVID O
- O
19 O
in O
a O
multiple O
sclerosis O
patient O
treated O
with O
Ocrelizumab O
. O

Cross O
- O
sectional O
Assessment O
of O
COVID O
- O
19 O
Vaccine O
Acceptance O
Among O
Health O
Care O
Workers O
in O
Los O
Angeles O
. O

Mediation O
analyses O
demonstrated O
two O
significant O
paths O
: O
in O
the O
first O
, O
CA O
was O
associated O
with O
elevated O
fear O
of O
COVID O
- O
19 O
( O
effect O
= O
. O
061 O
, O
. O
059 O
; O
p O
< O
0 O
. O
05 O
) O
and O
COVID O
- O
19 O
ASD O
( O
effect O
= O
. O
14 O
, O
. O
084 O
; O
p O
< O
0 O
. O
05 O
) O
through O
the O
mediation O
of O
CPTSD O
; O
in O
the O
second O
path O
, O
when O
controlling O
for O
the O
mediation O
of O
CPTSD O
, O
CA O
was O
associated O
with O
reduced O
fear O
of O
COVID O
- O
19 O
( O
effect O
= O
- O
. O
15 O
; O
p O
= O
0 O
. O
001 O
) O
, O
and O
COVID O
- O
19 O
ASD O
( O

effect O
= O
- O
. O
12 O
; O
p O
= O
0 O
. O
024 O
) O
. O

Further O
work O
is O
needed O
to O
understand O
whether O
immunomodulatory O
therapies O
affect O
COVID O
- O
19 O
incidence O
. O

Specific O
demographic O
, O
clinical O
, O
and O
imaging O
features O
are O
associated O
with O
increased O
mortality O
in O
COVID O
- O
19 O
infections O
. O

We O
performed O
a O
text O
mining O
analysis O
via O
essay O
task O
to O
clarify O
perceptions O
among O
final O
- O
year O
medical O
students O
toward O
the O
COVID O
- O
19 O
pandemic O
. O

We O
believe O
that O
the O
results O
of O
this O
survey O
will O
help O
to O
understand O
current O
heterogeneities O
in O
radiology O
practice O
and O
to O
identify O
needs O
and O
gaps O
in O
the O
organization O
and O
function O
of O
radiology O
departments O
worldwide O
in O
relation O
to O
the O
COVID O
- O
19 O
pandemic O
. O

We O
performed O
EBC O
RT O
- O
PCR O
for O
SARS O
- O
CoV O
- O
2 O
genes O
( O
E O
, O
S O
, O
N O
, O
ORF1ab O
) O
on O
NPS O
- O
positive O
( O
n O
= O
16 O
) O
and O
NPS O
- O
negative O
/ O
clinically O
positive O
COVID O
- O
19 O
patients O
( O
n O
= O
15 O
) O
using O
two O
commercial O
assays O
. O

This O
study O
provides O
evidence O
on O
the O
epidemic O
of O
COVID O
- O
19 O
by O
analyzing O
the O
epidemiological O
characteristics O
of O
confirmed O
cases O
in O
Tianjin O
. O

While O
protecting O
groups O
vulnerable O
to O
influenza O
is O
likely O
a O
useful O
starting O
point O
in O
the O
response O
to O
COVID O
- O
19 O
, O
strategies O
will O
likely O
need O
to O
be O
broadened O
to O
reflect O
the O
particular O
characteristics O
of O
individuals O
being O
hospitalised O
with O
COVID O
- O
19 O
. O

Clinical O
Practice O
Guidelines O
and O
Experts O
' O
Consensuses O
for O
Treatment O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Patients O
with O
Chinese O
Herbal O
Medicine O
: O
A O
Systematic O
Review O
. O

To O
investigate O
the O
effects O
of O
renin O
- O
angiotensin O
- O
aldosterone O
system O
( O
RAAS O
) O
inhibitors O
on O
the O
prognosis O
in O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Lichenoid O
eruptions O
with O
interface O
dermatitis O
and O
necrotic O
subepidermal O
blister O
associated O
with O
COVID O
- O
19 O
. O

Telehealth O
Use O
Among O
Safety O
- O
Net O
Organizations O
in O
California O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Criticality O
of O
physical O
/ O
social O
distancing O
, O
handwashing O
, O
respiratory O
hygiene O
and O
face O
- O
masking O
during O
the O
COVID O
- O
19 O
pandemic O
and O
beyond O
. O

This O
study O
indicates O
that O
the O
interaction O
energy O
of O
the O
top O
ten O
retrieved O
compounds O
with O
COVID O
- O
19 O
main O
protease O
is O
much O
higher O
than O
the O
interaction O
energy O
of O
some O
currently O
in O
use O
protease O
drugs O
such O
as O
ML188 O
, O
nelfinavir O
, O
lopinavir O
, O
ritonavir O
, O
and O
α O
- O
ketoamide O
. O

Independent O
associations O
between O
regional O
PM2 O
. O
5 O
/ O
PM10 O
exposure O
and O
COVID O
- O
19 O
incidence O
proportion O
and O
death O
rate O
were O
observed O
( O
COVID O
- O
19 O
incidence O
proportion O
: O
β O
= O
0 O
. O
71 O
, O
p O
= O
0 O
. O
003 O
, O
β O
= O
0 O
. O
61 O
, O
p O
= O
0 O
. O
031 O
, O
respectively O
; O
COVID O
- O
19 O
death O
rate O
: O
β O
= O
0 O
. O
68 O
, O
p O
= O
0 O
. O
004 O
and O
β O
= O
0 O
. O
61 O
, O
p O
= O
0 O
. O
029 O
, O
respectively O
) O
. O

COVID O
- O
19 O
dramatically O
affected O
radiology O
residencies O
during O
the O
early O
pandemic O
period O
. O

This O
analyses O
is O
interesting O
as O
a O
consequence O
of O
the O
strong O
causal O
relationship O
between O
the O
coronavirus O
( O
number O
of O
confirmed O
cases O
) O
and O
the O
commodity O
prices O
, O
the O
prediction O
of O
the O
evolution O
of O
COVID O
- O
19 O
can O
be O
useful O
to O
anticipate O
the O
future O
direction O
of O
the O
commodity O
prices O
. O

Methods O
: O
We O
conducted O
a O
web O
- O
based O
survey O
to O
investigate O
the O
behavioral O
responses O
during O
quarantine O
due O
to O
the O
COVID O
- O
19 O
outbreak O
in O
a O
cohort O
of O
pediatric O
patients O
with O
type O
1 O
diabetes O
. O

COVID O
- O
19 O
outbroke O
in O
Wuhan O
, O
China O
, O
in O
December O
2019 O
and O
promptly O
became O
a O
pandemic O
worldwide O
, O
endangering O
health O
and O
life O
but O
also O
causing O
mild O
- O
to O
- O
severe O
psychological O
distress O
to O
lots O
of O
people O
, O
including O
healthcare O
workers O
( O
HCWs O
) O
. O

We O
aim O
to O
describe O
electrolyte O
disturbance O
and O
explore O
risk O
factors O
for O
COVID O
- O
19 O
infection O
in O
patients O
visiting O
the O
ED O
. O

The O
DL O
algorithm O
achieved O
an O
AUC O
of O
0 O
. O
81 O
, O
sensitivity O
of O
0 O
. O
85 O
, O
and O
specificity O
of O
0 O
. O
72 O
in O
detecting O
COVID O
- O
19 O
using O
RT O
- O
PCR O
as O
the O
reference O
standard O
. O

The O
world O
is O
reeling O
under O
the O
crisis O
caused O
by O
corona O
virus O
disease O
( O
COVID O
- O
19 O
) O
, O
print O
, O
electronic O
and O
social O
media O
are O
flooded O
with O
numerous O
advisories O
issued O
by O
governments O
and O
other O
national O
& O
international O
agencies O
. O

Objective O
: O
To O
investigate O
the O
severity O
of O
stress O
, O
anxiety O
, O
depression O
and O
insomnia O
during O
the O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
in O
adults O
outside O
Hubei O
Province O
, O
China O
. O

Malignant O
Arrhythmias O
in O
Patients O
With O
COVID O
- O
19 O
: O
Incidence O
, O
Mechanisms O
, O
and O
Outcomes O
. O

A O
case O
series O
of O
COVID O
- O
19 O
patients O
with O
RD O
on O
disease O
modifying O
anti O
- O
rheumatic O
drugs O
( O
DMARDs O
) O
were O
studied O
by O
a O
retrospective O
chart O
review O
. O

All O
nursing O
homes O
from O
30 O
states O
that O
reported O
COVID O
- O
19 O
cases O
at O
the O
facility O
- O
level O
. O

Disposable O
customized O
aerosol O
containment O
chamber O
for O
oral O
cancer O
biopsy O
: O
A O
novel O
technique O
during O
COVID O
- O
19 O
pandemic O
. O

We O
examine O
these O
processes O
during O
the O
COVID O
- O
19 O
outbreak O
in O
Italy O
by O
leveraging O
data O
from O
Twitter O
and O
two O
online O
surveys O
, O
including O
a O
survey O
experiment O
. O

Its O
role O
was O
expanded O
in O
response O
to O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
which O
has O
placed O
unprecedented O
demands O
on O
health O
care O
workers O
and O
spotlighted O
the O
need O
for O
FHP O
strategies O
. O

A O
total O
of O
51 O
studies O
comprising O
571 O
pregnant O
women O
with O
COVID O
- O
19 O
pneumonia O
were O
included O
in O
the O
study O
. O

World O
Health O
Organization O
' O
s O
SOLIDARITY O
trial O
is O
a O
classic O
example O
of O
the O
global O
research O
protocol O
which O
can O
evaluate O
the O
preferred O
treatment O
to O
combat O
COVID O
- O
19 O
pandemic O
. O

T O
cells O
from O
COVID O
- O
19 O
patients O
had O
significantly O
higher O
levels O
of O
the O
exhausted O
marker O
PD O
- O
1 O
. O

The O
COVID O
- O
19 O
pandemic O
poses O
an O
existential O
threat O
to O
many O
US O
residential O
colleges O
: O
either O
they O
open O
their O
doors O
to O
students O
in O
September O
or O
they O
risk O
serious O
financial O
consequences O
. O

Teaching O
Analytical O
Chemistry O
in O
the O
Time O
of O
COVID O
- O
19 O
. O

Comparing O
News O
Articles O
and O
Tweets O
About O
COVID O
- O
19 O
in O
Brazil O
: O
Sentiment O
Analysis O
and O
Topic O
Modeling O
Approach O
. O

Vaccinating O
children O
against O
COVID O
- O
19 O
would O
contribute O
to O
the O
control O
of O
the O
pandemic O
and O
the O
recovery O
of O
the O
global O
economy O
. O

Using O
telehealth O
, O
we O
avoided O
exposure O
to O
a O
COVID O
- O
19 O
- O
positive O
patient O
who O
would O
not O
have O
met O
criteria O
for O
testing O
or O
droplet O
precautions O
. O

This O
study O
investigates O
individuals O
' O
health O
perceptions O
and O
health O
anxiety O
within O
the O
framework O
of O
functional O
health O
patterns O
( O
FHP O
) O
during O
COVID O
- O
19 O
pandemic O
. O

The O
information O
on O
serial O
interval O
can O
be O
useful O
in O
developing O
various O
policies O
regarding O
contact O
tracing O
and O
monitoring O
community O
transmission O
of O
COVID O
- O
19 O
. O

Despite O
these O
limitations O
, O
the O
development O
of O
COVID O
- O
19 O
treatment O
strategies O
has O
been O
accelerated O
to O
improve O
the O
clinical O
outcome O
of O
patients O
with O
COVID O
- O
19 O
, O
and O
some O
countries O
have O
efficiently O
kept O
it O
under O
control O
. O

Since O
the O
first O
recorded O
case O
of O
SARS O
- O
CoV O
- O
2 O
in O
Bangladesh O
on O
8th O
March O
2020 O
, O
COVID O
- O
19 O
has O
spread O
widely O
through O
different O
regions O
of O
the O
country O
, O
resulting O
in O
a O
necessity O
to O
re O
- O
evaluate O
the O
delivery O
of O
cardiovascular O
services O
, O
particularly O
procedures O
pertaining O
to O
interventional O
cardiology O
in O
resource O
- O
limited O
settings O
. O

The O
authors O
conducted O
a O
comprehensive O
electronic O
search O
and O
found O
three O
eligible O
studies O
, O
none O
of O
which O
was O
conducted O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
causative O
agent O
of O
coronavirus O
disease O
19 O
( O
COVID O
- O
19 O
) O
has O
rapidly O
spread O
to O
the O
entire O
world O
within O
a O
few O
months O
. O

The O
aim O
of O
this O
paper O
is O
to O
investigate O
the O
geographic O
reach O
of O
different O
language O
courses O
accessed O
by O
a O
worldwide O
audience O
seeking O
information O
on O
COVID O
- O
19 O
. O

Impact O
of O
coronavirus O
disease O
- O
2019 O
on O
chronic O
respiratory O
disease O
in O
South O
Korea O
: O
an O
NHIS O
COVID O
- O
19 O
database O
cohort O
study O
. O

[ O
Perception O
of O
the O
COVID O
- O
19 O
Pandemic O
among O
Pneumology O
Professionals O
in O
Germany O
] O
. O

The O
COVID O
- O
19 O
epidemic O
in O
the O
United O
States O
has O
hit O
in O
the O
midst O
of O
the O
opioid O
overdose O
crisis O
. O

This O
review O
presents O
supporting O
evidence O
of O
the O
impact O
of O
IL O
- O
15 O
immunotherapy O
on O
COVID O
- O
19 O
. O

Myocardial O
injury O
, O
detected O
by O
elevated O
plasma O
troponin O
levels O
, O
has O
been O
associated O
with O
mortality O
in O
patients O
hospitalized O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

To O
develop O
a O
protocol O
for O
a O
scoping O
review O
mapping O
as O
well O
as O
thematically O
analyzing O
the O
literature O
on O
the O
effect O
of O
, O
and O
responses O
to O
, O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
focused O
on O
people O
with O
disabilities O
with O
other O
layers O
of O
individual O
vulnerability O
or O
social O
disadvantage O
. O

Rainfall O
was O
not O
related O
whilst O
wind O
- O
speed O
plays O
positive O
role O
in O
spread O
of O
COVID O
- O
19 O
. O

Rapid O
Deployment O
of O
Chiropractic O
Telehealth O
at O
2 O
Worksite O
Health O
Centers O
in O
Response O
to O
the O
COVID O
- O
19 O
Pandemic O
: O
Observations O
from O
the O
Field O
. O

Working O
from O
home O
and O
income O
inequality O
: O
risks O
of O
a O
' O
new O
normal O
' O
with O
COVID O
- O
19 O
. O

The O
inverse O
correlation O
between O
BCG O
vaccination O
rates O
and O
COVID O
- O
19 O
case O
( O
r O
= O
- O
0 O
. O
338 O
, O
p O
= O
0 O
. O
0082 O
) O
and O
death O
( O
r O
= O
- O
0 O
. O
411 O
, O
p O
= O
0 O
. O
0011 O
) O
remained O
significant O
among O
the O
top O
61 O
countries O
with O
highest O
median O
age O
. O

Potential O
candidates O
will O
be O
identified O
and O
consecutively O
included O
in O
the O
emergency O
room O
or O
in O
the O
COVID O
- O
19 O
admission O
wards O
of O
two O
hospitals O
in O
Spain O
: O
Complejo O
Hospitalario O
de O
Navarra O
( O
Pamplona O
) O
and O
Hospital O
Mois O
è O
s O
Broggi O
( O
Sant O
Joan O
Desp O
í O
, O
Barcelona O
) O
. O

Estimating O
actual O
COVID O
- O
19 O
case O
numbers O
using O
cumulative O
death O
count O
- O
A O
method O
of O
measuring O
effectiveness O
of O
lockdown O
of O
non O
- O
essential O
activities O
: O
a O
South O
African O
case O
study O
. O

Based O
on O
the O
method O
of O
evidence O
- O
based O
pharmacy O
, O
clinical O
evidence O
of O
therapeutical O
drugs O
for O
COVID O
- O
19 O
were O
retrieved O
and O
summarized O
. O

Here O
we O
present O
results O
from O
a O
multiplex O
serology O
test O
for O
assessing O
the O
antibody O
responses O
to O
COVID O
- O
19 O
. O

We O
searched O
for O
publications O
related O
to O
ageism O
during O
the O
COVID O
- O
19 O
pandemic O
in O
Pubmed O
, O
Medline O
, O
and O
Embase O
. O

Inflammatory O
Bowel O
Disease O
Management O
During O
the O
COVID O
- O
19 O
Outbreak O
: O
The O
Ten O
Do O
' O
s O
and O
Don O
' O
ts O
from O
the O
ECCO O
- O
COVID O
Taskforce O
. O

We O
analyzed O
and O
compared O
the O
clinical O
manifestations O
, O
laboratory O
findings O
and O
radiological O
features O
of O
two O
independent O
cohorts O
of O
patients O
diagnosed O
with O
either O
COVID O
- O
19 O
( O
n O
= O
36 O
) O
or O
adenovirus O
pneumonia O
( O
n O
= O
18 O
) O
. O

Coronavirus O
Disease O
( O
COVID O
- O
19 O
) O
in O
Children O
: O
Indian O
Perspectives O
. O

Considering O
the O
risks O
and O
benefits O
, O
biologics O
for O
dermatological O
conditions O
might O
be O
continuously O
used O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Among O
other O
diagnostic O
tools O
, O
the O
CRISPR O
- O
Cas O
system O
is O
being O
investigated O
for O
rapid O
and O
specific O
diagnosis O
of O
COVID O
- O
19 O
. O

Letter O
to O
the O
Editor O
in O
Response O
to O
" O
COVID O
- O
19 O
and O
the O
Correctional O
Environment O
: O
The O
American O
Prison O
as O
a O
Focal O
Point O
for O
Public O
Health O
" O
. O

Novel O
and O
Controversial O
Therapies O
in O
COVID O
- O
19 O
. O

Dental O
profession O
is O
labeled O
as O
a O
high O
- O
risk O
profession O
, O
due O
to O
which O
dental O
care O
professionals O
are O
under O
tremendous O
pressure O
during O
the O
outbreak O
of O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
is O
a O
type O
of O
Novel O
Coronavirus O
Pneumonia O
( O
NCP O
) O
. O

Health O
care O
related O
to O
essential O
services O
has O
been O
affected O
by O
the O
pandemic O
with O
a O
reduction O
of O
visits O
for O
non O
- O
COVID O
- O
19 O
causes O
, O
which O
should O
serve O
as O
an O
alert O
for O
the O
health O
system O
in O
order O
not O
to O
lose O
the O
ground O
gained O
on O
this O
front O
. O

Translating O
Scientific O
Knowledge O
to O
Government O
Decision O
Makers O
Has O
Crucial O
Importance O
in O
the O
Management O
of O
the O
COVID O
- O
19 O
Pandemic O
. O

To O
reduce O
occurrence O
of O
severe O
illness O
from O
COVID O
- O
19 O
, O
pregnant O
women O
should O
be O
counseled O
about O
the O
potential O
risk O
for O
severe O
illness O
from O
COVID O
- O
19 O
, O
and O
measures O
to O
prevent O
infection O
with O
SARS O
- O
CoV O
- O
2 O
should O
be O
emphasized O
for O
pregnant O
women O
and O
their O
families O
. O

Due O
to O
the O
COVID O
- O
19 O
pandemic O
, O
Spring O
2020 O
quarter O
data O
was O
not O
included O
, O
given O
the O
transition O
of O
all O
classes O
to O
an O
online O
learning O
environment O
. O

Urgent O
measures O
to O
address O
issues O
connected O
to O
COVID O
- O
19 O
pandemic O
are O
, O
therefore O
, O
needed O
. O

COVID O
- O
19 O
, O
domestic O
violence O
and O
abuse O
, O
and O
urgent O
dental O
and O
oral O
and O
maxillofacial O
surgery O
care O
. O

These O
low O
values O
might O
have O
contributed O
to O
a O
deficiency O
in O
their O
immune O
response O
and O
thus O
made O
these O
patients O
susceptible O
to O
COVID O
- O
19 O
infection O
. O

We O
present O
preliminary O
results O
of O
a O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
impact O
assessment O
on O
testing O
for O
HIV O
, O
viral O
hepatitis O
and O
sexually O
transmitted O
infections O
in O
the O
WHO O
European O
Region O
. O

CT O
features O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pneumonia O
: O
experience O
of O
a O
single O
center O
in O
Southern O
Italy O
. O

Are O
SAARC O
countries O
prepared O
to O
combat O
COVID O
- O
19 O
to O
save O
young O
, O
working O
- O
age O
population O
? O

A O
total O
of O
6894 O
patients O
were O
tested O
for O
COVID O
- O
19 O
. O

Yet O
, O
dynamic O
changes O
in O
IL O
- O
6 O
levels O
and O
their O
prognostic O
value O
as O
an O
indicator O
of O
lung O
injury O
in O
COVID O
- O
19 O
patients O
have O
not O
been O
fully O
elucidated O
. O

Meanwhile O
, O
spatial O
autocorrelation O
, O
spatiotemporal O
clustering O
analysis O
and O
kernel O
density O
method O
were O
also O
applied O
to O
analyse O
the O
spatial O
clustering O
of O
COVID O
- O
19 O
. O

Since O
December O
2019 O
, O
novel O
coronavirus O
- O
( O
SARS O
- O
CoV O
- O
2 O
) O
infected O
pneumonia O
( O
COVID O
- O
19 O
) O
has O
rapidly O
spread O
throughout O
China O
. O

Novel O
Design O
for O
Door O
Handle O
- O
A O
Potential O
Technology O
to O
Reduce O
Hand O
Contamination O
in O
the O
COVID O
- O
19 O
Pandemic O
. O

Cardiac O
injury O
is O
associated O
with O
mortality O
and O
critically O
ill O
pneumonia O
in O
COVID O
- O
19 O
: O
A O
meta O
- O
analysis O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
a O
public O
health O
emergency O
posing O
unprecedented O
challenges O
for O
health O
authorities O
. O

Cerebrovascular O
and O
cardiovascular O
diseases O
were O
associated O
with O
an O
increased O
risk O
for O
poor O
outcome O
in O
patients O
with O
COVID O
- O
19 O
. O

The O
cohorts O
included O
four O
COVID O
- O
19 O
inpatients O
, O
four O
cases O
with O
postmortem O
SARS O
- O
CoV O
- O
2 O
diagnoses O
who O
died O
in O
the O
community O
, O
and O
eight O
SARS O
- O
CoV O
- O
2 O
- O
negative O
control O
cases O
. O

In O
conclusion O
, O
several O
haematological O
morphological O
abnormalities O
are O
more O
frequent O
in O
patients O
with O
COVID O
- O
19 O
disease O
, O
and O
several O
findings O
indicate O
that O
platelets O
play O
a O
fundamental O
role O
in O
the O
pathophysiology O
of O
the O
disease O
. O

Many O
subsequent O
studies O
revealed O
viral O
RNA O
of O
SARS O
- O
CoV O
- O
2 O
in O
fecal O
samples O
of O
COVID O
- O
19 O
patients O
. O

Monoclonal O
antibodies O
and O
antibody O
cocktails O
are O
a O
promising O
therapeutic O
and O
prophylaxis O
for O
COVID O
- O
19 O
. O

An O
additional O
210 O
( O
8 O
. O
7 O
% O
) O
cases O
were O
identified O
among O
2 O
, O
403 O
contacts O
of O
employees O
with O
diagnosed O
COVID O
- O
19 O
. O

Recent O
Understandings O
Toward O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
: O
From O
Bench O
to O
Bedside O
. O

This O
review O
discuss O
how O
mitochondrial O
dysfunction O
is O
associated O
with O
defective O
immune O
response O
in O
aging O
and O
different O
age O
- O
related O
diseases O
, O
and O
with O
many O
of O
the O
comorbidities O
associated O
with O
poor O
prognosis O
in O
the O
progression O
of O
COVID O
- O
19 O
. O

Immune O
Thrombocytopenic O
Purpura O
- O
Different O
Presentations O
in O
Two O
COVID O
- O
19 O
Patients O
. O

Women O
with O
COVID O
- O
19 O
have O
a O
high O
rate O
of O
preterm O
birth O
and O
CS O
. O
148 O
( O
6 O
. O
2 O
% O
) O
newborns O
isolated O
COVID O
- O
19 O
. O

As O
of O
May O
27th O
, O
the O
disease O
caused O
by O
SARS O
- O
CoV O
- O
2 O
( O
COVID O
- O
19 O
) O
has O
resulted O
in O
more O
than O
340 O
, O
000 O
deaths O
worldwide O
, O
with O
100 O
, O
000 O
deaths O
in O
the O
US O
alone O
. O

The O
case O
presentation O
is O
followed O
by O
a O
review O
of O
the O
literature O
to O
date O
on O
COVID O
- O
19 O
in O
regard O
to O
inflammatory O
bowel O
disease O
and O
pregnancy O
, O
respectively O
. O

In O
line O
with O
findings O
of O
this O
study O
, O
there O
is O
a O
dire O
need O
to O
initiate O
psychotherapeutic O
studies O
for O
medical O
professionals O
to O
boost O
up O
their O
psychosocial O
strengths O
that O
would O
make O
them O
resilient O
against O
COVID O
- O
19 O
. O

Diagnosis O
of O
vitamin O
D O
deficiency O
could O
be O
a O
helpful O
adjunct O
in O
assessing O
patients O
' O
potential O
of O
developing O
severe O
COVID O
- O
19 O
. O

As O
the O
radiation O
oncology O
research O
community O
was O
forced O
to O
work O
from O
home O
during O
the O
COVID O
- O
19 O
pandemic O
, O
lessons O
can O
be O
learned O
to O
face O
future O
adverse O
situations O
but O
also O
to O
improve O
work O
- O
life O
balance O
in O
general O
. O

Protease O
- O
activated O
receptor O
type O
1 O
( O
PAR1 O
) O
is O
the O
main O
thrombin O
receptor O
and O
may O
represent O
an O
essential O
link O
between O
coagulation O
and O
inflammation O
in O
the O
pathophysiology O
of O
COVID O
- O
19 O
. O

Current O
national O
primary O
care O
guidelines O
for O
COVID O
- O
19 O
provide O
guidance O
on O
infection O
control O
and O
minimising O
the O
risk O
of O
spread O
in O
primary O
care O
practices O
, O
while O
supporting O
the O
use O
of O
new O
technology O
and O
coordinated O
partnerships O
. O

The O
Effect O
of O
Social O
Media O
on O
Stress O
among O
Young O
Adults O
during O
COVID O
- O
19 O
Pandemic O
: O
Taking O
into O
Account O
Fatalism O
and O
Social O
Media O
Exhaustion O
. O

The O
Global O
Consortium O
to O
Study O
Neurological O
dysfunction O
in O
COVID O
- O
19 O
( O
GCS O
- O
NeuroCOVID O
) O
, O
endorsed O
by O
the O
Neurocritical O
Care O
Society O
( O
NCS O
) O
, O
was O
rapidly O
established O
to O
address O
this O
need O
in O
a O
tiered O
approach O
. O

Thereafter O
Lombardy O
has O
reported O
the O
highest O
prevalence O
of O
COVID O
- O
19 O
cases O
in O
the O
country O
, O
especially O
in O
Milano O
, O
Brescia O
and O
Bergamo O
provinces O
. O

As O
the O
number O
of O
COVID O
- O
19 O
cases O
increased O
in O
Massachusetts O
, O
the O
Massachusetts O
Department O
of O
Public O
Health O
mandated O
that O
all O
health O
care O
workers O
be O
screened O
for O
symptoms O
daily O
prior O
to O
entering O
any O
hospital O
or O
health O
care O
facility O
. O

Deaths O
from O
COVID O
- O
19 O
in O
healthcare O
workers O
in O
Italy O
- O
What O
can O
we O
learn O
? O

First O
, O
at O
the O
individual O
level O
, O
we O
deeply O
characterized O
3 O
acutely O
infected O
and O
58 O
recovered O
COVID O
- O
19 O
subjects O
by O
experimentally O
mapping O
their O
CD8 O
T O
- O
cell O
response O
through O
antigen O
stimulation O
to O
545 O
Human O
Leukocyte O
Antigen O
( O
HLA O
) O
class O
I O
presented O
viral O
peptides O
( O
class O
II O
data O
in O
a O
forthcoming O
study O
) O
. O

This O
paper O
examines O
the O
county O
- O
scale O
spatial O
and O
temporal O
patterns O
of O
confirmed O
cases O
of O
COVID O
- O
19 O
for O
South O
Carolina O
from O
March O
1st O
- O
September O
5th O
, O
2020 O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
caused O
enormous O
psychological O
impact O
worldwide O
. O

Extracted O
data O
included O
country O
, O
the O
total O
number O
of O
COVID O
- O
19 O
cases O
and O
the O
number O
of O
related O
deaths O
by O
gender O
. O

Osteoporosis O
and O
fragility O
fractures O
in O
elderly O
individuals O
pose O
a O
real O
challenge O
for O
an O
appropriate O
diagnosis O
and O
management O
, O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
efficacy O
of O
the O
DL O
algorithm O
for O
detecting O
COVID O
- O
19 O
pneumonia O
on O
CR O
compared O
with O
formal O
radiology O
reports O
. O

COVID O
- O
19 O
in O
children O
: O
the O
link O
in O
the O
transmission O
chain O
. O

In O
patients O
with O
moderate O
COVID O
- O
19 O
, O
antimalarial O
or O
antiviral O
agents O
were O
applied O
( O
78 O
% O
) O
. O
30 O
% O
of O
our O
observed O
patients O
died O
during O
the O
hospitalisation O
. O

When O
the O
COVID O
- O
19 O
pandemic O
struck O
US O
hospitals O
in O
early O
2020 O
, O
many O
nurse O
leaders O
went O
into O
crisis O
mode O
management O
. O

[ O
COVID O
- O
19 O
and O
resuming O
elective O
surgery O
. O
How O
do O
we O
get O
back O
to O
normal O
? O
] O

Elevated O
vitamin O
D O
levels O
could O
decrease O
COVID O
- O
19 O
PCR O
positivity O
, O
D O
- O
dime O
and O
CRP O
levels O
and O
the O
number O
of O
affected O
lung O
segments O
in O
COVID O
- O
19 O
- O
positive O
patients O
, O
thereby O
shortening O
the O
duration O
of O
hospital O
stays O
and O
alleviating O
the O
intensity O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
Pandemic O
and O
Mental O
Health O
of O
Vulnerable O
Two O
Groups O
: O
Developmental O
Trauma O
of O
the O
Child O
- O
Adolescents O
and O
Work O
Disaster O
of O
Health O
Care O
Workers O
. O

Comment O
on O
: O
Effectiveness O
of O
remdesivir O
in O
patients O
with O
COVID O
- O
19 O
under O
mechanical O
ventilation O
in O
an O
Italian O
ICU O
. O

The O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
is O
causing O
wide O
- O
spread O
interruptions O
in O
medical O
education O
. O

So O
far O
, O
cancer O
screening O
has O
been O
a O
causality O
of O
COVID O
- O
19 O
; O
however O
, O
the O
opposite O
may O
transpire O
for O
self O
- O
sampling O
. O

In O
this O
paper O
, O
the O
authors O
review O
the O
safety O
and O
practicality O
of O
elastomeric O
respirators O
for O
protecting O
themselves O
and O
others O
from O
the O
novel O
coronavirus O
or O
COVID O
- O
19 O
. O

In O
this O
study O
, O
we O
aimed O
to O
find O
out O
the O
30 O
- O
day O
readmission O
rate O
of O
mild O
and O
moderate O
severity O
coronavirus O
disease O
of O
2019 O
( O
COVID O
- O
19 O
) O
patients O
discharged O
from O
a O
tertiary O
care O
university O
hospital O
and O
to O
demonstrate O
the O
possible O
factors O
associated O
with O
readmission O
. O

Correction O
to O
: O
A O
randomized O
, O
open O
- O
label O
, O
adaptive O
, O
proof O
- O
of O
- O
concept O
clinical O
trial O
of O
modulation O
of O
host O
thromboinflammatory O
response O
in O
patients O
with O
COVID O
- O
19 O
: O
the O
DAWn O
- O
Antico O
study O
. O

Recent O
COVID O
- O
19 O
pandemic O
guidelines O
recommend O
genomic O
assessment O
of O
core O
biopsies O
to O
help O
guide O
treatment O
decisions O
in O
estrogen O
receptor O
( O
ER O
) O
- O
positive O
early O
- O
stage O
breast O
cancer O
. O

Finally O
, O
we O
provide O
a O
framework O
describing O
the O
different O
strategies O
, O
the O
advantages O
, O
and O
the O
challenges O
involved O
in O
obtaining O
useful O
TCR O
repertoire O
data O
to O
advance O
our O
fight O
against O
COVID O
- O
19 O
. O

This O
study O
aims O
to O
outline O
the O
main O
characteristics O
of O
deep O
venous O
thrombosis O
( O
DVT O
) O
and O
pulmonary O
embolism O
( O
PE O
) O
in O
COVID O
- O
19 O
patients O
, O
based O
on O
the O
experience O
of O
four O
high O
- O
volume O
COVID O
- O
19 O
hospitals O
in O
Northern O
Italy O
. O

This O
study O
gathered O
preliminary O
data O
on O
the O
impact O
of O
the O
U O
. O
S O
. O
response O
to O
the O
COVID O
- O
19 O
pandemic O
on O
the O
substance O
use O
, O
sexual O
behavior O
, O
and O
general O
well O
- O
being O
of O
U O
. O
S O
. O
college O
students O
. O

From O
a O
social O
science O
perspective O
at O
least O
, O
there O
is O
' O
no O
easy O
answer O
' O
to O
why O
one O
area O
should O
experience O
COVID O
- O
19 O
differently O
from O
another O
. O

COVID O
- O
19 O
disease O
with O
a O
high O
rate O
of O
contagious O
and O
highly O
nonspecific O
symptoms O
, O
is O
an O
infectious O
disease O
caused O
by O
a O
newly O
discovered O
coronavirus O
. O

Successful O
maintenance O
of O
process O
and O
outcomes O
for O
oesophageal O
cancer O
surgery O
in O
Ireland O
during O
the O
first O
wave O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Gustatory O
dysfunction O
seems O
to O
be O
an O
understudied O
symptom O
of O
COVID O
- O
19 O
and O
this O
may O
explain O
the O
inconsistencies O
of O
diagnostic O
criteria O
for O
COVID O
- O
19 O
case O
definition O
. O

This O
case O
demonstrates O
a O
lack O
of O
passive O
immunity O
of O
COVID O
- O
19 O
antibodies O
from O
a O
positive O
pregnant O
woman O
to O
her O
fetus O
, O
neither O
in O
utero O
nor O
at O
the O
time O
of O
birth O
. O

For O
- O
profit O
status O
is O
associated O
with O
the O
extent O
of O
an O
outbreak O
of O
COVID O
- O
19 O
in O
LTC O
homes O
and O
the O
number O
of O
resident O
deaths O
, O
but O
not O
the O
likelihood O
of O
outbreaks O
. O

COVID O
- O
19 O
Stress O
and O
Addictive O
Social O
Media O
Use O
( O
SMU O
) O
: O
Mediating O
Role O
of O
Active O
Use O
and O
Social O
Media O
Flow O
. O

Regarding O
fear O
about O
COVID O
- O
19 O
, O
patients O
with O
depression O
or O
anxiety O
showed O
higher O
scores O
on O
the O
fear O
questionnaire O
( O
p O
- O
value O
= O
0 O
. O
03 O
, O
p O
- O
value O
= O
0 O
. O
008 O
respectively O
) O
. O

Despite O
COVID O
- O
19 O
positivity O
of O
34 O
. O
8 O
% O
( O
46 O
of O
132 O
beds O
) O
, O
a O
risk O
- O
free O
management O
of O
hospital O
operation O
is O
possible O
to O
a O
certain O
extent O
if O
hygiene O
regulations O
and O
strict O
patient O
selection O
are O
followed O
. O

Real O
- O
time O
dissemination O
of O
epidemiological O
survey O
data O
from O
positive O
COVID O
- O
19 O
cases O
is O
critical O
to O
support O
efforts O
to O
contain O
or O
reduce O
spread O
of O
viral O
infection O
in O
the O
community O
. O

In O
order O
to O
help O
decide O
how O
to O
get O
the O
maximum O
health O
yield O
from O
this O
limited O
supply O
, O
we O
implemented O
a O
logistic O
regression O
model O
to O
predict O
COVID O
- O
19 O
death O
risk O
by O
age O
, O
race O
, O
and O
sex O
and O
did O
the O
same O
to O
predict O
COVID O
- O
19 O
case O
risk O
. O

Patients O
with O
cerebellar O
ataxia O
( O
CA O
) O
are O
particularly O
vulnerable O
to O
severe O
outcome O
if O
they O
contract O
COVID O
- O
19 O
because O
of O
the O
complexity O
of O
their O
disease O
, O
the O
presence O
of O
comorbidities O
, O
and O
their O
use O
of O
immunosuppressive O
therapies O
. O

US O
exports O
of O
beef O
and O
pork O
were O
particularly O
impacted O
by O
a O
wave O
of O
processing O
facility O
shutdowns O
in O
the O
wake O
of O
COVID O
- O
19 O
outbreaks O
among O
workers O
. O

We O
used O
internet O
search O
volume O
data O
from O
Google O
Trends O
to O
measure O
population O
- O
level O
interest O
in O
telehealth O
and O
telemedicine O
between O
January O
21 O
, O
2020 O
( O
when O
the O
first O
COVID O
- O
19 O
case O
was O
reported O
) O
, O
and O
March O
18 O
, O
2020 O
. O

Screening O
with O
HRCT O
chest O
and O
PCR O
testing O
for O
COVID O
- O
19 O
in O
asymptomatic O
patients O
undergoing O
a O
surgical O
or O
diagnostic O
procedure O
. O

COVID O
- O
19 O
and O
diabetes O
: O
Insulin O
requirements O
parallel O
illness O
severity O
in O
critically O
unwell O
patients O
. O

COVID O
- O
19 O
is O
now O
a O
global O
pandemic O
. O

As O
of O
October O
2020 O
, O
there O
are O
> O
1 O
million O
documented O
deaths O
with O
COVID O
- O
19 O
. O

Evidence O
suggests O
that O
the O
negative O
consequences O
of O
COVID O
- O
19 O
may O
extend O
far O
beyond O
its O
considerable O
death O
toll O
, O
having O
a O
significant O
impact O
on O
psychological O
well O
- O
being O
. O

All O
patients O
received O
hydroxychloroquine O
( O
400 O
mg O
twice O
daily O
for O
10 O
days O
) O
because O
that O
was O
part O
of O
standard O
of O
care O
treatment O
in O
Brazil O
for O
patients O
with O
severe O
COVID O
- O
19 O
. O

Furthermore O
, O
they O
were O
3 O
times O
more O
likely O
to O
experience O
COVID O
- O
19 O
mortality O
( O
OR O
3 O
. O
27 O
95 O
% O
CI O
1 O
. O
39 O
- O
7 O
. O
68 O
, O
P O
< O
. O
0001 O
) O
, O
compared O
to O
controls O
. O

Establishing O
a O
separate O
site O
with O
screening O
for O
COVID O
- O
19 O
infection O
can O
allow O
safe O
emergency O
surgery O
. O

Those O
students O
who O
had O
the O
worst O
evaluated O
current O
GSRH O
, O
in O
comparison O
to O
the O
situation O
before O
the O
COVID O
- O
19 O
outbreak O
, O
also O
demonstrated O
higher O
levels O
of O
anxiety O
, O
perceived O
stress O
, O
and O
emotion O
- O
oriented O
coping O
styles O
. O

Among O
943 O
COVID O
- O
19 O
patients O
, O
909 O
( O
96 O
. O
4 O
% O
) O
were O
severe O
or O
critical O
type O
. O

COVID O
- O
19 O
and O
thrombosis O
: O
Beyond O
a O
casual O
association O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
challenged O
this O
paradigm O
, O
particularly O
in O
the O
setting O
of O
cardiovascular O
disease O
( O
CVD O
) O
. O

The O
mixed O
- O
methods O
, O
cross O
- O
sectional O
survey O
assessed O
participants O
' O
perspectives O
regarding O
( O
1 O
) O
changes O
in O
physical O
, O
financial O
, O
professional O
, O
social O
, O
relational O
, O
and O
psychological O
levels O
of O
concern O
and O
( O
2 O
) O
the O
general O
impact O
of O
SIP O
due O
to O
COVID O
- O
19 O
, O
as O
well O
as O
the O
unique O
impact O
as O
a O
current O
or O
former O
foster O
youth O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
first O
reported O
in O
Kenya O
on O
March O
13 O
, O
2020 O
, O
is O
spreading O
rapidly O
. O

Automatic O
Screening O
of O
COVID O
- O
19 O
Using O
an O
Optimized O
Generative O
Adversarial O
Network O
. O

Dentists O
' O
Knowledge O
, O
Attitudes O
, O
and O
Awareness O
of O
Infection O
Control O
Measures O
during O
COVID O
- O
19 O
Outbreak O
: O
A O
Cross O
- O
Sectional O
Study O
in O
Saudi O
Arabia O
. O

Remdesivir O
( O
Veklury O
) O
is O
the O
first O
antiviral O
drug O
approved O
to O
treat O
patients O
ages O
12 O
and O
older O
who O
are O
hospitalized O
with O
COVID O
- O
19 O
. O
The O
drug O
is O
administered O
via O
slow O
IV O
infusion O
. O
Elevated O
liver O
enzymes O
are O
common O
with O
treatment O
. O

Responders O
recommended O
using O
private O
sector O
beds O
to O
increase O
NHS O
capacity O
and O
using O
the O
link O
between O
obesity O
and O
poor O
COVID O
- O
19 O
outcomes O
to O
push O
for O
prioritisation O
of O
bariatric O
patients O
. O

A O
case O
series O
and O
literature O
review O
of O
multiple O
sclerosis O
and O
COVID O
- O
19 O
: O
Clinical O
characteristics O
, O
outcomes O
and O
a O
brief O
review O
of O
immunotherapies O
. O

COVID O
- O
19 O
- O
associated O
pulmonary O
aspergillosis O
was O
diagnosed O
in O
eight O
patients O
( O
3 O
. O
3 O
% O
of O
239 O
ICU O
patients O
) O
, O
mostly O
affected O
non O
- O
immunocompromised O
patients O
( O
75 O
% O
) O
with O
severe O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
receiving O
corticosteroids O
. O

Background O
: O
The O
infectious O
disease O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
outbroke O
in O
2019 O
spread O
to O
multiple O
countries O
. O

Clinical O
symptoms O
of O
COVID O
- O
19 O
pneumonia O
in O
children O
: O
A O
protocol O
for O
systematic O
review O
and O
meta O
- O
analysis O
. O

The O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
affected O
almost O
every O
country O
on O
the O
globe O
, O
affecting O
185 O
countries O
with O
more O
than O
2 O
. O
6 O
million O
cases O
and O
182 O
, O
000 O
deaths O
as O
of O
April O
22 O
, O
2020 O
. O

Reshaping O
cardiology O
amidst O
COVID O
- O
19 O
: O
prioritizing O
medical O
education O
. O

This O
retrospective O
observational O
study O
compared O
several O
measures O
undertaken O
for O
patients O
who O
visited O
the O
emergency O
unit O
in O
two O
hospitals O
between O
March O
1 O
and O
May O
31 O
, O
2020 O
, O
during O
the O
COVID O
- O
19 O
pandemic O
and O
whose O
blood O
cultures O
tested O
positive O
for O
bacteremia O
with O
those O
for O
corresponding O
patients O
treated O
during O
the O
same O
period O
in O
2019 O
. O

Contact O
with O
blue O
- O
green O
spaces O
during O
the O
COVID O
- O
19 O
pandemic O
lockdown O
beneficial O
for O
mental O
health O
. O

The O
pandemic O
novel O
coronavirus O
infection O
, O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
has O
affected O
at O
least O
190 O
countries O
or O
territories O
, O
with O
465 O
, O
915 O
confirmed O
cases O
and O
21 O
, O
031 O
deaths O
. O

The O
data O
regarding O
palliative O
team O
involvement O
in O
patients O
with O
COVID O
- O
19 O
, O
however O
, O
remains O
scarce O
. O

Mitigation O
measures O
, O
including O
stay O
- O
at O
- O
home O
orders O
and O
public O
mask O
wearing O
, O
together O
with O
routine O
public O
health O
interventions O
such O
as O
case O
investigation O
with O
contact O
tracing O
and O
immediate O
self O
- O
quarantine O
after O
exposure O
, O
are O
recommended O
to O
prevent O
and O
control O
the O
transmission O
of O
SARS O
- O
CoV O
- O
2 O
, O
the O
virus O
that O
causes O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
( O
1 O
- O
3 O
) O
. O

A O
before O
- O
after O
study O
was O
performed O
to O
evaluate O
the O
effect O
of O
addition O
of O
corticosteroids O
to O
our O
institution O
' O
s O
COVID O
- O
19 O
treatment O
protocol O
on O
hospital O
mortality O
. O

Lymphopenia O
, O
elevated O
level O
of O
d O
- O
dimer O
, O
hs O
- O
CTnI O
and O
hs O
- O
CRP O
predicted O
clinical O
outcomes O
of O
young O
adults O
with O
severe O
COVID O
- O
19 O
. O

Conclusion O
In O
our O
roles O
as O
clinicians O
, O
supervisors O
, O
trainees O
, O
and O
researchers O
in O
primary O
and O
subspecialty O
care O
as O
well O
as O
in O
academia O
, O
pediatric O
psychologists O
have O
an O
ethical O
responsibility O
to O
address O
the O
disproportionate O
burden O
of O
this O
pandemic O
on O
vulnerable O
communities O
and O
to O
allocate O
our O
time O
and O
resources O
to O
ensuring O
health O
equity O
now O
and O
in O
the O
aftermath O
of O
COVID O
- O
19 O
. O

Recovery O
, O
restoration O
, O
and O
risk O
: O
a O
cross O
- O
sectional O
survey O
of O
the O
impact O
of O
COVID O
- O
19 O
on O
GPs O
in O
the O
first O
UK O
city O
to O
lock O
down O
. O

This O
rapid O
neutropenia O
recovery O
and O
the O
robust O
inflammatory O
response O
in O
COVID O
- O
19 O
raise O
concerns O
about O
G O
- O
CSF O
safety O
in O
patients O
with O
COVID O
- O
19 O
. O

COVID O
- O
19 O
and O
adolescent O
mental O
health O
in O
India O
. O

The O
COVID O
- O
19 O
outbreak O
pandemic O
is O
a O
situation O
without O
a O
tested O
action O
plan O
. O

In O
this O
review O
, O
we O
provide O
a O
comprehensive O
update O
on O
the O
epidemiology O
, O
presentation O
, O
transmission O
, O
risk O
factors O
, O
and O
public O
health O
measures O
associated O
with O
COVID O
- O
19 O
. O

Inpatient O
rehabilitation O
for O
COVID O
- O
19 O
patients O
was O
associated O
with O
substantial O
motor O
, O
respiratory O
, O
and O
functional O
improvement O
, O
especially O
in O
severe O
cases O
, O
although O
there O
remained O
mild O
persistent O
autonomy O
loss O
upon O
discharge O
. O

The O
growth O
factor O
result O
for O
daily O
cases O
was O
1 O
. O
09 O
± O
0 O
. O
00 O
and O
daily O
deaths O
was O
1 O
. O
07 O
± O
0 O
. O
03 O
for O
COVID O
- O
19 O
, O
and O
shows O
declining O
trends O
in O
GCC O
region O
. O

Fever O
, O
dry O
cough O
, O
dyspnea O
, O
and O
sore O
throat O
malaise O
were O
highly O
frequent O
among O
COVID O
- O
19 O
patients O
, O
while O
headache O
and O
diarrhea O
were O
the O
least O
frequently O
occurring O
manifestations O
. O

A O
72 O
- O
year O
- O
old O
Japanese O
man O
was O
diagnosed O
with O
COVID O
- O
19 O
and O
was O
transferred O
to O
our O
hospital O
due O
to O
deterioration O
of O
respiratory O
condition O
. O

Provision O
of O
community O
pharmacy O
services O
during O
COVID O
- O
19 O
pandemic O
: O
a O
cross O
sectional O
study O
of O
community O
pharmacists O
' O
experiences O
with O
preventative O
measures O
and O
sources O
of O
information O
. O

Thus O
, O
obesity O
should O
be O
recommended O
as O
a O
risk O
factor O
for O
the O
prognosis O
assessment O
of O
COVID O
- O
19 O
. O

Effect O
of O
the O
COVID O
- O
19 O
Pandemic O
in O
German O
Trauma O
Centres O
and O
Geriatric O
Trauma O
Centres O
DGU O
. O

The O
etiological O
diagnosis O
of O
COVID O
- O
19 O
is O
, O
and O
will O
remain O
for O
the O
foreseeable O
future O
, O
deeply O
based O
on O
direct O
identification O
of O
viral O
RNA O
by O
means O
of O
molecular O
biology O
techniques O
in O
biological O
materials O
, O
especially O
upper O
and O
lower O
respiratory O
tract O
specimens O
. O

To O
determine O
whether O
ambient O
air O
pollutants O
and O
meteorological O
variables O
are O
associated O
with O
daily O
COVID O
- O
19 O
incidence O
. O

For O
example O
, O
due O
to O
the O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
pandemic O
, O
many O
medical O
education O
programs O
temporarily O
discontinued O
in O
- O
person O
simulations O
to O
adhere O
to O
physical O
distancing O
guidelines O
. O

Neutrophil O
- O
to O
- O
Lymphocyte O
ratio O
as O
a O
potential O
biomarker O
for O
disease O
severity O
in O
COVID O
- O
19 O
patients O
. O

It O
included O
24 O
questions O
on O
demographics O
, O
clinical O
practice O
and O
procedure O
characteristics O
, O
impact O
of O
the O
pandemic O
, O
Telemedicine O
, O
and O
involvement O
in O
COVID O
- O
19 O
patient O
care O
. O

Clinical O
presentations O
and O
outcomes O
were O
compared O
between O
COVID O
- O
19 O
and O
non O
- O
COVID O
- O
19 O
patients O
. O

There O
were O
fears O
that O
health O
services O
would O
not O
be O
able O
to O
care O
for O
high O
numbers O
of O
COVID O
- O
19 O
patients O
. O

Five O
principles O
for O
pandemic O
preparedness O
: O
lessons O
from O
the O
Australian O
COVID O
- O
19 O
primary O
care O
response O
. O

In O
this O
article O
, O
two O
authors O
( O
T O
. O
V O
. O
and O
N O
. O
G O
. O
) O
from O
the O
Department O
of O
Neurosurgery O
who O
were O
deployed O
in O
the O
COVID O
- O
19 O
testing O
ward O
between O
April O
25 O
and O
May O
31 O
, O
2020 O
share O
their O
experience O
. O

The O
prevalence O
of O
COVID O
- O
19 O
in O
the O
overall O
outpatient O
and O
inpatient O
population O
undergoing O
hematologic O
treatment O
compared O
to O
that O
of O
the O
general O
population O
was O
analyzed O
. O

COVID O
- O
19 O
Optimizer O
Algorithm O
, O
Modeling O
and O
Controlling O
of O
Coronavirus O
Distribution O
Process O
. O

A O
complicated O
disease O
course O
was O
defined O
as O
hospitalisation O
for O
COVID O
- O
19 O
requiring O
non O
- O
invasive O
or O
invasive O
ventilation O
and O
/ O
or O
inotropic O
support O
, O
or O
a O
fatal O
outcome O
. O

Common O
ethical O
principles O
were O
used O
to O
present O
a O
distinct O
set O
of O
challenges O
experienced O
by O
a O
country O
with O
a O
low O
prevalence O
of O
COVID O
- O
19 O
. O

The O
evolution O
of O
the O
changes O
in O
the O
clinical O
course O
: O
a O
multicenter O
survey O
- O
related O
impression O
of O
the O
ophthalmologists O
at O
the O
peak O
of O
the O
COVID O
- O
19 O
pandemic O
in O
Turkey O
. O

Older O
age O
and O
elevated O
d O
- O
dimer O
are O
reported O
risk O
factors O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Although O
healthcare O
workers O
( O
HCWs O
) O
, O
especially O
those O
caring O
for O
COVID O
- O
19 O
patients O
, O
are O
considered O
as O
a O
high O
- O
risk O
group O
, O
the O
seroprevalence O
in O
HCWs O
wearing O
adequate O
personal O
protective O
equipment O
is O
thought O
to O
be O
no O
higher O
than O
that O
in O
other O
groups O
. O

With O
the O
current O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
concerns O
have O
been O
raised O
about O
the O
risk O
to O
children O
with O
inflammatory O
bowel O
diseases O
( O
IBD O
) O
. O

Methods O
: O
Utilizing O
the O
case O
of O
one O
of O
our O
own O
patients O
with O
asthma O
who O
developed O
COVID O
- O
19 O
as O
context O
, O
we O
review O
the O
recent O
literature O
discussing O
the O
risk O
of O
COVID O
- O
19 O
in O
patients O
with O
asthma O
, O
the O
management O
of O
asthma O
medications O
in O
the O
time O
of O
the O
pandemic O
, O
and O
the O
risk O
of O
viral O
transmission O
. O

Infectious O
Disease O
Vulnerability O
Index O
( O
IDVI O
) O
data O
were O
obtained O
to O
identify O
the O
capacity O
of O
countries O
receiving O
travellers O
from O
Wuhan O
to O
respond O
to O
COVID O
- O
19 O
. O

Demographic O
, O
COVID O
- O
19 O
- O
related O
household O
change O
, O
and O
household O
food O
waste O
data O
were O
collected O
in O
October O
2020 O
. O

To O
define O
the O
prevalence O
of O
pulmonary O
thromboembolic O
( O
PTE O
) O
disease O
diagnosed O
on O
CT O
pulmonary O
angiography O
( O
CTPA O
) O
in O
COVID O
- O
19 O
patients O
. O

This O
Special O
Report O
aims O
to O
summarize O
general O
principles O
for O
continuing O
multidisciplinary O
care O
during O
the O
SARS O
- O
CoV O
- O
2 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

COVID O
- O
19 O
has O
a O
wide O
spectrum O
of O
clinical O
phenotypes O
. O

We O
evaluated O
biopsied O
kidney O
samples O
from O
ten O
patients O
at O
our O
institution O
who O
had O
COVID O
- O
19 O
and O
clinical O
features O
of O
AKI O
, O
including O
proteinuria O
with O
or O
without O
hematuria O
. O

Autoantibodies O
were O
also O
reported O
in O
severe O
acute O
respiratory O
syndrome O
( O
SARS O
) O
as O
well O
as O
in O
COVID O
- O
19 O
. O

Radiological O
examinations O
were O
confirmed O
as O
effective O
methods O
for O
the O
screening O
and O
diagnosis O
of O
COVID O
- O
19 O
. O

As O
COVID O
- O
19 O
testing O
improves O
to O
rapidly O
generate O
results O
, O
selective O
retesting O
of O
patients O
may O
uncover O
additional O
COVID O
- O
19 O
cases O
and O
strengthen O
measures O
to O
minimise O
the O
spread O
of O
COVID O
- O
19 O
. O

Azole O
- O
Resistant O
COVID O
- O
19 O
- O
Associated O
Pulmonary O
Aspergillosis O
in O
an O
Immunocompetent O
Host O
: O
A O
Case O
Report O
. O

Expanded O
testing O
for O
SARS O
- O
CoV O
- O
2 O
is O
critical O
to O
characterizing O
the O
extent O
of O
community O
spread O
of O
COVID O
- O
19 O
and O
to O
identifying O
infectious O
cohorts O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
changed O
the O
way O
we O
practice O
medicine O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
causative O
agent O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
has O
caused O
a O
global O
pandemic O
, O
and O
safe O
, O
effective O
vaccines O
are O
urgently O
needed1 O
. O

Alteration O
of O
Liver O
Biomarkers O
in O
Patients O
with O
SARS O
- O
CoV O
- O
2 O
( O
COVID O
- O
19 O
) O
. O

EXPRESS O
: O
COVID O
- O
19 O
AND O
STROKE O
- O
UNDERSTANDING O
THE O
RELATIONSHIP O
AND O
ADAPTING O
SERVICES O
. O
A O
GLOBAL O
WORLD O
STROKE O
ORGANISATION O
PERSPECTIVE O
. O

The O
WHO O
had O
declared O
COVID O
- O
19 O
as O
the O
global O
public O
health O
emergency O
and O
subsequently O
as O
pandemic O
because O
of O
its O
worldwide O
spread O
. O

Since O
the O
World O
Health O
Organization O
declared O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
a O
Public O
Health O
Emergency O
of O
International O
Concern O
, O
COVID O
- O
19 O
infection O
and O
the O
associated O
mortality O
have O
increased O
exponentially O
, O
globally O
. O

The O
Impact O
of O
COVID O
- O
19 O
on O
the O
Faces O
of O
Frontline O
Healthcare O
Workers O
. O

Clinical O
distancing O
of O
hospitalized O
patients O
with O
advanced O
heart O
failure O
and O
cardiac O
transplantation O
during O
COVID O
- O
19 O
. O

A O
randomly O
diagnosed O
confirmed O
case O
of O
COVID O
- O
19 O
highlights O
the O
importance O
of O
computerized O
tomography O
of O
thorax O
in O
diagnosing O
asymptomatic O
patients O
. O

Using O
a O
structured O
discussion O
guide O
, O
trained O
healthcare O
staff O
from O
various O
disciplines O
contacted O
the O
residents O
' O
proxies O
to O
conduct O
COVID O
- O
19 O
focused O
ACP O
discussions O
. O

We O
have O
used O
a O
publicly O
available O
dataset O
of O
CT O
scans O
, O
which O
consists O
of O
349 O
CT O
scans O
labeled O
as O
being O
positive O
for O
COVID O
- O
19 O
and O
397 O
negative O
COVID O
- O
19 O
CT O
scans O
that O
are O
normal O
or O
contain O
other O
types O
of O
lung O
diseases O
. O

The O
emergence O
of O
SARS O
- O
CoV O
- O
2 O
( O
COVID O
- O
19 O
) O
as O
a O
novel O
coronavirus O
resulted O
in O
a O
global O
pandemic O
that O
necessitated O
the O
implementation O
of O
social O
distancing O
measures O
. O

COVID O
- O
19 O
survivors O
at O
6 O
months O
. O

The O
outbreak O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
has O
emphasized O
the O
urgency O
to O
develop O
effective O
therapeutics O
. O

Cardiac O
injury O
by O
hs O
- O
TnT O
was O
observed O
in O
34 O
. O
6 O
% O
of O
our O
COVID O
- O
19 O
patients O
. O

Finally O
, O
serologic O
results O
showed O
high O
levels O
of O
immunoglobulin O
G O
and O
immunoglobulin O
A O
antibodies O
against O
the O
S1 O
domain O
of O
the O
SARS O
- O
CoV O
- O
2 O
spike O
protein O
, O
and O
the O
patient O
was O
diagnosed O
with O
COVID O
- O
19 O
pneumonia O
. O

Large O
- O
scale O
events O
such O
as O
COVID O
- O
19 O
show O
that O
there O
are O
situations O
that O
can O
lead O
to O
huge O
stress O
on O
health O
infrastructure O
systems O
( O
HIS O
) O
. O

We O
evaluated O
the O
performance O
of O
two O
rapid O
fluorescence O
immunoassays O
( O
FIAs O
) O
, O
SOFIA O
SARS O
Antigen O
FIA O
( O
Quidel O
Corporation O
, O
San O
Diego O
, O
CA O
, O
USA O
) O
and O
STANDARD O
F O
COVID O
- O
19 O
Ag O
FIA O
( O
SD O
Biosensor O
Inc O
. O
, O
Gyeonggi O
- O
do O
, O
Republic O
of O
Korea O
) O
, O
which O
use O
an O
automated O
reader O
. O

There O
is O
not O
enough O
data O
on O
the O
effect O
of O
angiotensin O
- O
converting O
enzyme O
inhibitors O
( O
ACEIs O
) O
/ O
angiotensin O
receptor O
blockers O
( O
ARBs O
) O
on O
lung O
involvement O
in O
patients O
with O
COVID O
- O
19 O
pneumonia O
and O
hypertension O
( O
HT O
) O
. O

Clinical O
Characterization O
of O
162 O
COVID O
- O
19 O
patients O
in O
Israel O
: O
Preliminary O
Report O
from O
a O
Large O
Tertiary O
Center O
. O

A O
total O
of O
171 O
COVID O
- O
19 O
- O
related O
interventional O
trials O
were O
identified O
on O
Feb O
22 O
, O
2020 O
. O

The O
COVID O
- O
19 O
outbreak O
has O
brought O
new O
challenges O
to O
people O
' O
s O
physical O
and O
mental O
health O
. O

Patients O
were O
matched O
for O
risk O
factors O
of O
severe O
COVID O
- O
19 O
: O
age O
, O
sex O
, O
body O
mass O
index O
, O
diabetes O
mellitus O
, O
preexisting O
cardiopathy O
, O
chronic O
lung O
disease O
, O
and O
basal O
renal O
function O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
been O
a O
challenge O
globally O
. O

COVID O
- O
19 O
and O
Autism O
Research O
: O
Perspectives O
from O
Around O
the O
Globe O
. O

One O
of O
the O
main O
reasons O
of O
the O
great O
impact O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
on O
society O
is O
its O
unexpected O
spread O
, O
which O
has O
not O
allowed O
an O
adequate O
preparation O
. O

No O
case O
of O
COVID O
- O
19 O
occurred O
in O
this O
period O
. O

This O
was O
a O
retrospective O
cohort O
study O
of O
117 O
confirmed O
patients O
with O
COVID O
- O
19 O
which O
conducted O
at O
a O
tertiary O
hospital O
in O
Daegu O
, O
South O
Korea O
. O

Comment O
on O
Melatonin O
as O
a O
potential O
adjuvant O
treatment O
for O
COVID O
- O
19 O
. O

Assessment O
of O
Maternal O
and O
Neonatal O
SARS O
- O
CoV O
- O
2 O
Viral O
Load O
, O
Transplacental O
Antibody O
Transfer O
, O
and O
Placental O
Pathology O
in O
Pregnancies O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

COVID O
- O
19 O
patients O
with O
elevated O
AST O
exhibited O
significantly O
higher O
IL O
- O
6 O
( O
p O
< O
0 O
. O
001 O
) O
, O
ferritin O
( O
p O
< O
0 O
. O
001 O
) O
, O
LDH O
( O
p O
< O
0 O
. O
001 O
) O
and O
CRP O
( O
p O
< O
0 O
. O
05 O
) O
serum O
concentrations O
compared O
to O
patients O
with O
normal O
AST O
. O

This O
case O
illustrates O
an O
example O
of O
" O
collateral O
damage O
" O
caused O
by O
the O
COVID O
- O
19 O
pandemic O
. O

How O
Big O
Data O
and O
Artificial O
Intelligence O
Can O
Help O
Better O
Manage O
the O
COVID O
- O
19 O
Pandemic O
. O

Our O
purpose O
is O
to O
provide O
a O
practical O
review O
of O
the O
conditions O
that O
mimic O
COVID O
- O
19 O
. O

The O
Psychological O
Impact O
of O
COVID O
- O
19 O
Pandemic O
on O
the O
population O
of O
Bahrain O
. O

Isolation O
of O
COVID O
- O
19 O
patients O
in O
cohorted O
wards O
or O
single O
- O
patient O
rooms O
? O
Advantages O
and O
disadvantages O
to O
take O
into O
consideration O
. O

The O
aim O
of O
the O
study O
is O
to O
identify O
predictors O
of O
in O
- O
hospital O
mortality O
and O
discharge O
in O
a O
cohort O
of O
Lombardy O
patients O
with O
COVID O
- O
19 O
. O

This O
review O
will O
summarize O
the O
recommendations O
in O
current O
clinical O
practice O
guidelines O
and O
provide O
insight O
into O
the O
implementation O
strategies O
for O
traditional O
Chinese O
herbal O
medicine O
in O
COVID O
- O
19 O
patients O
. O

In O
particular O
, O
the O
coronavirus O
( O
COVID O
- O
19 O
) O
pandemic O
underscores O
the O
urgent O
need O
for O
developing O
recyclable O
facemasks O
due O
to O
the O
considerable O
environmental O
damage O
and O
health O
risks O
imposed O
by O
disposable O
masks O
and O
respirators O
. O

COVID O
- O
19 O
and O
multiple O
sclerosis O
: O
A O
description O
of O
two O
cases O
on O
alemtuzumab O
. O

Incarceration O
And O
Its O
Disseminations O
: O
COVID O
- O
19 O
Pandemic O
Lessons O
From O
Chicago O
' O
s O
Cook O
County O
Jail O
. O

With O
the O
continuing O
COVID O
- O
19 O
pandemic O
, O
local O
school O
districts O
, O
school O
leaders O
, O
and O
health O
professionals O
should O
develop O
greater O
awareness O
of O
potential O
problems O
with O
, O
and O
engage O
parents O
in O
developing O
specific O
guidance O
on O
controlling O
, O
screen O
time O
and O
promoting O
physical O
activity O
in O
a O
time O
- O
sensitive O
manner O
. O
[ O
Journal O
of O
Psychosocial O
Nursing O
and O
Mental O
Health O
Services O
, O
xx O
( O
x O
) O
, O
xx O
- O
xx O
. O
] O
. O

The O
Coronavirus O
Disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
caused O
by O
the O
virus O
SARS O
- O
CoV O
- O
2 O
is O
spreading O
very O
quickly O
around O
the O
world O
. O

The O
goal O
is O
to O
warrant O
high O
- O
quality O
cancer O
care O
, O
despite O
being O
an O
academic O
centre O
on O
the O
front O
line O
of O
Germany O
' O
s O
response O
to O
COVID O
- O
19 O
. O

Telemedicine O
has O
been O
widely O
implemented O
during O
the O
COVID O
- O
19 O
global O
pandemic O
to O
enable O
continuity O
of O
care O
of O
chronic O
illnesses O
. O

The O
most O
important O
predictor O
of O
when O
states O
adopted O
social O
distancing O
policies O
is O
political O
: O
All O
else O
equal O
, O
states O
led O
by O
Republican O
governors O
were O
slower O
to O
implement O
such O
policies O
during O
a O
critical O
window O
of O
early O
COVID O
- O
19 O
response O
. O

Baseline O
covariates O
included O
demographics O
, O
early O
warning O
scores O
, O
Charlson O
Comorbidity O
Indices O
and O
frailty O
( O
Clinical O
Frailty O
Scale O
, O
CFS O
) O
, O
linked O
to O
COVID O
- O
19 O
status O
. O

Management O
of O
acute O
cardiovascular O
events O
in O
patients O
with O
COVID O
- O
19 O
. O

In O
this O
paper O
, O
we O
provide O
a O
perspective O
on O
the O
work O
of O
DMCs O
for O
clinical O
trials O
of O
treatments O
for O
COVID O
- O
19 O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
represents O
a O
public O
health O
crisis O
of O
major O
proportions O
. O

During O
the O
COVID O
- O
19 O
pandemic O
, O
many O
healthcare O
staff O
and O
others O
who O
work O
for O
the O
NHS O
have O
been O
working O
from O
home O
( O
WFH O
) O
or O
shielding O
due O
to O
various O
health O
conditions O
, O
including O
pregnancy O
. O

Erratum O
: O
Initial O
ELSO O
Guidance O
Document O
: O
ECMO O
for O
COVID O
- O
19 O
Patients O
with O
Severe O
Cardiopulmonary O
Failure O
. O

Healthcare O
Providers O
on O
the O
Frontline O
: O
A O
Quantitative O
Investigation O
of O
the O
Stress O
and O
Recent O
Onset O
Psychological O
Impact O
of O
Delivering O
Health O
Care O
Services O
During O
COVID O
- O
19 O
in O
Kashmir O
. O

Currently O
, O
no O
proven O
effective O
drugs O
or O
vaccines O
are O
available O
for O
the O
management O
of O
COVID O
- O
19 O
disease O
. O

Higher O
loneliness O
scores O
were O
correlated O
with O
lower O
health O
ratings O
, O
life O
satisfaction O
and O
PA O
during O
COVID O
- O
19 O
( O
p O
< O
0 O
. O
001 O
) O
. O

However O
, O
in O
COVID O
- O
19 O
patients O
over O
the O
age O
of O
80 O
years O
, O
the O
cytotoxic O
T O
cell O
potential O
was O
diminished O
, O
especially O
in O
effector O
memory O
and O
terminally O
differentiated O
effector O
CD8 O
+ O
cells O
, O
showing O
that O
elderly O
patients O
have O
impaired O
cellular O
immunity O
against O
SARS O
- O
CoV O
- O
2 O
. O

Therefore O
, O
proving O
the O
effectiveness O
of O
NMES O
therapy O
for O
physical O
and O
muscle O
function O
in O
COVID O
- O
19 O
patients O
could O
support O
its O
systematic O
incorporation O
in O
post O
- O
ICU O
rehabilitation O
protocols O
of O
patients O
presenting O
with O
post O
- O
intensive O
care O
syndrome O
. O

COVID O
- O
19 O
pandemic O
: O
an O
opportunity O
to O
rethink O
the O
patients O
' O
pathway O
to O
an O
endodontist O
? O

Enhancing O
surveillance O
platforms O
could O
provide O
signals O
that O
indicate O
whether O
malaria O
, O
NTDs O
, O
and O
COVID O
- O
19 O
are O
syndemics O
( O
synergistic O
epidemics O
) O
. O

The O
aggregated O
clinical O
findings O
suggest O
that O
the O
clinical O
presentation O
and O
outcomes O
of O
COVID O
- O
19 O
appear O
consistent O
with O
those O
without O
HIV O
. O

Drawing O
on O
previous O
research O
of O
online O
health O
information O
seeking O
, O
this O
study O
asks O
the O
following O
research O
questions O
: O
how O
was O
the O
" O
# O
COVID O
- O
19 O
Patient O
Seeking O
Help O
" O
hashtag O
being O
used O
by O
patients O
in O
Wuhan O
seeking O
health O
information O
on O
Weibo O
at O
the O
peak O
of O
the O
outbreak O
? O

Epidemiological O
investigations O
were O
conducted O
among O
all O
close O
contacts O
of O
COVID O
- O
19 O
patients O
( O
or O
suspected O
patients O
) O
in O
Nanjing O
, O
Jiangsu O
Province O
, O
China O
, O
from O
Jan O
28 O
to O
Feb O
9 O
, O
2020 O
, O
both O
in O
clinic O
and O
in O
community O
. O

Management O
of O
STEMI O
during O
the O
COVID O
- O
19 O
pandemic O
: O
Lessons O
learned O
in O
2020 O
to O
prepare O
for O
2021 O
. O

Definitive O
diagnosis O
of O
COVID O
- O
19 O
based O
on O
RT O
- O
PCR O
or O
/ O
and O
serological O
testing O
3 O
. O

Clinical O
Outcomes O
Associated O
with O
Methylprednisolone O
in O
Mechanically O
Ventilated O
Patients O
with O
COVID O
- O
19 O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
had O
a O
profound O
impact O
on O
both O
the O
physical O
and O
mental O
well O
- O
being O
of O
the O
global O
population O
. O

To O
predict O
the O
onset O
and O
outcomes O
of O
a O
next O
wave O
, O
we O
first O
need O
to O
understand O
the O
pathologic O
mechanisms O
and O
features O
of O
COVID O
- O
19 O
from O
the O
point O
of O
view O
of O
the O
intricacies O
of O
clinical O
presentation O
, O
to O
the O
nuances O
of O
response O
to O
therapy O
. O

PLWH O
, O
compared O
to O
their O
HIV O
- O
uninfected O
peers O
, O
were O
more O
likely O
to O
engage O
in O
preventive O
measures O
and O
healthcare O
during O
the O
pandemic O
, O
potentially O
reducing O
their O
exposure O
to O
COVID O
- O
19 O
. O

Additionally O
, O
there O
have O
been O
concerns O
raised O
regarding O
COVID O
- O
19 O
- O
related O
myocarditis O
, O
of O
which O
reported O
biopsy O
- O
proven O
cases O
to O
date O
appear O
to O
be O
rare O
. O

Evidence O
supports O
an O
excess O
of O
deaths O
during O
the O
COVID O
- O
19 O
pandemic O
. O

This O
model O
is O
found O
to O
be O
effective O
in O
identifying O
severe O
COVID O
- O
19 O
cases O
on O
admission O
, O
with O
a O
sensitivity O
of O
84 O
. O
6 O
% O
, O
a O
specificity O
of O
84 O
. O
6 O
% O
, O
and O
an O
accuracy O
of O
100 O
% O
to O
predict O
the O
disease O
progression O
toward O
rapid O
deterioration O
. O

Protective O
immunity O
after O
COVID O
- O
19 O
has O
been O
questioned O
: O
What O
can O
we O
do O
without O
SARS O
- O
CoV O
- O
2 O
- O
IgG O
detection O
? O

COVID O
- O
19 O
is O
one O
of O
these O
infections O
that O
could O
be O
life O
threatening O
and O
highly O
contagious O
. O

Here O
we O
discuss O
the O
role O
of O
interferons O
in O
host O
antiviral O
immunity O
, O
and O
review O
the O
current O
data O
surrounding O
use O
of O
interferons O
in O
COVID O
- O
19 O
. O

Productivity O
losses O
accounted O
for O
99 O
. O
8 O
% O
( O
¥ O
2641 O
. O
61 O
billion O
/ O
¥ O
2646 O
. O
70 O
billion O
) O
of O
societal O
costs O
, O
which O
were O
mostly O
attributable O
to O
the O
effect O
of O
movement O
- O
restriction O
policies O
on O
people O
who O
did O
not O
have O
COVID O
- O
19 O
. O

This O
study O
reports O
an O
association O
between O
time O
of O
symptom O
onset O
( O
TOS O
) O
and O
length O
of O
hospital O
stay O
( O
LOS O
) O
in O
COVID O
- O
19 O
infection O
without O
epidemiological O
link O
. O

The O
early O
identification O
of O
individuals O
with O
suspected O
COVID O
- O
19 O
is O
critical O
in O
immediately O
quarantining O
such O
individuals O
. O

The O
First O
60 O
Days O
: O
Physical O
Therapy O
in O
a O
Neurosurgical O
Center O
Converted O
Into O
a O
COVID O
- O
19 O
Center O
in O
Brazil O
. O

Recommendations O
of O
' O
social O
distancing O
' O
and O
home O
quarantines O
to O
combat O
the O
global O
COVID O
- O
19 O
pandemic O
have O
implications O
for O
sex O
and O
intimacy O
, O
including O
sex O
work O
. O

Approximately O
, O
1 O
out O
of O
10 O
hospitalized O
non O
- O
critical O
COVID O
- O
19 O
patients O
presents O
conjunctivitis O
during O
the O
disease O
. O

Potential O
differential O
effects O
of O
renin O
- O
angiotensin O
system O
inhibitors O
on O
SARS O
- O
CoV O
- O
2 O
infection O
and O
lung O
injury O
in O
COVID O
- O
19 O
. O

To O
evaluate O
the O
effects O
of O
the O
COVID O
- O
19 O
pandemic O
on O
the O
sexual O
functioning O
of O
individuals O
who O
declared O
no O
medical O
history O
of O
the O
COVID O
- O
19 O
disease O
. O

Psychological O
Impact O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
Dental O
Interns O
in O
Riyadh O
, O
Saudi O
Arabia O
: O
A O
Cross O
- O
sectional O
Survey O
. O

Our O
findings O
show O
how O
COVID O
- O
19 O
outbreak O
hindered O
the O
accessibility O
to O
outpatient O
rehabilitation O
service O
. O

Real O
- O
Time O
Estimation O
of O
the O
Risk O
of O
Death O
from O
Novel O
Coronavirus O
( O
COVID O
- O
19 O
) O
Infection O
: O
Inference O
Using O
Exported O
Cases O
. O

Inpatient O
COVID O
- O
19 O
cases O
were O
confirmed O
by O
PCR O
and O
/ O
or O
hospital O
records O
. O

With O
the O
current O
state O
of O
a O
fragile O
healthcare O
system O
, O
a O
widespread O
outbreak O
of O
COVID O
- O
19 O
in O
Yemen O
could O
result O
in O
devastating O
consequences O
. O

Cochrane O
corner O
: O
effectiveness O
of O
quarantine O
in O
reducing O
the O
spread O
of O
COVID O
- O
19 O
. O

Personalized O
therapy O
approach O
for O
hospitalized O
patients O
with O
COVID O
- O
19 O
. O

As O
countries O
are O
easing O
up O
these O
measures O
and O
people O
are O
resuming O
their O
pre O
- O
pandemic O
activities O
, O
the O
second O
wave O
of O
COVID O
- O
19 O
is O
observed O
in O
many O
countries O
. O

The O
present O
study O
included O
13 O
patients O
( O
nine O
males O
and O
four O
females O
) O
with O
an O
average O
age O
of O
35 O
. O
4 O
years O
The O
oldest O
patient O
was O
of O
63 O
years O
which O
is O
considered O
a O
risk O
factor O
for O
developing O
severe O
COVID O
- O
19 O
infection O
. O

COVID O
- O
19 O
Pandemic O
: O
How O
is O
Bangladesh O
coping O
with O
the O
rapid O
spread O
of O
coronavirus O
infection O
? O

The O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
arises O
from O
the O
virus O
SARS O
- O
CoV O
- O
2 O
which O
is O
similar O
to O
the O
original O
SARS O
virus O
. O

Drugs O
considered O
for O
treatment O
of O
COVID O
- O
19 O
should O
consider O
effects O
on O
organelles O
including O
mitochondria O
functions O
. O

Information O
regarding O
the O
incidence O
and O
characteristics O
of O
COVID O
- O
19 O
pneumonia O
amongst O
pregnant O
women O
is O
scarce O
. O

Insights O
into O
pathogenesis O
of O
fatal O
COVID O
- O
19 O
pneumonia O
from O
histopathology O
with O
immunohistochemical O
and O
viral O
RNA O
studies O
. O

A O
total O
of O
2 O
, O
474 O
COVID O
- O
19 O
patients O
from O
February O
10th O
to O
March O
24th O
, O
2020 O
were O
admitted O
and O
treated O
in O
two O
branches O
( O
Optic O
Valley O
and O
Sino O
- O
French O
New O
City O
branch O
) O
of O
the O
Tongji O
Hospital O
. O

Demographic O
data O
, O
test O
results O
, O
treatments O
, O
and O
latest O
status O
of O
patients O
receiving O
inpatient O
COVID O
- O
19 O
pneumonia O
therapy O
were O
recorded O
. O

Non O
- O
invasive O
Thoracic O
Impedance O
Changes O
in O
COVID O
- O
19 O
Pulmonary O
Infection O
. O

Social O
, O
financial O
and O
psychological O
stress O
during O
an O
emerging O
pandemic O
: O
observations O
from O
a O
population O
survey O
in O
the O
acute O
phase O
of O
COVID O
- O
19 O
. O

Despite O
statistically O
higher O
rates O
of O
antiplatelet O
therapy O
and O
therapeutic O
anticoagulation O
in O
COVID O
- O
19 O
patients O
, O
we O
found O
a O
similar O
rate O
of O
ICH O
in O
patients O
with O
ARDS O
due O
to O
COVID O
- O
19 O
compared O
to O
other O
causes O
of O
ARDS O
. O

Public O
health O
leaders O
also O
need O
to O
know O
where O
COVID O
- O
19 O
transmission O
rates O
are O
accelerating O
or O
decelerating O
, O
whether O
those O
rates O
increase O
or O
decrease O
over O
short O
time O
frames O
because O
the O
pandemic O
can O
quickly O
escalate O
, O
and O
how O
many O
cases O
today O
are O
a O
function O
of O
new O
infections O
7 O
days O
ago O
. O

The O
initial O
growth O
of O
COVID O
- O
19 O
cases O
in O
Africa O
was O
rapid O
and O
showed O
large O
variations O
across O
countries O
. O

Motor O
and O
nonmotor O
symptoms O
significantly O
worsened O
in O
the O
COVID O
- O
19 O
group O
, O
requiring O
therapy O
adjustment O
in O
one O
third O
of O
cases O
. O

Letter O
: O
May O
Cooler O
Heads O
Prevail O
During O
a O
Pandemic O
: O
Stroke O
in O
COVID O
- O
19 O
Patients O
or O
COVID O
- O
19 O
in O
Stroke O
Patients O
? O

The O
T O
cells O
studies O
can O
be O
helpful O
in O
elucidating O
the O
pathways O
for O
development O
of O
vaccines O
, O
therapies O
, O
and O
diagnostics O
for O
COVID O
- O
19 O
and O
for O
filling O
these O
immunology O
knowledge O
gaps O
. O

We O
aim O
to O
predict O
the O
COVID O
- O
19 O
disease O
course O
and O
compare O
the O
effectiveness O
of O
mitigation O
measures O
across O
countries O
to O
inform O
policy O
decision O
making O
using O
a O
robust O
and O
parsimonious O
survival O
- O
convolution O
model O
. O

In O
this O
review O
, O
we O
consolidate O
the O
newly O
developed O
diagnostic O
tools O
for O
COVID O
- O
19 O
using O
emerging O
biosensing O
technologies O
and O
discuss O
their O
application O
promise O
. O

International O
teleproctoring O
in O
neurointerventional O
surgery O
and O
its O
potential O
impact O
on O
clinical O
trials O
in O
the O
era O
of O
COVID O
- O
19 O
: O
legal O
and O
technical O
considerations O
. O

An O
Excess O
Mortality O
( O
EM O
) O
of O
1255 O
deaths O
were O
estimated O
1 O
month O
after O
the O
first O
death O
classified O
by O
COVID O
- O
19 O
, O
and O
it O
would O
probably O
be O
more O
if O
the O
government O
had O
not O
taken O
early O
action O
. O

Likewise O
, O
natural O
and O
pharmaceutical O
inhibitors O
of O
furin O
may O
be O
candidate O
prophylactic O
interventions O
or O
, O
if O
used O
early O
in O
the O
COVID O
- O
19 O
, O
may O
prevent O
the O
development O
of O
critical O
symptoms O
. O

Among O
patients O
with O
COVID O
- O
19 O
infection O
, O
men O
had O
a O
significantly O
higher O
mortality O
than O
did O
women O
, O
and O
this O
difference O
was O
not O
completely O
explained O
by O
the O
higher O
prevalence O
of O
comorbidities O
in O
men O
. O

This O
review O
aims O
to O
consolidate O
and O
discuss O
the O
likely O
origins O
and O
genetic O
features O
of O
SARS O
- O
CoV O
- O
2 O
as O
well O
as O
the O
recent O
clinical O
findings O
and O
potential O
effective O
treatments O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
may O
present O
without O
cardinal O
symptoms O
as O
well O
as O
implicate O
a O
possible O
role O
for O
age O
- O
related O
changes O
in O
immunity O
in O
mediating O
the O
relationship O
between O
frailty O
and O
mortality O
. O

This O
case O
documents O
the O
occurrence O
of O
Graves O
' O
thyrotoxicosis O
following O
mild O
symptomatic O
COVID O
- O
19 O
. O

Outcomes O
and O
Mortality O
Among O
Adults O
Hospitalized O
With O
COVID O
- O
19 O
at O
US O
Medical O
Centers O
. O

Singapore O
' O
s O
experience O
in O
ensuring O
continuity O
of O
outpatient O
care O
during O
the O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
and O
the O
neurological O
disease O
therapeutic O
pipeline O
. O

IL O
- O
6 O
blockade O
for O
COVID O
- O
19 O
: O
a O
global O
scientific O
call O
to O
arms O
. O

The O
intensive O
care O
unit O
admission O
rate O
was O
36 O
. O
1 O
% O
in O
those O
with O
COVID O
- O
19 O
compared O
to O
16 O
. O
4 O
% O
of O
controls O
( O
aRR O
= O
1 O
. O
34 O
; O
95 O
% O
CI O
, O
0 O
. O
86 O
- O
2 O
. O
09 O
) O
. O

The O
hypothesis O
that O
these O
findings O
are O
a O
consequence O
not O
only O
of O
high O
probabilities O
of O
exposure O
, O
but O
also O
of O
high O
doses O
( O
as O
a O
product O
of O
both O
intensity O
and O
duration O
, O
with O
possible O
autonomous O
effects O
of O
peaks O
of O
exposure O
) O
deserves O
to O
be O
systematically O
tested O
, O
in O
order O
to O
reconstruct O
the O
web O
of O
causation O
of O
COVID O
- O
19 O
individual O
and O
clustered O
cases O
and O
to O
cope O
with O
situations O
at O
critical O
risk O
for O
SARS O
- O
CoV O
- O
2 O
, O
needing O
to O
be O
identified O
, O
mapped O
, O
and O
dealt O
with O
at O
the O
right O
time O
. O

Sex O
- O
Biased O
Vulnerability O
of O
the O
Heart O
to O
COVID O
- O
19 O
. O

Impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
the O
well O
- O
being O
of O
children O
with O
neurodevelopmental O
disabilities O
and O
their O
parents O
. O

We O
present O
a O
case O
of O
upper O
extremity O
arteriovenous O
graft O
thrombosis O
in O
a O
79 O
year O
old O
COVID O
- O
19 O
positive O
patient O
with O
end O
- O
stage O
renal O
disease O
. O

Most O
of O
the O
Iranian O
government O
expenditure O
during O
the O
last O
100 O
years O
on O
various O
disasters O
such O
as O
drought O
, O
flood O
, O
earthquake O
, O
and O
COVID O
- O
19 O
has O
been O
spent O
on O
involuntary O
costs O
including O
Response O
and O
Recovery O
. O

Donning O
and O
doffing O
of O
personal O
protective O
equipment O
protocol O
and O
key O
points O
of O
nursing O
care O
for O
patients O
with O
COVID O
- O
19 O
in O
ICU O
. O

The O
COVID O
- O
19 O
pandemic O
and O
the O
rapid O
adoption O
of O
digital O
care O
have O
generated O
a O
unique O
opportunity O
to O
continue O
developing O
a O
health O
service O
to O
both O
preserve O
and O
improve O
the O
person O
- O
centered O
care O
approach O
for O
persons O
with O
complex O
and O
long O
- O
term O
needs O
. O

Dental O
Teleradiology O
: O
A O
Powerful O
Strategy O
to O
Overcome O
the O
Impact O
of O
COVID O
- O
19 O
. O

We O
retrospectively O
analysed O
166 O
COVID O
- O
19 O
patients O
at O
Tongji O
Hospital O
( O
Wuhan O
) O
from O
8 O
February O
to O
21 O
March O
2020 O
. O

was O
more O
than O
50 O
% O
to O
75 O
% O
, O
and O
1 O
. O
94 O
( O
95 O
% O
CI O
, O
1 O
. O
46 O
- O
2 O
. O
59 O
; O
P O
< O
. O
001 O
) O
when O
COVID O
- O
19 O
ICU O
demand O
was O
more O
than O
75 O
% O
to O
100 O
% O
. O

As O
of O
April O
1 O
, O
45 O
patients O
had O
ongoing O
COVID O
- O
19 O
symptoms O
and O
/ O
or O
anosmia O
; O
107 O
/ O
141 O
( O
76 O
% O
) O
patients O
had O
household O
contacts O
, O
and O
of O
185 O
non O
- O
tested O
household O
contacts O
79 O
( O
43 O
% O
) O
had O
COVID O
- O
19 O
symptoms O
with O
46 O
/ O
79 O
( O
58 O
% O
) O
reporting O
anosmia O
. O

Computed O
tomography O
( O
CT O
) O
has O
been O
described O
as O
a O
diagnostic O
modality O
in O
the O
COVID O
- O
19 O
diagnosis O
and O
treatment O
plan O
. O

Engaging O
the O
vulnerable O
: O
A O
rapid O
review O
of O
public O
health O
communication O
aimed O
at O
migrants O
during O
the O
COVID O
- O
19 O
pandemic O
in O
Europe O
. O

The O
aim O
of O
this O
article O
was O
to O
review O
current O
literature O
surrounding O
the O
use O
of O
lung O
ultrasound O
in O
relation O
to O
COVID O
- O
19 O
and O
provide O
Sonographers O
with O
a O
quick O
and O
digestible O
reference O
guide O
for O
lung O
pathologies O
. O

Additional O
best O
practice O
guidance O
is O
provided O
on O
scientific O
publication O
reporting O
of O
quantitative O
CT O
imaging O
methods O
and O
the O
importance O
of O
contributing O
COVID O
- O
19 O
CT O
imaging O
datasets O
to O
open O
science O
research O
databases O
. O

As O
such O
, O
after O
mentioning O
some O
general O
background O
on O
the O
economic O
and O
medical O
implications O
of O
the O
pandemic O
on O
individuals O
, O
the O
healthcare O
system O
, O
and O
the O
society O
, O
we O
summarize O
some O
common O
aspects O
of O
the O
published O
literature O
on O
neurological O
manifestations O
of O
the O
COVID O
- O
19 O
infection O
. O

Inversely O
, O
patients O
with O
COVID O
- O
19 O
show O
lowered O
levels O
of O
blood O
cholesterol O
, O
high O
- O
density O
lipoproteins O
( O
HDL O
) O
and O
low O
- O
density O
lipoproteins O
. O

Effects O
of O
Licorice O
on O
clinical O
symptoms O
and O
laboratory O
signs O
in O
moderately O
ill O
patients O
with O
pneumonia O
from O
COVID O
- O
19 O
: O
A O
structured O
summary O
of O
a O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O

During O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
principles O
from O
both O
clinical O
and O
public O
health O
ethics O
cue O
clinicians O
and O
healthcare O
administrators O
to O
plan O
alternatives O
for O
frail O
older O
adults O
who O
prefer O
to O
avoid O
critical O
care O
, O
and O
for O
when O
critical O
care O
is O
not O
available O
due O
to O
crisis O
triaging O
. O

Assessing O
the O
impact O
of O
COVID O
- O
19 O
on O
persons O
with O
disabilities O
: O
development O
of O
a O
novel O
survey O
. O

[ O
Exercising O
in O
times O
of O
COVID O
- O
19 O
: O
what O
do O
experts O
recommend O
doing O
within O
four O
walls O
? O
] O

At O
present O
, O
several O
existing O
licensed O
drugs O
such O
as O
chloroquine O
, O
hydroxychloroquine O
, O
methylprednisolone O
, O
dexamethasone O
, O
and O
remdesivir O
have O
been O
used O
because O
of O
their O
potential O
efficacy O
in O
inhibiting O
COVID O
- O
19 O
. O

Google O
searches O
for O
the O
keywords O
of O
" O
wash O
hands O
" O
predict O
the O
speed O
of O
national O
spread O
of O
COVID O
- O
19 O
outbreak O
among O
21 O
countries O
. O

The O
role O
of O
the O
COVID O
- O
19 O
pandemic O
as O
a O
risk O
factor O
for O
suicide O
: O
What O
is O
its O
impact O
on O
the O
public O
mental O
health O
state O
today O
? O

When O
hospitals O
are O
subject O
to O
prolonged O
surges O
in O
patients O
, O
such O
as O
during O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
additional O
clinicians O
may O
be O
needed O
to O
care O
for O
the O
rapid O
increase O
of O
acutely O
ill O
patients O
. O

Information O
on O
COVID O
- O
19 O
vaccines O
and O
vaccinations O
. O

We O
observed O
a O
1 O
. O
6 O
% O
increase O
in O
interstitial O
lung O
abnormalities O
during O
the O
period O
of O
COVID O
- O
19 O
circulation O
. O

COVID O
- O
19 O
is O
a O
very O
smash O
and O
apprehensive O
health O
issue O
in O
the O
current O
world O
which O
broke O
the O
medical O
system O
of O
whole O
earth O
originated O
in O
the O
wholesale O
sea O
market O
of O
Wuhan O
city O
, O
Hubei O
province O
, O
China O
on O
December O
12 O
, O
2019 O
. O

Therefore O
, O
we O
call O
for O
a O
more O
holistic O
health O
systems O
- O
based O
model O
for O
COVID O
- O
19 O
outbreak O
response O
. O

In O
this O
review O
, O
we O
report O
on O
increased O
rates O
and O
severe O
prognosis O
of O
ischemic O
stroke O
among O
individuals O
with O
COVID O
- O
19 O
, O
probably O
explained O
by O
hypercoagulability O
and O
inflammation O
, O
documented O
since O
the O
early O
phase O
of O
disease O
. O
We O
confirm O
the O
presence O
of O
falling O
rates O
of O
new O
ischemic O
stroke O
admissions O
in O
hospitals O
, O
probably O
due O
to O
social O
consequences O
of O
the O
pandemic O
: O
fear O
to O
be O
infected O
or O
not O
adequately O
treated O
in O
the O
hospital O
. O

Behavioral O
change O
is O
the O
only O
prevention O
against O
the O
COVID O
- O
19 O
pandemic O
until O
vaccines O
become O
available O
. O

We O
included O
28 O
uninfected O
but O
highly O
exposed O
healthcare O
workers O
and O
39 O
hospitalized O
patients O
with O
COVID O
- O
19 O
. O

Urticarial O
eruption O
in O
COVID O
- O
19 O
infection O
. O

We O
searched O
3 O
databases O
and O
the O
COVID O
- O
19 O
resource O
centers O
of O
11 O
major O
journals O
and O
publishers O
. O

We O
recap O
here O
evidence O
that O
supports O
the O
use O
of O
human O
recombinant O
erythropoietin O
( O
EPO O
) O
for O
ameliorating O
course O
and O
outcome O
of O
seriously O
ill O
COVID O
- O
19 O
patients O
. O

This O
pilot O
study O
proposes O
that O
cold O
environment O
may O
be O
an O
additional O
risk O
factor O
for O
COVID O
- O
19 O
cases O
. O

Haloperidol O
, O
a O
widely O
used O
antipsychotic O
, O
has O
been O
suggested O
as O
potentially O
useful O
for O
patients O
with O
COVID O
- O
19 O
on O
the O
grounds O
of O
its O
in O
- O
vitro O
antiviral O
effects O
against O
SARS O
- O
CoV O
- O
2 O
, O
possibly O
through O
sigma O
- O
1 O
receptor O
antagonist O
effect O
. O

Respiratory O
symptoms O
are O
the O
most O
common O
presentation O
of O
an O
acute O
COVID O
- O
19 O
infection O
, O
but O
thromboembolic O
phenomena O
, O
encephalopathy O
and O
other O
neurological O
symptoms O
have O
been O
reported O
. O

Health O
Professional O
Frontline O
Leaders O
' O
Experiences O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
A O
Cross O
- O
Sectional O
Study O
. O

In O
this O
retrospective O
cohort O
study O
, O
patients O
with O
confirmed O
diagnosis O
of O
COVID O
- O
19 O
and O
AHRF O
receiving O
NIV O
in O
general O
wards O
were O
recruited O
from O
two O
university O
- O
affiliated O
hospitals O
. O

Will O
neurological O
care O
change O
over O
the O
next O
5 O
years O
due O
to O
the O
COVID O
- O
19 O
pandemic O
? O
Key O
informant O
consensus O
survey O
. O

The O
COVID O
- O
19 O
coronavirus O
crisis O
has O
posed O
an O
international O
challenge O
for O
all O
health O
systems O
. O

However O
, O
there O
are O
controversies O
about O
whether O
preexisting O
chronic O
kidney O
disease O
( O
CKD O
) O
and O
acute O
kidney O
injury O
complication O
( O
AKI O
) O
are O
involved O
in O
the O
COVID O
- O
19 O
pandemic O
. O

The O
Plastic O
Surgeon O
' O
s O
Role O
in O
the O
COVID O
- O
19 O
Crisis O
: O
Regarding O
Domestic O
Violence O
. O

Few O
studies O
have O
focused O
on O
the O
changes O
of O
NK O
, O
T O
- O
and O
B O
- O
cell O
subsets O
, O
inflammatory O
cytokines O
and O
virus O
- O
specific O
antibodies O
in O
patients O
with O
moderate O
COVID O
- O
19 O
. O

Vulnerable O
patients O
with O
risk O
factors O
such O
as O
elderly O
, O
cardiovascular O
diseases O
( O
eg O
, O
hypertension O
, O
coronary O
disease O
, O
or O
cardiomyopathy O
) O
, O
diabetes O
, O
and O
chronic O
kidney O
disease O
have O
worse O
outcomes O
after O
COVID O
- O
19 O
infection O
. O

Procedural O
precautions O
and O
personal O
protective O
equipment O
during O
head O
and O
neck O
instrumentation O
in O
the O
COVID O
- O
19 O
era O
. O

Research O
on O
COVID O
- O
19 O
based O
on O
ARIMA O
model O
Δ O
- O
Taking O
Hubei O
, O
China O
as O
an O
example O
to O
see O
the O
epidemic O
in O
Italy O
. O

[ O
What O
I O
talk O
about O
when O
I O
talk O
about O
COVID O
- O
19 O
] O
. O

Diagnostic O
approaches O
in O
COVID O
- O
19 O
: O
clinical O
updates O
. O

Multisystem O
Imaging O
Manifestations O
of O
COVID O
- O
19 O
, O
Part O
1 O
: O
Viral O
Pathogenesis O
and O
Pulmonary O
and O
Vascular O
System O
Complications O
. O

The O
population O
that O
newborns O
with O
COVID O
- O
19 O
that O
confirmed O
within O
28 O
d O
of O
birth O
are O
included O
. O

Conclusion O
A O
spectrum O
of O
abdominal O
imaging O
findings O
ranging O
from O
colitis O
to O
pancreatitis O
may O
be O
correlated O
with O
COVID O
- O
19 O
infection O
, O
even O
though O
the O
majority O
of O
our O
patients O
with O
gastrointestinal O
( O
GI O
) O
symptoms O
did O
not O
have O
identifiable O
GI O
pathology O
on O
imaging O
. O

Although O
a O
variety O
of O
existing O
drugs O
are O
being O
tested O
for O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
no O
efficacious O
treatment O
has O
been O
found O
so O
far O
, O
particularly O
for O
severe O
cases O
. O

Oral O
manifestations O
and O
the O
role O
of O
the O
oral O
healthcare O
workers O
in O
COVID O
- O
19 O
. O

This O
is O
the O
first O
study O
that O
analyzed O
the O
prevalence O
of O
head O
lice O
during O
COVID O
- O
19 O
pandemic O
. O

These O
components O
were O
: O
identification O
and O
diagnosis O
of O
close O
contacts O
; O
suspected O
cases O
and O
confirmed O
cases O
of O
COVID O
- O
19 O
; O
treatment O
of O
COVID O
- O
19 O
cases O
; O
compulsory O
quarantine O
of O
close O
contacts O
and O
suspected O
cases O
; O
and O
productivity O
losses O
for O
all O
affected O
residents O
. O

COVID O
- O
19 O
, O
triage O
decisions O
, O
and O
indirect O
ethics O
: O
A O
model O
for O
the O
re O
- O
evaluation O
of O
triage O
guidelines O
. O

Here O
we O
report O
our O
modelled O
homo O
- O
trimer O
structure O
of O
COVID O
- O
19 O
spike O
glycoprotein O
in O
both O
closed O
( O
ligand O
- O
free O
) O
and O
open O
( O
ligand O
- O
bound O
) O
conformation O
, O
which O
is O
involved O
in O
host O
cell O
adhesion O
. O

To O
reduce O
the O
state O
' O
s O
COVID O
- O
19 O
burden O
, O
California O
should O
expand O
comprehensive O
Medi O
- O
Cal O
to O
all O
eligible O
individuals O
regardless O
of O
immigration O
status O
. O

COVID O
- O
19 O
antibodies O
were O
detected O
in O
11 O
of O
the O
91 O
tested O
respondents O
( O
12 O
. O
1 O
% O
) O
, O
with O
no O
difference O
between O
respondents O
with O
( O
11 O
. O
8 O
% O
) O
or O
without O
( O
12 O
. O
5 O
% O
) O
a O
work O
- O
related O
exposure O
, O
including O
high O
- O
risk O
exposure O
. O

Changes O
in O
Stress O
, O
Anxiety O
, O
and O
Depression O
Levels O
of O
Subscribers O
to O
a O
Daily O
Supportive O
Text O
Message O
Program O
( O
Text4Hope O
) O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
Cross O
- O
Sectional O
Survey O
Study O
. O

Our O
results O
strongly O
indicated O
that O
the O
detection O
of O
asymptomatic O
COVID O
- O
19 O
or O
coexisting O
conditions O
must O
be O
strengthened O
in O
pediatric O
patients O
. O

The O
public O
heath O
response O
has O
been O
effective O
in O
virus O
testing O
, O
diagnosing O
and O
treating O
patients O
with O
COVID O
- O
19 O
. O

In O
this O
article O
, O
we O
present O
our O
analysis O
of O
various O
novel O
and O
important O
web O
- O
based O
applications O
that O
have O
been O
specifically O
developed O
during O
the O
COVID O
- O
19 O
pandemic O
and O
that O
can O
be O
used O
by O
the O
health O
professionals O
community O
to O
help O
in O
advancing O
their O
analysis O
and O
research O
. O

The O
series O
of O
public O
health O
interventions O
in O
three O
areas O
were O
temporally O
associated O
with O
the O
burden O
of O
COVID O
- O
19 O
- O
attributed O
hospital O
use O
. O

We O
propose O
the O
concept O
that O
administration O
of O
an O
unrelated O
live O
attenuated O
vaccine O
, O
such O
as O
MMR O
( O
measles O
, O
mumps O
, O
rubella O
) O
, O
could O
serve O
as O
a O
preventive O
measure O
against O
the O
worst O
sequelae O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Predicting O
Mechanical O
Ventilation O
Requirement O
and O
Mortality O
in O
COVID O
- O
19 O
using O
Radiomics O
and O
Deep O
Learning O
on O
Chest O
Radiographs O
: O
A O
Multi O
- O
Institutional O
Study O
. O

This O
article O
provides O
a O
comprehensive O
overview O
of O
available O
scientific O
knowledge O
about O
the O
role O
of O
ACE O
2 O
in O
the O
pathogenesis O
of O
COVID O
- O
19 O
, O
which O
is O
available O
up O
to O
current O
day O
. O

Air O
- O
pollutant O
mass O
concentration O
changes O
during O
COVID O
- O
19 O
pandemic O
in O
Shanghai O
, O
China O
. O

The O
existing O
literature O
does O
not O
suffice O
for O
assessing O
whether O
Lopinavir O
/ O
ritonavir O
has O
any O
benefit O
in O
SARS O
, O
MERS O
or O
COVID O
- O
19 O
. O

In O
this O
review O
, O
we O
aimed O
to O
summarize O
the O
concepts O
related O
to O
laparoscopic O
gynecological O
surgery O
during O
COVID O
- O
19 O
pandemic O
in O
the O
light O
of O
current O
literature O
. O

Antibody O
response O
in O
COVID O
- O
19 O
varies O
and O
depends O
on O
the O
time O
the O
serum O
is O
taken O
, O
on O
the O
severity O
of O
disease O
, O
and O
on O
the O
type O
of O
test O
used O
. O

Our O
findings O
show O
that O
a O
high O
proportion O
of O
COVID O
- O
19 O
cases O
in O
Honduras O
occurred O
among O
younger O
adults O
, O
who O
also O
constituted O
a O
significant O
proportion O
of O
severe O
and O
fatal O
cases O
. O

Impact O
of O
anti O
- O
rheumatic O
drugs O
and O
steroids O
on O
clinical O
course O
and O
prognosis O
of O
COVID O
- O
19 O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
clarify O
the O
effect O
of O
the O
COVID O
- O
19 O
pandemic O
on O
a O
comprehensive O
stroke O
center O
in O
Japan O
. O

To O
compare O
the O
performance O
of O
fever O
- O
, O
cough O
- O
, O
and O
dyspnea O
- O
specific O
ICD O
- O
10 O
codes O
with O
medical O
record O
review O
among O
patients O
tested O
for O
COVID O
- O
19 O
. O

In O
this O
paper O
, O
infection O
rate O
of O
COVID O
- O
19 O
is O
modelled O
globally O
at O
a O
0 O
. O
5 O
∘ O
resolution O
, O
using O
a O
Maximum O
Entropy O
- O
based O
Ecological O
Niche O
Model O
that O
identifies O
geographical O
areas O
potentially O
subject O
to O
a O
high O
infection O
rate O
. O

This O
corresponds O
to O
a O
continuous O
increase O
again O
in O
COVID O
- O
19 O
cases O
in O
Frankfurt O
since O
August O
, O
with O
an O
average O
of O
28 O
. O
6 O
incidences O
, O
compared O
to O
28 O
. O
7 O
incidences O
in O
April O
. O

The O
impact O
of O
COVID O
- O
19 O
on O
surgical O
trainees O
has O
been O
experienced O
globally O
and O
across O
all O
specialities O
. O

To O
buy O
or O
not O
buy O
food O
online O
: O
The O
impact O
of O
the O
COVID O
- O
19 O
epidemic O
on O
the O
adoption O
of O
e O
- O
commerce O
in O
China O
. O

There O
is O
currently O
no O
vaccine O
to O
prevent O
COVID O
- O
19 O
or O
therapeutic O
agent O
to O
treat O
COVID O
- O
19 O
. O

To O
systematically O
review O
and O
meta O
- O
analyse O
the O
rate O
of O
SARS O
- O
CoV O
- O
2 O
genome O
identification O
and O
the O
presence O
of O
SARS O
- O
CoV O
- O
2 O
antibodies O
in O
breastmilk O
of O
mothers O
with O
COVID O
- O
19 O
. O

While O
major O
efforts O
to O
conduct O
research O
on O
COVID O
- O
19 O
are O
being O
made O
, O
recruiting O
the O
anticipated O
number O
of O
participants O
into O
these O
studies O
is O
problematic O
. O

This O
review O
summarizes O
the O
current O
evidence O
on O
liver O
function O
abnormalities O
in O
COVID O
- O
19 O
patients O
and O
the O
effects O
of O
preexisting O
liver O
disease O
on O
the O
disease O
severity O
. O

Puzzling O
haze O
events O
in O
China O
during O
the O
coronavirus O
( O
COVID O
- O
19 O
) O
shutdown O
. O

The O
study O
aimed O
at O
developing O
an O
AI O
imaging O
analysis O
tool O
to O
classify O
COVID O
- O
19 O
lung O
infection O
based O
on O
portable O
CXRs O
. O

We O
report O
cases O
with O
recurrence O
of O
symptoms O
compatible O
with O
COVID O
- O
19 O
, O
with O
positive O
RT O
- O
PCR O
results O
, O
that O
could O
represent O
the O
occurrence O
of O
viral O
reactivation O
or O
reinfection O
. O

COVID O
- O
19 O
measures O
in O
schools O
can O
be O
summarized O
as O
follows O
: O
avoiding O
crowded O
/ O
close O
contact O
environments O
as O
much O
as O
possible O
, O
respecting O
the O
protective O
( O
social O
) O
distance O
, O
wearing O
appropriate O
masks O
, O
hand O
hygiene O
, O
and O
some O
essential O
protective O
measurements O
of O
classrooms O
and O
environment O
. O

Taking O
long O
term O
care O
from O
crisis O
to O
thriving O
in O
the O
time O
of O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
may O
affect O
the O
world O
severely O
in O
terms O
of O
quality O
of O
life O
, O
political O
, O
environmental O
, O
and O
economic O
sustainable O
development O
, O
and O
the O
global O
economy O
. O

COVID O
- O
19 O
is O
a O
severe O
acute O
respiratory O
syndrome O
caused O
by O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

The O
importance O
of O
seasonal O
influenza O
vaccination O
for O
people O
with O
disabilities O
during O
the O
COVID O
- O
19 O
pandemic O
. O

DM O
patients O
with O
COVID O
- O
19 O
are O
vulnerable O
to O
severe O
disease O
, O
especially O
for O
female O
patients O
. O

The O
second O
case O
was O
a O
58 O
- O
year O
- O
old O
man O
who O
fully O
recovered O
from O
COVID O
- O
19 O
pneumonia O
with O
treatment O
with O
methylprednisolone O
, O
MMF O
, O
azithromycin O
, O
favipiravir O
, O
hydroxychloroquine O
, O
and O
reduction O
in O
immunosuppression O
dosage O
. O

Multiple O
potential O
targets O
of O
opioids O
in O
the O
treatment O
of O
acute O
respiratory O
distress O
syndrome O
from O
COVID O
- O
19 O
. O

The O
recent O
response O
of O
crystallographers O
to O
the O
COVID O
- O
19 O
pandemic O
suggests O
that O
X O
- O
ray O
crystallography O
conducted O
at O
synchrotron O
beamlines O
will O
continue O
to O
play O
an O
essential O
role O
in O
structural O
biology O
and O
drug O
discovery O
for O
years O
to O
come O
. O

Answer O
The O
COVID O
- O
19 O
global O
pandemic O
affects O
all O
ages O
. O

Early O
identification O
of O
severe O
cases O
and O
the O
abovementioned O
complications O
of O
COVID O
- O
19 O
could O
decrease O
the O
morbidity O
and O
mortality O
caused O
by O
the O
disease O
. O

Based O
on O
the O
multi O
- O
source O
data O
of O
COVID O
- O
19 O
in O
the O
context O
of O
a O
global O
pandemic O
, O
this O
paper O
analyzes O
the O
propagation O
rules O
of O
disasters O
in O
the O
coupling O
of O
the O
spatial O
dimension O
of O
geographic O
reality O
and O
the O
dimension O
of O
network O
public O
opinion O
, O
and O
constructs O
a O
new O
gravity O
model O
- O
complex O
network O
- O
based O
geographic O
propagation O
model O
of O
the O
evolution O
chain O
of O
typical O
public O
health O
events O
. O

Clinical O
characteristics O
of O
confirmed O
COVID O
- O
19 O
cases O
and O
a O
hospital O
case O
fatality O
rate O
of O
21 O
% O
are O
comparable O
with O
other O
settings O
. O

We O
assessed O
quantitative O
differences O
in O
one O
US O
state O
in O
learner O
knowledge O
, O
satisfaction O
, O
and O
behaviors O
before O
and O
during O
the O
COVID O
- O
19 O
pandemic O
and O
conducted O
a O
qualitative O
thematic O
analysis O
of O
interviews O
with O
training O
system O
employees O
. O

Should O
repurposed O
drugs O
demonstrate O
efficacy O
against O
COVID O
- O
19 O
, O
they O
could O
be O
manufactured O
profitably O
at O
very O
low O
costs O
, O
for O
much O
less O
than O
current O
list O
prices O
. O

In O
this O
retrospective O
analysis O
of O
patients O
with O
COVID O
- O
19 O
, O
three O
clinical O
phenotypes O
were O
identified O
. O

In O
addition O
, O
in O
the O
COVID O
- O
19 O
period O
, O
joined O
by O
the O
United O
Kingdom O
, O
China O
and O
the O
United O
States O
continued O
their O
roles O
as O
the O
largest O
contributors O
to O
, O
and O
home O
to O
the O
main O
funders O
of O
, O
coronavirus O
related O
research O
. O

These O
consecutive O
suicides O
have O
aroused O
concern O
, O
and O
it O
is O
necessary O
to O
investigate O
the O
psychological O
issues O
of O
the O
medical O
staff O
in O
Italy O
regarding O
the O
COVID O
- O
19 O
. O

Objectives O
: O
We O
examined O
the O
effect O
of O
loneliness O
and O
the O
role O
of O
two O
mediating O
factors O
, O
depressive O
symptoms O
and O
malnutrition O
on O
subjective O
age O
among O
older O
adults O
during O
the O
2020 O
COVID O
- O
19 O
pandemic O
, O
and O
explored O
how O
the O
pandemic O
is O
affecting O
subjective O
age O
. O

Out O
- O
of O
- O
hospital O
cardiac O
arrest O
during O
the O
COVID O
- O
19 O
era O
in O
Bologna O
: O
System O
response O
to O
preserve O
performances O
. O

Conclusions O
: O
At O
our O
large O
tertiary O
comprehensive O
stroke O
center O
, O
we O
observed O
a O
significant O
and O
rapid O
decline O
in O
TS O
consults O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Answering O
the O
right O
questions O
for O
policymakers O
on O
COVID O
- O
19 O
. O

We O
followed O
34 O
patients O
with O
laboratory O
- O
confirmed O
COVID O
- O
19 O
infection O
who O
recovered O
fromthe O
infection O
. O

The O
rate O
at O
which O
COVID O
- O
19 O
has O
spread O
throughout O
the O
globe O
has O
been O
alarming O
. O

Low O
concentrations O
of O
type O
- O
I O
interferon O
( O
IFN O
) O
in O
blood O
seem O
to O
be O
associated O
with O
more O
severe O
forms O
of O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Clinical O
Features O
and O
Pathogenic O
Mechanisms O
of O
Gastrointestinal O
Injury O
in O
COVID O
- O
19 O
. O

A O
few O
studies O
have O
revealed O
the O
clinical O
characteristics O
of O
hospitalized O
patients O
with O
COVID O
- O
19 O
. O

Most O
of O
the O
participants O
were O
hesitant O
about O
COVID O
- O
19 O
vaccines O
. O

The O
role O
of O
anosmia O
and O
hyposmia O
as O
a O
potential O
COVID O
- O
19 O
related O
symptom O
is O
presented O
. O

One O
of O
the O
main O
goals O
of O
clinical O
and O
health O
psychology O
during O
this O
pandemic O
is O
to O
investigate O
the O
behavioral O
, O
cognitive O
, O
emotional O
, O
and O
psychobiological O
responses O
to O
the O
COVID O
- O
19 O
emergency O
as O
well O
as O
to O
the O
preventive O
measures O
that O
have O
been O
imposed O
by O
governments O
to O
limit O
the O
contagion O
, O
such O
as O
social O
isolation O
. O

Surge O
activation O
by O
the O
emergency O
department O
for O
COVID O
- O
19 O
. O

In O
this O
paper O
, O
we O
adopt O
the O
same O
inquiry O
framework O
as O
Zacharia O
et O
al O
. O
( O
2015 O
) O
and O
report O
strategies O
that O
we O
learned O
from O
STEM O
faculty O
about O
how O
they O
supported O
and O
guided O
virtual O
student O
lab O
- O
based O
learning O
in O
these O
five O
phases O
during O
the O
recent O
COVID O
- O
19 O
shutdown O
. O

The O
COVID O
- O
19 O
coronavirus O
pandemic O
has O
affected O
virtually O
every O
region O
of O
the O
globe O
. O

Anti O
- O
Neutrophilic O
Cytoplasmic O
Antibody O
( O
ANCA O
) O
Vasculitis O
Presented O
as O
Pulmonary O
Hemorrhage O
in O
a O
Positive O
COVID O
- O
19 O
Patient O
: O
A O
Case O
Report O
. O

Besides O
COVID O
- O
19 O
respiratory O
symptoms O
, O
skin O
manifestations O
have O
been O
largely O
reported O
, O
such O
as O
chilblain O
- O
like O
lesions O
, O
urticaria O
, O
maculopapular O
lesions O
, O
and O
also O
hair O
loss O
( O
1 O
) O
. O

This O
study O
aimed O
to O
identify O
patients O
receiving O
total O
hip O
arthroplasty O
( O
THA O
) O
for O
trauma O
during O
the O
peak O
of O
the O
COVID O
- O
19 O
pandemic O
in O
the O
UK O
and O
quantify O
the O
risks O
of O
contracting O
SARS O
- O
CoV O
- O
2 O
virus O
, O
the O
proportion O
of O
patients O
requiring O
treatment O
in O
an O
intensive O
care O
unit O
( O
ICU O
) O
, O
and O
rate O
of O
complications O
including O
mortality O
. O

Mortality O
- O
related O
immune O
features O
and O
COVID O
- O
19 O
. O

Even O
among O
those O
without O
COVID O
- O
19 O
, O
disruption O
of O
infrastructure O
and O
changes O
in O
human O
behavior O
as O
a O
result O
of O
the O
pandemic O
also O
have O
an O
upstream O
role O
in O
cardiovascular O
outcomes O
, O
which O
have O
already O
been O
documented O
in O
multiple O
locations O
. O

Moving O
forward O
: O
Ensuring O
quality O
research O
in O
vascular O
surgery O
during O
COVID O
- O
19 O
. O

A O
proportion O
of O
COVID O
- O
19 O
patients O
progress O
rapidly O
to O
acute O
respiratory O
failure O
. O

However O
, O
we O
do O
not O
encourage O
elective O
surgeries O
during O
this O
pandemic O
, O
which O
might O
put O
patients O
in O
conditions O
vulnerable O
to O
COVID O
- O
19 O
. O

Protecting O
higher O
education O
institutions O
from O
COVID O
- O
19 O
: O
insights O
from O
an O
Italian O
experience O
. O

Brazilian O
oral O
medicine O
and O
oral O
pathology O
: O
We O
are O
here O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
global O
pandemic O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
- O
driven O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
caused O
unprecedented O
human O
death O
and O
has O
seriously O
threatened O
the O
global O
economy O
. O

This O
study O
reports O
on O
the O
oral O
manifestations O
of O
an O
asymptomatic O
COVID O
- O
19 O
patient O
treated O
interdisciplinary O
by O
teleconsultation O
due O
to O
the O
sudden O
appearance O
of O
lesions O
in O
the O
oral O
mucosa O
. O

The O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
healthcare O
services O
in O
settings O
with O
under O
- O
resourced O
health O
systems O
such O
as O
that O
of O
Nigeria O
is O
likely O
to O
be O
substantial O
in O
the O
coming O
months O
. O

Based O
on O
these O
factors O
and O
in O
combination O
with O
related O
policies O
and O
regulations O
, O
a O
prevention O
and O
control O
program O
for O
the O
COVID O
- O
19 O
pneumonia O
in O
a O
children O
' O
s O
digestive O
endoscopy O
center O
was O
established O
to O
prevent O
the O
COVID O
- O
19 O
nosocomial O
infection O
. O

The O
immediate O
actions O
from O
both O
academia O
and O
industry O
have O
led O
to O
the O
development O
of O
many O
COVID O
- O
19 O
diagnostic O
systems O
that O
have O
secured O
fast O
- O
track O
regulatory O
approvals O
and O
have O
been O
serving O
our O
healthcare O
frontlines O
since O
the O
early O
stage O
of O
the O
pandemic O
. O

The O
knowledge O
that O
they O
are O
at O
increased O
risk O
of O
infection O
due O
to O
lack O
of O
protection O
has O
resulted O
in O
anger O
, O
frustration O
, O
fear O
, O
and O
a O
sense O
of O
violation O
that O
may O
have O
long O
- O
lasting O
implications O
. O
Sacrifi O
é O
: O
Le O
personnel O
de O
la O
sant O
é O
ontarien O
à O
l O
' O
é O
poque O
de O
la O
COVID O
- O
19R O
é O
sum O
é O
En O
Ontario O
, O
au O
Canada O
, O
le O
personnel O
de O
la O
sant O
é O
a O
eu O
à O
faire O
face O
à O
des O
risques O
sans O
pr O
é O
c O
é O
dent O
durant O
la O
pand O
é O
mie O
de O
COVID O
- O
19 O
. O

To O
recognize O
the O
period O
of O
exaggerated O
cytokine O
response O
in O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pneumonia O
, O
and O
to O
describe O
the O
clinical O
outcomes O
of O
using O
tocilizumab O
as O
a O
treatment O
option O
. O

This O
study O
was O
conducted O
to O
evaluate O
the O
clinical O
performance O
of O
the O
Isopollo O
COVID O
- O
19 O
detection O
kit O
( O
M O
Monitor O
, O
South O
Korea O
) O
for O
reverse O
transcription O
loop O
- O
mediated O
isothermal O
amplification O
( O
RT O
- O
LAMP O
) O
SARS O
- O
CoV O
- O
2 O
diagnosis O
, O
using O
the O
SARS O
- O
CoV O
- O
2 O
reverse O
transcription O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
protocol O
as O
the O
gold O
standard O
. O

The O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
virus O
is O
the O
cause O
of O
the O
ongoing O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
infecting O
millions O
of O
people O
and O
causing O
more O
than O
two O
million O
deaths O
. O

During O
the O
current O
COVID O
- O
19 O
global O
pandemic O
, O
the O
major O
efforts O
are O
channeled O
toward O
containing O
and O
minimizing O
the O
spread O
and O
maintaining O
the O
healthcare O
providers O
' O
safety O
. O

We O
aim O
to O
summarize O
the O
initial O
considerations O
and O
potential O
cardiovascular O
implications O
of O
COVID O
- O
19 O
for O
children O
and O
patients O
with O
congenital O
heart O
disease O
. O

This O
cohort O
study O
was O
conducted O
among O
veterans O
with O
COVID O
- O
19 O
, O
as O
confirmed O
by O
polymerase O
chain O
reaction O
or O
antigen O
testing O
in O
the O
laboratory O
from O
March O
through O
August O
2020 O
, O
cared O
for O
at O
any O
Department O
of O
Veterans O
Affairs O
( O
VA O
) O
hospital O
with O
10 O
or O
more O
patients O
with O
COVID O
- O
19 O
in O
the O
ICU O
. O

The O
prevalence O
of O
melancholy O
and O
depression O
increased O
after O
COVID O
- O
19 O
, O
but O
the O
presence O
or O
absence O
of O
the O
fund O
did O
not O
lead O
to O
a O
significant O
difference O
. O

Engaging O
Third O
- O
Year O
Medical O
Students O
on O
Their O
Internal O
Medicine O
Clerkship O
in O
Telehealth O
During O
COVID O
- O
19 O
. O

The O
analysis O
has O
found O
that O
COVID O
- O
19 O
transmission O
in O
four O
states O
( O
Kerala O
, O
Tamil O
Nadu O
, O
Karnataka O
and O
Telangana O
) O
strongly O
hinges O
upon O
the O
spatial O
distribution O
of O
population O
density O
. O

Patients O
were O
divided O
into O
two O
groups O
based O
on O
the O
results O
of O
real O
time O
reverse O
transcriptase O
- O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
for O
COVID O
- O
19 O
, O
and O
the O
accuracy O
of O
different O
laboratory O
parameters O
in O
predicting O
cases O
with O
positive O
RT O
- O
PCR O
was O
evaluated O
using O
area O
under O
the O
ROC O
curve O
( O
AUC O
) O
. O

This O
paper O
will O
provide O
guidance O
on O
how O
to O
best O
manage O
patients O
with O
end O
- O
stage O
kidney O
disease O
who O
will O
be O
or O
are O
being O
treated O
with O
home O
dialysis O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Together O
, O
our O
results O
demonstrate O
that O
sustained O
sub O
- O
clinical O
cognitive O
impairments O
might O
be O
a O
common O
complication O
after O
recovery O
from O
COVID O
- O
19 O
in O
young O
adults O
, O
regardless O
of O
clinical O
course O
that O
were O
unmasked O
by O
our O
diagnostic O
approach O
. O

The O
COVID O
- O
19 O
pandemic O
is O
an O
ongoing O
global O
challenge O
for O
public O
health O
systems O
. O

Age O
is O
not O
the O
only O
risk O
factor O
in O
COVID O
- O
19 O
: O
the O
role O
of O
comorbidities O
and O
of O
long O
staying O
in O
residential O
care O
homes O
. O

The O
New O
Virtual O
Reality O
: O
How O
COVID O
- O
19 O
Will O
Affect O
the O
Gastroenterology O
and O
Hepatology O
Fellowship O
Match O
. O

Participants O
will O
include O
frontline O
hospital O
and O
long O
- O
term O
care O
home O
staff O
that O
are O
involved O
in O
the O
management O
of O
COVID O
- O
19 O
patients O
in O
London O
, O
Ontario O
, O
Canada O
. O

The O
Challenge O
of O
Treating O
Kidney O
Transplant O
Recipients O
Infected O
with O
COVID O
- O
19 O
: O
Report O
of O
the O
First O
Cases O
in O
Israel O
. O

Adjuvant O
therapeutic O
effects O
of O
moxibustion O
on O
COVID O
- O
19 O
: O
A O
protocol O
for O
systematic O
review O
and O
meta O
- O
analysis O
. O

Pharmacological O
agents O
- O
antiviral O
and O
anti O
- O
inflammatory O
molecules O
- O
have O
not O
been O
able O
so O
far O
to O
achieve O
compelling O
results O
for O
the O
control O
of O
severe O
COVID O
- O
19 O
pneumonia O
. O

Here O
we O
report O
the O
use O
of O
remdesivir O
in O
a O
patient O
with O
COVID O
- O
19 O
and O
the O
prototypic O
genetic O
antibody O
deficiency O
X O
- O
linked O
agammaglobulinaemia O
( O
XLA O
) O
. O

The O
implementation O
of O
a O
mobile O
infusion O
unit O
embedded O
in O
a O
collaborative O
process O
resulted O
in O
rapid O
infusion O
of O
monoclonal O
antibodies O
to O
high O
- O
risk O
COVID O
- O
19 O
patients O
in O
skilled O
nursing O
facilities O
, O
who O
would O
otherwise O
be O
unable O
to O
access O
the O
novel O
therapies O
. O

En O
esta O
revisi O
ó O
n O
se O
aborda O
de O
manera O
pr O
á O
ctica O
la O
estrecha O
relaci O
ó O
n O
entre O
la O
tromboembolia O
venosa O
y O
la O
COVID O
- O
19 O
, O
enfatizando O
aspectos O
epidemiol O
ó O
gicos O
, O
factores O
de O
riesgo O
y O
tromboprofilaxis O
, O
as O
í O
como O
potenciales O
opciones O
de O
anticoagulaci O
ó O
n O
. O

Considering O
social O
determinants O
of O
health O
, O
we O
conducted O
a O
systematic O
review O
by O
searching O
five O
databases O
( O
Ovid O
- O
MEDLINE O
, O
EMBASE O
, O
PsycINFO O
, O
China O
National O
Knowledge O
Infrastructure O
and O
the O
World O
Health O
Organization O
COVID O
- O
19 O
database O
) O
for O
publications O
from O
inception O
to O
9 O
April O
2020 O
. O

Obtaining O
informed O
consent O
from O
vulnerable O
patients O
participating O
in O
clinical O
trials O
of O
investigational O
therapies O
for O
COVID O
- O
19 O
is O
a O
major O
ethical O
challenge O
. O

A O
married O
couple O
( O
age O
60 O
years O
) O
was O
simultaneously O
admitted O
to O
the O
emergency O
department O
on O
10 O
March O
2020 O
because O
of O
dyspnoea O
and O
fever O
, O
consistent O
with O
COVID O
- O
19 O
. O

The O
current O
epidemic O
situation O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
still O
remained O
severe O
. O

COVID O
- O
19 O
patients O
are O
prone O
to O
different O
arrhythmias O
including O
life O
- O
threatening O
ventricular O
arrhythmias O
with O
normal O
left O
ventricular O
systolic O
function O
and O
normal O
QTc O
, O
and O
they O
should O
be O
monitored O
for O
fever O
and O
electrolyte O
abnormality O
during O
their O
hospital O
stay O
. O

Telemedicine O
was O
a O
useful O
tool O
for O
following O
up O
patients O
with O
CLD O
and O
for O
reducing O
the O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
primary O
end O
point O
was O
time O
to O
hospitalization O
for O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
health O
system O
response O
of O
this O
country O
demonstrates O
that O
although O
developing O
countries O
face O
many O
health O
system O
challenges O
, O
political O
will O
, O
evidence O
- O
informed O
decision O
- O
making O
, O
respect O
for O
science O
, O
and O
timely O
, O
coordinated O
, O
collaborative O
actions O
can O
strengthen O
the O
resilience O
and O
response O
of O
the O
health O
system O
during O
a O
health O
emergency O
. O

Our O
findings O
suggest O
that O
residential O
elite O
athlete O
training O
facilities O
can O
successfully O
resume O
activity O
during O
the O
COVID O
- O
19 O
pandemic O
when O
strict O
reentry O
and O
infection O
prevention O
measures O
are O
followed O
. O

More O
attention O
should O
be O
paid O
to O
the O
mental O
health O
of O
frontline O
healthcare O
workers O
at O
the O
outbreak O
of O
COVID O
- O
19 O
in O
China O
. O

Mitigating O
the O
Impact O
of O
COVID O
- O
19 O
on O
Funded O
Clinical O
Research O
: O
Crucial O
Next O
Steps O
. O

Results O
of O
the O
multivariate O
logistic O
regression O
analysis O
showed O
that O
the O
odds O
ratio O
for O
a O
positive O
test O
was O
significantly O
increased O
in O
patients O
who O
had O
fever O
, O
ageusia O
and O
contact O
with O
a O
patient O
diagnosed O
with O
COVID O
- O
19 O
. O

The O
basic O
reproduction O
number O
can O
be O
accurately O
estimated O
within O
14 O
days O
after O
societal O
lockdown O
: O
The O
early O
stage O
of O
the O
COVID O
- O
19 O
epidemic O
in O
Denmark O
. O

Detailed O
data O
on O
clinical O
presentations O
and O
outcomes O
of O
children O
with O
COVID O
- O
19 O
in O
Europe O
are O
still O
lacking O
. O

Given O
the O
strong O
overlap O
of O
flu O
and O
other O
upper O
respiratory O
infections O
with O
COVID O
- O
19 O
, O
the O
winter O
season O
could O
prove O
challenging O
both O
to O
contain O
the O
spread O
of O
the O
virus O
and O
to O
differentiate O
the O
cause O
. O

The O
2019 O
novel O
coronavirus O
pneumonia O
( O
COVID O
- O
19 O
) O
is O
an O
ongoing O
global O
pandemic O
with O
a O
worldwide O
death O
toll O
of O
over O
416 O
, O
000 O
as O
of O
June O
10 O
, O
2020 O
. O

This O
study O
may O
provide O
helpful O
clues O
for O
the O
assessment O
and O
management O
of O
COVID O
- O
19 O
in O
T2D O
patients O
. O

The O
percentage O
of O
coronavirus O
disease O
of O
2019 O
( O
COVID O
- O
19 O
) O
patients O
with O
positive O
2019 O
- O
nCoV O
RNA O
varied O
from O
12 O
. O
9 O
% O
to O
91 O
. O
67 O
% O
among O
these O
studies O
. O

Clinical O
data O
of O
140 O
COVID O
- O
19 O
patients O
were O
recorded O
: O
The O
median O
age O
was O
63 O
. O
5 O
( O
range O
17 O
- O
99 O
) O
years O
; O
64 O
% O
were O
males O
. O

Mental O
care O
should O
be O
, O
therefore O
, O
considered O
in O
the O
present O
COVID O
- O
19 O
pandemic O
. O

Thus O
, O
it O
is O
important O
to O
assess O
the O
knowledge O
and O
attitude O
towards O
COVID O
- O
19 O
among O
hemodialysis O
technicians O
in O
this O
pandemic O
situation O
. O

Spatial O
and O
temporal O
dynamics O
of O
SARS O
- O
CoV O
- O
2 O
in O
COVID O
- O
19 O
patients O
: O
A O
systematic O
review O
and O
meta O
- O
analysis O
. O

Most O
instruments O
demonstrate O
high O
sensitivity O
for O
identifying O
nutritional O
risk O
, O
but O
none O
are O
acknowledged O
as O
the O
best O
for O
nutritional O
screening O
in O
older O
adults O
with O
COVID O
- O
19 O
. O

In O
this O
review O
, O
we O
will O
present O
an O
overview O
of O
the O
state O
- O
of O
- O
the O
- O
art O
knowledge O
on O
ACE2 O
biochemistry O
and O
pathophysiology O
, O
outlining O
open O
issues O
in O
the O
context O
of O
COVID O
- O
19 O
disease O
and O
potential O
experimental O
and O
clinical O
developments O
. O

Information O
on O
COVID O
- O
19 O
clusters O
( O
n O
≥ O
2 O
) O
, O
and O
morbidity O
and O
mortality O
of O
COVID O
- O
19 O
was O
collected O
. O

Considering O
the O
low O
cost O
, O
easy O
application O
, O
and O
lack O
of O
radiation O
exposure O
, O
LUS O
seems O
the O
ideal O
tool O
to O
be O
adopted O
in O
outpatient O
and O
primary O
care O
settings O
for O
the O
follow O
- O
up O
of O
patients O
with O
COVID O
- O
19 O
. O

Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
has O
been O
identified O
as O
a O
pandemic O
by O
the O
World O
Health O
Organization O
( O
WHO O
) O
. O

Neurologically O
Devastating O
Intraparenchymal O
Hemorrhage O
in O
COVID O
- O
19 O
Patients O
on O
Extracorporeal O
Membrane O
Oxygenation O
: O
A O
Case O
Series O
. O

In O
cases O
where O
DFL O
is O
required O
, O
in O
patients O
with O
COVID O
- O
19 O
positivity O
or O
unknown O
COVID O
- O
19 O
status O
, O
we O
describe O
the O
use O
of O
a O
modified O
endoscopy O
face O
mask O
as O
an O
adjunct O
to O
personal O
protection O
equipment O
to O
reduce O
occupational O
transmission O
of O
COVID O
- O
19 O
while O
performing O
DFL O
. O

Main O
outcomes O
included O
COVID O
- O
19 O
positivity O
, O
hospitalization O
, O
intensive O
care O
unit O
admission O
, O
mechanical O
ventilation O
, O
and O
death O
. O

Education O
institutions O
promptly O
implemented O
a O
set O
of O
steps O
to O
prevent O
the O
spread O
of O
COVID O
- O
19 O
among O
international O
Chinese O
students O
, O
such O
as O
restrictive O
physical O
exercise O
, O
mask O
wear O
, O
daily O
health O
reporting O
, O
etc O
. O

COVID O
- O
19 O
Curfews O
: O
Kenyan O
and O
Australian O
Litigation O
and O
Pandemic O
Protection O
. O

The O
response O
to O
the O
COVID O
- O
19 O
crisis O
has O
presented O
complex O
and O
unique O
challenges O
to O
DM O
and O
public O
health O
practitioners O
. O

This O
new O
disease O
( O
COVID O
- O
19 O
) O
has O
spread O
also O
in O
Italy O
starting O
from O
the O
first O
recognized O
case O
on O
February O
20 O
. O

Mass O
COVID O
- O
19 O
vaccinations O
are O
likely O
to O
be O
the O
light O
at O
the O
end O
of O
the O
tunnel O
. O

We O
highlight O
strategies O
for O
screening O
of O
hyperglycemia O
in O
persons O
without O
known O
diabetes O
treated O
for O
COVID O
- O
19 O
infection O
in O
low O
resource O
settings O
. O

Mental O
Health O
and O
Psychosocial O
Challenges O
in O
the O
COVID O
- O
19 O
Pandemic O
: O
Food O
for O
Thought O
for O
Cardiovascular O
Health O
Care O
Professionals O
. O

The O
COVID O
- O
19 O
pandemic O
has O
revealed O
starkly O
and O
publicly O
the O
close O
interconnections O
between O
social O
and O
economic O
equality O
, O
health O
equity O
, O
and O
population O
health O
. O

The O
novel O
coronavirus O
, O
named O
as O
2019 O
- O
nCoV O
or O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
has O
recently O
appeared O
in O
China O
and O
has O
spread O
worldwide O
, O
presenting O
a O
health O
threat O
to O
the O
global O
community O
. O

The O
emergence O
of O
the O
novel O
coronavirus O
infection O
( O
COVID O
- O
19 O
) O
began O
a O
series O
of O
unparalleled O
changes O
in O
health O
care O
systems O
worldwide O
. O

Impact O
of O
solid O
cancer O
on O
in O
- O
hospital O
mortality O
overall O
and O
among O
different O
subgroups O
of O
patients O
with O
COVID O
- O
19 O
: O
a O
nationwide O
, O
population O
- O
based O
analysis O
. O

Information O
about O
the O
impact O
of O
HIV O
coinfection O
on O
clinical O
characteristics O
of O
COVID O
- O
19 O
patients O
remains O
limited O
. O

In O
early O
postmortem O
examinations O
of O
COVID O
- O
19 O
patients O
, O
profuse O
viscous O
secretions O
were O
observed O
throughout O
the O
respiratory O
tract O
. O

Therefore O
, O
classifying O
patients O
with O
a O
high O
risk O
of O
severe O
stage O
of O
COVID O
- O
19 O
and O
managing O
patients O
by O
considering O
the O
risk O
factors O
could O
be O
helpful O
in O
the O
efficient O
management O
of O
COVID O
- O
19 O
patients O
. O

Persistence O
of O
serum O
and O
saliva O
antibody O
responses O
to O
SARS O
- O
CoV O
- O
2 O
spike O
antigens O
in O
COVID O
- O
19 O
patients O
. O

The O
management O
for O
COVID O
- O
19 O
patients O
with O
stroke O
is O
not O
only O
based O
on O
the O
traditional O
guidelines O
, O
but O
also O
based O
on O
the O
experience O
and O
new O
instructions O
from O
healthcare O
workers O
worldwide O
who O
are O
combatting O
COVID O
- O
19 O
. O

Objective O
: O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
cases O
caused O
by O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
continue O
to O
increase O
worldwide O
. O

Is O
it O
safe O
to O
lift O
COVID O
- O
19 O
travel O
bans O
? O
The O
Newfoundland O
story O
. O

" O
Lock O
- O
down O
' O
' O
for O
COVID O
- O
19 O
has O
' O
' O
locked O
up O
' O
' O
Urological O
emergencies O
in O
Greece O
. O

COVID O
- O
19 O
pandemic O
and O
home O
- O
based O
physical O
activity O
. O

This O
array O
can O
be O
used O
as O
a O
diagnostic O
tool O
, O
as O
an O
epidemiologic O
tool O
to O
more O
accurately O
estimate O
the O
disease O
burden O
of O
COVID O
- O
19 O
, O
and O
as O
a O
research O
tool O
to O
correlate O
antibody O
responses O
with O
clinical O
outcomes O
. O

Uncertainty O
surrounding O
the O
COVID O
- O
19 O
pandemic O
has O
the O
potential O
to O
trigger O
mental O
health O
problems O
, O
which O
include O
anxiety O
, O
stress O
, O
and O
depression O
. O

Indian O
blood O
donor O
selection O
guidelines O
: O
Review O
in O
the O
context O
of O
the O
ongoing O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
Presenting O
as O
Acute O
Limb O
Ischaemia O
. O

We O
reviewed O
the O
medical O
records O
of O
42 O
pregnant O
women O
diagnosed O
with O
COVID O
- O
19 O
from O
March O
13 O
, O
2020 O
, O
to O
March O
29 O
, O
2020 O
, O
when O
they O
were O
in O
their O
third O
trimester O
of O
pregnancy O
. O

We O
suggested O
that O
COVID O
- O
19 O
should O
be O
diagnosed O
as O
3 O
types O
: O
suspected O
case O
, O
clinical O
diagnosed O
case O
, O
and O
definite O
diagnosed O
case O
. O

Silver O
Linings O
: O
An O
Opportunity O
to O
Improve O
Clinical O
Paradigms O
After O
the O
COVID O
- O
19 O
Pandemic O
. O

Overall O
, O
69 O
% O
( O
n O
= O
94 O
) O
had O
sufficient O
knowledge O
, O
21 O
% O
( O
n O
= O
29 O
) O
had O
positive O
attitude O
, O
and O
74 O
% O
( O
n O
= O
101 O
) O
had O
good O
practices O
toward O
COVID O
- O
19 O
. O

All O
relevant O
articles O
providing O
information O
on O
PCR O
tested O
COVID O
- O
19 O
positive O
patient O
population O
with O
clinical O
characteristics O
and O
epidemiological O
information O
were O
selected O
for O
review O
and O
analysis O
. O

COVID O
- O
19 O
Mediated O
by O
Basigin O
Can O
Affect O
Male O
and O
Female O
Fertility O
. O

We O
included O
585 O
patients O
who O
were O
COVID O
- O
19 O
positive O
, O
of O
whom O
117 O
had O
active O
malignancy O
, O
defined O
as O
those O
receiving O
cancer O
- O
directed O
therapy O
or O
under O
active O
surveillance O
within O
6 O
months O
of O
admission O
. O

Letter O
: O
News O
From O
the O
COVID O
- O
19 O
Front O
Lines O
: O
How O
Neurosurgeons O
Are O
Contributing O
. O

Using O
PubMed O
/ O
Medline O
, O
EMBASE O
, O
and O
SCOPUS O
, O
a O
thorough O
literature O
search O
was O
performed O
to O
identify O
the O
studies O
reporting O
rate O
of O
PE O
among O
COVID O
- O
19 O
. O

While O
conventional O
technologies O
such O
as O
quantitative O
real O
time O
polymerase O
chain O
reaction O
( O
qRT O
- O
PCR O
) O
have O
been O
broadly O
used O
to O
detect O
COVID O
- O
19 O
, O
they O
are O
time O
- O
consuming O
, O
labor O
- O
intensive O
and O
are O
unavailable O
in O
remote O
settings O
. O

Risk O
Factors O
Associated O
With O
Clinical O
Outcomes O
in O
323 O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Hospitalized O
Patients O
in O
Wuhan O
, O
China O
. O

Short O
- O
term O
outpatient O
follow O
- O
up O
of O
COVID O
- O
19 O
patients O
: O
A O
multidisciplinary O
approach O
. O

BCG O
- O
induced O
trained O
immunity O
: O
can O
it O
offer O
protection O
against O
COVID O
- O
19 O
? O

Furthermore O
, O
nutritional O
status O
and O
the O
role O
of O
diet O
and O
lifestyle O
is O
considered O
, O
as O
it O
is O
known O
to O
affect O
patient O
outcomes O
in O
other O
severe O
infections O
and O
may O
play O
a O
role O
in O
COVID O
- O
19 O
infection O
. O

However O
, O
19 O
. O
76 O
% O
( O
10 O
, O
290 O
/ O
52 O
, O
066 O
) O
could O
not O
disinfect O
their O
homes O
each O
week O
, O
and O
18 O
. O
42 O
% O
( O
9589 O
/ O
52 O
, O
066 O
) O
could O
not O
distinguish O
differences O
in O
initial O
symptoms O
between O
the O
common O
cold O
and O
COVID O
- O
19 O
. O

The O
implications O
of O
these O
changes O
- O
and O
the O
indirect O
impact O
of O
COVID O
- O
19 O
- O
require O
further O
study O
. O

Furthermore O
, O
obesity O
is O
increasingly O
considered O
as O
a O
yet O
another O
risk O
factor O
, O
particularly O
, O
because O
it O
has O
been O
observed O
that O
people O
suffering O
from O
excessive O
body O
weight O
may O
experience O
a O
more O
severe O
course O
of O
COVID O
- O
19 O
infection O
. O

Point O
of O
care O
detection O
of O
COVID O
- O
19 O
: O
Advancement O
in O
biosensing O
and O
diagnostic O
methods O
. O

It O
is O
known O
that O
chronic O
cardiovascular O
diseases O
are O
associated O
with O
the O
risk O
of O
severe O
course O
and O
lethal O
outcomes O
both O
in O
COVID O
- O
19 O
and O
other O
infectious O
diseases O
. O

Reply O
to O
: O
Society O
of O
Onco O
- O
Anaesthesia O
and O
Perioperative O
Care O
advisory O
on O
anaesthesia O
in O
COVID O
- O
19 O
: O
What O
is O
lacking O
? O

Here O
, O
using O
Trimer O
- O
Tag O
technology O
, O
we O
produced O
both O
wild O
- O
type O
( O
WT O
) O
and O
furin O
site O
mutant O
( O
MT O
) O
S O
- O
Trimers O
for O
COVID O
- O
19 O
vaccine O
studies O
. O

Disrupting O
the O
intermolecular O
association O
of O
SARS O
- O
CoV O
- O
2 O
spike O
glycoprotein O
( O
S O
protein O
) O
with O
its O
cell O
surface O
receptor O
human O
angiotensin O
- O
converting O
enzyme O
2 O
( O
hACE2 O
) O
has O
been O
recognized O
as O
a O
promising O
therapeutic O
strategy O
against O
COVID O
- O
19 O
. O

The O
rapid O
emergence O
of O
COVID O
- O
19 O
could O
have O
direct O
and O
indirect O
impacts O
on O
food O
production O
systems O
and O
livelihoods O
of O
farmers O
. O

The O
COVID O
- O
19 O
pandemic O
caused O
an O
increased O
mortality O
in O
nursing O
homes O
due O
to O
its O
quick O
spread O
and O
the O
age O
- O
related O
high O
lethality O
. O

Therefore O
, O
telehealth O
should O
be O
an O
important O
tool O
in O
caring O
services O
while O
keeping O
patients O
and O
health O
providers O
safe O
during O
COVID O
- O
19 O
outbreak O
. O

While O
it O
is O
known O
that O
chloroquine O
and O
hydroxychloroquine O
, O
extensively O
explored O
as O
clinical O
agents O
for O
COVID O
- O
19 O
, O
have O
multiple O
cellular O
effects O
including O
inhibiting O
autophagy O
, O
there O
are O
also O
dose O
- O
limiting O
toxicities O
in O
patients O
that O
make O
clearly O
establishing O
their O
potential O
mechanisms O
- O
of O
- O
action O
problematic O
. O

: O
The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
may O
cause O
not O
only O
an O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
but O
also O
multiple O
organ O
damage O
and O
failure O
requiring O
intensive O
care O
and O
leading O
to O
death O
. O

The O
novel O
coronavirus O
infection O
( O
COVID O
- O
19 O
or O
Coronavirus O
disease O
2019 O
) O
that O
emerged O
from O
Wuhan O
, O
Hubei O
province O
of O
China O
has O
spread O
to O
many O
countries O
worldwide O
. O

Since O
December O
2019 O
, O
the O
world O
is O
affected O
by O
an O
outbreak O
of O
a O
new O
disease O
named O
COVID O
- O
19 O
, O
which O
is O
an O
acronym O
of O
' O
coronavirus O
disease O
2019 O
' O
. O

MS O
therapeutic O
decision O
- O
making O
should O
focus O
on O
the O
danger O
of O
poorly O
controlled O
autoimmune O
demyelination O
rather O
than O
perceived O
risks O
from O
COVID O
- O
19 O
. O

Now O
may O
be O
the O
time O
to O
address O
these O
underlying O
workforce O
challenges O
and O
emerge O
from O
the O
COVID O
- O
19 O
pandemic O
with O
a O
stronger O
health O
care O
workforce O
. O
Building O
upon O
historical O
exemplars O
in O
the O
context O
of O
the O
current O
crisis O
, O
the O
authors O
of O
this O
Perspective O
provide O
a O
roadmap O
to O
rapidly O
and O
safely O
increase O
the O
workforce O
for O
COVID O
- O
19 O
and O
beyond O
. O

To O
assess O
the O
significance O
of O
multiple O
laboratory O
blood O
values O
in O
patients O
with O
SARS O
- O
CoV O
- O
2 O
and O
develop O
a O
COVID O
- O
19 O
predictive O
equation O
, O
we O
conducted O
a O
literature O
search O
using O
PubMed O
to O
seek O
articles O
that O
included O
defined O
laboratory O
data O
points O
along O
with O
clinical O
disease O
progression O
. O

We O
retrospectively O
studied O
268 O
COVID O
- O
19 O
convalescent O
plasma O
donors O
and O
162 O
COVID O
- O
19 O
inpatients O
( O
total O
430 O
subjects O
, O
confirmed O
by O
RT O
- O
PCR O
) O
and O
2 O
, O
212 O
healthy O
volunteer O
first O
- O
time O
blood O
donors O
as O
a O
control O
group O
. O

COVID O
- O
19 O
, O
HCT O
and O
wine O
. O

Systemic O
inflammation O
as O
fuel O
for O
acute O
liver O
injury O
in O
COVID O
- O
19 O
. O

Therefore O
, O
we O
describe O
here O
some O
drugs O
already O
in O
the O
market O
with O
potential O
CatL O
inhibiting O
capacity O
that O
could O
be O
used O
to O
treat O
COVID O
- O
19 O
patients O
. O

Despite O
the O
challenges O
COVID O
- O
19 O
presents O
to O
the O
continuity O
of O
health O
disparities O
research O
, O
it O
also O
presents O
unprecedented O
opportunities O
to O
innovate O
. O

The O
COVID O
- O
19 O
pandemic O
, O
associated O
with O
the O
new O
coronavirus O
SARS O
- O
CoV O
- O
2 O
, O
has O
caused O
a O
surge O
in O
incidence O
worldwide O
, O
as O
well O
as O
a O
severe O
crisis O
in O
global O
health O
and O
economy O
. O

Statistical O
analyses O
revealed O
that O
the O
March O
16 O
presidential O
recommendation O
( O
limiting O
gatherings O
to O
≤ O
10 O
people O
) O
lowered O
the O
compound O
growth O
rate O
of O
COVID O
- O
19 O
for O
all O
counties O
in O
the O
US O
by O
6 O
. O
6 O
% O
, O
and O
the O
counties O
that O
implemented O
SIP O
after O
March O
16 O
had O
a O
further O
reduction O
of O
7 O
. O
8 O
% O
compared O
with O
the O
counties O
that O
did O
not O
implement O
SIP O
after O
March O
16 O
. O

To O
describe O
the O
clinical O
courses O
of O
adult O
patients O
admitted O
for O
COVID O
- O
19 O
and O
identify O
associations O
between O
inpatient O
clinical O
features O
and O
post O
- O
discharge O
need O
for O
acute O
care O
. O

COVID O
- O
19 O
is O
a O
pandemic O
, O
resulting O
in O
large O
number O
of O
deaths O
all O
over O
the O
world O
. O

A O
retrospective O
chart O
review O
was O
conducted O
on O
119 O
patients O
hospitalized O
for O
COVID O
- O
19 O
infection O
between O
March O
1 O
, O
2020 O
, O
and O
April O
20 O
, O
2020 O
. O

Onset O
of O
occupational O
hand O
eczema O
among O
healthcare O
workers O
during O
the O
SARS O
- O
CoV O
- O
2 O
pandemic O
: O
Comparing O
a O
single O
surgical O
site O
with O
a O
COVID O
- O
19 O
intensive O
care O
unit O
. O

Diabetes O
care O
providers O
answered O
a O
33 O
- O
item O
questionnaire O
regarding O
demographics O
, O
symptoms O
, O
and O
diabetes O
- O
and O
COVID O
- O
19 O
- O
related O
care O
and O
outcomes O
. O

This O
is O
a O
report O
of O
an O
atypical O
presentation O
of O
COVID O
- O
19 O
. O

Anti O
- O
inflammatory O
therapy O
for O
COVID O
- O
19 O
infection O
: O
the O
case O
for O
colchicine O
. O

Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
Immune O
- O
Engaging O
Cancer O
Treatment O
. O

The O
role O
of O
tracheostomy O
in O
COVID O
- O
19 O
- O
related O
ARDS O
is O
unknown O
. O

We O
fit O
a O
mathematical O
model O
to O
empirically O
estimated O
numbers O
of O
people O
infected O
, O
recovered O
, O
and O
died O
from O
COVID O
- O
19 O
in O
Manitoba O
. O

Trend O
and O
regression O
analysis O
give O
an O
idea O
of O
the O
incidence O
of O
COVID O
- O
19 O
in O
India O
while O
projection O
made O
by O
Verhulst O
( O
Logistic O
) O
Population O
Model O
for O
the O
confirmed O
cases O
of O
the O
study O
area O
are O
encouraging O
as O
the O
sample O
prediction O
is O
as O
same O
as O
the O
actual O
number O
of O
confirmed O
COVID O
- O
19 O
cases O
. O

We O
used O
data O
from O
the O
second O
wave O
of O
the O
Brazilian O
Longitudinal O
Study O
of O
Aging O
( O
ELSI O
- O
Brazil O
) O
, O
conducted O
through O
face O
- O
to O
- O
face O
interviews O
between O
August O
2019 O
and O
March O
2020 O
( O
before O
the O
onset O
of O
the O
epidemic O
) O
, O
in O
a O
representative O
national O
sample O
of O
adults O
aged O
50 O
and O
over O
, O
and O
data O
obtained O
through O
telephone O
interviews O
carried O
out O
among O
the O
same O
participants O
( O
ELSI O
- O
COVID O
- O
19 O
initiative O
) O
, O
conducted O
between O
May O
26 O
and O
June O
8 O
, O
2020 O
( O
during O
the O
epidemic O
) O
. O

In O
addition O
, O
seven O
patients O
who O
were O
not O
hospitalized O
in O
the O
COVID O
- O
19 O
cohort O
isolation O
ward O
who O
became O
positive O
during O
their O
admission O
were O
infected O
with O
severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
cluster O
A O
. O

Publishing O
in O
the O
time O
of O
pandemic O
: O
Editorial O
policy O
of O
a O
dermatology O
journal O
during O
COVID O
- O
19 O
. O

In O
total O
, O
five O
patients O
were O
admitted O
in O
an O
intensive O
care O
unit O
because O
of O
COVID O
- O
19 O
and O
one O
died O
from O
the O
disease O
. O

Using O
the O
case O
study O
of O
ventilators O
in O
the O
COVID O
- O
19 O
pandemic O
, O
we O
show O
how O
the O
moral O
frameworks O
that O
we O
might O
adopt O
in O
response O
to O
individual O
triage O
decisions O
do O
not O
translate O
straightforwardly O
to O
this O
regional O
- O
level O
triage O
question O
. O

This O
brief O
report O
describes O
what O
we O
know O
about O
the O
nature O
and O
costs O
of O
survivor O
loneliness O
and O
uses O
the O
COVID O
- O
19 O
pandemic O
as O
a O
lens O
through O
which O
to O
review O
the O
ways O
current O
DV O
interventions O
may O
help O
alleviate O
loneliness O
( O
as O
distinct O
from O
isolation O
) O
, O
and O
how O
these O
might O
be O
expanded O
to O
enhance O
survivor O
wellbeing O
, O
immediately O
and O
even O
after O
a O
return O
to O
" O
normal O
. O
" O

This O
commentary O
examines O
the O
occupational O
health O
and O
safety O
issues O
faced O
by O
the O
UK O
workers O
in O
the O
COVID O
- O
19 O
pandemic O
, O
against O
the O
background O
of O
government O
cuts O
in O
health O
care O
and O
in O
occupational O
health O
and O
safety O
budgets O
, O
and O
a O
deregulatory O
climate O
. O

Since O
the O
new O
coronavirus O
( O
COVID O
- O
19 O
) O
outbreak O
spread O
from O
China O
to O
other O
countries O
, O
it O
has O
been O
a O
curiosity O
for O
how O
and O
how O
long O
the O
number O
of O
cases O
will O
increase O
. O

Thailand O
began O
the O
COVID O
- O
19 O
screening O
protocol O
on O
3 O
January O
2020 O
. O

In O
2020 O
, O
the O
COVID O
- O
19 O
pandemic O
brought O
dramatic O
changes O
in O
the O
delivery O
of O
primary O
health O
care O
across O
the O
world O
, O
presumably O
changing O
the O
number O
of O
consultations O
for O
infectious O
diseases O
and O
antibiotic O
use O
. O

Considering O
the O
frequent O
use O
of O
remdesivir O
in O
patients O
with O
COVID O
- O
19 O
, O
physicians O
should O
be O
aware O
of O
this O
possible O
adverse O
event O
. O

Natural O
history O
of O
COVID O
- O
19 O
: O
back O
to O
basics O
. O

SARS O
- O
CoV O
- O
2 O
( O
2019 O
- O
nCoV O
) O
is O
the O
pathogenic O
coronavirus O
responsible O
for O
the O
global O
pandemic O
of O
COVID O
- O
19 O
disease O
. O

Early O
diagnosis O
and O
isolation O
of O
mild O
or O
asymptomatic O
COVID O
- O
19 O
patients O
is O
important O
to O
control O
the O
spread O
of O
SARS O
- O
CoV O
- O
2 O
. O

Coronavirus O
( O
COVID O
- O
19 O
) O
and O
Racial O
Disparities O
: O
a O
Perspective O
Analysis O
. O

Concomitant O
use O
of O
dexamethasone O
and O
tetracyclines O
: O
a O
potential O
therapeutic O
option O
for O
the O
management O
of O
severe O
COVID O
- O
19 O
infection O
? O

Probable O
anxiety O
and O
components O
of O
psychological O
resilience O
amid O
COVID O
- O
19 O
: O
A O
population O
- O
based O
study O
. O

The O
daily O
COVID O
- O
19 O
case O
count O
in O
two O
Brazilian O
states O
was O
used O
to O
show O
the O
potential O
limitations O
of O
long O
- O
term O
forecasting O
through O
the O
application O
of O
a O
mathematical O
model O
to O
the O
data O
. O

Otorhinolaryngologis O
from O
both O
the O
United O
Kingdom O
and O
Abroad O
were O
polled O
with O
regards O
to O
their O
experience O
of O
tracheostomy O
in O
COVID O
- O
19 O
positive O
ventilated O
patients O
. O

People O
who O
are O
exposed O
to O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
could O
develop O
a O
potentially O
fatal O
disease O
with O
lung O
involvement O
and O
severe O
cytokine O
storm O
syndrome O
( O
CSS O
) O
- O
coronavirus O
disease O
2019 O
( O
hereafter O
, O
COVID O
- O
19 O
) O
. O

The O
present O
article O
aims O
to O
provide O
a O
brief O
description O
of O
COVID O
- O
19 O
implications O
in O
dental O
office O
and O
to O
recommend O
preventive O
protocols O
for O
dental O
practitioners O
to O
ensure O
a O
safe O
and O
healthful O
workplace O
. O

Although O
, O
our O
understanding O
of O
COVID O
- O
19 O
has O
significantly O
increased O
since O
its O
outbreak O
, O
and O
multiple O
treatment O
approaches O
and O
pharmacological O
interventions O
have O
been O
tested O
or O
are O
currently O
under O
development O
to O
mitigate O
its O
risk O
- O
factors O
. O

When O
applied O
to O
COVID O
- O
19 O
preparations O
, O
an O
assembly O
line O
approach O
had O
the O
advantage O
that O
our O
ICU O
became O
easily O
scalable O
to O
manage O
an O
influx O
of O
additional O
staff O
as O
well O
as O
the O
increase O
in O
admissions O
. O

Antibody O
profiling O
against O
the O
SARS O
- O
CoV O
- O
2 O
S O
protein O
of O
the O
D614 O
variant O
by O
flow O
cytometry O
and O
assessment O
of O
neutralising O
antibody O
titres O
using O
pseudotyped O
lentiviruses O
expressing O
the O
SARS O
- O
CoV O
- O
2 O
S O
protein O
of O
either O
the O
D614 O
or O
G614 O
variant O
tagged O
with O
a O
luciferase O
reporter O
were O
performed O
on O
plasma O
samples O
from O
COVID O
- O
19 O
patients O
with O
known O
D614G O
status O
( O
n O
= O
44 O
infected O
with O
D614 O
, O
n O
= O
6 O
infected O
with O
G614 O
, O
n O
= O
7 O
containing O
all O
other O
clades O
: O
O O
, O

S O
, O
L O
, O
V O
, O
G O
, O
GH O
or O
GR O
) O
. O

Few O
studies O
have O
compared O
these O
clinical O
features O
and O
outcomes O
of O
COVID O
- O
19 O
to O
other O
acute O
respiratory O
illnesses O
. O

Regional O
Mechanical O
Thrombectomy O
Imaging O
Protocol O
in O
Patients O
Presenting O
with O
Acute O
Ischemic O
Stroke O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

This O
paper O
is O
intended O
to O
provide O
evidence O
- O
based O
perspectives O
for O
self O
- O
insured O
employers O
for O
managing O
population O
health O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
study O
included O
63 O
patients O
, O
with O
hip O
or O
knee O
OA O
, O
who O
had O
been O
scheduled O
for O
arthroplasty O
that O
was O
postponed O
because O
of O
COVID O
- O
19 O
. O

Coronavirus O
infection O
is O
rarely O
associated O
with O
conjunctivitis O
, O
with O
occasional O
cases O
reported O
in O
patients O
with O
confirmed O
COVID O
- O
19 O
, O
along O
with O
isolated O
cases O
of O
conjunctivitis O
as O
a O
presenting O
sign O
. O

While O
multiple O
guidelines O
have O
been O
issued O
regarding O
autopsy O
protocol O
in O
cases O
of O
suspected O
COVID O
- O
19 O
deaths O
, O
there O
is O
some O
variability O
in O
the O
recommendations O
. O

Post O
- O
COVID O
- O
19 O
fatigue O
and O
anhedonia O
were O
prevalent O
and O
commonly O
reported O
in O
the O
post O
- O
COVID O
- O
19 O
period O
, O
also O
the O
duration O
after O
2 O
consecutive O
negative O
PCR O
tests O
has O
an O
implication O
on O
the O
severity O
rating O
scale O
of O
both O
anhedonia O
and O
fatigue O
. O

Of O
these O
patients O
with O
severe O
COVID O
- O
19 O
, O
68 O
% O
( O
n O
= O
52 O
) O
died O
. O

Acute O
care O
admissions O
to O
the O
largest O
tertiary O
care O
referral O
hospital O
, O
designated O
national O
referral O
centers O
for O
cardiac O
, O
cancer O
and O
maternity O
hospital O
in O
the O
State O
of O
Qatar O
during O
March O
2020 O
( O
COVID O
- O
19 O
era O
) O
and O
January O
2020 O
and O
March O
2019 O
( O
pre O
- O
COVID O
- O
19 O
era O
) O
were O
compared O
. O

All O
adult O
patients O
admitted O
to O
the O
adult O
intensive O
care O
unit O
( O
AICU O
) O
, O
diagnosed O
with O
severe O
COVID O
- O
19 O
infection O
and O
requiring O
surgical O
tracheostomy O
between O
the O
March O
10 O
, O
2020 O
, O
and O
May O
1 O
, O
2020 O
, O
were O
included O
. O

The O
rate O
of O
symptomatic O
VTE O
in O
this O
group O
at O
42 O
days O
after O
discharge O
was O
2 O
. O
6 O
% O
, O
highlighting O
the O
need O
for O
large O
prospective O
randomized O
controlled O
trials O
of O
extended O
thromboprophylaxis O
after O
discharge O
in O
COVID O
- O
19 O
. O

To O
assess O
differences O
in O
qualitative O
and O
quantitative O
parameters O
of O
pulmonary O
perfusion O
from O
dual O
- O
energy O
computed O
tomography O
( O
CT O
) O
pulmonary O
angiography O
( O
DECT O
- O
PA O
) O
in O
patients O
with O
COVID O
- O
19 O
pneumonia O
with O
and O
without O
pulmonary O
embolism O
( O
PE O
) O
. O

The O
objective O
of O
this O
review O
was O
to O
identify O
the O
incidence O
of O
smell O
and O
taste O
dysfunction O
in O
COVID O
- O
19 O
, O
determine O
the O
onset O
of O
their O
symptoms O
and O
the O
risk O
factors O
of O
anosmia O
, O
hyposmia O
, O
ageusia O
or O
dysgeusia O
for O
COVID O
- O
19 O
infection O
. O

On O
21 O
January O
2020 O
, O
the O
city O
of O
Taizhou O
, O
China O
, O
reported O
its O
first O
imported O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
case O
and O
subsequently O
the O
number O
of O
cases O
rapidly O
increased O
. O

An O
outbreak O
of O
corona O
virus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
began O
in O
China O
in O
December O
2019 O
, O
and O
rapidly O
spread O
to O
become O
a O
worldwide O
pandemic O
. O

In O
COVID O
- O
19 O
patients O
, O
the O
maximum O
intensity O
projection O
of O
the O
lung O
CT O
is O
visualized O
to O
a O
physician O
, O
and O
the O
CT O
Involvement O
Score O
is O
calculated O
. O

Association O
of O
Cardiac O
Infection O
With O
SARS O
- O
CoV O
- O
2 O
in O
Confirmed O
COVID O
- O
19 O
Autopsy O
Cases O
. O

Our O
understanding O
of O
the O
hepatic O
consequences O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
infection O
and O
its O
resultant O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
evolved O
rapidly O
since O
the O
onset O
of O
the O
pandemic O
. O

We O
applied O
these O
methods O
to O
daily O
death O
counts O
attributed O
to O
COVID O
- O
19 O
in O
selected O
countries O
, O
reported O
up O
to O
June O
5 O
, O
2020 O
. O

As O
of O
20th O
April O
data O
available O
, O
statistical O
analyses O
by O
various O
methods O
have O
found O
that O
strong O
negative O
correlations O
with O
statistical O
significance O
exist O
between O
MAET O
and O
several O
COVID O
- O
19 O
cases O
including O
total O
cases O
, O
active O
cases O
, O
and O
cases O
per O
million O
of O
a O
country O
( O
Spearman O
correlation O
coefficients O
were O
- O
0 O
. O
45 O
, O
- O
0 O
. O
42 O
, O
and O
- O
0 O
. O
50 O
for O
total O
cases O
, O
active O
cases O
, O
and O
cases O
/ O
per O
million O
, O
respectively O
) O
. O

On O
March O
11 O
, O
2020 O
, O
the O
Director O
- O
General O
of O
the O
World O
Health O
Organization O
( O
WHO O
) O
declared O
the O
disease O
caused O
by O
SARS O
- O
CoV O
- O
2 O
( O
COVID O
- O
19 O
) O
as O
a O
pandemic O
. O

Conventional O
to O
online O
education O
during O
COVID O
- O
19 O
pandemic O
: O
Do O
develop O
and O
underdeveloped O
nations O
cope O
alike O
. O

COVID O
- O
19 O
cryptic O
transmission O
and O
genetic O
information O
blackouts O
: O
Need O
for O
effective O
surveillance O
policy O
to O
better O
understand O
disease O
burden O
. O

To O
do O
that O
, O
specific O
mortality O
from O
COVID O
- O
19 O
has O
been O
standardized O
for O
each O
Italian O
province O
and O
per O
age O
group O
( O
10 O
groups O
) O
ranging O
from O
0 O
to O
9 O
years O
to O
> O
90 O
years O
, O
based O
on O
the O
2019 O
national O
population O
figures O
. O

Blood O
group O
O O
may O
protects O
, O
and O
subjects O
with O
blood O
type O
B O
could O
be O
susceptible O
to O
COVID O
- O
19 O
mortality O
. O

For O
patients O
diagnosed O
with O
the O
novel O
coronavirus O
, O
COVID O
- O
19 O
, O
evidence O
is O
needed O
to O
understand O
the O
effect O
of O
treatment O
by O
physical O
therapists O
in O
the O
acute O
hospital O
on O
patient O
outcomes O
. O

The O
World O
Health O
Organization O
officially O
named O
this O
disease O
as O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Literature O
analysis O
showed O
that O
although O
most O
children O
are O
clearly O
protected O
from O
the O
development O
of O
severe O
COVID O
- O
19 O
, O
the O
reasons O
for O
this O
peculiarity O
are O
not O
fully O
understood O
. O

Severe O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
is O
currently O
managed O
with O
systemic O
glucocorticoids O
. O

Virtual O
Parkinson O
' O
s O
Disease O
Support O
Groups O
in O
the O
COVID O
- O
19 O
Era O
: O
Social O
Connection O
in O
the O
Time O
of O
Social O
Distancing O
. O

There O
is O
accumulating O
evidence O
for O
an O
overly O
activated O
immune O
response O
in O
severe O
COVID O
- O
19 O
, O
with O
several O
studies O
exploring O
the O
therapeutic O
role O
of O
immunomodulation O
. O

Conclusions O
: O
Our O
patient O
- O
based O
survey O
study O
in O
a O
real O
- O
world O
setting O
showed O
that O
COVID O
- O
19 O
resulted O
in O
a O
great O
impact O
on O
the O
healthcare O
of O
patients O
with O
IBD O
, O
and O
such O
an O
impact O
was O
more O
obvious O
in O
the O
epicenter O
compared O
to O
the O
non O
- O
epicenter O
area O
of O
COVID O
- O
19 O
. O

Accumulating O
evidence O
supports O
that O
the O
viral O
- O
induced O
hyper O
- O
inflammatory O
immune O
response O
plays O
a O
central O
role O
in O
COVID O
- O
19 O
pathogenesis O
. O

Between O
March O
29 O
and O
May O
, O
2020 O
, O
the O
words O
COVID O
- O
19 O
, O
SARS O
- O
CoV2 O
, O
COVID O
- O
19 O
and O
pregnancy O
, O
SARS O
- O
CoV2 O
and O
pregnancy O
, O
and O
SARS O
and O
pregnancy O
were O
searched O
in O
the O
PubMed O
and O
Google O
Scholar O
databases O
; O
the O
guidelines O
from O
well O
- O
known O
societies O
and O
institutions O
( O
Royal O
College O
of O
Obstetricians O
and O
Gynaecologists O
[ O
RCOG O
] O
, O
American O
College O
of O
Obstetricians O
and O
Gynecologists O
[ O
ACOG O
] O
, O
International O
Society O
of O
Ultrasound O
in O
Obstetrics O
& O
Gynecology O
[ O
ISUOG O
] O

, O
Centers O
for O
Disease O
Control O
and O
Prevention O
[ O
CDC O
] O
, O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
[ O
FIGO O
] O
) O
were O
also O
included O
. O

Risk O
Factors O
for O
In O
- O
hospital O
Mortality O
from O
COVID O
- O
19 O
Infection O
among O
Black O
Patients O
- O
An O
Urban O
Center O
Experience O
. O

The O
purpose O
of O
our O
study O
is O
to O
assess O
the O
impact O
of O
COVID O
- O
19 O
on O
the O
clinical O
responsibilities O
, O
training O
, O
and O
wellness O
of O
US O
radiation O
oncology O
residents O
. O

ACE2 O
( O
FC O
= O
+ O
1 O
. O
88 O
, O
p O
≤ O
0 O
. O
05 O
) O
and O
DPP4 O
( O
FC O
= O
+ O
3 O
, O
p O
< O
0 O
. O
01 O
) O
genes O
showed O
a O
significant O
overexpression O
in O
COVID O
- O
19 O
patients O
. O

Our O
analyses O
support O
anecdotal O
reports O
of O
staff O
struggling O
with O
the O
additional O
pressures O
brought O
on O
by O
COVID O
- O
19 O
. O

Electrochemical O
sensing O
: O
A O
prognostic O
tool O
in O
the O
fight O
against O
COVID O
- O
19 O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
changes O
in O
the O
utilization O
of O
RI O
services O
in O
both O
the O
public O
and O
private O
sectors O
following O
the O
COVID O
- O
19 O
pandemic O
. O

Coagulation O
profile O
in O
severe O
COVID O
- O
19 O
patients O
: O
what O
do O
we O
know O
so O
far O
? O

COVID O
- O
19 O
vaccination O
campaigns O
take O
shape O
. O

Letter O
to O
Editor O
regarding O
Prata O
et O
al O
. O
( O
2020 O
) O
, O
Temperature O
significantly O
changes O
COVID O
- O
19 O
transmission O
in O
( O
sub O
) O
tropical O
cities O
of O
Brazil O
. O
Science O
of O
Total O
Environment O
, O
v729 O
, O
138862 O
. O

COVID O
- O
19 O
Inmate O
Risk O
Appraisal O
( O
CIRA O
) O
: O
development O
and O
validation O
of O
a O
screening O
tool O
to O
assess O
COVID O
- O
19 O
vulnerability O
in O
prisons O
. O

The O
availability O
of O
such O
a O
method O
in O
today O
' O
s O
pandemic O
would O
help O
automate O
, O
prioritize O
, O
fasten O
, O
and O
broaden O
the O
treatment O
of O
COVID O
- O
19 O
patients O
globally O
. O

Forty O
patients O
were O
reviewed O
retrospectively O
over O
a O
follow O
- O
up O
period O
of O
32 O
days O
after O
being O
diagnosed O
with O
COVID O
- O
19 O
. O

To O
evaluate O
the O
effect O
of O
the O
COVID O
- O
19 O
pandemic O
on O
harm O
reduction O
services O
for O
adolescents O
and O
young O
adults O
in O
Boston O
, O
we O
conducted O
a O
quantitative O
assessment O
of O
the O
Community O
Care O
in O
Reach O
( O
CCIR O
) O
youth O
pilot O
program O
to O
determine O
gaps O
in O
services O
created O
by O
its O
closure O
during O
the O
peak O
of O
the O
pandemic O
( O
March O
19 O
- O
June O
21 O
, O
2020 O
) O
. O

Patients O
with O
COVID O
- O
19 O
were O
classified O
as O
having O
either O
minimal O
or O
severe O
disease O
. O

[ O
Position O
Paper O
for O
the O
State O
of O
the O
Art O
Application O
of O
Respiratory O
Support O
in O
Patients O
with O
COVID O
- O
19 O
- O
German O
Respiratory O
Society O
] O
. O

the O
aim O
was O
to O
evaluate O
nurses O
' O
self O
- O
efficacy O
, O
confidence O
and O
nurse O
- O
patient O
interaction O
during O
caring O
of O
patients O
with O
COVID O
- O
19 O
. O

It O
is O
publicly O
available O
and O
aims O
to O
help O
health O
care O
providers O
fight O
COVID O
- O
19 O
and O
improve O
patients O
' O
outcomes O
. O

While O
severe O
social O
- O
distancing O
measures O
have O
proven O
effective O
in O
slowing O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
second O
- O
wave O
scenarios O
are O
likely O
to O
emerge O
as O
restrictions O
are O
lifted O
. O

Therefore O
, O
an O
international O
online O
survey O
was O
launched O
in O
April O
2020 O
, O
in O
seven O
languages O
, O
to O
elucidate O
the O
behavioural O
and O
lifestyle O
consequences O
of O
COVID O
- O
19 O
restrictions O
. O

Seven O
patients O
received O
testing O
due O
to O
suspicious O
imaging O
findings O
with O
subsequent O
lab O
- O
confirmed O
COVID O
- O
19 O
. O

We O
aimed O
to O
survey O
the O
mental O
health O
of O
non O
- O
infectious O
disease O
specialist O
staff O
, O
specifically O
obstetricians O
and O
midwives O
, O
working O
in O
officially O
designated O
hospitals O
treating O
patients O
with O
COVID O
- O
19 O
. O

Currently O
, O
remdesivir O
received O
the O
FDA O
authorizes O
to O
use O
as O
an O
experimental O
drug O
for O
emergency O
use O
in O
COVID O
- O
19 O
patients O
. O

Here O
, O
we O
report O
our O
experience O
in O
designing O
, O
producing O
and O
dispatching O
three O
3D O
- O
printed O
objected O
intending O
to O
lower O
the O
risks O
of O
COVID O
- O
19 O
contamination O
by O
limiting O
direct O
contacts O
: O
( O
1 O
) O
fixed O
hand O
- O
free O
door O
openers O
, O
( O
2 O
) O
door O
hooks O
and O
( O
3 O
) O
button O
pushers O
. O

Model O
Calculations O
of O
Aerosol O
Transmission O
and O
Infection O
Risk O
of O
COVID O
- O
19 O
in O
Indoor O
Environments O
. O

Most O
COVID O
- O
19 O
patients O
experience O
asymptomatic O
/ O
mild O
symptoms O
, O
but O
some O
suffer O
critical O
symptoms O
requiring O
intensive O
care O
. O

Previous O
research O
has O
shown O
that O
rooms O
of O
patients O
with O
COVID O
- O
19 O
present O
the O
potential O
for O
healthcare O
- O
associated O
transmission O
through O
aerosols O
containing O
SARS O
- O
CoV O
- O
2 O
. O

COVID O
- O
19 O
mortality O
risk O
factors O
in O
older O
people O
in O
a O
long O
- O
term O
care O
center O
. O

We O
will O
also O
focus O
on O
the O
emerging O
literature O
on O
COVID O
- O
19 O
olfactory O
dysfunction O
, O
its O
unique O
features O
, O
and O
its O
important O
implications O
for O
this O
pandemic O
. O

COVID O
- O
19 O
Lockdown O
, O
Food O
Systems O
and O
Urban O
- O
Rural O
Partnership O
: O
Case O
of O
Nagpur O
, O
India O
. O

We O
report O
findings O
on O
causes O
of O
death O
and O
comorbidities O
of O
26 O
decedents O
that O
had O
clinically O
presented O
with O
severe O
COVID O
- O
19 O
. O

The O
results O
indicated O
a O
moderate O
level O
of O
knowledge O
and O
preventive O
practices O
in O
regard O
to O
COVID O
- O
19 O
in O
most O
of O
the O
respondents O
( O
56 O
. O
8 O
% O
and O
56 O
. O
5 O
% O
, O
respectively O
) O
. O

This O
study O
aimed O
to O
clarify O
the O
influencing O
factors O
for O
the O
anxiety O
level O
among O
the O
Chinese O
people O
during O
the O
COVID O
- O
19 O
pandemic O
, O
with O
a O
particular O
focus O
on O
the O
media O
exposure O
to O
different O
COVID O
- O
19 O
information O
. O

Currently O
no O
effective O
antiviral O
therapy O
has O
been O
found O
to O
treat O
COVID O
- O
19 O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
threatening O
billions O
of O
people O
worldwide O
. O

Digital O
surveillance O
has O
played O
a O
key O
role O
in O
containing O
the O
COVID O
- O
19 O
outbreak O
in O
China O
, O
Singapore O
, O
Israel O
, O
and O
South O
Korea O
. O

Proctology O
is O
one O
of O
the O
surgical O
specialties O
that O
has O
suffered O
the O
most O
during O
COVID O
- O
19 O
pandemic O
. O

The O
initial O
public O
health O
response O
to O
the O
breakout O
of O
COVID O
- O
19 O
required O
fundamental O
changes O
in O
individual O
behavior O
, O
such O
as O
isolation O
at O
home O
or O
wearing O
masks O
. O

It O
is O
important O
to O
recognize O
imaging O
features O
of O
COVID O
- O
19 O
pneumonia O
even O
in O
unsuspected O
patients O
. O

High O
Rates O
of O
COVID O
- O
19 O
Infection O
Among O
Indigenous O
Maya O
at O
a O
US O
Safety O
- O
Net O
Health O
System O
in O
California O
. O

Diabetic O
emergencies O
during O
the O
COVID O
- O
19 O
pandemic O
: O
A O
case O
- O
control O
study O
. O

COVID O
- O
19 O
deaths O
were O
higher O
in O
disproportionally O
black O
rural O
and O
small O
metro O
counties O
. O

Papers O
published O
between O
January O
1 O
, O
2020 O
, O
and O
25 O
March O
2020 O
were O
searched O
in O
English O
and O
the O
terms O
" O
2019 O
- O
nCoV O
, O
Covid O
- O
19 O
, O
Clinical O
Characteristics O
OR O
manifestation O
, O
method O
of O
detection O
, O
COVID O
- O
19 O
Genome O
and O
molecular O
test O
" O
were O
used O
. O

As O
we O
are O
in O
the O
midst O
of O
an O
ongoing O
pandemic O
of O
COVID O
- O
19 O
, O
scientists O
are O
struggling O
to O
understand O
how O
it O
resembles O
and O
differs O
from O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
( O
SARS O
- O
CoV O
) O
at O
the O
genomic O
and O
transcriptomic O
level O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
expected O
to O
continue O
to O
cause O
worldwide O
fatalities O
until O
the O
World O
population O
develops O
' O
herd O
immunity O
' O
, O
or O
until O
a O
vaccine O
is O
developed O
and O
used O
as O
a O
prevention O
. O

Inclusion O
criteria O
were O
all O
RR O
protocols O
evaluating O
traditional O
, O
complementary O
, O
and O
integrative O
medicine O
( O
TCIM O
) O
registered O
on O
PROSPERO O
, O
and O
all O
RRs O
indexed O
on O
PubMed O
or O
published O
on O
the O
Oxford O
COVID O
- O
19 O
Evidence O
Service O
. O

This O
study O
identified O
substantial O
increases O
in O
distress O
in O
the O
US O
during O
the O
emergence O
of O
the O
COVID O
- O
19 O
crisis O
that O
largely O
diminished O
in O
the O
weeks O
that O
followed O
and O
suggests O
that O
population O
level O
resilience O
in O
mental O
health O
may O
be O
occurring O
in O
response O
to O
the O
pandemic O
. O

Mandated O
Bacillus O
Calmette O
- O
Gu O
é O
rin O
( O
BCG O
) O
vaccination O
predicts O
flattened O
curves O
for O
the O
spread O
of O
COVID O
- O
19 O
. O

Long O
- O
distance O
airborne O
dispersal O
of O
SARS O
- O
CoV O
- O
2 O
in O
COVID O
- O
19 O
wards O
. O

Measures O
of O
loneliness O
included O
self O
- O
reported O
worsened O
loneliness O
due O
to O
the O
COVID O
- O
19 O
pandemic O
and O
loneliness O
severity O
based O
on O
the O
three O
- O
item O
University O
of O
California O
, O
Los O
Angeles O
( O
UCLA O
) O
Loneliness O
Scale O
. O

The O
Turkish O
Neonatal O
Society O
proposal O
for O
the O
management O
of O
COVID O
- O
19 O
in O
the O
neonatal O
intensive O
care O
unit O
. O

COVID O
- O
19 O
is O
a O
highly O
contagious O
disease O
that O
has O
affected O
all O
African O
countries O
including O
the O
Democratic O
Republic O
of O
Congo O
( O
DRC O
) O
. O

We O
therefore O
hypothesize O
that O
improving O
oral O
health O
could O
decrease O
the O
severity O
of O
COVID O
- O
19 O
symptoms O
and O
reduce O
the O
associated O
morbidity O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
their O
attitudes O
toward O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
testing O
, O
an O
important O
approach O
for O
minimizing O
infection O
and O
transmission O
. O

We O
will O
perform O
this O
study O
during O
the O
COVID O
- O
19 O
pandemic O
, O
and O
will O
administer O
interventions O
by O
teletherapy O
, O
and O
contact O
participants O
by O
telephone O
calls O
, O
text O
messages O
, O
and O
/ O
or O
teleconferences O
. O

To O
conclude O
, O
the O
COVID O
- O
19 O
emergency O
is O
having O
a O
highly O
negative O
impact O
on O
the O
activity O
of O
dentists O
practicing O
in O
the O
area O
of O
Modena O
and O
Reggio O
Emilia O
. O

Rigorous O
reporting O
of O
the O
clinical O
scenarios O
of O
fungal O
complications O
such O
as O
oropharyngeal O
candidiasis O
( O
OPC O
) O
which O
could O
cause O
life O
- O
threatening O
candidemia O
may O
help O
in O
understanding O
the O
ongoing O
pandemic O
and O
the O
potential O
role O
of O
dentists O
in O
frontline O
teams O
. O
1 O
, O
2 O
Therefore O
, O
we O
aim O
to O
describe O
a O
non O
- O
severe O
COVID O
- O
19 O
case O
with O
oral O
candidiasis O
according O
to O
the O
CARE O
guidelines O
. O
3 O
. O

The O
beneficial O
effects O
of O
polyphenols O
on O
COVID O
- O
19 O
might O
be O
due O
to O
multiple O
mechanisms O
. O

Epidemiological O
Differences O
of O
COVID O
- O
19 O
Over O
the O
World O
. O

Nursing O
students O
, O
mental O
health O
status O
during O
COVID O
- O
19 O
quarantine O
: O
evidence O
from O
three O
European O
countries O
. O

[ O
COVID O
- O
19 O
, O
Influenza O
and O
Economic O
Activity O
- O
An O
Impact O
Analysis O
Perspective O
] O
. O

More O
nurses O
changed O
from O
vaccination O
refusal O
to O
hesitancy O
or O
acceptance O
than O
those O
changed O
from O
acceptance O
to O
vaccination O
hesitancy O
or O
refusal O
( O
15 O
. O
5 O
% O
vs O
6 O
. O
8 O
% O
among O
all O
participants O
, O
P O
< O
0 O
. O
001 O
) O
. O
40 O
. O
0 O
% O
participants O
intended O
to O
accept O
COVID O
- O
19 O
vaccination O
, O
and O
those O
in O
private O
sector O
( O
OR O
: O
1 O
. O
67 O
, O
95 O
% O
CI O
: O
1 O
. O
11 O
- O
2 O
. O
51 O
) O
, O
with O
chronic O
conditions O
( O
OR O
: O
1 O
. O
83 O
, O
95 O
% O
CI O
: O
1 O
. O
22 O
- O
2 O
. O
77 O
) O
, O
encountering O
with O
suspected O

or O
confirmed O
COVID O
- O
19 O
patients O
( O
OR O
: O
1 O
. O
63 O
, O
95 O
% O
CI O
: O
1 O
. O
14 O
- O
2 O
. O
33 O
) O
, O
accepted O
influenza O
vaccination O

COVID O
- O
19 O
: O
The O
Nursing O
Administration O
Response O
. O

Coronavirus O
2019 O
( O
COVID O
- O
19 O
) O
, O
the O
disease O
caused O
by O
the O
virus O
, O
could O
potentially O
cause O
a O
medical O
catastrophe O
in O
Nepal O
. O

Connection O
, O
Contagion O
, O
and O
COVID O
- O
19 O
. O

The O
results O
show O
that O
the O
outbreak O
of O
COVID O
- O
19 O
created O
uncertainty O
among O
the O
public O
, O
and O
the O
official O
media O
intensified O
it O
because O
of O
the O
late O
dissemination O
of O
news O
about O
the O
outbreak O
' O
s O
real O
- O
time O
status O
. O

COVID O
- O
19 O
Lessons O
: O
The O
Alignment O
of O
Palliative O
Medicine O
and O
Trauma O
- O
Informed O
Care O
. O

Reduction O
in O
mobility O
and O
COVID O
- O
19 O
transmission O
. O

Hospital O
staff O
are O
vulnerable O
and O
at O
high O
risk O
of O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
infection O
. O

How O
does O
COVID O
- O
19 O
impact O
treatment O
decision O
- O
making O
for O
clinicians O
in O
localised O
kidney O
cancer O
. O

Around O
half O
of O
the O
participants O
were O
intending O
to O
practice O
PPMs O
, O
and O
three O
- O
quarters O
had O
good O
practice O
on O
the O
PPMs O
against O
COVID O
- O
19 O
. O

A O
Case O
Report O
of O
Suicide O
Attempt O
Caused O
by O
Acute O
and O
Transient O
Psychotic O
Disorder O
during O
the O
COVID O
- O
19 O
Outbreak O
. O

On O
multivariable O
logistic O
regression O
analysis O
, O
hospital O
location O
in O
Queens O
and O
COVID O
- O
19 O
positive O
testing O
were O
independently O
associated O
with O
treatment O
modifications O
. O

We O
aimed O
to O
evaluate O
the O
quantity O
of O
family O
meetings O
by O
telephone O
, O
video O
and O
in O
- O
person O
during O
the O
COVID O
- O
19 O
pandemic O
by O
manual O
chart O
review O
. O

A O
comprehensive O
and O
timely O
review O
of O
radiological O
role O
in O
the O
fight O
against O
COVID O
- O
19 O
remains O
urgent O
and O
mandatory O
. O

The O
purpose O
of O
this O
article O
is O
to O
describe O
opportunities O
in O
surgical O
simulation O
, O
and O
highlights O
the O
challenges O
associated O
with O
training O
in O
the O
COVID O
- O
19 O
era O
. O

The O
therapeutic O
potential O
of O
targeting O
ACE2 O
in O
COVID O
- O
19 O
. O

Knowledge O
, O
attitude O
and O
practice O
towards O
COVID O
- O
19 O
among O
workers O
of O
a O
tertiary O
hospital O
in O
Bayelsa O
State O
, O
Nigeria O
. O

While O
a O
higher O
severity O
of O
these O
patients O
could O
be O
expected O
from O
the O
addition O
of O
both O
respiratory O
and O
neurological O
injury O
, O
COVID O
- O
19 O
patients O
with O
strokes O
can O
present O
with O
mild O
or O
none O
respiratory O
symptoms O
. O

The O
CD4 O
+ O
T O
cell O
proportion O
was O
negatively O
associated O
with O
the O
CD8 O
+ O
T O
cell O
proportion O
in O
male O
COVID O
- O
19 O
patients O
; O
this O
correlation O
was O
non O
- O
significant O
in O
females O
. O

Geographical O
clustering O
of O
counties O
with O
high O
COVID O
- O
19 O
mortality O
, O
high O
chronic O
disease O
prevalence O
and O
high O
social O
vulnerability O
was O
found O
, O
especially O
in O
southern O
USA O
. O

Ultra O
- O
low O
- O
dose O
chest O
CT O
imaging O
of O
COVID O
- O
19 O
patients O
using O
a O
deep O
residual O
neural O
network O
. O

Reduced O
PICU O
respiratory O
admissions O
during O
COVID O
- O
19 O
. O

Evaluation O
of O
Curricular O
Adaptations O
Using O
Digital O
Transformation O
in O
a O
Medical O
School O
in O
Arabian O
Gulf O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

The O
different O
manifestations O
of O
COVID O
- O
19 O
in O
adults O
and O
children O
: O
a O
cohort O
study O
in O
an O
intensive O
care O
unit O
. O

Our O
participants O
showed O
stronger O
adherence O
to O
some O
COVID O
- O
19 O
precautionary O
measures O
( O
e O
. O
g O
. O
face O
mask O
wearing O
; O
96 O
. O
4 O
% O
) O
but O
not O
others O
( O
e O
. O
g O
. O
social O
distancing O
; O
42 O
. O
3 O
% O
) O
. O

For O
hematology O
cancer O
patients O
, O
PCR O
test O
for O
COVID O
- O
19 O
infection O
was O
requested O
as O
well O
. O

Furthermore O
, O
the O
direct O
U O
- O
shaped O
curvilinear O
effects O
and O
the O
indirect O
effects O
were O
more O
significant O
when O
COVID O
- O
19 O
event O
disruption O
was O
high O
. O

This O
issue O
appears O
in O
the O
midst O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
clinical O
picture O
of O
COVID O
- O
19 O
, O
and O
the O
fact O
that O
Angiotensin O
converting O
enzyme O
2 O
( O
ACE2 O
) O
is O
a O
receptor O
of O
SARS O
- O
CoV O
- O
2 O
, O
suggests O
that O
SARS O
- O
CoV O
- O
2 O
infection O
induces O
an O
imbalance O
in O
the O
renin O
- O
angiotensin O
system O
( O
RAS O
) O
. O

Methods O
: O
From O
January O
10 O
to O
May O
15 O
, O
2020 O
, O
clinical O
data O
of O
1 O
228 O
patients O
with O
COVID O
- O
19 O
in O
Renmin O
Hospital O
of O
Wuhan O
University O
was O
collected O
( O
554 O
males O
and O
674 O
females O
, O
with O
the O
range O
of O
age O
from O
10 O
to O
95 O
years O
old O
, O
the O
average O
age O
was O
55 O
. O
2 O
years O
old O
) O
. O

The O
new O
SARS O
- O
CoV O
- O
2 O
coronavirus O
is O
the O
causative O
agent O
of O
the O
COVID O
- O
19 O
pandemic O
outbreak O
that O
affected O
whole O
the O
world O
with O
more O
than O
6 O
million O
confirmed O
cases O
and O
over O
370 O
, O
000 O
deaths O
. O

May O
patients O
receiving O
5 O
- O
alpha O
- O
reductase O
inhibitors O
be O
in O
higher O
risk O
of O
COVID O
- O
19 O
complications O
? O

Impact O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
the O
Welfare O
of O
Animals O
in O
Australia O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
causing O
the O
pandemic O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
a O
global O
health O
crisis O
. O

In O
COVID O
- O
19 O
, O
elevated O
liver O
biochemistries O
present O
a O
diagnostic O
challenge O
and O
can O
often O
be O
monitored O
conservatively O
. O

The O
psychological O
impact O
of O
preexisting O
mental O
and O
physical O
health O
during O
the O
COVID O
- O
19 O
pandemic O
. O

During O
quarantine O
due O
to O
the O
COVID O
- O
19 O
, O
home O
risks O
to O
become O
a O
very O
dangerous O
place O
for O
victims O
of O
domestic O
violence O
. O

The O
Relationship O
Between O
Social O
Vulnerability O
and O
COVID O
- O
19 O
Incidence O
Among O
Louisiana O
Census O
Tracts O
. O

In O
Malaysia O
, O
the O
COVID O
- O
19 O
epidemic O
has O
checked O
the O
resilience O
of O
the O
agriculture O
sector O
. O

Although O
the O
prevalence O
of O
COVID O
- O
19 O
in O
patients O
with O
cardiovascular O
disease O
is O
under O
- O
reported O
, O
there O
is O
evidence O
that O
pre O
- O
existing O
cardiac O
disease O
can O
render O
individuals O
vulnerable O
. O

Studies O
of O
other O
coronaviruses O
, O
such O
as O
SARS O
and O
MERS O
, O
suggest O
that O
quercetin O
has O
sufficient O
potential O
to O
treat O
COVID O
- O
19 O
. O

The O
search O
for O
the O
relevant O
articles O
for O
review O
included O
the O
keywords O
" O
COVID O
- O
19 O
" O
AND O
" O
clinical O
trial O
" O
in O
PubMed O
, O
MEDLINE O
, O
Embase O
, O
Google O
scholar O
and O
Google O
electronic O
databases O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
an O
emerging O
zoonotic O
viral O
infection O
, O
which O
was O
started O
in O
Wuhan O
, O
China O
, O
in O
December O
2019 O
and O
transmitted O
to O
other O
countries O
worldwide O
as O
a O
pandemic O
outbreak O
. O

During O
May O
14 O
- O
June O
26 O
, O
Maine O
CDC O
enrolled O
1 O
, O
622 O
contacts O
of O
614 O
COVID O
- O
19 O
patients O
; O
190 O
( O
11 O
. O
7 O
% O
) O
eventually O
developed O
COVID O
- O
19 O
, O
highlighting O
the O
importance O
of O
identifying O
, O
quarantining O
, O
and O
monitoring O
contacts O
of O
COVID O
- O
19 O
patients O
to O
limit O
spread O
. O

Clinical O
characteristics O
and O
impacts O
of O
traditional O
Chinese O
medicine O
treatment O
on O
the O
convalescents O
of O
COVID O
- O
19 O
. O

Nurses O
caring O
for O
COVID O
- O
19 O
patients O
displayed O
negative O
emotions O
, O
particularly O
emotionally O
unstable O
and O
introverted O
nurses O
with O
a O
low O
RESE O
level O
. O

Diagnostic O
Laboratory O
Testing O
and O
Clinical O
Preparedness O
for O
Dengue O
Outbreaks O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
created O
challenges O
that O
have O
caused O
profound O
changes O
in O
health O
behaviors O
. O

Compared O
with O
70 O
660 O
hospitalised O
with O
influenza O
, O
those O
admitted O
with O
COVID O
- O
19 O
had O
more O
respiratory O
complications O
including O
pneumonia O
and O
acute O
respiratory O
distress O
syndrome O
, O
and O
higher O
30 O
- O
day O
mortality O
( O
2 O
. O
2 O
% O
to O
4 O
. O
3 O
% O
vs O
6 O
. O
3 O
% O
to O
24 O
. O
6 O
% O
) O
. O

Blood O
samples O
( O
n O
= O
173 O
) O
were O
collected O
from O
30 O
COVID O
- O
19 O
patients O
over O
a O
3 O
- O
month O
period O
after O
symptom O
onset O
and O
analyzed O
for O
SARS O
- O
CoV O
- O
2 O
- O
specific O
NAbs O
, O
using O
the O
lentiviral O
pseudotype O
assay O
, O
coincident O
with O
the O
levels O
of O
IgG O
and O
proinflammatory O
cytokines O
. O

COVID O
- O
19 O
has O
deteriorated O
the O
outcomes O
in O
elderly O
patients O
with O
hip O
fractures O
and O
associated O
with O
higher O
rates O
of O
mortality O
in O
the O
short O
term O
. O

Sixty O
- O
one O
EDs O
included O
a O
random O
sample O
of O
all O
patients O
diagnosed O
with O
COVID O
- O
19 O
between O
March O
1 O
and O
April O
30 O
, O
2020 O
. O

Most O
respondents O
reported O
anxiety O
related O
to O
the O
pandemic O
, O
with O
84 O
% O
being O
concerned O
about O
a O
friend O
or O
relative O
contracting O
COVID O
- O
19 O
, O
and O
with O
70 O
% O
fearful O
of O
becoming O
infected O
themselves O
. O

In O
this O
work O
, O
we O
utilized O
observations O
from O
both O
remote O
sensing O
and O
in O
- O
situ O
measurements O
to O
investigate O
impacts O
of O
COVID O
- O
19 O
lockdown O
on O
different O
air O
pollutions O
in O
different O
regions O
of O
China O
. O

COVID O
- O
19 O
has O
led O
to O
stigma O
and O
discrimination O
among O
various O
groups O
of O
people O
in O
different O
populations O
. O

Detailed O
data O
on O
the O
characteristics O
and O
outcomes O
of O
patients O
with O
COVID O
- O
19 O
in O
sub O
- O
Saharan O
Africa O
are O
limited O
. O

The O
common O
chest O
CT O
findings O
of O
COVID O
- O
19 O
are O
multiple O
ground O
glass O
opacity O
, O
consolidation O
, O
and O
interlobular O
septal O
thickening O
in O
both O
lungs O
, O
which O
are O
mostly O
distributed O
under O
the O
pleura O
. O

Since O
being O
first O
detected O
in O
China O
, O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
spread O
rapidly O
across O
the O
world O
, O
triggering O
a O
global O
pandemic O
with O
no O
viable O
cure O
in O
sight O
. O

Rapid O
Conversion O
from O
Clinic O
to O
Telehealth O
Behavioral O
Services O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Responses O
to O
the O
COVID O
- O
19 O
posts O
were O
measured O
using O
frequency O
, O
mean O
sentiment O
polarity O
, O
positive O
to O
negative O
sentiments O
ratio O
( O
PNSR O
) O
, O
and O
positive O
to O
negative O
emotions O
ratio O
( O
PNER O
) O
. O

A O
5 O
% O
increase O
in O
perceived O
infection O
risk O
was O
significantly O
associated O
with O
being O
1 O
. O
02 O
times O
( O
OR O
1 O
. O
02 O
, O
95 O
% O
CI O
1 O
. O
02 O
- O
1 O
. O
02 O
; O
P O
< O
. O
001 O
) O
more O
likely O
to O
report O
having O
close O
contact O
with O
> O
10 O
people O
, O
and O
being O
1 O
. O
01 O
times O
( O
OR O
1 O
. O
01 O
, O
95 O
% O
CI O
1 O
. O
01 O
- O
1 O
. O
01 O
; O
P O
< O
. O
001 O
) O
more O
likely O
to O
report O
that O
cohabitants O
disagreed O
with O
taking O
steps O
to O
reduce O
the O
risk O
of O
contracting O
COVID O
- O
19 O
. O

We O
retrospectively O
retrieved O
data O
for O
laboratory O
- O
confirmed O
patients O
admitted O
with O
COVID O
- O
19 O
- O
induced O
or O
influenza O
A O
- O
induced O
pneumonia O
from O
electronic O
medical O
records O
in O
Ningbo O
First O
Hospital O
, O
China O
. O

Observational O
studies O
and O
case O
reports O
have O
provided O
insights O
that O
older O
age O
and O
the O
presence O
of O
chronic O
diseases O
is O
frequently O
associated O
with O
a O
higher O
COVID O
- O
19 O
severity O
. O

Seven O
of O
those O
COVID O
- O
19 O
cases O
( O
26 O
% O
of O
all O
new O
cases O
) O
were O
asymptomatic O
and O
had O
no O
positive O
contact O
history O
, O
but O
were O
identified O
through O
a O
positive O
PCR O
test O
. O

A O
growing O
body O
of O
evidence O
is O
suggesting O
a O
significant O
association O
between O
the O
COVID O
- O
19 O
pandemic O
and O
population O
- O
level O
mental O
health O
. O

England O
has O
experienced O
one O
of O
the O
highest O
excess O
in O
all O
- O
cause O
mortality O
in O
Europe O
during O
the O
current O
COVID O
- O
19 O
pandemic O
. O

On O
this O
basis O
, O
this O
study O
provides O
scientific O
suggestions O
for O
management O
, O
technology O
selection O
, O
and O
operation O
of O
hospital O
wastes O
and O
wastewater O
disinfection O
in O
China O
, O
which O
is O
of O
great O
significance O
for O
development O
of O
national O
disinfection O
strategy O
for O
hospital O
wastes O
and O
wastewater O
during O
COVID O
- O
19 O
pandemic O
. O

This O
study O
aims O
to O
: O
( O
1 O
) O
provide O
timely O
information O
on O
the O
mental O
health O
impacts O
of O
the O
emerging O
COVID O
- O
19 O
crisis O
in O
a O
close O
to O
representative O
sample O
of O
Australian O
parents O
and O
children O
( O
0 O
- O
18 O
years O
) O
, O
( O
2 O
) O
identify O
adults O
and O
families O
most O
at O
risk O
of O
poor O
mental O
health O
outcomes O
, O
and O
( O
3 O
) O
identify O
factors O
to O
target O
through O
clinical O
and O
public O
health O
intervention O
to O
reduce O
risk O
. O

COVID O
- O
19 O
Surveillance O
in O
Youth O
Soccer O
During O
Small O
Group O
Training O
: O
A O
Safe O
Return O
to O
Sports O
Activity O
. O

Editorial O
: O
low O
population O
mortality O
from O
COVID O
- O
19 O
in O
countries O
south O
of O
latitude O
35 O
degrees O
North O
- O
supports O
vitamin O
D O
as O
a O
factor O
determining O
severity O
. O
Authors O
' O
reply O
. O

Recognizing O
this O
, O
New O
York O
City O
Health O
+ O
Hospitals O
established O
a O
clinician O
- O
staffed O
COVID O
- O
19 O
hotline O
for O
all O
New O
Yorkers O
. O

Association O
between O
trace O
levels O
of O
lithium O
in O
drinking O
water O
and O
COVID O
- O
19 O
- O
associated O
mortality O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
caused O
by O
SARS O
- O
CoV O
- O
2 O
appeared O
in O
Wuhan O
, O
China O
in O
December O
2019 O
and O
quickly O
spread O
around O
the O
world O
and O
is O
considered O
a O
global O
pandemic O
. O

Law O
, O
litigation O
and O
learning O
: O
a O
legacy O
from O
COVID O
- O
19 O
. O

Patients O
treated O
with O
curative O
- O
intent O
lung O
radiotherapy O
are O
in O
the O
group O
at O
highest O
risk O
of O
severe O
complications O
and O
death O
from O
COVID O
- O
19 O
. O

Approximately O
15 O
% O
of O
patients O
with O
COVID O
- O
19 O
progress O
to O
severe O
pneumonia O
and O
eventually O
develop O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
, O
septic O
shock O
and O
/ O
or O
multiple O
organ O
failure O
with O
high O
morbidity O
and O
mortality O
. O

COVID O
- O
19 O
was O
declared O
a O
global O
health O
emergency O
. O

Around O
15 O
% O
of O
laboratories O
restricted O
certain O
tests O
on O
patients O
with O
clinically O
suspected O
or O
confirmed O
COVID O
- O
19 O
over O
biosafety O
concerns O
. O

The O
PubMed O
/ O
MEDLINE O
/ O
WHO O
COVID O
- O
19 O
databases O
were O
reviewed O
for O
original O
and O
review O
articles O
, O
systematic O
reviews O
, O
meta O
- O
analyses O
, O
case O
series O
, O
and O
recommendations O
from O
medical O
societies O
and O
health O
organizations O
published O
through O
July O
3 O
, O
2020 O
. O

Moreover O
, O
COVID O
- O
19 O
mortality O
is O
correlated O
with O
disease O
severity O
, O
but O
indicators O
for O
severity O
grading O
have O
not O
been O
specified O
. O

Moreover O
, O
the O
evidence O
of O
a O
hyperinflammatory O
microenvironment O
provided O
the O
rationale O
to O
employ O
immunomodulating O
agents O
for O
therapeutic O
purposes O
in O
severe O
COVID O
- O
19 O
. O

To O
improve O
practices O
, O
WAHO O
has O
organized O
regional O
training O
workshops O
on O
laboratory O
diagnostic O
, O
surveillance O
and O
simulation O
exercises O
of O
outbreak O
response O
for O
key O
actors O
, O
as O
well O
as O
webinars O
on O
different O
aspects O
of O
COVID O
- O
19 O
pandemic O
surveillance O
, O
coordination O
and O
management O
. O

The O
COVID O
- O
19 O
pandemic O
is O
likely O
to O
have O
affected O
the O
psychological O
well O
- O
being O
and O
mental O
health O
of O
many O
people O
. O

Intervention O
groups O
: O
Outpatient O
and O
inpatient O
groups O
will O
receive O
the O
standard O
treatment O
regimen O
for O
mild O
and O
moderate O
COVID O
- O
19 O
, O
based O
on O
the O
Iranian O
Ministry O
of O
Health O
and O
Medical O
Education O
' O
s O
protocol O
, O
along O
with O
oral O
Ivermectin O
( O
MSD O
Company O
, O
France O
) O
at O
a O
single O
dose O
of O
0 O
. O
2 O
mg O
/ O
kg O
. O

Statement O
in O
support O
of O
the O
scientists O
, O
public O
health O
professionals O
, O
and O
medical O
professionals O
of O
China O
combatting O
COVID O
- O
19 O
. O

Most O
of O
the O
participants O
( O
95 O
% O
) O
agreed O
that O
the O
elderly O
or O
individuals O
with O
chronic O
illnesses O
such O
as O
diabetes O
and O
heart O
disease O
were O
more O
susceptible O
to O
severe O
COVID O
- O
19 O
infections O
. O

Pneumonia O
was O
the O
most O
common O
diagnosis O
among O
COPD O
patients O
hospitalized O
due O
to O
COVID O
- O
19 O
( O
59 O
% O
) O
; O
19 O
% O
of O
patients O
showed O
pulmonary O
infiltrates O
suggestive O
of O
pneumonia O
and O
heart O
failure O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
become O
the O
most O
critical O
pandemic O
of O
the O
21st O
Century O
and O
the O
most O
severe O
since O
the O
1918 O
influenza O
pandemic O
. O

We O
collected O
data O
on O
COVID O
- O
19 O
cases O
outside O
China O
during O
the O
early O
phase O
of O
the O
pandemic O
and O
used O
them O
to O
predict O
trends O
in O
importations O
and O
quantify O
the O
proportion O
of O
undetected O
imported O
cases O
. O

Conclusively O
, O
nigellidine O
has O
hepato O
- O
reno O
- O
protective O
/ O
antioxidant O
- O
immunomodulatory O
/ O
anti O
- O
inflammatory O
activities O
with O
inhibit O
- O
potentials O
of O
COVID O
- O
19 O
proteins O
. O

VL O
were O
poorly O
correlated O
with O
COVID O
- O
19 O
symptoms O
and O
outcome O
, O
excepted O
for O
dyspnea O
and O
anosmia O
, O
which O
were O
significantly O
associated O
with O
lower O
VL O
( O
p O
< O
. O
05 O
) O
. O

SARS O
- O
CoV O
- O
2 O
, O
the O
virus O
responsible O
for O
COVID O
- O
19 O
, O
causes O
widespread O
damage O
in O
the O
lungs O
in O
the O
setting O
of O
an O
overzealous O
immune O
response O
whose O
origin O
remains O
unclear O
. O

Headache O
, O
rhinorrhea O
, O
muscular O
pain O
, O
and O
sore O
throat O
were O
more O
common O
in O
influenza O
( O
91 O
% O
, O
91 O
% O
, O
94 O
% O
, O
and O
84 O
% O
, O
respectively O
) O
and O
common O
cold O
( O
89 O
% O
, O
81 O
% O
, O
94 O
% O
, O
and O
84 O
% O
, O
respectively O
) O
than O
in O
COVID O
- O
19 O
( O
21 O
% O
, O
4 O
% O
, O
29 O
% O
, O
and O
12 O
% O
, O
respectively O
) O
and O
SARS O
( O
45 O
% O
, O
12 O
% O
, O
55 O
% O
, O
and O
18 O
% O
, O
respectively O
) O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
global O
health O
emergency O
of O
novel O
COVID O
- O
19 O
is O
due O
to O
severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

Methods O
: O
The O
study O
involved O
91 O
patients O
applying O
with O
a O
medical O
history O
supportive O
of O
COVID O
- O
19 O
infection O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
first O
reported O
in O
Wuhan O
, O
the O
capital O
of O
Hubei O
, O
China O
, O
has O
been O
associated O
to O
a O
novel O
coronavirus O
, O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

Along O
with O
these O
efforts O
, O
standard O
precaution O
and O
control O
measures O
should O
also O
be O
taken O
at O
personal O
and O
community O
level O
to O
prevent O
the O
spreading O
of O
any O
contagion O
diseases O
, O
including O
COVID O
- O
19 O
. O

Interestingly O
, O
all O
deceased O
( O
100 O
% O
) O
had O
presented O
with O
clinical O
manifestations O
of O
COVID O
- O
19 O
and O
all O
had O
underlying O
multiple O
co O
morbid O
conditions O
. O

The O
survey O
collected O
data O
on O
rural O
quarantine O
implementation O
; O
COVID O
- O
19 O
infections O
and O
deaths O
in O
the O
survey O
villages O
; O
and O
effects O
of O
the O
quarantine O
on O
employment O
, O
income O
, O
education O
, O
health O
care O
, O
and O
government O
policies O
to O
address O
any O
negative O
impacts O
. O

Increasing O
research O
reports O
neurological O
manifestations O
of O
COVID O
- O
19 O
patients O
. O

New O
- O
onset O
AF O
in O
COVID O
- O
19 O
patients O
presumably O
has O
a O
notable O
impact O
on O
prognosis O
. O

A O
Rare O
Finding O
of O
Upper O
Limb O
Deep O
Venous O
Thrombosis O
in O
a O
Patient O
with O
COVID O
- O
19 O
. O

We O
propose O
possible O
avenues O
, O
such O
as O
dual O
- O
system O
theories O
, O
to O
further O
investigate O
this O
research O
question O
as O
well O
as O
others O
associated O
with O
face O
mask O
perceptions O
, O
face O
mask O
wearing O
and O
the O
COVID O
- O
19 O
pandemic O
. O

This O
letter O
reflects O
on O
this O
current O
debate O
and O
suggests O
angiotensin O
- O
converting O
enzyme O
inhibitors O
and O
ARBs O
are O
likely O
beneficial O
during O
COVID O
- O
19 O
infection O
for O
hypertensive O
and O
normotensive O
patients O
. O

Broadly O
, O
two O
modes O
of O
transmission O
of O
COVID O
- O
19 O
exist O
- O
direct O
and O
indirect O
. O

Zooming O
- O
out O
COVID O
- O
19 O
: O
Virtual O
clinical O
experiences O
in O
an O
emergency O
medicine O
clerkship O
. O

Melatonin O
is O
significantly O
associated O
with O
survival O
of O
intubated O
COVID O
- O
19 O
patients O
. O

The O
data O
included O
socio O
- O
economic O
characteristics O
, O
impact O
of O
COVID O
- O
19 O
on O
household O
income O
, O
health O
status O
, O
and O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
. O

Reply O
: O
What O
Happened O
to O
Electrocardiogram O
as O
a O
Screening O
Test O
to O
Recognize O
Cardiovascular O
Complications O
in O
COVID O
- O
19 O
Patients O
? O

Factors O
independently O
associated O
with O
symptoms O
of O
anxiety O
and O
/ O
or O
depression O
during O
COVID O
- O
19 O
were O
pre O
- O
existent O
anxiety O
( O
OR O
6 O
. O
1 O
, O
95 O
% O
CI O
4 O
. O
1 O
- O
9 O
. O
2 O
) O
or O
depression O
( O
OR O
6 O
. O
0 O
, O
95 O
% O
CI O
3 O
. O
5 O
- O
10 O
. O
2 O
) O
. O

Bronchial O
asthma O
has O
not O
been O
adequately O
assessed O
in O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

The O
majority O
( O
63 O
. O
1 O
% O
) O
were O
rehabilitation O
physicians O
and O
only O
12 O
. O
1 O
% O
had O
patients O
with O
spinal O
cord O
injury O
/ O
disease O
( O
SCI O
/ O
D O
) O
that O
they O
knew O
had O
COVID O
- O
19 O
. O

[ O
COVID O
- O
19 O
: O
Clinical O
, O
biological O
and O
radiological O
characteristics O
in O
adults O
, O
infants O
and O
pregnant O
women O
. O
An O
up O
- O
to O
- O
date O
review O
at O
the O
heart O
of O
the O
pandemic O
] O
. O

Heads O
- O
up O
Surgery O
: O
Endoscopes O
and O
Exoscopes O
for O
Otology O
and O
Neurotology O
in O
the O
Era O
of O
the O
COVID O
- O
19 O
Pandemic O
. O

At O
- O
admission O
hyperglycemia O
in O
previously O
unknown O
diabetes O
is O
not O
uncommonly O
encountered O
entity O
in O
patients O
with O
COVID O
- O
19 O
. O

School O
' O
s O
Out O
for O
COVID O
- O
19 O
: O
50 O
Ways O
BCBA O
Trainees O
in O
Special O
Education O
Settings O
Can O
Accrue O
Independent O
Fieldwork O
Experience O
Hours O
During O
the O
Pandemic O
. O

There O
is O
still O
insufficient O
evidence O
supporting O
maternal O
- O
fetal O
vertical O
transmission O
for O
COVID O
- O
19 O
- O
infected O
mothers O
in O
late O
pregnancy O
, O
and O
vaginal O
delivery O
may O
not O
increase O
the O
possibility O
of O
neonatal O
infection O
. O

A O
future O
vaccination O
campaign O
against O
COVID O
- O
19 O
at O
risk O
of O
vaccine O
hesitancy O
and O
politicisation O
. O

Although O
a O
viral O
infection O
is O
a O
major O
triggering O
factor O
of O
asthma O
and O
allergic O
diseases O
, O
asthma O
is O
suggested O
to O
be O
not O
a O
predisposing O
condition O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
infection O
. O

The O
presence O
of O
any O
underlying O
heart O
condition O
could O
influence O
outcomes O
during O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Minimizing O
the O
Impact O
of O
the O
COVID O
- O
19 O
Epidemic O
on O
Oncology O
Clinical O
Trials O
: O
Retrospective O
Study O
of O
Beijing O
Cancer O
Hospital O
. O

Pediatric O
Telebehavioral O
Health O
: O
A O
Transformational O
Shift O
in O
Care O
Delivery O
in O
the O
Era O
of O
COVID O
- O
19 O
. O

In O
addition O
, O
this O
analysis O
shows O
precisely O
where O
population O
groups O
are O
located O
that O
are O
particularly O
likely O
to O
under O
- O
report O
COVID O
- O
19 O
symptoms O
because O
of O
low O
physical O
access O
to O
healthcare O
facilities O
. O

The O
effect O
of O
race O
on O
composite O
thrombotic O
events O
in O
patients O
with O
COVID O
- O
19 O
. O

Laparotomy O
represents O
the O
safest O
option O
during O
COVID O
- O
19 O
outbreak O
: O
Authors O
' O
response O
to O
: O
" O
The O
COVID O
- O
19 O
pandemic O
should O
not O
take O
us O
back O
to O
the O
prelaparoscopic O
era O
" O
by O
Botteri O
et O
al O
. O
and O
" O
Emergency O
laparoscopic O
surgery O
during O
COVID O
- O
19 O
: O
what O
can O
we O
do O
and O
how O
to O
do O
it O
safely O
" O
by O
Bonapasta O
et O
al O
. O

COVID O
- O
19 O
vaccine O
affordability O
and O
accessibility O
. O

Conclusion O
: O
Because O
of O
the O
possibility O
of O
positive O
COVID O
- O
19 O
status O
in O
asymptomatic O
patients O
and O
the O
risk O
this O
poses O
to O
patients O
and O
staff O
, O
we O
recommend O
testing O
all O
asymptomatic O
patients O
for O
SARS O
- O
CoV O
- O
2 O
prior O
to O
elective O
surgeries O
. O

The O
identity O
% O
was O
96 O
. O
061 O
and O
51 O
. O
61 O
for O
COVID O
- O
19 O
/ O
SARS O
and O
COVID O
- O
19 O
/ O
MERS O
CoV O
sequence O
comparisons O
, O
respectively O
. O

Evaluation O
of O
the O
Design O
and O
Implementation O
of O
a O
Peer O
- O
To O
- O
Peer O
COVID O
- O
19 O
Contact O
Tracing O
Mobile O
App O
( O
COCOA O
) O
in O
Japan O
. O

These O
findings O
unveil O
a O
unique O
immunological O
profile O
in O
COVID O
- O
19 O
patients O
that O
will O
help O
to O
design O
effective O
stage O
- O
specific O
treatments O
for O
this O
potentially O
deadly O
disease O
. O

Here O
, O
we O
described O
three O
patients O
who O
had O
newly O
diagnosed O
DM O
associated O
with O
COVID O
- O
19 O
. O

Myasthenic O
crisis O
in O
COVID O
- O
19 O
. O

This O
article O
describes O
the O
author O
' O
s O
experience O
providing O
nursing O
care O
to O
a O
female O
patient O
who O
was O
diagnosed O
with O
COVID O
- O
19 O
after O
returning O
to O
Taiwan O
from O
overseas O
. O

The O
objective O
of O
this O
study O
was O
to O
better O
understand O
the O
factors O
associated O
with O
the O
heterogeneity O
of O
in O
- O
hospital O
COVID O
- O
19 O
morbidity O
and O
mortality O
across O
France O
, O
one O
of O
the O
countries O
most O
affected O
by O
COVID O
- O
19 O
in O
the O
early O
months O
of O
the O
pandemic O
. O

It O
proceeds O
to O
discuss O
whether O
the O
on O
- O
going O
unfolding O
of O
the O
COVID O
- O
19 O
pandemic O
illustrates O
the O
cascades O
metaphor O
. O

Early O
detection O
of O
neutralizing O
antibodies O
against O
SARS O
- O
CoV O
- O
2 O
in O
COVID O
- O
19 O
patients O
in O
Thailand O
. O

A O
mysterious O
surge O
of O
aspergillosis O
among O
non O
- O
SARS O
- O
CoV O
- O
2 O
patients O
during O
COVID O
- O
19 O
pandemic O
. O

Twelve O
patients O
with O
COVID O
- O
19 O
( O
seven O
men O
and O
five O
women O
) O
and O
twelve O
controls O
( O
eight O
men O
and O
four O
women O
) O
were O
included O
. O

The O
model O
system O
is O
calibrated O
to O
reproduce O
the O
initial O
exponential O
growth O
phase O
of O
the O
COVID O
- O
19 O
pandemic O
in O
Germany O
. O

The O
need O
for O
exercise O
sciences O
and O
an O
integrated O
response O
to O
COVID O
- O
19 O
: O
A O
position O
statement O
from O
the O
international O
HL O
- O
PIVOT O
network O
. O

Unraveling O
the O
Interconnection O
Patterns O
Across O
Lung O
Microbiome O
, O
Respiratory O
Diseases O
, O
and O
COVID O
- O
19 O
. O

This O
paper O
aims O
to O
explore O
the O
increased O
negative O
effects O
the O
digital O
divide O
is O
having O
in O
the O
elderly O
population O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Nurses O
endured O
high O
risks O
of O
psychological O
problems O
under O
the O
epidemic O
of O
COVID O
- O
19 O
in O
a O
longitudinal O
study O
in O
Wuhan O
China O
. O

COVID O
- O
19 O
PCR O
result O
was O
negative O
twice O
. O

The O
present O
study O
investigates O
if O
unemployment O
increases O
the O
risk O
of O
COVID O
- O
19 O
hospitalization O
for O
men O
and O
women O
of O
working O
age O
in O
Germany O
. O

However O
, O
the O
approved O
drugs O
ambroxol O
and O
ciprofloxacin O
showed O
potent O
activity O
at O
concentrations O
that O
are O
clinically O
relevant O
and O
within O
their O
known O
safety O
profiles O
, O
and O
so O
may O
provide O
potentially O
useful O
agents O
for O
preclinical O
and O
clinical O
studies O
in O
COVID O
- O
19 O
. O

Impact O
of O
COVID O
- O
19 O
on O
pregnancy O
and O
delivery O
- O
current O
knowledge O
. O

Infection O
control O
in O
non O
- O
clinical O
areas O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
global O
respiratory O
perspective O
on O
the O
COVID O
- O
19 O
pandemic O
: O
commentary O
and O
action O
proposals O
. O

The O
Urgency O
of O
Spiritual O
Care O
: O
COVID O
- O
19 O
and O
the O
Critical O
Need O
for O
Whole O
- O
Person O
Palliation O
. O

Concurrent O
Diagnosis O
of O
Acute O
Myeloid O
Leukemia O
and O
COVID O
- O
19 O
: O
A O
Management O
Challenge O
. O

COVID O
- O
19 O
is O
a O
concern O
among O
many O
of O
the O
first O
responders O
, O
and O
antibody O
testing O
was O
beneficial O
in O
easing O
their O
anxieties O
about O
going O
to O
work O
and O
performing O
work O
- O
related O
duties O
. O

Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
is O
an O
emerging O
viral O
infection O
that O
is O
rapidly O
spreading O
across O
the O
globe O
. O

COVID O
- O
19 O
et O
m O
é O
decine O
ambulatoire O
- O
Soins O
intensifs O
: O
survie O
à O
quel O
prix O
? O

Severe O
liver O
damage O
is O
associated O
with O
worse O
outcome O
in O
COVID O
- O
19 O
. O

Possible O
associations O
between O
the O
backgrounds O
of O
patients O
and O
the O
incidence O
of O
COVID O
- O
19 O
were O
assessed O
. O

The O
emergence O
of O
the O
novel O
coronavirus O
in O
Wuhan O
, O
China O
, O
which O
causes O
severe O
respiratory O
tract O
infections O
in O
humans O
( O
COVID O
- O
19 O
) O
, O
has O
become O
a O
global O
health O
concern O
. O

In O
this O
study O
, O
patients O
with O
COVID O
- O
19 O
anosmia O
had O
higher O
OC O
widths O
and O
volumes O
compared O
to O
control O
subjects O
. O

Globally O
, O
public O
health O
measures O
like O
face O
masks O
, O
hand O
hygiene O
and O
maintaining O
social O
distancing O
have O
been O
implemented O
to O
delay O
and O
reduce O
local O
transmission O
of O
COVID O
- O
19 O
. O

How O
the O
COVID O
- O
19 O
infection O
tsunami O
revolutionized O
the O
work O
of O
respiratory O
physiotherapists O
: O
an O
experience O
from O
Northern O
Italy O
. O

Objective O
: O
The O
aim O
of O
this O
study O
was O
to O
observe O
the O
liver O
function O
recovery O
of O
COVID O
- O
19 O
patients O
after O
discharge O
. O

During O
COVID O
- O
19 O
- O
associated O
hospitalizations O
, O
448 O
of O
458 O
( O
97 O
. O
8 O
% O
) O
completed O
pregnancies O
resulted O
in O
a O
live O
birth O
and O
10 O
( O
2 O
. O
2 O
% O
) O
resulted O
in O
a O
pregnancy O
loss O
. O

[ O
COVID O
- O
19 O
with O
post O
- O
chemotherapy O
agranulocytosis O
in O
childhood O
acute O
leukemia O
: O
a O
case O
report O
] O
. O

After O
excluding O
essential O
procedures O
, O
it O
was O
estimated O
that O
approximately O
30 O
, O
000 O
primary O
and O
3000 O
revision O
hip O
and O
knee O
arthroplasty O
procedures O
will O
be O
canceled O
each O
week O
while O
COVID O
- O
19 O
restrictions O
regarding O
nonessential O
surgery O
are O
in O
place O
. O

In O
the O
future O
, O
by O
increasing O
the O
number O
of O
samples O
of O
COVID O
- O
19 O
chest O
X O
- O
rays O
to O
the O
training O
dataset O
, O
the O
accuracy O
and O
robustness O
of O
our O
proposed O
models O
increase O
further O
. O

Significantly O
strong O
positive O
correlations O
were O
identified O
between O
daily O
RSVs O
of O
the O
terms O
" O
black O
seed O
, O
" O
" O
vitamin O
C O
, O
" O
" O
zinc O
, O
" O
and O
" O
quercetin O
, O
" O
and O
search O
queries O
for O
" O
coronavirus O
" O
and O
" O
COVID O
- O
19 O
" O
in O
the O
USA O
( O
Spearman O
' O
s O
correlation O
coefficient O
> O
0 O
. O
8 O
, O
p O
< O
0 O
. O
05 O
) O
, O
and O
between O
the O
RSVs O
of O
the O
terms O
" O
vitamin O
C O
" O
and O
" O
zinc O
, O
" O
and O
daily O
search O
queries O
for O
" O
coronavirus O
" O
and O
/ O
or O
" O
COVID O
- O
19 O
" O
in O
the O
UK O
( O
Spearman O
' O
s O

correlation O
coefficient O
> O
0 O
. O
8 O
, O
p O
< O
0 O
. O
05 O
) O
. O

The O
unusual O
experience O
of O
managing O
a O
severe O
COVID O
- O
19 O
case O
at O
home O
: O
what O
can O
we O
do O
and O
where O
do O
we O
go O
? O

Comment O
on O
' O
COVID O
- O
19 O
: O
a O
major O
cause O
of O
cachexia O
and O
sarcopenia O
' O
by O
Morley O
et O
al O
. O

The O
study O
aim O
was O
to O
examine O
the O
knowledge O
, O
perception O
, O
and O
attitude O
of O
dental O
professionals O
in O
Indonesia O
toward O
COVID O
- O
19 O
. O

Among O
78 O
patients O
with O
available O
Q O
- O
No O
questionnaires O
in O
the O
pre O
- O
COVID O
- O
19 O
era O
, O
11 O
( O
14 O
. O
1 O
% O
) O
displayed O
nocebo O
behaviour O
, O
which O
increased O
to O
16 O
( O
20 O
. O
5 O
% O
) O
amid O
the O
COVID O
- O
19 O
pandemic O
. O

Given O
the O
limited O
understanding O
of O
P O
- O
SILI O
, O
we O
describe O
the O
physiological O
basis O
of O
P O
- O
SILI O
and O
we O
show O
experimental O
data O
to O
comprehend O
the O
role O
of O
regional O
strain O
and O
heterogeneity O
in O
lung O
injury O
due O
to O
increased O
work O
of O
breathing O
. O
In O
addition O
, O
we O
discuss O
the O
current O
approach O
to O
respiratory O
support O
for O
COVID O
- O
19 O
under O
this O
point O
of O
view O
. O

This O
report O
summarizes O
views O
of O
experts O
from O
around O
the O
world O
on O
how O
lessons O
from O
past O
pandemics O
have O
shaped O
our O
current O
disease O
preparedness O
and O
response O
efforts O
, O
and O
how O
the O
COVID O
- O
19 O
pandemic O
may O
offer O
an O
opportunity O
to O
reinvent O
public O
health O
and O
healthcare O
systems O
to O
be O
more O
robust O
the O
next O
time O
a O
major O
challenge O
appears O
. O

COVID O
- O
19 O
and O
simultaneous O
thrombosis O
of O
two O
coronary O
arteries O
. O

If O
they O
become O
positive O
for O
SARS O
- O
CoV O
- O
2 O
RNA O
or O
COVID O
- O
19 O
, O
their O
biologic O
therapy O
should O
be O
either O
delayed O
or O
on O
hold O
temporarily O
. O

People O
with O
active O
cancer O
are O
recognised O
as O
at O
risk O
of O
COVID O
- O
19 O
complications O
, O
but O
it O
is O
unclear O
whether O
the O
much O
larger O
population O
of O
cancer O
survivors O
is O
at O
elevated O
risk O
. O

Our O
findings O
demonstrate O
induction O
of O
the O
type O
I O
IFN O
pathway O
in O
lesional O
sections O
of O
COVID O
- O
19 O
- O
associated O
chilblain O
- O
like O
lesions O
. O

Tabletop O
exercise O
to O
prepare O
institutions O
of O
higher O
education O
for O
an O
outbreak O
of O
COVID O
- O
19 O
. O

Seven O
COVID O
- O
19 O
PCR O
positive O
ARDS O
patients O
received O
liquid O
Curosurf O
( O
720 O
mg O
) O
in O
150 O
ml O
normal O
saline O
, O
divided O
into O
five O
30 O
ml O
aliquots O
) O
and O
delivered O
via O
a O
bronchoscope O
into O
second O
- O
generation O
bronchi O
. O

We O
propose O
a O
model O
for O
testing O
in O
a O
population O
experiencing O
an O
epidemic O
of O
COVID O
- O
19 O
, O
and O
derive O
an O
expression O
for O
TPP O
in O
terms O
of O
well O
- O
defined O
parameters O
related O
to O
testing O
and O
presence O
of O
other O
pathogens O
causing O
COVID O
- O
19 O
like O
symptoms O
. O

Our O
test O
was O
compared O
with O
three O
commercial O
methods O
, O
and O
was O
used O
to O
determine O
COVID O
- O
19 O
seroprevalence O
among O
healthcare O
workers O
and O
outpatients O
in O
Minnesota O
. O

LUS O
demonstrated O
promising O
discriminatory O
potential O
in O
people O
hospitalized O
with O
suspected O
COVID O
- O
19 O
. O

COVID O
- O
19 O
pandemic O
has O
played O
havoc O
at O
various O
levels O
throughout O
the O
world O
but O
has O
especially O
impacted O
the O
Health O
care O
professionals O
and O
put O
them O
at O
risk O
of O
mental O
ill O
health O
. O

Between O
March O
20 O
and O
May O
2 O
, O
2020 O
, O
the O
deep O
venous O
system O
of O
13 O
consecutive O
patients O
diagnosed O
with O
neurovascular O
diseases O
and O
non O
- O
severe O
COVID O
- O
19 O
was O
investigated O
with O
a O
systematic O
bedside O
DUS O
. O

To O
assess O
exposure O
, O
perceptions O
, O
workload O
, O
and O
possible O
burnout O
of O
HCPs O
during O
the O
COVID O
- O
19 O
pandemic O
we O
conducted O
a O
cross O
- O
sectional O
survey O
. O

Influenza O
and O
obesity O
: O
its O
odd O
relationship O
and O
the O
lessons O
for O
COVID O
- O
19 O
pandemic O
. O

Sociodemographic O
variables O
were O
related O
to O
a O
greater O
occupational O
balance O
, O
and O
the O
multivariate O
analysis O
showed O
that O
age O
( O
β O
= O
0 O
. O
071 O
; O
p O
= O
0 O
. O
001 O
) O
, O
the O
perception O
of O
having O
received O
enough O
information O
( O
β O
= O
0 O
. O
071 O
; O
p O
≤ O
0 O
. O
001 O
) O
, O
not O
telecommuting O
( O
β O
= O
- O
0 O
. O
047 O
; O
p O
= O
0 O
. O
022 O
) O
, O
and O
not O
being O
infected O
by O
COVID O
- O
19 O
( O
β O
= O
0 O
. O
055 O
; O
p O
= O
0 O
. O
007 O
) O
contributed O
to O
a O
better O
occupational O
balance O
. O

Clinical O
characteristics O
and O
outcomes O
of O
five O
critical O
COVID O
- O
19 O
patients O
treated O
with O
extracorporeal O
membrane O
oxygenation O
in O
Leishenshan O
Hospital O
in O
Wuhan O
. O

The O
primary O
outcome O
was O
the O
proportion O
of O
patients O
suspected O
of O
COVID O
- O
19 O
and O
normal O
LUS O
with O
critical O
outcomes O
during O
follow O
- O
up O
, O
defined O
as O
one O
or O
more O
of O
the O
following O
: O
need O
of O
non O
- O
invasive O
ventilation O
( O
NIV O
) O
, O
invasive O
mechanical O
ventilation O
, O
intensive O
care O
unit O
( O
ICU O
) O
stay O
or O
death O
. O

However O
, O
some O
of O
the O
challenges O
associated O
with O
the O
management O
of O
the O
EVD O
outbreaks O
persist O
and O
create O
obstacles O
for O
the O
effective O
management O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Detection O
of O
Hate O
Speech O
in O
COVID O
- O
19 O
- O
Related O
Tweets O
in O
the O
Arab O
Region O
: O
Deep O
Learning O
and O
Topic O
Modeling O
Approach O
. O

We O
aim O
to O
provide O
insights O
and O
scientific O
evidence O
regarding O
the O
pathogenesis O
of O
COVID O
- O
19 O
and O
therapeutic O
strategies O
targeting O
this O
disease O
. O

In O
multivariate O
analysis O
, O
elevated O
RDW O
was O
associated O
with O
9 O
- O
fold O
and O
16 O
- O
fold O
increased O
odds O
of O
severe O
COVID O
- O
19 O
and O
AKI O
, O
respectively O
. O

Many O
reports O
from O
several O
countries O
have O
underlined O
a O
remarkable O
increase O
in O
the O
cases O
of O
IPV O
during O
the O
COVID O
- O
19 O
emergency O
. O

Cyclosporine O
: O
hope O
for O
severe O
COVID O
- O
19 O
? O

Trinidad O
and O
Tobago O
, O
a O
small O
island O
developing O
state O
, O
has O
been O
ranked O
as O
number O
one O
in O
a O
report O
published O
by O
the O
University O
of O
Oxford O
that O
assessed O
responses O
to O
COVID O
- O
19 O
based O
on O
four O
of O
the O
six O
WHO O
criteria O
for O
rolling O
back O
COVID O
- O
19 O
" O
lockdown O
" O
measures O
. O

CONCLUSIONS O
In O
high O
- O
risk O
patients O
with O
COVID O
- O
19 O
- O
induced O
pneumonia O
and O
cardiovascular O
risk O
factors O
, O
a O
severe O
systemic O
inflammatory O
response O
can O
lead O
to O
atherosclerotic O
plaque O
rupture O
, O
which O
can O
manifest O
as O
acute O
coronary O
syndrome O
. O

A O
formal O
evaluation O
is O
required O
; O
however O
, O
mitigating O
public O
health O
interventions O
are O
required O
, O
especially O
as O
the O
burden O
of O
COVID O
- O
19 O
in O
the O
country O
has O
considerably O
come O
down O
. O

COVID O
- O
19 O
: O
Understanding O
the O
science O
of O
antibody O
testing O
and O
lessons O
from O
the O
HIV O
epidemic O
. O

In O
addition O
to O
the O
cardiotoxicity O
of O
experimental O
antivirals O
and O
potential O
interactions O
of O
experimental O
therapies O
with O
cardiovascular O
drugs O
, O
several O
strategies O
for O
cardiovascular O
protection O
have O
been O
recommended O
in O
COVID O
- O
19 O
patients O
with O
underlying O
CVD O
. O

Human O
Sialome O
and O
Coronavirus O
Disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
Pandemic O
: O
An O
Understated O
Correlation O
? O

ScienceDirect O
, O
Scopus O
, O
The O
National O
Centre O
for O
Biotechnology O
Information O
( O
NCBI O
) O
, O
Wiley O
Online O
Library O
, O
PubMed O
, O
and O
Google O
Scholar O
were O
used O
to O
search O
for O
relevant O
literature O
using O
keywords O
COVID O
- O
19 O
, O
vaccines O
, O
immunisation O
, O
herd O
immunity O
, O
pandemic O
, O
pharmacist O
and O
Australian O
healthcare O
. O

Policy O
and O
healthcare O
context O
played O
a O
key O
role O
in O
the O
response O
to O
COVID O
- O
19 O
. O

Owing O
to O
the O
convenience O
, O
reliability O
and O
contact O
- O
free O
feature O
of O
Mobile O
payment O
( O
M O
- O
payment O
) O
, O
it O
has O
been O
diffusely O
adopted O
in O
China O
during O
the O
COVID O
- O
19 O
pandemic O
to O
reduce O
the O
direct O
and O
indirect O
contacts O
in O
transactions O
, O
allowing O
social O
distancing O
to O
be O
maintained O
and O
facilitating O
stabilization O
of O
the O
social O
economy O
. O

Levels O
of O
Severity O
of O
Depressive O
Symptoms O
Among O
At O
- O
Risk O
Groups O
in O
the O
UK O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Data O
from O
a O
series O
of O
COVID O
- O
19 O
patients O
( O
978 O
patients O
; O
658 O
males O
[ O
66 O
. O
9 O
% O
] O
and O
324 O
females O
[ O
33 O
. O
1 O
% O
] O
) O
admitted O
to O
the O
selected O
hospitals O
in O
Tehran O
from O
20 O
February O
to O
19 O
March O
2020 O
were O
retrieved O
retrospectively O
from O
the O
Health O
Information O
System O
( O
HIS O
) O
of O
the O
hospitals O
. O

Takotsubo O
cardiomyopathy O
and O
COVID O
- O
19 O
infection O
. O

Compared O
to O
influenza O
, O
COVID O
- O
19 O
is O
a O
more O
severe O
disease O
, O
leading O
to O
more O
complications O
and O
higher O
mortality O
. O

In O
line O
with O
WHO O
recommendations O
, O
national O
guidelines O
and O
preventive O
measures O
should O
include O
the O
psychological O
consequences O
, O
the O
acceptance O
and O
normalization O
of O
fears O
and O
the O
promotion O
of O
resilience O
in O
the O
population O
in O
dealing O
with O
COVID O
- O
19 O
in O
order O
to O
counteract O
a O
further O
spread O
. O

This O
study O
confirmed O
the O
positive O
association O
between O
population O
migration O
and O
the O
number O
of O
confirmed O
COVID O
- O
19 O
cases O
. O

A O
statistically O
significant O
difference O
concerning O
impact O
and O
practice O
during O
the O
COVID O
- O
19 O
was O
observed O
between O
general O
practitioner O
and O
specialist O
working O
at O
different O
work O
places O
. O

Value O
of O
Immunizations O
during O
the O
COVID O
- O
19 O
Emergency O
. O

Harvey O
Risch O
, O
that O
reviewed O
several O
papers O
and O
argued O
that O
using O
hydroxychloroquine O
( O
HCQ O
) O
+ O
azithromycin O
( O
AZ O
) O
early O
to O
treat O
symptomatic O
COVID O
- O
19 O
cases O
in O
high O
- O
risk O
patients O
should O
be O
broadly O
applied O
. O

The O
aim O
of O
the O
current O
study O
was O
to O
report O
a O
snapshot O
of O
the O
psychological O
impact O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
and O
its O
correlated O
factors O
on O
medical O
staff O
in O
Guangdong O
, O
China O
. O

Azithromycin O
in O
patients O
with O
COVID O
- O
19 O
: O
Friend O
or O
foe O
? O

The O
World O
Health O
Organization O
( O
WHO O
) O
announced O
the O
epidemic O
disease O
caused O
by O
SARS O
- O
CoV O
- O
2 O
as O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

The O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
has O
placed O
enormous O
pressures O
on O
the O
Canadian O
healthcare O
system O
. O

There O
are O
an O
increasing O
number O
of O
clinical O
studies O
for O
COVID O
- O
19 O
, O
with O
several O
large O
cohort O
studies O
documenting O
initial O
signs O
and O
symptoms O
. O

Apparent O
difference O
in O
fatalities O
between O
Central O
Europe O
and O
East O
Asia O
due O
to O
SARS O
- O
COV O
- O
2 O
and O
COVID O
- O
19 O
: O
Four O
hypotheses O
for O
possible O
explanation O
. O

Vocal O
Cord O
Ulcer O
Following O
Endotracheal O
Intubation O
for O
Mechanical O
Ventilation O
in O
COVID O
- O
19 O
Pneumonia O
: O
A O
Case O
Report O
from O
Northern O
Italy O
. O

Till O
August O
17 O
, O
2020 O
, O
COVID O
- O
19 O
has O
caused O
21 O
. O
59 O
million O
confirmed O
cases O
in O
more O
than O
227 O
countries O
and O
territories O
, O
and O
26 O
naval O
ships O
. O

Twenty O
- O
four O
of O
the O
88 O
patients O
with O
COVID O
- O
19 O
included O
in O
the O
study O
died O
: O
10 O
/ O
23 O
( O
43 O
. O
4 O
% O
) O
patients O
diagnosed O
with O
dementia O
and O
14 O
/ O
65 O
( O
21 O
. O
5 O
% O
) O
controls O
; O
this O
difference O
was O
statistically O
significant O
. O

Pre O
- O
COVID O
- O
19 O
saliva O
samples O
showed O
an O
8 O
- O
fold O
range O
of O
IgA O
concentrations O
, O
suggesting O
a O
broad O
continuum O
of O
natural O
antibody O
resistance O
against O
the O
novel O
virus O
, O
though O
at O
levels O
lower O
than O
that O
observed O
in O
COVID O
- O
19 O
PCR O
- O
confirmed O
subjects O
. O

We O
have O
also O
discussed O
the O
in O
- O
line O
treatment O
strategies O
, O
preventive O
measures O
, O
and O
vaccines O
to O
combat O
the O
emergence O
of O
COVID O
- O
19 O
. O

This O
trial O
will O
inform O
management O
of O
patients O
after O
discharge O
following O
surgery O
in O
the O
COVID O
- O
19 O
pandemic O
and O
offer O
insights O
for O
management O
of O
patients O
who O
undergo O
nonelective O
surgery O
in O
a O
nonpandemic O
setting O
. O

The O
pandemic O
of O
Serious O
Acute O
Respiratory O
Syndrome O
Corona O
Virus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
that O
produces O
corona O
virus O
disease O
( O
COVID O
- O
19 O
) O
has O
challenged O
the O
entire O
mankind O
by O
rapidly O
spreading O
globally O
in O
210 O
countries O
affecting O
over O
25 O
million O
people O
and O
about O
1 O
million O
deaths O
worldwide O
. O

Statistical O
Forecast O
of O
Pollution O
Episodes O
in O
Macao O
during O
National O
Holiday O
and O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
health O
emergency O
has O
led O
many O
Headache O
providers O
to O
transition O
to O
virtual O
care O
overnight O
without O
preparation O
. O

Population O
in O
urban O
agglomerations O
of O
more O
than O
1 O
million O
, O
PM2 O
. O
5 O
air O
pollution O
mean O
annual O
exposure O
, O
life O
expectancy O
, O
hospital O
beds O
available O
, O
urban O
population O
, O
Global O
Health O
Security O
detection O
index O
and O
restrictions O
on O
international O
movement O
had O
the O
most O
significant O
effects O
on O
the O
initial O
growth O
of O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
and O
the O
lockdown O
has O
taken O
the O
world O
by O
storm O
. O

Abuse O
, O
self O
- O
harm O
and O
suicidal O
ideation O
in O
the O
UK O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
the O
pharmacological O
, O
physical O
, O
and O
psychological O
treatments O
of O
pain O
: O
findings O
from O
the O
Chronic O
Pain O
& O
COVID O
- O
19 O
Pan O
- O
Canadian O
Study O
. O

Though O
the O
current O
health O
priorities O
in O
managing O
COVID O
- O
19 O
remain O
restricted O
to O
containment O
and O
targeting O
pulmonary O
symptoms O
, O
the O
potential O
acute O
and O
long O
- O
term O
neuropsychiatric O
sequelae O
of O
the O
infection O
can O
increase O
morbidity O
and O
worsen O
the O
quality O
of O
life O
. O

A O
retrospective O
cohort O
study O
of O
healthcare O
workers O
who O
had O
self O
- O
isolated O
due O
to O
COVID O
- O
19 O
. O

Clinical O
deterioration O
accompanied O
by O
decreasing O
viral O
load O
in O
the O
second O
week O
after O
symptom O
onset O
was O
noted O
both O
in O
SARS O
and O
COVID O
- O
19 O
, O
suggesting O
that O
the O
lung O
damage O
at O
this O
phase O
is O
more O
related O
to O
excessive O
host O
immune O
response O
rather O
than O
uncontrolled O
viral O
replication O
. O

Using O
validated O
tools O
, O
perceived O
stress O
, O
anxiety O
, O
stress O
response O
styles O
, O
and O
sleep O
behaviors O
of O
undergraduate O
and O
graduate O
students O
from O
seven O
countries O
during O
the O
height O
of O
the O
COVID O
- O
19 O
pandemic O
were O
characterized O
in O
order O
to O
examine O
the O
relationships O
between O
these O
factors O
using O
mediation O
and O
moderation O
analyses O
. O

The O
first O
wave O
of O
the O
COVID O
- O
19 O
pandemic O
dramatically O
highlights O
the O
key O
roles O
of O
climate O
and O
air O
chemistry O
in O
viral O
epidemics O
. O

Only O
ten O
states O
provide O
a O
visual O
representation O
of O
the O
trend O
in O
COVID O
- O
19 O
data O
. O

Many O
countries O
across O
the O
globe O
utilized O
medical O
and O
non O
- O
medical O
facemasks O
as O
non O
- O
pharmaceutical O
intervention O
for O
reducing O
the O
transmission O
and O
infectivity O
of O
coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
. O

In O
this O
work O
, O
we O
propose O
a O
pipeline O
that O
uses O
CXR O
images O
to O
detect O
COVID O
- O
19 O
infection O
. O

We O
found O
statistically O
significant O
lower O
( O
P O
< O
0 O
. O
05 O
) O
scores O
for O
psychiatric O
patients O
compared O
to O
controls O
regarding O
the O
prevention O
and O
general O
knowledge O
of O
COVID O
- O
19 O
( O
P O
< O
0 O
. O
001 O
) O
, O
the O
WHO O
information O
about O
prevention O
measures O
( O
P O
= O
0 O
. O
041 O
) O
, O
and O
the O
ability O
to O
identify O
misinformation O
about O
COVID O
- O
19 O
( O
P O
< O
0 O
. O
001 O
) O
. O

Data O
from O
a O
questionnaire O
on O
the O
repercussions O
of O
COVID O
- O
19 O
were O
analyzed O
in O
relation O
to O
the O
clinical O
variables O
of O
114 O
PWE O
, O
with O
a O
significance O
level O
of O
p O
< O
0 O
. O
05 O
. O

Global O
medical O
systems O
have O
been O
heavily O
impacted O
by O
the O
COVID O
- O
19 O
pandemic O
. O

More O
than O
half O
were O
worried O
about O
being O
overly O
affected O
due O
to O
diabetes O
if O
infected O
with O
COVID O
- O
19 O
, O
about O
one O
- O
third O
about O
being O
characterized O
as O
a O
risk O
group O
due O
to O
diabetes O
and O
not O
being O
able O
to O
manage O
diabetes O
if O
infected O
. O

Severity O
and O
risk O
of O
COVID O
- O
19 O
in O
cancer O
patients O
: O
An O
evidence O
- O
based O
learning O
. O

Further O
, O
aerosol O
procedures O
did O
not O
increase O
the O
risk O
of O
COVID O
- O
19 O
during O
the O
pandemic O
provided O
proper O
universal O
precautions O
were O
followed O
. O

Hyperventilation O
: O
A O
Possible O
Explanation O
for O
Long O
- O
Lasting O
Exercise O
Intolerance O
in O
Mild O
COVID O
- O
19 O
Survivors O
? O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
responsible O
for O
at O
least O
2 O
546 O
527 O
cases O
and O
175 O
812 O
deaths O
as O
of O
April O
21 O
, O
2020 O
. O

We O
sought O
to O
evaluate O
the O
utilization O
and O
diagnostic O
yield O
of O
blood O
cultures O
during O
the O
COVID O
- O
19 O
pandemic O
to O
determine O
prevalence O
and O
common O
etiologies O
of O
bacteremia O
and O
to O
inform O
a O
diagnostic O
approach O
to O
relieve O
blood O
culture O
overutilization O
. O

Since O
the O
COVID O
- O
19 O
outbreak O
in O
Xinfadi O
market O
in O
Beijing O
in O
June O
2020 O
, O
large O
- O
scale O
screening O
of O
key O
populations O
has O
been O
carried O
out O
, O
challenging O
the O
nucleic O
acid O
testing O
capabilities O
of O
hospital O
laboratories O
. O

The O
study O
aimed O
to O
analyze O
the O
clinical O
trial O
characteristics O
and O
vaccine O
development O
progress O
of O
the O
new O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
registered O
with O
the O
World O
Health O
Organization O
International O
Clinical O
Trial O
Registry O
Platform O
( O
WHO O
ICTRP O
) O
. O
A O
comprehensive O
search O
of O
COVID O
- O
19 O
clinical O
trials O
since O
the O
establishment O
of O
the O
ICTRP O
to O
June O
11 O
, O
2020 O
, O
was O
conducted O
to O
record O
and O
analyze O
relevant O
characteristics O
. O

Chimeric O
antigen O
receptor O
T O
cell O
( O
CART O
) O
therapy O
, O
administration O
of O
certain O
T O
cell O
- O
agonistic O
antibodies O
, O
immune O
check O
point O
inhibitors O
, O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
caused O
by O
severe O
acute O
respiratory O
syndrome O
- O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
and O
Toxic O
shock O
syndrome O
( O
TSS O
) O
caused O
by O
streptococcal O
as O
well O
as O
staphylococcal O
superantigens O
share O
one O
common O
complication O
, O
that O
is O
T O
cell O
- O
driven O
cytokine O
release O
syndrome O
( O
CRS O
) O
accompanied O
by O
multiple O
organ O
dysfunction O
( O
MOD O
) O

. O

These O
outcomes O
displayed O
that O
intravenous O
infiltration O
of O
MSCs O
is O
a O
safe O
and O
efficacy O
treatment O
for O
COVID O
- O
19 O
pneumonia O
, O
a O
severe O
acute O
respiratory O
illness O
caused O
by O
the O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

The O
loss O
of O
smell O
was O
a O
key O
symptom O
of O
mild O
- O
to O
- O
moderate O
COVID O
- O
19 O
patients O
and O
was O
not O
associated O
with O
nasal O
obstruction O
and O
rhinorrhea O
. O

In O
reply O
to O
the O
letter O
to O
the O
editor O
" O
Tele O
( O
oral O
) O
medicine O
: O
A O
new O
approach O
during O
the O
COVID O
- O
19 O
crisis O
" O
. O

Recommendations O
on O
COVID O
- O
19 O
Computerized O
Tomography O
Study O
Reporting O
: O
The O
Need O
to O
Optimize O
Reporting O
Categories O
Based O
on O
Local O
Conditions O
and O
Available O
Resources O
. O

Impact O
of O
COVID O
- O
19 O
on O
Cancer O
Care O
Delivery O
in O
Africa O
: O
A O
Cross O
- O
Sectional O
Survey O
of O
Oncology O
Providers O
in O
Africa O
. O

Results O
indicated O
that O
COVID O
- O
19 O
- O
related O
worry O
was O
associated O
with O
substance O
use O
coping O
motives O
. O

Researchers O
attempted O
to O
develop O
and O
validate O
tools O
that O
measure O
certain O
psychological O
constructs O
( O
fear O
, O
anxiety O
) O
concerning O
COVID O
- O
19 O
. O

We O
collected O
samples O
of O
25 O
asymptomatic O
and O
27 O
symptomatic O
COVID O
- O
19 O
patients O
. O

Engage O
- O
PD O
is O
a O
single O
cohort O
implementation O
study O
of O
a O
coaching O
intervention O
grounded O
in O
self O
- O
determination O
theory O
being O
conducted O
at O
Columbia O
University O
Parkinson O
' O
s O
Foundation O
Center O
of O
Excellence O
in O
New O
York O
City O
, O
NY O
( O
USA O
) O
, O
the O
early O
epicenter O
of O
the O
COVID O
- O
19 O
pandemic O
in O
the O
United O
States O
. O

The O
COVID O
- O
19 O
emergency O
has O
had O
a O
dramatic O
impact O
on O
market O
incomes O
and O
income O
support O
policies O
. O

Interestingly O
, O
SARS O
- O
CoV O
- O
2 O
- O
specific O
IgM O
and O
IgG O
responses O
were O
significantly O
higher O
in O
COVID O
- O
19 O
hospitalized O
vs O
. O
non O
- O
hospitalized O
patients O
. O

Beyond O
the O
risks O
strictly O
related O
to O
the O
infection O
, O
concerns O
have O
been O
expressed O
for O
the O
psychological O
impact O
that O
COVID O
- O
19 O
may O
have O
, O
especially O
on O
vulnerable O
individuals O
with O
pre O
- O
existing O
mental O
health O
conditions O
. O

The O
current O
novel O
coronavirus O
( O
nCoV O
) O
pandemic O
, O
COVID O
- O
19 O
, O
was O
first O
reported O
in O
December O
2019 O
in O
Wuhan O
, O
China O
, O
and O
has O
spread O
globally O
, O
causing O
startling O
loss O
of O
life O
, O
stalling O
the O
global O
economy O
, O
and O
disrupting O
social O
life O
. O

Simulation O
- O
free O
estimation O
of O
an O
individual O
- O
based O
SEIR O
model O
for O
evaluating O
nonpharmaceutical O
interventions O
with O
an O
application O
to O
COVID O
- O
19 O
in O
the O
District O
of O
Columbia O
. O

More O
on O
COVID O
- O
19 O
coagulopathy O
in O
Caucasian O
patients O
. O

Therefore O
, O
these O
patients O
are O
at O
higher O
risk O
of O
infection O
with O
COVID O
- O
19 O
and O
a O
much O
higher O
risk O
of O
developing O
more O
serious O
forms O
. O

The O
outbreak O
of O
COVID O
- O
19 O
has O
laid O
unprecedented O
psychological O
stress O
on O
healthcare O
workers O
( O
HCWs O
) O
. O

Emergency O
bronchoscopy O
procedures O
on O
COVID O
- O
19 O
infected O
patients O
or O
patients O
with O
unknown O
infection O
status O
can O
be O
safely O
performed O
using O
modified O
full O
- O
face O
snorkel O
masks O
. O

The O
Corona O
virus O
disease O
19 O
( O
COVID O
- O
19 O
) O
has O
accounted O
for O
multiple O
deaths O
and O
economic O
woes O
. O
While O
the O
entire O
medical O
fraternity O
and O
scientists O
are O
putting O
their O
best O
feet O
forward O
to O
find O
a O
solution O
to O
contain O
this O
deadly O
pandemic O
, O
there O
is O
a O
growing O
interest O
in O
integrating O
other O
known O
alternative O
therapies O
in O
to O
standard O
care O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
recognized O
as O
a O
major O
threat O
to O
human O
health O
in O
2020 O
. O

Thus O
, O
this O
article O
provides O
the O
urgency O
of O
needed O
evidences O
through O
large O
population O
based O
randomized O
controlled O
trials O
and O
ecological O
studies O
to O
evaluate O
the O
potential O
role O
of O
vitamin O
D O
in O
COVID O
- O
19 O
. O

Proteinase O
release O
from O
activated O
neutrophils O
in O
mechanically O
ventilated O
patients O
with O
non O
- O
COVID O
- O
19 O
and O
COVID O
- O
19 O
pneumonia O
. O

Participants O
voluntarily O
provided O
sociodemographic O
data O
and O
completed O
the O
following O
scales O
: O
the O
Intolerance O
of O
Uncertainty O
Scale O
( O
IUS O
- O
12 O
) O
, O
the O
Fear O
of O
COVID O
- O
19 O
Scale O
( O
FCV O
- O
19S O
) O
, O
and O
the O
Brief O
Patient O
Health O
Questionnaire O
( O
PHQ O
- O
9 O
) O
Depression O
Scale O
. O

A O
serious O
epidemic O
of O
COVID O
- O
19 O
broke O
out O
in O
Wuhan O
, O
Hubei O
Province O
, O
China O
, O
and O
spread O
to O
other O
Chinese O
cities O
and O
several O
countries O
now O
. O

Novel O
beta O
- O
coronavirus O
( O
2019 O
- O
nCoV O
) O
is O
the O
cause O
of O
Coronavirus O
disease O
- O
19 O
( O
COVID O
- O
19 O
) O
, O
and O
on O
March O
12th O
2020 O
, O
the O
World O
Health O
Organization O
defined O
COVID O
- O
19 O
as O
a O
controllable O
pandemic O
. O

For O
patients O
with O
COVID O
- O
19 O
, O
several O
characteristics O
have O
been O
identified O
that O
may O
be O
associated O
with O
adverse O
outcomes O
. O

Within O
the O
limits O
of O
a O
survey O
, O
patients O
with O
COVID O
- O
19 O
might O
be O
at O
high O
risk O
for O
barotrauma O
during O
invasive O
( O
and O
allegedly O
lung O
- O
protective O
) O
mechanical O
ventilation O
. O

A O
basic O
investigation O
into O
the O
optimization O
of O
cylindrical O
tubes O
used O
as O
acoustic O
stethoscopes O
for O
auscultation O
in O
COVID O
- O
19 O
diagnosis O
. O

Our O
analysis O
and O
model O
show O
that O
there O
is O
no O
significant O
relation O
between O
economic O
freedom O
and O
death O
of O
COVID O
- O
19 O
. O

The O
most O
frequent O
complaint O
related O
to O
the O
COVID O
- O
19 O
vaccination O
was O
the O
fear O
of O
side O
effects O
. O

The O
ratio O
of O
elderly O
in O
combination O
with O
the O
dynamic O
variables O
associated O
with O
COVID O
- O
19 O
emerge O
as O
more O
significant O
risk O
predictors O
in O
comparison O
to O
socio O
- O
economic O
and O
demographic O
indicators O
. O

We O
assess O
the O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
gastroenterology O
and O
hepatology O
departments O
and O
specialists O
in O
Spain O
. O

Despite O
little O
progress O
in O
some O
areas O
, O
maternal O
and O
child O
undernutrition O
remains O
a O
major O
global O
health O
concern O
, O
particularly O
as O
improvements O
since O
2000 O
might O
be O
offset O
by O
the O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
pandemic O
effects O
on O
nursing O
education O
: O
looking O
through O
the O
lens O
of O
a O
developing O
country O
. O

Polymerase O
chain O
reaction O
( O
PCR O
) O
screening O
for O
COVID O
- O
19 O
infection O
, O
particularly O
in O
asymptomatic O
patients O
, O
should O
be O
encouraged O
as O
these O
patients O
are O
prone O
to O
postoperative O
respiratory O
failure O
. O

So O
, O
it O
is O
highly O
probable O
that O
immunological O
memory O
/ O
antibodies O
to O
DV O
in O
endemic O
countries O
may O
reduce O
the O
severity O
and O
spread O
of O
COVID O
- O
19 O
. O

Perceptions O
of O
risk O
and O
adherence O
to O
care O
in O
MS O
patients O
during O
the O
COVID O
- O
19 O
pandemic O
: O
A O
cross O
- O
sectional O
study O
. O

The O
median O
( O
IQR O
) O
duration O
was O
8 O
( O
6 O
- O
11 O
) O
and O
5 O
( O
4 O
- O
11 O
) O
days O
from O
exposure O
to O
onset O
in O
COVID O
- O
19 O
and O
non O
- O
COVID O
- O
19 O
cases O
, O
respectively O
. O

A O
multi O
- O
specialty O
nursing O
team O
plays O
a O
crucial O
role O
in O
key O
decision O
making O
, O
education O
, O
prevention O
, O
screening O
, O
assessment O
, O
diagnosis O
, O
management O
, O
data O
collection O
and O
dissemination O
of O
best O
practices O
during O
the O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
. O

The O
COVID O
- O
19 O
pandemic O
has O
negatively O
affected O
the O
mental O
health O
of O
the O
general O
population O
, O
and O
for O
healthcare O
workers O
( O
HCWs O
) O
it O
has O
been O
no O
different O
. O

Particular O
attention O
should O
be O
paid O
to O
employing O
public O
health O
campaigns O
to O
disseminate O
information O
on O
such O
services O
to O
reduce O
the O
enormity O
of O
distress O
and O
emotional O
impairment O
associated O
with O
COVID O
- O
19 O
in O
the O
United O
States O
. O

Scientific O
and O
ethical O
basis O
for O
social O
- O
distancing O
interventions O
against O
COVID O
- O
19 O
. O

We O
included O
34 O
patients O
with O
confirmed O
COVID O
- O
19 O
between O
March O
3 O
and O
March O
30 O
, O
2020 O
. O

Acute O
Esophageal O
Necrosis O
in O
a O
Patient O
With O
COVID O
- O
19 O
. O

Cases O
of O
COVID O
- O
19 O
were O
confirmed O
by O
polymerase O
chain O
reaction O
method O
with O
nasopharyngeal O
swab O
. O

Analyzing O
the O
dynamic O
decrease O
in O
platelet O
counts O
may O
be O
useful O
in O
the O
prognosis O
of O
patients O
with O
COVID O
- O
19 O
. O

During O
this O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
there O
is O
an O
international O
call O
to O
postpone O
all O
elective O
surgeries O
. O

Thus O
, O
low O
apoA O
- O
1 O
and O
HDL O
- O
C O
levels O
may O
be O
promising O
predictors O
for O
severe O
disease O
and O
in O
- O
hospital O
mortality O
in O
patients O
suffering O
from O
COVID O
- O
19 O
. O

Ongoing O
public O
education O
should O
address O
COVID O
- O
19 O
misconceptions O
. O

We O
discuss O
three O
examples O
of O
unverified O
information O
and O
the O
consequences O
in O
this O
time O
of O
high O
anxiety O
surrounding O
COVID O
- O
19 O
. O

Considering O
the O
issue O
of O
staff O
shortage O
that O
is O
facing O
every O
country O
in O
the O
world O
, O
and O
the O
complexity O
of O
COVID O
- O
19 O
, O
pediatricians O
may O
represent O
an O
important O
source O
of O
ready O
and O
skilled O
specialists O
that O
can O
quickly O
translate O
the O
pediatric O
practice O
in O
the O
COVID O
- O
19 O
care O
. O

The O
COVID O
- O
19 O
pandemic O
provided O
a O
unique O
setting O
to O
engage O
students O
to O
address O
SDOH O
directly O
with O
patients O
. O

The O
cardiac O
involvement O
in O
Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
is O
still O
under O
evaluation O
, O
especially O
in O
severe O
COVID O
- O
19 O
- O
related O
Acute O
Respiratory O
Distress O
Syndrome O
( O
ARDS O
) O
. O

This O
review O
aims O
to O
systematically O
synthesize O
the O
implemented O
national O
- O
level O
mental O
health O
policies O
released O
by O
the O
Chinese O
government O
during O
the O
COVID O
- O
19 O
outbreak O
, O
and O
summarize O
the O
implementation O
of O
those O
mental O
health O
policies O
. O

Analysis O
of O
scientific O
production O
on O
the O
new O
coronavirus O
( O
COVID O
- O
19 O
) O
: O
a O
bibliometric O
analysis O
. O

Narrative O
reports O
also O
identified O
COVID O
- O
19 O
- O
related O
unforeseen O
costs O
. O

Lombardy O
, O
the O
most O
populated O
and O
industrialized O
Italian O
region O
, O
was O
the O
epicentre O
of O
the O
first O
wave O
( O
March O
and O
April O
2020 O
) O
of O
COVID O
- O
19 O
in O
Italy O
and O
it O
is O
among O
the O
most O
air O
polluted O
areas O
of O
Europe O
. O

Many O
health O
care O
systems O
have O
relaxed O
clozapine O
blood O
monitoring O
requirements O
during O
the O
COVID O
- O
19 O
pandemic O
for O
practical O
reasons O
, O
and O
this O
presents O
an O
opportunity O
to O
implement O
permanent O
, O
long O
overdue O
changes O
in O
mandated O
monitoring O
that O
reflect O
what O
has O
been O
learned O
about O
the O
real O
risk O
for O
blood O
dyscrasias O
with O
clozapine O
. O

In O
this O
article O
, O
we O
reviewed O
the O
clinical O
aspects O
of O
2019 O
- O
nCoV O
infection O
, O
characteristics O
of O
liver O
transplant O
recipients O
, O
immunosuppressant O
usage O
, O
and O
potential O
drug O
interactions O
to O
provide O
recommendations O
to O
clinical O
staff O
managing O
liver O
transplant O
recipients O
during O
the O
COVID O
- O
19 O
epidemic O
. O

Application O
technology O
to O
fight O
the O
COVID O
- O
19 O
pandemic O
: O
Lessons O
learned O
in O
Thailand O
. O

In O
view O
of O
devastating O
effects O
of O
COVID O
- O
19 O
on O
human O
life O
, O
there O
is O
an O
urgent O
need O
for O
the O
licened O
vaccines O
or O
therapeutics O
for O
the O
SARS O
- O
CoV O
- O
2 O
infection O
. O

Moreover O
, O
evaluating O
and O
treating O
HF O
patients O
with O
comorbid O
COVID O
- O
19 O
represents O
a O
formidable O
clinical O
challenge O
as O
symptoms O
of O
both O
conditions O
may O
overlap O
and O
they O
may O
potentiate O
each O
other O
. O

With O
the O
rapid O
increase O
of O
infected O
patients O
and O
deaths O
, O
it O
is O
vital O
to O
explore O
an O
effective O
treatment O
for O
COVID O
- O
19 O
. O

Herein O
, O
we O
present O
a O
set O
of O
multidisciplinary O
consensus O
recommendations O
for O
the O
diagnosis O
and O
management O
of O
IR O
- O
pneumonitis O
in O
the O
setting O
of O
COVID O
- O
19 O
including O
: O
( O
1 O
) O
isolation O
procedures O
, O
( O
2 O
) O
recommended O
imaging O
and O
interpretation O
, O
( O
3 O
) O
adaptations O
to O
invasive O
testing O
, O
( O
4 O
) O
adaptations O
to O
the O
management O
of O
IR O
- O
pneumonitis O
, O
( O
5 O
) O
immunosuppression O
for O
steroid O
- O
refractory O
IR O
- O
pneumonitis O
, O
and O
( O
6 O
) O
management O
of O
suspected O
concurrent O
IR O
- O
pneumonitis O
and O
COVID O
- O
19 O
infection O

. O

The O
psychological O
impact O
of O
COVID O
- O
19 O
pandemic O
lockdowns O
: O
a O
review O
and O
meta O
- O
analysis O
of O
longitudinal O
studies O
and O
natural O
experiments O
. O

Strategies O
to O
overcome O
limitations O
in O
Otolaryngology O
residency O
training O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Since O
January O
2020 O
, O
novel O
coronavirus O
( O
SARS O
- O
Cov O
- O
2 O
) O
- O
infected O
pneumonia O
( O
COVID O
- O
19 O
) O
rapidly O
spread O
in O
Korea O
. O

Both O
Samsung O
S9 O
and O
S10 O
contain O
the O
same O
integrated O
pulse O
oximeter O
, O
thus O
over O
100 O
million O
smartphones O
in O
current O
global O
circulation O
could O
be O
used O
to O
obtain O
clinically O
accurate O
spot O
SpO O
2 O
measurements O
to O
support O
at O
home O
assessment O
of O
COVID O
- O
19 O
patients O
. O

The O
COVID O
- O
19 O
pandemic O
highlights O
the O
substantial O
public O
health O
, O
economic O
, O
and O
societal O
consequences O
of O
virus O
spillover O
from O
a O
wildlife O
reservoir O
. O

This O
study O
indicated O
that O
trace O
element O
status O
changed O
in O
pregnant O
women O
with O
COVID O
- O
19 O
. O

The O
high O
incidence O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
high O
mortality O
of O
critical O
patients O
have O
posed O
a O
great O
challenge O
to O
global O
public O
health O
resources O
. O

We O
proposed O
a O
mathematical O
model O
to O
estimate O
the O
R0 O
of O
COVID O
- O
19 O
in O
an O
outbreak O
occurring O
in O
both O
local O
and O
international O
clusters O
in O
light O
of O
published O
data O
. O

[ O
Systemic O
Lupus O
Erythematosus O
and O
COVID O
- O
19 O
] O
. O

Fecal O
- O
oral O
transmission O
of O
COVID O
- O
19 O
: O
Could O
hypochlorhydria O
play O
a O
role O
? O

We O
here O
also O
suggest O
that O
these O
antiviral O
drugs O
alone O
or O
in O
combination O
can O
simultaneously O
target O
both O
the O
entry O
pathways O
and O
thus O
can O
be O
considered O
as O
a O
potential O
treatment O
option O
for O
COVID O
- O
19 O
. O

The O
2020 O
COVID O
- O
19 O
pandemic O
. O

This O
study O
explores O
UK O
nurses O
' O
experiences O
of O
working O
in O
a O
respiratory O
environment O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Findings O
from O
this O
small O
group O
of O
cases O
suggest O
that O
there O
is O
currently O
no O
evidence O
for O
intrauterine O
infection O
caused O
by O
vertical O
transmission O
in O
women O
who O
develop O
COVID O
- O
19 O
pneumonia O
in O
late O
pregnancy O
. O

To O
study O
the O
expression O
of O
angiotensin O
- O
converting O
enzyme O
2 O
( O
ACE2 O
) O
and O
other O
key O
molecules O
of O
the O
RAS O
pathway O
in O
normal O
mice O
at O
different O
developmental O
stages O
, O
and O
to O
provide O
ideas O
for O
understanding O
the O
infection O
mechanism O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
as O
well O
as O
the O
diagnosis O
and O
treatment O
of O
children O
with O
COVID O
- O
19 O
. O

In O
the O
present O
study O
, O
we O
propose O
a O
compartmental O
epidemic O
model O
incorporating O
quarantine O
and O
isolation O
compartments O
to O
( O
i O
) O
describe O
the O
current O
transmission O
patterns O
of O
COVID O
- O
19 O
in O
India O
, O
( O
ii O
) O
assess O
the O
impact O
of O
currently O
implemented O
NPIs O
, O
and O
( O
iii O
) O
predict O
the O
future O
course O
of O
the O
pandemic O
with O
various O
scenarios O
of O
NPIs O
in O
India O
. O

Comparison O
of O
confirmed O
COVID O
- O
19 O
with O
SARS O
and O
MERS O
cases O
- O
Clinical O
characteristics O
, O
laboratory O
findings O
, O
radiographic O
signs O
and O
outcomes O
: O
A O
systematic O
review O
and O
meta O
- O
analysis O
. O

Opioids O
are O
most O
exploited O
for O
their O
analgesic O
effects O
but O
their O
usage O
in O
the O
palliation O
of O
dyspnoea O
, O
immunomodulation O
and O
lysosomotropism O
may O
represent O
potential O
usages O
of O
opioids O
in O
COVID O
- O
19 O
. O

Best O
Practice O
Guidance O
for O
Adult O
Infusion O
Centres O
during O
the O
COVID O
- O
19 O
Pandemic O
: O
Report O
from O
the O
COVID O
- O
19 O
International O
Organization O
for O
the O
Study O
of O
IBD O
[ O
IOIBD O
] O
Task O
Force O
. O

The O
COVID O
- O
19 O
outbreak O
, O
which O
was O
initially O
limited O
to O
Wuhan O
, O
China O
, O
has O
rapidly O
spread O
worldwide O
. O

The O
average O
intensity O
of O
intracity O
travel O
on O
the O
nth O
day O
in O
these O
cities O
during O
the O
development O
of O
the O
outbreak O
was O
positively O
related O
to O
the O
growth O
rate O
of O
the O
number O
of O
confirmed O
COVID O
- O
19 O
cases O
on O
the O
n O
+ O
5th O
day O
in O
these O
cities O
and O
had O
a O
significant O
linear O
relationship O
( O
P O
< O
0 O
. O
01 O
) O
. O

Although O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
clinical O
manifestations O
are O
mainly O
respiratory O
, O
major O
cardiac O
complications O
are O
being O
reported O
. O

Our O
study O
included O
27 O
patients O
( O
mean O
age O
, O
74 O
years O
; O
range O
, O
54 O
- O
90 O
years O
; O
20 O
men O
) O
who O
underwent O
head O
CT O
for O
suspected O
stroke O
( O
n O
= O
21 O
) O
or O
head O
trauma O
( O
n O
= O
6 O
) O
, O
additional O
chest O
CT O
for O
COVID O
- O
19 O
detection O
, O
and O
real O
- O
time O
reverse O
transcriptase O
polymerase O
chain O
reaction O
testing O
in O
a O
COVID O
- O
19 O
- O
endemic O
region O
. O

Ultimately O
, O
the O
number O
of O
excess O
COVID O
- O
19 O
cases O
produced O
by O
the O
evacuation O
depends O
on O
the O
ability O
of O
destination O
counties O
to O
meet O
evacuee O
needs O
while O
minimizing O
virus O
exposure O
through O
public O
health O
directives O
. O

Over O
6 O
, O
000 O
articles O
have O
been O
published O
as O
of O
20 O
April O
2020 O
, O
and O
at O
least O
15 O
online O
resource O
centers O
/ O
websites O
for O
COVID O
- O
19 O
have O
been O
created O
by O
publishers O
to O
enable O
fast O
and O
free O
access O
to O
the O
latest O
research O
, O
evidence O
, O
and O
data O
available O
. O

The O
Challenges O
for O
Labour O
Market O
Policy O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

Laboratory O
Biomarkers O
Predicting O
COVID O
- O
19 O
Severity O
in O
the O
Emergency O
Room O
. O

Revisiting O
Clinical O
Autopsies O
: O
Lessons O
to O
be O
Taken O
from O
the O
COVID O
- O
19 O
Pandemic O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
prevalence O
has O
caused O
many O
problems O
in O
society O
and O
disrupted O
many O
regular O
aspects O
of O
life O
. O

Suicide O
completions O
are O
the O
extreme O
consequences O
of O
COVID O
- O
19 O
related O
psychological O
burdens O
, O
which O
was O
reported O
in O
many O
countries O
including O
Bangladesh O
. O

Exploring O
changes O
in O
cigar O
smoking O
patterns O
and O
motivations O
to O
quit O
cigars O
among O
black O
young O
adults O
in O
the O
time O
of O
COVID O
- O
19 O
. O

This O
paper O
describes O
the O
adaptation O
of O
the O
Project O
Connections O
( O
PC O
) O
program O
, O
a O
low O
- O
threshold O
buprenorphine O
program O
in O
Baltimore O
, O
in O
response O
to O
the O
COVID O
- O
19 O
pandemic O
. O

We O
report O
here O
on O
the O
mental O
health O
of O
young O
adults O
and O
related O
psychological O
and O
behavioural O
responses O
to O
the O
pandemic O
and O
consider O
the O
role O
of O
these O
factors O
in O
fuelling O
the O
increase O
in O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
this O
group O
. O

Of O
Cross O
- O
immunity O
, O
Herd O
Immunity O
and O
Country O
- O
specific O
Plans O
: O
Experiences O
from O
COVID O
- O
19 O
in O
India O
. O

Severity O
of O
Chest O
Imaging O
is O
Correlated O
with O
Risk O
of O
Acute O
Neuroimaging O
Findings O
among O
Patients O
with O
COVID O
- O
19 O
. O

COVID O
- O
19 O
and O
oral O
lesions O
, O
short O
communication O
and O
review O
. O

Recommendations O
include O
implementing O
mental O
health O
measures O
together O
with O
protective O
measures O
against O
COVID O
- O
19 O
infection O
, O
prioritizing O
low O
- O
income O
people O
and O
those O
with O
underlying O
diseases O
. O

Association O
between O
Cardiovascular O
Burden O
and O
Requirement O
of O
Intensive O
Care O
among O
Patients O
with O
Mild O
COVID O
- O
19 O
. O

Association O
of O
diabetes O
and O
outcomes O
in O
patients O
with O
COVID O
- O
19 O
: O
Propensity O
score O
- O
matched O
analyses O
from O
a O
French O
retrospective O
cohort O
. O

Surgery O
was O
intially O
taken O
into O
account O
( O
however O
, O
twice O
delayed O
because O
of O
the O
COVID O
- O
19 O
pandemic O
) O
but O
later O
refused O
because O
it O
would O
have O
left O
the O
patient O
with O
dangerously O
few O
liver O
parenchyma O
. O

Purpose O
Our O
aim O
was O
to O
critically O
review O
recent O
literature O
on O
the O
use O
of O
telehealth O
for O
dysphagia O
during O
the O
COVID O
- O
19 O
pandemic O
and O
enhance O
this O
information O
in O
order O
to O
provide O
evidence O
- O
and O
practice O
- O
based O
clinical O
guidance O
during O
and O
after O
the O
pandemic O
. O

Drugs O
already O
approved O
for O
clinical O
use O
would O
be O
ideal O
candidates O
for O
rapid O
development O
as O
COVID O
- O
19 O
treatments O
. O

Influence O
of O
airborne O
transmission O
of O
SARS O
- O
CoV O
- O
2 O
on O
COVID O
- O
19 O
pandemic O
. O
A O
review O
. O

Perils O
of O
Precipitate O
Publication O
: O
Fraudulent O
and O
Substandard O
COVID O
- O
19 O
Research O
. O

Dynamic O
changes O
of O
CT O
manifestations O
and O
cellular O
immunity O
of O
patients O
with O
COVID O
- O
19 O
were O
regular O
and O
correlation O
was O
high O
between O
these O
two O
parameters O
. O

Methods O
: O
We O
developed O
a O
survey O
to O
evaluate O
surgeon O
' O
s O
perception O
of O
telemedicine O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Almost O
all O
respondents O
believed O
that O
professionals O
and O
volunteers O
involved O
in O
COVID O
- O
19 O
should O
receive O
psychological O
support O
. O

The O
recent O
Sars O
- O
Cov O
- O
2 O
pandemic O
( O
COVID O
- O
19 O
) O
has O
led O
to O
growing O
research O
to O
explain O
the O
poor O
clinical O
prognosis O
in O
some O
patients O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
the O
cause O
of O
the O
ongoing O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

At O
the O
time O
of O
writing O
( O
25 O
May O
2020 O
) O
, O
there O
have O
been O
nearly O
4 O
. O
4 O
million O
infections O
and O
300 O
, O
000 O
deaths O
worldwide O
related O
to O
COVID O
- O
19 O
, O
an O
infection O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

Vaccination O
is O
central O
to O
controlling O
COVID O
- O
19 O
. O

In O
this O
paper O
, O
we O
describe O
how O
Saudi O
Arabia O
responded O
to O
COVID O
- O
19 O
, O
how O
cancer O
care O
was O
re O
- O
restructured O
during O
this O
pandemic O
and O
how O
the O
recent O
MERS O
- O
CoV O
experience O
may O
have O
improved O
the O
Saudi O
response O
to O
COVID O
- O
19 O
. O

[ O
Re O
: O
" O
Strategy O
for O
the O
practice O
of O
digestive O
and O
oncological O
surgery O
during O
the O
COVID O
- O
19 O
epidemic O
" O
] O
. O

There O
is O
a O
high O
demand O
for O
SARS O
- O
CoV O
- O
2 O
testing O
to O
identify O
COVID O
- O
19 O
cases O
. O

In O
this O
cohort O
study O
and O
case O
investigation O
of O
a O
community O
outbreak O
of O
COVID O
- O
19 O
in O
Zhejiang O
province O
, O
individuals O
who O
rode O
a O
bus O
to O
a O
worship O
event O
with O
a O
patient O
with O
COVID O
- O
19 O
had O
a O
higher O
risk O
of O
SARS O
- O
CoV O
- O
2 O
infection O
than O
individuals O
who O
rode O
another O
bus O
to O
the O
same O
event O
. O

Prone O
positioning O
is O
an O
important O
non O
- O
pharmacologic O
strategy O
that O
should O
be O
considered O
for O
all O
invasively O
ventilated O
patients O
with O
moderate O
to O
severe O
ARDS O
( O
including O
those O
with O
COVID O
- O
19 O
) O
. O

We O
find O
that O
official O
COVID O
- O
19 O
mortality O
substantially O
understates O
actual O
mortality O
, O
excess O
deaths O
cannot O
be O
explained O
entirely O
by O
official O
COVID O
- O
19 O
death O
counts O
. O

The O
prognosis O
of O
COVID O
- O
19 O
moderate O
patients O
is O
good O
. O

The O
prevalence O
and O
prognosis O
of O
digestive O
system O
involvement O
, O
including O
gastrointestinal O
symptoms O
and O
liver O
injury O
, O
in O
patients O
with O
COVID O
- O
19 O
remains O
largely O
unknown O
. O

Pharmacy O
Internal O
Controls O
: O
A O
Call O
for O
Greater O
Vigilance O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
an O
infectious O
disease O
caused O
by O
SARS O
- O
Cov O
- O
2 O
, O
resulting O
in O
severe O
acute O
respiratory O
syndrome O
, O
with O
high O
potential O
of O
spreading O
and O
infecting O
humans O
worldwide O
. O

Methods O
Participants O
were O
Australians O
aged O
18 O
+ O
years O
that O
were O
employed O
in O
paid O
work O
prior O
to O
the O
COVID O
- O
19 O
pandemic O
who O
responded O
to O
an O
online O
or O
telephone O
survey O
from O
27th O
March O
to O
12th O
June O
2020 O
as O
part O
of O
a O
prospective O
longitudinal O
cohort O
study O
. O

Acute O
Increase O
in O
Deaths O
Among O
Patients O
With O
Adult O
Congenital O
Heart O
Disease O
During O
COVID O
- O
19 O
: O
Single O
- O
Center O
Experience O
. O

In O
the O
absence O
of O
effective O
treatment O
and O
/ O
or O
vaccines O
for O
COVID O
- O
19 O
, O
natural O
products O
of O
known O
therapeutic O
and O
antiviral O
activity O
could O
offer O
an O
inexpensive O
, O
effective O
option O
for O
managing O
the O
disease O
. O

The O
collateral O
cardiovascular O
damage O
of O
COVID O
- O
19 O
: O
only O
history O
will O
reveal O
the O
depth O
of O
the O
iceberg O
. O

Racial O
and O
Ethnic O
Disparities O
in O
COVID O
- O
19 O
- O
Related O
Infections O
, O
Hospitalizations O
, O
and O
Deaths O
: O
A O
Systematic O
Review O
. O

Our O
Roadmap O
has O
intentionally O
taken O
an O
international O
perspective O
and O
supports O
other O
work O
we O
have O
published O
in O
the O
Journal O
on O
our O
collective O
response O
to O
the O
COVID O
- O
19 O
crisis O
. O

Despite O
rigorous O
global O
containment O
and O
quarantine O
efforts O
, O
the O
incidence O
of O
the O
Severe O
Acute O
Respiratory O
Syndrome O
Coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
also O
known O
as O
COVID O
- O
19 O
, O
continues O
to O
surge O
, O
with O
more O
than O
12 O
million O
laboratory O
- O
confirmed O
cases O
and O
over O
500 O
, O
000 O
deaths O
worldwide O
( O
as O
of O
11 O
July O
2020 O
) O
. O

Here O
we O
report O
on O
a O
fluorescence O
- O
based O
SARS O
- O
CoV O
- O
2 O
neutralization O
assay O
that O
detects O
SARS O
- O
CoV O
- O
2 O
neutralizing O
antibodies O
in O
COVID O
- O
19 O
patient O
specimens O
and O
yields O
comparable O
results O
to O
plaque O
reduction O
neutralizing O
assay O
, O
the O
gold O
standard O
of O
serological O
testing O
. O

In O
this O
study O
, O
we O
present O
cases O
of O
severe O
COVID O
- O
19 O
treated O
with O
TCZ O
and O
glucocorticoids O
and O
discuss O
the O
treatment O
responses O
. O

To O
analyze O
the O
susceptibility O
of O
SARS O
- O
CoV O
- O
2 O
in O
pregnancy O
and O
the O
drugs O
that O
can O
be O
used O
to O
treat O
pregnancy O
with O
COVID O
- O
19 O
, O
so O
as O
to O
provide O
evidence O
for O
drug O
selection O
in O
clinic O
. O

Multisystem O
inflammatory O
syndrome O
in O
children O
( O
MIS O
- O
C O
) O
has O
been O
observed O
in O
temporal O
association O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
typically O
within O
2 O
to O
6 O
weeks O
of O
illness O
or O
exposure O
. O

The O
guidelines O
presented O
are O
based O
on O
a O
literature O
review O
and O
consensus O
among O
all O
Spanish O
Ophthalmology O
Societies O
regarding O
protection O
measures O
recommended O
for O
the O
ophthalmologic O
care O
of O
patients O
with O
or O
without O
confirmed O
COVID O
- O
19 O
in O
outpatient O
, O
inpatient O
, O
emergency O
and O
surgery O
settings O
. O

Here O
, O
we O
report O
the O
key O
recommendations O
to O
make O
this O
recommendation O
available O
also O
for O
the O
international O
community O
, O
provide O
the O
scientific O
methodology O
used O
to O
develop O
the O
recommendations O
, O
give O
additional O
thoughts O
and O
advices O
for O
the O
management O
of O
patients O
with O
rheumatic O
diseases O
during O
the O
COVID O
- O
19 O
pandemic O
, O
and O
discuss O
our O
recommendations O
in O
the O
context O
of O
other O
international O
recommendations O
. O

Multiple O
drivers O
of O
the O
COVID O
- O
19 O
spread O
: O
The O
roles O
of O
climate O
, O
international O
mobility O
, O
and O
region O
- O
specific O
conditions O
. O

Gastrointestinal O
and O
liver O
manifestations O
are O
not O
rare O
in O
patients O
with O
COVID O
- O
19 O
, O
but O
their O
prevalence O
might O
be O
affected O
by O
preexisting O
diseases O
. O

Lessons O
of O
COVID O
- O
19 O
: O
A O
roadmap O
for O
post O
- O
pandemic O
science O
. O

Therefore O
, O
insulin O
treatment O
for O
patients O
with O
COVID O
- O
19 O
and O
T2D O
should O
be O
used O
with O
caution O
. O

VA O
medical O
centers O
with O
the O
highest O
numbers O
of O
COVID O
- O
19 O
cases O
during O
the O
study O
period O
. O

Serum O
neopterin O
levels O
on O
hospitalization O
were O
significantly O
higher O
in O
severe O
COVID O
- O
19 O
disease O
than O
mild O
COVID O
- O
19 O
patients O
. O

In O
the O
backdrop O
of O
hospitals O
becoming O
hot O
zones O
and O
an O
increasing O
number O
of O
health O
care O
workers O
contracting O
the O
disease O
, O
it O
is O
crucial O
to O
formulate O
an O
approach O
while O
administering O
anesthesia O
during O
the O
testing O
times O
of O
COVID O
- O
19 O
pandemic O
. O

[ O
Prognostic O
value O
of O
myocardial O
injury O
in O
patients O
with O
COVID O
- O
19 O
] O
. O

We O
have O
also O
evaluated O
the O
impact O
of O
COVID O
- O
19 O
on O
our O
kidney O
transplant O
( O
KT O
) O
recipients O
and O
a O
control O
group O
of O
kidney O
living O
donors O
( O
KLD O
) O
. O

The O
COVID O
- O
19 O
pandemic O
had O
infected O
more O
than O
3 O
. O
5M O
people O
around O
the O
world O
and O
more O
than O
250K O
people O
died O
in O
187 O
countries O
by O
May O
2020 O
. O

Further O
, O
two O
multivariable O
linear O
regression O
analyses O
were O
fitted O
to O
explore O
the O
association O
of O
mental O
health O
selected O
outcomes O
, O
anxiety O
and O
depression O
, O
with O
some O
personal O
and O
working O
characteristics O
that O
are O
COVID O
- O
19 O
- O
related O
. O

Gemeinschaftlich O
in O
Krisenzeiten O
: O
NMR O
- O
Strukturbiologie O
gegen O
COVID O
- O
19 O
. O

Preparing O
pharmacy O
for O
the O
surge O
of O
patients O
with O
COVID O
- O
19 O
: O
Lessons O
from O
China O
. O

To O
analyse O
the O
quality O
of O
sleep O
of O
the O
Spanish O
population O
during O
the O
lockdown O
due O
to O
COVID O
- O
19 O
. O

The O
ongoing O
COVID O
- O
19 O
outbreak O
has O
revealed O
vulnerabilities O
in O
global O
healthcare O
responses O
. O

Use O
of O
Facebook O
by O
Academic O
Medical O
Centers O
in O
Taiwan O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
Observational O
Study O
. O

Inhaled O
corticosteroids O
( O
ICS O
) O
could O
increase O
both O
the O
risk O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
experiencing O
poor O
outcomes O
. O

[ O
Renin O
- O
Angiotensin O
- O
System O
( O
RAS O
) O
and O
COVID O
- O
19 O
- O
On O
The O
Prescription O
of O
RAS O
Blockers O
] O
. O

A O
total O
of O
154 O
COVID O
- O
19 O
- O
positive O
subjects O
were O
identified O
, O
residing O
in O
1 O
of O
2 O
Belgian O
nursing O
homes O
that O
experienced O
similar O
COVID O
- O
19 O
outbreaks O
. O

Emerging O
research O
describes O
a O
plethora O
of O
patient O
factors O
- O
including O
demographic O
, O
clinical O
, O
immunologic O
, O
hematological O
, O
biochemical O
, O
and O
radiographic O
findings O
- O
that O
may O
be O
of O
utility O
to O
clinicians O
to O
predict O
COVID O
- O
19 O
severity O
and O
mortality O
. O

Letter O
to O
the O
Editor O
: O
Wastewater O
- O
Based O
Epidemiology O
Can O
Overcome O
Representativeness O
and O
Stigma O
Issues O
Related O
to O
COVID O
- O
19 O
. O

[ O
COVID O
- O
19 O
, O
neoliberalism O
and O
health O
systems O
in O
30 O
european O
countries O
: O
relationship O
to O
deceases O
. O
] O

Worldwide O
COVID O
- O
19 O
epidemiology O
data O
indicate O
differences O
in O
disease O
incidence O
amongst O
sex O
and O
gender O
demographic O
groups O
. O

Methods O
The O
Cochrane O
Library O
, O
MEDLINE O
, O
and O
EMBASE O
were O
searched O
for O
studies O
relevant O
to O
COVID O
- O
19 O
severity O
, O
mortality O
, O
and O
inflammation O
in O
the O
context O
of O
ACEi O
/ O
ARB O
use O
. O

We O
set O
out O
to O
synthesize O
evidence O
on O
smoking O
and O
COVID O
- O
19 O
relationship O
drawn O
on O
cohort O
studies O
only O
which O
are O
published O
in O
non O
- O
Chinese O
population O
settings O
. O

In O
anticipation O
of O
the O
first O
peak O
of O
inpatients O
with O
COVID O
- O
19 O
in O
April O
2020 O
, O
the O
training O
manual O
was O
accessed O
261 O
times O
by O
167 O
unique O
users O
as O
clinicians O
anticipated O
being O
called O
into O
service O
. O

Despite O
frontline O
workers O
in O
ethnic O
minority O
communities O
in O
the O
United O
Kingdom O
' O
s O
National O
Health O
Service O
attempting O
to O
quell O
the O
pandemic O
, O
disproportionate O
numbers O
of O
BAME O
physicians O
and O
other O
health O
care O
workers O
have O
died O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
and O
surface O
water O
quality O
: O
Improved O
lake O
water O
quality O
during O
the O
lockdown O
. O

Hence O
, O
troponin O
levels O
may O
be O
used O
as O
an O
additional O
tool O
for O
risk O
stratification O
and O
a O
decision O
guide O
in O
patients O
hospitalized O
with O
COVID O
- O
19 O
. O

The O
association O
between O
COVID O
- O
19 O
outcomes O
and O
overweight O
/ O
obesity O
has O
biological O
and O
physiological O
plausibility O
. O

In O
addition O
, O
the O
COVID O
- O
19 O
pandemic O
is O
causing O
dangerous O
effects O
on O
the O
mental O
health O
of O
the O
world O
population O
, O
some O
of O
which O
can O
be O
attributed O
to O
its O
social O
impact O
( O
social O
distancing O
, O
financial O
issues O
, O
and O
quarantine O
) O
. O

COVID O
- O
19 O
pandemic O
and O
the O
social O
effects O
on O
clinic O
and O
scientific O
research O
: O
the O
" O
human O
factor O
" O
. O

Being O
on O
the O
front O
line O
of O
COVID O
- O
19 O
, O
being O
infected O
with O
coronavirus O
and O
having O
chronic O
diseases O
were O
also O
factors O
associated O
with O
a O
higher O
risk O
of O
anxiety O
. O

This O
is O
the O
first O
study O
investigating O
German O
HPs O
after O
the O
COVID O
- O
19 O
outbreak O
. O

Bilateral O
Pulmonary O
Embolism O
in O
a O
Discharged O
Patient O
With O
Resolved O
COVID O
- O
19 O
Pneumonia O
. O

However O
due O
to O
the O
COVID O
- O
19 O
pandemic O
, O
practices O
are O
rapidly O
adapting O
telemedicine O
for O
patient O
care O
. O

An O
inverse O
J O
- O
shaped O
association O
was O
observed O
between O
relative O
humidity O
and O
the O
COVID O
- O
19 O
incidence O
, O
with O
the O
highest O
risk O
at O
72 O
% O
. O

Hence O
, O
the O
virus O
infection O
causes O
respiratory O
center O
dysfunctions O
, O
leading O
to O
ARDS O
in O
COVID O
- O
19 O
patients O
. O

COVID O
- O
19 O
is O
an O
emerging O
rapidly O
evolving O
situation O
, O
which O
is O
widely O
disseminated O
all O
over O
the O
world O
. O

The O
principles O
behind O
these O
COVID O
- O
19 O
therapies O
are O
consistent O
with O
the O
observed O
chronic O
hypoxia O
through O
reduced O
mitochondrial O
function O
, O
and O
also O
the O
increased O
severity O
of O
this O
disease O
in O
ApoE4 O
- O
positive O
individuals O
. O

However O
, O
there O
is O
no O
evidence O
- O
based O
medicine O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
DPP O
- O
4 O
inhibitors O
in O
the O
treatment O
of O
COVID O
- O
19 O
patients O
with O
diabetes O
. O

Retrospective O
survey O
from O
vascular O
access O
team O
Lombardy O
net O
in O
COVID O
- O
19 O
era O
. O

However O
, O
it O
is O
also O
currently O
under O
discussion O
whether O
patients O
under O
immunosuppressive O
therapy O
also O
have O
a O
higher O
risk O
of O
suffering O
a O
severe O
course O
of O
the O
COVID O
- O
19 O
disease O
. O

Bacterial O
co O
- O
infections O
were O
dominant O
in O
all O
COVID O
- O
19 O
patients O
, O
Streptococcus O
pneumoniae O
was O
the O
most O
common O
, O
followed O
by O
Klebsiella O
pneumoniae O
and O
Haemophilus O
influenzae O
. O

We O
discuss O
factors O
that O
should O
be O
taken O
into O
account O
in O
the O
perioperative O
period O
and O
neurocritical O
care O
management O
of O
neurosurgical O
patients O
during O
a O
pandemic O
emergency O
; O
in O
particular O
, O
we O
will O
focus O
on O
the O
decision O
on O
whether O
to O
operate O
or O
not O
a O
patient O
during O
the O
COVID O
- O
19 O
pandemic O
and O
where O
and O
how O
to O
provide O
neurointensive O
care O
treatment O
. O

Possible O
link O
between O
anosmia O
and O
COVID O
- O
19 O
: O
sniffing O
out O
the O
truth O
. O

This O
study O
will O
provide O
the O
latest O
evidence O
for O
evaluating O
the O
efficacy O
and O
safety O
of O
bromhexine O
hydrochloride O
in O
the O
treatment O
of O
COVID O
- O
19 O
in O
children O
. O

Dexamethasone O
in O
the O
era O
of O
COVID O
- O
19 O
: O
friend O
or O
foe O
? O
An O
essay O
on O
the O
effects O
of O
dexamethasone O
and O
the O
potential O
risks O
of O
its O
inadvertent O
use O
in O
patients O
with O
diabetes O
. O

Cardiac O
involvement O
in O
COVID O
- O
19 O
patients O
: O
Risk O
factors O
, O
predictors O
, O
and O
complications O
: O
A O
review O
. O

Interestingly O
, O
most O
of O
the O
risk O
groups O
described O
for O
COVID O
- O
19 O
are O
at O
the O
same O
time O
groups O
that O
were O
associated O
with O
zinc O
deficiency O
. O

COVID O
- O
19 O
Pandemic O
: O
Perspective O
From O
Italian O
Pediatric O
Emergency O
Physicians O
. O

A O
high O
percentage O
of O
females O
and O
students O
in O
the O
fifth O
grade O
, O
as O
well O
as O
students O
with O
high O
levels O
of O
concern O
about O
the O
negative O
impact O
of O
COVID O
- O
19 O
on O
their O
education O
or O
employment O
, O
comprised O
those O
with O
poor O
sleep O
quality O
. O

Using O
Poisson O
regression O
and O
controlling O
for O
age O
, O
sex O
, O
race O
, O
date O
of O
enrollment O
, O
disease O
severity O
at O
enrollment O
, O
and O
history O
of O
high O
- O
risk O
comorbidities O
, O
the O
incidence O
rate O
ratio O
of O
adverse O
events O
on O
losartan O
relative O
to O
control O
was O
0 O
. O
69 O
( O
95 O
% O
CI O
: O
0 O
. O
49 O
- O
0 O
. O
97 O
) O
Conclusions O
: O
Losartan O
appeared O
safe O
for O
COVID O
- O
19 O
- O
related O
acute O
respiratory O
compromise O
. O

During O
surge O
capacity O
situations O
, O
such O
as O
the O
COVID O
- O
19 O
pandemic O
, O
reusable O
PPE O
is O
often O
recommended O
due O
to O
shortages O
. O

Neither O
length O
of O
isolation O
nor O
the O
perceived O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
were O
associated O
with O
psychotic O
experiences O
in O
the O
final O
models O
. O

Recent O
studies O
on O
COVID O
- O
19 O
patients O
have O
shown O
that O
vitamin O
D O
and O
selenium O
deficiencies O
are O
evident O
in O
patients O
with O
acute O
respiratory O
tract O
infections O
. O

The O
clinical O
picture O
of O
COVID O
- O
19 O
, O
which O
includes O
immune O
memory O
and O
reinfection O
, O
remains O
unclear O
and O
unpredictable O
. O

Detection O
of O
Hemosiderin O
- O
Laden O
Macrophages O
in O
Bronchoalveolar O
Lavage O
Fluid O
of O
COVID O
- O
19 O
Patients O
: O
Is O
Perls O
Stain O
a O
Potential O
Indicator O
of O
Oxidative O
Alveolar O
Damage O
? O

The O
present O
study O
suggests O
that O
it O
is O
greatly O
important O
to O
enlighten O
those O
have O
no O
concerns O
about O
this O
crisis O
of O
COVID O
- O
19 O
and O
modify O
their O
risk O
behavior O
via O
various O
ways O
, O
in O
order O
to O
prevent O
and O
control O
this O
viral O
pandemic O
. O

Does O
Social O
Stigma O
and O
Neglect O
Post O
- O
COVID O
- O
19 O
Matter O
? O
A O
Case O
Report O
on O
Brief O
Psychotic O
Disorder O
Post O
- O
COVID O
- O
19 O
and O
Self O
- O
Quarantine O
. O

A O
mathematical O
model O
of O
Coronavirus O
Disease O
( O
COVID O
- O
19 O
) O
containing O
asymptomatic O
and O
symptomatic O
classes O
. O

Although O
bilateral O
multiple O
ground O
glass O
opacities O
with O
some O
consolidation O
of O
reticular O
shadow O
located O
at O
peripheral O
of O
lung O
are O
reported O
characteristics O
of O
COVID O
- O
19 O
imaging O
findings O
, O
it O
is O
difficult O
to O
diagnose O
COVID O
- O
19 O
pneumonia O
just O
by O
CT O
findings O
. O

The O
prevalence O
of O
SARS O
- O
CoV O
- O
2 O
infection O
and O
the O
severity O
of O
the O
course O
of O
COVID O
- O
19 O
in O
patients O
with O
psoriasis O
treated O
with O
biologic O
therapy O
. O

Due O
to O
the O
COVID O
- O
19 O
crisis O
, O
many O
scheduled O
medical O
and O
surgical O
activities O
have O
been O
suspended O
. O

COVID O
- O
19 O
and O
the O
health O
of O
people O
who O
use O
drugs O
: O
What O
is O
and O
what O
could O
be O
? O

Practice O
of O
nitrous O
oxide O
inhalation O
sedation O
in O
dentistry O
during O
and O
after O
the O
COVID O
- O
19 O
pandemic O
. O

We O
detail O
the O
emerging O
possible O
cardiovascular O
risks O
associated O
with O
antimalarial O
use O
in O
COVID O
- O
19 O
and O
whether O
COVID O
- O
19 O
- O
related O
outcomes O
and O
cardiovascular O
risks O
may O
differ O
for O
antimalarials O
used O
in O
rheumatic O
diseases O
. O

This O
review O
aims O
to O
summarize O
the O
advances O
and O
challenges O
for O
COVID O
- O
19 O
vaccines O
development O
. O

Therefore O
, O
we O
aimed O
to O
quantify O
the O
impact O
of O
COVID O
- O
19 O
on O
the O
digestive O
system O
of O
children O
. O
In O
this O
meta O
- O
analysis O
, O
we O
searched O
PubMed O
, O
Embase O
, O
and O
Web O
of O
Science O
from O
January O
1 O
, O
2020 O
, O
to O
June O
31 O
, O
2020 O
. O

The O
findings O
revealed O
that O
without O
any O
previous O
history O
of O
CVD O
, O
the O
COVID O
- O
19 O
patients O
have O
developed O
some O
CVD O
complications O
like O
myocardial O
injury O
, O
cardiomyopathy O
, O
and O
venous O
thromboembolism O
after O
being O
infected O
with O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
and O
required O
for O
those O
patients O
an O
emergency O
clinical O
support O
to O
be O
aware O
to O
manage O
those O
complications O
. O

The O
PGS O
measures O
COVID O
- O
19 O
grief O
equivalently O
across O
demographic O
groups O
, O
and O
discriminates O
well O
between O
persons O
with O
and O
without O
dysfunctional O
grief O
using O
an O
optimized O
cut O
score O
of O
≥ O
7 O
( O
87 O
% O
sensitivity O
and O
71 O
% O
specificity O
) O
. O

Therapeutic O
blockade O
of O
inflammation O
in O
severe O
COVID O
- O
19 O
infection O
with O
intravenous O
N O
- O
acetylcysteine O
. O

Our O
study O
suggests O
that O
administration O
of O
clarithromycin O
for O
adjunctive O
surgical O
prophylaxis O
for O
non O
- O
elective O
cesarean O
deliveries O
may O
be O
a O
safe O
option O
that O
may O
provide O
suitable O
endometritis O
prophylaxis O
in O
cases O
where O
azithromycin O
is O
unavailable O
, O
as O
was O
the O
case O
during O
the O
start O
of O
COVID O
- O
19 O
pandemic O
, O
most O
especially O
for O
Black O
race O
women O
and O
women O
ages O
18 O
- O
29 O
years O
. O

Endocrinology O
in O
the O
time O
of O
COVID O
- O
19 O
: O
Management O
of O
pituitary O
tumours O
. O

The O
purpose O
of O
pulmonary O
rehabilitation O
in O
COVID O
- O
19 O
patients O
is O
to O
improve O
symptoms O
of O
dyspnea O
, O
relieve O
anxiety O
, O
reduce O
complications O
, O
minimize O
disability O
, O
preserve O
function O
, O
and O
improve O
quality O
of O
life O
. O

To O
examine O
outcomes O
among O
patients O
who O
were O
treated O
with O
the O
targeted O
anti O
- O
cytokine O
agents O
, O
anakinra O
or O
tocilizumab O
, O
for O
COVID O
- O
19 O
- O
related O
cytokine O
storm O
( O
COVID19 O
- O
CS O
) O
. O

Five O
biomarkers O
showed O
high O
accuracy O
for O
distinguishing O
COVID O
- O
19 O
patients O
from O
HCs O
with O
an O
area O
under O
the O
curve O
( O
AUC O
) O
up O
to O
0 O
. O
89 O
. O

Post O
COVID O
- O
19 O
Ophthalmic O
Manifestations O
in O
an O
Asian O
Indian O
Male O
. O

Our O
hospital O
footprint O
for O
Obstetrics O
was O
dramatically O
reduced O
to O
make O
room O
for O
the O
rapidly O
increasing O
numbers O
of O
COVID O
- O
19 O
patients O
, O
and O
established O
guidelines O
were O
quickly O
modified O
to O
reduce O
potential O
staff O
and O
patient O
exposures O
. O

T O
cell O
responses O
in O
patients O
with O
COVID O
- O
19 O
. O

Artificial O
intelligence O
( O
AI O
) O
researchers O
and O
radiologists O
have O
recently O
reported O
AI O
systems O
that O
accurately O
detect O
COVID O
- O
19 O
in O
chest O
radiographs O
. O

ClinicalTrials O
. O
gov O
was O
searched O
for O
19 O
drugs O
that O
have O
been O
identified O
as O
potential O
treatments O
for O
COVID O
- O
19 O
. O

To O
fight O
against O
the O
present O
pandemic O
scenario O
of O
COVID O
- O
19 O
outbreak O
, O
medication O
with O
drugs O
and O
vaccines O
is O
extremely O
essential O
other O
than O
ventilation O
support O
. O

Substance O
Use O
Disorders O
and O
Telehealth O
in O
the O
COVID O
- O
19 O
Pandemic O
Era O
: O
A O
New O
Outlook O
. O

The O
purpose O
of O
this O
study O
was O
to O
review O
current O
literature O
of O
the O
impact O
of O
COVID O
- O
19 O
on O
musicians O
and O
returning O
to O
singing O
. O

Our O
results O
indicate O
an O
early O
sustained O
transmission O
of O
COVID O
- O
19 O
in O
South O
Korea O
and O
support O
the O
implementation O
of O
social O
distancing O
measures O
to O
rapidly O
control O
the O
outbreak O
. O

Palliative O
Care O
in O
the O
Time O
of O
COVID O
- O
19 O
: O
Reflections O
From O
the O
Frontline O
. O

Does O
hydroxychloroquine O
reduce O
mortality O
for O
COVID O
- O
19 O
? O

Raising O
awareness O
of O
a O
possible O
association O
between O
these O
conditions O
is O
important O
so O
both O
are O
considered O
allowing O
appropriate O
investigations O
to O
be O
arranged O
to O
optimise O
the O
chance O
of O
neurological O
recovery O
and O
survival O
, O
while O
also O
protecting O
staff O
from O
potentially O
unrecognised O
COVID O
- O
19 O
. O

Atypical O
unilateral O
multifocal O
choroiditis O
in O
a O
COVID O
- O
19 O
positive O
patient O
. O

Due O
to O
the O
urgency O
of O
the O
cardiac O
conditions O
on O
presentation O
, O
we O
have O
operated O
on O
four O
patients O
who O
exhibited O
the O
spectrum O
of O
COVID O
- O
19 O
disease O
from O
asymptomatic O
to O
severe O
COVID O
- O
19 O
pneumonia O
. O

Patients O
with O
moderate O
- O
to O
- O
severe O
COVID O
- O
19 O
( O
moderate O
: O
SpO2 O
< O
94 O
% O
; O
severe O
: O
SpO2 O
< O
90 O
% O
) O
were O
included O
. O

Thrombin O
generation O
and O
tPA O
- O
ROTEM O
protocols O
for O
measurements O
in O
the O
COVID O
- O
19 O
populations O
were O
adjusted O
and O
validated O
. O

A O
hundred O
days O
into O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
. O

COVID O
- O
19 O
is O
a O
pandemic O
that O
has O
affected O
not O
only O
the O
United O
States O
, O
but O
the O
entire O
world O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
clinical O
significance O
of O
serum O
zinc O
in O
COVID O
- O
19 O
patients O
and O
to O
establish O
a O
correlation O
with O
disease O
severity O
. O

Additionally O
, O
the O
children O
and O
adolescents O
reported O
better O
general O
functioning O
during O
the O
COVID O
- O
19 O
period O
and O
had O
relatively O
low O
scores O
on O
the O
OCI O
- O
CV O
scale O
. O

Responses O
of O
three O
urban O
U O
. O
S O
. O
Children O
' O
s O
Hospitals O
to O
COVID O
- O
19 O
: O
Seattle O
, O
New O
York O
and O
New O
Orleans O
. O

The O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
, O
average O
size O
100 O
nm O
, O
can O
be O
aerosolized O
by O
cough O
, O
sneeze O
, O
speech O
and O
breath O
of O
infected O
persons O
. O

Results O
further O
suggested O
that O
COVID O
- O
19 O
stressors O
predicted O
greater O
family O
and O
coparent O
discord O
, O
which O
in O
turn O
predicted O
greater O
use O
of O
caustic O
parenting O
( O
reactive O
, O
inconsistent O
, O
aggressive O
) O
, O
which O
in O
turn O
predicted O
greater O
child O
and O
parent O
distress O
. O

Presently O
, O
there O
is O
lack O
of O
a O
vaccine O
that O
would O
lead O
to O
immunization O
against O
the O
virus O
COVID O
- O
19 O
, O
but O
here O
are O
some O
of O
the O
characteristics O
that O
various O
seaweeds O
have O
and O
which O
may O
provide O
a O
glimpse O
into O
potential O
solutions O
of O
this O
global O
health O
problem O
in O
the O
near O
future O
and O
possibly O
forearm O
us O
for O
any O
future O
such O
pandemics O
. O

It O
was O
also O
observed O
that O
the O
precautionary O
measures O
implemented O
by O
the O
UAE O
government O
correlated O
with O
a O
drop O
in O
the O
measured O
viral O
load O
in O
wastewater O
samples O
, O
which O
were O
in O
line O
with O
the O
reduction O
of O
COVID O
- O
19 O
cases O
reported O
in O
the O
population O
. O

The O
current O
COVID O
- O
19 O
pandemic O
has O
led O
to O
increased O
adoption O
of O
telemedicine O
with O
national O
orthopaedic O
governing O
bodies O
advocating O
its O
use O
, O
as O
evidence O
suggests O
that O
social O
distancing O
maybe O
necessary O
until O
2022 O
. O

Preparing O
your O
intensive O
care O
unit O
for O
the O
COVID O
- O
19 O
pandemic O
: O
practical O
considerations O
and O
strategies O
. O

Counties O
with O
high O
concentrations O
of O
non O
- O
Hispanic O
Blacks O
were O
disproportionately O
affected O
by O
COVID O
- O
19 O
throughout O
most O
of O
the O
pandemic O
, O
but O
other O
social O
determinants O
of O
health O
such O
as O
health O
insurance O
are O
now O
playing O
a O
more O
prominent O
role O
than O
race O
and O
ethnicity O
. O

Acute O
Stroke O
Presentation O
, O
Care O
, O
and O
Outcomes O
in O
Community O
Hospitals O
in O
Northern O
California O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Our O
model O
predicted O
COVID O
- O
19 O
test O
results O
with O
high O
accuracy O
using O
only O
eight O
binary O
features O
: O
sex O
, O
age O
≥ O
60 O
years O
, O
known O
contact O
with O
an O
infected O
individual O
, O
and O
the O
appearance O
of O
five O
initial O
clinical O
symptoms O
. O

Although O
type O
2 O
diabetes O
mellitus O
( O
T2DM O
) O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
develop O
a O
more O
severe O
condition O
compared O
to O
those O
without O
diabetes O
, O
the O
mechanisms O
for O
this O
are O
unknown O
. O

COVID O
- O
19 O
requires O
scaled O
interactions O
with O
populations O
in O
near O
real O
- O
time O
. O

However O
, O
the O
nutritional O
status O
of O
COVID O
- O
19 O
patients O
is O
unknown O
. O

Using O
the O
ClinicalTrials O
. O
gov O
and O
World O
Health O
Organization O
( O
WHO O
) O
databases O
, O
we O
shed O
light O
on O
the O
16 O
current O
approved O
clinical O
trials O
worldwide O
in O
search O
for O
a O
COVID O
- O
19 O
vaccine O
. O

Light O
- O
based O
technologies O
for O
management O
of O
COVID O
- O
19 O
pandemic O
crisis O
. O

COVID O
- O
19 O
media O
coverage O
decreasing O
despite O
deepening O
crisis O
. O

Community O
pharmacy O
response O
to O
infection O
control O
during O
COVID O
- O
19 O
. O
A O
cross O
- O
sectional O
survey O
. O

The O
experts O
reached O
consensus O
on O
the O
following O
parts O
: O
terms O
and O
definitions O
, O
principles O
of O
human O
caring O
for O
COVID O
- O
19 O
patients O
, O
and O
human O
caring O
measures O
for O
COVID O
- O
19 O
patients O
in O
different O
sites O
. O

A O
great O
number O
of O
patients O
contracted O
SARS O
- O
Cov O
- O
2 O
pneumonia O
( O
COVID O
- O
19 O
) O
. O

Healthcare O
workers O
are O
at O
the O
highest O
risk O
of O
contracting O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
, O
therefore O
, O
require O
constant O
protection O
. O

The O
impacts O
of O
the O
COVID O
- O
19 O
pandemic O
on O
commercial O
drivers O
cannot O
be O
adequately O
understood O
or O
acted O
upon O
in O
isolation O
from O
the O
endemic O
chronic O
stressors O
and O
interrelated O
health O
and O
safety O
disparities O
that O
characterize O
the O
profession O
. O

In O
addition O
, O
10 O
of O
their O
family O
members O
diagnosed O
with O
COVID O
- O
19 O
pneumonia O
were O
included O
in O
the O
control O
group O
. O

People O
may O
access O
healthcare O
facilities O
little O
bit O
late O
due O
to O
fear O
of O
contracting O
COVID O
- O
19 O
and O
present O
with O
severe O
symptoms O
, O
even O
with O
complications O
. O

If O
the O
virus O
spreads O
uncontrollably O
and O
rapidly O
, O
there O
is O
a O
risk O
of O
an O
unpredictable O
increase O
of O
patients O
with O
COVID O
- O
19 O
disease O
requiring O
hospital O
treatment O
. O

Here O
, O
we O
review O
antimicrobial O
and O
anti O
- O
inflammatory O
properties O
of O
AbM O
, O
HE O
and O
GF O
mushrooms O
, O
which O
could O
be O
used O
for O
the O
battle O
against O
COVID O
- O
19 O
. O

The O
clinical O
course O
of O
SARS O
- O
CoV O
- O
2 O
infection O
( O
COVID O
- O
19 O
) O
in O
children O
with O
hematologic O
malignancies O
is O
unclear O
. O

Correction O
to O
: O
Epidemiological O
and O
clinical O
characteristics O
of O
patients O
with O
suspected O
COVID O
- O
19 O
admitted O
in O
Metro O
Manila O
, O
Philippines O
. O

Flattening O
- O
the O
- O
curve O
associated O
with O
reduced O
COVID O
- O
19 O
case O
fatality O
rates O
- O
an O
ecological O
analysis O
of O
65 O
countries O
. O

[ O
Problems O
of O
mental O
health O
in O
the O
situation O
of O
COVID O
- O
19 O
pandemic O
] O
. O

Medical O
history O
, O
clinical O
symptoms O
, O
laboratory O
tests O
, O
CT O
imaging O
, O
and O
treatment O
were O
obtained O
through O
a O
standardized O
data O
collection O
form O
, O
and O
then O
independently O
reviewed O
by O
two O
investigators O
. O
2 O
of O
91 O
cases O
were O
infected O
with O
COVID O
- O
19 O
. O

In O
regression O
analyses O
controlling O
for O
demographics O
, O
professional O
role O
, O
and O
work O
setting O
, O
the O
risk O
of O
COVID O
- O
19 O
illness O
was O
higher O
for O
Black O
/ O
African O
- O
Americans O
( O
aOR O
2 O
. O
32 O
, O
99 O
% O
CI O
1 O
. O
45 O
, O
3 O
. O
70 O
, O
p O
< O
0 O
. O
01 O
) O
and O
Hispanic O
/ O
Latinos O
( O
aOR O
2 O
. O
19 O
, O
99 O
% O
CI O
1 O
. O
55 O
, O
3 O
. O
08 O
, O
p O
< O
0 O
. O
01 O
) O
compared O
with O
Whites O
. O

We O
conducted O
a O
literature O
search O
using O
PubMed O
to O
identify O
articles O
published O
in O
English O
language O
that O
reported O
on O
care O
recommendations O
for O
cancer O
patients O
during O
the O
COVID O
- O
19 O
pandemic O
from O
its O
inception O
up O
to O
1st O
June O
2020 O
, O
using O
the O
terms O
" O
( O
cancer O
or O
tumor O
) O
AND O
( O
COVID O
19 O
) O
" O
. O

Recently O
, O
the O
world O
imposition O
of O
social O
distance O
and O
self O
- O
isolation O
as O
the O
best O
preventive O
measures O
for O
the O
COVID O
- O
19 O
pandemic O
has O
created O
challenges O
in O
the O
health O
care O
and O
management O
of O
this O
population O
, O
which O
may O
trigger O
or O
aggravate O
BPSD O
, O
and O
most O
caregivers O
are O
not O
prepared O
to O
address O
it O
. O

Weight O
stigma O
reported O
by O
participants O
in O
2018 O
was O
examined O
as O
a O
predictor O
of O
binge O
eating O
, O
eating O
to O
cope O
, O
physical O
activity O
, O
depressive O
symptoms O
, O
and O
stress O
during O
COVID O
- O
19 O
. O

Globally O
, O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
still O
spreading O
rapidly O
. O

[ O
Interest O
of O
vitamin O
D O
in O
COVID O
- O
19 O
] O
. O

In O
a O
retrospective O
observational O
study O
, O
we O
evaluated O
AKI O
incidence O
, O
risk O
factors O
, O
and O
outcomes O
for O
3345 O
adults O
with O
COVID O
- O
19 O
and O
1265 O
without O
COVID O
- O
19 O
who O
were O
hospitalized O
in O
a O
large O
New O
York O
City O
health O
system O
and O
compared O
them O
with O
a O
historical O
cohort O
of O
9859 O
individuals O
hospitalized O
a O
year O
earlier O
in O
the O
same O
health O
system O
. O

Psychotherapists O
' O
vicarious O
traumatization O
during O
the O
COVID O
- O
19 O
pandemic O
. O

This O
study O
summarizes O
a O
single O
- O
centre O
experience O
, O
during O
the O
COVID O
- O
19 O
period O
in O
Italy O
, O
in O
the O
treatment O
of O
brain O
metastases O
with O
Gamma O
Knife O
stereotactic O
radiosurgery O
( O
GKRS O
) O
. O

All O
consecutive O
patients O
with O
COVID O
- O
19 O
who O
were O
treated O
during O
the O
months O
of O
March O
and O
April O
2020 O
at O
our O
institution O
were O
included O
. O

In O
a O
resource O
- O
poor O
country O
like O
India O
, O
where O
the O
health O
- O
care O
systems O
are O
difficult O
to O
access O
, O
overburdened O
, O
and O
unaffordable O
to O
many O
, O
the O
impact O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
can O
be O
devastating O
. O

Although O
liver O
failure O
does O
not O
seem O
to O
occur O
in O
the O
absence O
of O
pre O
- O
existing O
liver O
disease O
, O
hepatic O
involvement O
in O
COVID O
- O
19 O
may O
correlate O
with O
overall O
disease O
severity O
and O
serve O
as O
a O
prognostic O
factor O
for O
the O
development O
of O
ARDS O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
a O
public O
health O
crisis O
of O
unprecedented O
proportions O
that O
has O
altered O
the O
practice O
of O
medicine O
. O

An O
International O
survey O
on O
living O
kidney O
donation O
and O
transplant O
practices O
during O
the O
COVID O
- O
19 O
pandemic O
. O

We O
present O
the O
case O
of O
a O
young O
obese O
patient O
with O
recent O
COVID O
- O
19 O
( O
coronavirus O
disease O
2019 O
) O
who O
developed O
multisystem O
inflammatory O
syndrome O
( O
MIS O
) O
1 O
month O
after O
spontaneous O
resolution O
. O

COVID O
- O
19 O
skin O
manifestations O
: O
the O
new O
great O
imitator O
? O

Many O
drugs O
that O
have O
been O
proposed O
for O
treatment O
of O
COVID O
- O
19 O
are O
reported O
to O
cause O
cardiac O
adverse O
events O
, O
including O
ventricular O
arrhythmias O
. O

Symptom O
Shame O
in O
the O
COVID O
- O
19 O
Era O
: O
Battling O
Our O
Instincts O
. O

We O
included O
1613 O
participants O
in O
the O
first O
sample O
( O
COVID O
- O
19 O
period O
group O
: O
n O
= O
616 O
; O
reference O
period O
group O
: O
n O
= O
997 O
) O
and O
535 O
participants O
in O
the O
second O
sample O
( O
COVID O
- O
19 O
period O
group O
: O
n O
= O
313 O
; O
reference O
period O
group O
: O
n O
= O
222 O
) O
. O

As O
no O
vaccine O
or O
drugs O
are O
currently O
approved O
to O
specifically O
treat O
COVID O
- O
19 O
, O
identification O
of O
effective O
therapeutics O
is O
crucial O
to O
treat O
the O
afflicted O
and O
limit O
disease O
spread O
. O

Similarly O
, O
successfully O
implementing O
individual O
- O
and O
population O
- O
based O
behaviors O
that O
reduce O
the O
infectious O
inoculum O
intensity O
and O
force O
of O
infection O
, O
respectively O
, O
while O
testing O
and O
deploying O
COVID O
- O
19 O
vaccines O
is O
predicted O
to O
increase O
the O
" O
certainty O
of O
success O
" O
of O
demonstrating O
vaccine O
efficacy O
and O
controlling O
SARS O
- O
CoV O
- O
2 O
infection O
, O
disease O
, O
death O
, O
and O
the O
pandemic O
itself O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
, O
has O
inevitable O
consequences O
for O
medical O
care O
of O
patients O
without O
COVID O
- O
19 O
. O

Health O
and O
Economy O
in O
COVID O
- O
19 O
Era O
: O
A O
Plan O
for O
Reconstituting O
Long O
- O
Term O
Economic O
Security O
. O

During O
an O
ongoing O
outbreak O
of O
COVID O
- O
19 O
, O
unsuspected O
cases O
may O
be O
housed O
outside O
of O
dedicated O
isolation O
wards O
. O

At O
present O
, O
a O
double O
- O
digit O
number O
of O
efforts O
are O
devoted O
to O
the O
development O
of O
a O
vaccine O
against O
COVID O
- O
19 O
. O

The O
mental O
state O
and O
risk O
factors O
of O
Chinese O
medical O
staff O
and O
medical O
students O
in O
early O
stages O
of O
the O
COVID O
- O
19 O
epidemic O
. O

COVID O
- O
19 O
and O
influenza O
testing O
in O
New O
York O
City O
. O

Information O
on O
participants O
' O
socio O
- O
demographic O
characteristics O
, O
knowledge O
of O
clinical O
features O
of O
COVID O
- O
19 O
, O
risk O
assessment O
and O
infection O
control O
measures O
for O
preventing O
disease O
transmission O
, O
and O
attitude O
towards O
treating O
patients O
with O
COVID O
- O
19 O
were O
collected O
. O

Possible O
challenges O
in O
behavioral O
phenotyping O
of O
rodents O
following O
COVID O
- O
19 O
lockdown O
. O

Estimating O
vulnerability O
to O
COVID O
- O
19 O
in O
India O
. O

The O
Convergence O
of O
Opinion O
on O
Recommendations O
and O
Evidence O
process O
was O
used O
to O
make O
interim O
recommendation O
for O
the O
rehabilitation O
in O
the O
hospital O
and O
post O
- O
hospital O
phase O
in O
COVID O
- O
19 O
and O
post O
- O
COVID O
- O
19 O
patients O
, O
respectively O
. O
93 O
experts O
were O
asked O
to O
fill O
out O
13 O
multiple O
choice O
questions O
. O

Collectively O
, O
these O
data O
support O
further O
evaluation O
of O
the O
anti O
- O
cytokine O
and O
anti O
- O
viral O
activity O
of O
baricitinib O
and O
support O
its O
assessment O
in O
randomized O
trials O
in O
hospitalized O
COVID O
- O
19 O
patients O
. O

In O
this O
systematic O
review O
we O
meta O
- O
analyzed O
88 O
articles O
for O
risk O
factors O
of O
ICU O
admission O
and O
mortality O
in O
COVID O
- O
19 O
. O

Air O
pollution O
and O
geriatric O
mental O
health O
: O
perspectives O
on O
the O
COVID O
- O
19 O
pandemic O
. O

Thirteen O
COVID O
- O
19 O
adult O
patients O
under O
invasive O
mechanical O
ventilation O
who O
had O
received O
previous O
antiviral O
and O
/ O
or O
anti O
- O
inflammatory O
treatments O
( O
including O
steroids O
, O
lopinavir O
/ O
ritonavir O
, O
hydroxychloroquine O
and O
/ O
or O
tocilizumab O
, O
among O
others O
) O
were O
treated O
with O
allogeneic O
AT O
- O
MSC O
. O

Data O
related O
to O
the O
applicability O
of O
the O
Clinical O
Frailty O
Scale O
( O
CFS O
) O
for O
risk O
stratification O
in O
patients O
with O
COVID O
- O
19 O
are O
currently O
lacking O
. O

China O
is O
at O
the O
forefront O
of O
global O
efforts O
to O
develop O
COVID O
- O
19 O
vaccines O
and O
has O
five O
fast O
- O
tracked O
candidates O
at O
the O
final O
- O
stage O
, O
large O
- O
scale O
human O
clinical O
trials O
testing O
phase O
. O

Applying O
filters O
to O
protect O
our O
comprehensive O
cancer O
center O
from O
COVID O
- O
19 O
spread O
contributed O
to O
guaranteeing O
cancer O
care O
during O
the O
COVID O
- O
19 O
crisis O
in O
Milan O
. O

We O
examined O
the O
presence O
and O
temporal O
changes O
of O
the O
neutralizing O
activity O
of O
IgG O
fractions O
from O
43 O
COVID O
- O
19 O
- O
convalescent O
plasmas O
using O
cell O
- O
based O
assays O
with O
multiple O
endpoints O
. O

Nuanced O
considerations O
of O
five O
contingency O
planning O
strategies O
in O
response O
to O
COVID O
- O
19 O
are O
described O
, O
including O
COVID O
- O
19 O
- O
specific O
precautions O
, O
visitor O
restrictions O
, O
physician O
workforce O
considerations O
, O
operational O
adjustments O
, O
and O
group O
therapy O
changes O
. O

Pathophysiology O
of O
the O
COVID O
- O
19 O
- O
entry O
to O
the O
CNS O
through O
the O
nose O
. O

Based O
on O
the O
available O
data O
, O
it O
seems O
that O
there O
is O
still O
no O
evidence O
that O
COVID O
- O
19 O
can O
be O
transmitted O
via O
atypical O
modes O
of O
transmission O
. O

[ O
Prevention O
and O
early O
identification O
of O
COVID O
- O
19 O
suspected O
cases O
at O
the O
first O
level O
of O
care O
in O
Central O
America O
] O
. O

Lung O
Compliance O
in O
a O
Case O
Series O
of O
Four O
COVID O
- O
19 O
Patients O
at O
a O
Rural O
Institution O
. O

It O
has O
been O
reported O
that O
frequent O
occurrence O
of O
COVID O
- O
19 O
infection O
in O
these O
patients O
is O
associated O
with O
low O
cytosolic O
pH O
. O

A O
considerable O
percentage O
of O
the O
public O
exhibits O
conspiracy O
thinking O
toward O
the O
COVID O
- O
19 O
crisis O
in O
Iraqi O
Kurdistan O
. O

Shift O
in O
racial O
communities O
impacted O
by O
COVID O
- O
19 O
in O
California O
. O

[ O
Cardio O
- O
onco O
- O
hematology O
patients O
' O
management O
in O
the O
context O
of O
the O
current O
COVID O
- O
19 O
pandemic O
] O
. O

In O
COVID O
- O
19 O
patients O
, O
echocardiography O
remains O
the O
leading O
imaging O
exam O
for O
the O
diagnosis O
of O
IE O
. O

The O
Vatican O
City O
State O
Internal O
Healthcare O
System O
Response O
to O
COVID O
- O
19 O
Pandemic O
: O
Prevention O
and O
Control O
Strategies O
. O

Infants O
with O
COVID O
- O
19 O
had O
more O
normal O
chest O
X O
- O
rays O
. O

Immunization O
and O
vaccination O
of O
children O
during O
current O
COVID O
- O
19 O
pandemic O
: O
Impact O
and O
recommendation O
guidelines O
for O
India O
. O

Of O
the O
218 O
, O
070 O
NHI O
and O
14 O
, O
320 O
Medicaid O
beneficiaries O
who O
received O
COVID O
- O
19 O
tests O
, O
7 O
, O
777 O
and O
738 O
tested O
positive O
, O
respectively O
. O

These O
findings O
further O
identify O
the O
key O
inflammatory O
, O
thrombotic O
, O
and O
vascular O
factors O
that O
characterize O
and O
distinguish O
severe O
and O
fatal O
COVID O
- O
19 O
. O

We O
also O
intend O
to O
emphasize O
on O
standard O
infection O
control O
protocols O
and O
strategies O
that O
need O
to O
be O
considered O
in O
dental O
care O
settings O
during O
disease O
outbreaks O
like O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
. O

Diagnostic O
testing O
to O
identify O
persons O
infected O
with O
severe O
acute O
respiratory O
syndrome O
- O
related O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
infection O
is O
central O
to O
control O
the O
global O
pandemic O
of O
COVID O
- O
19 O
that O
began O
in O
late O
2019 O
. O

In O
COVID O
- O
19 O
, O
elevated O
serum O
IL O
- O
6 O
levels O
were O
associated O
with O
critical O
illness O
, O
usage O
of O
mechanical O
ventilation O
and O
complications O
including O
heart O
injury O
and O
ARDS O
, O
and O
could O
predict O
a O
fatal O
outcome O
. O

Utilizing O
a O
health O
system O
COVID O
- O
19 O
research O
registry O
, O
we O
assessed O
HCW O
risk O
for O
COVID O
- O
19 O
infection O
, O
hospitalization O
, O
and O
intensive O
care O
unit O
( O
ICU O
) O
admission O
. O

Methods O
: O
In O
this O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
clinical O
trial O
, O
we O
included O
31 O
adult O
patients O
with O
moderate O
COVID O
- O
19 O
who O
were O
admitted O
to O
the O
Fourth O
People O
' O
s O
Hospital O
of O
Nanning O
( O
Nanning O
, O
China O
) O
between O
January O
22 O
, O
2020 O
and O
February O
17 O
, O
2020 O
. O

Circulating O
markers O
of O
angiogenesis O
and O
endotheliopathy O
in O
COVID O
- O
19 O
. O

The O
ongoing O
severe O
acute O
respiratory O
sickness O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
pandemic O
has O
resulted O
in O
more O
than O
3 O
, O
600 O
, O
000 O
detected O
cases O
of O
COVID O
- O
19 O
illness O
and O
nearly O
260 O
, O
000 O
deaths O
worldwide O
as O
of O
May O
6 O
, O
2020 O
. O

This O
analysis O
reveals O
that O
unlike O
coronavirus O
infections O
of O
pregnant O
women O
caused O
by O
SARS O
and O
MERS O
, O
in O
these O
38 O
pregnant O
women O
COVID O
- O
19 O
did O
not O
lead O
to O
maternal O
deaths O
. O

Characteristics O
of O
registered O
clinical O
trials O
assessing O
treatments O
for O
COVID O
- O
19 O
: O
a O
cross O
- O
sectional O
analysis O
. O

To O
see O
the O
country O
free O
from O
COVID O
- O
19 O
, O
the O
responsible O
necessity O
to O
focus O
on O
the O
indigence O
to O
meet O
the O
public O
health O
requirements O
at O
a O
proper O
time O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
management O
of O
cancer O
patients O
and O
oncological O
treatments O
during O
the O
COVID O
- O
19 O
pandemic O
and O
to O
describe O
the O
containment O
measures O
performed O
in O
our O
outpatient O
clinic O
at O
Pavia O
( O
Lombardy O
) O
. O

Although O
fever O
is O
one O
of O
the O
main O
presenting O
symptoms O
of O
COVID O
- O
19 O
infection O
, O
little O
public O
attention O
has O
been O
given O
to O
fever O
as O
an O
evolved O
defense O
. O

Dynamic O
emergency O
department O
response O
to O
the O
evolving O
COVID O
- O
19 O
pandemic O
: O
the O
experience O
of O
a O
tertiary O
hospital O
in O
Singapore O
. O

Promoting O
healthy O
default O
options O
is O
critical O
at O
a O
time O
when O
engaging O
in O
healthy O
behaviors O
is O
difficult O
, O
but O
important O
, O
to O
both O
prevent O
and O
manage O
chronic O
disease O
and O
decrease O
COVID O
- O
19 O
risk O
. O

In O
this O
review O
, O
we O
reported O
our O
multi O
- O
disciplinary O
team O
experience O
with O
up O
to O
date O
literature O
guidance O
to O
propose O
a O
valid O
protocol O
for O
management O
of O
COVID O
- O
19 O
patients O
in O
limited O
resources O
setting O
. O

In O
our O
univariate O
analysis O
among O
adults O
, O
rates O
of O
leukopenia O
( O
38 O
. O
4 O
% O
versus O
13 O
. O
2 O
% O
; O
P O
= O
0 O
. O
04 O
) O
, O
low O
albumin O
levels O
( O
53 O
. O
8 O
% O
versus O
10 O
. O
2 O
% O
; O
P O
= O
0 O
. O
001 O
) O
, O
and O
shorter O
duration O
between O
transplantation O
and O
COVID O
- O
19 O
( O
P O
= O
0 O
. O
02 O
) O
, O
were O
higher O
among O
patients O
who O
died O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
an O
infectious O
disease O
with O
a O
high O
asymptomatic O
incidence O
. O

A O
rapid O
review O
of O
the O
published O
literature O
was O
conducted O
on O
October O
6 O
, O
2020 O
, O
through O
a O
search O
in O
six O
online O
databases O
to O
synthesize O
results O
from O
published O
original O
studies O
regarding O
the O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
older O
adults O
. O

We O
report O
a O
case O
of O
positive O
lung O
ultrasound O
findings O
consistent O
with O
COVID O
- O
19 O
in O
a O
woman O
with O
an O
initially O
negative O
RT O
- O
PCR O
result O
. O

Incorporating O
microscopic O
and O
molecular O
findings O
from O
brain O
tissue O
into O
what O
we O
know O
about O
clinical O
disease O
will O
inform O
best O
practice O
management O
guidance O
and O
direct O
research O
priorities O
as O
it O
relates O
to O
neurological O
morbidity O
from O
COVID O
- O
19 O
. O

To O
evaluate O
the O
incidence O
of O
pulmonary O
ischaemia O
in O
COVID O
- O
19 O
patients O
on O
extracorporeal O
membrane O
oxygenation O
( O
ECMO O
) O
, O
and O
its O
correlation O
with O
pulmonary O
artery O
thrombosis O
. O

This O
study O
demonstrates O
that O
loud O
speech O
without O
face O
coverings O
increases O
emission O
of O
respiratory O
droplets O
that O
carry O
oral O
bacteria O
and O
may O
also O
carry O
other O
pathogens O
such O
as O
COVID O
- O
19 O
. O

Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
rapidly O
become O
a O
global O
pandemic O
, O
with O
over O
1 O
. O
8 O
million O
confirmed O
cases O
worldwide O
to O
date O
. O

Management O
of O
pneumothorax O
in O
mechanically O
ventilated O
COVID O
- O
19 O
patients O
: O
early O
experience O
. O

Door O
to O
the O
cell O
for O
COVID O
- O
19 O
opened O
, O
leading O
way O
to O
therapies O
. O

Proposed O
Imaging O
Guidelines O
for O
Pregnant O
Women O
Suspected O
of O
Having O
COVID O
- O
19 O
. O

Children O
and O
adolescents O
are O
not O
indifferent O
to O
the O
dramatic O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
, O
and O
the O
need O
to O
be O
forced O
to O
live O
in O
confinement O
. O

Polypharmacy O
was O
associated O
with O
a O
dose O
response O
higher O
risk O
of O
COVID O
- O
19 O
. O

Attitude O
, O
practice O
, O
behavior O
, O
and O
mental O
health O
impact O
of O
COVID O
- O
19 O
on O
doctors O
. O

In O
patients O
with O
COVID O
- O
19 O
, O
the O
apparent O
favorable O
clinical O
response O
with O
arbidol O
and O
LPV O
/ O
r O
supports O
further O
LPV O
/ O
r O
only O
. O

New O
( O
re O
) O
purpose O
for O
an O
old O
drug O
: O
purinergic O
modulation O
may O
extinguish O
the O
COVID O
- O
19 O
thromboinflammatory O
firestorm O
. O

In O
this O
paper O
we O
have O
aimed O
at O
reported O
the O
incidence O
of O
invasive O
pulmonary O
aspergillosis O
for O
COVID O
- O
19 O
patients O
in O
our O
ICU O
, O
and O
at O
comparing O
the O
different O
definitions O
in O
order O
to O
assess O
their O
respective O
relevance O
. O

WHO O
( O
World O
Health O
Organization O
) O
- O
China O
Joint O
Mission O
fully O
confirms O
the O
success O
of O
" O
China O
' O
s O
model O
" O
against O
COVID O
- O
19 O
in O
the O
report O
. O

Teaching O
in O
the O
time O
of O
COVID O
- O
19 O
. O

The O
outbreak O
of O
COVID O
- O
19 O
has O
caused O
mental O
health O
problems O
and O
increased O
unemployment O
due O
to O
the O
economic O
recession O
. O

Molecular O
basis O
of O
the O
potential O
interaction O
of O
SARS O
- O
CoV O
- O
2 O
spike O
protein O
to O
CD147 O
in O
COVID O
- O
19 O
associated O
- O
lymphopenia O
. O

On O
12 O
March O
2020 O
, O
the O
WHO O
declared O
that O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
constitutes O
a O
pandemic O
. O

A O
Coordinated O
Response O
to O
the O
COVID O
- O
19 O
Pandemic O
in O
Missouri O
Nursing O
Homes O
. O

The O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
a O
novel O
human O
coronavirus O
causing O
the O
pandemic O
of O
severe O
pneumonia O
( O
Coronavirus O
Disease O
2019 O
, O
COVID O
- O
19 O
) O
. O

As O
of O
May O
13 O
, O
2020 O
, O
the O
number O
of O
confirmed O
SARS O
- O
CoV O
- O
2 O
( O
novel O
corona O
virus O
, O
COVID O
- O
19 O
) O
infections O
has O
risen O
to O
4 O
300 O
000 O
worldwide O
, O
with O
over O
1 O
300 O
000 O
confirmed O
cases O
in O
the O
United O
States O
. O

To O
date O
, O
no O
confirmed O
transmission O
of O
the O
virus O
has O
been O
confirmed O
within O
a O
laboratory O
setting O
; O
however O
, O
operating O
processes O
and O
procedures O
should O
be O
adapted O
to O
ensure O
safe O
working O
of O
samples O
of O
positive O
, O
negative O
, O
or O
unknown O
COVID O
- O
19 O
status O
. O

During O
COVID O
- O
19 O
pandemic O
, O
the O
health O
systems O
worldwide O
, O
along O
with O
the O
practice O
of O
chest O
diseases O
daily O
were O
affected O
. O

Digital O
Eye O
Strain O
Epidemic O
amid O
COVID O
- O
19 O
Pandemic O
- O
A O
Cross O
- O
sectional O
Survey O
. O

The O
findings O
of O
the O
current O
study O
present O
important O
data O
for O
health O
care O
professionals O
to O
help O
them O
understand O
the O
challenges O
faced O
by O
parents O
and O
children O
with O
leukaemia O
, O
especially O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Evidence O
for O
the O
associations O
between O
mental O
illness O
and O
the O
likelihood O
of O
a O
positive O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
test O
result O
and O
the O
clinical O
outcomes O
of O
COVID O
- O
19 O
is O
scarce O
. O

Emerging O
data O
show O
that O
the O
health O
and O
economic O
impacts O
of O
COVID O
- O
19 O
are O
being O
disproportionately O
borne O
by O
individuals O
who O
are O
not O
only O
biologically O
, O
but O
also O
socially O
vulnerable O
. O

Multi O
- O
Stage O
Group O
Testing O
Improves O
Efficiency O
of O
Large O
- O
Scale O
COVID O
- O
19 O
Screening O
. O

Nucleic O
acid O
approaches O
to O
antibody O
- O
based O
therapeutics O
for O
COVID O
- O
19 O
: O
A O
perspective O
. O

Intervention O
: O
COVID O
- O
19 O
Convalescent O
Plasma O
( O
CCP O
) O
in O
addition O
to O
standard O
therapy O
. O

COVID O
- O
19 O
has O
developed O
into O
a O
pandemic O
, O
hitting O
hard O
on O
our O
communities O
. O

BACKGROUND O
During O
the O
outbreak O
of O
COVID O
- O
19 O
, O
health O
care O
workers O
in O
the O
radiology O
department O
frequently O
interact O
with O
suspected O
patients O
and O
face O
a O
higher O
risk O
of O
infection O
and O
sudden O
surges O
in O
workload O
. O

Persistence O
of O
intestinal O
SARS O
- O
CoV O
- O
2 O
infection O
in O
patients O
with O
COVID O
- O
19 O
leads O
to O
re O
- O
admission O
after O
pneumonia O
resolved O
. O

Drawing O
on O
studies O
in O
other O
human O
and O
murine O
infections O
, O
including O
emerging O
data O
from O
COVID O
- O
19 O
, O
we O
consider O
the O
influence O
of O
antigen O
quantity O
and O
structure O
on O
the O
quality O
of O
the O
B O
cell O
response O
, O
the O
role O
of O
differential O
CD4 O
help O
, O
the O
importance O
of O
germinal O
center O
vs O
extrafollicular O
responses O
and O
the O
emerging O
concept O
that O
responses O
residing O
in O
non O
- O
lymphoid O
organs O
can O
participate O
in O
B O
cell O
memory O
. O

The O
model O
is O
sensitive O
to O
variations O
in O
the O
prevalence O
of O
COVID O
- O
19 O
and O
the O
cost O
of O
PPE O
. O

COVID O
- O
19 O
pandemic O
and O
the O
skin O
: O
what O
should O
dermatologists O
know O
? O

Interim O
Guidance O
for O
Basic O
and O
Advanced O
Life O
Support O
in O
Adults O
, O
Children O
, O
and O
Neonates O
With O
Suspected O
or O
Confirmed O
COVID O
- O
19 O
: O
From O
the O
Emergency O
Cardiovascular O
Care O
Committee O
and O
Get O
With O
The O
Guidelines O
- O
Resuscitation O
Adult O
and O
Pediatric O
Task O
Forces O
of O
the O
American O
Heart O
Association O
. O

COVID O
- O
19 O
vaccine O
- O
related O
messages O
should O
both O
address O
concerns O
about O
the O
vaccine O
and O
its O
development O
and O
reinforce O
benefits O
of O
the O
vaccine O
( O
both O
factors O
significant O
in O
both O
models O
) O
. O

We O
discuss O
the O
plight O
of O
urban O
poor O
African O
immigrants O
from O
the O
perspective O
of O
the O
right O
to O
food O
( O
food O
availability O
, O
accessibility O
and O
adequacy O
) O
for O
everyone O
during O
the O
COVID O
- O
19 O
in O
South O
Africa O
. O

We O
hope O
our O
initial O
experience O
in O
stepping O
up O
infection O
control O
measures O
for O
COVID O
- O
19 O
infection O
in O
ophthalmology O
can O
help O
ophthalmologists O
globally O
to O
prepare O
for O
the O
potential O
community O
outbreak O
or O
pandemic O
. O

We O
report O
here O
the O
case O
of O
a O
young O
patient O
requiring O
inpatient O
care O
due O
to O
severe O
decompensated O
liver O
disease O
( O
MELD O
24 O
) O
, O
justifying O
her O
referral O
from O
her O
local O
hospital O
to O
our O
high O
- O
volume O
LT O
unit O
, O
despite O
the O
unfavourable O
COVID O
- O
19 O
epidemiology O
in O
our O
Region O
. O

Severe O
acute O
respiratory O
syndrome O
- O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
virus O
strain O
that O
causes O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
was O
first O
identified O
in O
Wuhan O
, O
China O
in O
December O
2019 O
. O

We O
describe O
the O
management O
of O
the O
different O
pelvic O
floor O
dysfunctions O
during O
COVID O
- O
19 O
pandemic O
and O
a O
proposal O
to O
organize O
the O
urogynaecological O
services O
to O
diagnose O
( O
visits O
and O
diagnostic O
investigations O
) O
and O
to O
treat O
( O
conservative O
, O
pharmacological O
or O
surgery O
) O
in O
the O
interpandemic O
period O
and O
in O
the O
future O
. O

While O
one O
would O
expect O
the O
financial O
, O
mental O
, O
and O
physical O
stress O
due O
to O
COVID O
- O
19 O
to O
result O
in O
additional O
child O
maltreatment O
cases O
, O
we O
find O
that O
the O
actual O
number O
of O
reported O
allegations O
was O
approximately O
15 O
, O
000 O
lower O
( O
27 O
% O
) O
than O
expected O
for O
these O
two O
months O
. O

On O
March O
11th O
2020 O
, O
the O
World O
Health O
Organization O
( O
WHO O
) O
declared O
COVID O
- O
19 O
pandemic O
, O
with O
subsequent O
profound O
impact O
on O
the O
entire O
health O
care O
system O
. O

The O
analysis O
is O
based O
upon O
the O
dental O
diagnoses O
, O
management O
and O
geography O
of O
travel O
of O
over O
1 O
, O
500 O
attending O
patients O
in O
a O
five O
- O
week O
period O
during O
the O
rise O
and O
peak O
of O
COVID O
- O
19 O
in O
the O
UK O
. O

This O
study O
aimed O
at O
assessing O
the O
knowledge O
, O
attitudes O
and O
practices O
of O
a O
sample O
of O
Sudanese O
residents O
towards O
COVID O
- O
19 O
. O

We O
evaluated O
the O
relationship O
between O
the O
time O
to O
first O
reported O
importation O
and O
the O
Global O
Health O
Security O
Index O
( O
GHSI O
) O
overall O
score O
; O
13 O
, O
201 O
confirmed O
cases O
of O
COVID O
- O
19 O
were O
reported O
by O
48 O
countries O
in O
SSA O
during O
the O
54 O
days O
following O
the O
first O
known O
introduction O
to O
the O
region O
. O

This O
themed O
issue O
on O
global O
health O
research O
has O
come O
at O
an O
opportune O
time O
in O
the O
middle O
of O
the O
ongoing O
global O
public O
health O
crisis O
arising O
from O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
which O
has O
claimed O
nearly O
756 O
, O
000 O
lives O
in O
210 O
countries O
and O
territories O
around O
the O
world O
as O
of O
August O
15 O
, O
2020 O
. O

We O
searched O
MEDLINE O
, O
Embase O
, O
and O
Cochrane O
Central O
Register O
of O
Controlled O
Trials O
databases O
to O
identify O
cases O
of O
COVID O
- O
19 O
- O
associated O
CVT O
. O

Through O
the O
lens O
of O
paradoxes O
, O
this O
essay O
understands O
China O
' O
s O
COVID O
- O
19 O
responses O
, O
focusing O
on O
normal O
and O
non O
- O
normal O
governance O
, O
competing O
values O
, O
expertise O
and O
politics O
, O
centralization O
and O
decentralization O
, O
public O
and O
private O
, O
and O
technology O
and O
institution O
. O

[ O
The O
role O
of O
advance O
care O
planning O
and O
palliative O
care O
in O
new O
york O
city O
during O
COVID O
- O
19 O
pandemic O
] O
. O

The O
present O
information O
regarding O
the O
clinical O
features O
of O
COVID O
- O
19 O
infection O
in O
the O
dialysis O
population O
was O
collected O
, O
and O
the O
useful O
measures O
of O
COVID O
- O
19 O
infection O
prevention O
and O
infection O
control O
in O
the O
dialysis O
facilities O
were O
summarized O
. O

For O
detection O
and O
treatment O
of O
malaria O
, O
individuals O
may O
stop O
attending O
health O
facilities O
, O
out O
of O
fear O
of O
exposure O
to O
COVID O
- O
19 O
, O
or O
because O
they O
cannot O
afford O
transport O
, O
and O
health O
care O
workers O
require O
additional O
resources O
to O
protect O
themselves O
from O
COVID O
- O
19 O
. O

Dosing O
of O
thromboprophylaxis O
and O
mortality O
in O
critically O
ill O
COVID O
- O
19 O
patients O
. O

It O
is O
called O
COVID O
- O
19 O
because O
it O
was O
caused O
by O
the O
novel O
coronavirus O
( O
SARS O
- O
COV O
- O
2 O
) O
in O
2019 O
. O

We O
propose O
that O
sex O
differences O
in O
immunopathogenesis O
will O
inform O
mechanisms O
of O
COVID O
- O
19 O
, O
identify O
points O
for O
therapeutic O
intervention O
and O
improve O
vaccine O
design O
and O
increase O
vaccine O
efficacy O
. O

Amid O
the O
COVID O
- O
19 O
pandemic O
, O
women O
in O
medicine O
, O
including O
faculty O
, O
residents O
, O
medical O
students O
, O
and O
other O
health O
care O
workers O
( O
HCWs O
) O
, O
are O
facing O
unparalleled O
challenges O
. O

Based O
on O
the O
results O
of O
Least O
Absolute O
Shrinkage O
and O
Selection O
Operator O
( O
LASSO O
) O
logistic O
regression O
, O
age O
, O
and O
suggestive O
chest O
X O
- O
ray O
( O
CXR O
) O
findings O
for O
SARS O
- O
CoV O
- O
2 O
infection O
, O
cardiovascular O
diseases O
, O
diabetes O
mellitus O
, O
chronic O
lung O
diseases O
, O
and O
intensive O
care O
units O
admission O
had O
significant O
associations O
with O
positive O
RT O
- O
PCR O
results O
for O
COVID O
- O
19 O
infection O
. O

There O
were O
no O
deaths O
or O
admissions O
to O
the O
intensive O
care O
unit O
attributable O
to O
COVID O
- O
19 O
; O
7 O
. O
8 O
% O
of O
patients O
were O
hospitalized O
( O
excluding O
scheduled O
hospitalization O
) O
, O
and O
17 O
. O
1 O
% O
were O
admitted O
to O
the O
emergency O
department O
at O
least O
once O
during O
the O
monitoring O
period O
. O

AT O
and O
ARH O
showed O
significantly O
negative O
associations O
with O
COVID O
- O
19 O
with O
a O
significant O
interaction O
between O
them O
( O
0 O
. O
04 O
, O
95 O
% O
confidence O
interval O
: O
0 O
. O
004 O
- O
0 O
. O
07 O
) O
in O
Hubei O
. O

Antineutrophil O
Cytoplasmic O
Antibody O
- O
Associated O
Glomerulonephritis O
in O
a O
Case O
of O
Scleroderma O
After O
Recent O
Diagnosis O
With O
COVID O
- O
19 O
. O

Haematological O
manifestations O
, O
mechanisms O
of O
thrombosis O
and O
anti O
- O
coagulation O
in O
COVID O
- O
19 O
disease O
: O
A O
review O
. O

Non O
- O
survivors O
had O
higher O
percentage O
of O
the O
classic O
symptoms O
of O
COVID O
- O
19 O
than O
survivors O
. O

Psychological O
burden O
of O
the O
COVID O
- O
19 O
pandemic O
and O
its O
associated O
factors O
among O
frontline O
doctors O
of O
Bangladesh O
: O
a O
cross O
- O
sectional O
study O
. O

The O
serious O
glaring O
disequilibrium O
, O
in O
healthcare O
market O
, O
between O
supply O
and O
demand O
for O
scarce O
medical O
resources O
in O
several O
developed O
nations O
( O
including O
the O
USA O
, O
UK O
, O
France O
, O
Italy O
, O
Spain O
, O
etc O
. O
) O
imposes O
a O
fundamental O
question O
: O
which O
COVID O
- O
19 O
patient O
to O
save O
when O
facing O
scarce O
resources O
? O

The O
overall O
epidemic O
intensity O
of O
COVID O
- O
19 O
reduced O
slightly O
following O
days O
with O
higher O
temperatures O
with O
a O
relative O
risk O
( O
RR O
) O
was O
0 O
. O
96 O
( O
95 O
% O
CI O
: O
0 O
. O
93 O
, O
0 O
. O
99 O
) O
. O

We O
recommend O
all O
countries O
and O
international O
organizations O
to O
reconsider O
ways O
to O
make O
press O
conferences O
accessible O
to O
a O
wide O
audience O
in O
general O
, O
and O
to O
the O
hearing O
impaired O
communities O
in O
particular O
by O
including O
a O
SLI O
during O
their O
COVID O
- O
19 O
briefings O
, O
a O
primary O
step O
towards O
upholding O
the O
sustainable O
development O
pledge O
of O
" O
no O
one O
gets O
left O
behind O
. O
" O

We O
studied O
how O
National O
Health O
Service O
hospitals O
in O
England O
and O
Wales O
aimed O
to O
maintain O
effective O
and O
safe O
colorectal O
cancer O
( O
CRC O
) O
services O
during O
the O
first O
peak O
of O
the O
COVID O
- O
19 O
pandemic O
period O
( O
April O
2020 O
) O
. O

Plan O
for O
blood O
banks O
to O
protect O
blood O
donors O
and O
healthcare O
workers O
during O
COVID O
- O
19 O
pandemic O
. O

With O
this O
study O
, O
we O
sought O
to O
survey O
pediatric O
centers O
and O
highlight O
the O
variations O
in O
care O
related O
to O
perioperative O
medicine O
during O
the O
COVID O
- O
19 O
pandemic O
, O
including O
the O
availability O
of O
protective O
equipment O
, O
the O
practice O
of O
pediatric O
anesthesia O
, O
and O
economic O
impact O
. O

2020 O
will O
be O
remembered O
worldwide O
for O
the O
outbreak O
of O
Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
which O
quickly O
spread O
until O
it O
was O
declared O
as O
a O
global O
pandemic O
. O

Furthermore O
, O
we O
noted O
a O
lack O
of O
research O
focusing O
on O
the O
role O
of O
social O
media O
campaigns O
in O
public O
health O
awareness O
and O
public O
protection O
against O
the O
COVID O
- O
19 O
pandemic O
in O
Jordan O
as O
a O
developing O
country O
. O

With O
rising O
cases O
in O
many O
countries O
, O
and O
likely O
further O
peaks O
in O
the O
coming O
colder O
seasons O
, O
ventilator O
triage O
guidance O
remains O
a O
central O
part O
of O
the O
COVID O
- O
19 O
policy O
response O
. O

Using O
this O
methodology O
, O
we O
found O
that O
a O
small O
number O
of O
clinical O
and O
cytokine O
expression O
variables O
are O
predictive O
of O
presenting O
COVID O
- O
19 O
disease O
severity O
, O
raising O
questions O
about O
the O
mechanism O
by O
which O
COVID O
- O
19 O
creates O
severe O
illness O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
has O
now O
widely O
spread O
globally O
. O

Hyper O
- O
immune O
/ O
convalescent O
plasma O
: O
an O
old O
option O
and O
a O
valid O
strategy O
for O
treatment O
of O
COVID O
- O
19 O
? O

The O
more O
severe O
impact O
by O
COVID O
- O
19 O
on O
city O
dwellers O
and O
those O
exposed O
to O
toxic O
fumes O
leads O
to O
the O
primary O
health O
damage O
such O
as O
respiratory O
infections O
than O
on O
others O
. O

Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
Italy O
. O

Prediction O
and O
mitigation O
of O
mutation O
threats O
to O
COVID O
- O
19 O
vaccines O
and O
antibody O
therapies O
. O

Despite O
the O
high O
- O
risk O
conditions O
associated O
with O
worse O
outcomes O
, O
patients O
on O
HD O
did O
not O
exhibit O
extremely O
poor O
overall O
COVID O
- O
19 O
outcomes O
perhaps O
due O
to O
early O
diagnosis O
, O
prompt O
hospitalization O
, O
and O
antiviral O
therapy O
. O

Extraordinary O
steps O
have O
been O
taken O
to O
alleviate O
the O
current O
quick O
transmission O
of O
the O
Jordanian O
COVID O
- O
19 O
pandemic O
. O

Arrhythmias O
in O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
Wuhan O
, O
China O
: O
Incidences O
and O
implications O
. O

Furthermore O
, O
many O
healthcare O
workers O
have O
been O
reluctant O
in O
treating O
COVID O
- O
19 O
patients O
. O

There O
is O
no O
specific O
therapeutic O
drugs O
or O
licensed O
vaccines O
or O
treatments O
to O
fight O
against O
lethal O
COVID O
- O
19 O
infections O
. O

Social O
Media O
Activities O
, O
Emotion O
Regulation O
Strategies O
, O
and O
Their O
Interactions O
on O
People O
' O
s O
Mental O
Health O
in O
COVID O
- O
19 O
Pandemic O
. O

This O
article O
is O
three O
- O
fold O
: O
( O
i O
) O
we O
demystify O
the O
high O
sensitivities O
achieved O
by O
most O
recent O
COVID O
- O
19 O
classification O
models O
, O
( O
ii O
) O
under O
a O
close O
collaboration O
with O
Hospital O
Universitario O
Cl O
í O
nico O
San O
Cecilio O
, O
Granada O
, O
Spain O
, O
we O
built O
COVIDGR O
- O
1 O
. O
0 O
, O
a O
homogeneous O
and O
balanced O
database O
that O
includes O
all O
levels O
of O
severity O
, O
from O
normal O
with O
Positive O
RT O
- O
PCR O
, O
Mild O
, O
Moderate O
to O
Severe O
. O

Prevalence O
of O
Co O
- O
infection O
at O
the O
Time O
of O
Hospital O
Admission O
in O
COVID O
- O
19 O
Patients O
, O
A O
Multicenter O
Study O
. O

The O
World O
Health O
Organization O
( O
WHO O
) O
initially O
declared O
COVID O
- O
19 O
as O
a O
Public O
Health O
Emergency O
of O
International O
Concern O
( O
PHEIC O
) O
and O
later O
characterized O
it O
as O
a O
global O
pandemic O
on O
March O
11 O
, O
2020 O
. O

Calcification O
of O
the O
thoracic O
aorta O
on O
low O
- O
dose O
chest O
CT O
predicts O
severe O
COVID O
- O
19 O
. O

The O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
broke O
out O
in O
December O
2019 O
, O
is O
a O
global O
pandemic O
. O

Methylene O
Blue O
Inhibits O
the O
SARS O
- O
CoV O
- O
2 O
Spike O
- O
ACE2 O
Protein O
- O
Protein O
Interaction O
- O
a O
Mechanism O
that O
can O
Contribute O
to O
its O
Antiviral O
Activity O
Against O
COVID O
- O
19 O
. O

Ocular O
Pathology O
Recommendations O
during O
COVID O
- O
19 O
from O
the O
American O
Association O
of O
Ophthalmic O
Oncologists O
and O
Pathologists O
( O
AAOOP O
) O
. O

Interventional O
radiology O
participated O
in O
the O
care O
of O
hospitalized O
COVID O
- O
19 O
patients O
by O
performing O
a O
wide O
variety O
of O
necessary O
procedures O
. O

Making O
oral O
pathology O
lemonade O
from O
COVID O
- O
19 O
lemons O
. O

Many O
countries O
implemented O
a O
lockdown O
to O
control O
the O
spread O
of O
the O
COVID O
- O
19 O
pandemic O
. O

This O
study O
outlines O
the O
Greek O
translation O
and O
validation O
of O
the O
Fear O
of O
COVID O
- O
19 O
Scale O
( O
FCV O
- O
19S O
) O
in O
the O
general O
population O
. O

COVID O
- O
19 O
model O
- O
based O
practice O
changes O
in O
managing O
a O
large O
prostate O
cancer O
practice O
: O
following O
the O
trends O
during O
a O
month O
- O
long O
ordeal O
. O

Organized O
sporting O
events O
, O
from O
recreational O
to O
the O
Olympic O
level O
, O
have O
been O
cancelled O
to O
both O
mitigate O
the O
spread O
of O
COVID O
- O
19 O
and O
protect O
athletes O
and O
highly O
active O
individuals O
from O
potential O
acute O
and O
long O
- O
term O
infection O
- O
associated O
harms O
. O

The O
fibrinolysis O
- O
first O
strategy O
during O
the O
COVID O
- O
19 O
pandemic O
was O
associated O
with O
a O
lower O
rate O
of O
timely O
coronary O
reperfusion O
and O
increased O
rates O
of O
recurrent O
ischaemia O
, O
cardiogenic O
shock O
, O
and O
exacerbated O
heart O
failure O
. O

Based O
on O
systematic O
search O
in O
Web O
of O
Science O
, O
PubMed O
, O
Scopus O
, O
and O
Science O
Direct O
up O
to O
April O
22 O
, O
2020 O
, O
a O
total O
of O
52 O
eligible O
articles O
with O
6 O
, O
320 O
laboratory O
- O
confirmed O
COVID O
- O
19 O
cohorts O
were O
included O
. O

The O
guidelines O
for O
labor O
, O
delivery O
, O
and O
breastfeeding O
for O
COVID O
- O
19 O
positive O
patients O
vary O
, O
and O
this O
variability O
could O
create O
uncertainty O
and O
unnecessary O
harm O
. O

A O
suspected O
COVID O
- O
19 O
case O
was O
defined O
as O
a O
passenger O
or O
crew O
member O
who O
developed O
a O
fever O
or O
respiratory O
symptoms O
, O
and O
a O
confirmed O
COVID O
- O
19 O
case O
had O
laboratory O
- O
confirmation O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
infection O
. O

Nanobodies O
: O
an O
unexplored O
opportunity O
to O
combat O
COVID O
- O
19 O
. O

Publications O
of O
COVID O
- O
19 O
- O
related O
recommendations O
and O
guidelines O
, O
produced O
by O
health O
authorities O
and O
organizations O
, O
such O
as O
WHO O
, O
US O
- O
CDC O
, O
ECDC O
, O
the O
American O
College O
of O
Surgery O
and O
the O
Robert O
Koch O
Institute O
, O
were O
retrieved O
, O
assessed O
and O
referenced O
up O
to O
31st O
January O
2020 O
. O

Several O
COVID O
- O
19 O
vaccine O
efficacy O
trials O
are O
ongoing O
with O
others O
predicted O
to O
start O
soon O
. O

This O
study O
showed O
a O
low O
rate O
of O
confirmed O
COVID O
- O
19 O
in O
children O
. O

Critically O
ill O
COVID O
- O
19 O
patients O
with O
influenza O
were O
more O
prone O
to O
cardiac O
injury O
than O
those O
without O
influenza O
. O

Approximately O
15 O
% O
- O
20 O
% O
of O
patients O
infected O
with O
SARS O
- O
CoV O
- O
2 O
coronavirus O
( O
COVID O
- O
19 O
) O
progress O
beyond O
mild O
and O
self O
- O
limited O
disease O
to O
require O
supplemental O
oxygen O
for O
severe O
pneumonia O
; O
5 O
% O
of O
COVID O
- O
19 O
- O
infected O
patients O
further O
develop O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
and O
multiorgan O
failure O
. O

We O
believe O
that O
a O
genome O
browser O
based O
on O
the O
consensus O
sequence O
is O
better O
suited O
when O
considering O
worldwide O
effects O
and O
can O
become O
a O
valuable O
resource O
in O
the O
combating O
of O
COVID O
- O
19 O
. O

Introduction O
: O
The O
COVID O
- O
19 O
outbreak O
has O
become O
a O
worldwide O
public O
health O
emergency O
. O

More O
so O
, O
as O
Mauritius O
is O
bracing O
for O
its O
worst O
recession O
in O
40 O
years O
in O
the O
aftermath O
of O
the O
COVID O
- O
19 O
pandemic O
public O
health O
financing O
will O
be O
heavily O
impacted O
. O

This O
retrospective O
study O
included O
500 O
initial O
CXR O
from O
COVID O
- O
19 O
- O
suspected O
patients O
. O

One O
hundred O
four O
patients O
( O
70 O
. O
2 O
% O
) O
showed O
no O
COVID O
- O
19 O
- O
related O
symptoms O
. O

Currently O
, O
no O
approved O
treatments O
for O
COVID O
- O
19 O
are O
available O
, O
and O
it O
is O
likely O
to O
take O
at O
least O
12 O
- O
18 O
months O
to O
develop O
a O
new O
vaccine O
. O

The O
purpose O
of O
this O
paper O
is O
to O
discuss O
the O
role O
of O
a O
pharmacokinetic O
and O
viral O
load O
analysis O
as O
a O
basis O
for O
adjusting O
immunoglobulin O
dosing O
to O
treat O
COVID O
- O
19 O
. O

Seroconversion O
in O
household O
members O
of O
COVID O
- O
19 O
outpatients O
. O

This O
study O
included O
25 O
asymptomatic O
patients O
and O
35 O
patients O
with O
lung O
involvement O
who O
were O
diagnosed O
with O
COVID O
- O
19 O
as O
well O
as O
22 O
healthy O
volunteers O
. O

No O
treatment O
for O
COVID O
- O
19 O
is O
yet O
available O
; O
therefore O
, O
providing O
access O
to O
information O
about O
SARS O
- O
CoV O
- O
2 O
, O
the O
transmission O
route O
of O
the O
virus O
, O
and O
ways O
to O
prevent O
the O
spread O
of O
infection O
is O
a O
critical O
sanitary O
measure O
worldwide O
. O

Additionally O
, O
we O
found O
an O
association O
between O
the O
current O
smoking O
status O
and O
severe O
COVID O
- O
19 O
( O
OR O
= O
1 O
. O
51 O
; O
95 O
% O
CI O
: O
1 O
. O
12 O
- O
2 O
. O
05 O
; O
P O
< O
. O
008 O
) O
. O

The O
novel O
COVID O
- O
19 O
disease O
has O
spread O
worldwide O
, O
resulting O
in O
a O
new O
pandemic O
. O

The O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
virus O
responsible O
for O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
, O
has O
challenged O
practitioners O
with O
complex O
clinical O
scenarios O
as O
well O
as O
conflicting O
and O
scarce O
data O
to O
support O
treatment O
strategies O
. O

PAP O
with O
COVID O
- O
19 O
Radiology O
- O
Differential O
Diagnosis O
Discussion O
. O

Perhaps O
, O
the O
present O
genomic O
insights O
of O
this O
virus O
will O
provide O
a O
lead O
to O
the O
researchers O
to O
design O
or O
repurpose O
of O
antiviral O
drugs O
soon O
and O
future O
directions O
to O
control O
the O
spread O
of O
COVID O
- O
19 O
. O

In O
this O
study O
, O
children O
under O
24 O
months O
of O
age O
hospitalized O
with O
respiratory O
compromise O
due O
to O
COVID O
- O
19 O
were O
retrospectively O
analyzed O
according O
to O
the O
event O
of O
coinfection O
with O
respiratory O
syncytial O
virus O
. O

The O
instrumental O
role O
of O
CK2 O
in O
the O
SARS O
- O
CoV O
- O
2 O
infection O
has O
pointed O
out O
this O
protein O
kinase O
as O
promising O
therapeutic O
target O
in O
COVID O
- O
19 O
. O

This O
study O
was O
aimed O
to O
compare O
the O
epidemiological O
characteristics O
and O
outcomes O
of O
COVID O
- O
19 O
in O
diabetic O
versus O
non O
- O
diabetic O
individuals O
. O

A O
limited O
proportion O
of O
trainees O
( O
approximately O
10 O
% O
) O
were O
still O
seeing O
patients O
face O
- O
to O
- O
face O
for O
neuropsychological O
evaluations O
during O
the O
COVID O
- O
19 O
pandemic O
as O
of O
14 O
April O
2020 O
. O
Conclusions O
: O
The O
COVID O
- O
19 O
pandemic O
is O
impacting O
neuropsychological O
training O
and O
the O
well O
- O
being O
of O
trainees O
. O

During O
the O
current O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
epidemic O
, O
the O
concern O
for O
reducing O
disease O
transmission O
has O
led O
to O
a O
worldwide O
increase O
in O
face O
mask O
utilization O
. O

This O
study O
analyzed O
the O
application O
of O
classic O
prescriptions O
in O
the O
diagnosis O
and O
treatment O
schemes O
based O
on O
the O
Diagnosis O
and O
Treatment O
Schemes O
for O
Coronavirus O
Disease O
at O
the O
country O
, O
provincial O
and O
municipal O
levels O
, O
and O
further O
explored O
its O
disrobing O
effect O
on O
COVID O
- O
19 O
disease O
severe O
phase O
network O
, O
and O
selected O
representative O
prescriptions O
for O
core O
target O
screening O
and O
gene O
enrichment O
analysis O
, O
so O
as O
to O
reveal O
its O
mechanism O
of O
action O
. O

COVID O
- O
19 O
was O
diagnosed O
in O
100 O
/ O
34 O
, O
763 O
patients O
( O
0 O
. O
29 O
% O
) O
. O
20 O
/ O
100 O
patients O
( O
20 O
% O
) O
had O
severe O
COVID O
- O
19 O
defined O
as O
admission O
to O
the O
intensive O
care O
unit O
, O
mechanical O
ventilation O
, O
and O
/ O
or O
death O
. O

Viral O
load O
in O
respiratory O
samples O
is O
significantly O
lower O
and O
viral O
shedding O
significantly O
shorter O
in O
ICU O
survivors O
of O
COVID O
- O
19 O
associated O
acute O
respiratory O
failure O
. O

We O
describe O
traditional O
antimicrobial O
stewardship O
program O
( O
ASP O
) O
activities O
with O
a O
discussion O
of O
how O
these O
activities O
can O
be O
refocused O
in O
the O
setting O
of O
the O
COVID O
- O
19 O
pandemic O
. O

A O
lot O
is O
yet O
unknown O
and O
patients O
can O
experience O
long O
- O
term O
consequences O
as O
we O
know O
from O
the O
literature O
on O
the O
postintensive O
care O
syndrome O
, O
but O
COVID O
- O
19 O
has O
unique O
features O
to O
be O
investigated O
and O
understood O
. O

We O
conducted O
this O
study O
to O
explore O
environmental O
virus O
contamination O
and O
the O
effect O
of O
terminal O
disinfection O
in O
the O
isolation O
ward O
of O
patients O
with O
COVID O
- O
19 O
. O

Conclusions O
: O
The O
case O
study O
provides O
micro O
- O
level O
empirical O
evidence O
, O
which O
supports O
that O
appropriate O
university O
coping O
strategies O
of O
COVID O
- O
19 O
can O
contribute O
to O
SDGs O
, O
even O
it O
is O
widely O
perceived O
that O
the O
pandemic O
has O
brought O
strong O
negative O
impact O
on O
higher O
education O
and O
sustainable O
development O
. O

Postoperative O
myocardial O
injury O
in O
a O
patient O
with O
left O
ureteric O
stone O
and O
asymptomatic O
COVID O
- O
19 O
disease O
. O

Are O
All O
Patients O
with O
Cancer O
at O
Heightened O
Risk O
for O
Severe O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
? O

The O
doctor O
- O
patient O
relationship O
in O
the O
context O
of O
the O
COVID O
- O
19 O
pandemic O
. O

It O
is O
highly O
desirable O
to O
identify O
potential O
antiviral O
agents O
against O
SARS O
- O
CoV O
- O
2 O
from O
existing O
drugs O
available O
for O
other O
diseases O
and O
thus O
repurpose O
them O
for O
treatment O
of O
COVID O
- O
19 O
. O

The O
knowledge O
gained O
over O
the O
last O
few O
decades O
merits O
future O
exploration O
of O
the O
potential O
role O
of O
fish O
and O
its O
components O
in O
other O
conditions O
characterized O
by O
deregulated O
activation O
of O
immune O
cells O
and O
a O
cytokine O
storm O
like O
viral O
sepsis O
or O
COVID O
- O
19 O
. O

Nationwide O
public O
health O
restrictions O
due O
to O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
have O
disrupted O
people O
' O
s O
routine O
physical O
activities O
, O
yet O
little O
objective O
information O
is O
available O
on O
the O
extent O
to O
which O
physical O
activity O
has O
changed O
among O
patients O
with O
pre O
- O
existing O
cardiac O
diseases O
. O

Case O
reports O
of O
intracerebral O
hemorrhages O
in O
ventilated O
COVID O
- O
19 O
patients O
warrant O
precaution O
. O

NEWS2 O
is O
a O
valuable O
tool O
for O
appropriate O
clinical O
management O
of O
COVID O
- O
19 O
patients O
. O

The O
effects O
of O
temperature O
on O
the O
dynamics O
of O
the O
COVID O
- O
19 O
epidemic O
in O
China O
are O
unknown O
. O

We O
investigated O
whether O
countries O
with O
higher O
coverage O
of O
childhood O
live O
vaccines O
[ O
BCG O
or O
measles O
- O
containing O
- O
vaccine O
( O
MCV O
) O
] O
have O
reduced O
risk O
of O
COVID O
- O
19 O
related O
mortality O
, O
accounting O
for O
known O
systems O
differences O
between O
countries O
. O

Does O
social O
trust O
slow O
down O
or O
speed O
up O
the O
transmission O
of O
COVID O
- O
19 O
? O

Effect O
of O
COVID O
- O
19 O
Pandemic O
on O
Cannabis O
Use O
in O
Cancer O
Patients O
. O

Yet O
, O
the O
need O
to O
simultaneously O
care O
for O
children O
during O
the O
COVID O
- O
19 O
lockdown O
may O
also O
revive O
traditional O
gender O
roles O
, O
potentially O
counteracting O
such O
gains O
. O

KEY O
POINTS O
Acute O
inpatient O
psychiatric O
treatment O
of O
patients O
who O
have O
comorbid O
COVID O
- O
19 O
is O
a O
complex O
situation O
requiring O
multidisciplinary O
action O
. O

With O
the O
absence O
of O
specific O
treatment O
/ O
vaccines O
for O
the O
coronavirus O
COVID O
- O
19 O
, O
the O
most O
appropriate O
approach O
to O
control O
this O
infection O
is O
to O
quarantine O
people O
and O
isolate O
symptomatic O
people O
and O
suspected O
or O
infected O
cases O
. O

Moreover O
, O
lots O
of O
research O
is O
going O
on O
to O
find O
out O
effective O
vaccines O
or O
medicine O
, O
but O
still O
, O
no O
potent O
vaccine O
or O
drug O
is O
discovered O
to O
cure O
COVID O
- O
19 O
. O

We O
remain O
largely O
without O
effective O
prophylactic O
/ O
therapeutic O
interventions O
for O
COVID O
- O
19 O
. O

Hemostatic O
Abnormalities O
in O
COVID O
- O
19 O
: O
An O
Update O
. O

The O
current O
outbreak O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
an O
unprecedented O
example O
of O
how O
fast O
an O
infectious O
disease O
can O
spread O
around O
the O
globe O
( O
especially O
in O
urban O
areas O
) O
and O
the O
enormous O
impact O
it O
causes O
on O
public O
health O
and O
socio O
- O
economic O
activities O
. O

When O
COVID O
- O
19 O
ravaged O
the O
Wuhan O
district O
in O
China O
in O
early O
January O
2020 O
, O
without O
a O
deep O
understanding O
about O
the O
nature O
of O
COVID O
- O
19 O
, O
patients O
admitted O
to O
the O
TCM O
Hospital O
in O
Wuhan O
were O
immediately O
treated O
with O
TCM O
and O
reported O
later O
with O
> O
90 O
% O
efficacy O
. O

All O
current O
vaccines O
for O
COVID O
- O
19 O
utilize O
ancestral O
SARS O
- O
CoV O
- O
2 O
spike O
with O
the O
goal O
of O
generating O
protective O
neutralizing O
antibodies O
. O

Out O
of O
244 O
survey O
responses O
, O
a O
majority O
of O
GPs O
( O
76 O
. O
6 O
% O
) O
indicated O
having O
good O
knowledge O
of O
COVID O
- O
19 O
, O
relying O
mostly O
on O
state O
/ O
territory O
department O
of O
health O
( O
84 O
. O
4 O
% O
) O
and O
the O
RACGP O
( O
76 O
. O
2 O
% O
) O
websites O
to O
source O
up O
- O
to O
- O
date O
information O
. O

Perioperative O
management O
of O
elderly O
patients O
presenting O
with O
hip O
fracture O
during O
COVID O
- O
19 O
pandemic O
surge O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
is O
an O
evolving O
global O
pandemic O
that O
is O
predicted O
to O
strain O
healthcare O
resources O
at O
multiple O
locations O
throughout O
North O
America O
and O
the O
World O
. O

This O
study O
shows O
an O
increased O
incidence O
of O
GBS O
during O
the O
COVID O
- O
19 O
outbreak O
in O
northern O
Italy O
, O
supporting O
a O
pathogenic O
link O
. O

The O
impact O
of O
how O
innate O
immunity O
, O
humoral O
immunity O
, O
and O
cell O
- O
mediated O
immunity O
play O
a O
role O
in O
a O
harmful O
versus O
helpful O
response O
is O
discussed O
, O
establishing O
principles O
to O
guide O
the O
development O
and O
evaluation O
of O
a O
safe O
but O
effective O
COVID O
- O
19 O
vaccine O
. O

Social O
distancing O
is O
the O
core O
policy O
response O
to O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Convalescent O
plasma O
therapy O
in O
patients O
with O
COVID O
- O
19 O
. O

Barriers O
and O
facilitators O
to O
populational O
adherence O
to O
prevention O
and O
control O
measures O
of O
COVID O
- O
19 O
and O
other O
respiratory O
infectious O
diseases O
: O
a O
rapid O
qualitative O
evidence O
synthesis O
protocol O
. O

COVID O
- O
19 O
and O
neurodegeneration O
: O
what O
can O
we O
learn O
from O
the O
past O
? O

This O
is O
particularly O
important O
in O
health O
care O
settings O
for O
reducing O
exposure O
to O
respiratory O
viruses O
, O
like O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
virus O
that O
causes O
COVID O
- O
19 O
. O

Immunosensors O
that O
show O
increased O
specificity O
and O
sensitivity O
are O
considerably O
fast O
and O
do O
not O
imply O
costly O
reagents O
or O
instruments O
, O
reducing O
the O
cost O
for O
COVID O
- O
19 O
detection O
. O

The O
current O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
testing O
healthcare O
systems O
like O
never O
before O
and O
all O
efforts O
are O
now O
being O
put O
into O
controlling O
the O
COVID O
- O
19 O
crisis O
. O

Surgical O
management O
of O
bone O
and O
soft O
tissue O
sarcomas O
and O
skeletal O
metastases O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
infection O
has O
been O
associated O
with O
various O
complications O
such O
as O
acute O
respiratory O
distress O
syndrome O
, O
acute O
kidney O
failure O
, O
myocardial O
infection O
, O
and O
thromboembolism O
. O

There O
were O
significant O
correlations O
between O
poor O
sleep O
quality O
and O
the O
following O
parameters O
in O
the O
univariate O
logistic O
regression O
analysis O
: O
anxiety O
features O
( O
P O
value O
< O
0 O
. O
001 O
) O
, O
depressive O
features O
( O
P O
value O
< O
0 O
. O
001 O
) O
, O
and O
past O
history O
of O
COVID O
- O
19 O
( O
P O
value O
0 O
. O
003 O
) O
. O

Effect O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
on O
maternal O
, O
perinatal O
and O
neonatal O
outcome O
: O
systematic O
review O
. O

The O
impact O
of O
COVID O
- O
19 O
in O
2020 O
on O
the O
practice O
of O
arthroplasty O
resulted O
in O
nearly O
universal O
loss O
of O
volume O
and O
significant O
financial O
stress O
. O

The O
collateral O
damage O
of O
delaying O
diagnosis O
of O
breast O
cancer O
due O
to O
COVID O
- O
19 O
should O
be O
avoided O
when O
possible O
. O

Not O
survived O
COVID O
- O
19 O
patients O
showed O
a O
statistically O
significant O
increased O
age O
( O
77 O
± O
8 O
. O
31 O
vs O
65 O
. O
57 O
± O
8 O
. O
31 O
; O
P O
= O
0 O
. O
001 O
) O
, O
hypertension O
( O
77 O
. O
1 O
% O
vs O
53 O
. O
5 O
% O
; O
P O
= O
0 O
. O
018 O
) O
and O
coronary O
artery O
disease O
prevalence O
( O
28 O
. O
6 O
% O
vs O
10 O
. O
2 O
% O
; O
P O
= O
0 O
. O
009 O
) O
. O

Proper O
management O
of O
CVD O
patients O
with O
COVID O
- O
19 O
and O
monitoring O
COVID O
- O
19 O
patients O
for O
acute O
cardiac O
conditions O
is O
highly O
recommended O
to O
prevent O
mortality O
and O
critical O
situations O
. O

Knowledge O
, O
practice O
and O
associated O
factors O
towards O
the O
prevention O
of O
COVID O
- O
19 O
among O
high O
- O
risk O
groups O
: O
A O
cross O
- O
sectional O
study O
in O
Addis O
Ababa O
, O
Ethiopia O
. O

The O
coronavirus O
disease O
- O
19 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
exposed O
an O
underlying O
pandemic O
of O
neglect O
affecting O
women O
' O
s O
reproductive O
rights O
, O
particularly O
in O
the O
provision O
of O
abortion O
services O
and O
maternity O
care O
. O

We O
explore O
how O
underlying O
disease O
etiologies O
and O
common O
therapies O
used O
to O
treat O
these O
conditions O
exacerbate O
COVID O
- O
19 O
progression O
. O

HCP O
with O
direct O
contact O
and O
responsibility O
to O
treat O
COVID O
- O
19 O
patients O
exhibit O
a O
higher O
risk O
to O
experience O
depressive O
symptoms O
and O
burnout O
. O

Clinical O
course O
of O
severe O
patients O
with O
COVID O
- O
19 O
treated O
with O
tocilizumab O
: O
report O
from O
a O
cohort O
study O
in O
Spain O
. O

The O
pattern O
of O
outbreak O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
China O
during O
the O
flu O
season O
is O
further O
proof O
that O
meteorological O
conditions O
may O
potentially O
influence O
the O
susceptibility O
of O
human O
populations O
to O
coronaviruses O
, O
a O
situation O
that O
may O
become O
increasingly O
evident O
as O
the O
current O
global O
pandemic O
of O
COVID O
- O
19 O
unfolds O
. O

Fever O
is O
a O
widely O
recognised O
presenting O
symptom O
of O
COVID O
- O
19 O
. O

Nowadays O
, O
the O
number O
of O
patients O
with O
COVID O
- O
19 O
pneumonia O
worldwide O
is O
still O
increasing O
. O

Thirty O
patients O
with O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
confirmed O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
analysis O
underwent O
chest O
CT O
examinations O
. O

Influencing O
factors O
of O
COVID O
- O
19 O
spreading O
: O
a O
case O
study O
of O
Thailand O
. O

Conducting O
research O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Efficacy O
, O
safety O
and O
cost O
- O
effectiveness O
of O
hydroxychloroquine O
in O
children O
with O
COVID O
- O
19 O
: O
A O
call O
for O
evidence O
. O

Our O
study O
was O
conducted O
on O
1950 O
PCR O
test O
positive O
patients O
who O
were O
hospitalised O
for O
COVID O
- O
19 O
disease O
between O
March O
16 O
and O
July O
15 O
. O

Up O
to O
now O
, O
the O
COVID O
- O
19 O
pandemic O
has O
been O
effectively O
controlled O
in O
China O
. O

Available O
electronic O
databases O
have O
been O
comprehensively O
searched O
for O
articles O
published O
with O
full O
text O
available O
and O
with O
the O
key O
words O
" O
Trace O
elements O
" O
, O
" O
COVID O
- O
19 O
" O
, O
" O
Viral O
Infections O
" O
and O
" O
Immune O
Response O
" O
( O
i O
. O
e O
. O
separately O
Zn O
, O
Se O
, O
Fe O
, O
Cu O
, O
Mn O
, O
Mo O
, O
Cr O
, O
Li O
, O
Ni O
, O
Co O
) O
appearing O
in O
the O
title O
and O
abstract O
. O

The O
Greek O
experience O
reveals O
that O
harmonised O
collaboration O
among O
primary O
care O
, O
secondary O
facilities O
, O
designated O
hospitals O
and O
official O
authorities O
results O
in O
prompt O
and O
accurate O
management O
of O
the O
pandemic O
- O
related O
crisis O
of O
COVID O
- O
19 O
https O
: O
/ O
/ O
bit O
. O
ly O
/ O
3eSHVhG O
. O

This O
study O
analyses O
quantitatively O
the O
lethal O
effects O
of O
the O
pandemic O
through O
the O
study O
of O
infections O
, O
deaths O
, O
and O
recoveries O
on O
the O
13 O
most O
- O
affected O
COVID O
- O
19 O
countries O
as O
of O
1 O
s O
t O
June O
. O

Further O
evidence O
needs O
to O
be O
gathered O
on O
whether O
modulation O
of O
the O
renin O
angiotensin O
system O
would O
be O
advantageous O
due O
to O
upregulation O
of O
Mas O
activation O
or O
harmful O
due O
to O
the O
concomitant O
ACE O
- O
2 O
receptor O
upregulation O
in O
the O
acute O
management O
of O
COVID O
- O
19 O
. O

Fifteen O
( O
71 O
. O
43 O
% O
) O
COVID O
- O
19 O
patients O
had O
abnormal O
magnetic O
resonance O
findings O
, O
including O
raised O
myocardial O
native O
T1 O
( O
5 O
, O
23 O
. O
81 O
% O
) O
and O
T2 O
values O
( O
10 O
, O
47 O
. O
62 O
% O
) O
, O
decreased O
LVEF O
( O
1 O
, O
4 O
. O
76 O
% O
) O
, O
and O
RVEF O
( O
2 O
, O
9 O
. O
52 O
% O
) O
. O

Mental O
Health O
Care O
for O
Military O
Personnel O
in O
the O
COVID O
- O
19 O
Epidemic O
. O

Virtual O
advocacy O
days O
can O
be O
replicated O
nationwide O
to O
help O
trainees O
learn O
about O
advocacy O
efforts O
and O
find O
their O
legislative O
voices O
during O
COVID O
- O
19 O
and O
beyond O
. O

Up O
- O
regulation O
of O
NRP O
- O
1 O
protein O
in O
diabetic O
kidney O
cells O
hint O
at O
its O
importance O
in O
a O
population O
at O
risk O
of O
severe O
COVID O
- O
19 O
. O

Therefore O
, O
further O
descriptions O
of O
the O
pathological O
processes O
in O
those O
animals O
that O
show O
symptoms O
similar O
to O
those O
described O
in O
humans O
affected O
by O
COVID O
- O
19 O
would O
be O
highly O
valuable O
. O

Continuous O
monitoring O
of O
COVID O
- O
19 O
severity O
biomarkers O
and O
radiological O
imaging O
is O
crucial O
to O
assess O
disease O
progression O
, O
uncontrolled O
inflammation O
, O
and O
to O
avert O
irreversible O
multiorgan O
failure O
. O

Our O
hemodialysis O
unit O
experienced O
a O
COVID O
- O
19 O
outbreak O
despite O
following O
symptom O
- O
based O
screening O
guidelines O
. O

Accelerating O
the O
De O
- O
Personalization O
of O
Medicine O
: O
The O
Ethical O
Toxicities O
of O
COVID O
- O
19 O
. O

We O
conducted O
an O
initial O
search O
in O
PubMed O
using O
the O
Medical O
Subject O
Headings O
( O
MeSH O
) O
terms O
" O
meningitis O
, O
" O
and O
" O
encephalitis O
, O
" O
, O
and O
" O
COVID O
- O
19 O
" O
to O
affirm O
the O
need O
for O
a O
review O
on O
the O
topic O
of O
the O
relationship O
between O
meningitis O
/ O
encephalitis O
and O
SARS O
- O
CoV O
- O
2 O
infection O
. O

Investigation O
of O
COVID O
- O
19 O
comorbidities O
reveals O
genes O
and O
pathways O
coincident O
with O
the O
SARS O
- O
CoV O
- O
2 O
viral O
disease O
. O

We O
tested O
the O
null O
hypothesis O
that O
patients O
being O
screened O
for O
COVID O
- O
19 O
in O
the O
ED O
with O
normal O
vital O
signs O
and O
without O
hypoxia O
would O
have O
a O
point O
- O
of O
- O
care O
lung O
ultrasound O
( O
LUS O
) O
consistent O
with O
COVID O
- O
19 O
less O
than O
2 O
% O
of O
the O
time O
. O

Palliative O
Care O
for O
Cancer O
Patients O
During O
the O
COVID O
- O
19 O
Pandemic O
, O
With O
Special O
Focus O
on O
Lung O
Cancer O
. O

Both O
direct O
and O
indirect O
mechanisms O
through O
COVID O
- O
19 O
have O
been O
described O
to O
explain O
this O
relationship O
. O

COVID O
- O
19 O
patients O
with O
CPAP O
therapy O
were O
older O
and O
had O
higher O
levels O
of O
white O
blood O
cells O
( O
WBC O
) O
, O
procalcitonin O
( O
PCT O
) O
, O
C O
- O
reactive O
protein O
( O
CRP O
) O
, O
alanine O
aminotransferase O
( O
ALT O
) O
, O
D O
- O
dimer O
, O
but O
had O
lymphopenia O
. O

This O
consensus O
agreement O
is O
aimed O
at O
facilitating O
transparency O
and O
rigor O
in O
methodological O
approaches O
, O
and O
consistency O
in O
defining O
and O
reporting O
cases O
, O
exposures O
, O
confounders O
, O
stratification O
variables O
, O
and O
outcomes O
in O
relation O
to O
the O
pharmacoepidemiology O
of O
COVID O
- O
19 O
. O

The O
simulation O
decision O
support O
model O
we O
developed O
is O
capable O
of O
providing O
dynamic O
and O
real O
- O
time O
support O
for O
RFDS O
decision O
makers O
in O
understanding O
the O
system O
' O
s O
performance O
under O
uncertain O
COVID O
- O
19 O
demand O
. O

While O
SARS O
- O
CoV O
- O
2 O
, O
the O
causal O
pathogen O
of O
COVID O
- O
19 O
, O
has O
been O
detected O
in O
some O
patient O
brains O
, O
its O
ability O
to O
infect O
brain O
cells O
and O
impact O
their O
function O
are O
not O
well O
understood O
, O
and O
experimental O
models O
using O
human O
brain O
cells O
are O
urgently O
needed O
. O

Blood O
was O
sampled O
at O
admission O
in O
243 O
adult O
COVID O
- O
19 O
patients O
for O
analysis O
of O
coagulation O
biomarkers O
including O
FVIII O
and O
VWF O
on O
platelet O
- O
poor O
plasma O
. O

To O
the O
best O
of O
our O
knowledge O
, O
there O
is O
no O
published O
study O
on O
the O
use O
of O
interferon O
β O
- O
1a O
( O
IFN O
β O
- O
1a O
) O
in O
the O
treatment O
of O
severe O
COVID O
- O
19 O
. O

Regarding O
fluid O
therapy O
for O
the O
treatment O
of O
COVID O
- O
19 O
patients O
with O
shock O
in O
low O
- O
middle O
- O
income O
countries O
, O
we O
favor O
balanced O
crystalloids O
and O
recommend O
using O
a O
conservative O
fluid O
strategy O
for O
resuscitation O
. O

Incomplete O
KD O
may O
co O
- O
exist O
with O
COVID O
- O
19 O
infection O
in O
infant O
. O

However O
, O
recent O
data O
released O
by O
the O
National O
Aeronautics O
and O
Space O
Administration O
( O
NASA O
) O
, O
European O
Space O
Agency O
( O
ESA O
) O
, O
Copernicus O
Sentinel O
- O
5P O
Tropomi O
Instrument O
and O
Center O
for O
Research O
on O
Energy O
and O
Clean O
Air O
( O
CREA O
) O
indicate O
that O
the O
pollution O
in O
some O
of O
the O
epicenters O
of O
COVID O
- O
19 O
, O
such O
as O
Wuhan O
, O
Italy O
, O
Spain O
, O
USA O
, O
and O
Brazil O
, O
reduced O
by O
up O
to O
30 O
% O
. O

The O
present O
study O
aimed O
to O
investigate O
whether O
COVID O
- O
19 O
has O
any O
relationship O
with O
the O
occurrence O
of O
spontaneous O
ICH O
in O
young O
or O
not O
. O

A O
systematic O
review O
was O
conducted O
to O
assess O
the O
incidence O
of O
thrombotic O
complications O
in O
ICU O
- O
treated O
patients O
with O
COVID O
- O
19 O
. O

A O
culturally O
- O
competent O
approach O
to O
emergency O
management O
: O
What O
lessons O
can O
we O
learn O
from O
the O
COVID O
- O
19 O
? O

In O
the O
present O
days O
, O
the O
development O
of O
mathematical O
models O
to O
simulate O
the O
dynamic O
behavior O
of O
the O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
is O
considered O
an O
important O
theme O
due O
to O
the O
quantity O
of O
infected O
people O
worldwide O
. O

Comparison O
of O
Estimated O
Rates O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
Border O
Counties O
in O
Iowa O
Without O
a O
Stay O
- O
at O
- O
Home O
Order O
and O
Border O
Counties O
in O
Illinois O
With O
a O
Stay O
- O
at O
- O
Home O
Order O
. O

Previous O
studies O
demonstrated O
a O
higher O
COVID O
- O
19 O
fatality O
rate O
in O
men O
. O

The O
coronavirus O
pandemic O
( O
COVID O
- O
19 O
) O
has O
disrupted O
the O
routine O
neurosurgical O
education O
and O
practice O
worldwide O
and O
so O
more O
in O
developing O
countries O
. O

We O
present O
a O
phenomenological O
procedure O
of O
dealing O
with O
the O
COVID O
- O
19 O
( O
coronavirus O
disease O
2019 O
) O
data O
provided O
by O
government O
health O
agencies O
of O
11 O
different O
countries O
. O

The O
United O
States O
of O
America O
( O
USA O
) O
was O
the O
most O
productive O
country O
, O
352 O
( O
38 O
. O
4 O
% O
) O
. O
Conclusions O
: O
This O
is O
the O
first O
bibliometric O
study O
that O
provides O
detailed O
information O
about O
published O
literature O
on O
the O
COVID O
- O
19 O
vaccine O
. O

An O
outbreak O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
that O
began O
in O
Wuhan O
, O
China O
, O
has O
spread O
rapidly O
to O
many O
countries O
. O

During O
the O
first O
wave O
of O
the O
COVID O
- O
19 O
pandemic O
of O
Spring O
2020 O
, O
Denmark O
was O
one O
of O
the O
first O
countries O
to O
introduce O
lockdown O
measures O
, O
including O
closing O
of O
all O
daycare O
centers O
. O

Public O
health O
and O
policy O
efforts O
that O
improve O
care O
for O
foreign O
- O
born O
noncitizens O
, O
address O
crowded O
housing O
, O
and O
protect O
food O
service O
workers O
may O
help O
mitigate O
the O
spread O
of O
COVID O
- O
19 O
among O
minority O
communities O
. O

Chest O
CT O
for O
Screening O
of O
COVID O
- O
19 O
: O
Is O
it O
Feasible O
in O
Developing O
Countries O
? O

Where O
available O
, O
data O
from O
clinical O
trials O
involving O
patients O
with O
COVID O
- O
19 O
are O
reported O
. O

The O
psychological O
experience O
of O
nurses O
caring O
for O
COVID O
- O
19 O
patients O
can O
be O
summarized O
into O
4 O
themes O
. O

Safety O
and O
Efficacy O
of O
Hydroxychloroquine O
in O
COVID O
- O
19 O
: O
A O
Systematic O
Review O
and O
Meta O
- O
Analysis O
. O

Impact O
of O
COVID O
- O
19 O
on O
oral O
emergency O
services O
. O

This O
study O
provides O
examples O
of O
statistical O
tools O
and O
procedures O
to O
more O
thoroughly O
examine O
trends O
in O
COVID O
- O
19 O
case O
rate O
data O
. O

Here O
, O
we O
summarize O
the O
pathophysiologic O
contributions O
of O
different O
components O
of O
RAS O
in O
hypertension O
and O
their O
possible O
correlation O
with O
poor O
outcome O
observed O
in O
hypertensive O
patients O
with O
COVID O
- O
19 O
. O

Shaping O
the O
post O
- O
COVID O
- O
19 O
" O
New O
Normal O
" O
with O
Communication O
and O
Collaboration O
Platforms O
: O
state O
of O
the O
art O
communications O
for O
radiology O
, O
oncology O
, O
MDTs O
and O
beyond O
. O

A O
decrease O
in O
attendance O
at O
emergency O
departments O
among O
paediatric O
populations O
has O
been O
reported O
during O
the O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

We O
report O
an O
international O
case O
series O
of O
patients O
with O
confirmed O
COVID O
- O
19 O
infection O
who O
presented O
with O
suspected O
ST O
- O
segment O
elevation O
myocardial O
infarction O
. O

Neutralizing O
antibody O
titers O
were O
higher O
in O
COVID O
- O
19 O
individuals O
with O
BMI O
≥ O
30 O
( O
p O
= O
0 O
. O
0055 O
) O
. O

Several O
postinfectious O
presumably O
autoimmune O
complications O
of O
COVID O
- O
19 O
affecting O
the O
brain O
or O
peripheral O
large O
nerve O
fibers O
have O
been O
reported O
. O

A O
manual O
reduction O
of O
hernia O
under O
analgesia O
/ O
sedation O
( O
Taxis O
) O
in O
the O
acute O
inguinal O
hernia O
: O
a O
useful O
technique O
in O
COVID O
- O
19 O
times O
to O
reduce O
the O
need O
for O
emergency O
surgery O
- O
a O
literature O
review O
. O

To O
assess O
the O
awareness O
about O
COVID O
- O
19 O
and O
the O
problems O
being O
faced O
by O
young O
adults O
with O
T1DM O
amid O
nationwide O
lockdown O
in O
India O
. O

We O
found O
high O
rates O
of O
negative O
mental O
health O
outcomes O
in O
the O
Italian O
general O
population O
3 O
weeks O
into O
the O
COVID O
- O
19 O
lockdown O
measures O
and O
different O
COVID O
- O
19 O
related O
risk O
factors O
. O

Ambulatory O
, O
nonhospitalized O
patients O
who O
were O
quarantined O
in O
a O
designated O
hotel O
for O
COVID O
- O
19 O
patients O
and O
were O
recruited O
by O
an O
advertisement O
at O
the O
hotel O
. O

Positive O
result O
of O
Sars O
- O
Cov O
- O
2 O
in O
sputum O
from O
a O
cured O
patient O
with O
COVID O
- O
19 O
. O

Clinical O
course O
and O
outcomes O
of O
COVID O
- O
19 O
in O
rheumatic O
disease O
patients O
: O
a O
case O
cohort O
study O
with O
a O
diverse O
population O
. O

COVID O
RT O
- O
Assessing O
the O
Impact O
of O
COVID O
- O
19 O
on O
Radiotherapy O
in O
the O
UK O
. O

Moreover O
, O
several O
chest O
CT O
image O
features O
and O
laboratory O
indices O
are O
found O
to O
be O
highly O
related O
to O
COVID O
- O
19 O
severity O
, O
which O
could O
be O
valuable O
for O
the O
clinical O
diagnosis O
of O
COVID O
- O
19 O
. O

Some O
effective O
and O
targeted O
intervention O
measures O
can O
be O
implemented O
in O
order O
to O
avoid O
the O
occupational O
exposure O
of O
medical O
staff O
to O
COVID O
- O
19 O
. O

The O
acceptance O
rates O
for O
COVID O
- O
19 O
and O
influenza O
vaccines O
were O
29 O
. O
4 O
% O
and O
30 O
. O
9 O
% O
, O
respectively O
. O

Geographical O
distribution O
of O
COVID O
- O
19 O
in O
the O
World O
and O
Iran O
; O
Investigation O
of O
possible O
transmission O
roots O
. O

SARS O
- O
CoV O
- O
2 O
spike O
( O
S O
) O
mediates O
entry O
into O
cells O
and O
is O
critical O
for O
vaccine O
development O
against O
COVID O
- O
19 O
. O

Reliable O
circuits O
for O
staff O
as O
well O
as O
for O
patients O
are O
installed O
and O
treatment O
protocols O
are O
adapted O
to O
the O
current O
COVID O
- O
19 O
situation O
. O

The O
COVID O
- O
19 O
health O
crisis O
is O
exacerbating O
another O
pre O
- O
existing O
public O
health O
problem O
by O
increasing O
the O
severity O
and O
frequency O
of O
domestic O
violence O
, O
thus O
demonstrating O
the O
need O
to O
adopt O
significant O
and O
long O
- O
term O
measures O
. O

This O
represents O
an O
under O
- O
reported O
sequelae O
of O
COVID O
- O
19 O
. O

This O
study O
investigated O
whether O
there O
is O
an O
association O
between O
their O
prescription O
and O
the O
incidence O
of O
COVID O
- O
19 O
and O
all O
- O
cause O
mortality O
. O

In O
addition O
, O
the O
majority O
of O
participants O
felt O
that O
perception O
of O
or O
concern O
about O
future O
stigma O
related O
to O
a O
COVID O
- O
19 O
diagnosis O
or O
association O
of O
COVID O
- O
19 O
with O
the O
Jewish O
community O
was O
high O
and O
also O
significantly O
predicted O
distress O
and O
anxiety O
. O

This O
immunoregulation O
involves O
monocytes O
and O
macrophages O
, O
as O
well O
as O
Jak2 O
/ O
STAT3 O
, O
NF O
- O
kB O
, O
and O
inflammasome O
pathways O
, O
reducing O
the O
risk O
of O
cytokine O
storm O
syndrome O
, O
a O
major O
mortality O
factor O
in O
advanced O
COVID O
- O
19 O
disease O
. O

Emerging O
results O
indicate O
that O
an O
uncontrolled O
host O
immune O
response O
, O
leading O
to O
a O
life O
- O
threatening O
condition O
called O
cytokine O
release O
syndrome O
( O
also O
termed O
" O
cytokine O
storm O
" O
) O
, O
is O
the O
major O
driver O
of O
pathology O
in O
severe O
COVID O
- O
19 O
. O

Comparing O
the O
preventive O
behavior O
of O
medical O
students O
and O
physicians O
in O
the O
era O
of O
COVID O
- O
19 O
: O
Novel O
medical O
problems O
demand O
novel O
curricular O
interventions O
. O

Numerous O
societal O
changes O
in O
response O
to O
the O
COVID O
- O
19 O
pandemic O
, O
such O
as O
school O
closings O
and O
event O
cancellations O
, O
have O
caused O
anxiety O
and O
fear O
for O
children O
and O
young O
people O
. O

Given O
the O
paucity O
of O
strongly O
evidence O
- O
based O
regimens O
, O
the O
available O
data O
suggest O
that O
Chinese O
medicine O
could O
be O
considered O
as O
an O
adjunctive O
therapeutic O
option O
in O
the O
management O
of O
COVID O
- O
19 O
. O

Our O
estimates O
suggest O
that O
, O
if O
the O
reporting O
rate O
is O
less O
than O
50 O
% O
, O
the O
adjusted O
CFR O
of O
COVID O
- O
19 O
in O
Canada O
is O
likely O
to O
be O
less O
than O
2 O
% O
. O

Therefore O
, O
the O
present O
study O
validated O
three O
instruments O
assessing O
fear O
, O
beliefs O
, O
and O
preventive O
behaviors O
related O
to O
COVID O
- O
19 O
among O
individuals O
with O
mental O
illness O
. O

The O
COVID O
- O
19 O
( O
coronavirus O
disease O
2019 O
) O
pandemic O
has O
underscored O
the O
critical O
need O
for O
all O
countries O
to O
strengthen O
their O
health O
data O
and O
information O
systems O
and O
ensure O
the O
routes O
the O
data O
travel O
, O
from O
submission O
to O
use O
, O
are O
unobstructed O
. O

COVID O
- O
19 O
and O
Chloroquine O
/ O
Hydroxychloroquine O
: O
Is O
There O
Ophthalmological O
Concern O
? O

Analysis O
of O
Genomic O
Characteristics O
and O
Transmission O
Routes O
of O
Patients O
With O
Confirmed O
SARS O
- O
CoV O
- O
2 O
in O
Southern O
California O
During O
the O
Early O
Stage O
of O
the O
US O
COVID O
- O
19 O
Pandemic O
. O

Multivariable O
logistic O
regression O
analysis O
revealed O
that O
CVD O
( O
OR O
: O
2 O
. O
735 O
( O
95 O
% O
CI O
1 O
. O
495 O
to O
5 O
. O
003 O
) O
, O
p O
= O
0 O
. O
001 O
) O
was O
associated O
with O
critical O
COVID O
- O
19 O
condition O
, O
while O
patients O
with O
coronary O
heart O
disease O
were O
less O
likely O
to O
reach O
recovery O
standards O
( O
OR O
: O
0 O
. O
331 O
( O
95 O
% O
CI O
0 O
. O
125 O
to O
0 O
. O
880 O
) O
, O
p O
= O
0 O
. O
027 O
) O
. O

Impact O
of O
Human O
Disasters O
and O
COVID O
- O
19 O
Pandemic O
on O
Mental O
Health O
: O
Potential O
of O
Digital O
Psychiatry O
. O

The O
SARS O
- O
CoV O
- O
2 O
virus O
is O
a O
newly O
emergent O
pathogen O
first O
identified O
in O
Wuhan O
, O
China O
, O
and O
responsible O
for O
the O
COVID O
- O
19 O
global O
pandemic O
. O

The O
survey O
requested O
demographic O
and O
socioeconomic O
information O
, O
as O
well O
as O
information O
related O
to O
medical O
online O
learning O
and O
electronic O
devices O
; O
medical O
education O
status O
during O
the O
COVID O
- O
19 O
pandemic O
; O
mental O
health O
assessments O
; O
and O
e O
- O
learning O
knowledge O
, O
attitudes O
, O
and O
practices O
. O

Nonetheless O
, O
exact O
association O
and O
contribution O
of O
every O
cytokine O
towards O
COVID O
- O
19 O
pathology O
remains O
poorly O
understood O
. O

We O
present O
a O
case O
of O
COVID O
- O
19 O
pneumonia O
associated O
with O
spontaneous O
pneumothorax O
, O
pneumomediastinum O
and O
subcutaneous O
emphysema O
in O
an O
immunocompetent O
patient O
with O
no O
past O
history O
of O
smoking O
or O
chronic O
obstructive O
pulmonary O
disease O
( O
COPD O
) O
. O

To O
understand O
the O
impact O
of O
the O
shift O
to O
virtual O
medicine O
induced O
by O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
had O
on O
the O
workflow O
of O
medical O
scribes O
. O

Here O
, O
we O
analyze O
the O
impact O
of O
COVID O
- O
19 O
in O
placental O
endothelium O
, O
studying O
by O
immunofluorescence O
the O
expression O
of O
von O
Willebrand O
factor O
( O
vWf O
) O
, O
claudin O
- O
5 O
, O
and O
vascular O
endothelial O
( O
VE O
) O
cadherin O
in O
the O
decidua O
and O
chorionic O
villi O
of O
placentas O
from O
women O
with O
mild O
and O
severe O
COVID O
- O
19 O
in O
comparison O
to O
healthy O
controls O
. O

Reduction O
of O
Physical O
Activity O
Levels O
During O
the O
COVID O
- O
19 O
Pandemic O
Might O
Negatively O
Disturb O
Sleep O
Pattern O
. O

COVID O
- O
19 O
mortality O
rate O
was O
significantly O
higher O
in O
CKD O
patients O
( O
23 O
. O
1 O
% O
vs O
10 O
. O
2 O
% O
) O
with O
a O
1 O
. O
51 O
greater O
odds O
of O
dying O
( O
95 O
% O
CI O
: O
1 O
. O
19 O
- O
1 O
. O
90 O
) O
. O

The O
decrease O
in O
CRP O
and O
D O
- O
dimer O
suggests O
a O
possible O
protective O
effect O
related O
to O
ACEi O
/ O
ARB O
use O
in O
COVID O
- O
19 O
, O
however O
, O
more O
studies O
with O
larger O
sample O
sizes O
are O
needed O
to O
establish O
this O
effect O
. O

The O
elevated O
inflammatory O
cytokines O
suggest O
that O
a O
" O
cytokine O
storm O
" O
, O
also O
known O
as O
cytokine O
release O
syndrome O
( O
CRS O
) O
, O
may O
play O
a O
major O
role O
in O
the O
pathology O
of O
COVID O
- O
19 O
. O

We O
studied O
admission O
and O
dynamic O
demographic O
, O
hematological O
and O
biochemical O
co O
- O
variates O
in O
1449 O
hospitalized O
subjects O
with O
coronavirus O
infectious O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
in O
five O
hospitals O
in O
Wuhan O
, O
Hubei O
province O
, O
China O
. O

Evaluating O
chest O
CT O
, O
clinical O
symptoms O
, O
and O
laboratory O
results O
could O
facilitate O
the O
early O
diagnosis O
of O
COVID O
- O
19 O
, O
and O
judge O
disease O
progression O
. O

We O
here O
compared O
the O
sensitivity O
and O
specificity O
of O
seven O
commercial O
( O
SNIBE O
, O
Epitope O
, O
Euroimmun O
, O
Roche O
, O
Abbott O
, O
DiaSorin O
, O
Biosensor O
) O
and O
two O
in O
- O
house O
LIPS O
assays O
( O
LIPS O
N O
and O
LIPS O
S O
- O
RBD O
) O
IgG O
/ O
total O
Ab O
tests O
in O
serum O
samples O
from O
97 O
COVID O
- O
19 O
patients O
and O
100 O
controls O
, O
and O
correlated O
the O
results O
with O
the O
patients O
' O
clinical O
data O
and O
the O
time O
- O
point O
the O
test O
was O
performed O
. O

[ O
Application O
of O
tracheotomy O
in O
the O
treatment O
of O
severe O
cases O
of O
COVID O
- O
19 O
] O
. O

Primary O
care O
' O
s O
response O
to O
the O
novel O
coronavirus O
- O
19 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
arguably O
the O
most O
impactful O
natural O
experiment O
in O
our O
lifetime O
. O

Several O
trials O
, O
evaluating O
the O
safety O
and O
effectiveness O
of O
immunosuppressants O
commonly O
used O
in O
rheumatic O
diseases O
, O
are O
ongoing O
in O
patients O
with O
COVID O
- O
19 O
and O
CRS O
, O
some O
of O
which O
are O
achieving O
promising O
results O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
whether O
adverse O
RV O
remodeling O
( O
dysfunction O
/ O
dilation O
) O
predicts O
COVID O
- O
19 O
prognosis O
independent O
of O
clinical O
and O
biomarker O
risk O
stratification O
. O

Although O
Singapore O
was O
one O
of O
the O
first O
countries O
outside O
of O
China O
to O
be O
affected O
by O
COVID O
- O
19 O
, O
for O
the O
first O
2 O
. O
5 O
months O
since O
its O
first O
reported O
case O
on O
January O
23 O
, O
2020 O
, O
it O
remained O
one O
of O
the O
few O
nations O
with O
successful O
containment O
of O
spread O
of O
the O
pandemic O
with O
little O
mortality O
and O
zero O
intra O
- O
hospital O
transmissions O
, O
without O
instituting O
a O
major O
lockdown O
of O
the O
country O
. O

Objective O
: O
To O
understand O
the O
characteristics O
of O
clusters O
of O
COVID O
- O
19 O
cases O
in O
Tianjin O
, O
and O
provide O
epidemiological O
evidence O
for O
the O
prevention O
and O
control O
of O
COVID O
- O
19 O
. O

We O
propose O
anamorphic O
depth O
embedding O
- O
based O
lightweight O
CNN O
, O
called O
Anam O
- O
Net O
, O
to O
segment O
anomalies O
in O
COVID O
- O
19 O
chest O
CT O
images O
. O

We O
summarized O
the O
clinical O
features O
of O
COVID O
- O
19 O
reported O
in O
currently O
available O
observational O
studies O
. O

Acceptability O
of O
a O
COVID O
- O
19 O
vaccine O
among O
adults O
in O
the O
United O
States O
: O
How O
many O
people O
would O
get O
vaccinated O
? O

A O
mathematical O
model O
for O
COVID O
- O
19 O
pandemic O
- O
SIIR O
model O
: O
Effects O
of O
asymptomatic O
individuals O
. O

Lessons O
from O
healthcare O
personnel O
screening O
and O
management O
during O
H1N1 O
pandemic O
in O
preparation O
for O
the O
impending O
COVID O
- O
19 O
pandemic O
in O
a O
tertiary O
care O
hospital O
in O
India O
. O

COVID O
- O
19 O
patients O
requiring O
mechanical O
ventilation O
can O
overwhelm O
existing O
bed O
capacity O
. O

Tubular O
proteinuria O
was O
associated O
with O
mortality O
in O
COVID O
- O
19 O
in O
our O
restropective O
, O
observational O
study O
. O

The O
COVID O
- O
19 O
pandemic O
is O
a O
large O
- O
scale O
public O
health O
emergency O
that O
likely O
precipitated O
sleep O
disturbances O
in O
the O
community O
. O

Excessive O
inflammatory O
response O
and O
lymphopenia O
might O
be O
critical O
factors O
associated O
with O
severity O
of O
and O
mortality O
from O
COVID O
- O
19 O
. O

ACC O
. O
20 O
: O
Impact O
of O
social O
media O
at O
the O
virtual O
scientific O
sessions O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Seronegative O
COVID O
- O
19 O
was O
diagnosed O
for O
some O
patients O
, O
in O
whom O
antibody O
titers O
were O
less O
than O
the O
cut O
- O
off O
value O
in O
each O
test O
throughout O
the O
time O
courses O
. O

We O
conduct O
a O
comparative O
analysis O
of O
responses O
between O
lower O
- O
income O
and O
upper O
- O
income O
groups O
and O
assess O
their O
relative O
exposure O
to O
COVID O
- O
19 O
risks O
. O

New O
Zealand O
' O
s O
stated O
goal O
of O
eradicating O
COVID O
- O
19 O
included O
the O
enforcement O
of O
a O
national O
lockdown O
. O

Finally O
, O
although O
vaccine O
- O
associated O
aberrant O
inflammatory O
responses O
, O
including O
eosinophil O
accumulation O
in O
the O
respiratory O
tract O
, O
were O
observed O
in O
preclinical O
immunization O
studies O
targeting O
the O
related O
SARS O
- O
CoV O
and O
MERS O
- O
CoV O
pathogens O
, O
no O
similar O
complications O
have O
been O
reported O
clinically O
in O
response O
to O
the O
widespread O
dissemination O
of O
either O
of O
the O
two O
encapsulated O
mRNA O
- O
based O
vaccines O
for O
COVID O
- O
19 O
. O

COVID O
- O
19 O
Susceptibility O
in O
Bronchial O
Asthma O
. O

In O
this O
reviewer O
' O
s O
article O
, O
we O
report O
the O
information O
currently O
available O
on O
SARS O
- O
CoV O
- O
2 O
infection O
to O
help O
young O
doctors O
and O
hematologists O
to O
successfully O
manage O
patients O
with O
COVID O
- O
19 O
. O

The O
analysis O
considers O
differences O
in O
responses O
to O
two O
scales O
: O
the O
Perceived O
Severity O
of O
HIV O
Infection O
and O
the O
Perceived O
Severity O
of O
COVID O
- O
19 O
Infection O
. O

The O
prioritisation O
of O
scarce O
resources O
has O
a O
particular O
urgency O
within O
the O
context O
of O
the O
COVID O
- O
19 O
pandemic O
crisis O
. O

In O
this O
article O
reviewing O
literature O
data O
related O
to O
the O
use O
of O
escin O
, O
an O
agent O
having O
potent O
anti O
- O
inflammatory O
and O
anti O
- O
viral O
effects O
in O
lung O
injury O
, O
we O
suggest O
that O
it O
could O
represent O
a O
therapeutic O
opportunity O
as O
add O
- O
on O
therapy O
in O
ALI O
related O
to O
COVID O
- O
19 O
infection O
. O

After O
accounting O
for O
pre O
- O
COVID O
- O
19 O
trends O
, O
we O
show O
that O
experiencing O
loneliness O
and O
decreased O
physical O
activity O
are O
risk O
factors O
for O
worsening O
mental O
health O
during O
the O
pandemic O
. O

Countries O
with O
higher O
International O
Health O
Regulations O
score O
were O
significantly O
more O
likely O
to O
have O
lower O
incidence O
( O
β O
coefficient O
- O
24 O
, O
95 O
% O
CI O
- O
35 O
to O
- O
13 O
) O
and O
mortality O
( O
β O
coefficient O
- O
1 O
. O
7 O
, O
95 O
% O
CI O
- O
2 O
. O
5 O
to O
- O
1 O
. O
0 O
) O
per O
100 O
, O
000 O
population O
within O
30 O
days O
since O
the O
first O
COVID O
- O
19 O
diagnosis O
. O

We O
summarize O
examples O
of O
worldwide O
mobile O
phone O
technology O
initiatives O
that O
have O
enhanced O
patient O
care O
and O
public O
health O
outcomes O
in O
previous O
epidemics O
and O
the O
current O
COVID O
- O
19 O
pandemic O
. O

If O
contraindications O
exist O
to O
chemical O
prophylaxis O
, O
we O
recommend O
mechanical O
prophylaxis O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
devices O
or O
graduated O
compression O
stockings O
( O
GCS O
) O
for O
hospitalized O
COVID O
- O
19 O
patients O
in O
LMICs O
. O

COVID O
- O
19 O
and O
healthcare O
systems O
: O
What O
should O
we O
do O
next O
? O

The O
current O
COVID O
- O
19 O
outbreak O
caused O
a O
pandemic O
with O
millions O
of O
infected O
patients O
and O
death O
cases O
worldwide O
. O

COVID O
- O
19 O
amidst O
Ebola O
' O
s O
retreat O
. O

Our O
findings O
show O
clear O
ethnic O
differences O
in O
risk O
of O
hospitalization O
for O
COVID O
- O
19 O
which O
do O
not O
appear O
to O
be O
fully O
explained O
by O
known O
explanatory O
factors O
. O

A O
nationwide O
survey O
of O
dentists O
was O
carried O
out O
in O
Brazil O
, O
a O
new O
pandemic O
epicenter O
, O
to O
analyze O
how O
dental O
care O
coverage O
has O
been O
affected O
in O
public O
versus O
private O
networks O
, O
changes O
in O
routine O
and O
burdens O
, O
and O
how O
local O
prevalence O
of O
COVID O
- O
19 O
affects O
dental O
professionals O
. O

Conclusions O
: O
Five O
( O
5 O
. O
4 O
% O
) O
and O
15 O
( O
16 O
. O
3 O
% O
) O
participants O
tested O
positive O
and O
borderline O
, O
respectively O
, O
for O
SARS O
- O
CoV O
- O
2 O
IgG O
antibody O
during O
the O
COVID O
- O
19 O
pre O
- O
pandemic O
period O
. O

Newly O
emerging O
pandemics O
like O
COVID O
- O
19 O
call O
for O
predictive O
models O
to O
implement O
precisely O
tuned O
responses O
to O
limit O
their O
deep O
impact O
on O
society O
. O

The O
questionnaire O
asked O
for O
information O
about O
the O
COVID O
- O
19 O
situation O
in O
the O
respondent O
' O
s O
country O
and O
in O
their O
workplace O
, O
and O
what O
changes O
they O
were O
facing O
in O
their O
practices O
in O
light O
of O
the O
outbreak O
. O

Impact O
of O
COVID O
- O
19 O
on O
ST O
- O
segment O
elevation O
myocardial O
infarction O
care O
. O
The O
Spanish O
experience O
. O

Assessment O
of O
Lupus O
Anticoagulant O
Positivity O
in O
Patients O
With O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

To O
explore O
the O
psychology O
of O
nurses O
caring O
for O
COVID O
- O
19 O
patients O
. O

Recommendations O
for O
medical O
care O
of O
oncological O
patients O
during O
the O
COVID O
- O
19 O
epidemic O
: O
experiences O
from O
China O
. O

Methods O
: O
To O
assess O
ambulatory O
teleneurology O
satisfaction O
, O
we O
analyzed O
postvisit O
questionnaire O
data O
from O
patients O
and O
clinicians O
who O
completed O
teleneurology O
visits O
during O
the O
COVID O
- O
19 O
pandemic O
at O
Vanderbilt O
University O
Medical O
Center O
Department O
of O
Neurology O
( O
VUMC O
) O
. O

Thus O
, O
etoposide O
may O
have O
a O
role O
as O
salvage O
therapy O
in O
treatment O
of O
cytokine O
storm O
in O
COVID O
- O
19 O
. O

During O
COVID O
- O
19 O
, O
urologists O
have O
used O
web O
- O
based O
learning O
for O
their O
CME O
. O

If O
a O
patient O
with O
a O
gynecologic O
cancer O
presents O
with O
COVID O
- O
19 O
, O
surgical O
management O
should O
be O
postponed O
for O
at O
least O
15 O
days O
. O

COVID O
- O
19 O
: O
an O
update O
and O
cardiac O
involvement O
. O

Mathematical O
modeling O
of O
COVID O
- O
19 O
epidemic O
with O
effect O
of O
awareness O
programs O
. O

Letter O
: O
Neurosurgery O
at O
war O
with O
the O
COVID O
- O
19 O
pandemic O
: O
patient O
' O
s O
management O
from O
an O
African O
neurosurgical O
center O
. O

COVID O
- O
19 O
has O
offered O
unique O
learning O
opportunities O
for O
the O
health O
care O
sector O
. O

The O
inherent O
resistance O
of O
wild O
- O
type O
mice O
to O
SARS O
- O
CoV O
- O
2 O
, O
combined O
with O
a O
wealth O
of O
genetic O
tools O
that O
are O
available O
only O
for O
modifying O
mice O
, O
offers O
a O
unique O
opportunity O
to O
create O
a O
versatile O
set O
of O
genetically O
engineered O
mouse O
models O
useful O
for O
COVID O
- O
19 O
research O
. O

Three O
Reasons O
to O
Focus O
on O
Patient O
and O
Family O
Engagement O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Amid O
the O
global O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
outbreak O
, O
an O
89 O
- O
year O
- O
old O
male O
with O
chronic O
kidney O
disease O
presented O
with O
acute O
dacryocystitis O
and O
a O
persistent O
dry O
cough O
. O

These O
findings O
suggest O
that O
NAC O
may O
complement O
the O
management O
of O
COVID O
- O
19 O
infection O
, O
particularly O
when O
administered O
intravenously O
within O
an O
intensive O
care O
unit O
( O
ICU O
) O
environment O
. O

How O
do O
we O
fight O
COVID O
- O
19 O
? O
Military O
medical O
actions O
in O
the O
war O
against O
the O
COVID O
- O
19 O
pandemic O
in O
France O
. O

In O
this O
study O
, O
we O
explore O
the O
lived O
experience O
and O
perceptions O
of O
patients O
in O
isolation O
with O
COVID O
- O
19 O
in O
an O
Australian O
healthcare O
setting O
. O

Trends O
in O
Trauma O
Admissions O
During O
the O
COVID O
- O
19 O
Pandemic O
in O
Los O
Angeles O
County O
, O
California O
. O

American O
Association O
for O
Bronchology O
and O
Interventional O
Pulmonology O
( O
AABIP O
) O
Statement O
on O
the O
Use O
of O
Bronchoscopy O
and O
Respiratory O
Specimen O
Collection O
in O
Patients O
With O
Suspected O
or O
Confirmed O
COVID O
- O
19 O
Infection O
. O

In O
this O
situation O
, O
there O
is O
no O
doubt O
that O
vaccine O
is O
the O
primary O
prevention O
strategy O
to O
contain O
the O
wave O
of O
COVID O
- O
19 O
pandemic O
. O

An O
integrated O
autoencoder O
- O
based O
hybrid O
CNN O
- O
LSTM O
model O
for O
COVID O
- O
19 O
severity O
prediction O
from O
lung O
ultrasound O
. O

Multiple O
studies O
have O
reported O
a O
doubling O
in O
risk O
of O
Coronavirus O
Disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
among O
cancer O
patients O
. O

In O
South O
Korea O
, O
the O
first O
confirmed O
case O
of O
coronavirus O
2019 O
( O
COVID O
- O
19 O
) O
was O
detected O
on O
January O
20 O
, O
2020 O
. O

One O
hundred O
and O
sixty O
one O
consecutive O
severe O
and O
critical O
COVID O
- O
19 O
patients O
admitted O
in O
intensive O
care O
unit O
( O
ICU O
) O
were O
retrospectively O
reviewed O
in O
this O
multicenter O
study O
. O

Cerebral O
venous O
sinus O
thrombosis O
in O
patients O
with O
COVID O
- O
19 O
infection O
. O

Paintings O
by O
Edward O
Hopper O
( O
1940s O
and O
' O
50s O
) O
foretell O
the O
lockdown O
and O
social O
distancing O
of O
today O
' O
s O
COVID O
- O
19 O
pandemic O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
a O
novel O
virus O
that O
causes O
COVID O
- O
19 O
infection O
, O
has O
recently O
emerged O
and O
caused O
a O
deadly O
pandemic O
. O

The O
dandelion O
and O
focal O
crazy O
paving O
signs O
indicate O
mild O
COVID O
- O
19 O
. O

The O
Impact O
of O
COVID O
- O
19 O
Pandemic O
and O
Lockdown O
Measures O
on O
Quality O
of O
Life O
among O
Italian O
General O
Population O
. O

Cancer O
, O
COVID O
- O
19 O
, O
and O
the O
need O
for O
critique O
. O

Fungal O
disease O
occurs O
frequently O
in O
critically O
ill O
, O
mechanically O
ventilated O
COVID O
- O
19 O
patients O
. O

On O
May O
7 O
, O
2020 O
, O
Gilead O
Sciences O
, O
announced O
that O
the O
Japanese O
Ministry O
of O
Health O
, O
Labour O
and O
Welfare O
( O
MHLW O
) O
has O
granted O
regulatory O
approval O
of O
Veklury O
® O
( O
Remdesivir O
) O
as O
a O
treatment O
for O
SARS O
- O
CoV O
- O
2 O
infection O
, O
the O
virus O
that O
causes O
COVID O
- O
19 O
acute O
respiratory O
syndrome O
, O
under O
an O
exceptional O
approval O
pathway O
. O

However O
, O
current O
evidence O
indicates O
that O
a O
month O
of O
recovery O
may O
be O
too O
short O
an O
interval O
to O
guarantee O
complete O
pulmonary O
restitution O
even O
after O
COVID O
- O
19 O
infections O
not O
demanding O
hospital O
care O
. O

A O
61 O
- O
year O
- O
old O
male O
kidney O
transplant O
patient O
with O
a O
history O
of O
multiple O
biopsy O
- O
confirmed O
acute O
rejections O
and O
chronic O
allograft O
rejection O
was O
admitted O
to O
our O
COVID O
- O
19 O
Unit O
with O
dry O
cough O
, O
exertional O
dyspnea O
, O
oliguria O
, O
and O
abdominal O
distension O
. O

Local O
health O
systems O
aim O
to O
contain O
the O
COVID O
- O
19 O
pandemic O
and O
hospitals O
and O
health O
- O
care O
providers O
rush O
to O
provide O
the O
capacity O
for O
a O
surge O
of O
COVID O
- O
19 O
patients O
. O

We O
also O
analyzed O
research O
on O
coronaviruses O
, O
relating O
the O
results O
obtained O
to O
the O
management O
of O
the O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
is O
a O
new O
pandemic O
caused O
by O
a O
novel O
coronavirus O
, O
SARS O
- O
CoV O
- O
2 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
posed O
barriers O
to O
these O
programs O
. O

In O
this O
paper O
, O
we O
solved O
a O
time O
delay O
fractional O
COVID O
- O
19 O
SEIR O
epidemic O
model O
via O
Caputo O
fractional O
derivatives O
using O
a O
predictor O
- O
corrector O
method O
. O

This O
study O
aimed O
to O
examine O
the O
prevalence O
and O
predictors O
of O
depression O
and O
anxiety O
among O
senior O
high O
school O
students O
in O
Jordan O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
COVID O
- O
19 O
pandemic O
is O
posing O
a O
diverse O
challenge O
to O
people O
with O
obesity O
. O

World O
War O
against O
COVID O
- O
19 O
: O
How O
strong O
is O
our O
armamentarium O
? O

We O
describe O
our O
institutional O
experience O
with O
COVID O
- O
19 O
among O
10 O
SOT O
patients O
, O
including O
the O
clinical O
presentation O
, O
treatment O
modalities O
, O
and O
outcomes O
of O
7 O
renal O
transplant O
recipients O
, O
1 O
liver O
transplant O
recipient O
, O
1 O
heart O
transplant O
recipient O
, O
and O
1 O
lung O
transplant O
recipient O
. O

HCWs O
working O
in O
county O
- O
level O
hospitals O
in O
high O
- O
risk O
areas O
were O
more O
vulnerable O
to O
COVID O
- O
19 O
. O

Will O
Buying O
Follow O
Others O
Ease O
Their O
Threat O
of O
Death O
? O
An O
Analysis O
of O
Consumer O
Data O
during O
the O
Period O
of O
COVID O
- O
19 O
in O
China O
. O

COVID O
- O
19 O
response O
related O
lockdown O
has O
resulted O
in O
an O
economic O
crisis O
which O
may O
double O
levels O
of O
poverty O
, O
has O
exacerbated O
food O
insecurity O
, O
and O
disrupted O
TB O
services O
. O

If O
anything O
, O
the O
decline O
in O
mental O
health O
is O
worsening O
as O
the O
pandemic O
wears O
on O
and O
is O
becoming O
less O
related O
to O
local O
COVID O
- O
19 O
case O
rates O
. O

Therefore O
, O
WFA O
demonstrates O
real O
potential O
as O
a O
therapeutic O
agent O
to O
treat O
or O
prevent O
the O
spread O
of O
COVID O
- O
19 O
due O
to O
the O
reported O
interference O
in O
viral O
S O
- O
protein O
to O
host O
receptor O
binding O
and O
its O
lack O
of O
effect O
on O
ACE2 O
expression O
in O
the O
lungs O
. O

It O
remains O
unclear O
whether O
these O
pathogenic O
pathways O
are O
secondary O
to O
a O
failure O
to O
clear O
the O
virus O
because O
of O
maladaptive O
immune O
responses O
or O
if O
these O
are O
sequential O
COVID O
- O
19 O
defining O
illnesses O
. O

The O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
briefly O
described O
, O
as O
are O
the O
preliminary O
presenting O
signs O
and O
symptoms O
of O
COVID O
- O
19 O
infection O
. O

COVID O
- O
19 O
, O
caused O
by O
SARS O
- O
CoV O
- O
2 O
, O
is O
severe O
respiratory O
illnesses O
leading O
to O
millions O
of O
deaths O
worldwide O
in O
very O
short O
span O
. O

The O
main O
result O
was O
the O
effect O
of O
Baduanjin O
exercise O
on O
the O
quality O
of O
life O
in O
patients O
recovering O
from O
COVID O
- O
19 O
. O

Executive O
summary O
: O
It O
' O
s O
wrong O
not O
to O
test O
: O
The O
case O
for O
universal O
, O
frequent O
rapid O
COVID O
- O
19 O
testing O
. O

Emergency O
front O
- O
of O
- O
neck O
airway O
in O
the O
COVID O
- O
19 O
patient O
: O
Cannula O
or O
surgical O
cricothyroidotomy O
? O

Twenty O
cohort O
studies O
of O
28 O
355 O
hospitalised O
patients O
with O
COVID O
- O
19 O
infection O
were O
included O
. O

Pregnancy O
and O
Breastfeeding O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
Your O
Workplace O
Rights O
. O

Through O
an O
imitating O
social O
learning O
process O
, O
individual O
- O
level O
behavioral O
change O
on O
taking O
infection O
prevention O
actions O
have O
the O
potentials O
to O
significantly O
reduce O
the O
COVID O
- O
19 O
outbreak O
in O
terms O
of O
size O
and O
timing O
at O
city O
- O
level O
. O

Specifically O
, O
we O
offer O
real O
and O
mock O
data O
for O
a O
hypothetical O
ELISA O
to O
detect O
plasma O
antibodies O
to O
COVID O
- O
19 O
in O
infected O
patients O
who O
have O
had O
the O
disease O
. O

Detection O
of O
Phenotype O
- O
related O
Mutations O
of O
COVID O
- O
19 O
via O
the O
Whole O
Genomic O
Data O
. O

Identified O
hit O
compounds O
can O
be O
further O
taken O
for O
in O
vitro O
and O
in O
vivo O
studies O
to O
examine O
their O
effectiveness O
versus O
COVID O
- O
19 O
. O

Clinical O
Manifestations O
of O
Patients O
with O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
a O
Referral O
Center O
in O
Iran O
. O

Whether O
these O
medications O
increase O
the O
risk O
for O
mild O
or O
asymptomatic O
disease O
or O
are O
beneficial O
in O
COVID O
- O
19 O
treatment O
remains O
uncertain O
. O

Prior O
infection O
with O
intestinal O
coronaviruses O
moderates O
symptom O
severity O
and O
mortality O
in O
patients O
with O
COVID O
- O
19 O
: O
A O
hypothesis O
and O
preliminary O
evidence O
. O

Immunosuppression O
in O
a O
lung O
transplant O
recipient O
with O
COVID O
- O
19 O
? O
Lessons O
from O
an O
early O
case O
. O

Acute O
pulmonary O
embolism O
following O
acute O
type O
A O
aortic O
dissection O
in O
a O
patient O
with O
COVID O
- O
19 O
. O

The O
mortality O
rates O
and O
detailed O
clinical O
characteristics O
of O
natives O
and O
migrants O
dying O
with O
COVID O
- O
19 O
were O
explored O
by O
considering O
the O
medical O
charts O
of O
a O
representative O
sample O
of O
patients O
deceased O
in O
Italian O
hospitals O
( O
n O
= O
2 O
, O
687 O
) O
between O
February O
21st O
and O
April O
29th O
, O
2020 O
. O

Curcumin O
could O
reduce O
the O
frequency O
of O
Th17 O
cells O
and O
their O
related O
inflammatory O
factors O
in O
both O
mild O
and O
severe O
COVID O
- O
19 O
patients O
. O

In O
addition O
, O
in O
people O
with O
type O
2 O
diabetes O
, O
COVID O
- O
19 O
- O
related O
mortality O
was O
significantly O
higher O
in O
those O
with O
an O
HbA1c O
of O
59 O
mmol O
/ O
mol O
( O
7 O
· O
6 O
% O
) O
or O
higher O
than O
in O
those O
with O
an O
HbA1c O
of O
48 O
- O
53 O
mmol O
/ O
mol O
( O
HR O
1 O
· O
22 O
[ O
95 O
% O
CI O
1 O
· O
15 O
- O
1 O
· O
30 O
, O
p O
< O
0 O
· O
0001 O
] O
for O
59 O
- O
74 O
mmol O
/ O
mol O
[ O
7 O
· O
6 O
- O
8 O
· O
9 O
% O
] O
and O
1 O
· O
36 O
[ O
1 O
· O
24 O
- O
1 O
· O
50 O
, O
p O
< O
0 O
· O

0001 O
] O
for O
75 O
- O
85 O
mmol O
/ O
mol O
[ O
9 O
· O
0 O
- O
9 O
· O
9 O
% O
] O
) O
. O

Guidelines O
drafted O
by O
an O
expert O
group O
led O
by O
the O
French O
- O
speaking O
Association O
of O
Endocrine O
Surgery O
( O
AFCE O
) O
propose O
specific O
surgical O
management O
principles O
for O
thyroid O
, O
parathyroid O
, O
endocrine O
pancreas O
and O
adrenal O
surgery O
during O
and O
after O
the O
COVID O
- O
19 O
epidemic O
. O

During O
the O
COVID O
- O
19 O
pandemic O
, O
the O
implementation O
of O
antimicrobial O
stewardship O
strategies O
has O
been O
recommended O
. O

We O
conducted O
an O
online O
panel O
survey O
of O
a O
demographically O
representative O
sample O
of O
2010 O
adult O
New O
Zealanders O
during O
the O
COVID O
- O
19 O
lockdown O
; O
the O
final O
, O
weighted O
sample O
included O
261 O
daily O
smokers O
and O
71 O
weekly O
smokers O
. O

The O
critical O
bedside O
role O
in O
identifying O
and O
treating O
lung O
injury O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Several O
states O
have O
deemed O
abortions O
as O
nonessential O
services O
, O
effectively O
calling O
for O
a O
halt O
to O
abortion O
care O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
recent O
outbreak O
of O
COVID O
- O
19 O
has O
infected O
a O
large O
number O
of O
patients O
, O
increasing O
the O
importance O
of O
adequate O
disinfection O
of O
the O
hospital O
environment O
. O

Psychological O
adaptive O
difficulties O
and O
their O
management O
during O
COVID O
- O
19 O
pandemic O
in O
people O
with O
diabetes O
mellitus O
. O

Unlike O
severe O
acute O
respiratory O
syndrome O
, O
patients O
with O
COVID O
- O
19 O
had O
the O
highest O
viral O
load O
near O
presentation O
, O
which O
could O
account O
for O
the O
fast O
- O
spreading O
nature O
of O
this O
epidemic O
. O

Letter O
to O
the O
Editor O
: O
Risk O
of O
Hospital O
- O
Acquired O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Infection O
During O
Admission O
for O
Semiurgent O
Neurosurgical O
Procedures O
. O

Mediterranean O
Diet O
and O
COVID O
- O
19 O
: O
Hypothesizing O
Potential O
Benefits O
in O
People O
With O
Diabetes O
. O

[ O
COVID O
- O
19 O
in O
the O
Emergency O
Department O
of O
Bernhoven O
hospital O
] O
. O

We O
discuss O
a O
fractional O
- O
order O
SIRD O
mathematical O
model O
of O
the O
COVID O
- O
19 O
disease O
in O
the O
sense O
of O
Caputo O
in O
this O
article O
. O

As O
the O
number O
of O
cases O
of O
COVID O
- O
19 O
continues O
to O
grow O
, O
local O
health O
services O
are O
at O
risk O
of O
being O
overwhelmed O
with O
patients O
requiring O
intensive O
care O
. O

The O
outbreak O
of O
Corona O
Virus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
affected O
the O
lives O
of O
people O
all O
over O
the O
world O
. O

Healthcare O
workers O
( O
HCWs O
) O
are O
at O
the O
frontline O
of O
the O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
response O
, O
yet O
there O
is O
a O
paucity O
of O
literature O
on O
their O
knowledge O
, O
attitudes O
and O
practices O
( O
KAP O
) O
in O
relation O
to O
the O
pandemic O
. O

Thus O
, O
our O
data O
establish O
that O
SARS O
- O
CoV O
- O
2 O
causes O
specific O
manifestations O
of O
proximal O
tubule O
dysfunction O
and O
provide O
novel O
insights O
into O
COVID O
- O
19 O
severity O
and O
outcome O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
significantly O
impacted O
the O
availability O
of O
cardiology O
services O
and O
management O
of O
cardiac O
conditions O
. O

Effectiveness O
of O
Interferon O
Beta O
1a O
, O
compared O
to O
Interferon O
Beta O
1b O
and O
the O
usual O
therapeutic O
regimen O
to O
treat O
adults O
with O
moderate O
to O
severe O
COVID O
- O
19 O
: O
structured O
summary O
of O
a O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O

Coronavirus O
2019 O
disease O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
SARS O
- O
CoV O
- O
2 O
, O
can O
lead O
to O
cardiac O
impairment O
with O
various O
types O
of O
clinical O
manifestations O
, O
including O
heart O
failure O
and O
cardiogenic O
shock O
. O

Outpatient O
care O
for O
pregnant O
and O
puerperal O
women O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
results O
are O
highly O
significant O
for O
predicting O
future O
COVID O
- O
19 O
outbreaks O
and O
modeling O
cities O
based O
on O
environmental O
conditions O
. O

Adults O
≥ O
50 O
years O
with O
established O
ASCVD O
and O
no O
prior O
history O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
will O
be O
prospectively O
identified O
and O
pre O
- O
randomized O
in O
a O
1 O
: O
10 O
allocation O
ratio O
( O
∼ O
1 O
, O
500 O
IPE O
: O
∼ O
15 O
, O
000 O
usual O
care O
) O
stratified O
by O
age O
and O
previous O
respiratory O
health O
status O
to O
the O
intervention O
( O
IPE O
2 O
grams O
by O
mouth O
twice O
daily O
with O
meals O
) O
vs O
the O
control O
group O
( O
usual O
care O
) O
for O
a O
minimum O
follow O
- O
up O
duration O
of O
6 O
months O
. O

Around O
21 O
% O
of O
participants O
had O
PRA O
, O
42 O
. O
1 O
% O
had O
depression O
, O
and O
4 O
. O
4 O
% O
had O
COVID O
- O
19 O
anxiety O
. O

The O
emergence O
of O
the O
novel O
pathogenic O
member O
of O
this O
family O
in O
December O
2019 O
( O
SARS O
- O
CoV O
- O
2 O
, O
which O
causes O
COVID O
- O
19 O
) O
poses O
a O
global O
health O
emergency O
. O

We O
found O
278 O
physicians O
who O
died O
with O
COVID O
- O
19 O
infection O
, O
but O
complete O
details O
were O
missing O
for O
108 O
individuals O
. O

COVID O
- O
19 O
and O
a O
novel O
initiative O
to O
improve O
safety O
by O
3D O
printing O
personal O
protective O
equipment O
parts O
from O
computed O
tomography O
. O

All O
studies O
published O
between O
01 O
January O
- O
15 O
June O
2020 O
on O
COVID O
- O
19 O
cluster O
infections O
in O
English O
electronic O
databases O
were O
searched O
, O
including O
PubMed O
, O
Embase O
, O
Web O
of O
Knowledge O
, O
and O
Scopus O
. O

Transesophageal O
echocardiography O
probe O
cover O
: O
implementation O
of O
a O
cross O
- O
contamination O
containment O
strategy O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Conclusions O
: O
COVID O
- O
19 O
can O
significantly O
affect O
the O
heart O
function O
and O
lead O
to O
myocardial O
injury O
. O

[ O
Risk O
factors O
for O
the O
early O
development O
of O
septic O
shock O
in O
patients O
with O
severe O
COVID O
- O
19 O
] O
. O

The O
aims O
of O
the O
study O
are O
to O
understand O
the O
attitudes O
and O
precaution O
practices O
of O
non O
- O
infected O
pregnant O
women O
towards O
the O
COVID O
- O
19 O
outbreak O
in O
Singapore O
. O

Angiotensin O
- O
converting O
Enzyme O
Inhibitor O
/ O
Angiotensin O
Receptor O
Blocker O
Use O
and O
COVID O
- O
19 O
: O
Time O
to O
Change O
Practice O
or O
Keep O
Gathering O
Data O
? O

We O
found O
that O
among O
COVID O
- O
19 O
- O
positive O
individuals O
with O
IDD O
, O
a O
higher O
number O
of O
chronic O
medical O
conditions O
and O
male O
sex O
were O
characteristics O
associated O
with O
a O
greater O
likelihood O
of O
hospitalisation O
. O

The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
knowledge O
, O
attitude O
and O
practices O
towards O
SARS O
- O
CoV O
- O
2 O
among O
the O
nursing O
students O
of O
University O
of O
Palermo O
during O
the O
rapid O
rise O
period O
of O
the O
COVID O
- O
19 O
pandemic O
. O

In O
this O
paper O
, O
we O
have O
tried O
to O
understand O
the O
spreading O
capability O
of O
COVID O
- O
19 O
in O
India O
taking O
into O
account O
of O
the O
lockdown O
period O
. O

The O
clinical O
warning O
index O
of O
severe O
COVID O
- O
19 O
: O
discussion O
based O
on O
the O
clinical O
features O
and O
outcomes O
of O
4 O
patients O
. O

The O
association O
of O
chest O
radiographic O
findings O
and O
severity O
scoring O
with O
clinical O
outcomes O
in O
patients O
with O
COVID O
- O
19 O
presenting O
to O
the O
emergency O
department O
of O
a O
tertiary O
care O
hospital O
in O
Pakistan O
. O

[ O
ANMCO O
Position O
paper O
: O
Pulmonary O
circulation O
diseases O
and O
COVID O
- O
19 O
] O
. O

As O
much O
as O
56 O
. O
3 O
% O
of O
practitioners O
and O
87 O
. O
8 O
% O
of O
residents O
were O
working O
in O
hospitals O
treating O
COVID O
- O
19 O
. O

COVID O
- O
19 O
had O
become O
a O
pandemic O
raising O
concerns O
of O
widespread O
panic O
and O
increasing O
anxiety O
and O
stress O
in O
individuals O
all O
over O
the O
world O
( O
World O
Health O
Organization O
, O
2020a O
) O
. O

Investigation O
of O
SARS O
- O
CoV O
- O
2 O
in O
semen O
samples O
and O
the O
effects O
of O
COVID O
- O
19 O
on O
male O
sexual O
health O
by O
using O
semen O
analysis O
and O
serum O
male O
hormone O
profile O
: O
A O
cross O
- O
sectional O
, O
pilot O
study O
. O

Optimal O
Management O
of O
Acute O
Lymphoblastic O
Leukemia O
( O
ALL O
) O
in O
Adult O
Patients O
During O
the O
Novel O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Pandemic O
. O

Confinement O
during O
the O
COVID O
- O
19 O
pandemic O
is O
expected O
to O
have O
a O
serious O
and O
complex O
impact O
on O
the O
mental O
health O
of O
patients O
with O
an O
eating O
disorder O
( O
ED O
) O
and O
of O
patients O
with O
obesity O
. O

We O
employed O
a O
thorough O
strategy O
to O
identify O
subclinical O
COVID O
- O
19 O
disease O
, O
and O
after O
confirming O
the O
absence O
of O
active O
disease O
, O
proceeded O
with O
the O
CABG O
operation O
. O

During O
the O
COVID O
- O
19 O
outbreak O
, O
attention O
also O
must O
be O
given O
to O
children O
with O
infection O
by O
other O
pathogens O
infection O
. O

There O
is O
a O
risk O
of O
these O
patients O
presenting O
at O
a O
later O
stage O
with O
progressed O
disease O
and O
the O
best O
way O
forward O
would O
be O
to O
resume O
work O
with O
necessary O
precautions O
and O
universal O
effective O
COVID O
- O
19 O
testing O
. O

Lessons O
from O
a O
successful O
public O
health O
response O
to O
COVID O
- O
19 O
in O
a O
New O
South O
Wales O
residential O
aged O
care O
facility O
, O
2020 O
. O

Assessment O
of O
the O
Prevalence O
of O
Symptoms O
in O
Patients O
Under O
Institutional O
Isolation O
in O
COVID O
- O
19 O
Pandemic O
in O
India O
. O

Like O
all O
infectious O
diseases O
, O
the O
infection O
rate O
of O
COVID O
- O
19 O
is O
dependent O
on O
many O
variables O
. O

The O
Spanish O
government O
declared O
the O
lockdown O
on O
March O
14th O
, O
2020 O
to O
tackle O
the O
fast O
- O
spreading O
of O
COVID O
- O
19 O
. O

Many O
patients O
with O
inherited O
or O
acquired O
benign O
hematological O
disorders O
are O
at O
increased O
risk O
of O
developing O
severe O
complications O
from O
COVID O
- O
19 O
. O

The O
outbreak O
of O
Coronavirus O
( O
COVID O
- O
19 O
) O
has O
spread O
between O
people O
around O
the O
world O
at O
a O
rapid O
rate O
so O
that O
the O
number O
of O
infected O
people O
and O
deaths O
is O
increasing O
quickly O
every O
day O
. O

Therefore O
, O
DNVr O
may O
be O
a O
potentially O
effective O
antiviral O
for O
COVID O
- O
19 O
patients O
with O
long O
- O
term O
positive O
SARS O
- O
CoV O
- O
2 O
RNA O
. O

It O
is O
imperative O
that O
data O
are O
collected O
to O
determine O
the O
extent O
of O
the O
impact O
of O
COVID O
- O
19 O
in O
diverse O
communities O
in O
the O
country O
. O

Effect O
of O
COVID O
- O
19 O
on O
viral O
hepatitis O
services O
in O
Pakistan O
. O

In O
the O
skeletal O
muscle O
, O
through O
unbalanced O
RAS O
activity O
, O
SARS O
- O
CoV O
- O
2 O
could O
induce O
severe O
consequences O
such O
as O
loss O
of O
muscle O
mass O
, O
strength O
, O
and O
physical O
function O
, O
which O
will O
delay O
and O
interfere O
with O
the O
recovery O
process O
of O
patients O
with O
COVID O
- O
19 O
. O

AKI O
occurred O
in O
71 O
. O
1 O
% O
of O
COVID O
- O
19 O
KTRs O
( O
n O
= O
27 O
) O
, O
of O
whom O
6 O
( O
22 O
. O
2 O
% O
) O
patients O
required O
HD O
. O

These O
selected O
compounds O
can O
undergo O
lead O
optimization O
to O
be O
further O
developed O
as O
drugs O
that O
can O
be O
used O
in O
treating O
the O
COVID O
- O
19 O
disease O
. O

Univariable O
and O
multivariable O
logistic O
regression O
, O
adjusted O
for O
age O
, O
sex O
, O
comorbidities O
, O
cancer O
type O
, O
tumour O
stage O
, O
and O
antitumour O
treatments O
, O
were O
used O
to O
explore O
risk O
factors O
associated O
with O
COVID O
- O
19 O
disease O
severity O
. O

Keywords O
: O
COVID O
- O
19 O
, O
Coronavirus O
2019 O
, O
pandemic O
, O
public O
health O
. O

Further O
research O
and O
actions O
are O
necessary O
, O
especially O
after O
the O
COVID O
- O
19 O
pandemic O
, O
to O
identify O
how O
this O
reflection O
should O
be O
conducted O
and O
to O
supply O
evidence O
for O
further O
measures O
and O
revising O
emergency O
and O
disaster O
planning O
guidelines O
. O

The O
global O
outbreak O
of O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
in O
2020 O
has O
significantly O
affected O
the O
information O
environment O
as O
well O
as O
the O
daily O
life O
of O
individuals O
across O
the O
world O
, O
with O
information O
about O
COVID O
- O
19 O
dominating O
all O
media O
channels O
. O

The O
COVID O
- O
19 O
pandemic O
demonstrates O
the O
ongoing O
threat O
of O
pandemics O
caused O
by O
novel O
, O
previously O
unrecognized O
, O
or O
mutated O
pathogens O
with O
high O
transmissibility O
. O

Background O
: O
Coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
was O
declared O
a O
" O
pandemic O
" O
by O
the O
World O
Health O
Organization O
( O
WHO O
) O
in O
early O
March O
2020 O
. O

COVID O
- O
19 O
Confirms O
It O
: O
Paid O
Caregivers O
Are O
Essential O
Members O
of O
the O
Healthcare O
Team O
. O

COVID O
- O
19 O
causes O
COVID O
- O
19 O
disease O
that O
has O
similar O
symptoms O
as O
SARS O
- O
CoV O
. O

Background O
: O
The O
importance O
of O
advance O
care O
planning O
( O
ACP O
) O
discussions O
have O
been O
heightened O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
aim O
of O
this O
study O
was O
to O
elucidate O
an O
agenda O
for O
COVID O
- O
19 O
research O
with O
particular O
focus O
on O
its O
impact O
within O
MCH O
populations O
. O

Impact O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
Clinical O
Practice O
, O
Medical O
Education O
, O
and O
Research O
: O
An O
International O
Survey O
. O

Differentiation O
of O
COVID O
- O
19 O
signs O
and O
symptoms O
from O
allergic O
rhinitis O
and O
common O
cold O
- O
An O
ARIA O
- O
EAACI O
- O
GA2 O
LENconsensus O
. O

We O
found O
that O
an O
increase O
of O
only O
1 O
μ O
g O
/ O
m O
3 O
in O
PM O
2 O
. O
5 O
is O
associated O
with O
an O
8 O
% O
increase O
in O
the O
COVID O
- O
19 O
death O
rate O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
2 O
% O
, O
15 O
% O
) O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
now O
a O
worldwide O
challenge O
for O
public O
health O
. O

A O
report O
on O
COVID O
- O
19 O
epidemic O
in O
Pakistan O
using O
SEIR O
fractional O
model O
. O

Major O
stress O
sources O
included O
working O
in O
an O
isolated O
environment O
, O
concerns O
about O
personal O
protective O
equipment O
shortage O
and O
usage O
, O
physical O
and O
emotional O
exhaustion O
, O
intensive O
workload O
, O
fear O
of O
being O
infected O
, O
and O
insufficient O
work O
experiences O
with O
COVID O
- O
19 O
. O

HCQ O
should O
not O
be O
restricted O
in O
COVID O
- O
19 O
patients O
out O
of O
fear O
of O
cardiac O
mortality O
. O

Data O
about O
the O
presence O
of O
smell O
loss O
, O
the O
onset O
of O
smell O
loss O
and O
other O
COVID O
- O
19 O
symptoms O
such O
as O
ageusia O
and O
nasal O
congestion O
or O
rhinorrhea O
were O
recorded O
. O

It O
has O
shown O
antiviral O
effect O
specifically O
against O
SARS O
- O
CoV O
- O
2 O
in O
vitro O
and O
acts O
on O
cytokine O
signaling O
pathways O
that O
have O
been O
implicated O
in O
COVID O
- O
19 O
. O

We O
herein O
describe O
recent O
advances O
in O
understanding O
SARS O
- O
CoV O
- O
2 O
pathobiology O
and O
potential O
therapeutic O
targets O
that O
are O
involved O
in O
viral O
entry O
into O
host O
cells O
, O
viral O
spread O
in O
the O
body O
, O
and O
the O
subsequent O
COVID O
- O
19 O
progression O
. O

The O
use O
of O
these O
natural O
immunosuppressants O
as O
adjuvants O
to O
ameliorate O
the O
cytokine O
storm O
; O
in O
combination O
with O
antiviral O
agents O
and O
other O
treatment O
drugs O
currently O
in O
use O
presents O
a O
novel O
, O
synergistic O
approach O
for O
the O
treatment O
and O
effective O
cure O
of O
COVID O
- O
19 O
. O

A O
study O
involving O
over O
2000 O
online O
participants O
( O
US O
residents O
) O
tested O
a O
general O
framework O
regarding O
compliance O
with O
a O
directive O
in O
the O
context O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Background O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
originally O
, O
from O
Wuhan O
, O
China O
, O
has O
now O
spread O
to O
most O
countries O
across O
the O
globe O
and O
devastated O
global O
healthcare O
systems O
. O

In O
this O
interim O
review O
, O
we O
will O
summarize O
the O
neurological O
manifestations O
and O
their O
potential O
causes O
in O
COVID O
- O
19 O
. O

In O
this O
study O
, O
we O
developed O
and O
validated O
COVID O
- O
19 O
risk O
scores O
to O
identify O
patients O
with O
COVID O
- O
19 O
. O

COVID O
- O
19 O
Pandemic O
in O
India O
: O
What O
Lies O
Ahead O
[ O
published O
online O
ahead O
of O
print O
, O
2020 O
Apr O
20 O
] O
. O

Previous O
studies O
have O
reported O
the O
feasibility O
of O
utilizing O
deep O
learning O
methods O
to O
screen O
for O
COVID O
- O
19 O
using O
CXR O
and O
CT O
results O
. O

The O
multiple O
anti O
- O
inflammatory O
and O
immunomodulatory O
effects O
of O
Vitamin O
D O
could O
explain O
its O
protective O
role O
against O
immune O
hyper O
reaction O
and O
cytokine O
storm O
in O
patients O
with O
severe O
COVID O
- O
19 O
. O

The O
coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
containment O
and O
mitigation O
strategies O
may O
lead O
to O
excessive O
physical O
inactivity O
and O
sedentary O
behavior O
, O
drastically O
impacting O
cardiorespiratory O
fitness O
and O
overall O
health O
. O

This O
paper O
also O
reviews O
the O
literature O
to O
examine O
and O
comment O
on O
the O
detrimental O
effects O
of O
isolation O
, O
which O
has O
been O
enforced O
as O
one O
of O
the O
primary O
preventative O
measures O
to O
manage O
the O
spread O
of O
COVID O
- O
19 O
. O

The O
study O
was O
in O
one O
Police O
and O
one O
Fire O
& O
Rescue O
facility O
in O
England O
; O
it O
comprised O
of O
195 O
participants O
within O
a O
larger O
sample O
COVID O
- O
19 O
serodiagnostics O
study O
of O
keyworkers O
, O
EDSAB O
- O
HOME O
. O

The O
incidence O
of O
COVID O
- O
19 O
has O
also O
been O
higher O
in O
males O
compared O
with O
their O
female O
counterparts O
. O

Challenges O
and O
Opportunities O
for O
Lung O
Ultrasound O
in O
Novel O
Coronavirus O
Disease O
( O
COVID O
- O
19 O
) O
. O

Stigma O
related O
to O
COVID O
- O
19 O
infection O
: O
Are O
the O
Health O
Care O
Workers O
stigmatizing O
their O
own O
colleagues O
? O

The O
rapid O
pace O
at O
which O
COVID O
- O
19 O
studies O
are O
being O
published O
is O
surpassed O
only O
by O
the O
spread O
of O
the O
virus O
and O
the O
destruction O
wreaked O
by O
the O
pandemic O
globally O
. O

Coronavirus O
diseases O
( O
COVID O
- O
19 O
) O
is O
caused O
by O
a O
novel O
severe O
acute O
respiratory O
syndrome O
coronavirus O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
which O
is O
a O
positive O
single O
- O
stranded O
RNA O
virus O
having O
a O
large O
genome O
~ O
30 O
kb O
. O

What O
further O
should O
be O
done O
to O
control O
COVID O
- O
19 O
outbreaks O
in O
addition O
to O
cases O
isolation O
and O
contact O
tracing O
measures O
? O

We O
quantitatively O
estimated O
the O
relative O
benefits O
of O
COVID O
- O
19 O
vaccines O
, O
in O
terms O
of O
preventing O
infection O
and O
death O
, O
with O
a O
particular O
focus O
on O
effectiveness O
in O
elderly O
people O
. O

Acute O
Flaccid O
Quadriparesis O
in O
a O
Recovering O
COVID O
- O
19 O
Patient O
: O
A O
Clinical O
Dilemma O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
spreading O
worldwide O
. O

A O
novel O
extended O
approach O
under O
hesitant O
fuzzy O
sets O
to O
design O
a O
framework O
for O
assessing O
the O
key O
challenges O
of O
digital O
health O
interventions O
adoption O
during O
the O
COVID O
- O
19 O
outbreak O
. O

Anticipating O
the O
Need O
for O
Healthcare O
Resources O
Following O
the O
Escalation O
of O
the O
COVID O
- O
19 O
Outbreak O
in O
the O
Republic O
of O
Kazakhstan O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
caused O
by O
SARS O
- O
CoV O
- O
2 O
is O
an O
unprecedented O
global O
crisis O
that O
has O
not O
been O
experienced O
, O
which O
is O
still O
disrupting O
health O
systems O
, O
economies O
, O
and O
societies O
around O
the O
world O
by O
the O
rapid O
spread O
. O

Data O
were O
collected O
from O
June O
to O
July O
2020 O
, O
3 O
months O
after O
the O
COVID O
- O
19 O
state O
of O
emergency O
was O
declared O
in O
Israel O
. O

Management O
of O
high O
- O
risk O
patients O
with O
early O
intervention O
is O
a O
key O
to O
lower O
the O
fatality O
rate O
of O
COVID O
- O
19 O
pneumonia O
, O
as O
a O
majority O
of O
patients O
recover O
naturally O
. O

Viral O
pneumonia O
was O
correctly O
diagnosed O
at O
the O
initial O
CT O
study O
in O
the O
remaining O
49 O
patients O
with O
COVID O
- O
19 O
and O
two O
patients O
with O
adenovirus O
. O

A O
portion O
of O
publications O
provided O
intervention O
models O
to O
reinforce O
resilience O
among O
specific O
populations O
during O
the O
COVID O
- O
19 O
pandemic O
. O

IgG O
and O
IgM O
+ O
IgA O
responses O
were O
measured O
on O
1466 O
samples O
from O
1236 O
Spanish O
COVID O
- O
19 O
patients O
admitted O
to O
the O
hospital O
, O
two O
commercial O
ELISA O
kits O
( O
Vircell O
SL O
, O
Spain O
) O
based O
on O
the O
detection O
of O
antibodies O
against O
the O
viral O
spike O
protein O
and O
nucleoprotein O
, O
were O
used O
. O

During O
the O
COVID O
- O
19 O
pandemic O
, O
systematic O
delirium O
monitoring O
using O
validated O
tests O
( O
CAM O
- O
ICU O
or O
ICDSC O
) O
may O
be O
sacrificed O
. O

Inequities O
towards O
leprosy O
- O
affected O
people O
: O
A O
challenge O
during O
COVID O
- O
19 O
pandemic O
. O

Prior O
to O
the O
COVID O
- O
19 O
pandemic O
, O
laryngoscopy O
was O
the O
mandatory O
gold O
standard O
for O
the O
accurate O
assessment O
and O
diagnosis O
of O
inducible O
laryngeal O
obstruction O
. O

Creating O
a O
COVID O
- O
19 O
surge O
clinic O
to O
offload O
the O
emergency O
department O
. O

The O
Maghreb O
Central O
, O
like O
all O
the O
countries O
of O
the O
world O
, O
was O
strongly O
mobilized O
( O
governments O
, O
ministries O
of O
health O
, O
population O
, O
civil O
society O
) O
in O
the O
response O
against O
COVID O
- O
19 O
, O
immediately O
after O
the O
registration O
of O
the O
first O
cases O
on O
its O
territory O
( O
end O
of O
February O
, O
beginning O
of O
March O
) O
and O
according O
to O
pre O
- O
established O
control O
strategies O
. O

Pediatric O
asthma O
and O
COVID O
- O
19 O
: O
The O
known O
, O
the O
unknown O
, O
and O
the O
controversial O
. O

Items O
pertaining O
to O
COVID O
- O
19 O
knowledge O
were O
administered O
to O
US O
deaf O
adults O
from O
April O
17 O
, O
2020 O
, O
to O
May O
1 O
, O
2020 O
, O
via O
a O
bilingual O
American O
Sign O
Language O
/ O
English O
online O
survey O
platform O
. O

The O
results O
in O
this O
study O
can O
be O
used O
for O
the O
treatment O
of O
COVID O
- O
19 O
and O
can O
also O
form O
the O
basis O
of O
rational O
drug O
design O
against O
NSP16 O
of O
SARS O
- O
CoV O
- O
2 O
. O

The O
heme O
- O
HO O
system O
represents O
an O
interesting O
target O
for O
novel O
" O
proof O
of O
concept O
" O
studies O
in O
the O
context O
of O
COVID O
- O
19 O
. O

Background O
: O
In O
response O
to O
the O
COVID O
- O
19 O
pandemic O
, O
physical O
distancing O
measures O
have O
been O
implemented O
globally O
. O

Lockdown O
, O
quarantine O
, O
self O
- O
isolation O
, O
personal O
protection O
equipment O
, O
and O
social O
distancing O
have O
become O
words O
of O
daily O
usage O
ever O
since O
the O
world O
health O
organization O
declared O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
as O
a O
pandemic O
. O

Our O
results O
indicated O
that O
counties O
with O
higher O
mortality O
of O
some O
cancers O
and O
respiratory O
diseases O
are O
more O
vulnerable O
to O
fall O
into O
clusters O
of O
HH O
COVID O
- O
19 O
CFR O
. O

The O
results O
of O
our O
review O
demonstrate O
that O
the O
maternal O
characteristics O
, O
clinical O
symptoms O
, O
maternal O
and O
neonatal O
outcomes O
almost O
11 O
, O
000 O
cases O
of O
COVID O
- O
19 O
and O
pregnancy O
described O
in O
15 O
different O
countries O
are O
not O
worse O
or O
different O
from O
the O
general O
population O
. O

This O
regular O
feature O
comments O
on O
the O
role O
of O
health O
sciences O
librarians O
and O
information O
professionals O
in O
combating O
the O
COVID O
- O
19 O
infodemic O
. O

The O
APOE O
ε O
4 O
allele O
was O
associated O
with O
the O
presence O
of O
symptoms O
of O
COVID O
- O
19 O
. O

Early O
trends O
of O
socio O
- O
economic O
and O
health O
indicators O
influencing O
case O
fatality O
rate O
of O
COVID O
- O
19 O
pandemic O
. O

Our O
study O
found O
a O
significant O
association O
between O
lymphopenia O
, O
thrombocytopenia O
and O
elevated O
levels O
of O
CRP O
, O
PCT O
, O
LDH O
, O
D O
- O
dimer O
and O
COVID O
- O
19 O
severity O
. O

Conclusion O
: O
Forty O
six O
percentages O
of O
patients O
( O
mainly O
severe O
or O
critical O
cases O
) O
with O
COVID O
- O
19 O
showed O
fibrotic O
change O
on O
follow O
- O
up O
CT O
at O
early O
recovery O
phase O
, O
while O
the O
extent O
of O
fibrosis O
was O
not O
large O
. O

The O
effect O
of O
Echinacea O
spp O
. O
on O
the O
prevention O
or O
treatment O
of O
COVID O
- O
19 O
and O
other O
respiratory O
tract O
infections O
in O
humans O
: O
A O
rapid O
review O
. O

Finally O
, O
we O
provided O
the O
following O
strategies O
for O
working O
with O
elderly O
dementia O
patients O
: O
general O
preventive O
methods O
; O
dementia O
care O
at O
home O
and O
nursing O
facilities O
according O
to O
the O
activities O
of O
daily O
living O
and O
dementia O
characteristics O
; O
ICU O
care O
after O
COVID O
- O
19 O
infection O
; O
and O
public O
health O
care O
system O
and O
government O
response O
. O

Controversial O
Roles O
of O
the O
Renin O
Angiotensin O
System O
and O
Its O
Modulators O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

COVID O
- O
19 O
Presenting O
as O
Acute O
Hepatitis O
. O

Heightened O
Innate O
Immune O
Responses O
in O
the O
Respiratory O
Tract O
of O
COVID O
- O
19 O
Patients O
. O

Coronavirus O
disease O
of O
2019 O
( O
COVID O
- O
19 O
) O
is O
a O
disease O
caused O
by O
the O
novel O
coronavirus O
SARS O
- O
CoV O
- O
2 O
, O
which O
is O
characterized O
by O
a O
multitude O
of O
clinical O
abnormalities O
, O
including O
hypercoagulability O
. O

To O
identify O
features O
in O
the O
genome O
of O
the O
SARS O
- O
CoV O
- O
2 O
pathogen O
responsible O
for O
the O
COVID O
- O
19 O
pandemic O
that O
may O
contribute O
to O
its O
viral O
replication O
, O
host O
pathogenicity O
, O
and O
vulnerabilities O
, O
we O
investigated O
how O
and O
to O
what O
extent O
the O
SARS O
- O
CoV O
- O
2 O
genome O
sequence O
differs O
from O
other O
well O
- O
characterized O
human O
and O
animal O
coronavirus O
genomes O
. O

Analysis O
of O
hematological O
indexes O
of O
COVID O
- O
19 O
patients O
from O
fever O
clinics O
in O
Suzhou O
, O
China O
. O

The O
case O
definition O
used O
to O
investigate O
persons O
with O
suspected O
COVID O
- O
19 O
infection O
is O
not O
specific O
. O

Arterial O
hypertension O
represented O
one O
of O
the O
most O
common O
comorbidities O
in O
patients O
with O
COVID O
- O
19 O
. O

Clinical O
manifestations O
of O
COVID O
- O
19 O
caused O
by O
the O
novel O
coronavirus O
SARS O
- O
CoV O
- O
2 O
are O
associated O
with O
age O
. O

The O
Benefits O
of O
Vitamin O
D O
Supplementation O
for O
Athletes O
: O
Better O
Performance O
and O
Reduced O
Risk O
of O
COVID O
- O
19 O
. O

A O
systematic O
review O
and O
meta O
- O
analysis O
of O
pregnancy O
and O
COVID O
- O
19 O
: O
Signs O
and O
symptoms O
, O
laboratory O
tests O
, O
and O
perinatal O
outcomes O
. O

Overall O
, O
3471 O
US O
patients O
hospitalized O
with O
COVID O
- O
19 O
and O
pulmonary O
involvement O
were O
included O
. O

In O
univariate O
analyses O
, O
we O
also O
found O
that O
patients O
who O
died O
from O
COVID O
- O
19 O
had O
higher O
hyperinflammation O
markers O
than O
patients O
who O
survived O
: O
C O
- O
reactive O
protein O
( O
181 O
( O
IQR O
120 O
- O
220 O
) O
vs O
107 O
. O
4 O
( O
IQR O
30 O
- O
150 O
; O
p O
0 O
. O
05 O
) O
; O
lactate O
dehydrogenase O
( O
641 O
. O
8 O
( O
IQR O
465 O
. O
75 O
- O
853 O
. O
5 O
) O
vs O
361 O
( O
IQR O
250 O
- O
450 O
) O
, O
p O
0 O
. O
03 O
) O
; O
serum O
ferritin O
( O
1026 O
( O
IQR O
228 O
. O
3 O

- O
1536 O
. O
3 O
) O
vs O
861 O
. O
3 O
( O
IQR O
389 O
- O
1490 O
. O
5 O
) O
, O
p O
0 O
. O
04 O
) O
; O
D O
- O
dimer O
( O
12 O
, O
019 O
. O
8 O
( O
IQR O
843 O
. O
5 O
- O
25 O
, O
790 O
. O
5 O
) O
vs O
1544 O
. O
3 O

Mild O
versus O
severe O
COVID O
- O
19 O
: O
Laboratory O
markers O
. O

Collaborative O
and O
well O
- O
conducted O
randomised O
controlled O
trials O
across O
borders O
are O
required O
to O
generate O
robust O
data O
to O
inform O
common O
and O
consistent O
policies O
for O
COVID O
- O
19 O
and O
future O
pandemic O
planning O
and O
management O
; O
however O
, O
current O
use O
of O
systematic O
reviews O
of O
best O
available O
evidence O
can O
be O
considered O
to O
guide O
interim O
policies O
. O

As O
public O
health O
teams O
respond O
to O
the O
pandemic O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
containment O
and O
understanding O
of O
the O
modes O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
transmission O
is O
of O
utmost O
importance O
for O
policy O
making O
. O

Although O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
most O
commonly O
manifests O
with O
acute O
respiratory O
symptoms O
, O
one O
very O
common O
symptom O
of O
COVID O
- O
19 O
is O
pain O
. O

Since O
its O
emergence O
in O
Wuhan O
, O
China O
in O
late O
2019 O
, O
the O
origin O
and O
evolution O
of O
SARS O
- O
CoV O
- O
2 O
have O
been O
among O
the O
most O
debated O
issues O
related O
to O
COVID O
- O
19 O
. O

Nosocomial O
infection O
among O
patients O
with O
COVID O
- O
19 O
: O
A O
retrospective O
data O
analysis O
of O
918 O
cases O
from O
a O
single O
center O
in O
Wuhan O
, O
China O
. O

A O
moonshot O
approach O
toward O
the O
management O
of O
cancer O
patients O
in O
the O
COVID O
- O
19 O
time O
: O
what O
have O
we O
learned O
and O
what O
could O
the O
Italian O
network O
of O
cancer O
centers O
( O
Alliance O
Against O
Cancer O
, O
ACC O
) O
do O
after O
the O
pandemic O
wave O
? O

However O
, O
the O
epidemiological O
features O
and O
outcomes O
of O
AKI O
among O
COVID O
- O
19 O
patients O
with O
ARDS O
are O
unknown O
. O

However O
, O
many O
neurological O
complications O
reported O
in O
COVID O
- O
19 O
patients O
have O
highlighted O
a O
critical O
pattern O
of O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

Mesenchymal O
stem O
cells O
derived O
from O
perinatal O
tissues O
for O
treatment O
of O
critically O
ill O
COVID O
- O
19 O
- O
induced O
ARDS O
patients O
: O
a O
case O
series O
. O

During O
the O
initial O
COVID O
- O
19 O
outbreak O
up O
to O
28 O
. O
4 O
million O
elective O
operations O
were O
cancelled O
worldwide O
, O
in O
part O
owing O
to O
concerns O
that O
it O
would O
be O
unsustainable O
to O
maintain O
elective O
surgery O
capacity O
because O
of O
COVID O
- O
19 O
- O
related O
surgeon O
absence O
. O

Acute O
Kidney O
Injury O
in O
a O
Case O
Series O
of O
Patients O
with O
Confirmed O
COVID O
- O
19 O
( O
Coronavirus O
Disease O
2019 O
) O
: O
Role O
of O
Angiotensin O
- O
Converting O
Enzyme O
2 O
and O
Renin O
- O
Angiotensin O
System O
Blockade O
. O

Result O
showed O
that O
20 O
. O
4 O
% O
of O
the O
participants O
were O
having O
anxiety O
due O
to O
COVID O
- O
19 O
. O

Digital O
health O
information O
technologies O
can O
be O
applied O
in O
three O
aspects O
, O
namely O
digital O
patients O
, O
digital O
devices O
, O
and O
digital O
clinics O
, O
and O
could O
be O
useful O
in O
fighting O
the O
COVID O
- O
19 O
pandemic O
. O

Within O
- O
period O
changes O
in O
aerobic O
fitness O
showed O
a O
significant O
improvement O
following O
COVID O
- O
19 O
lockdown O
( O
p O
< O
0 O
. O
001 O
) O
and O
a O
significant O
decline O
during O
summer O
break O
( O
p O
< O
0 O
. O
001 O
) O
. O

Radiological O
findings O
for O
diagnosis O
of O
SARS O
- O
CoV O
- O
2 O
pneumonia O
( O
COVID O
- O
19 O
) O
. O

Maintaining O
compliance O
with O
personal O
preventive O
measures O
is O
important O
to O
achieve O
a O
balance O
of O
COVID O
- O
19 O
pandemic O
control O
and O
work O
resumption O
. O

Adult O
COVID O
- O
19 O
Patients O
Cared O
For O
in O
a O
Pediatric O
ICU O
Embedded O
in O
a O
Regional O
Biothreat O
Center O
: O
Disease O
Severity O
and O
Outcomes O
. O

The O
world O
is O
witnessing O
an O
unprecedented O
crisis O
with O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Here O
, O
we O
investigated O
the O
gene O
expression O
of O
ACE2 O
and O
identified O
associated O
pathways O
of O
SARS O
- O
Cov O
as O
a O
useful O
reference O
for O
a O
deepening O
understanding O
of O
COVID O
- O
19 O
. O

Commentary O
: O
Teleophthalmology O
in O
India O
: O
Hybrid O
approach O
will O
be O
a O
game O
changer O
in O
the O
COVID O
- O
19 O
Era O
. O

The O
objective O
of O
this O
study O
was O
to O
develop O
, O
evaluate O
, O
and O
deploy O
an O
automatic O
natural O
language O
processing O
pipeline O
to O
collect O
user O
- O
generated O
Twitter O
data O
as O
a O
complementary O
resource O
for O
identifying O
potential O
cases O
of O
COVID O
- O
19 O
in O
the O
United O
States O
that O
are O
not O
based O
on O
testing O
and O
, O
thus O
, O
may O
not O
have O
been O
reported O
to O
the O
Centers O
for O
Disease O
Control O
and O
Prevention O
. O

Malaria O
programmes O
are O
being O
affected O
in O
many O
ways O
by O
COVID O
- O
19 O
. O

This O
article O
constitutes O
a O
consensus O
statement O
on O
defining O
and O
managing O
COVID O
- O
19 O
- O
associated O
pulmonary O
aspergillosis O
, O
prepared O
by O
experts O
and O
endorsed O
by O
medical O
mycology O
societies O
. O

This O
article O
not O
only O
provides O
a O
looking O
glass O
into O
the O
thoughts O
of O
Internet O
users O
during O
the O
COVID O
- O
19 O
pandemic O
but O
we O
also O
perform O
a O
content O
- O
based O
predictive O
analysis O
of O
what O
makes O
a O
meme O
go O
viral O
. O

Patterns O
of O
care O
will O
evolve O
following O
the O
COVID O
- O
19 O
pandemic O
. O

We O
anticipate O
that O
the O
banded O
bag O
, O
which O
is O
economical O
, O
convenient O
, O
and O
highly O
practical O
, O
can O
be O
used O
as O
a O
safety O
- O
enhancing O
device O
for O
COVID O
- O
19 O
extubations O
. O

We O
present O
a O
case O
of O
COVID O
- O
19 O
hepatitis O
in O
a O
living O
donor O
liver O
allograft O
recipient O
whose O
donor O
subsequently O
tested O
positive O
for O
COVID O
- O
19 O
. O

This O
cohort O
study O
provides O
preliminary O
information O
on O
COVID O
- O
19 O
in O
people O
with O
TSC O
in O
Italy O
and O
suggests O
feasibility O
to O
systematically O
evaluate O
the O
role O
of O
mTOR O
inhibitors O
in O
SARS O
- O
CoV O
- O
2 O
infection O
. O

Although O
clinical O
manifestations O
of O
the O
2019 O
novel O
coronavirus O
disease O
pandemic O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
the O
novel O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
COV O
- O
2 O
) O
, O
are O
mainly O
respiratory O
symptoms O
, O
patients O
can O
also O
develop O
severe O
cardiovascular O
damage O
. O

Life O
experience O
, O
an O
optimistic O
attitude O
, O
understanding O
of O
the O
necessity O
of O
restrictions O
, O
and O
previous O
crises O
that O
have O
been O
mastered O
were O
the O
most O
important O
resources O
during O
the O
COVID O
- O
19 O
pandemic O
for O
older O
adults O
. O

A O
meta O
- O
analysis O
of O
prevalence O
studies O
showed O
that O
skin O
manifestations O
among O
patients O
with O
COVID O
- O
19 O
were O
reported O
in O
four O
countries O
( O
China O
, O
Thailand O
, O
France O
, O
and O
Italy O
) O
, O
with O
an O
overall O
prevalence O
of O
1 O
. O
0 O
% O
[ O
( O
95 O
% O
CI O
) O
0 O
. O
1 O
- O
1 O
. O
9 O
] O
among O
2 O
, O
621 O
patients O
. O

During O
the O
COVID O
- O
19 O
pandemic O
, O
the O
National O
Cancer O
Institute O
( O
NCI O
) O
is O
bringing O
to O
bear O
its O
considerable O
expertise O
and O
capabilities O
to O
understand O
, O
treat O
, O
and O
prevent O
the O
disease O
. O

On O
April O
17 O
, O
2020 O
, O
a O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
webinar O
was O
held O
by O
selected O
international O
experts O
in O
the O
field O
of O
intensive O
care O
and O
specialized O
respiratory O
ECMO O
centers O
from O
Germany O
, O
Italy O
, O
Spain O
, O
and O
the O
United O
Kingdom O
, O
which O
was O
hosted O
by O
the O
German O
Heart O
Centre O
Berlin O
/ O
Charit O
é O
. O

Our O
case O
highlights O
the O
unique O
barriers O
to O
care O
that O
COVID O
- O
19 O
poses O
to O
antepartum O
patients O
, O
particularly O
in O
the O
setting O
of O
pregnant O
women O
with O
persistent O
positive O
testing O
. O

On O
the O
other O
hand O
, O
remdesivir O
likely O
results O
in O
a O
large O
increase O
in O
the O
incidence O
of O
adverse O
effects O
in O
patients O
with O
COVID O
- O
19 O
( O
RR O
1 O
. O
29 O
, O
95 O
% O
CI O
0 O
. O
58 O
to O
2 O
. O
84 O
; O
moderate O
certainty O
evidence O
) O
. O

The O
COVID O
- O
19 O
disease O
caused O
by O
the O
SARS O
- O
CoV O
- O
2 O
has O
emerged O
as O
a O
worldwide O
pandemic O
and O
caused O
huge O
damage O
to O
the O
lives O
and O
economy O
of O
more O
than O
hundred O
countries O
. O

Knowledge O
on O
COVID O
- O
19 O
symptoms O
was O
highest O
in O
this O
order O
: O
fever O
> O
dry O
cough O
> O
difficulty O
breathing O
> O
fatigue O
> O
headache O
with O
no O
significant O
differences O
between O
lecturers O
and O
students O
. O

Our O
study O
demonstrated O
that O
the O
general O
population O
in O
Saudi O
Arabia O
has O
a O
moderate O
level O
of O
knowledge O
about O
COVID O
- O
19 O
transmission O
and O
preventive O
measures O
. O

Extensive O
Thrombosis O
in O
a O
Severe O
COVID O
- O
19 O
Patient O
Despite O
Prophylactic O
Low O
Molecular O
Weight O
Heparin O
. O

This O
study O
aimed O
to O
assess O
the O
attitudes O
and O
perceptions O
of O
clinical O
medical O
and O
dental O
students O
in O
Lagos O
, O
Nigeria O
, O
about O
volunteering O
during O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

There O
is O
evidence O
that O
the O
upregulation O
of O
immune O
checkpoint O
molecules O
in O
T O
cells O
, O
lymphopenia O
, O
and O
inflammatory O
cytokine O
secretion O
are O
associated O
with O
the O
severity O
of O
COVID O
- O
19 O
symptoms O
. O

Indian O
COVID O
- O
19 O
Risk O
Score O
, O
Comorbidities O
and O
Mortality O
. O

IDC O
has O
been O
shown O
to O
be O
beneficial O
for O
many O
conditions O
; O
however O
, O
the O
impact O
of O
IDC O
for O
COVID O
- O
19 O
is O
unknown O
. O

In O
late O
2019 O
, O
a O
new O
coronavirus O
- O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
- O
was O
discovered O
in O
Wuhan O
, O
China O
, O
and O
the O
World O
Health O
Organization O
later O
declared O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
a O
pandemic O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
challenges O
neurologists O
in O
counseling O
multiple O
sclerosis O
( O
MS O
) O
patients O
with O
respect O
to O
their O
risk O
for O
and O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
and O
in O
guiding O
disease O
- O
modifying O
treatment O
( O
DMT O
) O
. O

[ O
Cardiovascular O
Pathology O
in O
Patients O
With O
COVID O
- O
19 O
] O
. O

Citizens O
affected O
by O
substance O
use O
disorders O
are O
high O
- O
risk O
populations O
for O
both O
SARS O
- O
CoV O
- O
2 O
infection O
and O
COVID O
- O
19 O
- O
related O
mortality O
. O

Singapore O
has O
historically O
had O
very O
strong O
epidemiological O
surveillance O
and O
contact O
- O
tracing O
capacity O
and O
has O
shown O
in O
the O
COVID O
- O
19 O
epidemic O
evidence O
of O
a O
high O
sensitivity O
of O
case O
detection O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
perceptions O
and O
attitudes O
of O
South O
Carolina O
independent O
full O
- O
service O
restaurant O
operators O
in O
relation O
to O
the O
operational O
and O
economic O
effects O
of O
the O
COVID O
- O
19 O
pandemic O
. O

We O
then O
calculated O
the O
age O
- O
standardized O
death O
rate O
( O
ASDR O
) O
based O
on O
the O
current O
COVID O
- O
19 O
figures O
and O
for O
alternative O
scenarios O
of O
increased O
prevalence O
. O

For O
this O
reason O
, O
we O
investigated O
the O
different O
activation O
status O
profiles O
and O
the O
subset O
distribution O
of O
myeloid O
cells O
and O
their O
correlation O
with O
disease O
progression O
in O
40 O
COVID O
- O
19 O
patients O
at O
different O
stages O
of O
disease O
. O

Service O
learning O
in O
public O
health O
nursing O
education O
: O
How O
COVID O
- O
19 O
accelerated O
community O
- O
academic O
partnership O
. O

Importance O
should O
be O
attached O
to O
the O
preoperative O
evaluation O
of O
pregnant O
women O
with O
COVID O
- O
19 O
and O
the O
implementation O
of O
anesthesia O
plan O
. O

COVID O
- O
19 O
and O
Religious O
Ethics O
. O

Association O
between O
climatic O
variables O
and O
COVID O
- O
19 O
pandemic O
in O
National O
Capital O
Territory O
of O
Delhi O
, O
India O
. O

The O
prophylaxis O
and O
treatment O
potential O
of O
supplements O
for O
COVID O
- O
19 O
. O

The O
coronavirus O
has O
caused O
viral O
pneumonia O
in O
tens O
of O
thousands O
of O
people O
around O
the O
world O
, O
and O
the O
COVID O
- O
19 O
outbreak O
changed O
most O
countries O
' O
routines O
and O
concerns O
and O
transformed O
social O
behaviour O
. O

A O
significant O
association O
between O
political O
leaning O
and O
the O
COVID O
- O
19 O
growth O
rate O
was O
measured O
. O

While O
mortality O
was O
also O
similar O
, O
COVID O
- O
19 O
is O
characterized O
with O
increased O
thrombogenicity O
and O
high O
pulmonary O
embolism O
rates O
. O

About O
9 O
months O
have O
passed O
since O
the O
first O
anecdotal O
reports O
on O
the O
involvement O
of O
the O
olfactory O
and O
gustatory O
systems O
in O
the O
COVID O
- O
19 O
pathology O
. O

Has O
the O
COVID O
- O
19 O
Pandemic O
Opened O
Our O
Eyes O
to O
the O
Potential O
of O
Digital O
Teaching O
? O
A O
Survey O
of O
UK O
Vascular O
Surgery O
and O
Interventional O
Radiology O
Trainees O
. O

All O
patients O
referred O
to O
emergency O
rooms O
anywhere O
in O
Iran O
between O
12 O
and O
25 O
April O
2020 O
and O
who O
were O
sufficiently O
ill O
to O
require O
hospital O
admission O
with O
COVID O
- O
19 O
, O
confirmed O
by O
a O
positive O
COVID O
- O
19 O
test O
, O
were O
studied O
. O

Concerns O
have O
been O
raised O
that O
patients O
requiring O
emergency O
care O
may O
not O
have O
accessed O
healthcare O
services O
during O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
lockdown O
. O

Full O
Throttle O
: O
COVID O
- O
19 O
Open O
Science O
to O
Build O
Planetary O
Public O
Goods O
. O

COVID O
- O
19 O
has O
significantly O
greater O
mortality O
in O
the O
elderly O
and O
comorbid O
patients O
which O
includes O
hip O
fracture O
patients O
. O

This O
paper O
reiterates O
the O
adherence O
of O
school O
health O
protocols O
as O
significant O
in O
the O
delivery O
of O
face O
- O
to O
- O
face O
classes O
following O
national O
and O
international O
guidelines O
in O
mitigating O
the O
effects O
of O
COVID O
- O
19 O
pandemic O
as O
a O
public O
health O
crisis O
. O

The O
change O
in O
trends O
of O
newly O
confirmed O
COVID O
- O
19 O
cases O
before O
and O
after O
the O
social O
distancing O
campaign O
was O
significantly O
negative O
in O
the O
entire O
cohort O
( O
adjusted O
trend O
difference O
- O
2 O
. O
28 O
; O
95 O
% O
CI O
- O
3 O
. O
88 O
to O
- O
0 O
. O
68 O
) O
and O
the O
cluster O
infection O
group O
( O
adjusted O
trend O
difference O
- O
0 O
. O
96 O
; O
95 O
% O
CI O
- O
1 O
. O
83 O
to O
- O
0 O
. O
09 O
) O
. O

COVID O
- O
19 O
and O
Oral O
Surgery O
: O
A O
narrative O
review O
of O
preoperative O
mouth O
rinses O
. O

The O
development O
of O
acute O
respiratory O
distress O
syndrome O
indicates O
a O
serious O
form O
of O
COVID O
- O
19 O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
a O
member O
of O
the O
betacoronavirus O
family O
, O
which O
causes O
COVID O
- O
19 O
disease O
. O

Conclusions O
: O
The O
findings O
of O
this O
study O
have O
provided O
baseline O
information O
on O
the O
current O
state O
of O
Saudi O
nursing O
students O
' O
perceptions O
, O
knowledge O
, O
and O
preventive O
behavior O
toward O
COVID O
- O
19 O
as O
the O
crisis O
is O
happening O
. O

A O
critical O
appraisal O
of O
COVID O
- O
19 O
as O
a O
nosocomial O
infection O
: O
an O
African O
perspective O
. O

GLUT1 O
and O
COVID O
- O
19 O
deficiency O
syndrome O
. O

Procedures O
in O
COVID O
- O
19 O
Patients O
: O
Part O
- O
I O
. O

The O
standard O
RT O
- O
PCR O
assay O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
laborious O
and O
time O
- O
consuming O
, O
limiting O
testing O
availability O
. O

We O
report O
a O
patient O
with O
confirmed O
COVID O
- O
19 O
combined O
with O
asthma O
. O

Mental O
health O
problems O
experienced O
by O
patients O
with O
rheumatic O
diseases O
during O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
pneumonia O
versus O
EVALI O
, O
distinguishing O
the O
overlapping O
CT O
features O
in O
the O
COVID O
- O
19 O
era O
. O

A O
multicentre O
study O
of O
inpatients O
with O
cirrhosis O
+ O
COVID O
- O
19 O
compared O
with O
age O
/ O
gender O
- O
matched O
patients O
with O
COVID O
- O
19 O
alone O
and O
cirrhosis O
alone O
was O
performed O
. O

In O
this O
review O
, O
we O
summarize O
the O
strategies O
currently O
employed O
in O
the O
treatment O
of O
COVID O
- O
19 O
. O

No O
specific O
therapies O
/ O
vaccines O
are O
yet O
available O
for O
the O
treatment O
of O
COVID O
- O
19 O
. O

Transplant O
patients O
are O
particularly O
at O
a O
higher O
risk O
of O
contracting O
COVID O
- O
19 O
because O
of O
their O
immunosuppressed O
state O
, O
and O
they O
have O
the O
propensity O
to O
develop O
opportunistic O
infections O
. O

The O
institution O
of O
social O
distancing O
and O
punitive O
measures O
to O
contain O
the O
spread O
of O
COVID O
- O
19 O
through O
human O
- O
to O
- O
human O
transmission O
has O
environmental O
, O
health O
and O
economic O
impact O
. O

Clinical O
implications O
of O
the O
hematologic O
profile O
of O
COVID O
- O
19 O
patients O
including O
cytokine O
storm O
, O
coagulation O
profile O
, O
and O
thrombophilic O
complications O
are O
under O
- O
recognized O
. O

Meta O
- O
Analysis O
of O
Atrial O
Fibrillation O
in O
Patients O
With O
COVID O
- O
19 O
. O

The O
authors O
conducted O
a O
cross O
- O
sectional O
study O
to O
describe O
changes O
in O
outpatient O
clinic O
visits O
and O
to O
compare O
the O
rates O
of O
cesarean O
and O
instrumental O
deliveries O
between O
two O
periods O
of O
time O
: O
March O
- O
April O
2020 O
( O
during O
the O
COVID O
- O
19 O
outbreak O
) O
with O
March O
- O
April O
of O
the O
preceding O
year O
, O
2019 O
. O

Among O
patients O
who O
were O
COVID O
- O
19 O
negative O
, O
alternative O
etiologies O
included O
treatment O
- O
related O
toxicity O
( O
26 O
% O
) O
, O
atypical O
pneumonia O
( O
22 O
% O
) O
, O
and O
disease O
progression O
( O
22 O
% O
) O
. O

The O
ratio O
of O
fatal O
cases O
in O
very O
elderly O
patients O
with O
COVID O
- O
19 O
is O
no O
higher O
than O
that O
reported O
in O
non O
- O
elderly O
patients O
was O
, O
and O
probably O
due O
to O
a O
low O
immune O
response O
. O

The O
study O
aimed O
to O
explore O
the O
prevalence O
and O
possible O
risk O
factors O
to O
prevent O
the O
face O
mask O
related O
adverse O
skin O
reactions O
during O
the O
ongoing O
COVID O
- O
19 O
after O
a O
recommendation O
of O
face O
mask O
wearing O
for O
public O
use O
in O
Thailand O
. O

Our O
analysis O
of O
data O
on O
COVID O
- O
19 O
- O
related O
mortality O
in O
Spain O
, O
Italy O
, O
and O
Sweden O
has O
shown O
that O
, O
in O
the O
range O
of O
30 O
to O
90 O
years O
of O
age O
, O
each O
dependency O
of O
the O
logarithm O
of O
mortality O
upon O
age O
is O
linear O
, O
and O
all O
regression O
lines O
are O
strictly O
parallel O
to O
those O
related O
to O
the O
total O
mortality O
in O
accordance O
with O
the O
Gompertz O
law O
. O

COVID O
- O
19 O
is O
a O
multisystem O
illness O
that O
has O
considerable O
long O
- O
term O
physical O
, O
psychological O
, O
cognitive O
, O
social O
and O
vocational O
sequelae O
in O
survivors O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
creates O
a O
need O
to O
protect O
health O
care O
workers O
( O
HCWs O
) O
from O
patients O
undergoing O
aerosol O
- O
generating O
procedures O
which O
may O
transmit O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

We O
hypothesized O
that O
LBW O
is O
a O
risk O
factor O
for O
severe O
COVID O
- O
19 O
in O
non O
- O
elderly O
subjects O
. O

In O
this O
study O
, O
we O
examined O
the O
impact O
of O
epidemic O
information O
and O
rumors O
on O
public O
' O
s O
worries O
and O
attitude O
toward O
prevention O
measures O
during O
the O
outbreak O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
Management O
in O
Iran O
as O
One O
of O
the O
Most O
Affected O
Countries O
in O
the O
World O
: O
Advantages O
and O
Weaknesses O
. O

Aspartate O
aminotransferase O
: O
A O
prognostic O
marker O
rather O
than O
a O
specific O
liver O
injury O
marker O
in O
COVID O
- O
19 O
. O

Non O
- O
febrile O
COVID O
- O
19 O
patients O
were O
common O
and O
often O
became O
critically O
ill O
: O
a O
retrospective O
multicenter O
cohort O
study O
. O

Patients O
with O
COVID O
- O
19 O
develop O
a O
wide O
spectrum O
of O
glomerular O
and O
tubular O
diseases O
. O

KEY O
POINTS O
: O
• O
Inflammatory O
cytokines O
play O
an O
essential O
role O
in O
the O
pathogenesis O
of O
COVID O
- O
19 O
• O
ACE2 O
dysfunctions O
are O
related O
to O
the O
with O
COVID O
- O
19 O
and O
autoimmune O
diseases O
• O
The O
use O
autoimmune O
diseases O
drugs O
can O
be O
useful O
in O
treating O
COVID O
- O
19 O
. O

Only O
three O
patients O
were O
suspected O
to O
have O
COVID O
- O
19 O
before O
admission O
. O

Next O
, O
chemical O
similarity O
( O
or O
diversity O
) O
and O
PubMed O
searches O
made O
it O
possible O
to O
repurpose O
and O
assess O
approved O
or O
experimental O
drugs O
for O
COVID O
- O
19 O
. O

COVID O
- O
19 O
Infection O
in O
Heart O
Transplantation O
: O
Case O
Reports O
. O

The O
majority O
of O
the O
studies O
reflect O
a O
good O
knowledge O
, O
positive O
attitude O
, O
and O
good O
practice O
towards O
COVID O
- O
19 O
respective O
to O
their O
countries O
. O

The O
challenge O
of O
social O
distancing O
, O
providing O
care O
for O
those O
infected O
by O
COVID O
- O
19 O
, O
continuing O
appropriate O
treatment O
of O
time O
- O
sensitive O
diseases O
, O
and O
the O
looming O
threat O
of O
health O
care O
worker O
infections O
required O
swift O
planning O
and O
restructuring O
of O
training O
programs O
. O

Initial O
success O
in O
the O
identification O
and O
management O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
indicates O
human O
- O
to O
- O
human O
transmission O
in O
Wuhan O
, O
China O
. O

The O
COVID O
- O
19 O
pandemic O
caused O
by O
the O
SARS O
- O
CoV O
- O
2 O
virus O
, O
which O
first O
emerged O
in O
December O
2019 O
, O
represents O
an O
ongoing O
global O
public O
health O
emergency O
. O

Tenecteplase O
( O
and O
common O
sense O
) O
in O
short O
supply O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
systematic O
review O
of O
COVID O
- O
19 O
and O
obstructive O
sleep O
apnoea O
. O

Anxiety O
among O
front O
- O
line O
health O
- O
care O
workers O
supporting O
patients O
with O
COVID O
- O
19 O
: O
A O
global O
survey O
. O

Combating O
COVID O
- O
19 O
Lockdown O
Inactivity O
in O
the O
African O
Population O
: O
Use O
of O
Cultural O
practices O
and O
One O
Health O
Approach O
. O

Patients O
with O
end O
- O
stage O
renal O
disease O
( O
ESRD O
) O
in O
hemodialysis O
facilities O
require O
specific O
protocols O
to O
be O
planned O
and O
promptly O
executed O
for O
the O
management O
of O
suspected O
/ O
confirmed O
cases O
of O
COVID O
- O
19 O
with O
respect O
to O
prevention O
, O
protection O
, O
screening O
, O
and O
isolation O
. O

We O
observed O
4 O
times O
increase O
in O
the O
consumption O
of O
hand O
sanitizers O
after O
COVID O
- O
19 O
outbreak O
. O

There O
is O
a O
clear O
need O
for O
guidance O
on O
the O
rehabilitation O
of O
COVID O
- O
19 O
survivors O
. O

Lactate O
dehydrogenase O
elevations O
is O
associated O
with O
severity O
of O
COVID O
- O
19 O
: O
a O
meta O
- O
analysis O
. O

Understanding O
and O
Addressing O
Latinx O
COVID O
- O
19 O
Disparities O
in O
Washington O
State O
. O

Risk O
Factors O
for O
Mortality O
in O
Hospitalized O
Patients O
with O
COVID O
- O
19 O
: O
An O
Overview O
in O
a O
Mexican O
Population O
. O

In O
this O
study O
, O
we O
aimed O
to O
investigate O
the O
role O
of O
chest O
CT O
severity O
score O
and O
imaging O
features O
in O
the O
prediction O
of O
the O
prognosis O
of O
COVID O
- O
19 O
patients O
. O

Differential O
Diagnosis O
of O
COVID O
- O
19 O
Enanthema O
. O

Meanwhile O
, O
the O
taskforce O
aims O
to O
develop O
a O
nation O
- O
wide O
clinical O
guidance O
to O
be O
used O
by O
health O
care O
workers O
and O
untrained O
laypersons O
to O
resuscitate O
COVID O
- O
19 O
suspected O
and O
diagnosed O
patients O
. O

This O
review O
was O
based O
on O
an O
electronic O
search O
of O
the O
literature O
in O
the O
Scopus O
, O
Science O
Direct O
, O
and O
PubMed O
database O
published O
from O
December O
2019 O
to O
July O
2020 O
using O
combinations O
of O
the O
following O
keywords O
: O
SARS O
- O
CoV O
- O
2 O
transmission O
, O
COVID O
- O
19 O
transmission O
, O
coronavirus O
transmission O
, O
waterborne O
, O
wastewater O
, O
airborne O
, O
solid O
waste O
, O
fomites O
, O
and O
fecal O
- O
oral O
transmission O
. O

Due O
to O
the O
profound O
effect O
of O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
on O
healthcare O
systems O
, O
surgical O
programs O
across O
the O
country O
have O
paused O
surgical O
operations O
and O
have O
been O
utilizing O
virtual O
visits O
to O
help O
maintain O
public O
safety O
. O

Controlled O
clinical O
studies O
should O
be O
conducted O
to O
determine O
whether O
ARBs O
may O
be O
included O
as O
additional O
therapy O
for O
COVID O
- O
19 O
patients O
. O

Methods O
In O
this O
exploratory O
study O
, O
an O
analysis O
of O
the O
correlation O
between O
the O
frequencies O
of O
the O
Met O
allele O
of O
the O
COMT O
gene O
across O
28 O
countries O
, O
obtained O
from O
the O
public O
domain O
Allele O
Frequency O
Database O
( O
ALFRED O
) O
, O
and O
the O
COVID O
- O
19 O
prevalence O
and O
mortality O
rates O
in O
these O
countries O
, O
obtained O
from O
the O
Johns O
Hopkins O
Medical O
University O
web O
- O
based O
dashboard O
, O
was O
carried O
out O
while O
controlling O
for O
population O
size O
and O
median O
age O
in O
each O
country O
. O

A O
five O
- O
step O
approach O
was O
taken O
to O
( O
1 O
) O
assess O
the O
COVID O
- O
19 O
situation O
and O
decide O
to O
formulate O
a O
response O
; O
( O
2 O
) O
mobilise O
and O
coordinate O
Human O
Factors O
/ O
Ergonomics O
( O
HFE O
) O
specialists O
; O
( O
3 O
) O
ideate O
, O
with O
HFE O
specialists O
collaborating O
to O
identify O
, O
analyse O
the O
issues O
and O
opportunities O
, O
and O
develop O
strategies O
, O
plans O
and O
processes O
; O
( O
4 O
) O
generate O
outputs O
and O
solutions O
; O
and O
( O
5 O
) O
respond O
to O
the O
COVID O
- O
19 O
situation O
via O
targeted O
support O
and O
guidance O
. O

Conclusions O
: O
Despite O
variability O
in O
data O
collection O
and O
time O
coverage O
among O
countries O
, O
we O
illustrate O
an O
overall O
similar O
pattern O
of O
sex O
differences O
in O
COVID O
- O
19 O
mortality O
in O
Europe O
. O

The O
aim O
of O
this O
document O
is O
to O
provide O
specific O
recommendations O
on O
the O
use O
of O
cardiovascular O
magnetic O
resonance O
( O
CMR O
) O
protocols O
in O
the O
era O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
COVID O
- O
19 O
epidemic O
, O
which O
began O
in O
Wuhan O
in O
December O
2019 O
, O
quickly O
spread O
all O
over O
the O
world O
, O
leading O
in O
a O
few O
months O
to O
a O
high O
number O
of O
deaths O
also O
in O
healthcare O
workers O
. O

Is O
Increased O
Sleep O
Responsible O
for O
Reductions O
in O
Myocardial O
Infarction O
During O
the O
COVID O
- O
19 O
Pandemic O
? O

Before O
COVID O
- O
19 O
, O
in O
both O
periods O
most O
contacts O
( O
67 O
% O
in O
January O
- O
February O
2020 O
and O
60 O
% O
in O
March O
- O
April O
2019 O
) O
required O
information O
about O
clinical O
activity O
, O
while O
fewer O
( O
33 O
% O
in O
January O
- O
February O
2020 O
and O
40 O
% O
in O
March O
- O
April O
2019 O
) O
requested O
logistic O
information O
. O

This O
online O
, O
cross O
- O
sectional O
survey O
recruited O
399 O
participants O
from O
two O
university O
hospitals O
, O
and O
they O
were O
administered O
a O
self O
- O
reported O
questionnaire O
on O
demographic O
, O
personal O
, O
and O
clinical O
characteristics O
, O
as O
well O
as O
COVID O
- O
19 O
- O
related O
stressors O
and O
coping O
. O

We O
describe O
post O
- O
mortem O
pulmonary O
histopathologic O
findings O
of O
COVID O
- O
19 O
pneumonia O
in O
patients O
with O
a O
spectrum O
of O
disease O
course O
, O
from O
rapid O
demise O
to O
prolonged O
hospitalisation O
. O

Adults O
with O
respiratory O
- O
related O
chronic O
diseases O
were O
extremely O
/ O
very O
( O
conditional O
odds O
ratio O
1 O
. O
16 O
, O
95 O
% O
CI O
1 O
. O
00 O
- O
1 O
. O
35 O
) O
and O
moderately O
likely O
( O
conditional O
odds O
ratio O
1 O
. O
23 O
, O
95 O
% O
CI O
1 O
. O
04 O
- O
1 O
. O
45 O
) O
to O
use O
a O
mobile O
phone O
app O
to O
track O
their O
location O
and O
receive O
push O
notifications O
about O
whether O
they O
have O
been O
exposed O
to O
COVID O
- O
19 O
. O

Analysis O
of O
Factors O
Causing O
False O
- O
Negative O
Real O
- O
Time O
Polymerase O
Chain O
Reaction O
Results O
in O
Oropharyngeal O
and O
Nasopharyngeal O
Swabs O
of O
Patients O
With O
COVID O
- O
19 O
. O

Incidence O
of O
smell O
and O
taste O
dysfunction O
was O
higher O
in O
Europe O
( O
34 O
to O
86 O
% O
) O
, O
North O
America O
( O
19 O
to O
71 O
% O
) O
and O
the O
Middle O
East O
( O
36 O
to O
98 O
% O
) O
when O
compared O
to O
the O
Asian O
cohorts O
( O
11 O
to O
15 O
% O
) O
in O
COVID O
- O
19 O
positive O
patients O
. O

Survival O
and O
predictors O
of O
deaths O
of O
patients O
hospitalised O
due O
to O
COVID O
- O
19 O
from O
a O
retrospective O
and O
multicentre O
cohort O
study O
in O
Brazil O
. O

Limiting O
Patient O
Autonomy O
: O
Mandatory O
COVID O
- O
19 O
Diagnostic O
Testing O
. O

Extension O
of O
COVID O
- O
19 O
pulmonary O
parenchyma O
lesions O
based O
on O
real O
- O
life O
visual O
assessment O
on O
initial O
chest O
CT O
is O
an O
independent O
predictor O
of O
poor O
patient O
outcome O
. O

The O
ongoing O
COVID O
- O
19 O
crisis O
and O
its O
impact O
serve O
as O
an O
important O
period O
for O
adequate O
mental O
healthcare O
, O
promotion O
, O
research O
, O
and O
holistic O
biopsychosocial O
management O
of O
psychiatric O
disorders O
, O
especially O
in O
vulnerable O
groups O
. O

This O
position O
paper O
of O
the O
Respiratory O
Support O
and O
Chronic O
Care O
Group O
of O
the O
French O
Society O
of O
Respiratory O
Diseases O
is O
intended O
to O
help O
respiratory O
clinicians O
involved O
in O
care O
of O
COVID O
- O
19 O
pandemic O
in O
the O
rational O
use O
of O
non O
- O
invasive O
techniques O
such O
as O
oxygen O
therapy O
, O
CPAP O
, O
non O
- O
invasive O
ventilation O
and O
high O
flow O
oxygen O
therapy O
in O
managing O
patients O
outside O
intensive O
care O
unit O
( O
ICU O
) O
. O

In O
early O
June O
2020 O
, O
more O
than O
6 O
, O
400 O
, O
000 O
COVID O
- O
19 O
( O
coronavirus O
- O
19 O
disease O
) O
cases O
were O
diagnosed O
across O
the O
world O
and O
more O
than O
380 O
, O
000 O
deaths O
were O
linked O
to O
COVID O
- O
19 O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
primary O
causative O
organism O
in O
corona O
virus O
disease O
- O
19 O
( O
COVID O
- O
19 O
) O
infections O
, O
is O
a O
novel O
member O
of O
the O
human O
coronavirus O
family O
which O
was O
first O
identified O
in O
Wuhan O
, O
China O
, O
towards O
the O
end O
of O
2019 O
. O

Increased O
TLR O
/ O
MyD88 O
signaling O
in O
patients O
with O
obesity O
: O
is O
there O
a O
link O
to O
COVID O
- O
19 O
disease O
severity O
? O

Hence O
, O
the O
number O
of O
COVID O
- O
19 O
cases O
is O
inaccurately O
predicted O
. O

There O
is O
an O
abundance O
of O
the O
academic O
literature O
and O
media O
reports O
on O
the O
potential O
of O
drugs O
that O
could O
attenuate O
or O
exacerbate O
COVID O
- O
19 O
disease O
. O

Myoclonus O
and O
cerebellar O
ataxia O
following O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

A O
randomized O
, O
multicentre O
, O
open O
- O
label O
phase O
II O
proof O
- O
of O
- O
concept O
trial O
investigating O
the O
clinical O
efficacy O
and O
safety O
of O
the O
addition O
of O
convalescent O
plasma O
to O
the O
standard O
of O
care O
in O
patients O
hospitalized O
with O
COVID O
- O
19 O
: O
the O
Donated O
Antibodies O
Working O
against O
nCoV O
( O
DAWn O
- O
Plasma O
) O
trial O
. O

The O
lack O
of O
clinically O
effective O
therapies O
for O
COVID O
- O
19 O
calls O
for O
the O
consideration O
of O
novel O
adjunct O
therapeutic O
approaches O
. O

A O
prothrombotic O
state O
is O
reported O
with O
severe O
COVID O
- O
19 O
infection O
, O
which O
can O
manifest O
in O
venous O
and O
arterial O
thrombotic O
events O
. O

Although O
health O
care O
workers O
( O
HCWs O
) O
are O
at O
higher O
risk O
of O
acquiring O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
it O
is O
unclear O
whether O
they O
are O
at O
risk O
of O
poorer O
outcomes O
. O

Marketing O
innovations O
during O
a O
global O
crisis O
: O
A O
study O
of O
China O
firms O
' O
response O
to O
COVID O
- O
19 O
. O

Social O
costs O
of O
tourism O
during O
the O
COVID O
- O
19 O
pandemic O
. O

An O
anonymized O
web O
- O
based O
questionnaire O
was O
used O
to O
assess O
demographics O
, O
CL O
history O
, O
and O
activity O
, O
CL O
wear O
habits O
and O
perceived O
risk O
of O
infection O
due O
to O
CL O
wear O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
2020 O
COVID O
- O
19 O
pandemic O
, O
which O
preppers O
consider O
a O
' O
mid O
- O
level O
' O
event O
, O
and O
which O
many O
of O
them O
were O
well O
- O
prepared O
for O
, O
makes O
clear O
that O
scholarly O
attention O
to O
prepper O
' O
s O
motivations O
and O
methods O
is O
both O
timely O
and O
valuable O
. O

On O
the O
importance O
of O
early O
testing O
even O
when O
imperfect O
in O
a O
pandemic O
such O
as O
COVID O
- O
19 O
. O

Some O
early O
English O
language O
news O
coverage O
of O
COVID O
- O
19 O
epidemiology O
focused O
on O
studies O
that O
examined O
how O
SARS O
- O
CoV O
- O
2 O
( O
the O
coronavirus O
that O
causes O
COVID O
- O
19 O
) O
was O
evolving O
at O
the O
genetic O
level O
. O

In O
this O
study O
of O
recipients O
of O
allogeneic O
( O
Allo O
) O
and O
autologous O
( O
Auto O
) O
hematopoietic O
cell O
transplant O
and O
CD19 O
- O
directed O
chimeric O
antigen O
receptor O
T O
cell O
( O
CAR O
T O
) O
therapy O
at O
Memorial O
Sloan O
Kettering O
Cancer O
Center O
, O
we O
aimed O
to O
identify O
clinical O
variables O
associated O
with O
COVID O
- O
19 O
severity O
and O
assess O
lymphocyte O
populations O
. O
METHODSWe O
retrospectively O
investigated O
patients O
diagnosed O
between O
March O
15 O
, O
2020 O
, O
and O
May O
7 O
, O
2020 O
. O

However O
, O
prophylaxis O
of O
COVID O
- O
19 O
misinformation O
might O
be O
achieved O
by O
taking O
concrete O
steps O
to O
improve O
trust O
in O
science O
and O
scientists O
, O
such O
as O
building O
understanding O
of O
the O
scientific O
process O
and O
supporting O
open O
science O
initiatives O
. O

It O
was O
first O
described O
in O
2019 O
, O
developed O
into O
an O
epidemic O
in O
January O
2020 O
and O
has O
spread O
the O
global O
to O
the O
present O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
outbreak O
and O
cancer O
patient O
management O
: O
Viewpoint O
from O
radio O
- O
oncologists O
. O

Mixed O
- O
effects O
models O
were O
applied O
to O
assess O
associations O
among O
COVID O
- O
19 O
- O
related O
income O
loss O
, O
financial O
strain O
, O
and O
pandemic O
- O
related O
worries O
about O
health O
, O
with O
anxiety O
and O
depression O
, O
controlling O
for O
multiple O
covariates O
including O
pre O
- O
COVID O
- O
19 O
income O
. O

Early O
changes O
in O
laboratory O
parameters O
are O
predictors O
of O
mortality O
and O
ICU O
admission O
in O
patients O
with O
COVID O
- O
19 O
: O
a O
systematic O
review O
and O
meta O
- O
analysis O
. O

C4 O
article O
: O
Implications O
of O
COVID O
- O
19 O
in O
transplantation O
. O

Health O
outcomes O
of O
people O
with O
COVID O
- O
19 O
range O
from O
no O
symptoms O
to O
severe O
illness O
and O
death O
. O

Awake O
prone O
positioning O
has O
been O
widely O
used O
in O
patients O
with O
COVID O
- O
19 O
respiratory O
failure O
to O
avoid O
intubation O
despite O
limited O
evidence O
. O

to O
assess O
the O
epidemiology O
and O
features O
of O
de O
novo O
surgical O
diseases O
in O
patients O
admitted O
with O
COVID O
- O
19 O
, O
and O
their O
impact O
on O
patients O
and O
healthcare O
system O
. O

There O
is O
much O
discussion O
of O
adopting O
COVID O
- O
19 O
immunity O
certificates O
to O
allow O
those O
proven O
to O
have O
antibodies O
to O
the O
SARS O
- O
CoV O
- O
2 O
virus O
that O
causes O
COVID O
- O
19 O
to O
resume O
normal O
life O
and O
help O
restart O
the O
economy O
. O

This O
brief O
report O
describes O
COVID O
- O
19 O
response O
strategies O
and O
outcomes O
in O
Florida O
through O
May O
31 O
, O
2020 O
. O

In O
this O
discussion O
article O
, O
challenges O
for O
journalism O
that O
have O
arisen O
in O
reporting O
on O
the O
scientific O
aspects O
of O
the O
COVID O
- O
19 O
pandemic O
are O
described O
. O
At O
the O
beginning O
of O
the O
pandemic O
, O
there O
was O
a O
real O
epistemic O
uncertainty O
due O
to O
the O
lack O
of O
established O
facts O
. O

COMMENTSSay O
What O
? O
! O
Ableist O
Logic O
Used O
in O
Misguided O
Attempt O
to O
Combat O
Ageism O
During O
COVID O
- O
19 O
. O

Because O
dentists O
are O
at O
a O
higher O
risk O
of O
contracting O
the O
disease O
, O
the O
present O
study O
assessed O
the O
fear O
and O
anxiety O
among O
dental O
practitioners O
of O
becoming O
infected O
with O
COVID O
- O
19 O
. O

Alcohol O
use O
and O
mental O
health O
during O
COVID O
- O
19 O
lockdown O
: O
A O
cross O
- O
sectional O
study O
in O
a O
sample O
of O
UK O
adults O
. O

COVID O
- O
19 O
can O
be O
promptly O
detected O
by O
QCT O
. O

Adapting O
practice O
in O
mental O
healthcare O
settings O
during O
the O
COVID O
- O
19 O
pandemic O
and O
other O
contagions O
: O
systematic O
review O
. O

In O
this O
article O
, O
the O
authors O
discuss O
the O
expedited O
vaccine O
development O
process O
for O
COVID O
- O
19 O
vaccines O
; O
the O
likely O
vaccine O
prioritisation O
schedule O
and O
anticipated O
key O
target O
groups O
; O
the O
behavioural O
and O
social O
drivers O
of O
vaccination O
acceptance O
, O
including O
the O
work O
required O
to O
facilitate O
this O
; O
and O
the O
implications O
for O
general O
practice O
. O

The O
importance O
of O
wearing O
masks O
in O
curtailing O
the O
COVID O
- O
19 O
pandemic O
. O

Medical O
professionals O
should O
consider O
subgroups O
of O
the O
population O
when O
establishing O
various O
means O
to O
deliver O
information O
on O
COVID O
- O
19 O
. O

In O
this O
retrospective O
single O
- O
center O
study O
, O
we O
listed O
patients O
from O
March O
11 O
, O
2020 O
to O
September O
2 O
, O
2020 O
, O
with O
laboratory O
- O
confirmed O
COVID O
- O
19 O
, O
critical O
illness O
and O
cerebral O
microbleeds O
. O

This O
study O
examined O
the O
available O
literature O
to O
explore O
the O
association O
between O
, O
and O
the O
wider O
impact O
of O
, O
COVID O
- O
19 O
on O
BAME O
communities O
. O

A O
single O
- O
centre O
observational O
cohort O
study O
of O
44 O
patients O
infected O
with O
COVID O
- O
19 O
was O
carried O
out O
between O
6 O
April O
and O
21 O
April O
2020 O
in O
Groupe O
Hospitalier O
Intercommunal O
Le O
Raincy O
- O
Montfermeil O
( O
GHILRM O
) O
. O

Challenges O
to O
neonatal O
care O
in O
Cambodia O
amid O
the O
COVID O
- O
19 O
pandemic O
. O

At O
the O
COVID O
- O
19 O
spring O
2020 O
pandemic O
peak O
in O
Spain O
, O
prevalence O
of O
SARS O
- O
CoV O
- O
2 O
infection O
in O
a O
cohort O
of O
578 O
randomly O
selected O
health O
care O
workers O
( O
HCWs O
) O
from O
Hospital O
Cl O
í O
nic O
de O
Barcelona O
was O
11 O
. O
2 O
% O
. O

Hence O
, O
we O
planned O
to O
synthesize O
the O
current O
data O
that O
will O
help O
in O
a O
better O
understanding O
of O
COVID O
- O
19 O
in O
children O
. O

Since O
several O
of O
the O
currently O
administered O
drugs O
against O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
are O
possibly O
hepatotoxic O
, O
the O
management O
of O
patients O
with O
COVID O
- O
19 O
and O
liver O
failure O
is O
still O
an O
almost O
unexplored O
field O
. O

Our O
results O
corroborate O
international O
research O
that O
indicate O
a O
greater O
psychological O
vulnerability O
in O
women O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
overall O
average O
score O
of O
the O
disease O
- O
related O
knowledge O
of O
patients O
with O
COVID O
- O
19 O
was O
( O
79 O
. O
19 O
± O
14 O
. O
25 O
) O
, O
the O
self O
- O
care O
situation O
was O
positively O
correlated O
with O
knowledge O
of O
prevention O
and O
control O
( O
r O
= O
0 O
. O
265 O
, O
P O
= O
0 O
. O
004 O
) O
and O
total O
score O
of O
disease O
- O
related O
knowledge O
( O
r O
= O
0 O
. O
206 O
, O
P O
= O
0 O
. O
025 O
) O
; O
the O
degree O
of O
anxiety O
was O
negatively O
correlated O
with O
the O
knowledge O
of O
diagnosis O
and O
treatment O
( O
r O
= O
- O
0 O
. O
182 O
, O
P O
= O
0 O
. O
049 O
) O
. O

We O
surveyed O
five O
Accreditation O
Council O
for O
Graduate O
Medical O
Education O
- O
accredited O
orthopaedic O
residency O
programs O
within O
cities O
highly O
affected O
by O
the O
COVID O
- O
19 O
pandemic O
about O
clinical O
and O
curricular O
changes O
. O

Effect O
of O
age O
on O
death O
due O
to O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
: O
Application O
of O
Poisson O
regression O
model O
. O

Man O
- O
Specific O
, O
GalNAc O
/ O
T O
/ O
Tn O
- O
Specific O
and O
Neu5Ac O
- O
Specific O
Seaweed O
Lectins O
as O
Glycan O
Probes O
for O
the O
SARS O
- O
CoV O
- O
2 O
( O
COVID O
- O
19 O
) O
Coronavirus O
. O

Centralization O
of O
the O
ST O
elevation O
myocardial O
infarction O
care O
network O
in O
the O
Lombardy O
region O
during O
the O
COVID O
- O
19 O
outbreak O
. O

This O
review O
aims O
to O
summarize O
the O
evidence O
about O
COVID O
- O
19 O
infection O
in O
pregnant O
women O
and O
to O
encourage O
the O
scientific O
community O
to O
investigate O
the O
use O
of O
Vitamin O
D O
and O
Myo O
- O
inositol O
which O
could O
represent O
a O
possible O
preventive O
treatment O
for O
pregnant O
women O
or O
women O
undergoing O
assisted O
reproductive O
technologies O
( O
ART O
) O
. O

The O
present O
study O
examined O
who O
engaged O
in O
preparatory O
purchasing O
of O
safety O
and O
health O
care O
products O
during O
the O
early O
stages O
of O
the O
spread O
of O
COVID O
- O
19 O
and O
what O
stimulated O
this O
action O
. O

Incidental O
findings O
suggestive O
of O
COVID O
- O
19 O
in O
asymptomatic O
cancer O
patients O
undergoing O
18F O
- O
FDG O
PET O
/ O
CT O
in O
a O
low O
prevalence O
region O
. O

CHM O
, O
especially O
classical O
Chinese O
herbal O
formulas O
, O
could O
be O
used O
as O
potential O
candidates O
for O
COVID O
- O
19 O
in O
this O
battle O
. O

Author O
Correction O
: O
A O
dynamic O
COVID O
- O
19 O
immune O
signature O
includes O
associations O
with O
poor O
prognosis O
. O

ICP O
protocols O
varied O
in O
how O
HCAs O
followed O
recommended O
guidelines O
, O
responded O
to O
COVID O
- O
19 O
exposures O
, O
performed O
infection O
surveillance O
, O
and O
implemented O
precautions O
. O

This O
study O
aimed O
to O
identifying O
the O
presence O
of O
SARS O
- O
CoV O
- O
2 O
RNA O
in O
raw O
and O
treated O
wastewater O
during O
the O
COVID O
- O
19 O
outbreak O
in O
Tehran O
, O
Qom O
and O
Anzali O
cities O
( O
Iran O
) O
. O

Our O
results O
suggest O
the O
necessity O
of O
continuous O
controlling O
policy O
in O
these O
areas O
and O
some O
other O
complementary O
strategies O
to O
mitigate O
the O
contagious O
rate O
of O
the O
COVID O
- O
19 O
. O

Risch O
Responds O
to O
" O
How O
to O
Consider O
Low O
Reported O
Death O
Rates O
in O
COVID O
- O
19 O
" O
. O

The O
Ultrasound O
- O
Guided O
Triage O
: O
A O
New O
Tool O
for O
Prehospital O
Management O
of O
COVID O
- O
19 O
Pandemic O
. O

COVID O
- O
19 O
- O
CT O
- O
CXR O
: O
a O
freely O
accessible O
and O
weakly O
labeled O
chest O
X O
- O
ray O
and O
CT O
image O
collection O
on O
COVID O
- O
19 O
from O
biomedical O
literature O
. O

Ecological O
inheritance O
for O
a O
post O
COVID O
- O
19 O
world O
. O

All O
deceased O
patients O
had O
postoperative O
complications O
associated O
with O
operation O
or O
COVID O
- O
19 O
, O
including O
respiratory O
failure O
, O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
, O
short O
of O
breath O
, O
dyspnea O
, O
fever O
, O
cough O
, O
fatigue O
or O
myalgia O
, O
cardiopulmonary O
system O
, O
shock O
/ O
infection O
, O
acute O
kidney O
injury O
and O
severe O
lymphopenia O
. O

In O
addition O
, O
this O
article O
used O
Normalized O
Difference O
Vegetation O
Index O
( O
NDVI O
) O
to O
systematically O
analyze O
the O
characteristics O
of O
air O
pollution O
in O
the O
country O
and O
used O
the O
Pearson O
correlation O
coefficient O
to O
explore O
the O
relationship O
between O
NDVI O
and O
the O
air O
pollutant O
concentrations O
during O
the O
COVID O
- O
19 O
period O
. O

Three O
hundred O
participants O
with O
nucleic O
acid O
test O
- O
confirmed O
COVID O
- O
19 O
were O
included O
in O
this O
study O
. O

Of O
43 O
patients O
who O
developed O
COVID O
- O
19 O
- O
related O
life O
- O
threatening O
neurologic O
involvement O
, O
17 O
survivors O
( O
40 O
% O
) O
had O
new O
neurologic O
deficits O
at O
hospital O
discharge O
, O
and O
11 O
patients O
( O
26 O
% O
) O
died O
. O

With O
the O
global O
outbreak O
of O
the O
COVID O
- O
19 O
pandemic O
, O
hospitals O
in O
Canada O
and O
around O
the O
world O
have O
been O
forced O
to O
consider O
conservation O
strategies O
to O
ensure O
continued O
availability O
of O
personal O
protective O
equipment O
( O
PPE O
) O
for O
healthcare O
providers O
. O

Self O
- O
care O
of O
Frontline O
Health O
Care O
Workers O
: O
During O
COVID O
- O
19 O
Pandemic O
. O

How O
Should O
a O
Safe O
and O
Effective O
COVID O
- O
19 O
Vaccine O
be O
Allocated O
? O
Health O
Economists O
Need O
to O
be O
Ready O
to O
Take O
the O
Baton O
. O

COVID O
- O
19 O
information O
contact O
and O
participation O
analysis O
and O
dynamic O
prediction O
in O
the O
Chinese O
Sina O
- O
microblog O
. O

A O
call O
from O
the O
European O
Academy O
of O
Neurology O
on O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
led O
to O
over O
92 O
million O
cases O
and O
1 O
. O
9 O
million O
deaths O
worldwide O
since O
its O
outbreak O
. O

A O
living O
meta O
- O
ecological O
study O
of O
the O
consequences O
of O
the O
COVID O
- O
19 O
pandemic O
on O
mental O
health O
. O

We O
also O
discuss O
the O
epidemiology O
pathogenesis O
, O
clinical O
, O
and O
multi O
- O
organ O
consequences O
, O
and O
highlight O
some O
of O
the O
research O
gaps O
regarding O
COVID O
- O
19 O
. O

COVID O
- O
19 O
and O
opportunities O
for O
international O
cooperation O
in O
health O
. O

Should O
we O
try O
the O
antiinflammatory O
natural O
product O
, O
celastrol O
, O
for O
COVID O
- O
19 O
? O

Lifestyle O
Risk O
Factors O
for O
Cardiovascular O
Disease O
in O
Relation O
to O
COVID O
- O
19 O
Hospitalization O
: O
A O
Community O
- O
Based O
Cohort O
Study O
of O
387 O
, O
109 O
Adults O
in O
UK O
. O

Perioperative O
planning O
in O
the O
COVID O
- O
19 O
pandemic O
: O
Cardiovascular O
perfusion O
and O
device O
- O
related O
issues O
. O

COVID O
- O
19 O
Case O
Report O
: O
An O
84 O
- O
Year O
- O
Old O
Man O
with O
Exacerbation O
of O
Multiple O
Comorbidities O
Due O
to O
COVID O
- O
19 O
Managed O
by O
a O
Multidisciplinary O
Team O
Using O
Patient O
- O
Reported O
Outcomes O
. O

This O
study O
aimed O
to O
evaluate O
the O
clinical O
characteristics O
and O
outcomes O
including O
mortality O
and O
viral O
shedding O
period O
in O
COVID O
- O
19 O
patients O
with O
cancer O
in O
Japan O
. O

The O
aim O
of O
this O
cohort O
study O
is O
to O
compare O
the O
incidence O
of O
PE O
during O
a O
3 O
- O
year O
period O
and O
to O
assess O
the O
characteristics O
of O
PE O
in O
COVID O
- O
19 O
. O

Suicide O
rates O
, O
alone O
, O
are O
expected O
to O
rise O
for O
Michiganders O
due O
to O
the O
economic O
downturn O
, O
isolation O
and O
quarantine O
, O
increased O
substance O
use O
, O
insomnia O
, O
and O
increased O
access O
to O
guns O
associated O
with O
the O
COVID O
- O
19 O
pandemic O
. O

Early O
identification O
and O
properly O
treatment O
are O
very O
important O
to O
prevent O
IgG4 O
- O
RD O
patients O
with O
COVID O
- O
19 O
from O
progression O
to O
severe O
condition O
. O

There O
is O
an O
increasing O
amount O
of O
literature O
describing O
the O
pathogenesis O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pneumonia O
and O
its O
associated O
complications O
. O

COVID O
- O
19 O
mortality O
showed O
no O
significant O
association O
with O
temperature O
. O

One O
of O
her O
family O
members O
was O
diagnosed O
with O
COVID O
- O
19 O
. O

Evidence O
, O
rationality O
, O
and O
ignorance O
: O
Agnotological O
issues O
in O
COVID O
- O
19 O
science O
. O

It O
is O
also O
urgent O
to O
set O
up O
an O
international O
or O
national O
cohort O
to O
address O
the O
risk O
factors O
associated O
with O
infection O
, O
the O
natural O
history O
of O
COVID O
- O
19 O
, O
including O
the O
disease O
type O
, O
surrogate O
markers O
for O
critically O
ill O
, O
long O
- O
term O
sequelae O
, O
and O
reinfection O
after O
exposure O
, O
identify O
responders O
to O
glucocorticoid O
, O
and O
establish O
optimal O
treatment O
strategies O
for O
disease O
control O
. O

Cross O
- O
country O
evidence O
on O
the O
association O
between O
contact O
tracing O
and O
COVID O
- O
19 O
case O
fatality O
rates O
. O

Future O
investigations O
into O
aberrant O
cytokine O
levels O
in O
COVID O
- O
19 O
patients O
with O
neurological O
symptoms O
as O
well O
as O
the O
efficacy O
of O
cytokine O
storm O
- O
targeting O
treatments O
will O
be O
critical O
in O
elucidating O
the O
pathogenic O
mechanisms O
and O
effective O
treatments O
of O
COVID O
- O
19 O
. O

[ O
COVID O
- O
19 O
pandemic O
: O
storms O
and O
challenges O
] O
. O

Home O
Dialysis O
: O
Lessons O
from O
COVID O
- O
19 O
and O
Other O
Viral O
Outbreaks O
. O

The O
JRC O
COVID O
- O
19 O
In O
Vitro O
Diagnostic O
Devices O
and O
Test O
Methods O
Database O
, O
aimed O
to O
collect O
in O
a O
single O
place O
all O
publicly O
available O
information O
on O
performance O
of O
CE O
- O
marked O
in O
vitro O
diagnostic O
medical O
devices O
( O
IVDs O
) O
as O
well O
as O
in O
house O
laboratory O
- O
developed O
devices O
and O
related O
test O
methods O
for O
COVID O
- O
19 O
, O
is O
here O
presented O
. O

No O
proved O
COVID O
- O
19 O
emerged O
among O
102 O
interviewed O
. O

Response O
to O
' O
Impact O
of O
immunosuppression O
on O
mortality O
in O
critically O
ill O
COVID O
- O
19 O
patients O
' O
. O

We O
analyzed O
income O
inequalities O
in O
the O
incidence O
of O
COVID O
- O
19 O
, O
categorizing O
the O
census O
tracts O
into O
quintiles O
based O
on O
the O
income O
indicator O
. O

Absence O
of O
symptoms O
on O
the O
ASGE O
COVID O
- O
19 O
risk O
screening O
questionnaire O
was O
highly O
predictive O
of O
a O
negative O
RT O
- O
PCR O
test O
( O
99 O
. O
43 O
% O
negative O
predictive O
value O
) O
, O
whereas O
the O
positive O
predictive O
value O
was O
low O
( O
2 O
. O
46 O
% O
) O
in O
symptomatic O
patients O
. O

COVID O
- O
19 O
anxiety O
was O
measured O
with O
a O
modified O
Spielberger O
State O
- O
Trait O
Anxiety O
Inventory O
. O

Our O
models O
performed O
effectively O
as O
a O
screening O
test O
for O
COVID O
- O
19 O
, O
excluding O
the O
illness O
with O
high O
- O
confidence O
by O
use O
of O
clinical O
data O
routinely O
available O
within O
1 O
h O
of O
presentation O
to O
hospital O
. O

Coronavirus O
infectious O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
currently O
one O
of O
the O
most O
important O
public O
health O
crises O
affecting O
the O
global O
human O
population O
. O

Additionally O
, O
severe O
COVID O
- O
19 O
was O
associated O
with O
increased O
neutrophil O
counts O
( O
P O
< O
. O
001 O
) O
, O
C O
- O
reactive O
protein O
( O
P O
< O
. O
001 O
) O
, O
procalcitonin O
( O
P O
= O
. O
024 O
) O
and O
decreased O
lymphocyte O
counts O
( O
P O
= O
. O
001 O
) O
, O
hemoglobin O
( O
P O
< O
. O
001 O
) O
, O
total O
protein O
( O
TP O
) O
( O
P O
< O
. O
001 O
) O
, O
and O
albumin O
( O
ALB O
) O
( O
P O
< O
. O
001 O
) O
. O

Coping O
With O
COVID O
- O
19 O
. O

It O
is O
not O
known O
whether O
nursing O
homes O
with O
private O
equity O
( O
PE O
) O
ownership O
have O
performed O
better O
or O
worse O
than O
other O
nursing O
homes O
during O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

Therefore O
, O
particular O
care O
to O
the O
patients O
with O
underlying O
diseases O
is O
needed O
during O
the O
treatment O
of O
COVID O
- O
19 O
patients O
. O

As O
of O
April O
18 O
, O
2020 O
, O
there O
have O
been O
a O
total O
of O
10 O
, O
653 O
confirmed O
cases O
and O
232 O
deaths O
due O
to O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
Korea O
. O

In O
early O
January O
2020 O
, O
2 O
patients O
were O
treated O
with O
the O
Zap O
- O
X O
robot O
prior O
to O
a O
national O
COVID O
- O
19 O
lockdown O
. O

News O
coverage O
of O
the O
COVID O
- O
19 O
pandemic O
: O
Missed O
opportunities O
to O
promote O
health O
sustaining O
behaviors O
. O

The O
coordinated O
immune O
response O
of O
the O
host O
is O
the O
key O
of O
the O
successful O
combat O
of O
the O
body O
against O
SARS O
- O
CoV O
- O
2 O
infection O
and O
is O
decisive O
for O
the O
development O
and O
progression O
of O
COVID O
- O
19 O
. O

Research O
points O
to O
interleukin O
6 O
( O
IL O
- O
6 O
) O
as O
a O
crucial O
signature O
of O
the O
cytokine O
storm O
, O
and O
the O
clinical O
use O
of O
the O
IL O
- O
6 O
inhibitor O
tocilizumab O
shows O
potential O
for O
treatment O
of O
COVID O
- O
19 O
patient O
. O

Intimate O
partner O
violence O
crisis O
in O
the O
COVID O
- O
19 O
pandemic O
: O
how O
can O
radiologists O
make O
a O
difference O
? O

Thrombotic O
and O
bleeding O
or O
thrombotic O
pathologies O
are O
significant O
accompaniments O
to O
acute O
respiratory O
syndrome O
and O
lung O
complications O
in O
COVID O
- O
19 O
. O

We O
developed O
and O
disseminated O
actionable O
Information O
, O
Education O
and O
Communication O
( O
IEC O
) O
messages O
on O
prevention O
and O
control O
during O
the O
ongoing O
COVID O
- O
19 O
pandemic O
by O
selecting O
five O
key O
message O
themes O
of O
prevention O
. O

Ecotoxic O
response O
of O
nematodes O
to O
ivermectin O
, O
a O
potential O
anti O
- O
COVID O
- O
19 O
drug O
treatment O
. O

These O
trends O
confirm O
a O
vulnerable O
, O
but O
essential O
, O
workforce O
with O
higher O
risks O
for O
COVID O
- O
19 O
complications O
than O
would O
have O
been O
true O
of O
U O
. O
S O
. O
farmworkers O
as O
a O
group O
in O
earlier O
years O
. O

Crucial O
laboratory O
parameters O
in O
COVID O
- O
19 O
diagnosis O
and O
prognosis O
: O
An O
updated O
meta O
- O
analysis O
. O

Update O
to O
coagulopathy O
in O
COVID O
- O
19 O
: O
Manifestations O
and O
management O
. O

The O
pharmaceutical O
technology O
unit O
of O
the O
Geneva O
University O
Hospitals O
played O
a O
significant O
role O
in O
the O
fight O
against O
COVID O
- O
19 O
through O
four O
different O
missions O
: O
( O
1 O
) O
providing O
enough O
hydroalcoholic O
solution O
at O
the O
peak O
of O
the O
pandemic O
; O
( O
2 O
) O
facing O
supply O
chain O
management O
issues O
; O
( O
3 O
) O
adapting O
the O
workload O
to O
the O
crisis O
and O
, O
above O
all O
, O
( O
4 O
) O
managing O
the O
human O
resources O
necessary O
to O
handle O
these O
activities O
. O

COVID O
- O
19 O
is O
an O
infectious O
disease O
caused O
by O
2019 O
- O
nCoV O
and O
characterizes O
as O
an O
atypical O
pneumonia O
. O

Pathophysiology O
and O
pharmacological O
management O
of O
pulmonary O
and O
cardiovascular O
features O
of O
COVID O
- O
19 O
. O

Conclusions O
Based O
on O
this O
nationwide O
survey O
with O
almost O
1 O
, O
000 O
respondents O
, O
the O
COVID O
- O
19 O
pandemic O
substantially O
reduced O
the O
activity O
of O
endoscopy O
units O
in O
private O
and O
public O
settings O
. O

The O
current O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
made O
us O
aware O
of O
the O
weaknesses O
and O
often O
the O
inadequacies O
of O
our O
current O
technologies O
and O
practices O
and O
has O
presented O
us O
with O
a O
huge O
challenge O
: O
to O
reorganize O
the O
way O
we O
work O
and O
sometimes O
even O
think O
, O
in O
order O
to O
ensure O
the O
safety O
of O
our O
patients O
. O

Our O
study O
is O
the O
first O
to O
compare O
four O
new O
commercially O
available O
assays O
using O
75 O
sera O
from O
patients O
tested O
positive O
or O
negative O
by O
SARS O
- O
CoV O
- O
2 O
PCR O
: O
the O
anti O
SARS O
- O
CoV O
- O
2 O
ELISA O
( O
IgG O
) O
( O
Euroimmun O
, O
Germany O
) O
, O
the O
EDI O
New O
Coronavirus O
COVID O
- O
19 O
IgG O
ELISA O
, O
( O
Epitope O
diagnostics O
( O
EDI O
) O
, O
USA O
) O
, O
the O
recomWell O
SARS O
- O
CoV O
- O
2 O
IgG O
ELISA O
( O
Mikrogen O
, O
Germany O
) O
, O
and O
the O
SARS O

- O
CoV O
- O
2 O
Virachip O
IgG O
( O
Viramed O
, O
Germany O
) O
. O

The O
study O
found O
that O
the O
proposed O
model O
can O
support O
physicians O
to O
easily O
diagnose O
suspected O
cases O
of O
COVID O
- O
19 O
based O
on O
their O
medical O
records O
without O
subjecting O
the O
specimen O
to O
laboratory O
tests O
. O

PTSD O
was O
associated O
with O
lower O
age O
, O
female O
gender O
, O
lack O
of O
social O
support O
, O
and O
a O
range O
of O
pandemic O
- O
related O
variables O
such O
as O
economic O
concerns O
, O
expecting O
economic O
loss O
, O
having O
been O
in O
quarantine O
or O
isolation O
, O
being O
at O
high O
risk O
for O
complications O
from O
COVID O
- O
19 O
infection O
, O
and O
having O
concern O
for O
family O
and O
close O
friends O
. O

Use O
of O
dexamethasone O
, O
remdesivir O
, O
convalescent O
plasma O
and O
prone O
positioning O
in O
the O
treatment O
of O
severe O
COVID O
- O
19 O
infection O
in O
pregnancy O
: O
A O
case O
report O
. O

The O
COVID O
- O
19 O
pandemic O
has O
led O
to O
large O
proportions O
of O
the O
labour O
market O
moving O
to O
remote O
work O
, O
while O
others O
have O
become O
unemployed O
. O

We O
characterized O
peripheral O
blood O
T O
, O
NK O
and O
NKT O
cells O
in O
45 O
patients O
with O
COVID O
- O
19 O
pneumonia O
( O
COVID O
- O
19 O
subjects O
) O
and O
19 O
healthy O
donors O
( O
HDs O
) O
. O

A O
condition O
of O
hypercoagulability O
has O
been O
frequently O
reported O
in O
COVID O
- O
19 O
patients O
, O
and O
this O
very O
fact O
may O
complicate O
KRT O
management O
. O

Famotidine O
has O
since O
been O
shown O
to O
improve O
patient O
outcomes O
and O
reduce O
symptom O
severity O
in O
patients O
acutely O
ill O
with O
COVID O
- O
19 O
. O

Compassionate O
drug O
( O
mis O
) O
use O
during O
pandemics O
: O
lessons O
for O
COVID O
- O
19 O
from O
2009 O
. O

The O
rate O
of O
stroke O
among O
patients O
with O
COVID O
- O
19 O
infection O
may O
increase O
in O
the O
future O
as O
they O
share O
the O
common O
risk O
factors O
. O

Radiographers O
and O
radiation O
therapists O
are O
key O
patient O
- O
facing O
health O
practitioners O
supporting O
the O
delivery O
of O
optimal O
patient O
care O
during O
the O
COVID O
- O
19 O
pandemic O
. O

There O
is O
no O
effective O
therapy O
against O
COVID O
- O
19 O
available O
so O
far O
. O

Single O
- O
dose O
Oxford O
- O
AstraZeneca O
COVID O
- O
19 O
vaccine O
followed O
by O
a O
12 O
- O
week O
booster O
. O

COVID O
- O
19 O
Trials O
and O
Tribulations O
by O
Rebecca O
Gliksman O
MD O
MPH O
. O

Altered O
pulmonary O
blood O
volume O
distribution O
as O
a O
biomarker O
for O
predicting O
outcomes O
in O
COVID O
- O
19 O
disease O
. O

As O
the O
next O
generation O
of O
public O
health O
leaders O
, O
we O
believe O
that O
only O
by O
investing O
in O
these O
issues O
can O
we O
begin O
to O
address O
the O
social O
and O
economic O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
. O

We O
also O
find O
that O
state O
orders O
, O
an O
increase O
in O
the O
number O
of O
COVID O
- O
19 O
cases O
, O
precipitation O
and O
temperature O
contribute O
to O
reducing O
human O
mobility O
. O

COVID O
- O
19 O
was O
declared O
a O
pandemic O
by O
the O
World O
Health O
Organization O
in O
March O
2020 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
highlighted O
the O
importance O
of O
social O
determinants O
of O
health O
in O
affecting O
health O
outcomes O
. O

One O
- O
fourth O
of O
urological O
providers O
were O
deployed O
to O
assist O
with O
COVID O
- O
19 O
care O
. O

We O
summarize O
the O
available O
literature O
on O
COVID O
- O
19 O
suggesting O
an O
increased O
risk O
for O
severe O
disease O
progression O
in O
cancer O
patients O
, O
and O
we O
discuss O
the O
possibility O
that O
SARS O
- O
CoV O
- O
2 O
could O
contribute O
to O
cancer O
development O
. O

Signal O
amplification O
by O
reversible O
exchange O
for O
COVID O
- O
19 O
antiviral O
drug O
candidates O
. O

Sixth O
, O
AAT O
inhibition O
of O
elastase O
can O
antagonize O
the O
formation O
of O
neutrophil O
extracellular O
traps O
( O
NETs O
) O
, O
a O
complex O
extracellular O
structure O
comprised O
of O
neutrophil O
- O
derived O
DNA O
, O
histones O
, O
and O
proteases O
, O
and O
implicated O
in O
the O
immunothrombosis O
of O
COVID O
- O
19 O
; O
indeed O
, O
AAT O
has O
been O
shown O
to O
change O
the O
shape O
and O
adherence O
of O
non O
- O
COVID O
- O
19 O
- O
related O
NETs O
. O

Noninvasive O
respiratory O
support O
( O
NRS O
) O
such O
as O
noninvasive O
ventilation O
( O
NIV O
) O
and O
high O
flow O
nasal O
therapy O
( O
HFNT O
) O
have O
been O
used O
in O
the O
treatment O
of O
acute O
hypoxemic O
respiratory O
failure O
( O
AHRF O
) O
related O
to O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
and O
other O
viral O
infections O
. O

The O
preferable O
outcomes O
of O
this O
case O
could O
be O
attributable O
to O
some O
factors O
: O
multidisciplinary O
medical O
management O
, O
the O
mother O
' O
s O
young O
age O
, O
and O
COVID O
- O
19 O
infection O
during O
the O
late O
trimester O
. O

The O
coronavirus O
diseases O
2019 O
( O
COVID O
- O
19 O
) O
pneumonia O
with O
spontaneous O
pneumothorax O
: O
a O
case O
report O
. O

Available O
data O
indicate O
that O
cyclosporine O
may O
have O
a O
beneficial O
effect O
on O
COVID O
- O
19 O
, O
which O
is O
caused O
by O
the O
coronavirus O
SARS O
- O
COV2 O
. O

This O
review O
examined O
the O
literature O
for O
the O
anti O
- O
COVID O
- O
19 O
effects O
of O
bee O
honey O
and O
propolis O
, O
with O
the O
aim O
of O
optimizing O
the O
use O
of O
these O
handy O
products O
as O
prophylactic O
or O
adjuvant O
treatments O
for O
people O
infected O
with O
severe O
acute O
respiratory O
syndrome O
- O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

Randomized O
controlled O
trials O
will O
be O
included O
if O
they O
recruited O
participants O
with O
COVID O
- O
19 O
for O
assessing O
the O
effect O
of O
Chinese O
medicine O
vs O
control O
( O
placebo O
, O
no O
treatment O
, O
and O
other O
therapeutic O
agents O
) O
. O

Because O
COVID O
- O
19 O
has O
already O
begun O
to O
precipitate O
huge O
increases O
in O
mental O
health O
problems O
, O
clinical O
psychological O
science O
must O
assert O
a O
leadership O
role O
in O
guiding O
a O
national O
response O
to O
this O
secondary O
crisis O
. O

We O
present O
four O
patients O
suffering O
from O
the O
loss O
of O
consciousness O
and O
seizure O
during O
the O
clinical O
course O
of O
COVID O
- O
19 O
infection O
. O

Being O
in O
touch O
: O
narrative O
assessment O
of O
patients O
receiving O
online O
integrative O
oncology O
treatments O
during O
COVID O
- O
19 O
. O

In O
this O
review O
article O
, O
we O
describe O
the O
systematic O
strategies O
to O
combat O
COVID O
- O
19 O
from O
the O
radiology O
department O
in O
Tongji O
hospital O
in O
Wuhan O
, O
P O
. O
R O
. O

We O
also O
studied O
whether O
the O
above O
outcomes O
of O
COVID O
- O
19 O
cases O
were O
related O
to O
air O
temperature O
( O
AT O
) O
, O
relative O
humidity O
( O
RH O
) O
, O
or O
air O
quality O
index O
( O
AQI O
) O
by O
performing O
Pearson O
' O
s O
analysis O
or O
Spearman O
' O
s O
analysis O
. O

Herein O
, O
we O
will O
briefly O
review O
( O
1 O
) O
anti O
- O
inflammatory O
and O
anti O
- O
thrombotic O
effects O
of O
vitamin O
D O
, O
( O
2 O
) O
vitamin O
D O
receptor O
and O
vitamin O
D O
receptor O
ligand O
, O
( O
3 O
) O
protective O
role O
of O
vitamin O
D O
against O
endothelial O
dysfunction O
, O
( O
4 O
) O
risk O
of O
vitamin O
D O
deficiency O
, O
( O
5 O
) O
vitamin O
D O
deficiency O
in O
association O
with O
endothelial O
dysfunction O
, O
( O
6 O
) O
the O
characteristics O
of O
vitamin O
D O
relevant O
to O
COVID O
- O
19 O
, O
( O
7 O
) O
the O
role O
of O
vitamin O
D O
on O
innate O
and O
adaptive O
response O
, O
( O
8 O
) O
biomarkers O
of O
endothelial O
cell O
activation O

contributing O
to O
cytokine O
storm O
, O
and O
( O
9 O
) O
the O
bidirectional O
relationship O
between O
inflammation O

Reducing O
COVID O
- O
19 O
burden O
for O
populations O
will O
require O
equitable O
and O
effective O
risk O
- O
based O
allocations O
of O
scarce O
preventive O
resources O
, O
including O
vaccinations1 O
. O

The O
global O
spread O
of O
COVID O
- O
19 O
constitutes O
the O
most O
dangerous O
pandemic O
to O
emerge O
during O
the O
last O
one O
hundred O
years O
. O

Managing O
nonmedical O
opioid O
use O
among O
patients O
with O
cancer O
pain O
during O
the O
COVID O
- O
19 O
Pandemic O
using O
the O
CHAT O
model O
and O
telehealth O
. O

A O
spatiotemporal O
analysis O
of O
the O
impact O
of O
COVID O
- O
19 O
on O
child O
abuse O
and O
neglect O
in O
the O
city O
of O
Los O
Angeles O
, O
California O
. O

Trends O
in O
prescribing O
for O
nursing O
home O
( O
NH O
) O
residents O
, O
which O
may O
have O
been O
influenced O
by O
the O
COVID O
- O
19 O
pandemic O
, O
have O
not O
been O
characterized O
. O

Many O
people O
have O
suffered O
from O
symptoms O
like O
COVID O
- O
19 O
during O
this O
pandemic O
, O
and O
some O
people O
have O
cured O
without O
taking O
any O
treatment O
or O
taking O
minor O
pharmacological O
and O
non O
- O
pharmacological O
treatments O
. O

Thus O
it O
is O
unclear O
, O
when O
and O
if O
liver O
transplantation O
can O
be O
safely O
offered O
to O
patients O
who O
suffered O
from O
COVID O
- O
19 O
. O

The O
adjusted O
odds O
ratio O
and O
95 O
% O
CIs O
for O
COVID O
- O
19 O
infection O
and O
long O
- O
term O
hospitalization O
comparing O
exposure O
to O
RAAS O
inhibitors O
and O
nonexposure O
to O
RAAS O
inhibitors O
was O
1 O
. O
161 O
( O
0 O
. O
958 O
- O
1 O
. O
407 O
) O
and O
0 O
. O
863 O
( O
0 O
. O
533 O
- O
1 O
. O
397 O
) O
, O
respectively O
. O

Older O
adults O
are O
particularly O
affected O
by O
the O
current O
COVID O
- O
19 O
( O
SARS O
- O
CoV O
- O
2 O
) O
pandemic O
. O

The O
study O
found O
that O
there O
is O
a O
considerable O
and O
constant O
growth O
of O
Indian O
publications O
on O
COVID O
- O
19 O
from O
mid O
- O
April O
. O

Diagnostic O
performance O
of O
COVID O
- O
19 O
serological O
assays O
during O
early O
infection O
: O
A O
systematic O
review O
and O
meta O
- O
analysis O
of O
11 O
516 O
samples O
. O

We O
validate O
the O
hypothesis O
of O
fractional O
exponents O
i O
) O
by O
numerical O
simulation O
for O
disease O
propagation O
in O
graphs O
imposing O
a O
local O
structure O
to O
allowed O
disease O
transmissions O
and O
ii O
) O
by O
fitting O
the O
model O
to O
a O
COVID O
- O
19 O
data O
set O
provided O
by O
John O
Hopkins O
University O
( O
JHUCSSE O
) O
for O
the O
period O
Jan O
- O
31 O
- O
20 O
to O
Mar O
- O
24 O
- O
20 O
, O
for O
the O
countries O
of O
Italy O
, O
Germany O
, O
Iran O
, O
and O
France O
. O

The O
paper O
also O
explores O
how O
CI O
can O
be O
a O
catalyst O
for O
managing O
the O
current O
COVID O
- O
19 O
pandemic O
and O
charting O
the O
path O
to O
post O
crisis O
. O

These O
observations O
question O
the O
role O
of O
IL O
- O
6 O
as O
a O
contributing O
factor O
in O
COVID O
- O
19 O
. O

Besides O
acute O
inflammation O
at O
OE O
, O
infection O
of O
mature O
and O
immature O
olfactory O
neurons O
, O
and O
the O
supporting O
sustentacular O
cells O
by O
SARS O
- O
CoV O
- O
2 O
may O
contribute O
to O
the O
unique O
olfactory O
dysfunction O
of O
COVID O
- O
19 O
which O
is O
not O
reported O
with O
SARS O
- O
CoV O
. O

After O
power O
analysis O
, O
128 O
subjects O
were O
divided O
into O
2 O
groups O
according O
to O
real O
- O
time O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
COVID O
- O
19 O
testing O
results O
. O

As O
one O
of O
the O
most O
urgent O
public O
health O
events O
, O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
attracted O
worldwide O
attention O
. O

Knowledge O
, O
Attitudes O
, O
and O
Practices O
of O
the O
Vietnamese O
as O
Key O
Factors O
in O
Controlling O
COVID O
- O
19 O
. O

Successful O
management O
of O
migraine O
with O
avoidance O
of O
in O
- O
person O
clinic O
and O
emergency O
department O
visits O
further O
benefits O
the O
current O
urgent O
societal O
goal O
of O
maintaining O
social O
distance O
to O
contain O
the O
COVID O
- O
19 O
pandemic O
. O

There O
is O
limited O
information O
describing O
the O
full O
spectrum O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
the O
duration O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
RNA O
detection O
in O
children O
. O

Pulmonary O
embolism O
remains O
an O
important O
cause O
of O
morbidity O
and O
mortality O
in O
the O
UK O
, O
particularly O
following O
the O
outbreak O
of O
the O
novel O
coronavirus O
2019 O
( O
COVID O
- O
19 O
) O
, O
where O
those O
infected O
have O
an O
increased O
prevalence O
of O
venous O
thromboembolic O
events O
. O

This O
placebo O
- O
controlled O
trial O
is O
designed O
to O
determine O
the O
efficacy O
of O
a O
single O
1 O
. O
2 O
- O
g O
dose O
of O
oral O
azithromycin O
to O
prevent O
COVID O
- O
19 O
patient O
progression O
to O
hospitalization O
. O

To O
prevent O
the O
spread O
of O
COVID O
- O
19 O
, O
Ministry O
of O
Health O
of O
Republic O
of O
Turkey O
and O
international O
institutions O
have O
published O
documents O
defining O
hygiene O
rules O
. O

To O
identify O
the O
county O
- O
level O
effects O
of O
social O
determinants O
of O
health O
( O
SDoH O
) O
on O
COVID O
- O
19 O
( O
corona O
virus O
disease O
2019 O
) O
mortality O
rates O
by O
rural O
- O
urban O
residence O
and O
estimate O
county O
- O
level O
exceedance O
probabilities O
for O
detecting O
clusters O
. O

Rapidly O
measuring O
spatial O
accessibility O
of O
healthcare O
resources O
provides O
an O
improved O
understanding O
of O
how O
well O
the O
healthcare O
infrastructure O
is O
equipped O
to O
save O
people O
' O
s O
lives O
during O
the O
COVID O
- O
19 O
pandemic O
. O

We O
estimated O
the O
number O
of O
individuals O
at O
increased O
risk O
of O
severe O
disease O
( O
defined O
as O
those O
with O
at O
least O
one O
condition O
listed O
as O
" O
at O
increased O
risk O
of O
severe O
COVID O
- O
19 O
" O
in O
current O
guidelines O
) O
by O
age O
( O
5 O
- O
year O
age O
groups O
) O
, O
sex O
, O
and O
country O
for O
188 O
countries O
using O
prevalence O
data O
from O
the O
Global O
Burden O
of O
Diseases O
, O
Injuries O
, O
and O
Risk O
Factors O
Study O
( O
GBD O
) O
2017 O
and O
UN O
population O
estimates O
for O
2020 O
. O

Differences O
were O
most O
marked O
in O
the O
highest O
quartile O
: O
25 O
% O
of O
Green O
House O
/ O
small O
NHs O
had O
COVID O
- O
19 O
case O
rates O
per O
1000 O
resident O
days O
higher O
than O
0 O
. O
08 O
, O
with O
the O
corresponding O
figures O
for O
other O
NHs O
being O
0 O
. O
15 O
( O
< O
50 O
beds O
) O
and O
0 O
. O
74 O
( O
≥ O
50 O
beds O
) O
. O

The O
emergence O
of O
novel O
COVID O
- O
19 O
causes O
an O
over O
- O
load O
in O
health O
system O
and O
high O
mortality O
rate O
. O

With O
the O
following O
parameters O
such O
as O
age O
> O
52 O
years O
, O
C O
- O
reactive O
protein O
> O
64 O
. O
79 O
mg O
/ O
L O
, O
lactate O
dehydrogenase O
> O
245 O
U O
/ O
L O
, O
D O
- O
dimer O
> O
0 O
. O
96 O
μ O
g O
/ O
mL O
, O
serum O
amyloid O
A O
> O
100 O
. O
02 O
mg O
/ O
L O
, O
or O
albumin O
< O
36 O
g O
/ O
L O
, O
the O
progress O
of O
COVID O
- O
19 O
to O
critical O
stage O
should O
be O
closely O
observed O
and O
possibly O
prevented O
. O

The O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
resulted O
in O
fewer O
emergency O
presentations O
of O
many O
acute O
medical O
and O
surgical O
conditions O
. O

Mental O
health O
crisis O
under O
COVID O
- O
19 O
pandemic O
in O
Hong O
Kong O
, O
China O
. O

This O
review O
is O
aimed O
at O
highlighting O
the O
critical O
aspects O
associated O
with O
COVID O
- O
19 O
and O
its O
presumed O
microvascular O
angiopathic O
consequences O
on O
the O
cardiovascular O
system O
leading O
to O
multi O
- O
organ O
dysfunction O
. O

All O
patients O
with O
laboratory O
- O
confirmed O
COVID O
- O
19 O
infection O
by O
RT O
- O
PCR O
in O
the O
North O
of O
Jordan O
admitted O
between O
March O
15 O
and O
April O
2 O
, O
2020 O
were O
included O
. O

The O
outbreak O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
seriously O
endangers O
people O
' O
s O
health O
. O

The O
isolation O
and O
properties O
of O
neutralizing O
monoclonal O
antibodies O
from O
COVID O
- O
19 O
patients O
provide O
additional O
information O
on O
what O
vaccines O
should O
try O
to O
elicit O
. O

Effect O
of O
COVID O
- O
19 O
on O
Tuberculosis O
Notification O
, O
South O
Korea O
. O

COVID O
- O
19 O
: O
Additional O
Precautions O
against O
Aerosols O
for O
the O
Slit O
Lamp O
User O
. O

Cross O
- O
country O
comparisons O
of O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
have O
largely O
been O
applied O
to O
mortality O
analyses O
. O

The O
COVID O
- O
19 O
pandemic O
negatively O
affected O
older O
adults O
' O
mental O
health O
and O
social O
well O
- O
being O
in O
the O
short O
term O
. O

Results O
: O
Of O
253 O
suspected O
cases O
, O
20 O
were O
laboratory O
- O
confirmed O
as O
having O
SARS O
- O
CoV O
- O
2 O
infection O
by O
RT O
- O
PCR O
, O
whereas O
COVID O
- O
19 O
diagnosis O
was O
ruled O
out O
in O
the O
remaining O
233 O
. O

The O
COVID O
- O
19 O
outbreak O
has O
posed O
unique O
challenges O
to O
the O
emergency O
department O
rostering O
. O

Elevation O
of O
blood O
glucose O
level O
predicts O
worse O
outcomes O
in O
hospitalized O
patients O
with O
COVID O
- O
19 O
: O
a O
retrospective O
cohort O
study O
. O

In O
this O
review O
, O
we O
have O
discussed O
the O
challenges O
of O
COVID O
- O
19 O
in O
Ethiopia O
in O
terms O
of O
health O
, O
economy O
, O
and O
social O
life O
, O
and O
the O
silver O
linings O
in O
terms O
of O
research O
opportunities O
, O
technological O
transformation O
, O
reading O
culture O
, O
and O
family O
discussion O
. O

We O
aimed O
to O
identify O
the O
prevalence O
of O
delayed O
immunization O
and O
explore O
the O
reasons O
and O
barriers O
for O
delayed O
immunization O
during O
the O
COVID O
- O
19 O
pandemic O
in O
the O
Qassim O
region O
, O
Saudi O
Arabia O
. O

Correction O
to O
: O
COVID O
- O
19 O
coronavirus O
: O
recommended O
personal O
protective O
equipment O
for O
the O
orthopaedic O
and O
trauma O
surgeon O
. O

December O
2019 O
saw O
a O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
from O
China O
quickly O
spread O
globally O
. O

Ensuring O
that O
COVID O
- O
19 O
screening O
chatbots O
provide O
high O
- O
quality O
service O
is O
critical O
but O
not O
sufficient O
for O
widespread O
adoption O
. O

During O
the O
U O
. O
K O
. O
' O
s O
lockdown O
in O
response O
to O
the O
COVID O
- O
19 O
pandemic O
, O
both O
food O
shortages O
and O
stockpiling O
were O
well O
- O
publicised O
events O
. O

Excess O
ascorbate O
( O
as O
expected O
in O
intravenous O
treatment O
proposed O
for O
COVID O
- O
19 O
management O
, O
for O
example O
) O
oxidizes O
and O
/ O
or O
degrades O
hemoglobin O
and O
albumin O
, O
as O
evidenced O
by O
UV O
- O
vis O
spectroscopy O
, O
gel O
electrophoresis O
, O
and O
mass O
spectrometry O
. O

Here O
, O
we O
describe O
the O
case O
of O
a O
45 O
- O
year O
- O
old O
male O
, O
successfully O
treated O
for O
Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
. O

Ambient O
nitrogen O
dioxide O
pollution O
and O
spreadability O
of O
COVID O
- O
19 O
in O
Chinese O
cities O
. O

SARS O
- O
CoV O
- O
2 O
Virions O
or O
Ubiquitous O
Cell O
Structures O
? O
Actual O
Dilemma O
in O
COVID O
- O
19 O
Era O
. O

To O
remedy O
these O
limitations O
, O
this O
paper O
introduces O
an O
automatic O
methodology O
based O
on O
an O
ensemble O
of O
deep O
transfer O
learning O
for O
the O
detection O
of O
COVID O
- O
19 O
. O

When O
the O
COVID O
- O
19 O
pandemic O
struck O
, O
surgical O
services O
had O
to O
design O
and O
implement O
a O
new O
system O
to O
safely O
manage O
patients O
and O
prevent O
workforce O
exposure O
. O

This O
manuscript O
summarizes O
available O
evidence O
so O
far O
and O
provides O
guidance O
for O
both O
general O
neurologists O
and O
NMD O
specialists O
dealing O
with O
NMD O
patients O
in O
the O
time O
of O
COVID O
- O
19 O
. O

Knowledge O
and O
Perceptions O
of O
COVID O
- O
19 O
among O
the O
General O
Public O
in O
Singapore O
: O
A O
Cross O
- O
sectional O
Online O
Survey O
. O

Although O
well O
- O
designed O
meta O
- O
analyses O
about O
COVID O
- O
19 O
disease O
have O
already O
been O
published O
, O
the O
majority O
are O
of O
low O
quality O
. O

Moreover O
, O
this O
paper O
provides O
comprehensive O
guidance O
on O
the O
most O
suitable O
respiratory O
support O
for O
newborns O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Studies O
resorting O
to O
structure O
- O
based O
drug O
design O
for O
COVID O
- O
19 O
are O
plethoric O
and O
show O
good O
promise O
. O

Low O
- O
dose O
radiation O
therapy O
: O
could O
it O
be O
a O
game O
- O
changer O
for O
COVID O
- O
19 O
? O

The O
severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
has O
been O
recently O
identified O
as O
the O
culprit O
of O
the O
highly O
infectious O
, O
outbreak O
named O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
China O
. O

Cardiovascular O
manifestations O
in O
severe O
and O
critical O
patients O
with O
COVID O
- O
19 O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
currently O
causing O
a O
pandemic O
and O
will O
likely O
persist O
in O
endemic O
form O
in O
the O
foreseeable O
future O
. O

Eosinophilia O
in O
Asthma O
Patients O
Is O
Protective O
Against O
Severe O
COVID O
- O
19 O
Illness O
. O

We O
present O
a O
longitudinal O
case O
of O
COVID O
- O
19 O
psychosis O
in O
a O
patient O
who O
underwent O
comprehensive O
diagnostic O
evaluation O
. O

During O
preventive O
and O
mandatory O
social O
isolation O
decreed O
by O
the O
Argentine O
National O
Government O
to O
contain O
the O
spread O
of O
COVID O
- O
19 O
, O
the O
city O
of O
Buenos O
Aires O
has O
experienced O
a O
marked O
decrease O
in O
vehicular O
traffic O
. O

Telephone O
consultation O
during O
Coronavirus O
outbreak O
in O
a O
Pediatric O
Emergency O
Department O
: O
methodological O
approach O
of O
a O
tertiary O
care O
center O
in O
a O
COVID O
- O
19 O
hospital O
setting O
. O

A O
large O
number O
of O
COVID O
- O
19 O
interventional O
clinical O
trials O
were O
registered O
soon O
after O
the O
pandemic O
onset O
: O
a O
descriptive O
analysis O
. O

We O
report O
on O
the O
pediatric O
block O
practice O
digitized O
due O
to O
the O
COVID O
- O
19 O
pandemic O
. O

However O
, O
the O
characteristics O
of O
COVID O
- O
19 O
- O
associated O
coagulopathy O
( O
CAC O
) O
are O
distinct O
from O
those O
seen O
with O
bacterial O
sepsis O
- O
induced O
coagulopathy O
( O
SIC O
) O
and O
disseminated O
intravascular O
coagulation O
( O
DIC O
) O
, O
with O
CAC O
usually O
showing O
increased O
D O
- O
dimer O
and O
fibrinogen O
levels O
but O
initially O
minimal O
abnormalities O
in O
prothrombin O
time O
and O
platelet O
count O
. O

Our O
findings O
confirm O
low O
COVID O
- O
19 O
incidence O
in O
Greece O
and O
possibly O
the O
effectiveness O
of O
early O
measures O
. O

The O
presented O
measures O
may O
guide O
dental O
faculties O
and O
dental O
practices O
during O
the O
early O
stage O
of O
the O
COVID O
- O
19 O
crisis O
. O

A O
total O
of O
325 O
healthcare O
workers O
participated O
; O
among O
them O
151 O
COVID O
- O
19 O
- O
infected O
healthcare O
workers O
were O
included O
. O

Among O
824 O
650 O
patients O
with O
hypertension O
, O
16 O
898 O
( O
2 O
. O
0 O
% O
) O
were O
tested O
for O
COVID O
- O
19 O
. O

We O
describe O
a O
case O
report O
of O
a O
50 O
- O
year O
- O
old O
male O
without O
previous O
known O
comorbidity O
who O
was O
found O
unresponsive O
due O
to O
COVID O
- O
19 O
- O
related O
neurological O
complications O
. O

Therefore O
, O
this O
study O
aimed O
to O
assess O
the O
levels O
of O
anxiety O
, O
depression O
and O
stress O
during O
the O
period O
of O
social O
distancing O
due O
to O
COVID O
- O
19 O
in O
students O
from O
a O
campus O
of O
the O
Federal O
Institute O
in O
the O
metropolitan O
area O
of O
Porto O
Alegre O
/ O
RS O
. O

This O
study O
included O
23 O
asymptomatic O
patients O
and O
35 O
patients O
with O
lung O
involvement O
who O
were O
diagnosed O
with O
COVID O
- O
19 O
as O
well O
as O
22 O
healthy O
volunteers O
. O

Analysis O
of O
COVID O
- O
19 O
under O
- O
reporting O
in O
Brazil O
. O

D O
- O
dimer O
concentration O
has O
been O
used O
by O
institutions O
to O
identify O
candidates O
for O
intensified O
anticoagulant O
treatment O
for O
venous O
thromboembolism O
prevention O
and O
for O
the O
mitigation O
of O
the O
microthrombotic O
complications O
associated O
with O
COVID O
- O
19 O
. O

The O
impact O
of O
secondary O
infections O
by O
multidrug O
- O
resistant O
bacteria O
in O
COVID O
- O
19 O
- O
infected O
patients O
has O
yet O
to O
be O
evaluated O
. O

Effects O
of O
Renin O
- O
Angiotensin O
Inhibition O
on O
ACE2 O
( O
Angiotensin O
- O
Converting O
Enzyme O
2 O
) O
and O
TMPRSS2 O
( O
Transmembrane O
Protease O
Serine O
2 O
) O
Expression O
: O
Insights O
Into O
COVID O
- O
19 O
. O

Ten O
patients O
who O
recovered O
from O
COVID O
- O
19 O
pneumonia O
without O
complications O
underwent O
self O
- O
reported O
questionnaires O
about O
1 O
month O
after O
discharge O
. O

We O
will O
perform O
analyses O
using O
definitions O
for O
confirmed O
, O
probable O
and O
possible O
COVID O
- O
19 O
and O
report O
serology O
results O
( O
where O
available O
) O
. O

Hospital O
staff O
from O
five O
national O
COVID O
- O
19 O
designated O
hospitals O
in O
Chongqing O
participated O
. O

Both O
patients O
with O
critical O
COVID O
- O
19 O
required O
mechanical O
ventilation O
and O
extracorporeal O
membrane O
oxygenation O
. O

Further O
data O
are O
needed O
to O
propose O
full O
- O
dose O
therapeutic O
anticoagulation O
for O
patients O
with O
coronary O
thrombosis O
and O
COVID O
- O
19 O
infection O
. O

We O
leveraged O
use O
of O
video O
communication O
systems O
installed O
in O
all O
COVID O
- O
19 O
rooms O
to O
reduce O
the O
number O
of O
in O
- O
room O
providers O
and O
frequency O
of O
contact O
. O

This O
study O
evaluated O
the O
role O
of O
eosinopenia O
as O
a O
diagnostic O
and O
prognostic O
indicator O
in O
COVID O
- O
19 O
infection O
. O

Telelactation O
: O
A O
Necessary O
Skill O
With O
Puppet O
Adjuncts O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Data O
normalization O
is O
a O
key O
challenge O
for O
the O
secondary O
use O
of O
EHRs O
for O
COVID O
- O
19 O
research O
across O
institutions O
. O

This O
study O
examined O
the O
association O
between O
dynamic O
angiopoietin O
- O
2 O
assessment O
and O
COVID O
- O
19 O
short O
- O
and O
long O
- O
term O
clinical O
course O
. O

Particularly O
, O
in O
the O
light O
of O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
there O
is O
decreased O
capacity O
to O
see O
patients O
in O
the O
outpatient O
clinic O
and O
mHealth O
has O
become O
an O
important O
component O
of O
many O
AF O
outpatient O
clinics O
. O

Contact O
with O
a O
suspected O
or O
confirmed O
case O
of O
COVID O
- O
19 O
was O
identified O
in O
6 O
patients O
. O

Lastly O
, O
we O
identify O
a O
number O
of O
recommendations O
for O
providing O
much O
- O
needed O
support O
for O
commercial O
fishermen O
in O
light O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
results O
indicated O
that O
dysbiosis O
occurred O
in O
COVID O
- O
19 O
patients O
and O
changes O
in O
the O
gut O
microbial O
community O
were O
associated O
with O
disease O
severity O
and O
hematological O
parameters O
. O

COVID O
- O
19 O
unlikely O
to O
cause O
birth O
defects O
, O
but O
doctors O
await O
fall O
births O
. O

The O
Chinese O
population O
has O
expressed O
great O
concern O
since O
the O
COVID O
- O
19 O
outbreak O
. O

Hospitals O
need O
to O
find O
a O
safe O
and O
rapid O
method O
for O
respiratory O
specimen O
collection O
as O
the O
number O
of O
patients O
suspicious O
for O
coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
rapidly O
grows O
. O

No O
association O
of O
COVID O
- O
19 O
transmission O
with O
temperature O
or O
UV O
radiation O
in O
Chinese O
cities O
. O

Is O
SARS O
- O
CoV O
- O
2 O
Also O
an O
Enteric O
Pathogen O
With O
Potential O
Fecal O
- O
Oral O
Transmission O
? O
A O
COVID O
- O
19 O
Virological O
and O
Clinical O
Review O
. O

Assessment O
of O
pre O
- O
existing O
conditions O
and O
chest O
CT O
scan O
EATV O
on O
admission O
may O
provide O
a O
threshold O
point O
potentially O
useful O
for O
predicting O
cardiovascular O
complications O
of O
COVID O
- O
19 O
. O

We O
aim O
to O
analyze O
possible O
associations O
between O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
and O
spontaneous O
subarachnoid O
hemorrhage O
( O
SAH O
) O
, O
in O
a O
comprehensive O
neurological O
center O
. O
We O
conducted O
a O
retrospective O
case O
series O
of O
4 O
patients O
infected O
by O
COVID O
- O
19 O
, O
who O
developed O
spontaneous O
SAH O
. O

Recent O
articles O
have O
uncovered O
genomic O
characteristics O
and O
clinical O
features O
of O
COVID O
- O
19 O
( O
Chan O
et O
al O
. O
, O
2020 O
; O
Chang O
et O
al O
. O
, O
2020 O
; O
Guan O
et O
al O
. O
, O
2020 O
; O
Zhu O
et O
al O
. O
, O
2020 O
) O
, O
while O
our O
understanding O
of O
COVID O
- O
19 O
is O
still O
limited O
. O

Only O
a O
few O
case O
reports O
of O
spinal O
cord O
imaging O
findings O
are O
described O
in O
COVID O
- O
19 O
, O
which O
include O
transverse O
myelitis O
, O
acute O
disseminated O
encephalomyelitis O
and O
post O
- O
infectious O
Guillain O
Barre O
' O
syndrome O
. O

Diabetes O
Mellitus O
and O
COVID O
- O
19 O
: O
Unholy O
Association O
of O
Two O
Pandemics O
. O

This O
study O
illustrates O
that O
IAV O
has O
a O
unique O
ability O
to O
aggravate O
SARS O
- O
CoV O
- O
2 O
infection O
, O
and O
thus O
, O
prevention O
of O
IAV O
infection O
is O
of O
great O
significance O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
total O
of O
3261 O
subjects O
completed O
an O
online O
survey O
, O
which O
was O
disseminated O
through O
the O
mainstream O
social O
media O
platforms O
in O
Spain O
and O
included O
the O
Occupational O
Balance O
Questionnaire O
( O
OBQ O
) O
, O
sociodemographic O
variables O
, O
and O
factors O
related O
to O
COVID O
- O
19 O
infection O
. O

It O
demonstrates O
the O
importance O
of O
the O
prevalence O
of O
COVID O
- O
19 O
in O
terms O
of O
determining O
the O
ability O
of O
a O
test O
to O
yield O
a O
diagnosis O
. O

We O
report O
here O
the O
first O
case O
of O
a O
patient O
with O
bilateral O
unusual O
dot O
- O
blot O
retinal O
hemorrhages O
and O
retinal O
venous O
dilation O
who O
presented O
shortly O
thereafter O
a O
PCR O
- O
proven O
COVID O
- O
19 O
. O

Stochastic O
SIRC O
epidemic O
model O
with O
time O
- O
delay O
for O
COVID O
- O
19 O
. O

Although O
corticosteroids O
dampen O
the O
dysregulated O
immune O
system O
and O
sometimes O
are O
prescribed O
as O
an O
adjunctive O
treatment O
for O
pneumonia O
, O
their O
effectiveness O
in O
the O
treatment O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
remains O
controversial O
. O

EU O
- O
China O
relations O
in O
the O
time O
of O
COVID O
- O
19 O
. O

Finally O
, O
techniques O
are O
offered O
to O
render O
culturally O
competent O
care O
to O
African O
- O
Americans O
diagnosed O
with O
COVID O
- O
19 O
who O
present O
concomitantly O
with O
health O
disparities O
. O

Cohort O
studies O
reporting O
risk O
estimates O
for O
the O
D O
- O
dimer O
and O
severity O
of O
COVID O
- O
19 O
association O
were O
searched O
and O
included O
to O
perform O
a O
meta O
- O
analysis O
. O

Computed O
tomography O
( O
CT O
) O
can O
provide O
important O
information O
in O
COVID O
- O
19 O
, O
especially O
for O
patients O
with O
moderate O
to O
severe O
disease O
as O
well O
as O
those O
with O
worsening O
cardiopulmonary O
status O
. O

COVID O
- O
19 O
pandemic O
is O
establishing O
telemedicine O
in O
the O
health O
care O
delivery O
system O
of O
countries O
. O

Besides O
the O
principal O
respiratory O
symptoms O
, O
the O
COVID O
- O
19 O
has O
been O
associated O
with O
an O
important O
array O
of O
dermatological O
manifestations O
. O

A O
high O
proportion O
of O
surgeons O
admitted O
being O
afraid O
of O
working O
during O
the O
COVID O
- O
19 O
pandemic O
, O
which O
had O
various O
implications O
for O
their O
attitude O
towards O
surgical O
practice O
. O

In O
the O
current O
COVID O
- O
19 O
pandemic O
, O
there O
has O
been O
concern O
regarding O
the O
use O
of O
ibuprofen O
and O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
by O
COVID O
- O
19 O
infected O
patients O
. O

COVID O
- O
19 O
et O
m O
é O
decine O
ambulatoire O
- O
Outils O
d O
’ O
é O
valuation O
pour O
le O
m O
é O
decin O
traitant O
dans O
le O
cadre O
du O
retour O
au O
travail O
des O
personnes O
vuln O
é O
rables O
. O

The O
major O
presenting O
symptom O
complex O
of O
said O
COVID O
- O
19 O
sample O
population O
included O
fever O
( O
48 O
% O
) O
, O
cough O
( O
31 O
% O
) O
, O
and O
shortness O
of O
breath O
( O
17 O
% O
) O
. O

The O
French O
general O
population O
' O
s O
attitudes O
toward O
lockdown O
against O
COVID O
- O
19 O
: O
a O
fragile O
consensus O
. O

Prognostic O
value O
of O
lymphocyte O
count O
in O
severe O
COVID O
- O
19 O
patients O
with O
corticosteroid O
treatment O
. O

Active O
search O
, O
early O
testing O
and O
treatment O
of O
symptomatic O
elderly O
patients O
with O
comorbidities O
should O
be O
prioritized O
for O
containing O
the O
spread O
of O
COVID O
- O
19 O
and O
reducing O
mortality O
. O

In O
the O
present O
COVID O
- O
19 O
pandemic O
situation O
, O
there O
is O
a O
gradual O
increase O
in O
number O
of O
patients O
with O
post O
- O
COVID O
- O
19 O
sequalae O
. O

The O
unprecedented O
nature O
of O
the O
COVID O
- O
19 O
pandemic O
has O
challenged O
how O
and O
whether O
patients O
with O
heart O
disease O
are O
able O
to O
safely O
access O
center O
- O
based O
exercise O
training O
and O
cardiac O
rehabilitation O
( O
CR O
) O
. O

The O
COVID O
- O
19 O
has O
posed O
a O
wide O
range O
of O
urgent O
questions O
: O
about O
the O
disease O
, O
testing O
, O
immunity O
, O
treatments O
, O
and O
outcomes O
. O

Interventions O
are O
required O
on O
knowledge O
, O
stress O
, O
and O
fear O
regarding O
COVID O
- O
19 O
in O
the O
population O
studied O
. O

COVID O
- O
19 O
is O
a O
disease O
caused O
by O
a O
SARS O
- O
COV2 O
. O

Conflicting O
results O
exist O
regarding O
the O
epidemiology O
of O
VTE O
for O
unselected O
anticoagulated O
COVID O
- O
19 O
patients O
hospitalized O
in O
general O
wards O
. O

Our O
appraisals O
of O
these O
topics O
are O
made O
after O
nearly O
2 O
months O
of O
national O
COVID O
- O
19 O
mitigation O
measures O
, O
like O
social O
distancing O
and O
limited O
" O
non O
- O
essential O
" O
movement O
outside O
the O
home O
but O
also O
as O
states O
are O
gradually O
lifting O
stricter O
directives O
and O
reopening O
economic O
sectors O
. O

Currently O
, O
there O
is O
an O
urgent O
need O
to O
find O
a O
treatment O
for O
the O
highly O
infectious O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
. O

The O
COVID O
- O
19 O
infodemic O
showed O
a O
characteristic O
of O
gradual O
progress O
, O
which O
can O
be O
divided O
into O
5 O
stages O
: O
incubation O
, O
outbreak O
, O
stalemate O
, O
control O
, O
and O
recovery O
. O

The O
only O
certainty O
is O
uncertainty O
: O
An O
analysis O
of O
the O
impact O
of O
COVID O
- O
19 O
uncertainty O
on O
regional O
stock O
markets O
. O

This O
implies O
the O
need O
for O
hygienic O
recommendations O
and O
use O
of O
personal O
protective O
equipment O
( O
PPE O
) O
for O
medical O
staff O
and O
other O
services O
to O
minimize O
COVID O
- O
19 O
infection O
of O
both O
health O
- O
care O
workers O
and O
patients O
. O

This O
narrative O
commentary O
describes O
similarities O
between O
these O
conditions O
, O
mainly O
focusing O
on O
modalities O
of O
risk O
communication O
, O
strategies O
to O
counteract O
fake O
news O
, O
actions O
to O
enhance O
the O
expertise O
of O
health O
operators O
, O
and O
finally O
on O
new O
skills O
that O
could O
derive O
as O
a O
lesson O
from O
COVID O
- O
19 O
. O

selection O
and O
current O
treatment O
maintenance O
; O
6 O
) O
manage O
MS O
/ O
NMOSD O
patients O
infected O
with O
COVID O
- O
19 O
. O

Significance O
of O
clinical O
phenomes O
of O
patients O
with O
COVID O
- O
19 O
infection O
: O
A O
learning O
from O
3795 O
patients O
in O
80 O
reports O
. O

The O
aim O
of O
this O
study O
was O
to O
explore O
the O
effect O
of O
hypertension O
on O
the O
outcomes O
of O
patients O
with O
COVID O
- O
19 O
by O
using O
propensity O
score O
- O
matching O
( O
PSM O
) O
analysis O
. O

Application O
of O
a O
Modified O
Endoscopy O
Face O
Mask O
for O
Flexible O
Laryngoscopy O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Frequency O
of O
Pulmonary O
Embolism O
in O
Patients O
With O
COVID O
- O
19 O
. O

Treatment O
was O
defined O
by O
the O
most O
recent O
vitamin O
D O
type O
and O
dose O
, O
and O
treatment O
changes O
between O
the O
time O
of O
the O
most O
recent O
vitamin O
D O
level O
and O
time O
of O
COVID O
- O
19 O
testing O
. O

Is O
the O
COVID O
- O
19 O
Pandemic O
a O
Good O
Time O
to O
Include O
Aspergillus O
Molecular O
Detection O
to O
Categorize O
Aspergillosis O
in O
ICU O
Patients O
? O
A O
Monocentric O
Experience O
. O

COVID O
- O
19 O
patients O
with O
DM O
had O
higher O
severe O
infection O
and O
case O
- O
mortality O
rates O
compared O
with O
those O
without O
DM O
( O
21 O
. O
4 O
vs O
. O
10 O
. O
6 O
% O
and O
28 O
. O
5 O
vs O
. O
13 O
. O
3 O
% O
, O
respectively O
, O
all O
p O
< O
0 O
. O
01 O
) O
. O

On O
12 O
March O
2020 O
the O
UK O
entered O
the O
' O
delay O
phase O
' O
of O
the O
COVID O
- O
19 O
pandemic O
response O
. O

Literature O
research O
was O
conducted O
through O
a O
methodical O
search O
on O
Pubmed O
databases O
on O
critical O
illness O
- O
associated O
microbleeds O
and O
cerebral O
microbleeds O
described O
in O
patients O
with O
COVID O
- O
19 O
. O

Assessing O
the O
psychological O
response O
to O
the O
COVID O
- O
19 O
: O
A O
response O
to O
Bitan O
et O
al O
. O
" O
Fear O
of O
COVID O
- O
19 O
scale O
: O
Psychometric O
characteristics O
, O
reliability O
and O
validity O
in O
the O
Israeli O
population O
" O
. O

Supporting O
the O
Medically O
Fragile O
: O
Individualized O
Approach O
to O
Empowering O
Young O
Adults O
With O
Chronic O
Disease O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Views O
of O
patients O
with O
inflammatory O
bowel O
disease O
on O
the O
COVID O
- O
19 O
pandemic O
: O
a O
global O
survey O
. O

Rare O
Case O
of O
a O
Disappearing O
Pituitary O
Adenoma O
During O
the O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Pandemic O
. O

While O
anecdotal O
evidence O
is O
plentiful O
even O
for O
COVID O
- O
19 O
, O
this O
study O
provides O
rigorous O
analysis O
to O
support O
that O
a O
reliable O
telecommunications O
infrastructure O
and O
a O
high O
level O
of O
digitization O
is O
crucial O
to O
keep O
the O
economy O
running O
under O
pandemic O
conditions O
. O

A O
significant O
proportion O
of O
patients O
with O
COVID O
- O
19 O
require O
intensive O
care O
and O
mechanical O
ventilation O
, O
thus O
requiring O
sedation O
and O
analgesia O
. O

The O
aim O
of O
this O
study O
was O
to O
provide O
simulated O
training O
for O
best O
- O
practice O
management O
of O
COVID O
- O
19 O
presentations O
for O
residency O
program O
trainees O
in O
Shanghai O
, O
China O
. O

The O
dilemma O
of O
renin O
- O
angiotensin O
system O
inhibitors O
in O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
: O
insights O
into O
lung O
fluid O
handling O
and O
gas O
exchange O
in O
heart O
failure O
patients O
. O

The O
emergence O
of O
COVID O
- O
19 O
disease O
due O
to O
SARS O
- O
CoV O
- O
2 O
at O
the O
end O
of O
2019 O
was O
rapidly O
associated O
with O
the O
isolation O
of O
the O
strain O
from O
co O
- O
culture O
onto O
VERO O
cells O
. O

The O
participants O
answered O
psychometric O
questionnaires O
that O
assessed O
psychological O
well O
- O
being O
, O
pseudoscientific O
beliefs O
and O
the O
ability O
to O
discriminate O
between O
scientific O
and O
pseudoscientific O
information O
about O
COVID O
- O
19 O
. O

COVID O
- O
19 O
has O
had O
a O
significant O
impact O
on O
orthopaedic O
training O
. O

By O
assuming O
same O
efficiency O
of O
social O
distancing O
against O
seasonal O
influenza O
and O
COVID O
- O
19 O
transmission O
, O
isolation O
/ O
quarantine O
and O
social O
distancing O
could O
lead O
to O
a O
48 O
. O
1 O
% O
( O
95 O
% O
CI O
: O
35 O
. O
4 O
% O
- O
58 O
. O
1 O
% O
) O
and O
34 O
. O
6 O
% O
( O
95 O
% O
CI O
: O
31 O
. O
3 O
% O
- O
38 O
. O
2 O
% O
) O
reduction O
of O
the O
transmissibility O
of O
COVID O
- O
19 O
. O

Data O
extraction O
focused O
on O
sinonasal O
pathophysiology O
in O
COVID O
- O
19 O
. O

The O
response O
of O
the O
American O
College O
of O
Surgeons O
( O
ACS O
) O
to O
the O
COVID O
- O
19 O
pandemic O
was O
vigorous O
and O
effective O
because O
it O
had O
mature O
programs O
in O
surgical O
quality O
and O
health O
policy O
and O
advocacy O
, O
the O
legacy O
of O
decades O
of O
work O
by O
its O
officers O
and O
leaders O
and O
its O
current O
executive O
director O
, O
David O
Hoyt O
. O

Hospitalized O
patients O
with O
COVID O
- O
19 O
experiencing O
respiratory O
symptoms O
have O
different O
complications O
( O
inflammatory O
, O
co O
- O
infection O
and O
thrombotic O
) O
that O
are O
identifiable O
by O
analytics O
patterns O
. O

Technologies O
to O
Optimize O
the O
Care O
of O
Severe O
COVID O
- O
19 O
Patients O
for O
Health O
Care O
Providers O
Challenged O
by O
Limited O
Resources O
. O

Healthcare O
Failure O
Mode O
and O
Effect O
Analysis O
( O
HFMEA O
) O
as O
an O
Effective O
Mechanism O
in O
Preventing O
Infection O
Caused O
by O
Accompanying O
Caregivers O
During O
COVID O
- O
19 O
- O
Experience O
of O
a O
City O
Medical O
Center O
in O
Taiwan O
. O

COVID O
- O
19 O
put O
a O
stop O
to O
the O
operative O
experience O
of O
surgical O
residents O
, O
leaving O
reassignment O
of O
the O
team O
, O
to O
the O
frontlines O
. O

Data O
on O
coronavirus O
infectivity O
and O
severity O
of O
COVID O
- O
19 O
disease O
, O
as O
well O
as O
the O
climatic O
variables O
were O
obtained O
from O
official O
sources O
( O
Ministry O
of O
Health O
and O
Spanish O
Meteorological O
Agency O
, O
respectively O
) O
. O

Capsules O
of O
broccoli O
seeds O
containing O
glucoraphanin O
were O
being O
taken O
before O
the O
onset O
of O
SARS O
- O
CoV O
- O
2 O
infection O
and O
were O
continued O
daily O
for O
over O
a O
month O
after O
the O
first O
COVID O
- O
19 O
symptoms O
. O

This O
study O
endeavours O
to O
comprehensively O
the O
study O
the O
spectrum O
of O
ENT O
manifestations O
in O
mild O
and O
asymptomatic O
COVID O
- O
19 O
and O
observe O
the O
natural O
course O
of O
anosmia O
and O
dysgeusia O
consequent O
to O
SARS O
- O
Cov O
- O
2 O
infection O
. O

The O
role O
of O
computed O
tomography O
scan O
in O
the O
diagnosis O
of O
COVID O
- O
19 O
pneumonia O
. O

The O
scan O
statistic O
analysis O
resulted O
in O
14 O
spatial O
risk O
clusters O
for O
COVID O
- O
19 O
among O
persons O
deprived O
of O
liberty O
; O
the O
highest O
- O
risk O
cluster O
was O
in O
the O
Federal O
District O
. O

COVID O
- O
19 O
response O
measures O
and O
violence O
against O
children O
. O

Surgical O
Training O
During O
and O
After O
COVID O
- O
19 O
: O
A O
Joint O
Trainee O
and O
Trainers O
Manifesto O
. O

Although O
COVID O
- O
19 O
was O
initially O
considered O
a O
pulmonary O
problem O
, O
it O
soon O
became O
clear O
that O
various O
other O
organs O
were O
involved O
. O

Re O
- O
tasking O
the O
use O
of O
pre O
- O
existing O
medications O
and O
potential O
therapeutic O
options O
for O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
: O
systematic O
review O
of O
clinical O
studies O
. O

Amongst O
the O
many O
spiraling O
effects O
of O
the O
current O
COVID O
- O
19 O
pandemic O
has O
been O
an O
intense O
interest O
in O
finding O
historical O
frames O
of O
reference O
for O
our O
current O
predicament O
. O

In O
patients O
hospitalized O
for O
COVID O
- O
19 O
, O
the O
use O
of O
a O
prophylactic O
dosage O
of O
enoxaparin O
appears O
to O
be O
associated O
with O
similar O
in O
- O
hospital O
overall O
mortality O
compared O
to O
higher O
doses O
. O

Urinary O
viral O
shedding O
of O
COVID O
- O
19 O
was O
detected O
from O
day O
1 O
to O
day O
52 O
after O
disease O
onset O
. O

COVID O
- O
19 O
got O
induced O
into O
Indian O
states O
mainly O
due O
to O
International O
travels O
with O
the O
very O
first O
patient O
travelling O
from O
Wuhan O
, O
China O
. O

Among O
the O
countries O
affected O
severely O
by O
COVID O
- O
19 O
, O
the O
United O
States O
tops O
the O
list O
. O

Following O
the O
World O
Health O
Organization O
' O
s O
statement O
on O
COVID O
- O
19 O
' O
s O
pandemic O
status O
on O
March O
11 O
, O
2020 O
, O
searches O
for O
" O
ACL O
, O
" O
" O
meniscus O
" O
and O
" O
rotator O
cuff O
" O
declined O
by O
34 O
. O
78 O
% O
, O
43 O
. O
95 O
% O
, O
and O
31 O
. O
37 O
% O
, O
and O
search O
for O
" O
ACL O
surgery O
, O
" O
" O
meniscus O
surgery O
" O
and O
" O
rotator O
cuff O
surgery O
" O
declined O
by O
42 O
. O
70 O
% O
, O
51 O
. O
88 O
% O
, O
and O
53 O
. O
32 O
% O
, O
respectively O
. O

We O
aim O
to O
demonstrate O
that O
a O
chest O
X O
- O
ray O
( O
CXR O
) O
scoring O
system O
for O
COVID O
- O
19 O
patients O
correlates O
with O
patient O
outcome O
and O
has O
a O
prognostic O
value O
. O

Prediction O
of O
COVID O
- O
19 O
incidence O
and O
transmissibility O
rates O
are O
essential O
to O
inform O
disease O
control O
policy O
and O
allocation O
of O
limited O
resources O
( O
especially O
to O
hotspots O
) O
, O
and O
also O
to O
prepare O
towards O
healthcare O
facilities O
demand O
. O

We O
report O
a O
case O
of O
delayed O
presentation O
of O
STEMI O
as O
ventricular O
septal O
rupture O
during O
the O
COVID O
- O
19 O
pandemic O
, O
a O
rare O
presentation O
in O
the O
current O
age O
of O
primary O
percutaneous O
coronary O
intervention O
. O
( O
Level O
of O
Difficulty O
: O
Beginner O
. O
) O
. O

In O
our O
patient O
, O
the O
acute O
symptoms O
of O
vertigo O
and O
tinnitus O
coincided O
with O
the O
diagnosis O
of O
COVID O
- O
19 O
. O

Managing O
Endovascular O
Workload O
during O
COVID O
- O
19 O
Outbreak O
- O
The O
Singapore O
Experience O
. O

Impacts O
of O
the O
COVID O
- O
19 O
pandemic O
on O
field O
instruction O
and O
remote O
teaching O
alternatives O
: O
Results O
from O
a O
survey O
of O
instructors O
. O

COVID O
- O
19 O
vaccination O
program O
( O
1 O
) O
. O

Charles O
Moore O
in O
The O
Telegraph O
recently O
described O
the O
NHS O
as O
' O
lumbering O
' O
. O
1 O
Far O
from O
this O
description O
, O
it O
has O
been O
our O
experience O
that O
the O
NHS O
has O
rapidly O
transformed O
across O
specialties O
in O
order O
to O
respond O
to O
the O
unprecedented O
global O
crisis O
of O
COVID O
- O
19 O
. O

Therefore O
, O
the O
aim O
of O
this O
study O
was O
to O
investigate O
the O
echocardiographic O
features O
of O
cardiac O
injury O
related O
to O
COVID O
- O
19 O
and O
their O
prognostic O
value O
. O

Methods O
Severe O
and O
critical O
COVID O
- O
19 O
patients O
from O
Shanghai O
were O
included O
. O

COVID O
- O
19 O
caused O
by O
SARS O
- O
CoV O
- O
2 O
has O
already O
infected O
more O
than O
6 O
. O
3 O
million O
people O
worldwide O
as O
of O
1st O
June O
2020 O
and O
caused O
a O
global O
medical O
emergency O
. O

In O
many O
countries O
, O
traditional O
practices O
, O
based O
on O
natural O
products O
( O
NPs O
) O
have O
been O
in O
use O
to O
slow O
down O
COVID O
- O
19 O
infection O
. O

In O
this O
COVID O
- O
19 O
pandemic O
, O
there O
are O
not O
many O
sound O
studies O
focusing O
on O
the O
extensive O
socioeconomic O
impact O
ushered O
in O
with O
this O
disaster O
. O

As O
the O
world O
' O
s O
economies O
come O
out O
of O
the O
lockdown O
imposed O
by O
the O
COVID O
- O
19 O
pandemic O
, O
there O
is O
an O
urgent O
need O
for O
technologies O
to O
mitigate O
COVID O
- O
19 O
transmission O
in O
confined O
spaces O
such O
as O
buildings O
. O

Tracheostomy O
in O
the O
COVID O
- O
19 O
Era O
: O
The O
Apneic O
Approach O
. O

This O
work O
represents O
one O
of O
the O
early O
papers O
on O
the O
use O
of O
GNNs O
to O
forecast O
COVID O
- O
19 O
incidence O
dynamics O
and O
our O
methods O
are O
competitive O
to O
existing O
methods O
. O

Because O
of O
the O
misconception O
that O
African O
traditional O
medicines O
can O
cure O
/ O
prevent O
all O
diseases O
, O
some O
Africans O
may O
opt O
for O
COVID O
- O
19 O
prevention O
and O
management O
by O
self O
- O
medicating O
. O

[ O
Suicidal O
behavior O
in O
light O
of O
COVID O
- O
19 O
outbreak O
: O
Clinical O
challenges O
and O
treatment O
perspectives O
] O
. O

COVID O
- O
19 O
is O
a O
highly O
contagious O
respiratory O
disease O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
two O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

The O
advent O
of O
COVID O
- O
19 O
vaccines O
will O
play O
a O
major O
role O
in O
helping O
to O
end O
the O
pandemic O
that O
has O
killed O
millions O
worldwide O
. O

Under O
the O
rapidly O
evolving O
circumstances O
of O
the O
COVID O
- O
19 O
pandemic O
, O
most O
clinical O
trials O
of O
experimental O
treatments O
in O
the O
United O
States O
have O
focused O
on O
later O
stages O
of O
the O
disease O
process O
. O

Overall O
114 O
articles O
included O
in O
this O
study O
; O
52 O
251 O
COVID O
- O
19 O
confirmed O
patients O
( O
20 O
studies O
) O
, O
10 O
037 O
SARS O
( O
51 O
studies O
) O
, O
and O
8139 O
MERS O
patients O
( O
43 O
studies O
) O
were O
included O
. O

Seropositivity O
of O
IgG O
antibodies O
against O
SARS O
- O
CoV O
- O
2 O
was O
measured O
as O
a O
mark O
of O
COVID O
- O
19 O
infection O
. O

There O
was O
a O
significant O
association O
between O
AST O
and O
severity O
of O
COVID O
- O
19 O
with O
a O
pooled O
OR O
of O
4 O
. O
48 O
( O
95 O
% O
CI O
3 O
. O
24 O
- O
7 O
. O
21 O
; O
P O
< O
0 O
. O
001 O
) O
, O
and O
a O
pooled O
WMD O
of O
3 O
. O
35 O
( O
95 O
% O
CI O
, O
2 O
. O
07 O
to O
4 O
. O
64 O
; O
P O
< O
0 O
. O
001 O
) O
. O

Thus O
, O
this O
study O
increases O
the O
knowledge O
of O
specific O
myeloid O
subsets O
involved O
in O
the O
pathogenesis O
of O
COVID O
- O
19 O
disease O
and O
could O
be O
useful O
for O
the O
design O
of O
therapeutic O
strategies O
for O
fighting O
SARS O
- O
CoV O
- O
2 O
infection O
. O

Nineteen O
patients O
with O
neurological O
symptoms O
and O
mild O
to O
critical O
COVID O
- O
19 O
were O
prospectively O
included O
. O

Previously O
, O
we O
provided O
a O
first O
overview O
of O
available O
literature O
on O
SARS O
- O
CoV O
- O
2 O
and O
COVID O
- O
19 O
, O
relevant O
for O
anaesthetists O
and O
intensivists O
. O

The O
psychiatry O
- O
palliative O
care O
liaison O
team O
effectively O
provided O
palliative O
care O
services O
during O
the O
early O
phase O
and O
peak O
of O
New O
York O
City O
' O
s O
COVID O
- O
19 O
crisis O
, O
managing O
up O
to O
16 O
new O
cases O
per O
day O
and O
provided O
longitudinal O
follow O
- O
up O
, O
thereby O
enabling O
palliative O
care O
specialists O
to O
focus O
on O
providing O
services O
requiring O
specialist O
- O
level O
palliative O
care O
expertise O
. O

This O
short O
review O
summarizes O
the O
key O
points O
as O
to O
why O
COVID O
- O
19 O
is O
not O
jest O
ready O
to O
fly O
. O

COVID O
- O
19 O
Pandemic O
: O
Knowledge O
and O
Perceptions O
of O
the O
Public O
and O
Healthcare O
Professionals O
. O

Psychosocial O
support O
for O
healthcare O
frontliners O
during O
COVID O
- O
19 O
pandemic O
in O
Malaysia O
. O

Whether O
gender O
- O
related O
disparities O
in O
the O
access O
to O
the O
diagnosis O
of O
COVID O
- O
19 O
may O
explain O
such O
a O
result O
need O
to O
be O
explored O
. O

Cardiovascular O
diseases O
burden O
in O
COVID O
- O
19 O
: O
Systematic O
review O
and O
meta O
- O
analysis O
. O

Once O
familiar O
with O
this O
framework O
, O
palliative O
care O
clinicians O
may O
use O
it O
to O
educate O
their O
non O
- O
palliative O
care O
colleagues O
about O
a O
timely O
and O
critical O
component O
of O
care O
, O
now O
and O
beyond O
the O
COVID O
- O
19 O
era O
. O

Analyzing O
inter O
- O
reader O
variability O
affecting O
deep O
ensemble O
learning O
for O
COVID O
- O
19 O
detection O
in O
chest O
radiographs O
. O

The O
optimal O
solution O
of O
how O
to O
effectively O
balance O
the O
resumption O
of O
standard O
surgical O
care O
while O
doing O
everything O
possible O
to O
limit O
the O
spread O
of O
COVID O
- O
19 O
is O
undetermined O
, O
and O
could O
include O
strategies O
such O
as O
social O
distancing O
, O
screening O
forms O
and O
tests O
including O
temperature O
screening O
, O
segregation O
of O
inpatient O
and O
outpatient O
teams O
, O
proper O
use O
of O
protective O
gear O
, O
and O
the O
use O
of O
ambulatory O
surgery O
centers O
( O
ASCs O
) O
to O
provide O
elective O
, O
yet O
ultimately O
essential O
, O
surgical O
care O
while O
conserving O
resources O
and O
protecting O
the O
health O
of O
patients O
and O
health O
- O
care O
providers O
. O

We O
collected O
presenting O
data O
from O
22445 O
people O
attending O
with O
suspected O
COVID O
- O
19 O
between O
26 O
March O
2020 O
and O
28 O
May O
2020 O
. O

Meta O
- O
analysis O
showed O
that O
a O
greater O
proportion O
of O
severe O
or O
critically O
COVID O
- O
19 O
patients O
were O
male O
( O
62 O
. O
3 O
% O
) O
, O
and O
the O
2 O
main O
clinical O
symptoms O
were O
fever O
( O
87 O
. O
4 O
% O
) O
and O
cough O
( O
66 O
. O
3 O
% O
) O
. O

Overall O
, O
113 O
/ O
152 O
( O
74 O
% O
) O
participants O
reported O
shortness O
of O
breath O
within O
the O
prior O
week O
( O
median O
score O
3 O
out O
of O
10 O
[ O
IQR O
0 O
- O
5 O
] O
) O
, O
vs O
47 O
/ O
152 O
( O
31 O
% O
) O
pre O
- O
COVID O
- O
19 O
infection O
( O
0 O
, O
IQR O
0 O
- O
1 O
) O
, O
p O
< O
0 O
. O
001 O
. O

HCWs O
were O
most O
worried O
about O
the O
relatively O
mild O
symptoms O
of O
COVID O
- O
19 O
. O

SARS O
- O
CoV O
- O
2 O
, O
that O
causes O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
; O
CoV O
- O
19 O
) O
has O
the O
unusual O
capacity O
to O
attack O
many O
different O
types O
of O
human O
host O
cells O
simultaneously O
via O
novel O
clathrin O
- O
and O
caveolae O
- O
independent O
endocytic O
pathways O
, O
becoming O
injurious O
to O
diverse O
cells O
, O
tissues O
and O
organ O
systems O
and O
exploiting O
any O
immune O
weakness O
in O
the O
host O
. O

There O
are O
numerous O
studies O
and O
guidelines O
for O
administration O
of O
thromboprophylaxis O
for O
COVID O
- O
19 O
cases O
. O

[ O
The O
heart O
and O
COVID O
- O
19 O
: O
A O
first O
update O
] O
. O

Wastewater O
surveillance O
of O
SARS O
- O
CoV O
- O
2 O
can O
be O
an O
effective O
tool O
in O
early O
detection O
of O
outbreak O
and O
determination O
of O
COVID O
- O
19 O
prevalence O
within O
a O
population O
, O
complementing O
clinical O
testing O
and O
providing O
decision O
makers O
guidance O
on O
restricting O
or O
relaxing O
movement O
. O

Biochemical O
biomarkers O
alterations O
in O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Fondaparinux O
and O
bleeding O
risk O
in O
COVID O
- O
19 O
: O
unsolved O
question O
. O

Medications O
used O
to O
treat O
atrial O
fibrillation O
, O
such O
as O
antiarrhythmic O
drugs O
and O
anticoagulants O
, O
may O
have O
significant O
drug O
interactions O
with O
emerging O
COVID O
- O
19 O
treatments O
. O

Obesity O
prolongs O
the O
hospital O
stay O
in O
patients O
affected O
by O
COVID O
- O
19 O
, O
and O
may O
impact O
on O
SARS O
- O
COV O
- O
2 O
shedding O
. O

Living O
with O
children O
, O
having O
contracted O
COVID O
- O
19 O
before O
the O
prior O
2 O
weeks O
, O
being O
pessimistic O
about O
the O
vaccine O
and O
working O
in O
healthcare O
, O
were O
risk O
factors O
for O
insomnia O
symptoms O
. O

Eight O
hundred O
and O
forty O
- O
one O
Chinese O
college O
students O
( O
Mage O
= O
19 O
. O
50 O
years O
, O
SD O
= O
1 O
. O
580 O
) O
completed O
the O
measures O
of O
stressors O
of O
COVID O
- O
19 O
, O
stress O
consequences O
, O
rumination O
, O
and O
psychological O
support O
. O

In O
December O
2019 O
, O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
outbreak O
occurred O
in O
Wuhan O
. O

Since O
SARS O
- O
CoV O
- O
2 O
binds O
to O
angiotensin O
- O
converting O
enzyme O
2 O
( O
ACE2 O
) O
for O
entering O
into O
host O
cells O
, O
to O
target O
COVID O
- O
19 O
from O
therapeutic O
angle O
, O
we O
engineered O
a O
hexapeptide O
corresponding O
to O
the O
ACE2 O
- O
interacting O
domain O
of O
SARS O
- O
CoV O
- O
2 O
( O
AIDS O
) O
that O
inhibits O
the O
association O
between O
receptor O
- O
binding O
domain O
- O
containing O
spike O
S1 O
and O
ACE O
- O
2 O
. O

Impact O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
the O
Urology O
Residency O
Match O
in O
Singapore O
. O

Rapid O
implementation O
and O
improvement O
of O
a O
virtual O
student O
placement O
model O
in O
response O
to O
the O
COVID O
- O
19 O
pandemic O
. O

Corona O
Virus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
a O
global O
health O
emergency O
. O

Response O
by O
Cohen O
et O
al O
to O
Letter O
Regarding O
Article O
, O
" O
Association O
of O
Inpatient O
Use O
of O
Angiotensin O
- O
Converting O
Enzyme O
Inhibitors O
and O
Angiotensin O
II O
Receptor O
Blockers O
With O
Mortality O
Among O
Patients O
With O
Hypertension O
Hospitalized O
With O
COVID O
- O
19 O
" O
. O

Being O
primarily O
a O
respiratory O
disease O
, O
COVID O
- O
19 O
is O
mainly O
associated O
with O
pneumonia O
or O
minor O
upper O
respiratory O
tract O
symptoms O
; O
however O
, O
different O
organs O
can O
sustain O
considerable O
( O
if O
not O
terminal O
) O
damage O
because O
of O
coronavirus O
. O

Comparison O
of O
cardiovascular O
metabolic O
characteristics O
and O
impact O
on O
COVID O
- O
19 O
and O
MERS O
. O

The O
antiviral O
effects O
of O
Novaferon O
, O
a O
potent O
antiviral O
protein O
drug O
, O
on O
COVID O
- O
19 O
was O
evaluated O
in O
the O
laboratory O
, O
and O
in O
a O
randomized O
, O
open O
- O
label O
, O
parallel O
- O
group O
trial O
. O

Point O
- O
of O
- O
care O
COVID O
- O
19 O
assays O
that O
are O
more O
sensitive O
than O
the O
current O
RT O
- O
PCR O
( O
reverse O
transcription O
polymerase O
chain O
reaction O
) O
gold O
standard O
assay O
are O
needed O
to O
improve O
disease O
control O
efforts O
. O

Report O
of O
Two O
COVID O
- O
19 O
ARDS O
( O
CARDS O
) O
Cases O
Who O
Survived O
without O
Intubation O
and O
Mechanical O
Ventilation O
. O

Background O
: O
This O
study O
evaluated O
factors O
linked O
with O
perceived O
stress O
related O
to O
the O
COVID O
- O
19 O
pandemic O
and O
lockdown O
and O
addictive O
behaviors O
prior O
to O
and O
during O
lockdown O
in O
a O
sample O
of O
students O
who O
indicated O
engaging O
in O
alcohol O
consumption O
behaviors O
before O
lockdown O
. O

We O
describe O
two O
critically O
ill O
COVID O
- O
19 O
patients O
who O
developed O
ST O
elevation O
that O
resolved O
on O
repeat O
ECG O
without O
any O
intervention O
. O

SARS O
- O
CoV O
- O
2 O
may O
result O
in O
dramatic O
cardiovascular O
complications O
, O
whereas O
the O
severity O
of O
COronaVIrus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
the O
incidence O
of O
fatalities O
tend O
to O
increase O
in O
patients O
with O
pre O
- O
existing O
cardiovascular O
complications O
. O

Repurposing O
anticancer O
drugs O
for O
the O
management O
of O
COVID O
- O
19 O
. O

Endocrinologists O
have O
had O
to O
make O
rapid O
changes O
to O
services O
so O
that O
resources O
can O
be O
focused O
on O
the O
COVID O
- O
19 O
response O
to O
help O
prevent O
spread O
of O
the O
virus O
. O

The O
overall O
COVID O
- O
19 O
infection O
rate O
of O
the O
study O
population O
at O
any O
time O
was O
22 O
% O
. O

Restricting O
mobility O
is O
a O
central O
aim O
for O
lowering O
contact O
rates O
and O
preventing O
COVID O
- O
19 O
transmission O
. O

We O
evaluated O
SARS O
- O
CoV O
- O
2 O
serology O
in O
the O
entire O
personnel O
of O
a O
COVID O
- O
19 O
- O
free O
otolaryngology O
department O
in O
a O
highly O
affected O
area O
. O

Emerging O
New O
Psychiatric O
Symptoms O
and O
the O
Worsening O
of O
Pre O
- O
existing O
Mental O
Disorders O
during O
the O
COVID O
- O
19 O
Pandemic O
: O
A O
Canadian O
Multisite O
Study O
: O
Nouveaux O
sympt O
ô O
mes O
psychiatriques O
é O
mergents O
et O
d O
é O
t O
é O
rioration O
des O
troubles O
mentaux O
pr O
é O
existants O
durant O
la O
pand O
é O
mie O
de O
la O
COVID O
- O
19 O
: O
une O
é O
tude O
canadienne O
multisite O
. O

This O
paper O
looks O
at O
the O
issues O
associated O
with O
mass O
testing O
of O
prisoners O
for O
COVID O
- O
19 O
. O

In O
this O
report O
we O
describe O
the O
clinical O
presentation O
, O
laboratory O
findings O
and O
outcomes O
of O
four O
patients O
that O
were O
referred O
for O
urgent O
cardiothoracic O
intervention O
and O
tested O
positive O
for O
COVID O
- O
19 O
. O

Here O
, O
we O
conducted O
a O
search O
for O
ongoing O
clinical O
trials O
for O
the O
treatment O
of O
COVID O
- O
19 O
at O
the O
clinicaltrials O
. O
gov O
database O
on O
April O
2 O
, O
2020 O
. O

The O
pandemic O
caused O
by O
coronavirus O
COVID O
- O
19 O
is O
having O
a O
worldwide O
impact O
that O
affects O
health O
and O
the O
economy O
and O
indirectly O
affects O
air O
pollution O
in O
cities O
. O

Antiviral O
therapy O
in O
patients O
with O
COVID O
- O
19 O
with O
prosthetic O
heart O
valves O
might O
be O
an O
issue O
responsible O
for O
an O
uncontrolled O
INR O
. O

Effective O
therapies O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
are O
urgently O
needed O
, O
and O
preclinical O
data O
suggest O
alpha O
- O
1 O
adrenergic O
receptor O
antagonists O
( O
α O
1 O
- O
AR O
antagonists O
) O
may O
be O
effective O
in O
reducing O
mortality O
related O
to O
hyperinflammation O
. O

In O
contrast O
to O
severe O
acute O
COVID O
- O
19 O
, O
such O
' O
long O
COVID O
' O
is O
seemingly O
more O
likely O
in O
women O
than O
in O
men O
. O

There O
is O
no O
evidence O
supporting O
COVID O
- O
19 O
- O
specific O
ventilatory O
settings O
, O
and O
the O
vast O
amount O
of O
available O
literature O
suggests O
that O
evidence O
- O
based O
, O
lung O
- O
protective O
ventilation O
( O
i O
. O
e O
. O
tidal O
volume O
≤ O
6 O
ml O
/ O
kg O
, O
plateau O
pressure O
≤ O
30 O
cmH2O O
) O
should O
be O
enforced O
in O
all O
mechanically O
ventilated O
patients O
with O
COVID O
- O
19 O
ARDS O
. O

Our O
network O
- O
based O
analysis O
strengthens O
the O
understanding O
of O
the O
molecular O
basis O
of O
the O
neurological O
manifestations O
observed O
in O
COVID O
- O
19 O
and O
also O
suggests O
drug O
for O
repurposing O
. O

Modality O
alignment O
contrastive O
learning O
for O
severity O
assessment O
of O
COVID O
- O
19 O
from O
lung O
ultrasound O
and O
clinical O
information O
. O

This O
contrast O
triggered O
us O
explore O
the O
causes O
, O
with O
the O
background O
that O
a O
vaccine O
for O
effective O
immunization O
or O
a O
drug O
to O
tackle O
COVID O
- O
19 O
is O
not O
too O
close O
to O
reality O
. O

The O
concept O
of O
home O
- O
based O
accessibility O
( O
HBA O
) O
is O
introduced O
, O
and O
novel O
research O
questions O
are O
addressed O
: O
( O
i O
) O
What O
type O
of O
households O
had O
zero O
home O
deliveries O
before O
COVID O
- O
19 O
lockdown O
? O

Our O
analyses O
suggest O
that O
patients O
of O
Asian O
and O
black O
backgrounds O
suffered O
disproportionate O
rates O
of O
premature O
death O
from O
COVID O
- O
19 O
. O

The O
available O
evidence O
of O
the O
treatment O
of O
COVID O
- O
19 O
with O
traditional O
Chinese O
medicine O
will O
be O
summarized O
, O
and O
evaluation O
of O
the O
efficacy O
and O
the O
adverse O
effects O
of O
these O
treatments O
will O
be O
made O
. O

COVID O
- O
19 O
in O
Critical O
Care O
Units O
: O
Rethinking O
the O
Humanization O
of O
Nursing O
Care O
. O

Among O
30 O
children O
with O
mild O
COVID O
- O
19 O
, O
seven O
had O
no O
symptoms O
, O
fifteen O
had O
low O
or O
mediate O
fever O
, O
and O
eight O
presented O
with O
cough O
, O
nasal O
congestion O
, O
diarrhea O
, O
headache O
, O
or O
fatigue O
. O

A O
multivariate O
modified O
Poisson O
regression O
analysis O
was O
then O
performed O
to O
determine O
significant O
predictors O
for O
increased O
adverse O
events O
in O
patients O
with O
COVID O
- O
19 O
pneumonia O
. O

Hospitalized O
COVID O
- O
19 O
HCW O
had O
fewer O
comorbidities O
and O
a O
better O
prognosis O
than O
NHCW O
. O

COVID O
- O
19 O
: O
preparing O
for O
superspreader O
potential O
among O
Umrah O
pilgrims O
to O
Saudi O
Arabia O
. O

Overall O
, O
this O
review O
provides O
early O
insights O
and O
directions O
for O
ongoing O
research O
regarding O
the O
pathophysiological O
mechanisms O
that O
may O
explain O
the O
severe O
COVID O
- O
19 O
disease O
phenotype O
observed O
amongst O
the O
BAME O
population O
. O

The O
higher O
affective O
risk O
perception O
groups O
were O
more O
likely O
to O
practice O
transmission O
- O
reducing O
measures O
( O
adjusted O
odds O
ratio O
, O
3 O
. O
24 O
- O
4 O
. O
81 O
; O
95 O
confidence O
interval O
, O
1 O
. O
76 O
- O
6 O
. O
96 O
) O
during O
both O
COVID O
- O
19 O
and O
MERS O
- O
CoV O
. O

In O
light O
of O
the O
current O
COVID O
- O
19 O
pandemic O
, O
migrant O
workers O
are O
now O
exposed O
to O
additional O
stressors O
of O
the O
virus O
and O
related O
responses O
. O

Neutrophil O
- O
to O
- O
lymphocyte O
ratio O
on O
admission O
to O
predict O
the O
severity O
and O
mortality O
of O
COVID O
- O
19 O
patients O
: O
A O
meta O
- O
analysis O
. O

The O
finding O
from O
our O
review O
highlights O
the O
potential O
role O
of O
this O
modality O
in O
the O
triage O
, O
diagnosis O
, O
and O
follow O
- O
up O
of O
COVID O
- O
19 O
patients O
. O

This O
is O
a O
retrospective O
single O
- O
center O
study O
of O
417 O
consecutive O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
admitted O
to O
Jaber O
Al O
- O
Ahmad O
Hospital O
in O
Kuwait O
between O
February O
24 O
, O
2020 O
and O
May O
24 O
, O
2020 O
. O

The O
majority O
of O
the O
participants O
were O
aware O
of O
common O
COVID O
- O
19 O
symptoms O
like O
fever O
and O
cough O
( O
79 O
. O
8 O
and O
67 O
. O
2 O
% O
, O
respectively O
) O
, O
but O
less O
than O
half O
were O
aware O
that O
smell O
or O
taste O
dysfunction O
might O
be O
a O
symptom O
of O
COVID O
- O
19 O
( O
44 O
. O
3 O
and O
30 O
. O
2 O
% O
, O
respectively O
) O
. O

The O
North O
American O
Layman O
' O
s O
Understanding O
of O
COVID O
- O
19 O
: O
Are O
We O
Doing O
Enough O
? O

The O
whole O
world O
is O
dealing O
with O
the O
COVID O
- O
19 O
pandemic O
, O
and O
healthcare O
professionals O
are O
the O
most O
affected O
group O
. O

We O
established O
a O
working O
group O
within O
the O
International O
Late O
Effects O
of O
Childhood O
Cancer O
Guideline O
Harmonization O
Group O
( O
IGHG O
) O
to O
summarize O
existing O
evidence O
and O
worldwide O
recommendations O
regarding O
evidence O
about O
factors O
/ O
conditions O
associated O
with O
risk O
for O
a O
severe O
course O
of O
COVID O
- O
19 O
in O
CAYA O
cancer O
survivors O
, O
and O
to O
develop O
a O
consensus O
statement O
to O
provide O
guidance O
for O
healthcare O
practitioners O
and O
CAYA O
cancer O
survivors O
regarding O
COVID O
- O
19 O
. O

COVID O
- O
19 O
amplified O
the O
authorship O
gender O
gap O
in O
ophthalmology O
. O

The O
COVID O
- O
19 O
pandemic O
emerges O
a O
reminder O
that O
wide O
spectrum O
discrepancy O
in O
response O
to O
SARS O
- O
CoV O
- O
2 O
infection O
and O
antiviral O
drugs O
among O
different O
populations O
might O
be O
due O
to O
their O
different O
ACE2 O
SNPs O
and O
/ O
or O
miRNAs O
profile O
. O

Internal O
Medicine O
and O
COVID O
- O
19 O
. O

The O
mean O
score O
for O
EQ O
- O
5D O
- O
5L O
in O
COVID O
- O
19 O
patients O
was O
low O
in O
this O
study O
. O

Background O
The O
use O
of O
chest O
CT O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
diagnosis O
or O
triage O
in O
health O
care O
settings O
with O
limited O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
polymerase O
chain O
reaction O
( O
PCR O
) O
capacity O
is O
controversial O
. O

As O
of O
late O
May O
2020 O
, O
the O
global O
death O
rate O
due O
to O
COVID O
- O
19 O
was O
357 O
, O
714 O
and O
441 O
in O
KSA O
alone O
. O

Asthma O
and O
COVID O
- O
19 O
: O
Preconceptions O
About O
Predisposition O
. O

Health O
Equity O
During O
COVID O
- O
19 O
. O

Approximately O
one O
- O
fifth O
( O
21 O
. O
9 O
% O
) O
of O
the O
hospitalized O
COVID O
- O
19 O
patients O
were O
admitted O
to O
the O
ICU O
and O
16 O
. O
9 O
% O
received O
IMV O
; O
most O
patients O
( O
73 O
. O
6 O
% O
) O
did O
not O
require O
ICU O
admission O
or O
IMV O
, O
and O
12 O
. O
4 O
% O
required O
both O
. O

The O
global O
COVID O
- O
19 O
pandemic O
has O
the O
potential O
to O
indirectly O
impact O
the O
transmission O
dynamics O
and O
prevention O
of O
HIV O
and O
other O
sexually O
transmitted O
infections O
( O
STI O
) O
. O

Currently O
, O
over O
100 O
countries O
are O
fighting O
against O
a O
common O
enemy O
, O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
( O
SARS O
- O
CoV O
) O
- O
2 O
, O
which O
causes O
COVID O
- O
19 O
. O

In O
this O
paper O
, O
we O
first O
focus O
on O
summarizing O
the O
state O
- O
of O
- O
the O
- O
art O
research O
works O
related O
to O
deep O
learning O
applications O
for O
COVID O
- O
19 O
medical O
image O
processing O
. O

COVID O
- O
19 O
: O
Epidemiology O
, O
Pathology O
, O
Diagnosis O
, O
Treatment O
, O
and O
Impact O
. O

How O
should O
I O
manage O
immunosuppression O
in O
a O
kidney O
transplant O
patient O
with O
COVID O
- O
19 O
? O
An O
ERA O
- O
EDTA O
DESCARTES O
expert O
opinion O
. O

Could O
COVID O
- O
19 O
Infect O
the O
Consumer O
Price O
Index O
? O
1 O
. O

There O
is O
mixed O
evidence O
surrounding O
the O
relationship O
between O
tobacco O
use O
and O
COVID O
- O
19 O
infection O
/ O
progression O
. O

In O
this O
review O
, O
we O
examine O
the O
potential O
role O
of O
NO O
during O
SARS O
- O
CoV O
- O
2 O
infection O
from O
the O
perspective O
of O
the O
unique O
physical O
, O
chemical O
and O
biological O
properties O
and O
potential O
mechanisms O
of O
NO O
in O
COVID O
- O
19 O
, O
as O
well O
as O
possible O
therapeutic O
strategies O
using O
inhaled O
NO O
. O

Alveolar O
SARS O
- O
CoV O
- O
2 O
viral O
load O
is O
tightly O
correlated O
with O
severity O
in O
COVID O
- O
19 O
ARDS O
. O

Our O
data O
suggest O
that O
BCG O
vaccination O
might O
be O
associated O
with O
a O
decrease O
in O
the O
incidence O
of O
sickness O
during O
the O
COVID O
- O
19 O
pandemic O
( O
adjusted O
odds O
ratio O
[ O
AOR O
] O
0 O
. O
58 O
, O
p O
< O
0 O
. O
05 O
) O
, O
and O
lower O
incidence O
of O
extreme O
fatigue O
. O

Diabetes O
and O
COVID O
- O
19 O
risk O
: O
an O
miRNA O
perspective O
. O

After O
analyses O
were O
adjusted O
for O
sociodemographic O
and O
lifestyle O
factors O
, O
a O
higher O
risk O
of O
COVID O
- O
19 O
was O
observed O
for O
pre O
- O
frail O
( O
risk O
ratio O
( O
RR O
) O
1 O
. O
47 O
[ O
95 O
% O
CI O
1 O
. O
26 O
; O
1 O
. O
71 O
] O
) O
and O
frail O
( O
RR O
2 O
. O
66 O
[ O
95 O
% O
CI O
2 O
. O
04 O
; O
3 O
. O
47 O
] O
) O
individuals O
compared O
to O
those O
classified O
as O
robust O
using O
the O
frailty O
phenotype O
. O

Even O
in O
the O
absence O
of O
a O
COVID O
- O
19 O
diagnosis O
, O
skin O
findings O
should O
be O
evaluated O
carefully O
in O
this O
pandemic O
period O
. O

COVID O
- O
19 O
and O
Acute O
Pancreatitis O
: O
What O
Do O
Surgeons O
Need O
to O
Know O
? O

A O
challenging O
case O
of O
psoriasis O
flare O
- O
up O
after O
COVID O
- O
19 O
infection O
. O

Exploring O
an O
unsung O
stigma O
factor O
in O
COVID O
- O
19 O
. O

D O
- O
Dimer O
- O
Driven O
Anticoagulation O
Reduces O
Mortality O
in O
Intubated O
COVID O
- O
19 O
Patients O
: O
A O
Cohort O
Study O
With O
a O
Propensity O
- O
Matched O
Analysis O
. O

COVID O
- O
19 O
- O
related O
severity O
, O
self O
- O
efficacy O
, O
and O
preventive O
behaviors O
correlated O
with O
mental O
health O
. O

Thirty O
- O
five O
coinfected O
patients O
were O
identified O
by O
matching O
the O
reported O
cases O
in O
National O
Notifiable O
Infectious O
Disease O
Report O
system O
for O
COVID O
- O
19 O
and O
HIV O
in O
Wuhan O
by O
time O
of O
April O
19 O
, O
2020 O
. O

The O
high O
mortality O
of O
severe O
2019 O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
cases O
is O
mainly O
caused O
by O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
, O
which O
is O
characterized O
by O
increased O
permeability O
of O
the O
alveolar O
epithelial O
barriers O
, O
pulmonary O
oedema O
and O
consequently O
inflammatory O
tissue O
damage O
. O

Science O
in O
the O
fight O
against O
the O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Evolving O
global O
and O
national O
criteria O
for O
identifying O
a O
suspected O
case O
of O
COVID O
- O
19 O
. O

Liver O
Injury O
in O
Critically O
Ill O
and O
Non O
- O
critically O
Ill O
COVID O
- O
19 O
Patients O
: O
A O
Multicenter O
, O
Retrospective O
, O
Observational O
Study O
. O

Competency O
- O
based O
medical O
education O
for O
postgraduates O
in O
the O
minimally O
invasive O
surgery O
department O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
63 O
- O
Year O
- O
Old O
Woman O
with O
SARS O
- O
CoV O
- O
2 O
Infection O
, O
Who O
Developed O
Severe O
COVID O
- O
19 O
Pneumonia O
and O
Was O
Supported O
with O
Convalescent O
Plasma O
Therapy O
. O

The O
mortality O
of O
30 O
patients O
with O
epilepsy O
and O
COVID O
- O
19 O
was O
36 O
. O
67 O
% O
. O

During O
COVID O
- O
19 O
, O
which O
is O
more O
effective O
in O
work O
accident O
prevention O
behavior O
of O
healthcare O
professionals O
: O
Safety O
awareness O
or O
fatalism O
perception O
? O

Finally O
, O
we O
have O
summarised O
some O
of O
the O
measures O
that O
can O
be O
taken O
by O
institutions O
and O
individuals O
to O
minimise O
the O
impact O
of O
COVID O
- O
19 O
pandemic O
on O
our O
mental O
well O
being O
. O

[ O
Cardiac O
rehabilitation O
and O
secondary O
prevention O
programs O
during O
the O
COVID O
- O
19 O
pandemic O
: O
what O
' O
s O
" O
COVID O
on O
" O
? O
] O

Admissions O
to O
St O
Thomas O
' O
Hospital O
, O
London O
with O
laboratory O
- O
confirmed O
COVID O
- O
19 O
. O

In O
late O
December O
2019 O
, O
an O
outbreak O
of O
a O
novel O
coronavirus O
( O
infection O
from O
which O
results O
in O
the O
disease O
named O
COVID O
- O
19 O
) O
was O
reported O
, O
and O
, O
due O
to O
the O
rapid O
spread O
of O
the O
virus O
in O
other O
parts O
of O
the O
world O
, O
the O
World O
Health O
Organization O
declared O
a O
state O
of O
emergency O
. O

To O
reperfuse O
or O
not O
to O
reperfuse O
: O
a O
case O
report O
of O
Wellens O
' O
syndrome O
with O
suspected O
COVID O
- O
19 O
infection O
. O

Emerging O
from O
COVID O
- O
19 O
: O
prioritising O
the O
burden O
of O
loneliness O
in O
older O
people O
. O

Our O
research O
has O
revealed O
that O
due O
to O
the O
lockdown O
imposed O
by O
the O
government O
in O
response O
to O
COVID O
- O
19 O
, O
the O
sleeping O
patterns O
of O
the O
students O
was O
affected O
the O
most O
. O

To O
analyze O
the O
frequency O
of O
COVID O
- O
19 O
compared O
to O
other O
respiratory O
infections O
, O
and O
to O
describe O
the O
radiologic O
manifestations O
of O
COVID O
- O
19 O
in O
pediatric O
patients O
. O

Given O
the O
concern O
for O
COVID O
- O
19 O
acquisition O
in O
health O
care O
settings O
, O
pregnant O
persons O
with O
high O
- O
risk O
pregnancies O
- O
such O
as O
persons O
living O
with O
HIV O
( O
PLHIV O
) O
- O
are O
increasingly O
investigating O
the O
option O
of O
a O
home O
birth O
. O

Later O
WHO O
declared O
that O
SARS O
- O
CoV O
- O
2 O
was O
responsible O
for O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

QTc O
interval O
prolongation O
, O
COVID O
- O
19 O
and O
chloroquine O
. O

We O
investigated O
esophageal O
pressure O
allowing O
determination O
of O
transpulmonary O
pressures O
( O
PL O
) O
and O
elastances O
( O
EL O
) O
during O
a O
decremental O
PEEP O
trial O
from O
20 O
to O
6 O
cm O
H2O O
in O
a O
cohort O
of O
COVID O
- O
19 O
ARDS O
patients O
. O

The O
outbreak O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
the O
United O
States O
has O
raised O
growing O
concerns O
for O
the O
transplant O
patient O
population O
. O

To O
evaluate O
the O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
hospital O
admissions O
and O
outcomes O
in O
patients O
admitted O
with O
acute O
ischemic O
stroke O
. O

Of O
3201 O
patients O
undergoing O
hemodialysis O
, O
325 O
patients O
were O
diagnosed O
with O
COVID O
- O
19 O
( O
incidence O
rate O
: O
102 O
per O
1 O
, O
000 O
patients O
on O
hemodialysis O
, O
compared O
with O
3 O
per O
1 O
, O
000 O
in O
the O
general O
population O
) O
. O

The O
use O
of O
ancient O
immunotherapeutic O
technique O
- O
the O
convalescent O
plasma O
( O
CP O
) O
therapy O
, O
may O
act O
as O
an O
immediate O
and O
available O
option O
to O
control O
the O
COVID O
- O
19 O
pandemic O
. O

Five O
were O
hospitalized O
; O
two O
died O
from O
COVID O
- O
19 O
complications O
; O
another O
died O
from O
sarcoma O
. O

The O
possible O
depletion O
of O
zinc O
with O
the O
oxidative O
events O
of O
COVID O
- O
19 O
is O
especially O
relevant O
to O
the O
fertility O
of O
affected O
couples O
. O

Republic O
of O
Kazakhstan O
will O
be O
able O
to O
reduce O
the O
rates O
of O
infections O
and O
deaths O
among O
its O
population O
by O
developing O
and O
following O
a O
consistent O
strategy O
targeting O
COVID O
- O
19 O
in O
a O
number O
of O
inter O
- O
related O
directions O
. O

Impact O
of O
COVID O
- O
19 O
pandemic O
on O
the O
continuity O
of O
care O
for O
dermatologic O
patients O
on O
systemic O
therapy O
during O
the O
period O
of O
strict O
lockdown O
. O

In O
COVID O
- O
19 O
pandemic O
epicenters O
cancer O
care O
was O
severely O
impacted O
. O

Systemic O
Involvement O
of O
Novel O
Coronavirus O
( O
COVID O
- O
19 O
) O
: O
A O
Review O
of O
Literature O
. O

Top O
problems O
of O
adolescents O
and O
young O
adults O
with O
ADHD O
during O
the O
COVID O
- O
19 O
pandemic O
. O

However O
, O
little O
is O
known O
about O
how O
residential O
SUD O
treatment O
programs O
are O
impacted O
by O
the O
COVID O
- O
19 O
pandemic O
. O

In O
this O
paper O
, O
we O
have O
analysed O
the O
trend O
, O
countries O
affected O
regionally O
and O
the O
variation O
of O
cases O
at O
the O
country O
level O
on O
COVID O
- O
19 O
dataset O
. O

Dyslipidemia O
Increases O
the O
Risk O
of O
Severe O
COVID O
- O
19 O
: O
A O
Systematic O
Review O
, O
Meta O
- O
analysis O
, O
and O
Meta O
- O
regression O
. O

The O
most O
common O
neurological O
manifestation O
of O
COVID O
- O
19 O
infection O
is O
an O
olfactory O
deficit O
. O

Clinical O
characteristics O
and O
manifestations O
in O
older O
patients O
with O
COVID O
- O
19 O
. O

Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
a O
pneumonia O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

Critically O
ill O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
have O
a O
profound O
hypercoagulable O
state O
and O
often O
develop O
coagulopathy O
which O
leads O
to O
organ O
failure O
and O
death O
. O

Response O
to O
the O
letter O
, O
" O
The O
cardiovascular O
burden O
of O
congenital O
heart O
disease O
- O
not O
only O
in O
times O
of O
COVID O
- O
19 O
" O
. O

It O
has O
been O
now O
clearly O
established O
that O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
virus O
causing O
COVID O
- O
19 O
, O
infects O
the O
host O
cell O
through O
biding O
and O
being O
internalized O
with O
angiotensin O
converting O
enzyme O
2 O
( O
ACE2 O
) O
, O
a O
surface O
protein O
expressed O
in O
a O
noticeable O
number O
of O
human O
cells O
, O
especially O
in O
those O
of O
upper O
and O
lower O
respiratory O
tracts O
, O
heart O
, O
kidney O
, O
testis O
, O
adipose O
tissue O
, O
gastrointestinal O
system O
and O
in O
lymphocytes O
. O

However O
, O
whether O
or O
not O
this O
peptide O
can O
help O
discriminate O
high O
- O
risk O
COVID O
- O
19 O
patients O
remains O
unclear O
. O

We O
suggest O
that O
the O
circulating O
fetal O
stem O
cells O
might O
have O
an O
immune O
- O
protective O
effect O
to O
mothers O
and O
contribute O
to O
the O
often O
mild O
and O
even O
asymptomatic O
post O
- O
COVID O
- O
19 O
pregnancies O
. O

Hospital O
mortality O
in O
mechanically O
ventilated O
COVID O
- O
19 O
patients O
in O
Mexico O
. O

Evolution O
of O
COVID O
- O
19 O
management O
in O
critical O
care O
: O
review O
and O
perspective O
from O
a O
hospital O
in O
the O
United O
Kingdom O
. O

A O
total O
of O
438 O
samples O
collected O
from O
85 O
patients O
with O
confirmed O
COVID O
- O
19 O
. O

We O
systematically O
searched O
the O
literature O
on O
health O
education O
during O
COVID O
- O
19 O
, O
severe O
acute O
respiratory O
syndrome O
( O
SARS O
) O
and O
middle O
east O
respiratory O
syndrome O
( O
MERS O
) O
epidemics O
in O
Medline O
( O
via O
PubMed O
) O
, O
Cochrane O
Library O
, O
EMBASE O
, O
Web O
of O
Science O
, O
China O
Biology O
Medicine O
disc O
( O
CBM O
) O
, O
China O
National O
Knowledge O
Infrastructure O
( O
CNKI O
) O
, O
and O
Wanfang O
Data O
from O
their O
inception O
until O
March O
31 O
, O
2020 O
. O

At O
the O
end O
of O
December O
2019 O
, O
they O
emerged O
a O
new O
coronavirus O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
triggering O
a O
pandemic O
of O
an O
acute O
respiratory O
syndrome O
( O
COVID O
- O
19 O
) O
in O
humans O
. O

Here O
, O
we O
report O
the O
successful O
treatment O
of O
11 O
cases O
of O
severe O
COVID O
- O
19 O
pneumonia O
with O
favipiravir O
and O
methylprednisolone O
. O

A O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
outbreak O
associated O
with O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
has O
been O
spreading O
widely O
through O
person O
- O
to O
- O
person O
transmission O
. O

The O
ongoing O
global O
pandemic O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
caused O
a O
huge O
number O
of O
human O
deaths O
. O

Building O
a O
resilient O
NHS O
, O
for O
COVID O
- O
19 O
and O
beyond O
. O

More O
than O
two O
- O
thirds O
of O
PDs O
believed O
that O
the O
COVID O
- O
19 O
pandemic O
would O
have O
a O
moderate O
( O
57 O
% O
) O
or O
severe O
( O
14 O
% O
) O
adverse O
impact O
on O
IC O
fellowship O
training O
, O
and O
21 O
% O
of O
the O
PDs O
expected O
their O
current O
fellows O
' O
average O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
volume O
to O
be O
below O
250 O
. O

Professional O
football O
clubs O
and O
empirical O
evidence O
from O
the O
COVID O
- O
19 O
crisis O
: O
Time O
for O
sport O
entrepreneurship O
? O

As O
the O
COVID O
- O
19 O
pandemic O
wears O
on O
, O
its O
psychological O
, O
emotional O
, O
and O
existential O
toll O
continues O
to O
grow O
and O
indeed O
may O
now O
rival O
the O
physical O
suffering O
caused O
by O
the O
illness O
. O

The O
current O
consortium O
critically O
examines O
the O
telemedicine O
frameworks O
, O
identifies O
gaps O
in O
its O
implementation O
and O
investigates O
the O
changes O
in O
telemedicine O
framework O
/ O
s O
during O
COVID O
- O
19 O
across O
the O
globe O
. O

In O
this O
case O
report O
, O
we O
aim O
to O
share O
our O
experience O
about O
the O
first O
organ O
donation O
during O
the O
COVID O
- O
19 O
pandemic O
in O
Turkey O
. O

Does O
life O
expectancy O
, O
death O
rate O
and O
public O
health O
expenditure O
matter O
in O
sustaining O
economic O
growth O
under O
COVID O
- O
19 O
: O
Empirical O
evidence O
from O
Nigeria O
? O

This O
systemic O
review O
will O
evaluate O
the O
efficacy O
and O
safety O
of O
Lianhua O
Qingwen O
combined O
with O
Conventional O
antiviral O
Western O
Medicine O
in O
the O
treatment O
of O
COVID O
- O
19 O
. O

Psychological O
impact O
of O
COVID O
- O
19 O
pandemic O
on O
general O
population O
in O
West O
Bengal O
: O
A O
cross O
- O
sectional O
study O
. O

The O
SOM O
analysis O
showed O
that O
the O
variables O
that O
presented O
a O
more O
significant O
relationship O
with O
the O
numbers O
of O
cases O
and O
deaths O
by O
COVID O
- O
19 O
were O
influenza O
vaccine O
applied O
, O
Intensive O
Care O
Unit O
( O
ICU O
) O
, O
ventilators O
, O
physicians O
, O
nurses O
, O
and O
the O
Human O
Development O
Index O
( O
HDI O
) O
. O

Novel O
social O
distancing O
rules O
imposed O
by O
governments O
and O
agencies O
during O
the O
COVID O
- O
19 O
pandemic O
have O
caused O
older O
adults O
to O
experience O
a O
degree O
of O
social O
isolation O
and O
loneliness O
that O
is O
unprecedented O
. O

Management O
of O
peritoneal O
dialysis O
under O
COVID O
- O
19 O
: O
The O
experience O
in O
Sichuan O
Province O
People O
' O
s O
Hospital O
, O
China O
. O

Therefore O
, O
they O
are O
vulnerable O
to O
various O
infections O
including O
COVID O
- O
19 O
. O

Although O
the O
world O
is O
still O
in O
the O
stage O
of O
COVID O
- O
19 O
pandemic O
, O
the O
treatment O
of O
new O
cases O
and O
critically O
ill O
patients O
is O
the O
focus O
of O
the O
current O
work O
. O

Perceived O
Job O
Insecurity O
and O
Depressive O
Symptoms O
among O
Italian O
Dentists O
: O
The O
Moderating O
Role O
of O
Fear O
of O
COVID O
- O
19 O
. O

Risk O
Stratification O
of O
COVID O
- O
19 O
Patients O
Using O
Ambulatory O
Oxygen O
Saturation O
in O
the O
Emergency O
Department O
. O

The O
COVID O
- O
19 O
patients O
on O
admission O
with O
the O
higher O
levels O
of O
AST O
might O
have O
longer O
hospital O
stays O
. O

Our O
study O
suggests O
that O
patients O
who O
demonstrate O
acute O
deterioration O
, O
a O
protracted O
course O
of O
illness O
with O
non O
- O
resolving O
symptoms O
, O
worsening O
dyspnoea O
, O
persistent O
oxygen O
requirements O
or O
significantly O
raised O
D O
- O
dimer O
levels O
should O
be O
investigated O
for O
PE O
, O
particularly O
in O
the O
context O
of O
COVID O
- O
19 O
infection O
. O

On O
January O
31 O
, O
2020 O
, O
the O
World O
Health O
Organization O
( O
WHO O
) O
declared O
the O
outbreak O
of O
a O
novel O
coronavirus O
responsible O
for O
an O
infection O
termed O
COVID O
- O
19 O
as O
a O
global O
public O
health O
emergency O
. O

Repurposing O
of O
Tetracyclines O
for O
COVID O
- O
19 O
Neurological O
and O
Neuropsychiatric O
Manifestations O
: O
A O
Valid O
Option O
to O
Control O
SARS O
- O
CoV O
- O
2 O
- O
Associated O
Neuroinflammation O
? O

In O
this O
study O
, O
with O
the O
aid O
of O
immunoinformatics O
tools O
, O
we O
tried O
to O
design O
a O
multi O
- O
epitope O
vaccine O
that O
can O
be O
used O
for O
the O
prevention O
and O
treatment O
of O
COVID O
- O
19 O
. O

In O
this O
case O
study O
, O
a O
patient O
who O
was O
in O
late O
pregnancy O
( O
35 O
+ O
2 O
weeks O
of O
pregnancy O
) O
and O
suffering O
from O
severe O
COVID O
- O
19 O
was O
extremely O
irritable O
during O
ECMO O
- O
assisted O
treatment O
after O
she O
underwent O
a O
cesarean O
section O
. O

Timing O
of O
infection O
after O
surgery O
in O
our O
series O
would O
raise O
the O
possibility O
of O
hospital O
transmission O
of O
COVID O
- O
19 O
: O
from O
asymptomatic O
patients O
at O
the O
time O
of O
bariatric O
surgery O
to O
the O
healthcare O
workers O
versus O
acquiring O
the O
COVID O
- O
19 O
infection O
by O
non O
- O
infected O
patients O
in O
the O
perioperative O
period O
. O

As O
the O
current O
coronavirus O
pandemic O
continues O
and O
cases O
of O
COVID O
- O
19 O
critical O
illness O
rise O
, O
physicians O
and O
scientists O
across O
the O
globe O
are O
working O
to O
understand O
and O
study O
its O
pathophysiology O
. O

The O
overall O
hypothesis O
is O
that O
HBO2 O
is O
safe O
and O
reduces O
the O
inflammatory O
response O
in O
COVID O
- O
19 O
pneumonitis O
by O
attenuation O
of O
the O
innate O
immune O
system O
, O
increase O
hypoxia O
tolerance O
and O
thereby O
prevent O
organ O
failure O
and O
reduce O
mortality O
. O

The O
Influence O
of O
Coronavirus O
Diseases O
2019 O
( O
COVID O
- O
19 O
) O
Pandemic O
and O
the O
Quarantine O
Practices O
on O
University O
Students O
' O
Beliefs O
About O
the O
Online O
Learning O
Experience O
in O
Jordan O
. O

Information O
about O
the O
adverse O
health O
effects O
of O
disinfectants O
and O
ways O
to O
minimize O
exposure O
should O
be O
included O
in O
COVID O
- O
19 O
pandemic O
educational O
materials O
. O

We O
aimed O
to O
evaluate O
cardiovascular O
damage O
in O
patients O
with O
COVID O
- O
19 O
and O
determine O
the O
correlation O
of O
high O
- O
sensitivity O
cardiac O
- O
specific O
troponin O
T O
( O
hs O
- O
cTnT O
) O
and O
N O
- O
terminal O
pro O
- O
B O
- O
type O
natriuretic O
peptide O
( O
NT O
- O
proBNP O
) O
with O
the O
severity O
of O
COVID O
- O
19 O
. O

Alimentary O
system O
is O
directly O
attacked O
by O
SARS O
- O
COV O
- O
2 O
and O
further O
prevents O
immune O
dysregulation O
caused O
by O
COVID O
- O
19 O
. O

There O
are O
key O
challenges O
for O
psychiatry O
that O
require O
urgent O
attention O
to O
ensure O
mental O
health O
well O
- O
being O
for O
all O
- O
COVID O
- O
19 O
- O
positive O
patients O
, O
healthcare O
professionals O
, O
first O
responders O
, O
people O
with O
psychiatric O
disorders O
and O
the O
general O
population O
. O

COVID O
- O
19 O
in O
a O
Patient O
with O
Liver O
Cirrhosis O
. O

Given O
the O
inhibition O
of O
autophagy O
and O
its O
immunomodulatory O
action O
, O
CQ O
shows O
positive O
efficacy O
against O
cancer O
and O
viral O
diseases O
, O
including O
Coronavirus O
2019 O
( O
COVID O
- O
19 O
) O
. O

There O
are O
limited O
data O
describing O
the O
presenting O
characteristics O
and O
outcomes O
among O
US O
persons O
with O
HIV O
( O
PWH O
) O
requiring O
hospitalization O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Artificial O
intelligence O
tools O
based O
upon O
deep O
learning O
of O
COVID O
- O
19 O
chest O
X O
- O
rays O
are O
feasible O
in O
the O
acute O
outbreak O
setting O
. O

This O
study O
analyses O
the O
influence O
of O
the O
perceived O
threat O
of O
COVID O
- O
19 O
on O
subjective O
mental O
well O
- O
being O
with O
an O
online O
survey O
( O
n O
= O
711 O
) O
. O

The O
coronavirus O
disease O
of O
2019 O
, O
also O
known O
as O
COVID O
- O
19 O
, O
has O
been O
declared O
a O
global O
pandemic O
. O

Multiple O
linear O
regression O
analysis O
revealed O
a O
significant O
correlation O
between O
COVID O
- O
19 O
- O
associated O
cases O
and O
traffic O
and O
outdoor O
injuries O
. O

We O
focus O
our O
study O
on O
6 O
representative O
cities O
in O
China O
: O
Wuhan O
, O
the O
epicenter O
of O
COVID O
- O
19 O
in O
China O
, O
together O
with O
Beijing O
, O
Tianjin O
, O
Hangzhou O
, O
Suzhou O
, O
and O
Shenzhen O
, O
which O
are O
five O
major O
cities O
from O
three O
key O
economic O
zones O
. O

Impact O
of O
COVID O
- O
19 O
on O
Work O
- O
Related O
Musculoskeletal O
Disorders O
for O
Cardiac O
Sonographers O
. O

Role O
of O
angiotensin O
- O
converting O
enzyme O
2 O
and O
pericytes O
in O
cardiac O
complications O
of O
COVID O
- O
19 O
infection O
. O

The O
present O
study O
investigated O
hospitalization O
data O
of O
patients O
receiving O
radiotherapy O
at O
Anhui O
Cancer O
Hospital O
during O
the O
COVID O
- O
19 O
epidemic O
and O
analyzed O
the O
impact O
of O
the O
epidemic O
on O
the O
clinical O
data O
of O
radiotherapy O
patients O
to O
provide O
references O
for O
the O
feasibility O
and O
safety O
of O
radiotherapy O
at O
other O
medical O
institutions O
. O

Given O
the O
rapid O
spread O
of O
new O
coronavirus O
within O
the O
prison O
system O
, O
this O
study O
' O
s O
objective O
was O
to O
identify O
spatial O
clusters O
for O
the O
occurrence O
of O
COVID O
- O
19 O
in O
the O
incarcerated O
population O
and O
analyze O
temporal O
trends O
of O
confirmed O
cases O
in O
the O
Brazilian O
prison O
system O
. O

Health O
care O
workers O
were O
divided O
into O
two O
groups O
based O
on O
working O
with O
COVID O
- O
19 O
patients O
at O
the O
frontline O
or O
not O
. O

Transforming O
Aging O
Services O
: O
Area O
Agencies O
on O
Aging O
and O
the O
COVID O
- O
19 O
Response O
. O

Mount O
Sinai O
NY O
Surgeon O
on O
the O
Front O
Lines O
of O
the O
COVID O
- O
19 O
Pandemic O
in O
Brooklyn O
, O
NY O
, O
USA O
. O

AKI O
in O
Hospitalized O
Patients O
with O
and O
without O
COVID O
- O
19 O
: O
A O
Comparison O
Study O
. O

On O
the O
basis O
of O
our O
review O
of O
the O
published O
literature O
, O
we O
speculate O
that O
several O
unifying O
cutaneous O
and O
systemic O
mechanisms O
may O
explain O
COVID O
- O
19 O
‒ O
associated O
pernio O
: O
( O
1 O
) O
SARS O
- O
CoV O
- O
2 O
cell O
infection O
occurs O
through O
the O
cellular O
receptor O
angiotensin O
- O
converting O
enzyme O
2 O
mediated O
by O
transmembrane O
protease O
serine O
2 O
, O
subsequently O
affecting O
the O
renin O
- O
angiotensin O
- O
aldosterone O
system O
with O
an O
increase O
in O
the O
vasoconstricting O
, O
pro O
- O
inflammatory O
, O
and O
prothrombotic O
angiotensin O
II O
pathway O
. O
( O
2 O
) O
Severe O
acute O
respiratory O

syndrome O
coronavirus O
2 O
cell O
infection O
triggers O
an O
immune O
response O
with O
robust O
IFN O
- O
I O
release O
in O
patients O
predisposed O
to O
COVID O
- O
19 O
‒ O
associated O
pernio O
. O
( O
3 O
) O

Attention O
needs O
to O
be O
paid O
to O
patients O
with O
diabetes O
and O
COVID O
- O
19 O
who O
use O
insulin O
. O

Among O
3 O
, O
460 O
, O
932 O
patients O
( O
16 O
% O
HIV O
positive O
) O
, O
22 O
, O
308 O
were O
diagnosed O
with O
COVID O
- O
19 O
, O
of O
whom O
625 O
died O
. O

This O
study O
examines O
the O
discursive O
construction O
of O
residential O
care O
during O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
in O
3 O
leading O
American O
newspapers O
: O
The O
New O
York O
Times O
, O
USA O
Today O
, O
and O
The O
New O
York O
Post O
. O

And O
new O
methods O
have O
been O
searching O
for O
determination O
of O
the O
COVID O
- O
19 O
. O

The O
proposed O
neural O
network O
model O
consists O
of O
seven O
convolutional O
layers O
with O
rectified O
linear O
unit O
, O
softmax O
( O
last O
layer O
) O
activation O
functions O
and O
max O
pooling O
layers O
which O
were O
trained O
using O
the O
publicly O
available O
COVID O
- O
19 O
dataset O
. O

A O
total O
of O
218 O
COVID O
- O
19 O
- O
positive O
patients O
from O
March O
18 O
, O
2020 O
, O
to O
April O
8 O
, O
2020 O
, O
with O
a O
malignant O
diagnosis O
were O
identified O
. O

Hand O
Hygiene O
Knowledge O
and O
Practices O
among O
Domestic O
Hajj O
Pilgrims O
: O
Implications O
for O
Future O
Mass O
Gatherings O
Amidst O
COVID O
- O
19 O
. O

Can O
we O
learn O
from O
others O
? O
The O
Swedish O
intensive O
care O
unit O
database O
for O
COVID O
- O
19 O
cases O
. O

She O
had O
contact O
with O
a O
COVID O
- O
19 O
patient O
. O

Combined O
with O
further O
research O
, O
this O
experience O
offers O
the O
possibility O
of O
reducing O
injection O
frequency O
and O
inherent O
delays O
in O
medication O
administration O
, O
particularly O
in O
the O
community O
setting O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
sample O
of O
the O
patient O
' O
s O
tears O
was O
taken O
, O
and O
the O
nucleic O
acid O
test O
for O
COVID O
- O
19 O
was O
still O
positive O
two O
weeks O
later O
. O

Inference O
of O
COVID O
- O
19 O
epidemiological O
distributions O
from O
Brazilian O
hospital O
data O
. O

Using O
a O
large O
multi O
- O
center O
electronic O
health O
record O
network O
, O
we O
conducted O
a O
comparative O
cohort O
study O
of O
patients O
with O
SARDs O
diagnosed O
with O
COVID O
- O
19 O
( O
identified O
by O
diagnostic O
code O
or O
positive O
molecular O
test O
) O
versus O
non O
- O
SARD O
comparators O
with O
COVID O
- O
19 O
, O
matched O
by O
age O
, O
sex O
, O
race O
/ O
ethnicity O
, O
and O
body O
mass O
index O
( O
primary O
model O
) O
and O
comorbidities O
and O
health O
care O
utilization O
( O
extended O
model O
) O
. O

About O
the O
influence O
of O
COVID O
- O
19 O
pandemic O
, O
51 O
% O
of O
respondents O
reported O
changing O
some O
aspect O
of O
their O
lifestyle O
. O

Lymphocyte O
subsets O
in O
peripheral O
blood O
and O
typing O
of O
human O
leukocyte O
antigens O
were O
analyzed O
in O
all O
groups O
, O
with O
killer O
cell O
immunoglobulin O
like O
receptor O
genes O
analyzed O
only O
in O
COVID O
- O
19 O
- O
positive O
patients O
and O
healthy O
controls O
. O

Consecutive O
COVID O
- O
19 O
inpatients O
undergoing O
clinical O
transthoracic O
echocardiography O
at O
3 O
New O
York O
City O
hospitals O
were O
studied O
; O
images O
were O
analyzed O
by O
a O
central O
core O
laboratory O
blinded O
to O
clinical O
and O
biomarker O
data O
. O

Povidone O
mouthwash O
could O
be O
a O
viable O
solution O
before O
dental O
care O
that O
should O
be O
studied O
to O
reduce O
the O
viral O
load O
off O
COVID O
- O
19 O
. O

It O
was O
determined O
that O
burn O
cases O
were O
reduced O
by O
half O
during O
the O
COVID O
- O
19 O
compared O
to O
the O
previous O
2 O
years O
. O

The O
Centers O
for O
Disease O
Control O
and O
Prevention O
provides O
a O
list O
of O
conditions O
and O
associated O
behaviors O
, O
including O
smoking O
, O
conferring O
vulnerability O
to O
severe O
COVID O
- O
19 O
illness O
regardless O
of O
age O
. O

This O
study O
will O
evaluate O
the O
effectiveness O
of O
various O
treatments O
for O
asymptomatic O
COVID O
- O
19 O
. O

Basrah O
Preliminary O
Experience O
With O
COVID O
- O
19 O
: O
A O
Report O
on O
6404 O
Patients O
. O

The O
Course O
of O
Mild O
and O
Moderate O
COVID O
- O
19 O
Infections O
- O
The O
Unexpected O
Long O
- O
Lasting O
Challenge O
. O

Clinical O
practice O
guidance O
for O
hepatology O
and O
liver O
transplant O
providers O
during O
the O
COVID O
- O
19 O
pandemic O
: O
APASL O
expert O
panel O
consensus O
recommendations O
. O

In O
light O
of O
the O
limited O
data O
available O
for O
COVID O
- O
19 O
- O
related O
impact O
on O
chronic O
pain O
patients O
, O
this O
review O
explores O
the O
changes O
in O
the O
healthcare O
delivery O
system O
due O
to O
social O
distancing O
and O
safety O
precautions O
to O
provide O
the O
appropriate O
management O
of O
chronic O
pain O
patients O
during O
the O
COVID O
- O
19 O
pandemic O
. O

In O
addition O
, O
the O
use O
of O
ARBs O
and O
ACEIs O
before O
or O
after O
COVID O
- O
19 O
infection O
did O
not O
affect O
a O
patient O
' O
s O
risk O
of O
contracting O
COVID O
- O
19 O
nor O
did O
it O
contribute O
to O
a O
worse O
prognosis O
for O
the O
disease O
. O

The O
odds O
of O
testing O
positive O
for O
COVID O
- O
19 O
were O
four O
- O
fold O
higher O
in O
African O
Americans O
than O
non O
- O
African O
Americans O
( O
OR O
4 O
. O
58 O
, O
95 O
% O
CI O
4 O
. O
25 O
- O
4 O
. O
94 O
, O
P O
< O
0 O
. O
0001 O
) O
. O

Blood O
donor O
recruitment O
in O
Guangzhou O
, O
China O
, O
during O
the O
2019 O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
epidemic O
. O

Rapid O
radiological O
improvement O
of O
COVID O
- O
19 O
pneumonia O
after O
treatment O
with O
tocilizumab O
. O

Moreover O
, O
majority O
of O
the O
pregnant O
women O
and O
their O
households O
expressed O
their O
concern O
about O
using O
preventive O
measures O
against O
COVID O
- O
19 O
. O

Domestic O
Violence O
and O
Safe O
Storage O
of O
Firearms O
in O
the O
COVID O
- O
19 O
Era O
. O

The O
current O
coronavirus O
COVID O
- O
19 O
pandemic O
, O
which O
originated O
in O
Wuhan O
, O
China O
, O
has O
raised O
significant O
social O
, O
psychological O
and O
economic O
concerns O
in O
addition O
to O
direct O
medical O
issues O
. O

Coronavirus O
Disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
has O
been O
associated O
with O
potentially O
life O
threatening O
cardiovascular O
complications O
, O
including O
fulminant O
myocarditis O
and O
cardiac O
tamponade O
. O

Finally O
, O
we O
focus O
on O
the O
impact O
of O
COVID O
- O
19 O
emergency O
on O
medicolegal O
practices O
in O
Italy O
and O
the O
United O
States O
, O
as O
well O
as O
the O
responses O
of O
the O
forensic O
scientific O
community O
to O
the O
emerging O
concerns O
related O
to O
the O
pandemic O
. O

Impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
urgent O
dental O
care O
delivery O
in O
a O
Swiss O
university O
center O
for O
dental O
medicine O
. O

Famotidine O
use O
in O
hospitalized O
patients O
with O
COVID O
- O
19 O
is O
associated O
with O
a O
lower O
risk O
of O
mortality O
, O
lower O
risk O
of O
combined O
outcome O
of O
mortality O
and O
intubation O
, O
and O
lower O
levels O
of O
serum O
markers O
for O
severe O
disease O
in O
hospitalized O
patients O
with O
COVID O
- O
19 O
. O
( O
Equation O
is O
included O
in O
full O
- O
text O
article O
. O
) O
. O

Mild O
COVID O
- O
19 O
can O
cause O
severe O
bilateral O
conjunctivitis O
. O

Altered O
immune O
cell O
differentiation O
in O
the O
lungs O
of O
patients O
with O
critical O
COVID O
- O
19 O
. O

Comment O
on O
" O
The O
Prevalence O
of O
Olfactory O
and O
Gustatory O
Dysfunction O
in O
COVID O
- O
19 O
Patients O
: O
A O
Systematic O
Review O
and O
Meta O
- O
analysis O
" O
. O

Current O
challenge O
of O
COVID O
- O
19 O
has O
created O
an O
opportunity O
for O
these O
countries O
to O
adopt O
online O
teaching O
as O
a O
major O
tool O
of O
education O
. O

The O
novel O
COVID O
- O
19 O
disease O
is O
a O
contagious O
acute O
respiratory O
infectious O
disease O
whose O
causative O
agent O
has O
been O
demonstrated O
to O
be O
a O
new O
virus O
of O
the O
coronavirus O
family O
, O
SARS O
- O
CoV O
- O
2 O
. O

COVID O
- O
19 O
in O
Post O
- O
Operative O
Patients O
: O
Imaging O
Findings O
. O

COVID O
- O
19 O
and O
remembering O
Professor O
Dennis O
H O
. O
Wright O
. O

Rapid O
Telehealth O
Implementation O
during O
the O
COVID O
- O
19 O
Global O
Pandemic O
: O
A O
Rapid O
Review O
. O

No O
cases O
of O
COVID O
- O
19 O
infection O
were O
recorded O
in O
operated O
patients O
and O
in O
medical O
staff O
. O

The O
aim O
of O
this O
protocol O
is O
to O
conduct O
a O
systematic O
review O
and O
meta O
- O
analysis O
on O
peer O
- O
reviewed O
articles O
which O
described O
clinical O
data O
of O
OD O
in O
COVID O
- O
19 O
patients O
. O

In O
multivariate O
analysis O
, O
testing O
positive O
for O
COVID O
- O
19 O
was O
associated O
with O
increasing O
age O
up O
to O
age O
50 O
years O
( O
relative O
risk O
, O
1 O
. O
06 O
; O
95 O
% O
CI O
, O
1 O
. O
01 O
- O
1 O
. O
09 O
; O
P O
= O
. O
02 O
) O
; O
non O
- O
White O
race O
( O
relative O
risk O
, O
2 O
. O
54 O
; O
95 O
% O
CI O
, O
1 O
. O
26 O
- O
5 O
. O
12 O
; O
P O
= O
. O
009 O
) O
, O
and O
likely O
deficient O
vitamin O
D O
status O
( O
relative O
risk O
, O
1 O
. O
77 O
; O
95 O
% O
CI O
, O
1 O
. O
12 O
- O
2 O
. O
81 O
; O
P O
= O
. O
02 O
) O
compared O
with O
likely O
sufficient O
vitamin O
D O
status O
. O

During O
the O
COVID O
- O
19 O
, O
community O
mental O
health O
care O
workers O
( O
CMHWs O
) O
faced O
much O
heavier O
workloads O
, O
which O
make O
them O
vulnerable O
to O
mental O
problems O
. O

The O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
has O
increased O
unemployment O
and O
food O
insecurity O
in O
the O
United O
States O
( O
US O
) O
. O

The O
eosinophil O
results O
of O
routine O
CBC O
from O
the O
first O
50 O
admitted O
COVID O
- O
19 O
- O
positive O
patients O
were O
compared O
with O
the O
eosinophil O
results O
of O
50 O
patients O
with O
confirmed O
influenza O
infection O
at O
the O
time O
of O
presentation O
to O
the O
emergency O
department O
at O
Coney O
Island O
Hospital O
in O
Brooklyn O
, O
New O
York O
. O

Many O
studies O
reporting O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
complications O
have O
involved O
case O
series O
or O
small O
cohorts O
that O
could O
not O
establish O
a O
causal O
association O
with O
COVID O
- O
19 O
or O
provide O
risk O
estimates O
in O
different O
care O
settings O
. O

We O
also O
included O
concomitant O
suspected O
COVID O
- O
19 O
( O
subsequently O
confirmed O
not O
to O
have O
COVID O
- O
19 O
) O
patients O
and O
patients O
who O
had O
recovered O
from O
it O
. O

Older O
age O
, O
hypertension O
, O
cardiovascular O
disease O
, O
diabetes O
mellitus O
and O
obesity O
significantly O
increase O
morbidity O
and O
mortality O
in O
COVID O
- O
19 O
patients O
. O

Based O
upon O
the O
study O
' O
s O
newly O
created O
sequential O
mediation O
model O
, O
communication O
strategies O
for O
encouraging O
COVID O
- O
19 O
preventive O
behaviors O
are O
offered O
. O

Mechanical O
ventilator O
as O
a O
shared O
resource O
for O
the O
COVID O
- O
19 O
pandemic O
. O

Our O
findings O
suggest O
that O
habitual O
use O
of O
vitamin O
D O
supplements O
is O
related O
to O
a O
lower O
risk O
of O
COVID O
- O
19 O
infection O
, O
although O
we O
cannot O
rule O
out O
the O
possibility O
that O
the O
inverse O
association O
is O
due O
to O
residual O
confounding O
or O
selection O
bias O
. O

While O
moderate O
amounts O
of O
fear O
of O
a O
COVID O
- O
19 O
infection O
may O
be O
functional O
, O
generalized O
anxiety O
and O
the O
potentially O
resulting O
distress O
and O
psychopathology O
may O
possibly O
be O
detrimental O
to O
people O
' O
s O
health O
. O

Patients O
with O
severe O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
disease O
suffer O
from O
many O
thrombotic O
complications O
including O
deep O
vein O
thrombosis O
, O
pulmonary O
embolism O
, O
myocardial O
infarction O
( O
MI O
) O
, O
and O
stroke O
. O

Hundreds O
of O
cases O
of O
children O
and O
adolescents O
with O
Kawasaki O
disease O
( O
KD O
) O
- O
like O
hyperinflammatory O
illness O
have O
been O
reported O
in O
Europe O
and O
the O
United O
States O
during O
the O
peak O
of O
the O
COVID O
- O
19 O
pandemic O
with O
or O
without O
shock O
and O
cardiac O
dysfunction O
. O

Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
an O
ongoing O
public O
health O
emergency O
and O
new O
knowledge O
about O
its O
immunopathogenic O
mechanisms O
is O
deemed O
necessary O
in O
the O
attempt O
to O
reduce O
the O
death O
burden O
, O
globally O
. O

Nine O
soldiers O
had O
at O
least O
one O
positive O
COVID O
- O
19 O
diagnostic O
test O
result O
. O

Apart O
from O
maximal O
supportive O
treatment O
, O
this O
could O
be O
due O
to O
cladribine O
reducing O
inflammatory O
response O
, O
which O
probably O
contributes O
considerably O
to O
severe O
courses O
of O
COVID O
- O
19 O
pneumonia O
. O

Repurposing O
Sigma O
- O
1 O
Receptor O
Ligands O
for O
COVID O
- O
19 O
Therapy O
? O

Many O
studies O
were O
carried O
out O
to O
understand O
the O
impact O
of O
weather O
on O
spread O
and O
severity O
of O
COVID O
- O
19 O
and O
vice O
- O
versa O
. O

Patient O
outcomes O
after O
humeral O
fracture O
surgery O
during O
the O
COVID O
- O
19 O
outbreak O
in O
Spain O
. O

Radiation O
Therapy O
Department O
Reorganization O
during O
the O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Outbreak O
: O
Keys O
to O
Securing O
Staff O
and O
Patients O
During O
the O
First O
Weeks O
of O
the O
Crisis O
and O
Impact O
on O
Radiation O
Therapy O
Practice O
from O
a O
Single O
Institution O
Experience O
. O

The O
success O
of O
the O
Sustainable O
Development O
Goals O
( O
SDGs O
) O
is O
predicated O
on O
multisectoral O
collaboration O
( O
MSC O
) O
, O
and O
the O
COVID O
- O
19 O
pandemic O
makes O
it O
more O
urgent O
to O
learn O
how O
this O
can O
be O
done O
better O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
a O
novel O
coronavirus O
that O
has O
caused O
a O
worldwide O
pandemic O
of O
the O
human O
respiratory O
illness O
COVID O
- O
19 O
, O
resulting O
in O
a O
severe O
threat O
to O
public O
health O
and O
safety O
. O

We O
performed O
a O
longitudinal O
evaluation O
of O
the O
disease O
course O
of O
smokers O
, O
former O
smokers O
, O
and O
COPD O
patients O
with O
COVID O
- O
19 O
without O
other O
comorbidities O
, O
from O
hospitalization O
to O
hospital O
discharge O
. O

The O
occupations O
mostly O
endangered O
by O
COVID O
- O
19 O
as O
the O
result O
of O
exposure O
to O
SARS O
- O
CoV O
- O
2 O
bioaerosol O
, O
or O
to O
other O
bioaerosols O
which O
may O
exacerbate O
this O
disease O
, O
include O
: O
health O
care O
workers O
, O
social O
workers O
, O
breeders O
of O
fur O
animals O
, O
slaughterhouse O
workers O
, O
workers O
engaged O
in O
the O
processing O
and O
selling O
of O
seafood O
, O
and O
probably O
also O
agricultural O
workers O
, O
mainly O
in O
the O
developing O
countries O
. O

As O
there O
is O
no O
clear O
consensus O
on O
ophthalmology O
guidelines O
across O
countries O
, O
this O
paper O
highlights O
the O
differences O
in O
international O
ophthalmic O
care O
recommendations O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Chest O
images O
and O
thorough O
review O
of O
clinical O
findings O
could O
provide O
value O
for O
proper O
differential O
diagnoses O
of O
COVID O
- O
19 O
patients O
, O
but O
they O
are O
not O
sufficiently O
sensitive O
for O
initial O
diagnoses O
. O

Medical O
populism O
and O
the O
COVID O
- O
19 O
pandemic O
. O

Older O
survivors O
of O
cancer O
in O
the O
COVID O
- O
19 O
pandemic O
: O
Reflections O
and O
recommendations O
for O
future O
care O
. O

The O
number O
and O
immune O
status O
of O
monocytes O
were O
detected O
by O
flow O
cytometry O
in O
32 O
COVID O
- O
19 O
patients O
and O
18 O
healthy O
individuals O
. O

Our O
findings O
indicated O
that O
both O
the O
use O
of O
MSHs O
, O
the O
rise O
of O
AT O
, O
and O
the O
improvement O
of O
air O
quality O
were O
beneficial O
to O
the O
survival O
of O
COVID O
- O
19 O
patients O
. O

COVID O
- O
19 O
disease O
has O
shocked O
the O
world O
by O
its O
spread O
and O
contagiousness O
. O

This O
was O
a O
cohort O
study O
of O
patients O
hospitalized O
with O
COVID O
- O
19 O
at O
IRCCS O
San O
Raffaele O
Hospital O
between O
25th O
February O
and O
6th O
April O
2020 O
( O
NCT04318366 O
) O
. O

Stress O
and O
Anxiety O
Management O
During O
the O
COVID O
- O
19 O
Pandemic O
( O
Lessons O
Learnt O
from O
a O
Cohort O
of O
Orthopaedic O
Registrars O
Redeployed O
to O
ITU O
) O
. O

Patients O
older O
than O
80 O
years O
old O
with O
COVID O
- O
19 O
have O
multiple O
unique O
risk O
factors O
which O
can O
be O
associated O
with O
increased O
cardiovascular O
involvement O
and O
death O
. O

Often O
patients O
affected O
by O
HHT O
experience O
a O
sense O
of O
loneliness O
due O
to O
the O
rarity O
of O
this O
pathology O
and O
COVID O
- O
19 O
pandemic O
adds O
a O
burden O
for O
them O
and O
their O
caregivers O
who O
have O
to O
face O
emotional O
experiences O
that O
interfere O
with O
personal O
, O
social O
and O
working O
functioning O
. O

Forecasting O
imported O
COVID O
- O
19 O
cases O
in O
South O
Korea O
using O
mobile O
roaming O
data O
. O

COVID O
- O
19 O
and O
Myocarditis O
: O
What O
Do O
We O
Know O
So O
Far O
? O

From O
25 O
to O
29 O
April O
2020 O
, O
the O
state O
of O
Indiana O
undertook O
testing O
of O
3 O
, O
658 O
randomly O
chosen O
state O
residents O
for O
the O
novel O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
virus O
, O
the O
agent O
causing O
COVID O
- O
19 O
disease O
. O

Most O
residents O
with O
positive O
immunochromatography O
tests O
( O
70 O
. O
8 O
% O
) O
referred O
previous O
contact O
with O
a O
confirmed O
COVID O
- O
19 O
case O
. O

A O
New O
Normal O
Is O
Paramount O
for O
Public O
Health O
Research O
and O
Practice O
: O
A O
Student O
Perspective O
on O
COVID O
- O
19 O
. O

A O
correlation O
analysis O
was O
performed O
between O
VEGF O
- O
A O
levels O
, O
inflammation O
parameters O
, O
and O
clinical O
characteristics O
of O
the O
cases O
for O
pregnant O
women O
with O
COVID O
- O
19 O
. O

Patients O
suffering O
from O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
can O
develop O
neurological O
sequelae O
, O
such O
as O
headache O
and O
neuroinflammatory O
or O
cerebrovascular O
disease O
. O

Notably O
, O
one O
COVID O
- O
19 O
case O
had O
a O
coexisting O
infection O
with O
human O
parainfluenza O
virus O
( O
4 O
. O
2 O
% O
, O
1 O
/ O
24 O
) O
and O
bocavirus O
was O
the O
most O
common O
virus O
tending O
to O
occur O
in O
co O
- O
infection O
with O
other O
respiratory O
pathogens O
. O

The O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
developed O
into O
a O
pandemic O
on O
March O
11 O
. O

The O
new O
pandemic O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
causes O
a O
wide O
range O
of O
clinical O
consequences O
, O
from O
asymptomatic O
infection O
to O
acute O
respiratory O
failure O
and O
it O
is O
very O
heterogeneous O
. O

This O
study O
aimed O
to O
develop O
and O
validate O
a O
bedside O
risk O
analysis O
system O
for O
predicting O
the O
clinical O
severity O
and O
prognosis O
of O
patients O
with O
COVID O
- O
19 O
. O

Does O
the O
Impact O
of O
COVID O
- O
19 O
Improve O
the O
Doctor O
- O
Patient O
Relationship O
in O
China O
? O

Kaplan O
- O
Meier O
analysis O
was O
used O
to O
plotted O
survival O
curve O
and O
analyze O
the O
impact O
of O
myocardial O
injury O
on O
the O
survival O
outcome O
of O
COVID O
- O
19 O
patients O
. O

The O
analysis O
shows O
that O
CQ O
and O
HCQ O
do O
not O
have O
efficacy O
in O
treatment O
of O
patients O
with O
severe O
COVID O
- O
19 O
. O

Additional O
experimental O
and O
clinical O
studies O
explaining O
more O
the O
relationships O
between O
NEP O
and O
COVID O
- O
19 O
will O
greatly O
benefit O
in O
designing O
the O
future O
treatment O
approaches O
. O

SARS O
- O
CoV O
- O
2 O
Presence O
in O
the O
Saliva O
, O
Tears O
, O
and O
Cerumen O
of O
COVID O
- O
19 O
Patients O
. O

Background O
Preventive O
practices O
are O
the O
mainstay O
to O
mitigate O
the O
spread O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Timing O
of O
remdesivir O
for O
COVID O
- O
19 O
. O

Sensitivity O
analysis O
showed O
that O
the O
Capital O
Region O
had O
the O
highest O
number O
of O
COVID O
- O
19 O
cases O
per O
100 O
, O
000 O
tested O
, O
but O
Region O
Zealand O
had O
a O
higher O
number O
of O
hospitalized O
and O
similar O
number O
of O
deaths O
per O
100 O
, O
000 O
tested O
as O
the O
Capital O
Region O
over O
time O
. O

To O
develop O
a O
palliative O
care O
resource O
tool O
kit O
for O
holistic O
care O
of O
patients O
affected O
with O
COVID O
- O
19 O
and O
to O
support O
the O
health O
- O
care O
workers O
looking O
after O
them O
to O
enable O
palliative O
care O
integration O
with O
COVID O
- O
I9 O
management O
. O

The O
recent O
studies O
have O
revealed O
about O
a O
possible O
connection O
among O
COVID O
- O
19 O
, O
ischemic O
stroke O
, O
and O
excessive O
Neutrophil O
Extracellular O
Traps O
( O
NETs O
) O
formation O
. O

The O
present O
Clinical O
Opinion O
represents O
a O
summary O
of O
the O
epidemiological O
evidence O
and O
possible O
pathophysiological O
mechanisms O
regarding O
PCOS O
and O
COVID O
- O
19 O
. O

A O
plea O
to O
apply O
principles O
of O
quarantine O
ethics O
to O
prisoners O
and O
immigration O
detainees O
during O
the O
COVID O
- O
19 O
crisis O
. O

Editorial O
: O
COVID O
- O
19 O
and O
its O
impact O
on O
SUD O
treatment O
. O

In O
light O
of O
this O
scenario O
, O
in O
this O
review O
, O
we O
suggest O
a O
flow O
chart O
for O
the O
pathologist O
called O
on O
to O
ascertain O
the O
cause O
of O
death O
of O
a O
subject O
with O
historical O
and O
clinical O
findings O
of O
COVID O
- O
19 O
status O
or O
without O
any O
anamnestic O
, O
diagnostic O
, O
or O
exposure O
information O
. O

Typical O
findings O
were O
frequently O
found O
in O
the O
PMCT O
in O
SARS O
- O
CoV O
- O
2 O
- O
associated O
deaths O
, O
which O
were O
taken O
into O
account O
when O
classifying O
the O
death O
as O
COVID O
- O
19 O
. O

In O
this O
article O
, O
we O
aim O
to O
provide O
a O
to O
- O
the O
- O
point O
review O
of O
current O
literature O
regarding O
efficacy O
of O
repurposed O
drugs O
against O
COVID O
- O
19 O
and O
other O
respiratory O
infections O
caused O
by O
coronaviruses O
. O

The O
progressive O
results O
were O
quite O
conflicting O
as O
severe O
cases O
of O
COVID O
- O
19 O
shows O
an O
increase O
in O
the O
level O
of O
several O
cytokines O
that O
can O
augment O
inflammation O
to O
the O
bronchial O
tracts O
, O
worsening O
the O
asthma O
attacks O
. O

There O
was O
a O
nonsignificant O
decrease O
in O
the O
mean O
hospital O
length O
of O
stay O
for O
inpatients O
with O
confirmed O
or O
suspected O
COVID O
- O
19 O
from O
5 O
. O
5 O
to O
2 O
. O
7 O
days O
from O
March O
to O
May O
2020 O
( O
P O
= O
. O
11 O
) O
. O

Data O
mining O
of O
prescription O
records O
of O
COVID O
- O
19 O
patients O
will O
not O
cancel O
the O
need O
for O
conducting O
controlled O
clinical O
trials O
, O
but O
could O
substantially O
assist O
in O
trial O
design O
, O
drug O
choice O
, O
inclusion O
and O
exclusion O
criteria O
, O
and O
prioritization O
. O

We O
aimed O
to O
identify O
high O
- O
risk O
groups O
whose O
mental O
health O
conditions O
were O
vulnerable O
to O
the O
COVID O
- O
19 O
outbreak O
. O

The O
Panbio O
™ O
COVID O
- O
19 O
Ag O
Rapid O
Test O
Device O
performed O
well O
as O
a O
POC O
test O
for O
early O
diagnosis O
of O
COVID O
- O
19 O
in O
primary O
healthcare O
centres O
. O

Cases O
and O
deaths O
affected O
stock O
returns O
and O
volatility O
in O
the O
emerging O
markets O
, O
while O
only O
cases O
of O
COVID O
- O
19 O
affected O
stock O
returns O
, O
volatility O
, O
and O
trading O
volume O
in O
the O
developed O
markets O
. O

With O
COVID O
- O
19 O
resurge O
compounded O
by O
seasonal O
winter O
pressures O
, O
we O
reflect O
and O
share O
lessons O
learnt O
from O
the O
first O
wave O
of O
pandemic O
to O
guide O
future O
strategy O
. O

First O
section O
obtained O
patients O
sociodemographic O
information O
, O
while O
knowledge O
of O
patients O
regarding O
cross O
- O
infection O
control O
during O
COVID O
- O
19 O
pandemic O
was O
evaluated O
in O
second O
section O
. O

Immune O
responses O
and O
residual O
SARS O
- O
CoV O
- O
2 O
in O
two O
critically O
ill O
COVID O
- O
19 O
patients O
before O
and O
after O
lung O
transplantation O
. O

Gastrointestinal O
manifestations O
of O
COVID O
- O
19 O
. O

The O
results O
of O
this O
study O
suggest O
that O
routine O
treatment O
combined O
with O
XBJ O
can O
better O
improve O
the O
clinical O
outcomes O
of O
COVID O
- O
19 O
patients O
. O

At O
the O
same O
time O
, O
the O
need O
for O
non O
- O
COVID O
- O
19 O
- O
related O
dysphagia O
care O
persists O
. O

The O
predictive O
model O
analyzed O
by O
ROC O
curves O
was O
similar O
in O
the O
2 O
groups O
( O
P O
= O
. O
701 O
) O
, O
with O
AUCs O
of O
0 O
. O
808 O
in O
the O
confirmed O
COVID O
- O
19 O
group O
( O
0 O
. O
750 O
- O
0 O
. O
865 O
) O
and O
0 O
. O
812 O
in O
the O
ruled O
out O
COVID O
- O
19 O
group O
( O
0 O
. O
760 O
- O
0 O
. O
864 O
) O
. O

In O
order O
to O
better O
address O
this O
major O
health O
crisis O
, O
which O
has O
given O
rise O
to O
numerous O
scientific O
publications O
, O
we O
have O
synthesized O
the O
main O
original O
clinical O
studies O
to O
facilitate O
the O
day O
- O
to O
- O
day O
management O
of O
patients O
with O
COVID O
- O
19 O
. O

As O
a O
secondary O
outcome O
, O
we O
will O
measure O
knowledge O
about O
behaviors O
that O
can O
prevent O
the O
spread O
of O
COVID O
- O
19 O
. O

A O
severe O
form O
of O
COVID O
- O
19 O
occurred O
in O
473 O
patients O
, O
and O
the O
most O
frequent O
symptoms O
were O
dyspnea O
( O
n O
= O
332 O
) O
and O
altered O
level O
of O
consciousness O
( O
n O
= O
301 O
) O
. O

The O
primary O
blame O
for O
the O
high O
rates O
of O
COVID O
- O
19 O
infections O
and O
deaths O
has O
been O
assigned O
to O
formal O
LTSS O
care O
settings O
, O
specifically O
nursing O
homes O
. O

Real O
- O
time O
diagnosis O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
in O
fresh O
sputum O
by O
electrochemical O
tracing O
; O
correlation O
between O
COVID O
- O
19 O
and O
viral O
- O
induced O
ROS O
in O
lung O
/ O
respiratory O
epithelium O
during O
this O
pandemic O
. O

Second O
, O
a O
compilation O
from O
published O
sources O
and O
an O
analysis O
of O
nutritional O
data O
from O
10 O
European O
countries O
was O
performed O
, O
and O
the O
relationship O
between O
country O
nutritional O
status O
and O
epidemiological O
COVID O
- O
19 O
data O
( O
available O
in O
the O
Worldometers O
database O
) O
was O
evaluated O
following O
an O
ecological O
study O
design O
. O

How O
to O
monitor O
the O
brain O
in O
COVID O
- O
19 O
patients O
? O

Psychometric O
analyses O
were O
performed O
on O
the O
M5 O
in O
relation O
to O
psychological O
tests O
, O
COVID O
- O
19 O
psychological O
burden O
, O
and O
diagnostic O
data O
collected O
during O
the O
evaluation O
. O

Unpaid O
carers O
caring O
for O
a O
person O
living O
with O
dementia O
( O
PLWD O
) O
who O
were O
accessing O
paid O
home O
care O
before O
COVID O
- O
19 O
and O
residing O
in O
the O
UK O
were O
eligible O
to O
take O
part O
. O

There O
were O
small O
- O
large O
significant O
interrelationships O
between O
insomnia O
, O
mental O
health O
, O
fear O
of O
COVID O
- O
19 O
, O
and O
preventive O
behaviors O
. O

Diagnosis O
and O
combating O
COVID O
- O
19 O
using O
wearable O
Oura O
smart O
ring O
with O
deep O
learning O
methods O
. O

Stay O
- O
at O
- O
home O
circumstances O
do O
not O
produce O
sleep O
disorders O
: O
An O
international O
survey O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Who O
can O
go O
back O
to O
work O
when O
the O
COVID O
- O
19 O
pandemic O
remits O
? O

Perceived O
risk O
of O
infection O
while O
traveling O
during O
the O
COVID O
- O
19 O
pandemic O
: O
Insights O
from O
Columbus O
, O
OH O
. O

84 O
. O
43 O
% O
) O
in O
COVID O
- O
19 O
patients O
. O

High O
self O
- O
protection O
score O
was O
the O
main O
factor O
that O
prevented O
medical O
staff O
from O
contracting O
COVID O
- O
19 O
infection O
. O

We O
reviewed O
the O
available O
evidence O
to O
ascertain O
the O
presence O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
blood O
viremia O
and O
the O
virus O
' O
blood O
transmissibility O
, O
as O
well O
as O
evidence O
of O
blood O
- O
aerosol O
generation O
and O
operating O
room O
contamination O
from O
spinal O
surgical O
procedures O
. O

Given O
the O
rapid O
global O
spread O
of O
novel O
Corona O
Virus O
Disease O
( O
COVID O
- O
19 O
) O
, O
coupled O
with O
the O
high O
rate O
of O
missed O
diagnosis O
of O
viral O
sepsis O
caused O
by O
SARS O
- O
CoV O
- O
2 O
infection O
, O
it O
is O
urgent O
to O
evaluate O
the O
multiple O
organ O
failure O
score O
and O
viral O
sepsis O
in O
COVID O
- O
19 O
patients O
, O
so O
as O
to O
determine O
the O
clinical O
characteristics O
of O
viral O
sepsis O
more O
accurately O
and O
reveal O
the O
risk O
factors O
related O
to O
mortality O
. O

Preliminary O
tests O
using O
the O
FDE O
model O
showed O
that O
self O
- O
quarantine O
may O
not O
be O
as O
efficient O
as O
strict O
social O
distancing O
in O
slowing O
COVID O
- O
19 O
spread O
. O

This O
case O
report O
describes O
an O
otherwise O
healthy O
53 O
- O
year O
- O
old O
woman O
who O
tested O
positive O
for O
COVID O
- O
19 O
and O
was O
admitted O
to O
the O
cardiac O
care O
unit O
in O
March O
2020 O
for O
acute O
myopericarditis O
with O
systolic O
dysfunction O
, O
confirmed O
on O
cardiac O
magnetic O
resonance O
imaging O
, O
the O
week O
after O
onset O
of O
fever O
and O
dry O
cough O
due O
to O
COVID O
- O
19 O
. O

Patients O
with O
COVID O
- O
19 O
may O
present O
with O
features O
consistent O
with O
ST O
- O
segment O
elevation O
myocardial O
infarction O
and O
patent O
coronary O
arteries O
. O

AKI O
in O
COVID O
- O
19 O
has O
a O
multifactorial O
origin O
, O
in O
which O
direct O
viral O
invasion O
of O
kidney O
cells O
, O
activation O
of O
the O
renin O
- O
angiotensin O
aldosterone O
system O
, O
a O
hyperinflammatory O
response O
, O
hypercoagulability O
, O
and O
nonspecific O
factors O
such O
as O
hypotension O
and O
hypoxemia O
may O
be O
involved O
. O

Many O
nations O
are O
employing O
combinations O
of O
containment O
and O
mitigation O
strategies O
, O
where O
early O
diagnosis O
of O
COVID O
- O
19 O
is O
vital O
in O
controlling O
illness O
progression O
and O
limiting O
viral O
spread O
within O
the O
population O
. O

Most O
respondents O
( O
88 O
% O
) O
felt O
they O
had O
good O
to O
excellent O
knowledge O
of O
virus O
transmission O
, O
and O
predominantly O
accessed O
( O
74 O
% O
) O
and O
trusted O
( O
60 O
% O
) O
Canadian O
news O
television O
, O
newspapers O
/ O
magazines O
, O
or O
non O
- O
government O
news O
websites O
for O
COVID O
- O
19 O
information O
. O

We O
aimed O
to O
assess O
the O
prevalence O
and O
predictors O
of O
depression O
, O
anxiety O
, O
and O
their O
comorbidity O
among O
essential O
workers O
in O
Brazil O
and O
Spain O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Characteristics O
and O
outcomes O
of O
patients O
hospitalized O
for O
COVID O
- O
19 O
and O
cardiac O
disease O
in O
Northern O
Italy O
. O

Letter O
: O
gastrointestinal O
symptoms O
pre O
- O
admission O
are O
associated O
with O
greater O
severity O
of O
COVID O
- O
19 O
. O

Finally O
, O
the O
information O
available O
on O
the O
guidelines O
for O
action O
in O
patients O
with O
COVID O
- O
19 O
using O
combined O
hormonal O
contraception O
is O
collected O
. O

Effect O
of O
WeChat O
consultation O
group O
on O
residents O
staying O
at O
home O
in O
Sichuan O
and O
Chongqing O
regions O
during O
the O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
outbreak O
in O
China O
: O
a O
cross O
- O
sectional O
study O
. O

Immune O
determinants O
of O
COVID O
- O
19 O
disease O
presentation O
and O
severity O
. O

MSC O
may O
have O
pleiotropic O
activities O
in O
COVID O
- O
19 O
, O
with O
the O
capacity O
to O
fight O
inflammation O
and O
repair O
lesions O
in O
several O
organs O
. O

Digital O
Pathology O
During O
the O
COVID O
- O
19 O
Outbreak O
in O
Italy O
: O
Survey O
Study O
. O

COVID O
- O
19 O
, O
Psychological O
Well O
- O
being O
and O
Physical O
Activity O
Levels O
in O
Older O
Adults O
During O
the O
Nationwide O
Lockdown O
in O
Spain O
. O

Our O
simulations O
showed O
that O
South O
Korea O
has O
kept O
the O
spread O
of O
COVID O
- O
19 O
at O
a O
low O
level O
through O
extensive O
medical O
testing O
. O

More O
important O
, O
patients O
under O
active O
treatment O
for O
cancer O
are O
at O
high O
risk O
of O
developing O
severe O
evolution O
of O
COVID O
- O
19 O
. O

Asthma O
, O
followed O
by O
COPD O
and O
lung O
cancer O
, O
was O
the O
most O
common O
lung O
comorbidity O
associated O
with O
COVID O
- O
19 O
, O
while O
the O
higher O
mortality O
rate O
was O
found O
in O
COPD O
. O

Burn O
management O
during O
the O
COVID O
- O
19 O
pandemic O
: O
recommendations O
and O
considerations O
. O

With O
the O
current O
COVID O
- O
19 O
pandemic O
, O
caused O
by O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
there O
is O
an O
urgent O
need O
for O
new O
therapies O
and O
prevention O
strategies O
that O
can O
help O
curtail O
disease O
spread O
and O
reduce O
mortality O
. O

We O
found O
that O
the O
presence O
, O
distribution O
, O
and O
location O
of O
CT O
lesions O
were O
associated O
with O
the O
presence O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
disparities O
: O
An O
urgent O
call O
for O
race O
reporting O
and O
representation O
in O
clinical O
research O
. O

Replicating O
and O
projecting O
the O
path O
of O
COVID O
- O
19 O
with O
a O
model O
- O
implied O
reproduction O
number O
. O

Immune O
dysregulation O
characterized O
by O
T O
cell O
exhaustion O
and O
high O
level O
of O
inflammatory O
cytokines O
is O
associated O
with O
severe O
COVID O
- O
19 O
. O

Virtual O
Cafes O
: O
An O
Innovative O
Way O
for O
Rapidly O
Disseminating O
Educational O
Best O
Practices O
and O
Building O
Community O
During O
COVID O
- O
19 O
. O

However O
, O
the O
data O
about O
the O
possible O
role O
of O
cholesterol O
carrying O
lipoproteins O
and O
their O
receptors O
in O
relation O
to O
infection O
are O
scarce O
and O
the O
connection O
of O
lipid O
- O
associated O
pathologies O
with O
COVID O
- O
19 O
disease O
is O
in O
its O
infancy O
. O

Conclusions O
: O
Our O
study O
shows O
that O
the O
WHO O
severity O
classification O
is O
reliable O
in O
predicting O
a O
severe O
outcome O
among O
COVID O
- O
19 O
patients O
. O

This O
cohort O
study O
included O
all O
pediatric O
and O
adult O
patient O
encounters O
at O
the O
Department O
of O
Otolaryngology O
- O
Head O
& O
Neck O
Surgery O
in O
a O
tertiary O
care O
, O
academic O
, O
multisubspecialty O
, O
multisite O
practice O
located O
in O
an O
early O
hot O
spot O
for O
the O
COVID O
- O
19 O
pandemic O
from O
March O
17 O
to O
May O
1 O
, O
2020 O
. O

In O
discussions O
of O
COVID O
- O
19 O
in O
the O
US O
, O
social O
bots O
managed O
to O
trigger O
bot O
- O
to O
- O
human O
anger O
transmission O
. O

Compare O
the O
diagnostic O
properties O
of O
five O
case O
definitions O
of O
suspected O
COVID O
- O
19 O
that O
were O
used O
or O
proposed O
in O
Chile O
during O
the O
first O
eight O
months O
of O
the O
pandemic O
. O

Anti O
- O
SARS O
- O
Cov O
- O
2 O
IgA O
in O
Current O
Scenario O
of O
IgM O
and O
IgG O
Rapid O
Test O
: O
a O
New O
Alternative O
for O
the O
Diagnostic O
of O
COVID O
- O
19 O
. O

On O
March O
11 O
, O
2020 O
the O
WHO O
announced O
a O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

However O
, O
so O
far O
there O
has O
been O
scant O
attention O
paid O
to O
other O
important O
areas O
of O
psychiatry O
during O
COVID O
- O
19 O
, O
including O
medico O
- O
legal O
aspects O
and O
human O
rights O
. O

First O
and O
Second O
Wave O
COVID O
- O
19 O
Fear O
Impact O
: O
Israeli O
and O
Russian O
Social O
Work O
Student O
Fear O
, O
Mental O
Health O
and O
Substance O
Use O
. O

The O
survey O
consisted O
of O
20 O
questions O
on O
four O
topics O
: O
patients O
' O
characteristics O
, O
contact O
with O
the O
hospital O
, O
consequences O
of O
the O
COVID O
- O
19 O
pandemic O
and O
concerns O
about O
COVID O
- O
19 O
. O

The O
results O
from O
the O
model O
analysis O
shows O
that O
aggressive O
and O
effective O
mass O
testing O
as O
well O
as O
individual O
self O
initiated O
behaviour O
change O
play O
a O
big O
role O
in O
getting O
rid O
of O
the O
COVID O
- O
19 O
epidemic O
otherwise O
the O
rate O
of O
infection O
will O
continue O
to O
increase O
despite O
the O
increased O
rate O
of O
recovery O
. O

To O
predict O
infection O
risks O
, O
we O
modelled O
S O
- O
protein O
: O
ACE2 O
complexes O
from O
215 O
vertebrate O
species O
, O
calculated O
changes O
in O
the O
energy O
of O
the O
complex O
caused O
by O
mutations O
in O
each O
species O
, O
relative O
to O
human O
ACE2 O
, O
and O
correlated O
these O
changes O
with O
COVID O
- O
19 O
infection O
data O
. O

The O
optimal O
anesthesia O
management O
for O
patients O
with O
stroke O
undergoing O
mechanical O
thrombectomy O
( O
MT O
) O
during O
the O
COVID O
- O
19 O
pandemic O
has O
become O
a O
matter O
of O
controversy O
. O

Non O
- O
intubated O
patients O
with O
acute O
respiratory O
failure O
due O
to O
COVID O
- O
19 O
could O
benefit O
from O
awake O
proning O
. O

Type O
I O
interferon O
: O
From O
innate O
response O
to O
treatment O
for O
COVID O
- O
19 O
. O

It O
is O
not O
known O
whether O
and O
how O
various O
disease O
modifying O
therapies O
, O
especially O
immunosuppressive O
drugs O
, O
affect O
COVID O
- O
19 O
risk O
and O
disease O
course O
. O

This O
paper O
describes O
the O
impact O
of O
COVID O
- O
19 O
on O
cardiac O
surgery O
services O
in O
the O
greater O
Los O
Angeles O
area O
. O

Finally O
, O
the O
purpose O
of O
this O
review O
is O
to O
share O
this O
idea O
with O
health O
professionals O
to O
ignite O
the O
debate O
and O
call O
for O
critical O
reflection O
, O
so O
that O
it O
can O
contribute O
to O
the O
undertaking O
of O
more O
and O
better O
clinical O
designs O
to O
validate O
the O
benefits O
of O
using O
high O
doses O
of O
vitaminD O
for O
the O
benefit O
of O
public O
health O
and O
especially O
in O
times O
of O
crisis O
for O
COVID O
- O
19 O
. O

Face O
masks O
in O
general O
, O
and O
N95 O
filtering O
facepiece O
respirators O
( O
FRs O
) O
that O
protect O
against O
SARS O
- O
Cov O
- O
2 O
virion O
in O
particular O
, O
have O
become O
scarce O
during O
the O
ongoing O
COVID O
- O
19 O
global O
pandemic O
. O

Model O
training O
data O
from O
701 O
patients O
with O
COVID O
- O
19 O
were O
collected O
across O
practices O
within O
the O
Family O
Health O
Centers O
network O
at O
New O
York O
University O
Langone O
Health O
. O

Community O
risk O
factors O
, O
including O
contact O
with O
a O
COVID O
- O
19 O
positive O
individual O
and O
residential O
COVID O
- O
19 O
incidence O
, O
are O
more O
strongly O
associated O
with O
SARS O
- O
CoV O
- O
2 O
seropositivity O
among O
healthcare O
workers O
than O
exposure O
in O
the O
workplace O
. O

We O
aimed O
to O
analyze O
the O
effect O
of O
lockdown O
imposed O
due O
to O
the O
COVID O
- O
19 O
pandemic O
on O
the O
care O
of O
patients O
with O
kidney O
diseases O
in O
India O
. O

Can O
nanotechnology O
help O
in O
the O
fight O
against O
COVID O
- O
19 O
? O

Three O
main O
themes O
emerged O
: O
( O
i O
) O
challenging O
moments O
of O
COVID O
- O
19 O
, O
during O
which O
the O
participants O
reported O
physical O
and O
psychological O
challenges O
relating O
to O
working O
conditions O
of O
the O
hospital O
in O
the O
initial O
months O
of O
the O
pandemic O
; O
( O
ii O
) O
the O
professional O
role O
as O
nurses O
, O
in O
where O
the O
participants O
dispelled O
their O
worries O
and O
demonstrated O
commitment O
to O
their O
role O
as O
nurses O
; O
and O
( O
iii O
) O
support O
for O
nurses O
, O
which O
originated O
from O
their O
family O
, O
friends O
and O
leaders O
from O
their O
organizations O
for O
them O
to O
persevere O
and O
overcome O
the O
unprecedented O
challenges O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
and O
Anxiety O
amongst O
Doctors O
: O
A O
Pakistani O
Perspective O
. O

COVID O
- O
19 O
: O
Looking O
Into O
the O
Overlooked O
. O

In O
this O
systematic O
review O
and O
meta O
- O
analysis O
, O
we O
aimed O
to O
evaluate O
the O
prevalence O
of O
dementia O
in O
patients O
with O
COVID O
- O
19 O
and O
its O
association O
with O
mortality O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
the O
identified O
cause O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
continues O
unabated O
. O

Current O
Status O
of O
COVID O
- O
19 O
Vaccine O
Development O
: O
Focusing O
on O
Antigen O
Design O
and O
Clinical O
Trials O
on O
Later O
Stages O
. O

IL O
- O
2R O
/ O
lymphocytes O
were O
superior O
compared O
with O
other O
markers O
for O
the O
identification O
of O
COVID O
- O
19 O
with O
critical O
illness O
, O
not O
only O
from O
mild O
but O
also O
from O
severe O
illness O
. O

Severe O
asthma O
during O
the O
COVID O
- O
19 O
pandemic O
: O
Clinical O
observations O
. O

Clinical O
characteristics O
and O
severity O
of O
COVID O
- O
19 O
among O
Mexican O
adults O
. O

This O
was O
a O
retrospective O
chart O
review O
of O
263 O
COVID O
- O
19 O
positive O
patients O
requiring O
intubation O
in O
the O
intensive O
care O
units O
at O
MedStar O
Georgetown O
University O
Hospital O
and O
MedStar O
Washington O
Hospital O
Center O
between O
March O
1st O
and O
July O
26th O
, O
2020 O
. O

Professional O
colleges O
were O
the O
main O
source O
of O
new O
information O
about O
COVID O
- O
19 O
. O

The O
majority O
( O
84 O
. O
3 O
% O
) O
of O
the O
students O
wanted O
to O
maintain O
the O
online O
course O
after O
the O
end O
of O
COVID O
- O
19 O
. O

The O
variplex O
RT O
- O
LAMP O
may O
serve O
as O
a O
rapid O
test O
to O
be O
combined O
with O
a O
RT O
- O
PCR O
assay O
to O
increase O
the O
diagnostic O
accuracy O
in O
patients O
with O
suspected O
COVID O
- O
19 O
infection O
. O

We O
are O
discovering O
patients O
with O
COVID O
- O
19 O
are O
at O
increased O
risk O
of O
acute O
cardiac O
injury O
, O
arrythmias O
, O
thromboembolic O
complications O
( O
pulmonary O
embolism O
and O
acute O
stroke O
) O
, O
and O
secondary O
infection O
to O
name O
a O
few O
. O

This O
article O
is O
the O
third O
in O
a O
series O
of O
3 O
on O
the O
management O
of O
COVID O
- O
19 O
in O
clinical O
dental O
care O
and O
presents O
a O
set O
of O
recommendations O
and O
standards O
to O
be O
implemented O
in O
the O
context O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
increase O
in O
the O
number O
of O
studies O
related O
to O
the O
health O
of O
university O
students O
has O
attracted O
attention O
at O
the O
time O
of O
COVID O
- O
19 O
. O

We O
need O
to O
be O
honest O
about O
the O
scale O
of O
the O
obstacles O
ahead O
and O
realise O
that O
the O
health O
challenges O
and O
economic O
consequences O
of O
the O
COVID O
- O
19 O
pandemic O
are O
potentially O
devastating O
. O
We O
must O
also O
prepare O
to O
make O
difficult O
ethical O
decisions O
about O
restarting O
elective O
hip O
and O
knee O
arthroplasty O
. O

This O
signage O
- O
named O
the O
' O
COVID O
- O
19 O
Flag O
' O
- O
is O
placed O
outside O
of O
the O
individual O
theatre O
to O
ensure O
that O
staff O
are O
informed O
of O
the O
infection O
risk O
with O
the O
cases O
underway O
. O

Using O
a O
mathematical O
model O
, O
we O
explore O
the O
problem O
of O
availability O
versus O
overdemand O
of O
critical O
hospital O
processes O
( O
e O
. O
g O
. O
, O
critical O
beds O
) O
in O
the O
face O
of O
a O
steady O
epidemic O
expansion O
such O
as O
is O
occurring O
from O
the O
COVID O
- O
19 O
pandemic O
. O

Priapism O
in O
COVID O
- O
19 O
: O
A O
thromboembolic O
complication O
. O

Finally O
, O
AND O
" O
COVID O
- O
19 O
" O
was O
included O
in O
this O
algorithm O
. O

COVID O
- O
19 O
pneumonia O
following O
double O
- O
sleeve O
lobectomy O
for O
lung O
cancer O
. O

The O
economics O
of O
COVID O
- O
19 O
pandemic O
: O
A O
survey O
. O

Neglected O
tropical O
diseases O
in O
non O
- O
endemic O
countries O
in O
the O
era O
of O
COVID O
- O
19 O
pandemic O
: O
the O
great O
forgotten O
. O

Chronic O
lymphocytic O
leukaemia O
in O
COVID O
- O
19 O
. O

COVID O
- O
19 O
patients O
may O
be O
asymptomatic O
or O
show O
various O
clinical O
manifestations O
, O
including O
acute O
symptoms O
such O
as O
fever O
, O
fatigue O
, O
sore O
throat O
; O
pneumonia O
presenting O
as O
acute O
respiratory O
distress O
syndrome O
; O
and O
multiple O
organ O
failure O
. O

Understanding O
the O
effects O
of O
COVID O
- O
19 O
on O
the O
health O
and O
safety O
of O
immigrant O
hospitality O
workers O
in O
the O
United O
States O
. O

Adjuvant O
corticosteroid O
therapy O
for O
critically O
ill O
patients O
with O
COVID O
- O
19 O
. O

The O
aim O
of O
this O
study O
is O
to O
determine O
how O
stakeholder O
engagement O
can O
be O
adapted O
for O
the O
conduct O
of O
COVID O
- O
19 O
- O
related O
clinical O
trials O
in O
sub O
- O
Saharan O
Africa O
. O

Owing O
to O
its O
strong O
infectivity O
and O
onset O
in O
populations O
, O
early O
detection O
of O
infectious O
cases O
of O
COVID O
- O
19 O
is O
of O
great O
significance O
to O
control O
the O
epidemic O
. O

COVID O
- O
19 O
is O
an O
infectious O
disease O
that O
can O
lead O
to O
severe O
acute O
respiratory O
syndrome O
. O

Severe O
Clostridium O
difficile O
colitis O
as O
potential O
late O
complication O
associated O
with O
COVID O
- O
19 O
. O

Update O
for O
Anaesthetists O
on O
Clinical O
Features O
of O
COVID O
- O
19 O
Patients O
and O
Relevant O
Management O
. O

The O
association O
between O
air O
quality O
and O
COVID O
- O
19 O
is O
commonly O
attributed O
to O
the O
risk O
of O
transmission O
. O

All O
consecutive O
COVID O
- O
19 O
patients O
admitted O
to O
our O
Clinic O
between O
March O
1 O
, O
2020 O
, O
and O
May O
1 O
, O
2020 O
, O
who O
were O
tested O
at O
hospital O
admission O
for O
anti O
- O
S1RBD O
and O
anti O
- O
NP O
IgG O
were O
enrolled O
. O

To O
understand O
the O
roles O
of O
different O
transport O
modes O
in O
the O
spread O
of O
COVID O
- O
19 O
pandemic O
across O
Chinese O
cities O
, O
this O
paper O
looks O
at O
the O
factors O
influencing O
the O
number O
of O
imported O
cases O
from O
Wuhan O
and O
the O
spread O
speed O
and O
pattern O
of O
the O
pandemic O
. O

[ O
Ocular O
manifestations O
of O
coronavirus O
infection O
COVID O
- O
19 O
( O
clinical O
observation O
) O
] O
. O

COVID O
- O
19 O
imposes O
severe O
and O
tragic O
consequences O
on O
people O
' O
s O
health O
due O
to O
the O
high O
rate O
of O
spread O
and O
potentially O
fatal O
impacts O
. O

Parenteral O
anticoagulants O
, O
such O
as O
heparin O
and O
low O
- O
molecular O
- O
weights O
heparins O
, O
are O
widely O
used O
in O
the O
management O
of O
COVID O
- O
19 O
patients O
. O

COVID O
- O
19 O
infection O
itself O
has O
also O
been O
described O
as O
a O
risk O
factor O
for O
stroke O
. O

Perspectives O
from O
a O
webinar O
: O
COVID O
- O
19 O
and O
sexual O
and O
reproductive O
health O
and O
rights O
. O

This O
case O
- O
control O
study O
recruited O
1173 O
frontline O
and O
1173 O
age O
- O
and O
sex O
- O
matched O
non O
- O
frontline O
medical O
workers O
during O
the O
COVID O
- O
19 O
outbreak O
( O
February O
11 O
to O
26 O
, O
2020 O
) O
. O

COVID O
- O
19 O
was O
addressed O
in O
13 O
interviews O
. O

Based O
on O
these O
observations O
, O
age O
is O
a O
more O
important O
driver O
of O
poor O
outcomes O
in O
COVID O
- O
19 O
than O
sex O
. O

The O
objective O
of O
this O
study O
was O
to O
describe O
the O
association O
between O
neighborhood O
factors O
and O
number O
of O
COVID O
- O
19 O
cases O
. O

Intimate O
partner O
violence O
( O
IPV O
) O
is O
a O
significant O
national O
and O
global O
public O
health O
concern O
, O
with O
COVID O
- O
19 O
pandemic O
increasing O
IPV O
and O
associated O
health O
issues O
. O

The O
results O
from O
this O
study O
are O
particularly O
salient O
to O
public O
health O
, O
as O
they O
can O
guide O
targeted O
intervention O
measures O
, O
lowering O
the O
magnitude O
and O
spread O
of O
COVID O
- O
19 O
. O

We O
inferred O
that O
Arbidol O
/ O
IFN O
- O
2 O
b O
therapy O
can O
be O
used O
as O
an O
effective O
method O
to O
improve O
the O
COVID O
- O
19 O
pneumonia O
of O
mild O
patients O
, O
although O
it O
helpless O
with O
accelerating O
the O
virus O
clearance O
. O

The O
COVID O
- O
19 O
pandemic O
caused O
by O
the O
SARS O
- O
CoV O
- O
2 O
requires O
a O
fast O
development O
of O
antiviral O
drugs O
. O

Changes O
to O
routine O
clinical O
approaches O
during O
the O
corona O
virus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
are O
necessary O
to O
decrease O
the O
risk O
of O
infection O
in O
patients O
and O
healthcare O
providers O
. O

They O
are O
susceptible O
to O
severe O
clinically O
adverse O
events O
and O
higher O
mortality O
from O
COVID O
- O
19 O
infection O
as O
well O
as O
morbidity O
and O
mortality O
from O
their O
underlying O
malignancy O
. O

Combining O
measles O
serological O
data O
, O
local O
contact O
patterns O
, O
and O
vaccination O
coverage O
into O
a O
cohort O
model O
, O
we O
predicted O
the O
age O
- O
adjusted O
population O
immunity O
in O
Kenya O
and O
estimated O
the O
probability O
of O
outbreaks O
when O
contact O
- O
reducing O
COVID O
- O
19 O
interventions O
are O
lifted O
. O

Pain O
Management O
During O
COVID O
- O
19 O
and O
Steroids O
: O
Striking O
a O
Balance O
. O

Rheumatological O
aspects O
of O
pathogenesis O
and O
treatment O
of O
COVID O
- O
19 O
infection O
. O

A O
picture O
of O
medically O
assisted O
reproduction O
activities O
during O
the O
COVID O
- O
19 O
pandemic O
in O
Europe O
. O

This O
case O
report O
describes O
the O
clinical O
course O
of O
a O
patient O
with O
COVID O
- O
19 O
pneumonia O
whose O
severe O
hypoxemia O
, O
probably O
caused O
by O
DIC O
and O
pulmonary O
embolism O
, O
showed O
remarkable O
improvement O
with O
combination O
heparin O
and O
nafamostat O
therapy O
. O

COVID O
- O
19 O
Has O
Increased O
Medicaid O
Enrollment O
, O
But O
Short O
- O
Term O
Enrollment O
Changes O
Are O
Unrelated O
To O
Job O
Losses O
. O

These O
findings O
not O
only O
provide O
novel O
evidence O
for O
meaning O
making O
model O
but O
also O
shed O
light O
on O
the O
underlying O
mechanism O
, O
suggesting O
an O
effective O
strategy O
to O
cope O
with O
stressful O
events O
such O
as O
the O
ongoing O
COVID O
- O
19 O
pandemic O
. O

Evaluation O
of O
retinotoxicity O
of O
COVID O
- O
19 O
treatment O
: O
Hydroxychloroquine O
and O
lopinavir O
/ O
ritonavir O
. O

Researchers O
all O
around O
the O
globe O
are O
working O
to O
discover O
a O
drug O
to O
cure O
from O
COVID O
- O
19 O
. O

High O
IL O
- O
17A O
and O
GM O
- O
CSF O
protein O
levels O
in O
the O
serum O
of O
COVID O
- O
19 O
patients O
were O
associated O
with O
a O
more O
severe O
clinical O
course O
. O

Here O
, O
using O
PCR O
with O
reverse O
transcription O
, O
serology O
, O
sequencing O
the O
viral O
genome O
and O
virus O
isolation O
, O
we O
show O
that O
2 O
out O
of O
15 O
dogs O
from O
households O
with O
confirmed O
human O
cases O
of O
COVID O
- O
19 O
in O
Hong O
Kong O
were O
found O
to O
be O
infected O
with O
SARS O
- O
CoV O
- O
2 O
. O

We O
systematically O
searched O
11 O
electronic O
databases O
until O
29 O
May O
2020 O
for O
studies O
in O
English O
reporting O
original O
data O
on O
AKI O
and O
kidney O
replacement O
therapy O
( O
KRT O
) O
in O
hospitalized O
COVID O
- O
19 O
patients O
. O

Because O
recovery O
from O
COVID O
- O
19 O
- O
associated O
respiratory O
failure O
can O
be O
prolonged O
, O
tracheostomy O
may O
facilitate O
patient O
management O
and O
optimize O
the O
use O
of O
mechanical O
ventilators O
. O

How O
and O
When O
Does O
Inclusive O
Leadership O
Curb O
Psychological O
Distress O
During O
a O
Crisis O
? O
Evidence O
From O
the O
COVID O
- O
19 O
Outbreak O
. O

We O
collected O
data O
from O
electrocardiograms O
and O
the O
electronic O
medical O
record O
of O
COVID O
- O
19 O
positive O
( O
COVID O
+ O
) O
and O
negative O
( O
COVID O
- O
) O
individuals O
admitted O
to O
our O
medical O
intensive O
care O
unit O
between O
February O
29 O
and O
June O
28 O
, O
2020 O
. O

Prevalence O
of O
symptoms O
of O
temporomandibular O
disorders O
, O
oral O
behaviors O
, O
anxiety O
, O
and O
depression O
in O
Dentistry O
students O
during O
the O
period O
of O
social O
isolation O
due O
to O
COVID O
- O
19 O
. O

Many O
patients O
with O
COVID O
- O
19 O
are O
asymptomatic O
. O

To O
illustrate O
the O
variety O
of O
possible O
presentations O
of O
pulmonary O
emboli O
in O
COVID O
- O
19 O
population O
, O
two O
cases O
of O
patients O
in O
their O
sixties O
are O
described O
, O
one O
without O
any O
predisposing O
risk O
factors O
and O
one O
with O
history O
of O
asthma O
and O
obesity O
. O

On O
March O
29th O
2020 O
, O
97 O
, O
689 O
cases O
of O
COVID O
- O
19 O
have O
been O
diagnosed O
only O
in O
Italy O
, O
with O
73 O
, O
880 O
actually O
positive O
cases O
, O
a O
daily O
increase O
of O
3815 O
cases O
, O
27 O
, O
386 O
hospitalized O
and O
3906 O
patients O
in O
intensive O
care O
units O
, O
causing O
a O
total O
of O
10 O
, O
779 O
known O
deaths O
. O

The O
simulation O
model O
estimated O
the O
highest O
number O
of O
total O
daily O
new O
COVID O
- O
19 O
cases O
, O
in O
the O
pre O
- O
symptomatic O
compartmental O
state O
, O
to O
be O
65 O
cases O
, O
with O
an O
epidemic O
curve O
growing O
to O
its O
peak O
in O
49 O
days O
and O
terminating O
in O
a O
duration O
of O
83 O
days O
, O
and O
a O
total O
simulated O
cumulative O
case O
count O
of O
1048 O
cases O
. O

An O
Eye O
on O
COVID O
: O
Hurricane O
Preparedness O
at O
a O
COVID O
- O
19 O
Alternative O
Care O
Site O
. O

Very O
recently O
, O
hydroxychloroquine O
in O
combination O
with O
azithromycin O
treatment O
was O
reported O
to O
be O
effective O
for O
COVID O
- O
19 O
. O

Observational O
studies O
suggest O
indolent O
cardiovascular O
involvement O
after O
recovery O
from O
acute O
COVID O
- O
19 O
. O

Importantly O
, O
the O
response O
has O
utilized O
adaptive O
and O
innovative O
technology O
and O
robust O
risk O
communication O
and O
community O
engagement O
to O
deliver O
an O
effective O
response O
to O
the O
COVID O
- O
19 O
pandemic O
. O

In O
contrast O
to O
other O
acute O
viral O
smell O
impairment O
, O
COVID O
- O
19 O
- O
associated O
smell O
loss O
seems O
to O
be O
only O
rarely O
accompanied O
by O
a O
severely O
blocked O
nose O
. O

COVID O
- O
19 O
not O
only O
constitutes O
a O
serious O
public O
health O
problem O
and O
a O
global O
major O
threat O
to O
the O
poorest O
and O
most O
vulnerable O
social O
groups O
and O
neighborhoods O
of O
the O
world O
, O
creating O
a O
potential O
pandemic O
of O
inequality O
, O
but O
also O
poses O
an O
enormous O
challenge O
from O
the O
perspective O
of O
public O
health O
, O
ethics O
, O
economy O
, O
environment O
, O
and O
politics O
. O

COVID O
- O
19 O
studies O
are O
primarily O
from O
the O
inpatient O
setting O
, O
skewing O
towards O
severe O
disease O
. O

Herein O
, O
we O
will O
review O
the O
role O
of O
oxidative O
stress O
as O
a O
key O
player O
in O
both O
aging O
and O
COVID O
- O
19 O
and O
highlight O
why O
some O
individuals O
may O
have O
better O
or O
poorer O
outcomes O
because O
of O
this O
. O

Hospital O
workers O
have O
been O
the O
most O
frequently O
and O
severely O
affected O
professional O
group O
during O
the O
COVID O
- O
19 O
pandemic O
, O
and O
have O
a O
big O
impact O
on O
transmission O
. O

Mild O
COVID O
- O
19 O
infection O
- O
predicting O
symptomatic O
phase O
and O
outcome O
: O
A O
study O
from O
AIIMS O
, O
New O
Delhi O
. O

Teaching O
Surgical O
Residents O
in O
the O
COVID O
- O
19 O
Era O
: O
The O
Value O
of O
a O
Simulation O
Strategy O
. O

Also O
, O
comparison O
results O
with O
other O
countries O
demonstrate O
that O
India O
has O
less O
death O
rate O
or O
more O
immunity O
against O
COVID O
- O
19 O
. O

The O
global O
COVID O
- O
19 O
pandemic O
due O
to O
the O
novel O
coronavirus O
SARS O
- O
CoV O
- O
2 O
has O
challenged O
the O
availability O
of O
traditional O
surface O
disinfectants O
. O

The O
world O
is O
currently O
overwhelmed O
by O
a O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
. O

Authors O
strongly O
recommend O
recent O
COVID O
- O
19 O
pandemic O
as O
a O
call O
for O
continuous O
, O
more O
cooperative O
, O
and O
collective O
global O
research O
. O

Our O
meta O
- O
analysis O
showed O
that O
the O
severity O
of O
patients O
with O
COVID O
- O
19 O
significance O
related O
to O
D O
- O
dimer O
concentrations O
. O

We O
reviewed O
the O
data O
of O
patients O
admitted O
to O
our O
ED O
during O
the O
month O
of O
March O
and O
analyzed O
the O
results O
of O
our O
triage O
method O
in O
separating O
COVID O
- O
19 O
positive O
from O
negative O
patients O
. O

The O
ongoing O
global O
pandemic O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
has O
been O
a O
Public O
Health O
Emergency O
of O
International O
Concern O
, O
which O
was O
officially O
declared O
by O
the O
World O
Health O
Organization O
. O

On O
February O
29 O
, O
2020 O
, O
a O
patient O
infected O
with O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
passed O
away O
in O
a O
hospital O
in O
Seattle O
- O
King O
County O
, O
the O
first O
reported O
COVID O
- O
19 O
- O
related O
death O
in O
the O
United O
States O
. O

[ O
Management O
of O
patients O
with O
lymphatic O
diseases O
and O
lipoedema O
during O
the O
COVID O
- O
19 O
pandemic O
. O
Recommendations O
of O
the O
Spanish O
Group O
of O
Lymphology O
] O
. O

, O
11 O
. O
44 O
- O
32 O
. O
34 O
mg O
/ O
L O
) O
were O
commonly O
noted O
in O
COVID O
- O
19 O
patients O
with O
VTE O
. O

Association O
between O
COVID O
- O
19 O
and O
headache O
: O
What O
evidence O
and O
history O
tell O
us O
. O

Spine O
Surgery O
and O
COVID O
- O
19 O
: O
Challenges O
and O
Strategies O
from O
the O
Front O
Lines O
. O

East O
meets O
West O
in O
COVID O
- O
19 O
therapeutics O
. O

Systemic O
complement O
activation O
is O
associated O
with O
respiratory O
failure O
in O
COVID O
- O
19 O
patients O
and O
provides O
a O
rationale O
for O
investigating O
complement O
inhibitors O
in O
future O
clinical O
trials O
. O

Face O
masks O
use O
have O
shown O
a O
great O
potential O
for O
preventing O
respiratory O
virus O
transmission O
including O
COVID O
- O
19 O
. O

Metformin O
use O
and O
risk O
of O
COVID O
- O
19 O
among O
patients O
with O
type O
II O
diabetes O
mellitus O
: O
an O
NHIS O
- O
COVID O
- O
19 O
database O
cohort O
study O
. O

COVID O
- O
19 O
Pandemic O
and O
Impact O
on O
Patients O
with O
Autism O
Spectrum O
Disorder O
. O

The O
importance O
of O
mentorship O
and O
sponsorship O
for O
thoracic O
surgery O
residency O
applicants O
during O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
. O

Pulmonary O
intravascular O
coagulation O
in O
COVID O
- O
19 O
: O
possible O
pathogenesis O
and O
recommendations O
on O
anticoagulant O
/ O
thrombolytic O
therapy O
. O

Data O
from O
20 O
European O
countries O
and O
the O
USA O
and O
Canada O
showed O
that O
the O
variance O
of O
crude O
CFR O
of O
COVID O
- O
19 O
is O
predominantly O
( O
80 O
- O
96 O
% O
) O
determined O
by O
the O
proportion O
of O
older O
individuals O
who O
are O
diagnosed O
with O
SARS O
- O
CoV O
- O
2 O
. O

Furthermore O
, O
our O
results O
demonstrated O
that O
recent O
history O
of O
COVID O
- O
19 O
did O
not O
hamper O
viral O
memory O
T O
- O
cell O
pool O
against O
common O
viruses O
( O
Cytomegalovirus O
, O
Epstein O
- O
Barr O
- O
virus O
and O
Flu O
- O
virus O
) O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
a O
novel O
human O
coronavirus O
responsible O
for O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Statins O
and O
COVID O
- O
19 O
: O
To O
Suspend O
or O
Not O
to O
Suspend O
? O
That O
is O
the O
Question O
! O

This O
review O
remarks O
the O
need O
to O
: O
( O
1 O
) O
determine O
which O
potential O
pharmacological O
interventions O
have O
a O
negative O
impact O
on O
muscle O
quality O
and O
quantity O
; O
( O
2 O
) O
define O
a O
feasible O
and O
reliable O
pharmacological O
protocol O
to O
achieve O
a O
balance O
between O
desired O
and O
undesired O
medication O
effects O
in O
the O
treatment O
of O
this O
novel O
disease O
; O
( O
3 O
) O
implement O
practical O
strategies O
to O
reduce O
muscle O
weakness O
during O
bed O
rest O
hospitalization O
and O
( O
4 O
) O
develop O
a O
specific O
, O
early O
and O
safe O
protocol O
- O
based O
care O
of O
functional O
interventions O
for O
older O
adults O
affected O
by O
COVID O
- O
19 O
during O
and O
after O
hospitalization O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
is O
having O
a O
profound O
effect O
on O
the O
provision O
of O
medical O
care O
. O

Is O
a O
COVID O
- O
19 O
prediction O
model O
based O
on O
symptom O
tracking O
through O
an O
app O
applicable O
in O
primary O
care O
? O

COVID O
- O
19 O
is O
an O
emerging O
outbreak O
similar O
to O
previous O
pandemics O
caused O
by O
Severe O
Acute O
Respiratory O
Syndrome O
( O
SARS O
) O
and O
Middle O
East O
Respiratory O
Syndrome O
( O
MERS O
) O
. O

As O
of O
today O
, O
there O
is O
a O
lack O
of O
definitive O
treatment O
options O
for O
COVID O
- O
19 O
pneumonia O
. O

Despite O
the O
lack O
of O
relevant O
and O
accurate O
nationwide O
statistics O
on O
family O
violence O
in O
China O
, O
multiple O
reports O
seem O
to O
suggest O
that O
family O
violence O
has O
surged O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Like O
previous O
works O
, O
we O
identify O
that O
the O
COVID O
- O
19 O
evolution O
shows O
various O
power O
- O
law O
exponents O
( O
no O
just O
a O
single O
one O
) O
and O
share O
some O
universality O
among O
geographical O
regions O
. O

Cardiovascular O
disease O
was O
weakly O
associated O
with O
non O
- O
ICU O
hospitalization O
for O
COVID O
- O
19 O
, O
but O
not O
with O
ICU O
hospitalization O
, O
after O
adjustment O
for O
other O
risk O
factors O
. O

The O
main O
characteristics O
and O
challenging O
symptoms O
of O
COVID O
- O
19 O
, O
caused O
by O
the O
novel O
coronavirus O
SARS O
- O
CoV O
- O
2 O
, O
are O
related O
to O
re O
- O
spiratory O
distress O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
and O
the O
World O
Health O
Organization O
( O
WHO O
) O
declared O
it O
a O
pandemic O
on O
11 O
March O
2020 O
. O

Implementation O
lessons O
from O
the O
transition O
to O
telehealth O
during O
COVID O
- O
19 O
: O
a O
survey O
of O
clinicians O
and O
young O
people O
from O
youth O
mental O
health O
services O
. O

It O
is O
not O
clear O
whether O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
and O
its O
severity O
differ O
in O
pregnant O
compared O
to O
the O
nonpregnant O
outcome O
. O

The O
COVID O
- O
19 O
epidemic O
represents O
a O
special O
risk O
for O
kidney O
patients O
due O
to O
their O
comorbidities O
and O
advanced O
age O
, O
and O
the O
need O
for O
hemodialysis O
treatment O
in O
group O
rooms O
. O

The O
authors O
review O
updates O
in O
the O
treatment O
of O
herpes O
simplex O
virus O
, O
cytomegalovirus O
, O
hepatitis O
B O
and O
C O
viruses O
, O
human O
immunodeficiency O
virus O
, O
and O
COVID O
- O
19 O
during O
pregnancy O
. O

CHA2DS2 O
- O
VASc O
score O
acceptably O
predicts O
60 O
- O
day O
mortality O
in O
COVID O
- O
19 O
patients O
( O
area O
ROC O
, O
0 O
. O
748 O
; O
95 O
% O
CI O
, O
0 O
. O
733 O
- O
0 O
. O
764 O
) O
, O
but O
not O
its O
embolic O
risk O
( O
area O
ROC O
, O
0 O
. O
411 O
; O
95 O
% O
CI O
, O
0 O
. O
147 O
- O
0 O
. O
675 O
) O
. O
Conclusions O
AF O
in O
COVID O
- O
19 O
patients O
is O
associated O
with O
a O
higher O
number O
of O
complications O
and O
60 O
- O
day O
mortality O
. O

About O
half O
of O
the O
patients O
at O
Mulago O
National O
Referral O
Hospital O
lack O
adequate O
knowledge O
and O
practice O
on O
COVID O
- O
19 O
prevention O
. O

A O
living O
mapping O
review O
for O
COVID O
- O
19 O
funded O
research O
projects O
: O
three O
- O
month O
update O
. O

However O
, O
scarce O
clinical O
data O
is O
available O
and O
generally O
limited O
to O
the O
Chinese O
population O
due O
to O
the O
first O
cases O
were O
identified O
in O
Wuhan O
( O
Hubei O
, O
China O
) O
. O
This O
article O
describes O
the O
rationale O
and O
design O
of O
the O
HOPE O
COVID O
- O
19 O
( O
Health O
Outcome O
Predictive O
Evaluation O
for O
COVID O
19 O
) O
registry O
( O
ClinicalTrials O
. O
gov O
Identifier O
: O
NCT04334291 O
) O
. O

A O
projection O
for O
psychiatry O
in O
the O
post O
- O
COVID O
- O
19 O
era O
: O
potential O
trends O
, O
challenges O
, O
and O
directions O
. O

The O
percentages O
of O
current O
smokers O
( O
4 O
. O
1 O
% O
vs O
16 O
% O
, O
p O
= O
0 O
. O
00003 O
) O
and O
never O
smokers O
( O
71 O
. O
6 O
% O
vs O
56 O
. O
8 O
% O
, O
p O
= O
0 O
. O
0014 O
) O
were O
significantly O
different O
between O
COVID O
- O
19 O
and O
non O
- O
COVID O
19 O
patients O
. O

Patients O
with O
critically O
COVID O
- O
19 O
usually O
require O
invasive O
respiratory O
support O
, O
and O
the O
airway O
management O
is O
particularly O
important O
and O
the O
prognosis O
is O
poor O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
a O
novel O
coronavirus O
) O
, O
which O
was O
first O
identified O
amid O
an O
outbreak O
of O
respiratory O
illness O
cases O
in O
Wuhan O
, O
China O
and O
declared O
a O
global O
health O
emergency O
, O
is O
currently O
considered O
an O
additional O
challenge O
in O
the O
management O
of O
patients O
with O
breast O
cancer O
( O
BC O
) O
. O

This O
study O
examines O
the O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
fracture O
incidence O
and O
characteristics O
. O

Performance O
of O
prediction O
models O
for O
COVID O
- O
19 O
: O
the O
Caudine O
Forks O
of O
the O
external O
validation O
. O

Although O
it O
is O
only O
possible O
to O
recognise O
resilience O
retrospectively O
, O
the O
COVID O
- O
19 O
pandemic O
has O
occurred O
at O
a O
point O
in O
human O
history O
when O
, O
uniquely O
, O
sufficient O
knowledge O
is O
available O
on O
the O
early O
- O
life O
determinants O
of O
health O
to O
indicate O
clearly O
that O
a O
focus O
on O
maternal O
, O
neonatal O
, O
and O
child O
health O
( O
MNCH O
) O
will O
promote O
later O
resilience O
. O

This O
guide O
does O
not O
set O
a O
standard O
of O
practice O
but O
contains O
recommendations O
that O
may O
avoid O
some O
of O
the O
" O
lessons O
learned O
" O
with O
the O
COVID O
- O
19 O
pandemic O
. O

The O
aim O
of O
this O
paper O
was O
to O
integrate O
multiple O
transactional O
data O
sets O
( O
GPS O
mobility O
data O
from O
Google O
and O
Apple O
as O
well O
as O
disease O
statistics O
from O
the O
European O
Centre O
for O
Disease O
Prevention O
and O
Control O
) O
to O
study O
the O
role O
of O
social O
distancing O
policies O
in O
26 O
countries O
and O
analyze O
the O
transmission O
rate O
of O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
over O
the O
course O
of O
5 O
weeks O
. O

Also O
, O
the O
prevailing O
evidence O
reveales O
the O
antiviral O
effects O
of O
those O
phytochemicals O
, O
including O
anti O
- O
SARS O
- O
CoV O
activity O
, O
which O
could O
pave O
the O
road O
in O
providing O
suitable O
lead O
compounds O
in O
the O
treatment O
of O
COVID O
- O
19 O
. O

The O
laboratory O
- O
confirmed O
and O
clinically O
diagnosed O
COVID O
- O
19 O
groups O
consisted O
of O
69 O
( O
M O
/ O
F O
43 O
/ O
26 O
, O
mean O
age O
50 O
. O
9 O
± O
14 O
. O
0 O
years O
) O
and O
51 O
patients O
( O
M O
/ O
F O
24 O
/ O
27 O
, O
mean O
age O
50 O
. O
9 O
± O
18 O
. O
8 O
years O
) O
, O
respectively O
. O

Of O
3993 O
hospitalized O
patients O
with O
COVID O
- O
19 O
, O
AKI O
occurred O
in O
1835 O
( O
46 O
% O
) O
patients O
; O
347 O
( O
19 O
% O
) O
of O
the O
patients O
with O
AKI O
required O
dialysis O
. O

Results O
Among O
1 O
, O
470 O
patients O
who O
visited O
the O
fever O
clinic O
, O
84 O
patients O
were O
hospitalized O
, O
and O
45 O
of O
them O
were O
diagnosed O
as O
having O
COVID O
- O
19 O
. O

There O
were O
no O
statistically O
significant O
differences O
in O
terms O
of O
clinical O
characteristics O
between O
patients O
with O
COVID O
- O
19 O
and O
the O
rest O
of O
the O
unit O
. O

The O
low O
incidence O
of O
COVID O
- O
19 O
infection O
in O
a O
community O
- O
based O
ambulatory O
surgery O
center O
is O
supported O
by O
a O
positive O
RT O
- O
PCR O
test O
rate O
of O
. O
80 O
% O
. O

Recent O
spread O
of O
severe O
acute O
respiratory O
coronavirus O
syndrome O
- O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
has O
led O
to O
the O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
, O
resulting O
in O
new O
challenges O
across O
all O
medical O
specialties O
. O

To O
experimentally O
evaluate O
the O
effects O
of O
personal O
protective O
equipment O
( O
PPE O
) O
on O
participants O
' O
perceptions O
of O
police O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
60 O
- O
year O
- O
old O
man O
and O
a O
61 O
- O
year O
- O
old O
woman O
diagnosed O
with O
mild O
COVID O
- O
19 O
were O
admitted O
to O
our O
hospital O
. O

This O
study O
aimed O
to O
evaluate O
differences O
between O
sexes O
concerning O
COVID O
- O
19 O
- O
related O
pneumonia O
. O

Factors O
associated O
with O
preventive O
behaviours O
of O
COVID O
- O
19 O
among O
hospital O
staff O
in O
Iran O
in O
2020 O
: O
an O
application O
of O
the O
Protection O
Motivation O
Theory O
. O

Long O
- O
term O
, O
neuropsychiatric O
complications O
of O
COVID O
- O
19 O
are O
common O
and O
consequential O
. O

The O
objective O
of O
this O
study O
is O
to O
review O
the O
findings O
of O
epidemiological O
and O
in O
vitro O
studies O
about O
the O
association O
between O
smoking O
and O
the O
risk O
of O
contracting O
COVID O
- O
19 O
, O
taking O
into O
account O
disease O
severity O
. O

The O
COVID O
- O
19 O
pandemic O
caused O
the O
shutdown O
of O
entire O
nations O
all O
over O
the O
world O
. O

Genomic O
characterization O
of O
SARS O
- O
CoV O
- O
2 O
identified O
in O
a O
reemerging O
COVID O
- O
19 O
outbreak O
in O
Beijing O
' O
s O
Xinfadi O
market O
in O
2020 O
. O

Highly O
probable O
COVID O
- O
19 O
on O
the O
basis O
of O
symptoms O
and O
signs O
was O
less O
frequent O
in O
the O
IBD O
group O
( O
3 O
. O
8 O
% O
vs O
6 O
. O
3 O
% O
; O
OR O
: O
0 O
. O
45 O
, O
95 O
% O
CI O
: O
0 O
. O
28 O
- O
0 O
. O
75 O
) O
. O

Tocilizumab O
for O
treatment O
of O
mechanically O
ventilated O
patients O
with O
COVID O
- O
19 O
. O

Accordingly O
, O
we O
aim O
to O
provide O
a O
comprehensive O
review O
on O
COVID O
- O
19 O
myocarditis O
and O
its O
long O
- O
term O
heart O
failure O
sequelae O
. O

Recommendations O
for O
Tiered O
Stratification O
of O
Urological O
Surgery O
Urgency O
in O
the O
COVID O
- O
19 O
Era O
. O

DisCoVering O
potential O
candidates O
of O
RNAi O
- O
based O
therapy O
for O
COVID O
- O
19 O
using O
computational O
methods O
. O

Sixty O
seven O
patients O
( O
52 O
% O
) O
needed O
oxygen O
For O
treatment O
of O
COVID O
- O
19 O
infection O
, O
half O
( O
n O
= O
66 O
) O
received O
antivirals O
. O

Here O
, O
a O
model O
integrating O
the O
daily O
intercity O
migration O
network O
, O
which O
constructed O
from O
real O
- O
world O
migration O
records O
and O
the O
Susceptible O
- O
Exposed O
- O
Infected O
- O
Removed O
model O
, O
is O
utilized O
to O
predict O
the O
epidemic O
spreading O
of O
the O
COVID O
- O
19 O
in O
more O
than O
300 O
cities O
in O
China O
. O

Nurses O
can O
help O
change O
the O
course O
of O
the O
COVID O
- O
19 O
pandemic O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
produced O
a O
world O
- O
wide O
collapse O
of O
social O
and O
economic O
infrastructure O
, O
as O
well O
as O
constrained O
our O
freedom O
of O
movement O
. O

It O
is O
important O
that O
the O
emergency O
physician O
maintain O
a O
high O
degree O
of O
suspicion O
for O
arterial O
thromboembolic O
disease O
in O
patients O
who O
are O
infected O
with O
COVID O
- O
19 O
even O
in O
the O
absence O
of O
typical O
respiratory O
symptoms O
. O

This O
online O
survey O
addressed O
the O
impact O
and O
perception O
of O
the O
COVID O
- O
19 O
pandemic O
on O
dental O
practice O
in O
Saudi O
Arabia O
. O

The O
web O
portal O
' O
s O
primary O
objective O
is O
to O
publish O
a O
well O
- O
arranged O
visualization O
and O
clear O
explanation O
of O
basic O
information O
consisting O
of O
the O
overall O
numbers O
of O
performed O
tests O
, O
confirmed O
cases O
of O
COVID O
- O
19 O
, O
COVID O
- O
19 O
- O
related O
deaths O
, O
the O
daily O
and O
cumulative O
overviews O
of O
people O
with O
a O
positive O
COVID O
- O
19 O
case O
, O
performed O
tests O
, O
location O
and O
country O
of O
infection O
of O
people O
with O
a O
positive O
COVID O
- O
19 O
case O
, O
hospitalizations O
of O
patients O
with O
COVID O
- O
19 O
, O
and O
distribution O
of O
personal O
protective O
equipment O
. O

Hopefully O
, O
we O
will O
promote O
better O
understanding O
of O
this O
organ O
in O
COVID O
- O
19 O
infection O
and O
the O
potential O
transmission O
route O
that O
can O
be O
helpful O
in O
setting O
recommendations O
on O
best O
practices O
and O
protective O
guidelines O
to O
mitigate O
the O
disease O
spread O
. O

Meanwhile O
, O
restrictions O
imposed O
in O
response O
to O
diseases O
transmissions O
( O
e O
. O
g O
. O
stay O
- O
at O
- O
home O
measures O
for O
COVID O
- O
19 O
) O
may O
directly O
exacerbate O
the O
social O
support O
received O
by O
these O
foreign O
domestic O
works O
and O
their O
ability O
to O
access O
health O
- O
related O
information O
. O

An O
invited O
commentary O
on O
: O
" O
Evidence O
based O
management O
guideline O
for O
the O
COVID O
- O
19 O
pandemic O
- O
Review O
article O
" O
. O

We O
report O
our O
experience O
in O
managing O
a O
patient O
with O
COVID O
- O
19 O
complicated O
by O
a O
right O
atrial O
thrombus O
. O

Due O
to O
COVID O
- O
19 O
, O
these O
centers O
are O
encountering O
additional O
challenges O
cutting O
across O
interventions O
of O
rooming O
in O
, O
breastfeeding O
, O
milk O
expression O
, O
and O
provision O
of O
donor O
milk O
and O
kangaroo O
mother O
care O
. O

Using O
Information O
Technology O
To O
Improve O
COVID O
- O
19 O
Care O
At O
New O
York O
City O
Health O
+ O
Hospitals O
. O

In O
this O
review O
, O
we O
discuss O
vascular O
implications O
of O
COVID O
- O
19 O
and O
relate O
this O
to O
circulating O
biomarker O
, O
endothelial O
, O
erythrocyte O
and O
platelet O
dysfunction O
. O

Chemokines O
and O
chemokine O
receptors O
during O
COVID O
- O
19 O
infection O
. O

Graphene O
: O
A O
Disruptive O
Opportunity O
for O
COVID O
- O
19 O
and O
Future O
Pandemics O
? O

The O
mental O
health O
impact O
of O
COVID O
- O
19 O
and O
lockdown O
- O
related O
stressors O
among O
adults O
in O
the O
UK O
. O

Radiomics O
features O
based O
on O
chest O
CT O
images O
help O
clinicians O
to O
categorize O
the O
patients O
of O
COVID O
- O
19 O
into O
different O
stages O
. O

Australian O
Quarantine O
Policy O
: O
From O
Centralization O
to O
Coordination O
with O
mid O
- O
Pandemic O
COVID O
- O
19 O
Shifts O
. O

On O
March O
13 O
, O
2020 O
, O
the O
World O
Health O
Organization O
declared O
COVID O
- O
19 O
a O
pandemic O
. O

Ethnic O
Disparities O
in O
Hospitalization O
for O
COVID O
- O
19 O
: O
a O
Community O
- O
Based O
Cohort O
Study O
in O
the O
UK O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
emerged O
into O
the O
human O
population O
in O
late O
2019 O
and O
caused O
the O
global O
COVID O
- O
19 O
pandemic O
. O

Since O
December O
2019 O
, O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
become O
a O
major O
health O
problem O
that O
is O
spreading O
all O
over O
the O
world O
. O

Due O
to O
the O
COVID O
- O
19 O
pandemic O
, O
important O
elective O
procedures O
, O
such O
as O
screening O
colonoscopy O
, O
have O
been O
delayed O
or O
cancelled O
, O
and O
there O
may O
be O
a O
very O
long O
waitlist O
for O
rescheduling O
once O
the O
moratorium O
is O
lifted O
. O

COVID O
- O
19 O
and O
the O
crisis O
of O
national O
development O
. O

Informing O
parents O
of O
children O
with O
CF O
about O
COVID O
- O
19 O
by O
teleconference O
may O
decrease O
anxiety O
. O

Median O
time O
from O
transplant O
to O
COVID O
- O
19 O
testing O
was O
2822 O
days O
( O
IQR O
1272 O
- O
4592 O
) O
. O

The O
global O
burden O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
to O
public O
health O
and O
global O
economy O
has O
stressed O
the O
need O
for O
rapid O
and O
simple O
diagnostic O
methods O
. O

Radiology O
podcasting O
as O
a O
model O
for O
asynchronous O
remote O
learning O
in O
the O
COVID O
- O
19 O
era O
. O

Dyspnea O
and O
pleuritic O
chest O
pain O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
findings O
of O
the O
research O
show O
that O
there O
are O
eighteen O
different O
results O
of O
COVID O
- O
19 O
that O
have O
been O
identified O
according O
to O
the O
Turkish O
people O
' O
s O
daily O
routines O
. O

Familiarity O
with O
COVID O
- O
19 O
symptoms O
, O
2 O
. O

At O
present O
, O
the O
law O
of O
COVID O
- O
19 O
spread O
in O
cities O
is O
not O
clear O
. O

General O
health O
status O
of O
children O
with O
asthma O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Epidemiology O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Caused O
by O
Severe O
Acute O
Respiratory O
Syndrome O
Coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

A O
case O
of O
extremely O
prolonged O
viral O
shedding O
: O
Could O
cell O
cultures O
be O
a O
diagnostic O
tool O
to O
drive O
COVID O
- O
19 O
patient O
discharge O
? O

The O
COVID O
- O
19 O
Pandemic O
Illuminates O
Persistent O
and O
Emerging O
Disparities O
among O
Rural O
Black O
Populations O
. O

SARS O
- O
CoV O
- O
2 O
RNA O
was O
measured O
by O
reverse O
transcription O
real O
- O
time O
PCR O
according O
to O
scheduled O
time O
- O
points O
: O
first O
swab O
after O
2 O
weeks O
from O
COVID O
- O
19 O
onset O
, O
then O
at O
one O
- O
week O
intervals O
until O
negativity O
. O

Digital O
psychiatry O
in O
low O
- O
and O
middle O
- O
income O
countries O
post O
- O
COVID O
- O
19 O
: O
Opportunities O
, O
challenges O
, O
and O
solutions O
. O

COVID O
- O
19 O
is O
the O
potential O
to O
transmit O
either O
mother O
to O
fetus O
or O
mother O
/ O
caregiver O
to O
neonates O
. O

Effect O
of O
the O
Phytochemical O
Agents O
Against O
the O
SARS O
- O
CoV O
and O
Selected O
Some O
of O
them O
for O
Application O
to O
COVID O
- O
19 O
: O
A O
Mini O
- O
Review O
. O

Early O
COVID O
- O
19 O
intervention O
trials O
have O
re O
- O
emphasized O
the O
subtle O
, O
but O
important O
cardiotoxic O
sequelae O
of O
potential O
therapies O
on O
outcomes O
. O

Severity O
of O
the O
injuries O
increased O
, O
with O
augmentation O
of O
the O
number O
of O
tissues O
involved O
and O
longer O
expected O
time O
of O
recovery O
. O
during O
the O
confinement O
period O
of O
the O
COVID O
- O
19 O
pandemic O
, O
despite O
an O
important O
reduction O
of O
medical O
activities O
, O
the O
amount O
and O
severity O
of O
hand O
emergency O
cases O
increased O
. O

These O
findings O
have O
implications O
for O
the O
management O
of O
hip O
fractures O
, O
in O
particular O
the O
need O
for O
COVID O
- O
19 O
testing O
. O

To O
examine O
the O
impact O
of O
home O
confinement O
during O
the O
COVID O
- O
19 O
pandemic O
on O
the O
sleep O
patterns O
and O
sleep O
disturbances O
in O
Italian O
children O
and O
adolescents O
. O

We O
will O
conduct O
this O
systematic O
review O
and O
meta O
- O
analysis O
to O
assess O
the O
effectiveness O
and O
safety O
of O
acupuncture O
for O
COVID O
- O
19 O
. O

Letter O
to O
the O
Editor O
- O
in O
response O
to O
: O
Cardiac O
injury O
prediction O
and O
lymphocyte O
immunity O
and O
inflammation O
analysis O
in O
hospitalized O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Efficacy O
and O
Safety O
of O
Anti O
- O
malarial O
Drugs O
( O
Chloroquine O
and O
Hydroxy O
- O
Chloroquine O
) O
in O
Treatment O
of O
COVID O
- O
19 O
Infection O
: O
A O
Systematic O
Review O
and O
Meta O
- O
Analysis O
. O

The O
new O
coronavirus O
( O
CoV O
) O
, O
called O
novel O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
belongs O
to O
the O
Coronaviridae O
family O
which O
was O
originated O
from O
the O
sea O
market O
in O
Wuhan O
city O
in O
China O
, O
at O
the O
end O
of O
the O
year O
2019 O
. O

In O
conclusion O
, O
longer O
quarantine O
periods O
might O
be O
more O
justified O
for O
COVID O
- O
19 O
patients O
with O
cough O
, O
higher O
levels O
of O
leucocytes O
, O
neutrophils O
and O
ESR O
and O
lower O
levels O
of O
CD3 O
+ O
CD4 O
+ O
lymphocytes O
. O

The O
chi O
- O
square O
test O
was O
used O
to O
conduct O
a O
univariate O
analysis O
of O
the O
factors O
influencing O
the O
severity O
of O
COVID O
- O
19 O
, O
and O
ordinal O
logistic O
regression O
analysis O
was O
used O
to O
identify O
the O
factors O
related O
to O
the O
severity O
of O
COVID O
- O
19 O
. O

To O
analyse O
the O
impact O
of O
the O
COVID O
- O
19 O
epidemic O
and O
the O
lockdown O
measures O
on O
the O
follow O
- O
up O
and O
control O
of O
chronic O
diseases O
in O
primary O
care O
. O

This O
protocol O
of O
systematic O
review O
and O
meta O
- O
analysis O
will O
clarify O
the O
safety O
and O
effectiveness O
of O
rehabilitation O
exercises O
on O
different O
COVID O
- O
19 O
patients O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
nutritional O
risks O
among O
older O
patients O
with O
COVID O
- O
19 O
and O
their O
associated O
clinical O
outcomes O
using O
four O
nutritional O
risk O
screening O
( O
NRS O
) O
tools O
: O
Nutrition O
Risk O
Screening O
2002 O
( O
NRS O
2002 O
) O
, O
Malnutrition O
Universal O
Screening O
Tool O
( O
MUST O
) O
, O
Mini O
Nutrition O
Assessment O
Shortcut O
( O
MNA O
- O
sf O
) O
, O
and O
Nutrition O
Risk O
Index O
( O
NRI O
) O
. O

Despite O
the O
limited O
availability O
of O
laboratory O
testing O
for O
COVID O
- O
19 O
our O
actions O
enabled O
us O
to O
lead O
a O
strict O
risk O
- O
management O
policy O
while O
maintaining O
most O
of O
the O
available O
workforce O
. O

The O
findings O
of O
this O
study O
may O
enhance O
our O
knowledge O
about O
the O
pathogenesis O
of O
COVID O
- O
19 O
. O

We O
investigated O
olfactory O
dysfunction O
caused O
by O
COVID O
- O
19 O
using O
BSIT O
, O
and O
found O
a O
high O
rate O
of O
moderate O
- O
mild O
level O
symptoms O
with O
a O
high O
level O
of O
recovery O
in O
the O
3 O
- O
month O
follow O
- O
up O
. O

[ O
COVID O
- O
19 O
- O
2019 O
] O
. O

Patients O
with O
COVID O
- O
19 O
pneumonia O
had O
lower O
levels O
of O
abnormal O
laboratory O
parameters O
( O
white O
blood O
cell O
count O
, O
lymphocyte O
count O
, O
procalcitonin O
level O
, O
erythrocyte O
sedimentation O
rate O
and O
C O
- O
reactive O
protein O
level O
) O
and O
more O
extensive O
radiographic O
involvement O
. O

COVID O
- O
19 O
in O
Canada O
and O
the O
use O
of O
Personal O
Protective O
Equipment O
. O

Social O
distancing O
is O
an O
important O
component O
of O
the O
response O
to O
the O
COVID O
- O
19 O
pandemic O
. O

Critically O
ill O
COVID O
- O
19 O
patients O
have O
significantly O
increased O
risk O
of O
death O
. O

. O
53 O
[ O
95 O
% O
CI O
1 O
. O
20 O
- O
1 O
. O
95 O
] O
) O
were O
associated O
with O
COVID O
- O
19 O
mortality O
. O

The O
COVID O
- O
19 O
outbreak O
has O
played O
havoc O
within O
healthcare O
systems O
, O
with O
radiology O
sharing O
a O
substantial O
burden O
. O

Letter O
to O
the O
Editor O
Impact O
of O
the O
COVID O
- O
19 O
Pandemic O
on O
Neurosurgical O
Residency O
Training O
in O
New O
Orleans O
. O

The O
in O
hospital O
mortality O
was O
significantly O
higher O
in O
the O
COVID O
- O
19 O
group O
( O
5 O
. O
6 O
% O
vs O
. O
27 O
. O
3 O
% O
, O
p O
= O
. O
016 O
) O
. O

Early O
differences O
in O
cytokine O
production O
distinguish O
severity O
of O
COVID O
- O
19 O
. O

We O
have O
evaluated O
27 O
asymptomatic O
subjects O
, O
with O
retinal O
fundoscopic O
, O
optical O
coherence O
tomography O
( O
OCT O
) O
and O
OCT O
angiography O
fourteen O
days O
after O
hospital O
discharge O
due O
to O
COVID O
- O
19 O
bilateral O
pneumonia O
. O

The O
most O
frequent O
diagnoses O
made O
on O
brain O
MR O
imaging O
in O
patients O
with O
COVID O
- O
19 O
were O
acute O
and O
subacute O
infarcts O
. O

This O
review O
concludes O
that O
the O
drugs O
mentioned O
above O
are O
having O
different O
properties O
and O
act O
differently O
in O
combating O
the O
COVID O
- O
19 O
viruses O
. O

Here O
, O
we O
will O
describe O
the O
YU O
- O
Thru O
system O
in O
detail O
so O
that O
other O
countries O
experiencing O
COVID O
- O
19 O
outbreaks O
can O
take O
advantage O
of O
this O
system O
. O

A O
total O
of O
80 O
patients O
with O
confirmed O
COVID O
- O
19 O
and O
acute O
hypoxic O
respiratory O
failure O
will O
be O
enrolled O
, O
40 O
in O
the O
active O
and O
40 O
in O
the O
control O
group O
. O

Local O
measures O
enable O
COVID O
- O
19 O
containment O
with O
fewer O
restrictions O
due O
to O
cooperative O
effects O
. O

Among O
29 O
pregnant O
COVID O
- O
19 O
- O
infected O
women O
( O
13 O
confirmed O
and O
16 O
clinical O
diagnosed O
) O
, O
the O
majority O
had O
higher O
education O
( O
56 O
. O
6 O
% O
) O
, O
half O
were O
employed O
( O
51 O
. O
7 O
% O
) O
, O
and O
their O
mean O
age O
was O
29 O
years O
. O

In O
the O
current O
COVID O
- O
19 O
pandemic O
, O
CF O
patients O
self O
- O
isolating O
could O
find O
this O
intervention O
provides O
important O
support O
, O
therefore O
the O
programme O
was O
made O
available O
on O
YouTube O
in O
April O
2020 O
and O
linked O
to O
the O
websites O
of O
the O
CF O
charities O
funding O
the O
research O
. O

Acute O
chilblains O
were O
observed O
during O
COVID O
- O
19 O
pandemic O
in O
children O
and O
teenagers O
. O

In O
Asia O
, O
the O
COVID O
- O
19 O
brings O
a O
catastrophe O
where O
after O
China O
mainland O
, O
countries O
like O
Iran O
and O
South O
Korea O
have O
been O
affected O
. O

We O
report O
15 O
kidney O
transplant O
recipients O
from O
the O
Columbia O
University O
kidney O
transplant O
program O
who O
required O
hospitalization O
for O
confirmed O
COVID O
- O
19 O
, O
and O
describe O
their O
management O
, O
clinical O
course O
, O
and O
outcomes O
. O

Post O
- O
mortem O
analyses O
of O
COVID O
- O
19 O
kidney O
tissue O
suggest O
that O
renal O
tubular O
cells O
and O
podocytes O
are O
affected O
. O

Developments O
in O
medical O
education O
in O
response O
to O
the O
COVID O
- O
19 O
pandemic O
: O
A O
rapid O
BEME O
systematic O
review O
: O
BEME O
Guide O
No O
. O
63 O
. O

Adult O
inpatients O
( O
≥ O
18 O
years O
old O
) O
with O
COVID O
- O
19 O
who O
underwent O
multiple O
( O
≥ O
5 O
times O
) O
nucleic O
acid O
tests O
with O
nasal O
and O
pharyngeal O
swabs O
were O
recruited O
from O
Renmin O
Hospital O
of O
Wuhan O
University O
, O
including O
general O
patients O
( O
n O
= O
70 O
) O
, O
severe O
patients O
( O
n O
= O
195 O
) O
, O
and O
critical O
patients O
( O
n O
= O
43 O
) O
. O

Cytokine O
Storm O
in O
Novel O
Coronavirus O
Disease O
( O
COVID O
- O
19 O
) O
: O
Expert O
Management O
Considerations O
. O

Individuating O
Possibly O
Repurposable O
Drugs O
and O
Drug O
Targets O
for O
COVID O
- O
19 O
Treatment O
Through O
Hypothesis O
- O
Driven O
Systems O
Medicine O
Using O
CoVex O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
caused O
by O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
and O
currently O
has O
detrimental O
human O
health O
, O
community O
, O
and O
economic O
impacts O
around O
the O
world O
. O

The O
current O
study O
investigates O
beliefs O
and O
tobacco O
use O
behaviors O
and O
COVID O
- O
19 O
infection O
among O
a O
sample O
of O
smokers O
and O
never O
- O
smokers O
. O

COVID O
- O
19 O
is O
a O
new O
contagious O
disease O
caused O
by O
a O
new O
coronavirus O
known O
as O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

Overall O
, O
525 O
patients O
with O
COVID O
- O
19 O
enrolled O
with O
a O
median O
age O
of O
64 O
years O
( O
IQR O
19 O
) O
, O
and O
49 O
. O
33 O
% O
men O
. O

COVID O
- O
19 O
outbreak O
had O
a O
major O
impact O
on O
the O
organization O
of O
care O
in O
Italy O
, O
and O
a O
survey O
to O
evaluate O
provision O
of O
for O
arrhythmia O
during O
COVID O
- O
19 O
outbreak O
( O
March O
- O
April O
2020 O
) O
was O
launched O
. O

Higher O
trust O
levels O
in O
mass O
media O
, O
health O
agencies O
, O
scientists O
, O
and O
pharmaceutical O
companies O
was O
significantly O
associated O
with O
higher O
COVID O
- O
19 O
vaccine O
acceptance O
. O

The O
influence O
of O
ACE O
inhibitors O
and O
ARBs O
on O
hospital O
length O
of O
stay O
and O
survival O
in O
people O
with O
COVID O
- O
19 O
. O

In O
this O
mini O
- O
review O
, O
we O
highlight O
possible O
genetic O
determinants O
of O
COVID O
- O
19 O
and O
the O
contribution O
of O
aerosol O
exposure O
as O
a O
potentially O
important O
transmission O
route O
of O
SARS O
- O
CoV O
- O
2 O
. O

Early O
Effects O
of O
COVID O
- O
19 O
on O
Oral O
and O
Maxillofacial O
Surgery O
Residency O
Training O
- O
Results O
From O
a O
National O
Survey O
. O

COVID O
- O
19 O
has O
led O
to O
a O
global O
crisis O
not O
only O
in O
the O
health O
sector O
but O
also O
in O
the O
economic O
, O
social O
and O
education O
sectors O
, O
as O
well O
as O
the O
lives O
of O
common O
man O
. O

The O
first O
COVID O
- O
19 O
infectious O
disease O
case O
was O
reported O
in O
Europe O
, O
and O
on O
13 O
March O
2020 O
the O
WHO O
reported O
that O
Europe O
had O
become O
the O
epicentre O
of O
the O
coronavirus O
pandemic O
. O

The O
microorganism O
causing O
COVID O
- O
19 O
was O
named O
as O
Severe O
Acute O
Respiratory O
Syndrome O
Coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
or O
2019 O
- O
nCoV O
) O
. O

Risk O
of O
COVID O
- O
19 O
in O
Patients O
Taking O
Proton O
Pump O
Inhibitors O
. O

In O
conclusion O
, O
hypertensive O
patients O
with O
COVID O
- O
19 O
treated O
with O
ACEIs O
/ O
ARBS O
have O
a O
lower O
mortality O
but O
further O
research O
is O
needed O
. O

A O
relevant O
portion O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
patients O
develop O
severe O
disease O
with O
negative O
outcomes O
. O

curated O
culturally O
relevant O
digital O
content O
to O
raise O
awareness O
of O
the O
pandemic O
' O
s O
inequitable O
impact O
on O
Latinos O
and O
promote O
solutions O
for O
health O
equity O
, O
with O
a O
unique O
combination O
of O
website O
blog O
posts O
exploring O
pandemic O
effects O
on O
Latinos O
, O
peer O
- O
modeled O
stories O
of O
people O
responding O
meaningfully O
to O
the O
crisis O
, O
podcast O
episodes O
and O
Tweetchats O
engaging O
people O
in O
COVID O
- O
19 O
solutions O
for O
Latinos O
, O
action O
tools O
and O
campaigns O
equipping O
school O
leaders O
to O
make O
grassroots O
changes O
, O
and O
supplying O
advocates O
with O
a O
local O
data O
tool O
on O
health O
equity O
identification O
. O

Despite O
considerable O
attention O
dedicated O
to O
COVID O
- O
19 O
, O
the O
link O
between O
metabolic O
syndrome O
and O
SARS O
- O
CoV O
- O
2 O
infection O
remains O
unclear O
. O

COVID O
- O
19 O
: O
more O
than O
a O
cytokine O
storm O
. O

At O
this O
early O
stage O
of O
the O
pandemic O
, O
medical O
datasets O
at O
the O
individual O
level O
are O
not O
available O
; O
therefore O
, O
it O
is O
challenging O
to O
conclude O
how O
different O
factors O
have O
impacted O
COVID O
- O
19 O
susceptibility O
. O

Hospitals O
did O
better O
when O
the O
prevalence O
of O
COVID O
- O
19 O
in O
their O
surrounding O
communities O
was O
lower O
. O

The O
primary O
outcomes O
of O
interest O
were O
pooled O
ORs O
of O
severe O
illness O
, O
all O
- O
cause O
death O
, O
and O
the O
composite O
of O
severe O
illness O
and O
death O
attributable O
to O
COVID O
- O
19 O
in O
males O
versus O
females O
in O
cancer O
patients O
. O

The O
most O
serious O
health O
issue O
today O
is O
the O
rapid O
outbreak O
of O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

The O
outbreak O
of O
the O
novel O
COVID O
- O
19 O
, O
which O
began O
silently O
in O
Wuhan O
City O
, O
China O
, O
has O
now O
taken O
the O
form O
of O
a O
pandemic O
, O
with O
its O
claws O
spreading O
rapidly O
in O
many O
countries O
, O
with O
new O
and O
new O
cases O
emerging O
rapidly O
. O

I O
discuss O
shortcomings O
in O
the O
ways O
that O
history O
is O
often O
used O
in O
school O
science O
, O
and O
examine O
how O
knowledge O
of O
previous O
pandemics O
might O
help O
in O
teaching O
about O
COVID O
- O
19 O
. O

Increased O
IL O
- O
12p70 O
levels O
were O
observed O
in O
OTHERS O
group O
as O
compared O
to O
COVID O
- O
19 O
group O
. O

Co O
- O
infection O
in O
COVID O
- O
19 O
, O
a O
cohort O
study O
. O

By O
fitting O
linear O
regression O
models O
with O
penalized O
splines O
on O
NO2 O
, O
we O
found O
that O
the O
association O
between O
COVID O
- O
19 O
mortality O
and O
NO2 O
varies O
when O
data O
were O
aggregated O
( O
1 O
) O
at O
the O
city O
level O
, O
( O
2 O
) O
under O
two O
different O
aggregation O
strategies O
, O
and O
( O
3 O
) O
at O
the O
provincial O
level O
, O
indicating O
the O
presence O
of O
MAUP O
. O

This O
study O
aimed O
to O
identify O
the O
role O
of O
the O
human O
development O
index O
( O
HDI O
) O
in O
the O
incidence O
and O
mortality O
rates O
of O
COVID O
- O
19 O
worldwide O
. O

Preserving O
equipoise O
and O
performing O
randomised O
trials O
for O
COVID O
- O
19 O
social O
distancing O
interventions O
. O

This O
indicates O
that O
the O
so O
far O
anti O
- O
epidemic O
activities O
to O
control O
COVID O
- O
19 O
are O
insufficient O
. O

We O
observed O
high O
30 O
- O
day O
all O
- O
cause O
mortality O
among O
HNC O
patients O
with O
COVID O
- O
19 O
, O
but O
most O
were O
not O
on O
active O
cancer O
therapy O
. O

Comparing O
South O
Korea O
and O
Italy O
' O
s O
healthcare O
systems O
and O
initiatives O
to O
combat O
COVID O
- O
19 O
. O

No O
conclusive O
evidence O
exists O
to O
support O
the O
discontinuation O
of O
angiotensin O
- O
converting O
enzyme O
inhibitors O
( O
ACEI O
) O
, O
angiotensin O
receptor O
blockers O
or O
thiazolidinediones O
because O
of O
COVID O
- O
19 O
in O
people O
with O
diabetes O
. O

Currently O
, O
no O
review O
so O
far O
available O
proposing O
IF O
as O
an O
encouraging O
strategy O
in O
the O
prevention O
of O
COVID O
- O
19 O
. O

In O
December O
2019 O
, O
a O
novel O
coronavirus O
known O
as O
SARS O
- O
CoV O
- O
2 O
was O
first O
detected O
in O
Wuhan O
, O
China O
, O
causing O
outbreaks O
of O
the O
coronavirus O
disease O
COVID O
- O
19 O
that O
has O
now O
spread O
globally O
. O

COVID O
- O
19 O
was O
classified O
as O
" O
definitive O
" O
( O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
polymerase O
chain O
reaction O
[ O
PCR O
] O
- O
positive O
) O
, O
" O
possible O
" O
( O
characteristic O
symptoms O
and O
negative O
PCR O
) O
, O
and O
" O
suspected O
" O
( O
characteristic O
symptoms O
but O
PCR O
not O
performed O
) O
. O

Interestingly O
, O
health O
care O
workers O
in O
non O
- O
COVID O
- O
19 O
- O
units O
had O
similar O
risk O
as O
University O
employees O
. O

SARS O
- O
CoV O
- O
2 O
caused O
COVID O
- O
19 O
has O
reached O
a O
pandemic O
level O
. O

Larger O
sample O
size O
study O
are O
needed O
to O
investigate O
the O
effects O
of O
HCQ O
in O
the O
treatment O
of O
COVID O
- O
19 O
. O

Results O
suggest O
that O
mental O
health O
symptoms O
during O
the O
early O
stages O
of O
the O
COVID O
- O
19 O
pandemic O
were O
prevalent O
nationally O
, O
regardless O
of O
state O
of O
residence O
and O
especially O
among O
young O
, O
psychosocially O
vulnerable O
groups O
. O

This O
review O
from O
the O
British O
Society O
of O
Thoracic O
Imaging O
explores O
both O
the O
thoracic O
and O
extra O
- O
thoracic O
complications O
of O
COVID O
- O
19 O
, O
recognising O
the O
importance O
of O
a O
holistic O
approach O
to O
patient O
follow O
- O
up O
. O

In O
this O
article O
, O
we O
systematically O
review O
the O
brief O
history O
of O
COVID O
- O
19 O
and O
its O
epidemic O
and O
clinical O
characteristics O
, O
highlighting O
the O
strategies O
used O
to O
control O
and O
prevent O
the O
disease O
in O
China O
, O
which O
may O
help O
other O
countries O
respond O
to O
the O
outbreak O
. O

A O
small O
cohort O
of O
patients O
with O
COVID O
- O
19 O
infection O
underwent O
neck O
or O
cervical O
spine O
CT O
imaging O
for O
indications O
including O
stroke O
, O
trauma O
, O
and O
neck O
pain O
. O

[ O
Epidemiology O
and O
public O
health O
in O
the O
COVID O
- O
19 O
epidemic O
] O
. O

Designing O
anticoronavirus O
disease O
2019 O
( O
anti O
- O
COVID O
- O
19 O
) O
agents O
is O
the O
primary O
concern O
of O
medicinal O
chemists O
/ O
drug O
designers O
nowadays O
. O

Exploring O
Epidemiological O
Behavior O
of O
Novel O
Coronavirus O
( O
COVID O
- O
19 O
) O
Outbreak O
in O
Bangladesh O
. O

COVID O
- O
19 O
pneumonia O
in O
a O
large O
cohort O
of O
patients O
treated O
with O
biological O
and O
targeted O
synthetic O
antirheumatic O
drugs O
. O

Including O
parents O
as O
partners O
in O
early O
stages O
of O
COVID O
- O
19 O
research O
helped O
determine O
priorities O
, O
led O
to O
more O
feasible O
data O
collection O
methods O
, O
and O
hopefully O
has O
improved O
the O
relevance O
, O
applicability O
and O
value O
of O
research O
findings O
to O
parents O
and O
children O
. O

Urticaria O
and O
COVID O
- O
19 O
infection O
: O
a O
critical O
appraisal O
. O

Impact O
of O
Quarantine O
During O
COVID O
- O
19 O
Pandemic O
on O
the O
Quality O
of O
Life O
of O
Patients O
with O
Allergic O
Conjunctivitis O
. O

Possible O
association O
between O
IgA O
vasculitis O
and O
COVID O
- O
19 O
. O

Arterial O
thromboembolism O
associated O
with O
COVID O
- O
19 O
and O
elevated O
D O
- O
dimer O
levels O
. O

COVID O
- O
19 O
Outbreak O
: O
Infection O
Control O
and O
Management O
Protocol O
for O
Vascular O
and O
Interventional O
Radiology O
Departments O
- O
Consensus O
Document O
. O

Little O
is O
known O
about O
the O
associated O
factors O
with O
organizational O
citizenship O
behavior O
among O
Chinese O
nurses O
combating O
COVID O
- O
19 O
. O

Organ O
donation O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Healthcare O
systems O
around O
the O
world O
are O
struggling O
to O
maintain O
a O
sufficient O
workforce O
to O
provide O
adequate O
care O
during O
the O
COVID O
- O
19 O
pandemic O
. O

At O
the O
start O
of O
the O
pandemic O
, O
many O
suspected O
COVID O
- O
19 O
dialysis O
patients O
were O
diverted O
to O
the O
emergency O
department O
( O
ED O
) O
for O
testing O
/ O
treatment O
, O
placing O
a O
tremendous O
burden O
on O
the O
ED O
and O
inpatient O
dialysis O
units O
. O

Corticosteroid O
use O
was O
also O
associated O
with O
a O
delay O
in O
SARS O
- O
CoV O
- O
2 O
coronavirus O
RNA O
clearance O
in O
the O
competing O
risk O
analysis O
( O
subhazard O
ratio O
1 O
. O
59 O
, O
95 O
% O
CI O
1 O
. O
17 O
- O
2 O
. O
15 O
, O
P O
= O
0 O
. O
003 O
) O
. O
CONCLUSIONAdministra O
of O
corticosteroids O
in O
severe O
COVID O
- O
19 O
- O
related O
ARDS O
is O
associated O
with O
increased O
28 O
- O
day O
mortality O
and O
delayed O
SARS O
- O
CoV O
- O
2 O
coronavirus O
RNA O
clearance O
after O
adjustment O
for O
time O
- O
varying O
confounders O
. O
FUNDINGNone O
. O

One O
Size O
Does O
Not O
Fit O
All O
: O
How O
to O
Rapidly O
Deploy O
Intubation O
Practice O
Changes O
in O
a O
Pediatric O
Hospital O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Changes O
in O
waitlist O
inactivations O
, O
waitlist O
additions O
, O
deceased O
donor O
recovery O
, O
and O
transplant O
volumes O
from O
the O
pre O
- O
COVID O
- O
19 O
( O
January O
19 O
- O
March O
15 O
, O
2020 O
) O
to O
the O
COVID O
- O
19 O
era O
( O
March O
15 O
- O
May O
9 O
, O
2020 O
) O
. O

This O
approach O
contributes O
not O
only O
to O
the O
short O
- O
term O
COVID O
- O
19 O
control O
but O
also O
long O
- O
term O
strengthening O
of O
the O
sustainable O
and O
resilient O
health O
system O
in O
the O
lower O
income O
countries O
. O

About O
9 O
in O
10 O
respondents O
( O
90 O
. O
4 O
% O
) O
perceived O
that O
they O
are O
susceptible O
to O
COVID O
- O
19 O
. O

Patients O
with O
DS O
are O
among O
the O
high O
- O
risk O
populations O
with O
respect O
to O
severe O
COVID O
- O
19 O
and O
should O
receive O
the O
vaccine O
as O
soon O
as O
possible O
. O

The O
Poisson O
distributed O
lag O
non O
- O
linear O
model O
( O
DLNM O
) O
was O
constructed O
to O
evaluate O
the O
non O
- O
linear O
delayed O
effects O
of O
ambient O
temperature O
on O
death O
, O
by O
using O
the O
daily O
new O
death O
of O
COVID O
- O
19 O
and O
ambient O
temperature O
data O
from O
January O
10 O
to O
March O
31 O
, O
2020 O
, O
in O
Wuhan O
, O
China O
. O

SARS O
- O
CoV O
- O
2 O
virus O
and O
liver O
expression O
of O
host O
receptors O
: O
Putative O
mechanisms O
of O
liver O
involvement O
in O
COVID O
- O
19 O
. O

During O
emergency O
mode O
teaching O
in O
the O
summer O
semester O
of O
2020 O
, O
a O
pilot O
project O
on O
practical O
classroom O
teaching O
under O
COVID O
- O
19 O
conditions O
was O
undertaken O
the O
Skills O
Lab O
Dresden O
, O
the O
Interprofessional O
Medical O
Training O
Centre O
( O
MITZ O
) O
. O

By O
12 O
June O
2020 O
, O
over O
7 O
. O
5 O
million O
confirmed O
cases O
of O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
with O
more O
than O
421 O
, O
000 O
deaths O
in O
the O
world O
have O
been O
reported O
to O
the O
WHO O
. O

SARS O
- O
CoV O
- O
2 O
and O
Multi O
- O
Organ O
damage O
- O
What O
men O
' O
s O
health O
specialists O
should O
know O
about O
the O
COVID O
- O
19 O
pathophysiology O
. O

Although O
studies O
assessing O
cardiovascular O
comorbidities O
and O
myocardial O
injury O
in O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
patients O
have O
been O
published O
, O
no O
reports O
focused O
on O
clinical O
outcomes O
of O
myocardial O
injury O
in O
patients O
with O
and O
without O
chronic O
coronary O
syndromes O
( O
CCS O
) O
are O
currently O
available O
. O

Clinical O
Outcomes O
of O
COVID O
- O
19 O
Patients O
with O
Type O
2 O
Diabetes O
: O
A O
Population O
- O
Based O
Study O
in O
Korea O
. O

Nursing O
Professional O
Development O
Specialist O
' O
s O
Role O
in O
Adapting O
Education O
, O
Onboarding O
, O
and O
Just O
- O
in O
- O
Time O
Education O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Finally O
, O
the O
findings O
indicate O
one O
more O
proof O
that O
social O
distancing O
of O
methods O
of O
1 O
to O
2 O
meter O
physical O
distance O
with O
masks O
use O
and O
city O
disinfection O
have O
an O
important O
role O
in O
policy O
making O
to O
be O
adopted O
globally O
as O
well O
as O
individual O
- O
scale O
preventive O
methods O
to O
achieve O
COVID O
- O
19 O
pandemics O
reduction O
. O

Among O
the O
eight O
cases O
diagnosed O
with O
COVID O
- O
19 O
, O
most O
were O
female O
( O
n O
= O
6 O
) O
, O
and O
either O
doctors O
( O
n O
= O
4 O
) O
or O
nurses O
( O
n O
= O
4 O
) O
. O

Invasive O
pulmonary O
aspergillosis O
associated O
with O
COVID O
- O
19 O
in O
a O
kidney O
transplant O
recipient O
. O

In O
severe O
acute O
respiratory O
syndrome O
( O
SARS O
) O
epidemic O
60 O
% O
of O
patients O
had O
hepatic O
injury O
, O
due O
to O
phylogenetic O
similarities O
of O
the O
viruses O
it O
is O
assumed O
that O
COVID O
- O
19 O
is O
associated O
with O
acute O
liver O
injury O
. O

Oncologists O
should O
bear O
in O
mind O
that O
patients O
with O
cancer O
have O
more O
anxiety O
than O
expected O
under O
unprecedented O
circumstances O
such O
as O
the O
COVID O
- O
19 O
pandemic O
. O

The O
rapid O
outbreak O
of O
the O
COVID O
- O
19 O
pandemic O
is O
putting O
humanity O
in O
front O
of O
enormous O
health O
risks O
. O

The O
events O
of O
the O
current O
COVID O
- O
19 O
pandemic O
have O
further O
emphasised O
existing O
issues O
within O
our O
health O
systems O
. O

These O
antibodies O
represent O
promising O
clinical O
candidates O
for O
treatment O
or O
prevention O
of O
COVID O
- O
19 O
. O

Moreover O
, O
MIS O
- O
C O
patients O
had O
reduced O
neutralizing O
activity O
compared O
to O
COVID O
- O
19 O
cohorts O
, O
indicating O
a O
reduced O
protective O
serological O
response O
. O

Extra O
- O
pulmonary O
manifestations O
of O
COVID O
- O
19 O
are O
still O
emerging O
in O
the O
community O
, O
and O
physicians O
and O
researchers O
are O
working O
together O
globally O
to O
strengthen O
the O
clinical O
management O
of O
these O
patients O
. O

Among O
these O
, O
9 O
( O
3 O
. O
9 O
% O
) O
died O
due O
to O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
caused O
many O
adults O
with O
intellectual O
/ O
developmental O
disabilities O
( O
IDD O
) O
to O
lose O
their O
daily O
routines O
and O
social O
support O
, O
and O
as O
a O
result O
, O
many O
adults O
with O
IDD O
are O
increasingly O
reliant O
on O
their O
family O
caregivers O
. O

COVID O
- O
19 O
pandemic O
is O
a O
World O
Health O
Organization O
day O
- O
to O
- O
day O
work O
and O
has O
a O
significant O
crisis O
on O
the O
physical O
and O
mental O
health O
of O
humans O
. O

Surveillance O
and O
Isolation O
Based O
Strategies O
to O
Prevent O
COVID O
- O
19 O
in O
a O
Dialysis O
Center O
of O
Tehran O
, O
a O
Customized O
Approach O
. O

Findings O
demonstrate O
that O
social O
distancing O
measures O
are O
related O
to O
concerns O
of O
contracting O
the O
virus O
and O
discriminatory O
attitudes O
toward O
those O
who O
are O
presumed O
to O
be O
living O
with O
COVID O
- O
19 O
. O

Healthcare O
workers O
accounted O
for O
a O
small O
proportion O
of O
COVID O
- O
19 O
cases O
in O
Singapore O
with O
favourable O
outcomes O
. O

This O
review O
compares O
the O
multifaceted O
characteristics O
of O
the O
three O
coronaviruses O
including O
COVID O
- O
19 O
, O
SARS O
and O
MERS O
. O

While O
several O
cases O
of O
seizures O
have O
been O
reported O
in O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
patients O
, O
there O
is O
no O
specific O
data O
to O
suggest O
an O
association O
of O
COVID O
- O
19 O
with O
epilepsy O
. O

This O
article O
intends O
to O
use O
molecular O
docking O
technology O
to O
find O
potential O
inhibitors O
that O
can O
respond O
to O
COVID O
- O
19 O
from O
active O
compounds O
in O
Mongolian O
medicine O
. O

Determinants O
of O
COVID O
- O
19 O
Mortality O
in O
Patients O
With O
Cancer O
From O
a O
Community O
Oncology O
Practice O
in O
Brazil O
. O

This O
was O
correlated O
with O
reduced O
IgM O
and O
IgG O
levels O
compared O
to O
convalescent O
COVID O
- O
19 O
patients O
. O

Coronavirus O
( O
COVID O
- O
19 O
) O
detection O
from O
chest O
radiology O
images O
using O
convolutional O
neural O
networks O
. O

Three O
patients O
were O
diagnosed O
with O
COVID O
- O
19 O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
a O
neoteric O
virus O
belonging O
to O
the O
beta O
coronavirus O
class O
has O
created O
a O
global O
health O
concern O
, O
responsible O
for O
an O
outbreak O
of O
severe O
acute O
respiratory O
illness O
, O
the O
COVID O
- O
19 O
pandemic O
. O

RMHive O
is O
being O
led O
and O
developed O
by O
health O
care O
workers O
using O
experience O
- O
based O
co O
- O
design O
( O
EBCD O
) O
processes O
as O
a O
mobile O
app O
to O
support O
the O
mental O
health O
challenges O
posed O
by O
the O
COVID O
- O
19 O
pandemic O
to O
health O
care O
workers O
. O

We O
observed O
a O
reduction O
over O
time O
in O
the O
proportion O
of O
patients O
with O
COVID O
- O
19 O
requiring O
intensive O
care O
, O
along O
with O
decreasing O
median O
values O
of O
viral O
load O
. O

The O
COVID O
- O
19 O
pandemic O
has O
imposed O
unprecedented O
health O
and O
socioeconomic O
challenges O
on O
public O
health O
, O
disrupting O
it O
on O
a O
global O
scale O
. O

We O
reviewed O
the O
clinical O
records O
of O
the O
confirmed O
COVID O
- O
19 O
patients O
aged O
60 O
years O
or O
more O
consecutively O
admitted O
to O
our O
ED O
over O
a O
6 O
- O
week O
period O
( O
March O
1st O
to O
April O
15th O
, O
2020 O
) O
. O

We O
report O
two O
cases O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
patients O
who O
developed O
pulmonary O
embolism O
and O
transient O
anti O
- O
phospholipid O
antibodies O
. O

The O
COVID O
- O
19 O
pandemic O
has O
strained O
hospital O
resources O
and O
necessitated O
the O
need O
for O
predictive O
models O
to O
forecast O
patient O
care O
demands O
in O
order O
to O
allow O
for O
adequate O
staffing O
and O
resource O
allocation O
. O

It O
has O
been O
written O
based O
on O
a O
limited O
number O
of O
publications O
, O
recommendations O
of O
national O
and O
international O
liver O
and O
organ O
transplantation O
societies O
, O
and O
experiences O
of O
patients O
with O
COVID O
- O
19 O
around O
the O
world O
. O

Clinical O
manifestations O
of O
blood O
cell O
parameters O
and O
inflammatory O
factors O
in O
92 O
patients O
with O
COVID O
- O
19 O
. O

This O
study O
aimed O
to O
evaluate O
the O
risk O
perception O
of O
COVID O
- O
19 O
among O
college O
students O
in O
China O
during O
the O
quarantine O
, O
explore O
its O
related O
factors O
, O
and O
provide O
reference O
for O
future O
study O
. O

A O
total O
of O
16 O
cancer O
patients O
with O
asymptomatic O
COVID O
- O
19 O
infection O
were O
confirmed O
. O

The O
present O
study O
included O
658 O
hospitalized O
patients O
with O
confirmed O
COVID O
- O
19 O
. O

Asthma O
and O
COVID O
- O
19 O
: O
a O
systematic O
review O
. O

We O
aim O
to O
investigate O
effects O
of O
reduction O
in O
AMS O
resources O
during O
the O
COVID O
- O
19 O
pandemic O
on O
antimicrobial O
prescribing O
. O

The O
current O
meta O
- O
analysis O
of O
retrospective O
studies O
was O
carried O
out O
to O
summarize O
available O
findings O
on O
the O
association O
between O
liver O
injury O
and O
severity O
of O
COVID O
- O
19 O
infection O
. O

Understanding O
these O
conditions O
of O
vulnerability O
can O
facilitate O
the O
development O
of O
strategies O
to O
monitor O
the O
evolution O
of O
COVID O
- O
19 O
and O
orient O
measures O
for O
prevention O
and O
health O
promotion O
. O

University O
buildings O
are O
one O
of O
the O
most O
relevant O
closed O
environments O
in O
which O
the O
COVID O
- O
19 O
event O
clearly O
pointed O
out O
stakeholders O
' O
needs O
toward O
safety O
issues O
, O
especially O
because O
of O
the O
possibility O
of O
day O
- O
to O
- O
day O
presences O
of O
the O
same O
users O
( O
i O
. O
e O
. O
students O
, O
teachers O
) O
and O
overcrowding O
causing O
long O
- O
lasting O
contacts O
with O
possible O
" O
infectors O
" O
. O

Treatment O
of O
out O
- O
of O
- O
hospital O
cardiac O
arrest O
in O
the O
COVID O
- O
19 O
era O
: O
A O
100 O
days O
experience O
from O
the O
Lombardy O
region O
. O

The O
Impact O
of O
COVID O
- O
19 O
on O
the O
Conduct O
of O
Clinical O
Trials O
for O
Medical O
Products O
in O
Korea O
. O

Estimating O
the O
risk O
of O
outbreaks O
of O
COVID O
- O
19 O
associated O
with O
shore O
leave O
by O
merchant O
ship O
crews O
: O
simulation O
studies O
for O
New O
Zealand O
. O

Presence O
of O
Genetic O
Variants O
Among O
Young O
Men O
With O
Severe O
COVID O
- O
19 O
. O

In O
the O
week O
prior O
to O
the O
conference O
, O
the O
severity O
of O
the O
COVID O
- O
19 O
pandemic O
in O
New O
York O
City O
and O
the O
USA O
was O
becoming O
apparent O
. O

Meningitis O
as O
an O
Initial O
Presentation O
of O
COVID O
- O
19 O
: O
A O
Case O
Report O
. O

COVID O
- O
19 O
infection O
poses O
a O
serious O
risk O
to O
patients O
and O
- O
due O
to O
its O
contagious O
nature O
- O
to O
those O
healthcare O
workers O
( O
HCWs O
) O
treating O
them O
. O

Possibility O
of O
using O
ultraviolet O
radiation O
for O
disinfecting O
the O
novel O
COVID O
- O
19 O
. O

Clinical O
Characteristics O
of O
47 O
Death O
Cases O
With O
COVID O
- O
19 O
: O
A O
Retrospective O
Study O
at O
a O
Tertiary O
Center O
in O
Lahore O
. O

The O
available O
evidence O
suggests O
that O
CQ O
or O
HCQ O
does O
not O
improve O
clinical O
outcomes O
in O
COVID O
- O
19 O
. O

Recent O
data O
indicate O
that O
severe O
COVID O
- O
19 O
causes O
a O
cytokine O
release O
storm O
and O
is O
associated O
with O
worse O
clinical O
outcomes O
and O
IL O
- O
6 O
plays O
an O
important O
role O
. O

The O
first O
patient O
received O
liver O
transplantation O
due O
to O
hepatitis O
B O
virus O
- O
related O
hepatocellular O
carcinoma O
and O
was O
confirmed O
to O
have O
COVID O
- O
19 O
9 O
days O
later O
. O

Use O
of O
mouthwashes O
against O
COVID O
- O
19 O
in O
dentistry O
. O

During O
the O
era O
of O
COVID O
- O
19 O
( O
COronaVIrus O
Disease O
of O
2019 O
) O
, O
telework O
has O
been O
adopted O
extensively O
in O
developing O
countries O
for O
the O
first O
time O
. O

In O
addition O
to O
the O
primary O
goals O
, O
the O
registry O
will O
provide O
a O
vital O
platform O
for O
characterizing O
the O
course O
, O
epidemiology O
, O
clinical O
features O
, O
and O
prognosis O
of O
patients O
tested O
for O
COVID O
- O
19 O
in O
the O
ED O
setting O
. O

The O
Meaning O
of O
Care O
and O
Ethics O
to O
Mitigate O
the O
Harshness O
of O
Triage O
in O
Second O
- O
Wave O
Scenario O
Planning O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Together O
, O
these O
results O
are O
the O
first O
to O
show O
the O
direct O
impact O
that O
the O
SARS O
- O
CoV O
- O
2 O
spike O
protein O
could O
have O
on O
brain O
endothelial O
cells O
; O
thereby O
offering O
a O
plausible O
explanation O
for O
the O
neurological O
consequences O
seen O
in O
COVID O
- O
19 O
patients O
. O

The O
findings O
from O
the O
case O
reports O
and O
case O
series O
indicate O
that O
the O
risk O
of O
death O
or O
severe O
disease O
from O
COVID O
- O
19 O
in O
HIV O
positive O
patients O
was O
lower O
than O
observed O
in O
the O
general O
population O
, O
which O
may O
indicate O
a O
possible O
protective O
effect O
of O
uncontrolled O
HIV O
in O
preventing O
the O
complications O
associated O
with O
the O
massive O
inflammatory O
response O
. O

COVID O
- O
19 O
- O
related O
demands O
were O
associated O
with O
greater O
work O
stress O
, O
and O
hence O
stronger O
COVID O
- O
19 O
vaccination O
intention O
. O

In O
seeking O
to O
limit O
the O
number O
of O
new O
infections O
of O
COVID O
- O
19 O
, O
governments O
around O
the O
world O
have O
implemented O
national O
lockdowns O
and O
guidelines O
about O
safe O
behaviours O
. O

While O
, O
initially O
body O
mass O
index O
( O
BMI O
) O
did O
not O
find O
a O
mention O
in O
the O
data O
, O
it O
is O
now O
clearly O
emerging O
that O
obesity O
is O
one O
of O
the O
profound O
risk O
factors O
for O
complications O
of O
COVID O
- O
19 O
. O

Cardiac O
Troponin O
I O
Is O
an O
Independent O
Predictor O
for O
Mortality O
in O
Hospitalized O
Patients O
With O
COVID O
- O
19 O
. O

Corrigendum O
to O
' O
The O
psychological O
impact O
of O
COVID O
- O
19 O
pandemic O
on O
health O
careworkers O
in O
a O
MERS O
- O
CoV O
endemic O
country O
' O
[ O
Journal O
of O
Infection O
and O
Public O
Health O
13 O
( O
2020 O
) O
877 O
- O
882 O
] O
. O

Epidemiological O
characteristics O
of O
COVID O
- O
19 O
patients O
in O
convalescence O
period O
. O

During O
the O
COVID O
- O
19 O
pandemic O
, O
the O
effectiveness O
of O
the O
combination O
of O
hydroxychloroquine O
and O
azithromycin O
is O
widely O
discussed O
. O

We O
performed O
a O
prospective O
cohort O
study O
of O
67 O
patients O
admitted O
to O
the O
hospital O
for O
COVID O
- O
19 O
pneumonia O
. O

Rescue O
therapy O
for O
severe O
COVID O
- O
19 O
- O
associated O
acute O
respiratory O
distress O
syndrome O
with O
tissue O
plasminogen O
activator O
: O
A O
case O
series O
. O

In O
order O
to O
facilitate O
the O
scientific O
community O
to O
fight O
against O
COVID O
- O
19 O
, O
we O
have O
developed O
a O
method O
for O
predicting O
IL O
- O
6 O
inducing O
peptides O
/ O
epitopes O
. O

An O
extensive O
environmental O
sampling O
campaign O
of O
both O
toilet O
and O
non O
- O
toilet O
environments O
was O
performed O
in O
a O
dedicated O
hospital O
building O
for O
patients O
with O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
and O
the O
associated O
environmental O
factors O
were O
analyzed O
. O

Conclusion O
: O
The O
Spanish O
adult O
population O
, O
especially O
young O
people O
, O
students O
and O
very O
active O
men O
, O
decreased O
daily O
self O
- O
reported O
PA O
and O
increased O
ST O
during O
COVID O
- O
19 O
confinement O
. O

Saliva O
was O
obtained O
from O
34 O
patients O
who O
had O
recovered O
from O
documented O
COVID O
- O
19 O
or O
had O
documented O
positive O
serologies O
. O

Diabetes O
has O
emerged O
as O
an O
important O
risk O
factor O
for O
severe O
illness O
and O
death O
from O
COVID O
- O
19 O
. O

During O
the O
COVID O
- O
19 O
pandemic O
, O
the O
management O
of O
patients O
suddenly O
changed O
and O
telemedicine O
has O
been O
proven O
to O
be O
as O
effective O
as O
outpatient O
care O
. O

We O
think O
the O
effect O
of O
IP O
was O
significant O
in O
this O
reduction O
; O
nevertheless O
, O
these O
are O
preliminary O
results O
that O
need O
larger O
- O
scale O
trials O
on O
COVID O
- O
19 O
patients O
. O

Gradually O
, O
it O
is O
seen O
that O
, O
many O
patients O
with O
COVID O
- O
19 O
infection O
have O
mild O
symptoms O
or O
are O
asymptomatic O
. O

Then O
, O
the O
actual O
data O
for O
each O
country O
were O
fitted O
to O
a O
regression O
model O
utilizing O
the O
excel O
solver O
software O
to O
assess O
the O
current O
and O
future O
trajectory O
of O
novel O
COVID O
- O
19 O
and O
its O
impact O
. O

The O
study O
analyzed O
retrospectively O
patients O
underwent O
chest O
CT O
at O
hospital O
admission O
for O
COVID O
- O
19 O
pneumonia O
suspicion O
, O
between O
February O
21 O
and O
March O
6 O
, O
2020 O
. O

Of O
1629 O
consecutive O
hospitalized O
adult O
patients O
with O
confirmed O
COVID O
- O
19 O
from O
March O
1st O
thru O
March O
31 O
, O
2020 O
, O
1461 O
patients O
were O
included O
in O
final O
analysis O
. O
327 O
patients O
died O
during O
hospitalization O
and O
1134 O
survived O
to O
discharge O
. O

We O
have O
done O
a O
comprehensive O
review O
of O
the O
literature O
using O
suitable O
keywords O
on O
the O
search O
engines O
of O
PubMed O
, O
SCOPUS O
, O
Google O
Scholar O
and O
Research O
Gate O
in O
the O
first O
week O
of O
May O
2020 O
including O
' O
COVID O
- O
19 O
' O
, O
' O
telemedicine O
' O
and O
' O
remote O
consultations O
' O
. O

Brief O
Report O
: O
Changes O
in O
PrEP O
Use O
, O
Sexual O
Practice O
, O
and O
Use O
of O
Face O
Mask O
During O
Sex O
Among O
MSM O
During O
the O
Second O
Wave O
of O
COVID O
- O
19 O
in O
Melbourne O
, O
Australia O
. O

Sofosbuvir O
/ O
daclatasvir O
regimens O
for O
the O
treatment O
of O
COVID O
- O
19 O
: O
an O
individual O
patient O
data O
meta O
- O
analysis O
. O

Mental O
Health O
Impact O
of O
COVID O
- O
19 O
in O
Radiation O
Oncology O
Health O
Care O
Workers O
of O
Asian O
Countries O
. O

These O
findings O
bear O
important O
implications O
for O
many O
other O
countries O
and O
regions O
to O
better O
understand O
and O
respond O
to O
their O
local O
epidemics O
associated O
with O
the O
ongoing O
COVID O
- O
19 O
pandemic O
. O

Several O
studies O
report O
outcomes O
of O
COVID O
- O
19 O
in O
predominately O
well O
persons O
. O

State O
and O
local O
governments O
imposed O
social O
distancing O
measures O
in O
March O
and O
April O
2020 O
to O
contain O
the O
spread O
of O
the O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
. O

The O
awareness O
, O
attitudes O
and O
actions O
survey O
which O
explores O
the O
impact O
of O
COVID O
- O
19 O
, O
on O
including O
access O
to O
healthcare O
, O
use O
of O
technology O
for O
health O
condition O
management O
, O
mental O
health O
, O
depression O
, O
well O
- O
being O
and O
lifestyle O
behaviours O
. O

Plasma O
provided O
by O
COVID O
- O
19 O
convalescent O
patients O
may O
provide O
therapeutic O
relief O
as O
the O
number O
of O
COVID O
- O
19 O
cases O
escalates O
steeply O
worldwide O
. O

Key O
Words O
: O
Health O
systems O
approach O
, O
COVID O
- O
19 O
pandemic O
, O
Quality O
of O
healthcare O
, O
Safe O
care O
. O

Among O
emergency O
medical O
services O
agencies O
with O
complete O
data O
on O
hospital O
survival O
( O
7085 O
total O
patients O
) O
, O
survival O
to O
discharge O
was O
lower O
during O
the O
pandemic O
compared O
with O
2019 O
( O
6 O
. O
6 O
% O
vs O
9 O
. O
8 O
% O
; O
adjusted O
RR O
, O
0 O
. O
83 O
[ O
95 O
% O
CI O
, O
0 O
. O
69 O
- O
1 O
. O
00 O
] O
; O
P O
= O
. O
048 O
) O
, O
primarily O
in O
communities O
with O
moderate O
to O
very O
high O
COVID O
- O
19 O
mortality O
( O
interaction O
P O
= O
. O
049 O
) O
. O

The O
emergence O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
; O
previously O
provisionally O
named O
2019 O
novel O
coronavirus O
or O
2019 O
- O
nCoV O
) O
disease O
( O
COVID O
- O
19 O
) O
in O
China O
at O
the O
end O
of O
2019 O
has O
caused O
a O
large O
global O
outbreak O
and O
is O
a O
major O
public O
health O
issue O
. O

COVID O
- O
19 O
: O
The O
New O
Ultrasound O
Alphabet O
in O
SARS O
- O
CoV O
- O
2 O
Era O
. O

Statistical O
regression O
analysis O
shows O
that O
such O
mobility O
reductions O
are O
significantly O
and O
negatively O
associated O
with O
COVID O
- O
19 O
growth O
rates O
two O
weeks O
later O
. O

In O
this O
paper O
, O
we O
show O
a O
strong O
correlation O
between O
turnstile O
entries O
data O
of O
the O
New O
York O
City O
( O
NYC O
) O
subway O
provided O
by O
NYC O
Metropolitan O
Transport O
Authority O
and O
COVID O
- O
19 O
deaths O
and O
cases O
reported O
by O
the O
NYC O
Department O
of O
Health O
from O
March O
to O
May O
2020 O
. O

Nurses O
at O
the O
Front O
Line O
of O
COVID O
- O
19 O
: O
Roles O
, O
Responsibilities O
, O
Risks O
, O
and O
Rights O
. O

Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
Outbreak O
in O
a O
San O
Francisco O
Homeless O
Shelter O
. O

Among O
the O
57 O
clinical O
samples O
from O
patients O
with O
COVID O
- O
19 O
, O
47 O
were O
tested O
positive O
by O
the O
kit O
B O
, O
while O
35 O
, O
29 O
, O
28 O
, O
30 O
, O
and O
29 O
were O
found O
positive O
by O
the O
kits O
A O
, O
C O
, O
D O
, O
E O
, O
and O
F O
, O
respectively O
. O

The O
global O
outbreak O
of O
COVID O
- O
19 O
has O
brought O
changes O
in O
adolescents O
' O
daily O
routines O
, O
restrictions O
to O
in O
- O
person O
interactions O
, O
and O
serious O
concerns O
about O
the O
situation O
. O

In O
addition O
, O
it O
can O
contribute O
to O
evaluate O
the O
immunogenicity O
of O
novel O
future O
vaccines O
and O
medicines O
for O
the O
treatment O
and O
prevention O
of O
COVID O
- O
19 O
disease O
. O

In O
April O
, O
as O
the O
COVID O
- O
19 O
outbreak O
intensified O
in O
New O
York O
City O
, O
a O
radiation O
oncology O
was O
redeployed O
to O
an O
internal O
medicine O
service O
. O

Will O
COVID O
- O
19 O
generate O
global O
preparedness O
? O

Nutritional O
status O
of O
micronutrients O
as O
a O
possible O
and O
modifiable O
risk O
factor O
for O
COVID O
- O
19 O
: O
a O
UK O
perspective O
. O

Approximately O
63 O
. O
9 O
% O
of O
patients O
with O
COVID O
- O
19 O
had O
an O
elevated O
D O
- O
dimer O
level O
on O
ICU O
admission O
. O

Support O
vector O
machine O
( O
SVM O
) O
demonstrated O
a O
promising O
detection O
accuracy O
after O
32 O
features O
were O
detected O
to O
be O
significantly O
associated O
with O
the O
COVID O
- O
19 O
severeness O
. O

We O
searched O
the O
electronic O
database O
of O
the O
two O
pediatric O
units O
of O
Mayo O
Hospital O
, O
Lahore O
, O
Pakistan O
, O
for O
children O
who O
had O
been O
admitted O
to O
the O
ward O
between O
April O
2020 O
and O
July O
2020 O
and O
were O
diagnosed O
with O
COVID O
- O
19 O
. O

Classic O
, O
indeterminate O
, O
normal O
and O
non O
- O
COVID O
- O
19 O
manifestations O
on O
both O
the O
18FDG O
- O
PETand O
low O
dose O
CT O
component O
are O
described O
as O
an O
aid O
for O
radiologists O
and O
nuclear O
medicine O
physicians O
when O
reporting O
18FDG O
PET O
/ O
CT O
. O

These O
results O
suggest O
the O
need O
to O
further O
assess O
the O
long O
terms O
risks O
of O
prolonged O
QT O
dispersion O
in O
the O
setting O
of O
COVID O
- O
19 O
infection O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
an O
emerging O
infectious O
disease O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

To O
assess O
the O
impact O
of O
work O
- O
related O
changes O
on O
the O
mental O
health O
( O
MH O
) O
of O
dentists O
during O
the O
peak O
of O
COVID O
- O
19 O
pandemic O
in O
the O
UK O
. O

Nursing O
' O
s O
response O
to O
COVID O
- O
19 O
: O
Lessons O
learned O
from O
SARS O
in O
Taiwan O
. O

Some O
studies O
have O
demonstrated O
a O
significant O
number O
of O
false O
- O
negative O
RT O
- O
PCR O
tests O
while O
displaying O
significant O
tomographic O
findings O
, O
in O
the O
early O
days O
of O
symptoms O
of O
COVID O
- O
19 O
. O

Safety O
and O
effectiveness O
concerns O
of O
lopinavir O
/ O
ritonavir O
in O
COVID O
- O
19 O
affected O
patients O
: O
a O
retrospective O
series O
. O

The O
COVID O
- O
19 O
outbreak O
is O
deeply O
influencing O
the O
global O
social O
and O
economic O
framework O
, O
due O
to O
restrictive O
measures O
adopted O
worldwide O
by O
governments O
to O
counteract O
the O
pandemic O
contagion O
. O

No O
direct O
link O
was O
found O
between O
fear O
of O
COVID O
- O
19 O
and O
quality O
of O
life O
. O

World O
Health O
Organization O
has O
declared O
the O
ongoing O
outbreak O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
a O
Public O
Health O
Emergency O
of O
International O
Concern O
. O

The O
Impact O
of O
COVID O
- O
19 O
Pandemic O
in O
Children O
With O
Cancer O
: O
A O
Report O
From O
Saudi O
Arabia O
. O

In O
the O
void O
created O
by O
a O
lack O
of O
clinical O
experience O
with O
COVID O
- O
19 O
, O
artificial O
intelligence O
( O
AI O
) O
may O
be O
an O
important O
tool O
to O
bolster O
clinical O
judgment O
and O
decision O
making O
. O

Among O
the O
weather O
indicators O
, O
temperature O
( O
° O
C O
) O
was O
found O
to O
have O
a O
negative O
correlation O
, O
while O
humidity O
and O
air O
quality O
highlighted O
a O
positive O
correlation O
with O
daily O
new O
cases O
of O
COVID O
- O
19 O
in O
New O
Jersey O
. O

Secondary O
Cerebrovascular O
Prevention O
in O
Light O
of O
the O
COVID O
- O
19 O
Pandemic O
. O

We O
collected O
data O
on O
demographic O
information O
, O
comorbidities O
, O
preoperative O
COVID O
- O
19 O
test O
results O
, O
whether O
COVID O
- O
19 O
respiratory O
or O
other O
symptoms O
were O
developed O
during O
hospitalization O
, O
hospital O
length O
of O
stay O
, O
discharge O
disposition O
, O
and O
postoperative O
COVID O
- O
19 O
test O
results O
. O

On O
CPD O
analysis O
, O
COVID O
- O
19 O
was O
associated O
with O
increased O
volume O
of O
neutrophils O
, O
lymphocytes O
, O
and O
monocytes O
, O
whereas O
conductivity O
was O
decreased O
for O
neutrophils O
and O
increased O
for O
lymphocytes O
. O

Potential O
therapeutic O
value O
of O
dexmedetomidine O
in O
COVID O
- O
19 O
patients O
admitted O
to O
ICU O
. O

Internationally O
lost O
COVID O
- O
19 O
cases O
. O

Since O
there O
are O
already O
ample O
of O
articles O
on O
the O
background O
, O
development O
timeline O
, O
and O
overall O
commentary O
, O
this O
paper O
adopts O
a O
mixed O
approach O
by O
combining O
supplementary O
secondary O
data O
on O
the O
COVID O
- O
19 O
timeline O
in O
Macao O
( O
focusing O
on O
government O
interventions O
that O
can O
affect O
the O
tourism O
and O
hospitality O
industry O
) O
and O
primary O
qualitative O
in O
- O
depth O
interviews O
with O
senior O
management O
personnel O
( O
holding O
positions O
of O
Director O
or O
above O
) O
from O
major O
integrated O
resorts O
in O
Macao O
to O
get O
insights O
on O
industry O
strategic O
responses O
and O
expectation O
on O
future O
. O

The O
proportion O
of O
employees O
with O
poor O
COVID O
- O
19 O
prevention O
was O
high O
. O

Kawa O
- O
COVID O
- O
19 O
likely O
represents O
a O
new O
systemic O
inflammatory O
syndrome O
temporally O
associated O
with O
SARS O
- O
CoV O
- O
2 O
infection O
in O
children O
. O

We O
aimed O
to O
describe O
the O
epidemiology O
of O
cardiac O
arrhythmias O
in O
ICU O
patients O
with O
COVID O
- O
19 O
. O

With O
the O
COVID O
- O
19 O
outbreak O
, O
that O
emerged O
in O
China O
in O
December O
2019 O
and O
went O
global O
, O
leading O
to O
a O
pandemic O
, O
it O
is O
seen O
that O
debates O
on O
" O
global O
risk O
society O
" O
started O
again O
in O
the O
media O
and O
among O
social O
scientists O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
a O
highly O
transmissible O
and O
pathogenic O
coronavirus O
that O
emerged O
in O
late O
2019 O
and O
has O
caused O
a O
pandemic O
of O
acute O
respiratory O
disease O
, O
named O
' O
coronavirus O
disease O
2019 O
' O
( O
COVID O
- O
19 O
) O
, O
which O
threatens O
human O
health O
and O
public O
safety O
. O

Individuals O
with O
higher O
education O
experienced O
a O
greater O
increase O
in O
depressive O
symptoms O
and O
a O
greater O
decrease O
in O
life O
satisfaction O
from O
before O
to O
during O
COVID O
- O
19 O
in O
comparison O
to O
those O
with O
lower O
education O
. O

Comment O
on O
: O
" O
Controversies O
regarding O
mask O
usage O
in O
ophthalmic O
units O
in O
the O
United O
Kingdom O
during O
the O
COVID O
- O
19 O
pandemic O
" O
. O

Modelling O
the O
effects O
of O
media O
coverage O
and O
quarantine O
on O
the O
COVID O
- O
19 O
infections O
in O
the O
UK O
. O

CSANZ O
Position O
Statement O
on O
the O
Evaluation O
of O
Patients O
Presenting O
With O
Suspected O
Acute O
Coronary O
Syndromes O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Teicoplanin O
: O
an O
alternative O
drug O
for O
the O
treatment O
of O
COVID O
- O
19 O
? O

In O
the O
midst O
of O
the O
COVID O
- O
19 O
pandemic O
, O
United O
States O
( O
U O
. O
S O
. O
) O
educational O
institutions O
must O
weigh O
incomplete O
scientific O
evidence O
to O
inform O
decisions O
about O
how O
best O
to O
re O
- O
open O
schools O
without O
sacrificing O
public O
health O
. O

To O
determine O
CT O
' O
s O
role O
in O
the O
early O
detection O
of O
COVID O
- O
19 O
infection O
and O
serial O
CT O
changes O
in O
the O
disease O
course O
in O
patients O
with O
COVID O
- O
19 O
pneumonia O
. O

The O
clinical O
performance O
of O
the O
BD O
Veritor O
System O
for O
Rapid O
Detection O
of O
SARS O
- O
CoV O
- O
2 O
nucleocapsid O
antigen O
( O
Veritor O
) O
, O
a O
chromatographic O
immunoassay O
used O
for O
SARS O
- O
CoV O
- O
2 O
point O
- O
of O
- O
care O
testing O
, O
was O
evaluated O
using O
nasal O
specimens O
from O
individuals O
with O
COVID O
- O
19 O
symptoms O
. O

A O
COVID O
- O
19 O
- O
associated O
prothrombotic O
state O
has O
been O
mentioned O
in O
multiple O
recent O
research O
articles O
. O

Kidney O
function O
on O
admission O
predicts O
in O
- O
hospital O
mortality O
in O
COVID O
- O
19 O
. O

COVID O
- O
19 O
emergency O
in O
the O
hospital O
: O
How O
the O
clinical O
psychology O
unit O
is O
responding O
. O

In O
the O
propensity O
score O
- O
matched O
analysis O
, O
the O
adjusted O
hazard O
ratio O
for O
suspected O
/ O
confirmed O
COVID O
- O
19 O
, O
confirmed O
COVID O
- O
19 O
, O
and O
COVID O
- O
19 O
related O
mortality O
were O
0 O
. O
85 O
( O
95 O
% O
CI O
0 O
. O
67 O
, O
1 O
. O
08 O
) O
, O
0 O
. O
80 O
( O
95 O
% O
CI O
0 O
. O
49 O
, O
1 O
. O
30 O
) O
, O
and O
0 O
. O
87 O
( O
95 O
% O
CI O
0 O
. O
34 O
, O
2 O
. O
20 O
) O
respectively O
. O

The O
calm O
after O
the O
storm O
: O
re O
- O
starting O
ART O
treatments O
safely O
in O
the O
wake O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Based O
on O
these O
previous O
results O
in O
patients O
with O
psoriasis O
and O
rheumatoid O
arthritis O
, O
an O
expanded O
access O
clinical O
trial O
was O
approved O
by O
the O
Cuban O
regulatory O
agency O
for O
COVID O
- O
19 O
critically O
, O
severely O
and O
moderately O
ill O
patients O
. O

Findings O
From O
an O
estimated O
340 O
residency O
programs O
around O
NYC O
, O
recruitment O
yielded O
91 O
responses O
, O
representing O
24 O
specialties O
and O
2 O
, O
306 O
residents O
. O
45 O
. O
1 O
% O
of O
programs O
reported O
at O
least O
one O
resident O
with O
confirmed O
COVID O
- O
19 O
: O
101 O
resident O
physicians O
were O
confirmed O
COVID O
- O
19 O
- O
positive O
, O
with O
additional O
163 O
residents O
presumed O
positive O
for O
COVID O
- O
19 O
based O
on O
symptoms O
but O
awaiting O
or O
unable O
to O
obtain O
testing O
. O
56 O
. O
5 O
% O
of O
programs O
had O
a O
resident O
waiting O
for O
, O
or O
unable O
to O
obtain O
, O
COVID O
- O
19 O
testing O
. O

To O
fight O
the O
COVID O
- O
19 O
pandemic O
, O
lockdown O
has O
been O
decreed O
in O
many O
countries O
worldwide O
. O

This O
study O
aimed O
to O
assess O
their O
psychological O
health O
status O
at O
the O
peak O
of O
COVID O
- O
19 O
and O
to O
identify O
some O
coping O
strategies O
. O

Antibodies O
in O
the O
breast O
milk O
of O
a O
maternal O
woman O
with O
COVID O
- O
19 O
. O

Inclusion O
Criteria O
: O
• O
Provision O
of O
informed O
consent O
by O
the O
participant O
• O
Age O
≥ O
18 O
years O
• O
Confirmed O
SARS O
- O
CoV O
- O
2 O
by O
nucleic O
acid O
testing O
in O
the O
past O
5 O
days O
• O
COVID O
- O
19 O
related O
symptom O
initiation O
within O
5 O
days O
• O
Female O
patients O
of O
childbearing O
potential O
must O
have O
a O
negative O
pregnancy O
test O
at O
Screening O
. O

Mapping O
the O
T O
cell O
response O
to O
COVID O
- O
19 O
. O

Adaptive O
innovations O
to O
provide O
services O
to O
children O
with O
developmental O
disabilities O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
top O
three O
sources O
of O
COVID O
- O
19 O
vaccine O
information O
were O
health O
agencies O
( O
57 O
. O
7 O
% O
) O
, O
mass O
media O
( O
49 O
. O
5 O
% O
) O
, O
and O
personal O
social O
networks O
( O
40 O
. O
5 O
% O
) O
. O

Are O
Medicinal O
Plants O
an O
Alternative O
Strategy O
to O
Combat O
COVID O
- O
19 O
? O

The O
novel O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
has O
had O
a O
significant O
impact O
on O
public O
health O
, O
economic O
activity O
, O
and O
mental O
health O
as O
it O
spread O
across O
the O
globe O
. O

At O
present O
, O
no O
vaccines O
or O
therapeutic O
regimens O
with O
proven O
efficacy O
are O
available O
for O
the O
management O
of O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
in O
March O
of O
2020 O
necessitated O
the O
removal O
of O
medical O
students O
from O
direct O
patient O
care O
activities O
to O
prevent O
disease O
spread O
and O
to O
conserve O
personal O
protective O
equipment O
. O

Among O
the O
first O
2118 O
articles O
on O
COVID O
- O
19 O
published O
in O
scholarly O
journals O
, O
533 O
( O
25 O
% O
) O
contained O
original O
data O
. O

Although O
scientific O
information O
on O
COVID O
- O
19 O
is O
constantly O
increasing O
, O
it O
mainly O
focuses O
on O
genetic O
, O
epidemiological O
aspects O
, O
and O
public O
health O
measures O
, O
leaving O
aside O
possible O
effects O
on O
mental O
health O
. O

[ O
Commercial O
airline O
routes O
and O
international O
distribution O
of O
COVID O
- O
19 O
] O
. O

The O
early O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
adults O
with O
type O
1 O
or O
type O
2 O
diabetes O
: O
A O
national O
cohort O
study O
. O

Scrutinizing O
the O
heterogeneous O
spreading O
of O
COVID O
- O
19 O
outbreak O
in O
large O
territorial O
countries O
. O

Possibilities O
and O
pitfalls O
? O
Moderate O
drinking O
and O
alcohol O
abstinence O
at O
home O
since O
the O
COVID O
- O
19 O
lockdown O
. O

We O
describe O
5 O
patients O
with O
previously O
known O
type O
2 O
diabetes O
and O
no O
history O
of O
DKA O
, O
who O
presented O
to O
the O
emergency O
department O
with O
new O
- O
onset O
DKA O
and O
COVID O
- O
19 O
. O

The O
antimalarials O
chloroquine O
( O
CQ O
) O
and O
its O
analog O
, O
hydroxychloroquine O
( O
HCQ O
) O
, O
have O
been O
tested O
for O
COVID O
- O
19 O
treatment O
, O
and O
several O
conflicting O
evidence O
has O
been O
obtained O
. O

We O
evaluate O
this O
universal O
testing O
approach O
in O
the O
STRIDE O
individual O
- O
based O
epidemiological O
model O
in O
the O
context O
of O
the O
Belgian O
COVID O
- O
19 O
epidemic O
. O

Italy O
was O
the O
first O
country O
after O
China O
to O
be O
affected O
by O
COVID O
- O
19 O
. O

The O
RCTs O
selected O
compared O
any O
type O
of O
convalescent O
plasma O
vs O
placebo O
or O
standard O
of O
care O
for O
patients O
with O
confirmed O
or O
suspected O
COVID O
- O
19 O
in O
any O
treatment O
setting O
. O

Results O
: O
Of O
149 O
patients O
, O
35 O
were O
hospitalized O
in O
the O
COVID O
- O
19 O
restrictions O
period O
. O

COVID O
- O
19 O
virus O
and O
children O
: O
What O
do O
we O
know O
? O

Response O
of O
major O
air O
pollutants O
to O
COVID O
- O
19 O
lockdowns O
in O
China O
. O

To O
assess O
the O
differences O
in O
mean O
scores O
, O
and O
identify O
factors O
associated O
with O
knowledge O
, O
attitudes O
, O
and O
practices O
toward O
COVID O
- O
19 O
, O
the O
data O
were O
run O
through O
univariate O
and O
multivariable O
regression O
analyses O
, O
respectively O
. O

However O
, O
no O
targeted O
medication O
or O
vaccines O
for O
COVID O
- O
19 O
are O
yet O
available O
. O

Of O
the O
latter O
, O
411 O
were O
involved O
with O
the O
COVID O
- O
19 O
response O
, O
of O
whom O
315 O
( O
77 O
% O
) O
were O
applying O
their O
acquired O
skills O
in O
85 O
countries O
. O

Ethical O
obligations O
for O
supporting O
healthcare O
workers O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Improving O
integration O
between O
data O
systems O
, O
utilizing O
specialized O
alerts O
, O
and O
expanding O
telehealth O
represent O
strategies O
that O
hospitals O
should O
consider O
when O
using O
HIT O
for O
delivering O
hospital O
care O
in O
the O
context O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Out O
of O
a O
total O
of O
3641 O
articles O
related O
to O
COVID O
- O
19 O
, O
only O
26 O
( O
0 O
. O
7 O
% O
) O
articles O
had O
an O
educational O
theme O
. O

As O
an O
aerosol O
- O
generating O
procedure O
, O
tracheostomy O
increases O
the O
exposure O
of O
health O
care O
workers O
to O
COVID O
- O
19 O
infection O
. O

The O
Radiology O
Virtual O
Reading O
Room O
: O
During O
and O
Beyond O
the O
COVID O
- O
19 O
Pandemic O
. O

Ulcer O
pressure O
prevention O
and O
opportunity O
for O
innovation O
during O
the O
COVID O
- O
19 O
crisis O
. O

The O
psychological O
impact O
of O
COVID O
- O
19 O
among O
a O
sample O
of O
Italian O
patients O
with O
functional O
neurological O
disorders O
: O
A O
preliminary O
study O
. O

Biobanked O
pre O
- O
COVID O
- O
19 O
plasma O
from O
these O
SLE O
subjects O
and O
healthy O
controls O
were O
tested O
for O
anti O
- O
IFN O
α O
IgG O
autoantibodies O
by O
ELISA O
. O

Further O
, O
this O
study O
provides O
support O
for O
a O
questionnaire O
measure O
of O
experiences O
related O
to O
the O
COVID O
- O
19 O
pandemic O
that O
can O
be O
applied O
in O
future O
work O
to O
advance O
understanding O
of O
risk O
and O
resilience O
in O
response O
to O
stressful O
events O
. O

Staff O
Mental O
Health O
Self O
- O
Assessment O
During O
the O
COVID O
- O
19 O
Outbreak O
. O

The O
majority O
of O
residents O
( O
66 O
% O
) O
perceived O
that O
residents O
were O
at O
higher O
risk O
of O
contracting O
COVID O
- O
19 O
compared O
to O
attendings O
. O

The O
COVID O
- O
19 O
crisis O
is O
a O
stark O
reminder O
that O
modern O
society O
is O
vulnerable O
to O
a O
special O
species O
of O
trouble O
: O
the O
creeping O
crisis O
. O

Due O
to O
COVID O
- O
19 O
, O
various O
countries O
introduced O
lockdowns O
and O
limited O
citizen O
movements O
. O

State O
- O
level O
Stay O
- O
at O
- O
home O
Orders O
and O
Objectively O
Measured O
Movement O
in O
the O
United O
States O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Triage O
Considerations O
for O
Patients O
Referred O
for O
Structural O
Heart O
Disease O
Intervention O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
An O
ACC O
/ O
SCAI O
Position O
Statement O
. O

The O
prevalence O
of O
Abnormal O
Liver O
function O
tests O
in O
patients O
of O
COVID O
- O
19 O
is O
59 O
. O
04 O
% O
. O

Patients O
with O
iRMD O
on O
corticosteroids O
, O
but O
not O
methotrexate O
, O
or O
tumour O
necrosis O
factor O
alpha O
and O
interleukin O
- O
6 O
inhibitors O
, O
should O
be O
considered O
as O
more O
likely O
to O
develop O
severe O
COVID O
- O
19 O
. O

Since O
the O
identification O
of O
critical O
patients O
is O
crucial O
for O
developing O
effective O
management O
strategies O
, O
we O
evaluated O
clinical O
characteristics O
, O
laboratory O
data O
, O
treatment O
provided O
, O
and O
oxygenation O
to O
identify O
potential O
predictors O
of O
mortality O
among O
critical O
COVID O
- O
19 O
pneumonia O
patients O
. O

Chemosensory O
Dysfunction O
in O
COVID O
- O
19 O
: O
Integration O
of O
Genetic O
and O
Epidemiological O
Data O
Points O
to O
D614G O
Spike O
Protein O
Variant O
as O
a O
Contributing O
Factor O
. O

The O
crisis O
in O
the O
health O
system O
caused O
by O
COVID O
- O
19 O
has O
left O
some O
important O
humanitarian O
deficits O
on O
how O
to O
care O
for O
the O
sick O
in O
their O
last O
days O
of O
life O
. O

COVID O
- O
19 O
and O
OCD O
: O
Potential O
impact O
of O
exposure O
and O
response O
prevention O
therapy O
. O

The O
COVID O
- O
19 O
pandemic O
has O
changed O
psychopharmacologica O
prescribing O
and O
management O
of O
patients O
around O
the O
world O
. O

Thus O
far O
, O
history O
and O
science O
are O
directing O
towards O
an O
immense O
potential O
impact O
of O
air O
pollution O
on O
the O
COVID O
- O
19 O
pandemic O
. O

Lung O
ultrasonography O
, O
a O
rapid O
, O
reliable O
, O
bedside O
, O
nonradiating O
and O
repeatable O
examination O
, O
with O
its O
sensitivity O
closed O
to O
chest O
CT O
and O
much O
higher O
than O
the O
chest O
X O
- O
ray O
for O
COVID O
patients O
, O
has O
proved O
to O
be O
in O
COVID O
- O
19 O
pandemic O
as O
crucial O
diagnostic O
and O
monitoring O
tool O
of O
patients O
with O
acute O
respiratory O
failure O
. O

Take O
proactive O
measures O
for O
the O
pandemic O
COVID O
- O
19 O
infection O
in O
the O
dialysis O
facilities O
. O

These O
data O
were O
compared O
to O
real O
- O
world O
confirmed O
cases O
and O
deaths O
of O
COVID O
- O
19 O
. O

Multimodality O
Imaging O
for O
Cardiac O
Evaluation O
in O
Patients O
with O
COVID O
- O
19 O
. O

Evaluation O
of O
Job O
Strain O
of O
Family O
Physicians O
in O
COVID O
- O
19 O
Pandemic O
Period O
- O
An O
Example O
from O
Turkey O
. O

Dysregulated O
IL O
- O
1 O
β O
and O
IL O
- O
6 O
responses O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
severe O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

To O
investigate O
the O
computed O
tomography O
( O
CT O
) O
characteristics O
and O
diagnostic O
value O
of O
novel O
coronavirus O
pneumonia O
( O
NCP O
or O
COVID O
- O
19 O
) O
in O
pregnancy O
. O

To O
analyze O
the O
incidence O
of O
the O
clinical O
presentations O
suggestive O
for O
COVID O
- O
19 O
infection O
among O
patients O
with O
Multiple O
Sclerosis O
in O
the O
province O
of O
Lecco O
, O
in O
the O
North O
Italy O
, O
the O
closest O
province O
capital O
to O
Bergamo O
. O

Teaching O
biochemistry O
and O
molecular O
biology O
online O
in O
Nigeria O
: O
Missed O
opportunities O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
present O
article O
assesses O
the O
effects O
of O
shattered O
social O
identity O
and O
moral O
injuries O
experienced O
by O
health O
care O
professionals O
( O
HCPs O
) O
due O
to O
the O
COVID O
- O
19 O
pandemic O
. O

We O
included O
all O
260 O
patients O
with O
COVID O
- O
19 O
admitted O
to O
nine O
ICUs O
at O
the O
Karolinska O
University O
Hospital O
( O
Stockholm O
, O
Sweden O
) O
between O
9 O
March O
and O
20 O
April O
2020 O
. O

We O
discuss O
ongoing O
solar O
energy O
safety O
net O
programs O
in O
the O
largest O
off O
- O
grid O
solar O
markets O
of O
Bangladesh O
, O
India O
, O
Kenya O
, O
and O
Nigeria O
, O
and O
how O
such O
programs O
are O
affected O
by O
the O
COVID O
- O
19 O
pandemic O
. O

Pulmonary O
sequelae O
of O
pediatric O
patients O
after O
discharge O
for O
COVID O
- O
19 O
: O
An O
observational O
study O
. O

Background O
: O
The O
year O
2020 O
has O
been O
marked O
by O
the O
emergence O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Rationale O
and O
evidence O
on O
the O
use O
of O
tocilizumab O
in O
COVID O
- O
19 O
: O
A O
systematic O
review O
. O
Authors O
' O
reply O
. O

In O
this O
prospective O
study O
, O
diffusion O
tensor O
imaging O
( O
DTI O
) O
and O
3D O
high O
- O
resolution O
T1WI O
sequences O
were O
acquired O
in O
60 O
recovered O
COVID O
- O
19 O
patients O
( O
56 O
. O
67 O
% O
male O
; O
age O
: O
44 O
. O
10 O
± O
16 O
. O
00 O
) O
and O
39 O
age O
- O
and O
sex O
- O
matched O
non O
- O
COVID O
- O
19 O
controls O
( O
56 O
. O
41 O
% O
male O
; O
age O
: O
45 O
. O
88 O
± O
13 O
. O
90 O
) O
. O

Host O
excessive O
inflammatory O
immune O
response O
to O
SARS O
- O
CoV O
- O
2 O
infection O
is O
thought O
to O
underpin O
the O
pathogenesis O
of O
COVID O
- O
19 O
associated O
severe O
pneumonitis O
and O
acute O
lung O
injury O
( O
ALI O
) O
or O
acute O
respiratory O
distress O
syndrome O
( O
ARDS O
) O
. O

T O
- O
cell O
dysregulation O
in O
COVID O
- O
19 O
. O

It O
is O
believed O
that O
COVID O
- O
19 O
, O
in O
those O
with O
underlying O
health O
conditions O
or O
comorbidities O
, O
has O
an O
increasingly O
rapid O
and O
severe O
progression O
, O
often O
leading O
to O
death O
. O

The O
COVID O
- O
19 O
mortality O
rate O
in O
people O
< O
65 O
years O
old O
during O
the O
period O
of O
fatalities O
from O
the O
epidemic O
was O
equivalent O
to O
the O
mortality O
rate O
from O
driving O
between O
4 O
and O
82 O
miles O
per O
day O
for O
13 O
countries O
and O
5 O
states O
, O
and O
was O
higher O
( O
equivalent O
to O
the O
mortality O
rate O
from O
driving O
106 O
- O
483 O
miles O
per O
day O
) O
for O
8 O
other O
states O
and O
the O
UK O
. O

In O
areas O
with O
a O
high O
rate O
of O
dengue O
fever O
, O
serological O
screening O
for O
dengue O
fever O
should O
be O
considered O
as O
part O
of O
COVID O
- O
19 O
investigation O
, O
especially O
if O
symptoms O
or O
a O
full O
blood O
count O
are O
suggestive O
. O

The O
lack O
of O
effective O
pharmaceutical O
interventions O
for O
SARS O
- O
CoV O
- O
2 O
raises O
the O
possibility O
of O
COVID O
- O
19 O
recurrence O
. O

Although O
the O
necessity O
to O
use O
online O
methods O
during O
the O
COVID O
- O
19 O
pandemic O
may O
have O
accelerated O
awareness O
, O
concerns O
over O
workload O
duplication O
and O
inequality O
of O
access O
may O
remain O
. O

The O
COVID O
- O
19 O
pandemic O
is O
an O
unprecedented O
event O
with O
wide O
- O
ranging O
implications O
. O

To O
preserve O
resources O
in O
preparation O
for O
a O
COVID O
- O
19 O
surge O
, O
Boston O
Medical O
Center O
( O
BMC O
) O
implemented O
workflows O
to O
decrease O
ambulatory O
in O
- O
person O
visits O
effective O
March O
16th O
, O
2020 O
. O

Psychological O
Stressors O
Predicting O
Increased O
Drinking O
During O
the O
COVID O
- O
19 O
Crisis O
: O
A O
Longitudinal O
National O
Survey O
Study O
of O
Workers O
in O
Finland O
. O

Total O
operative O
cases O
fell O
by O
a O
third O
during O
the O
COVID O
- O
19 O
outbreak O
. O

Impact O
of O
COVID O
- O
19 O
on O
maxillofacial O
surgery O
practice O
: O
a O
worldwide O
survey O
. O

This O
structural O
and O
functional O
analysis O
illustrates O
why O
mutations O
at O
E484 O
and O
K417 O
adversely O
affect O
major O
classes O
of O
nAbs O
to O
SARS O
- O
CoV O
- O
2 O
with O
consequences O
for O
next O
- O
generation O
COVID O
- O
19 O
vaccines O
. O

Last O
, O
we O
review O
the O
current O
evidence O
on O
drugs O
which O
have O
been O
evaluated O
or O
are O
currently O
tested O
for O
the O
treatment O
of O
COVID O
- O
19 O
patients O
. O

How O
is O
COVID O
- O
19 O
pandemic O
impacting O
mental O
health O
of O
children O
and O
adolescents O
? O

We O
firstly O
suggest O
that O
as O
a O
result O
of O
the O
health O
and O
economic O
impacts O
associated O
with O
COVID O
- O
19 O
, O
credit O
- O
taking O
is O
likely O
to O
escalate O
further O
in O
terms O
of O
the O
number O
of O
borrowers O
and O
loan O
amounts O
. O

Reimagining O
Residency O
Selection O
: O
Part O
3 O
- O
A O
Practical O
Guide O
to O
Ranking O
Applicants O
in O
the O
Post O
- O
COVID O
- O
19 O
Era O
. O

Here O
, O
we O
review O
the O
lung O
POCUS O
findings O
in O
patients O
with O
COVID O
- O
19 O
. O

Therefore O
, O
the O
present O
systematic O
review O
and O
meta O
- O
analysis O
was O
undertaken O
to O
explore O
the O
feasibility O
of O
rapid O
diagnostic O
tests O
in O
the O
management O
of O
the O
COVID O
- O
19 O
outbreak O
. O

Fifteen O
paper O
compromising O
5 O
studies O
on O
COVID O
- O
19 O
, O
8 O
studies O
on O
SARS O
- O
CoV O
and O
2 O
studies O
on O
MERS O
- O
CoV O
were O
included O
. O

Therefore O
, O
in O
each O
case O
it O
is O
necessary O
to O
study O
the O
interaction O
and O
mutual O
influence O
of O
different O
components O
of O
the O
treatment O
program O
prescribed O
to O
such O
patients O
. O
The O
purpose O
of O
this O
work O
was O
to O
evaluate O
the O
effect O
of O
coagulation O
activity O
on O
the O
course O
of O
a O
novel O
coronavirus O
infection O
( O
COVID O
- O
19 O
) O
and O
to O
justify O
the O
management O
of O
comorbid O
patients O
having O
been O
received O
novel O
oral O
anticoagulants O
( O
NOACs O
) O
in O
previously O
selected O
doses O
according O
to O
indications O
in O
concomitant O
somatic O
diseases O
. O

This O
institutional O
review O
board O
- O
approved O
, O
retrospective O
study O
assessed O
all O
patients O
with O
diagnostic O
radiology O
examinations O
performed O
at O
an O
academic O
medical O
center O
with O
eight O
affiliated O
outpatient O
facilities O
before O
( O
January O
1 O
, O
2020 O
, O
to O
March O
8 O
, O
2020 O
) O
and O
after O
( O
June O
7 O
, O
2020 O
, O
to O
July O
15 O
, O
2020 O
) O
the O
COVID O
- O
19 O
shutdown O
. O

Return O
to O
school O
in O
the O
COVID O
- O
19 O
era O
: O
considerations O
for O
temperature O
measurement O
. O

Results O
from O
our O
study O
suggest O
that O
all O
children O
are O
at O
risk O
of O
COVID O
- O
19 O
infection O
though O
they O
may O
present O
with O
mild O
illness O
or O
no O
symptoms O
. O

Among O
39 O
COVID O
- O
19 O
cases O
, O
10 O
were O
asymptomatic O
and O
37 O
were O
imported O
from O
aboard O
. O

Therefore O
, O
the O
aim O
of O
this O
systematic O
review O
and O
meta O
- O
analysis O
to O
ascertain O
the O
present O
impact O
of O
the O
COVID O
- O
19 O
outbreak O
on O
the O
prevalence O
of O
stress O
, O
anxiety O
, O
depression O
and O
sleep O
disturbance O
among O
nurses O
. O

Real O
time O
polymerase O
chain O
reaction O
( O
RT O
- O
PCR O
) O
testing O
confirmed O
COVID O
- O
19 O
. O

Hence O
, O
dexamethasone O
may O
be O
useful O
for O
the O
short O
- O
term O
in O
severe O
, O
intubated O
, O
COVID O
- O
19 O
patients O
, O
but O
could O
be O
outright O
dangerous O
during O
recovery O
since O
the O
virus O
will O
not O
only O
persist O
, O
but O
the O
body O
will O
be O
prevented O
from O
generating O
protective O
antibodies O
. O

Most O
of O
the O
donors O
know O
COVID O
- O
19 O
, O
its O
transmission O
routes O
and O
manifestations O
. O

Coronavirus O
pandemic O
( O
COVID O
- O
19 O
) O
has O
infected O
more O
than O
ten O
million O
persons O
worldwide O
. O

In O
addition O
to O
re O
- O
evaluating O
the O
control O
of O
the O
COVID O
- O
19 O
epidemic O
in O
China O
, O
this O
study O
provided O
a O
model O
for O
monitoring O
outbreaks O
of O
COVID O
- O
19 O
in O
different O
countries O
across O
the O
world O
. O

COVID O
- O
19 O
, O
Substance O
Use O
, O
Anorexia O
Nervosa O
, O
22q11 O
. O
2 O
Deletion O
Syndrome O
, O
and O
Stress O
. O

Clinical O
trials O
should O
also O
be O
undertaken O
to O
use O
statins O
, O
which O
are O
lipid O
- O
lowering O
drugs O
but O
have O
anti O
- O
inflammatory O
and O
immunomodulatory O
properties O
to O
prevent O
acute O
lung O
injury O
in O
COVID O
- O
19 O
infection O
. O

Obstructive O
Sleep O
Apnea O
, O
Obesity O
, O
and O
Noninvasive O
Ventilation O
: O
Considerations O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
continues O
to O
spread O
rapidly O
worldwide O
. O

Single O
- O
cell O
RNAseq O
( O
scRNAseq O
) O
- O
based O
deconvolution O
of O
genomic O
states O
of O
peripheral O
immune O
cells O
revealed O
distinct O
gene O
modules O
that O
were O
associated O
with O
COVID O
- O
19 O
outcome O
. O

Generally O
, O
COVID O
- O
19 O
has O
three O
possible O
transmission O
routes O
, O
including O
pre O
- O
symptomatic O
, O
symptomatic O
and O
asymptomatic O
transmission O
, O
among O
which O
the O
last O
one O
has O
brought O
a O
severe O
challenge O
for O
the O
containment O
of O
the O
disease O
. O

To O
assess O
the O
level O
of O
anxiety O
among O
doctors O
during O
COVID O
- O
19 O
pandemic O
and O
the O
associated O
risk O
factors O
. O

We O
enrolled O
all O
consecutive O
patients O
admitted O
to O
internal O
medicine O
wards O
of O
Padova O
University O
Hospital O
between O
7 O
March O
and O
30 O
April O
, O
2020 O
, O
for O
COVID O
- O
19 O
- O
related O
pneumonia O
( O
cases O
) O
vs O
non O
- O
COVID O
- O
19 O
pneumonia O
( O
controls O
) O
. O

The O
Tele O
- O
Future O
is O
Now O
: O
Will O
Telemedicine O
& O
# O
39 O
; O
s O
Footprint O
Be O
Permanent O
Post O
- O
COVID O
- O
19 O
? O

The O
effects O
of O
renin O
- O
angiotensin O
system O
inhibitors O
( O
RASI O
) O
in O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
with O
hypertension O
: O
A O
retrospective O
, O
single O
- O
center O
trial O
. O

COVID O
- O
19 O
pandemic O
has O
created O
havoc O
all O
over O
the O
globe O
and O
spared O
no O
one O
regardless O
of O
status O
, O
gender O
, O
location O
and O
ethnicity O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
posed O
a O
significant O
challenge O
to O
physicians O
and O
healthcare O
systems O
worldwide O
. O

The O
COVID O
- O
19 O
global O
pandemic O
is O
an O
unprecedented O
health O
threat O
for O
which O
behavior O
is O
critical O
to O
prevent O
spread O
and O
personal O
factors O
could O
contribute O
to O
decisions O
for O
protective O
action O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
been O
classified O
as O
a O
pandemic O
, O
and O
mental O
hospitals O
located O
in O
epidemic O
centers O
have O
been O
affected O
. O

The O
pandemic O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
disrupted O
immunization O
programs O
around O
the O
globe O
, O
potentially O
increasing O
life O
- O
threatening O
vaccine O
- O
preventable O
diseases O
. O

Effects O
of O
temperature O
variation O
and O
humidity O
on O
the O
death O
of O
COVID O
- O
19 O
in O
Wuhan O
, O
China O
. O

Unlike O
other O
coronavirus O
diseases O
, O
there O
is O
a O
geographically O
disproportionate O
distribution O
of O
the O
incidence O
of O
COVID O
- O
19 O
cases O
around O
the O
world O
. O

Thus O
, O
this O
study O
aimed O
to O
determine O
the O
epidemic O
trend O
and O
prediction O
of O
COVID O
- O
19 O
in O
Iran O
. O

To O
understand O
the O
range O
and O
severity O
of O
neurologic O
involvement O
among O
children O
and O
adolescents O
associated O
with O
COVID O
- O
19 O
. O

There O
is O
an O
urgent O
need O
to O
rapidly O
distinguish O
COVID O
- O
19 O
from O
other O
respiratory O
conditions O
, O
including O
influenza O
, O
at O
first O
- O
presentation O
. O

Among O
1954 O
hospitalized O
patients O
with O
COVID O
- O
19 O
, O
377 O
patients O
were O
RAAS O
inhibitor O
users O
, O
and O
1577 O
patients O
were O
nonusers O
. O

Case O
discussions O
were O
successfully O
executed O
both O
in O
person O
and O
by O
video O
telecommunications O
during O
the O
2020 O
COVID O
- O
19 O
pandemic O
. O

Coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
now O
considered O
a O
pandemic O
causing O
Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
, O
multiple O
fatalities O
and O
morbidities O
which O
have O
been O
associated O
with O
it O
worldwide O
. O

The O
beneficial O
effects O
of O
tenofovir O
and O
protease O
- O
inhibitors O
in O
reducing O
the O
risk O
of O
SARS O
- O
CoV O
- O
2 O
infection O
and O
death O
from O
COVID O
- O
19 O
in O
PLWHA O
remain O
inconclusive O
. O

COVID O
- O
19 O
will O
lead O
to O
a O
marked O
loss O
of O
transplant O
opportunities O
and O
a O
significantly O
larger O
national O
waiting O
list O
. O

Twitter O
offers O
a O
powerful O
means O
to O
share O
information O
, O
suggest O
ways O
to O
help O
and O
highlight O
useful O
initiatives O
during O
the O
global O
COVID O
- O
19 O
pandemic O
. O

Review O
of O
chest O
CT O
manifestations O
of O
COVID O
- O
19 O
infection O
. O

Radical O
Approaches O
During O
Unusual O
Circumstances O
: O
Intellectual O
Property O
Regulation O
and O
the O
COVID O
- O
19 O
Dilemma O
. O

Mistrust O
in O
biomedical O
research O
and O
vaccine O
hesitancy O
: O
the O
forefront O
challenge O
in O
the O
battle O
against O
COVID O
- O
19 O
in O
Italy O
. O

The O
aggressive O
surgical O
treatment O
and O
outcome O
of O
a O
colon O
cancer O
patient O
with O
COVID O
- O
19 O
in O
Wuhan O
, O
China O
. O

Surgical O
Smoke O
in O
the O
Era O
of O
the O
COVID O
- O
19 O
Pandemic O
- O
Is O
It O
Time O
to O
Reconsider O
Policies O
on O
Smoke O
Evacuation O
? O

Three O
hundred O
and O
sixty O
- O
one O
people O
in O
the O
United O
Kingdom O
participated O
in O
a O
2 O
( O
self O
- O
isolation O
vs O
. O
no O
self O
- O
isolation O
) O
x O
2 O
( O
perceived O
COVID O
- O
19 O
symptomatology O
vs O
. O
no O
perceived O
COVID O
- O
19 O
symptomatology O
) O
x O
2 O
( O
exposure O
to O
COVID O
- O
19 O
news O
vs O
. O
control O
) O
experiment O
online O
. O

Mental O
health O
of O
staff O
working O
in O
intensive O
care O
during O
COVID O
- O
19 O
. O

Determining O
the O
spatial O
effects O
of O
COVID O
- O
19 O
using O
the O
spatial O
panel O
data O
model O
. O

The O
survey O
assessed O
various O
outcome O
measures O
, O
including O
the O
General O
Health O
Questionnaire O
- O
12 O
( O
GHQ O
- O
12 O
) O
, O
health O
status O
, O
satisfaction O
with O
daily O
life O
activities O
, O
work O
, O
leisure O
, O
and O
new O
activities O
, O
and O
anxiety O
over O
COVID O
- O
19 O
. O

Effects O
of O
COVID O
- O
19 O
pandemic O
on O
burns O
epidemiology O
. O

Countries O
affected O
by O
COVID O
- O
19 O
have O
different O
demographics O
, O
socioeconomic O
, O
and O
lifestyle O
health O
indicators O
. O

Economics O
of O
COVID O
- O
19 O
: O
challenges O
and O
the O
way O
forward O
for O
health O
policy O
during O
and O
after O
the O
pandemic O
. O

Almost O
all O
ADEs O
concerned O
COVID O
- O
19 O
patients O
( O
92 O
. O
5 O
% O
) O
, O
with O
an O
appreciable O
number O
from O
the O
Americas O
( O
67 O
. O
7 O
% O
) O
. O

COVID O
- O
19 O
Infection O
in O
Medical O
Laboratory O
Professional O
: O
a O
Note O
. O

CONCLUSIONS O
Lymphocytosis O
is O
an O
unexpected O
finding O
in O
patients O
diagnosed O
with O
COVID O
- O
19 O
infection O
and O
the O
elevated O
lymphocytes O
may O
be O
indicative O
of O
other O
conditions O
. O

A O
rapid O
transition O
to O
voluntary O
breath O
hold O
from O
device O
- O
assisted O
moderate O
deep O
inspiration O
breath O
hold O
for O
patients O
receiving O
breast O
radiotherapy O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Data O
of O
252 O
confirmed O
COVID O
- O
19 O
patients O
were O
collected O
at O
Pak O
Emirates O
Military O
Hospital O
( O
PEMH O
) O
from O
10th O
April O
2020 O
to O
31st O
August O
2020 O
. O

I O
discuss O
the O
findings O
' O
contribution O
to O
sexuality O
and O
masculinity O
studies O
, O
and O
the O
methodological O
possibilities O
that O
they O
raise O
for O
qualitative O
scholars O
studying O
social O
phenomena O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
review O
of O
newborn O
outcomes O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Cardiac O
biometric O
variables O
and O
arrhythmic O
events O
during O
COVID O
- O
19 O
pandemic O
lockdown O
in O
patients O
with O
an O
implantable O
cardiac O
monitor O
for O
syncope O
work O
- O
up O
. O

Our O
patients O
with O
COVID O
- O
19 O
also O
had O
greater O
prevalence O
of O
obesity O
and O
diabetes O
and O
lower O
rates O
of O
end O
- O
stage O
organ O
disease O
and O
cancers O
. O

Regulators O
in O
numerous O
countries O
have O
authorised O
or O
approved O
COVID O
- O
19 O
vaccines O
for O
human O
use O
, O
with O
more O
expected O
to O
be O
licensed O
in O
2021 O
. O

Conclusion O
The O
failure O
to O
practice O
the O
already O
known O
preventive O
practices O
is O
probably O
one O
of O
the O
most O
important O
factors O
in O
the O
progression O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Univariate O
and O
multivariate O
analysis O
demonstrated O
that O
hemoglobin O
level O
and O
pro O
- O
inflammatory O
neutrophils O
and O
C O
- O
reactive O
protein O
( O
CRP O
) O
, O
can O
be O
used O
as O
independent O
factors O
affecting O
the O
severity O
of O
COVID O
- O
19 O
; O
Meanwhile O
, O
pro O
- O
inflammatory O
neutrophils O
and O
CRP O
can O
be O
used O
as O
an O
independent O
influencing O
factor O
for O
adverse O
clinical O
outcome O
of O
death O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
has O
led O
to O
a O
pandemic O
since O
March O
2020 O
. O

Half O
of O
women O
whose O
pelvic O
reconstructive O
procedures O
were O
postponed O
because O
of O
the O
COVID O
- O
19 O
pandemic O
were O
upset O
because O
of O
the O
delay O
in O
care O
, O
especially O
those O
who O
are O
emotionally O
and O
socially O
vulnerable O
during O
the O
COVID O
- O
19 O
pandemic O
. O

In O
multivariable O
analyses O
, O
an O
F O
/ O
P O
≥ O
877 O
was O
associated O
with O
greater O
odds O
of O
identifying O
a O
COVID O
- O
19 O
case O
( O
OR O
: O
11 O
. O
27 O
, O
CI O
: O
4 O
- O
31 O
. O
2 O
, O
p O
< O
0 O
. O
001 O
) O
. O

More O
people O
sought O
help O
for O
anxiety O
disorders O
during O
the O
COVID O
- O
19 O
restrictions O
compared O
with O
corresponding O
data O
from O
2018 O
and O
2019 O
. O

Observational O
data O
suggest O
an O
acquired O
prothrombotic O
state O
may O
contribute O
to O
the O
pathophysiology O
of O
COVID O
- O
19 O
. O

Primary O
outcomes O
are O
the O
mortality O
of O
neonates O
with O
COVID O
- O
19 O
and O
SARS O
- O
CoV O
- O
2 O
infection O
of O
neonates O
born O
to O
mothers O
with O
COVID O
- O
19 O
. O

On O
the O
basis O
of O
the O
Decree O
of O
the O
President O
of O
the O
Russian O
Federation O
dated O
may O
06 O
. O
2020 O
№ O
313 O
of O
the O
Ministry O
of O
health O
of O
the O
Russian O
Federation O
, O
together O
with O
the O
FSS O
and O
Rospotrebnadzor O
, O
additional O
insurance O
guarantees O
are O
provided O
to O
doctors O
, O
middle O
and O
Junior O
medical O
personnel O
of O
medical O
organizations O
, O
drivers O
of O
ambulances O
who O
work O
directly O
with O
patients O
who O
have O
confirmed O
the O
presence O
of O
a O
new O
coronavirus O
infection O
( O
COVID O
- O
19 O
) O
. O

To O
describe O
the O
experience O
of O
tele O
- O
consultations O
addressed O
at O
the O
centre O
of O
excellence O
of O
a O
multi O
- O
tier O
ophthalmology O
hospital O
network O
in O
India O
during O
the O
ongoing O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
lockdown O
. O

Public O
interest O
in O
spa O
therapy O
during O
the O
COVID O
- O
19 O
pandemic O
: O
analysis O
of O
Google O
Trends O
data O
among O
Turkey O
. O

One O
study O
showed O
that O
severe O
COVID O
- O
19 O
cases O
, O
which O
included O
more O
elderly O
patients O
, O
had O
longer O
incubation O
periods O
. O

In O
this O
series O
of O
seven O
COVID O
- O
19 O
autopsies O
, O
thrombosis O
was O
a O
prominent O
feature O
in O
multiple O
organs O
, O
in O
some O
cases O
despite O
full O
anticoagulation O
and O
regardless O
of O
timing O
of O
the O
disease O
course O
, O
suggesting O
that O
thrombosis O
plays O
a O
role O
very O
early O
in O
the O
disease O
process O
. O

The O
coronavirus O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
led O
to O
an O
unprecedented O
emergency O
scenario O
for O
all O
aspects O
of O
health O
care O
, O
including O
urology O
. O

Although O
the O
total O
number O
of O
patients O
with O
PAH O
/ O
CTEPH O
recognized O
to O
have O
COVID O
- O
19 O
was O
small O
, O
the O
impact O
of O
COVID O
- O
19 O
on O
broader O
clinic O
operations O
, O
testing O
, O
and O
treatment O
was O
substantial O
. O

Results O
were O
categorised O
into O
positive O
and O
negative O
findings O
for O
COVID O
- O
19 O
. O

Italy O
was O
the O
first O
European O
country O
suffering O
from O
COVID O
- O
19 O
. O

Continuation O
of O
these O
efforts O
, O
coupled O
with O
tailored O
prevention O
and O
health O
education O
messaging O
for O
younger O
aged O
children O
, O
may O
help O
to O
reduce O
the O
transmission O
of O
COVID O
- O
19 O
among O
children O
until O
other O
therapeutic O
interventions O
or O
vaccines O
are O
available O
. O

Fast O
diagnostic O
methods O
can O
control O
and O
prevent O
the O
spread O
of O
pandemic O
diseases O
like O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
and O
assist O
physicians O
to O
better O
manage O
patients O
in O
high O
workload O
conditions O
. O

It O
is O
our O
hope O
that O
these O
recommendations O
help O
supporting O
clinician O
management O
decisions O
to O
best O
care O
for O
hospitalized O
COVID O
- O
19 O
patients O
in O
the O
region O
and O
worldwide O
. O

Active O
and O
Effective O
Measures O
for O
the O
Care O
of O
Patients O
With O
Cancer O
During O
the O
COVID O
- O
19 O
Spread O
in O
China O
. O

The O
parallel O
analysis O
of O
COVID O
- O
19 O
and O
diabetes O
mellitus O
pathogenesis O
has O
proposed O
that O
the O
control O
of O
the O
inflammation O
through O
the O
interfering O
with O
the O
critical O
points O
of O
major O
signaling O
pathways O
may O
provide O
the O
new O
therapeutic O
approaches O
. O

Women O
assessed O
during O
the O
COVID O
- O
19 O
pandemic O
reported O
high O
rates O
of O
psychological O
distress O
. O

The O
COVID O
- O
19 O
pandemic O
has O
placed O
significant O
pressure O
on O
health O
and O
social O
care O
. O

However O
, O
there O
are O
lack O
of O
study O
assessing O
COVID O
- O
19 O
related O
human O
stress O
and O
its O
' O
associations O
with O
other O
relevant O
factors O
affecting O
quality O
of O
life O
in O
the O
country O
, O
and O
which O
were O
explored O
in O
the O
present O
study O
. O

To O
investigate O
the O
clinical O
features O
of O
patients O
who O
had O
two O
demonstrated O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
episodes O
. O

To O
this O
end O
, O
in O
this O
focused O
review O
, O
several O
lines O
of O
evidence O
are O
provided O
to O
suggest O
that O
in O
addition O
to O
bradykinin O
, O
two O
closely O
related O
vasoactive O
peptides O
, O
substance O
P O
and O
neurotensin O
, O
are O
also O
likely O
to O
drive O
microvascular O
permeability O
and O
inflammation O
, O
and O
be O
responsible O
for O
development O
of O
COVID O
- O
19 O
pathology O
. O

In O
this O
retrospective O
study O
, O
all O
critically O
ill O
COVID O
- O
19 O
patients O
admitted O
to O
two O
intensive O
care O
units O
in O
March O
and O
April O
2020 O
were O
eligible O
. O

Most O
patients O
recovered O
from O
COVID O
- O
19 O
, O
including O
25 O
% O
patients O
initially O
requiring O
intubation O
. O

We O
aimed O
to O
ascertain O
the O
cumulative O
risk O
of O
fatal O
or O
critical O
care O
unit O
- O
treated O
COVID O
- O
19 O
in O
people O
with O
diabetes O
and O
compare O
it O
with O
that O
of O
people O
without O
diabetes O
, O
and O
to O
investigate O
risk O
factors O
for O
and O
build O
a O
cross O
- O
validated O
predictive O
model O
of O
fatal O
or O
critical O
care O
unit O
- O
treated O
COVID O
- O
19 O
among O
people O
with O
diabetes O
. O

A O
retrospective O
cohort O
study O
METHODS O
: O
Inclusion O
of O
all O
patients O
hospitalized O
for O
COVID O
- O
19 O
between O
March O
1 O
, O
2020 O
, O
and O
June O
1 O
, O
2020 O
in O
Zuyderland O
Medical O
Centre O
, O
The O
Netherlands O
. O

We O
used O
logistic O
regression O
analyses O
and O
one O
- O
way O
ANOVAs O
to O
investigate O
associations O
between O
believing O
you O
had O
had O
COVID O
- O
19 O
and O
binary O
and O
continuous O
outcomes O
respectively O
. O

To O
date O
, O
there O
is O
no O
effective O
antiviral O
therapy O
for O
COVID O
- O
19 O
patients O
, O
and O
therapeutic O
strategies O
are O
based O
on O
experience O
treating O
previously O
recognized O
coronaviruses O
. O

Total O
deaths O
are O
significantly O
higher O
than O
historical O
trends O
in O
Florida O
even O
when O
accounting O
for O
COVID O
- O
19 O
- O
related O
deaths O
. O

[ O
Coronavirus O
( O
SARS O
- O
CoV O
- O
2 O
) O
- O
Outbreak O
in O
North O
Rhine O
- O
Westphalia O
( O
District O
of O
Heinsberg O
) O
- O
First O
diagnosis O
of O
a O
COVID O
- O
19 O
manifestation O
in O
a O
couple O
] O
. O

Already O
instances O
of O
patients O
with O
COVID O
- O
19 O
have O
been O
reported O
with O
mild O
( O
anosmia O
and O
ageusia O
) O
to O
severe O
( O
encephalopathy O
) O
neurological O
manifestations O
, O
and O
if O
that O
is O
so O
, O
then O
it O
gives O
us O
more O
reasons O
to O
be O
frightened O
of O
this O
killer O
virus O
. O

In O
current O
status O
, O
spread O
of O
COVID O
- O
19 O
in O
person O
- O
to O
- O
person O
could O
be O
caused O
mainly O
by O
respiratory O
droplets O
, O
which O
leads O
to O
the O
spread O
of O
the O
influenza O
virus O
in O
both O
community O
and O
clinicians O
. O

In O
a O
large O
cohort O
of O
ambulatory O
confirmed O
COVID O
- O
19 O
patients O
with O
multiple O
self O
- O
collected O
sample O
time O
points O
, O
we O
compared O
202 O
matched O
nasal O
- O
oropharyngeal O
swabs O
and O
oral O
salivary O
fluid O
sample O
pairs O
by O
RT O
- O
PCR O
. O

[ O
Impact O
of O
the O
COVID O
- O
19 O
pandemic O
on O
heart O
failure O
hospitalizations O
] O
. O

Methods O
: O
Patients O
with O
IBD O
from O
Hubei O
province O
( O
the O
epicenter O
of O
COVID O
- O
19 O
) O
and O
Guangdong O
province O
( O
a O
non O
- O
epicenter O
area O
) O
, O
China O
were O
surveyed O
during O
the O
pandemic O
. O

As O
of O
date O
, O
there O
is O
no O
approved O
vaccine O
or O
treatment O
for O
COVID O
- O
19 O
though O
there O
are O
ongoing O
research O
studies O
to O
formulate O
a O
treatment O
. O

Routine O
history O
, O
physical O
examination O
, O
laboratory O
testing O
, O
electrocardiography O
, O
and O
plain O
x O
- O
ray O
imaging O
may O
often O
suffice O
for O
such O
patients O
, O
but O
given O
overlap O
between O
COVID O
- O
19 O
and O
typical O
cardiovascular O
diagnoses O
such O
as O
heart O
failure O
and O
acute O
myocardial O
infarction O
, O
need O
frequently O
arises O
for O
advanced O
imaging O
techniques O
to O
assist O
in O
differential O
diagnosis O
and O
management O
. O

Because O
in O
FH O
patients O
the O
level O
of O
low O
density O
lipoprotein O
cholesterol O
( O
LDL O
- O
C O
) O
is O
elevated O
from O
birth O
and O
it O
correlates O
with O
the O
degree O
of O
systemic O
endothelial O
dysfunction O
, O
both O
heterozygous O
FH O
( O
HeFH O
) O
patients O
and O
, O
in O
particular O
, O
homozygous O
FH O
( O
HoFH O
) O
patients O
have O
a O
dysfunctional O
endothelium O
prone O
to O
further O
damage O
by O
the O
direct O
viral O
attack O
and O
the O
hyper O
- O
inflammatory O
reaction O
typical O
of O
severe O
COVID O
- O
19 O
. O

Mexico O
has O
a O
high O
number O
of O
infected O
individuals O
and O
deaths O
by O
COVID O
- O
19 O
as O
well O
as O
an O
important O
burden O
of O
metabolic O
diseases O
; O
nevertheless O
, O
reports O
about O
features O
of O
Mexican O
individuals O
with O
COVID O
- O
19 O
are O
scarce O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
also O
known O
as O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
known O
to O
cause O
a O
cluster O
of O
flu O
- O
like O
illnesses O
and O
pneumonia O
with O
evolving O
understanding O
of O
other O
systemic O
manifestations O
. O

However O
, O
existing O
inequalities O
in O
access O
to O
certain O
basic O
necessities O
of O
life O
( O
water O
, O
sanitation O
facility O
, O
and O
food O
storage O
) O
create O
layered O
vulnerabilities O
to O
COVID O
- O
19 O
and O
can O
render O
the O
preventive O
measures O
ineffective O
or O
simply O
counterproductive O
. O

We O
also O
review O
and O
summarize O
the O
current O
COVID O
- O
19 O
literature O
in O
an O
effort O
to O
provide O
practical O
evidence O
- O
based O
biosafety O
guidance O
for O
medical O
examiner O
- O
coroner O
offices O
encountering O
COVID O
- O
19 O
at O
autopsy O
. O

We O
concluded O
that O
the O
increase O
in O
hospitalizations O
for O
SARI O
, O
the O
lack O
of O
specific O
information O
on O
the O
etiological O
agent O
, O
and O
the O
predominance O
of O
cases O
among O
the O
elderly O
during O
the O
same O
period O
in O
which O
there O
was O
an O
increase O
in O
the O
number O
of O
new O
cases O
of O
COVID O
- O
19 O
are O
all O
consistent O
with O
the O
hypothesis O
that O
severe O
cases O
of O
COVID O
- O
19 O
are O
already O
being O
detected O
by O
SARI O
surveillance O
, O
placing O
an O
overload O
on O
the O
health O
system O
. O

Critical O
adjustments O
in O
a O
department O
of O
orthopaedics O
through O
the O
COVID O
- O
19 O
pandemic O
. O

The O
authors O
discuss O
several O
scenarios O
in O
community O
- O
based O
and O
non O
- O
hospital O
US O
settings O
for O
COVID O
- O
19 O
diagnostic O
processes O
. O

COVID O
- O
19 O
most O
commonly O
presents O
with O
fever O
, O
cough O
, O
fatigue O
and O
anorexia O
and O
among O
patients O
with O
existing O
hypertension O
and O
cardiovascular O
disease O
. O

Contrasting O
to O
earlier O
COVID O
- O
19 O
studies O
, O
which O
have O
concentrated O
on O
clinical O
, O
pathological O
, O
and O
virological O
topics O
, O
this O
study O
focused O
on O
the O
behavioral O
changes O
of O
birders O
. O

Based O
on O
the O
mechanisms O
described O
earlier O
, O
our O
hypothesis O
is O
that O
light O
could O
reduce O
the O
lethality O
of O
COVID O
- O
19 O
. O

Real O
- O
time O
polymerase O
- O
chain O
- O
reaction O
( O
RT O
- O
PCR O
) O
- O
confirmed O
COVID O
- O
19 O
patients O
undergoing O
chest O
- O
CT O
( O
non O
- O
enhanced O
, O
enhanced O
, O
pulmonary O
- O
angiography O
[ O
CT O
- O
PA O
] O
) O
from O
March O
- O
April O
2020 O
were O
retrospectively O
included O
( O
COVID O
- O
19 O
- O
cohort O
) O
. O

These O
comorbidities O
are O
prevalent O
in O
patients O
with O
kidney O
disease O
, O
hence O
the O
significant O
burden O
of O
COVID O
- O
19 O
on O
kidney O
transplant O
programs O
. O

The O
COVID O
- O
19 O
pandemic O
has O
had O
significant O
health O
, O
social O
, O
and O
economic O
consequences O
internationally O
. O

Prevention O
of O
skin O
damage O
caused O
by O
the O
protective O
equipment O
used O
to O
mitigate O
COVID O
- O
19 O
. O

Compared O
with O
SARS O
and O
MERS O
, O
COVID O
- O
19 O
appears O
less O
lethal O
, O
acknowledging O
the O
limited O
number O
of O
cases O
reported O
to O
date O
and O
that O
one O
woman O
remains O
in O
a O
critical O
condition O
. O

Application O
of O
the O
PDCA O
cycle O
for O
standardized O
nursing O
management O
in O
a O
COVID O
- O
19 O
intensive O
care O
unit O
. O

N95 O
Usage O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

No O
recurrence O
or O
deterioration O
of O
the O
patient O
' O
s O
condition O
was O
found O
within O
seven O
weeks O
of O
treatment O
and O
follow O
- O
up O
, O
and O
no O
adverse O
events O
occurred O
, O
indicating O
that O
oral O
Chinese O
medicine O
decoction O
was O
able O
to O
improve O
the O
pulmonary O
inflammation O
and O
fibrosis O
in O
a O
patient O
recovering O
from O
COVID O
- O
19 O
, O
but O
further O
research O
is O
still O
needed O
. O

It O
may O
take O
time O
to O
obtain O
a O
vaccine O
for O
the O
current O
COVID O
- O
19 O
, O
and O
the O
virus O
genome O
may O
keep O
an O
evolution O
and O
mutations O
, O
so O
a O
universal O
and O
effective O
vaccine O
for O
the O
coronavirus O
may O
not O
be O
possible O
. O

Objective O
: O
During O
the O
ongoing O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
outbreak O
, O
robust O
detection O
of O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
is O
a O
key O
element O
for O
clinical O
management O
and O
to O
interrupt O
transmission O
chains O
. O

Chronic O
liver O
disease O
independently O
associated O
with O
COVID O
- O
19 O
severity O
: O
evidence O
based O
on O
adjusted O
effect O
estimates O
. O

We O
conducted O
a O
prospective O
, O
single O
- O
arm O
, O
phase O
1 O
/ O
2 O
clinical O
trial O
enrolling O
patients O
aged O
≥ O
50 O
years O
, O
who O
were O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
positive O
, O
at O
phase O
2 O
or O
3 O
with O
lung O
involvement O
at O
imaging O
study O
and O
oxygen O
requirement O
. O

Clinical O
and O
demographic O
data O
were O
collected O
through O
the O
national O
platform O
for O
COVID O
- O
19 O
surveillance O
. O

Currently O
, O
little O
in O
- O
depth O
evidence O
is O
known O
about O
the O
application O
of O
extracorporeal O
membrane O
oxygenation O
( O
ECMO O
) O
therapy O
in O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
patients O
. O

The O
effect O
of O
COVID O
- O
19 O
on O
hijra O
( O
third O
gender O
) O
people O
in O
Bangladesh O
. O

Here O
, O
the O
seasonal O
signals O
of O
the O
COVID O
- O
19 O
time O
series O
are O
extracted O
using O
the O
EEMD O
method O
, O
and O
a O
modified O
Susceptible O
, O
Exposed O
, O
Infectious O
, O
Recovered O
( O
SEIR O
) O
model O
incorporated O
with O
seasonal O
factors O
is O
introduced O
to O
quantify O
its O
impact O
on O
the O
current O
COVID O
- O
19 O
pandemic O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
significantly O
affected O
the O
well O
- O
being O
of O
individuals O
worldwide O
. O

This O
was O
a O
descriptive O
observational O
study O
of O
an O
early O
cohort O
of O
adults O
with O
COVID O
- O
19 O
pneumonia O
admitted O
from O
25 O
March O
to O
11 O
May O
2020 O
. O

A O
total O
of O
86 O
patients O
with O
COVID O
- O
19 O
were O
analyzed O
, O
including O
the O
clinical O
, O
laboratory O
and O
imaging O
features O
. O

These O
data O
identify O
defective O
Bcl O
- O
6 O
+ O
TFH O
cell O
generation O
and O
dysregulated O
humoral O
immune O
induction O
early O
in O
COVID O
- O
19 O
disease O
, O
providing O
a O
mechanistic O
explanation O
for O
the O
limited O
durability O
of O
antibody O
responses O
in O
coronavirus O
infections O
, O
and O
suggest O
that O
achieving O
herd O
immunity O
through O
natural O
infection O
may O
be O
difficult O
. O

A O
COVID O
- O
minimal O
pathway O
comprised O
of O
physical O
space O
modifications O
and O
operational O
changes O
may O
allow O
urgent O
cancer O
treatment O
to O
safely O
continue O
during O
the O
COVID O
- O
19 O
pandemic O
, O
even O
during O
the O
surge O
- O
phase O
. O

From O
January O
17 O
, O
2020 O
to O
February O
23 O
, O
2020 O
, O
three O
paediatric O
cases O
of O
COVID O
- O
19 O
were O
reported O
in O
Qingdao O
, O
Shandong O
Province O
, O
China O
. O

Infrared O
thermography O
, O
COVID O
- O
19 O
and O
pressure O
ulcer O
risk O
. O

The O
authors O
find O
it O
worthwhile O
to O
share O
their O
hypothesis O
, O
which O
can O
pave O
a O
way O
to O
future O
research O
in O
COVID O
- O
19 O
detection O
. O

The O
Winter O
Respiratory O
Viral O
Season O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

A O
total O
of O
417 O
( O
76 O
. O
8 O
% O
) O
parents O
and O
176 O
( O
76 O
. O
5 O
% O
) O
youth O
reported O
at O
least O
1 O
incident O
of O
COVID O
- O
19 O
vicarious O
racial O
discrimination O
online O
and O
/ O
or O
in O
person O
( O
parents O
: O
481 O
[ O
88 O
. O
5 O
% O
] O
; O
youth O
: O
211 O
[ O
91 O
. O
9 O
% O
] O
) O
. O

Detrimental O
Health O
Behaviour O
Changes O
among O
Females O
Living O
in O
Rural O
Areas O
during O
the O
COVID O
- O
19 O
Pandemic O
. O

A O
case O
of O
goggle O
- O
mask O
- O
related O
impetigo O
at O
the O
time O
of O
the O
COVID O
- O
19 O
pandemic O
. O

Fully O
adjusting O
for O
meteorology O
, O
this O
study O
shows O
that O
the O
COVID O
- O
19 O
responses O
were O
associated O
with O
much O
more O
reductions O
in O
traffic O
- O
related O
UFPs O
than O
PM2 O
. O
5 O
in O
the O
Seattle O
region O
, O
in O
contrast O
to O
the O
reverse O
trend O
from O
the O
direct O
empirical O
data O
comparison O
. O

Respiratory O
follow O
- O
up O
of O
patients O
with O
COVID O
- O
19 O
pneumonia O
. O

The O
COVID O
- O
19 O
pandemic O
has O
complicated O
our O
democratic O
processes O
. O

[ O
Vulnerability O
and O
health O
risks O
of O
people O
with O
diabetes O
to O
COVID O
- O
19 O
] O
. O

COVID O
- O
19 O
Panic O
Framework O
were O
also O
conceptualized O
with O
the O
following O
themes O
arranged O
from O
negative O
to O
positive O
behaviors O
: O
Indifference O
, O
Annihilation O
, O
Nihilism O
, O
Paranoia O
, O
Sadness O
, O
Fear O
, O
Transmission O
of O
Virus O
, O
Shock O
, O
Government O
Blaming O
, O
Anxiety O
, O
Relating O
to O
Past O
Pandemics O
, O
Worry O
on O
Self O
/ O
Family O
/ O
Others O
, O
Information O
Dissemination O
, O
Composure O
, O
Compliance O
, O
Protection O
, O
Cautiousness O
, O
Optimism O
, O
and O
Health O
Consciousness O
. O

Elderly O
, O
homebound O
individuals O
comprise O
a O
vulnerable O
segment O
of O
society O
who O
have O
been O
disproportionately O
affected O
by O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
through O
a O
myriad O
of O
unique O
challenges O
. O

[ O
Olfactory O
dysfunction O
in O
COVID O
- O
19 O
, O
a O
review O
of O
the O
evidence O
and O
implications O
for O
pandemic O
management O
] O
. O

Root O
cause O
contributions O
for O
the O
disparity O
overlap O
between O
COVID O
- O
19 O
and O
cancer O
. O

Communicating O
with O
medical O
library O
users O
during O
COVID O
- O
19 O
. O

Co O
- O
infections O
have O
an O
unknown O
impact O
on O
the O
morbidity O
and O
mortality O
of O
the O
new O
clinical O
syndrome O
called O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Challenges O
in O
Women O
with O
Diabetes O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

[ O
Evaluation O
of O
COVID O
- O
19 O
emergency O
and O
state O
of O
alarm O
impact O
on O
Neonatal O
Screening O
Programs O
in O
Madrid O
: O
endocrine O
and O
metabolic O
disorders O
program O
and O
hearing O
program O
review O
. O
] O

COVID O
- O
19 O
: O
Unique O
public O
health O
issues O
facing O
Black O
, O
Asian O
and O
minority O
ethnic O
communities O
. O

The O
general O
and O
special O
emergency O
management O
was O
optimized O
for O
the O
efficient O
treatment O
of O
COVID O
- O
19 O
- O
positive O
patients O
and O
the O
staff O
were O
trained O
in O
the O
use O
of O
protective O
equipment O
. O

This O
document O
serves O
to O
guide O
interventional O
and O
general O
radiologists O
in O
safely O
performing O
IR O
procedures O
on O
patients O
with O
suspected O
or O
confirmed O
COVID O
- O
19 O
, O
using O
the O
best O
evidence O
, O
guidelines O
and O
expert O
recommendations O
available O
. O

In O
December O
2019 O
, O
pneumonia O
associated O
with O
a O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
was O
reported O
in O
Wuhan O
, O
China O
. O

Implications O
of O
all O
the O
available O
evidence O
Evidence O
suggests O
that O
COVID O
- O
19 O
produces O
a O
hypercoagulable O
state O
and O
thromboprophylaxis O
is O
recommended O
in O
hospitalised O
patients O
to O
prevent O
excess O
mortality O
from O
TE O
. O

Given O
these O
problems O
can O
have O
significant O
impacts O
throughout O
the O
lifespan O
, O
preventing O
the O
negative O
repercussions O
of O
COVID O
- O
19 O
on O
children O
' O
s O
mental O
health O
is O
essential O
. O

Male O
sex O
, O
older O
age O
, O
chronic O
kidney O
disease O
, O
pneumonia O
, O
hospitalization O
, O
intensive O
care O
unit O
admission O
, O
intubation O
, O
and O
health O
care O
in O
public O
health O
services O
, O
were O
independent O
factors O
increasing O
the O
risk O
of O
death O
due O
to O
COVID O
- O
19 O
( O
p O
< O
0 O
. O
001 O
) O
. O

A O
retrospective O
analysis O
of O
the O
epidemiology O
, O
clinical O
manifestations O
, O
and O
imaging O
characteristics O
of O
familial O
cluster O
- O
onset O
COVID O
- O
19 O
. O

COVID O
- O
19 O
diagnoses O
were O
associated O
with O
counties O
with O
greater O
monolingual O
Spanish O
speakers O
, O
employment O
rates O
, O
heart O
disease O
deaths O
, O
less O
social O
distancing O
, O
and O
days O
since O
the O
first O
reported O
case O
. O

Patients O
with O
pre O
- O
existing O
cardiovascular O
disease O
and O
risk O
factors O
are O
more O
likely O
to O
experience O
adverse O
outcomes O
associated O
with O
the O
novel O
coronavirus O
disease O
- O
2019 O
( O
COVID O
- O
19 O
) O
. O

Pediatric O
behavioral O
telehealth O
in O
the O
age O
of O
COVID O
- O
19 O
: O
Brief O
evidence O
review O
and O
practice O
considerations O
. O

Review O
of O
registered O
clinical O
trials O
for O
the O
treatment O
of O
COVID O
- O
19 O
. O

This O
review O
of O
current O
studies O
on O
COVID O
- O
19 O
provides O
insight O
into O
the O
radiological O
role O
in O
the O
detection O
, O
diagnosis O
, O
and O
monitoring O
for O
COVID O
- O
19 O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
has O
disproportionately O
impacted O
the O
African O
American O
community O
. O

The O
Kingdom O
of O
Saudi O
Arabia O
( O
KSA O
) O
reported O
170 O
, O
639 O
cases O
and O
1430 O
deaths O
from O
COVID O
- O
19 O
since O
the O
first O
case O
emerged O
in O
the O
country O
on O
March O
2 O
through O
June O
25 O
, O
2020 O
. O

Our O
findings O
suggest O
that O
moderate O
intensity O
physical O
activity O
may O
attenuate O
the O
negative O
impact O
of O
parenting O
stress O
on O
social O
relationships O
and O
satisfaction O
with O
one O
' O
s O
environment O
in O
working O
mothers O
during O
the O
COVID O
- O
19 O
pandemic O
. O

Findings O
from O
this O
review O
suggest O
current O
gaps O
in O
COVID O
- O
19 O
policies O
and O
provide O
recommendations O
such O
implementing O
" O
family O
- O
friendly O
" O
policies O
that O
are O
inclusive O
and O
have O
flexible O
eligibility O
criteria O
. O

Mitigation O
strategies O
that O
slow O
but O
do O
not O
interrupt O
transmission O
will O
still O
lead O
to O
COVID O
- O
19 O
epidemics O
rapidly O
overwhelming O
health O
systems O
, O
with O
substantial O
excess O
deaths O
in O
lower O
- O
income O
countries O
resulting O
from O
the O
poorer O
health O
care O
available O
. O

To O
take O
specific O
precautions O
and O
keep O
a O
safe O
practice O
during O
providing O
ophthalmology O
health O
services O
without O
compromising O
the O
patient O
' O
s O
safety O
as O
well O
as O
the O
team O
workers O
and O
the O
community O
in O
the O
pandemic O
stage O
of O
corona O
virus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

Confronted O
with O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
New O
York O
City O
Health O
+ O
Hospitals O
, O
the O
city O
' O
s O
public O
health O
care O
system O
, O
rapidly O
expanded O
capacity O
across O
its O
eleven O
acute O
care O
hospitals O
and O
three O
new O
field O
hospitals O
. O

To O
assess O
the O
QTc O
- O
prolonging O
potential O
of O
chloroquine O
in O
COVID O
- O
19 O
patients O
and O
to O
evaluate O
whether O
this O
prolongation O
increases O
with O
the O
cumulative O
dose O
of O
chloroquine O
and O
is O
associated O
with O
the O
peak O
plasma O
concentration O
of O
chloroquine O
. O

To O
examine O
the O
magnitude O
of O
sex O
differences O
in O
survival O
from O
the O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
in O
Europe O
across O
age O
groups O
and O
regions O
. O

As O
the O
COVID O
- O
19 O
pandemic O
has O
unfolded O
, O
Hate O
Speech O
on O
social O
media O
about O
China O
and O
Chinese O
people O
has O
encouraged O
social O
stigmatization O
. O

Every O
COVID O
- O
19 O
patient O
presenting O
with O
concomitant O
pneumococcal O
pneumonia O
during O
March O
2020 O
in O
a O
tertiary O
teaching O
Hospital O
In O
Barcelona O
, O
Spain O
. O

Transpacific O
Aeromedical O
Evacuation O
for O
a O
Ruptured O
Brain O
Arteriovenous O
Malformation O
During O
the O
COVID O
- O
19 O
Pandemic O
. O

Using O
the O
query O
" O
china O
+ O
and O
+ O
coronavirus O
" O
to O
scrape O
from O
the O
Twitter O
API O
, O
we O
have O
obtained O
3 O
, O
457 O
, O
402 O
key O
tweets O
about O
China O
relating O
to O
COVID O
- O
19 O
. O

The O
recommendations O
were O
grouped O
into O
10 O
subjects O
: O
Prevention O
of O
infection O
in O
pregnant O
women O
; O
prevention O
of O
infection O
in O
health O
care O
personnel O
attending O
pregnant O
women O
; O
form O
of O
presentation O
and O
severity O
in O
pregnant O
women O
; O
maternal O
- O
fetal O
transmission O
( O
vertical O
and O
perinatal O
) O
; O
maternal O
- O
fetal O
control O
of O
the O
pregnant O
woman O
with O
COVID O
- O
19 O
; O
control O
of O
the O
severely O
pregnant O
woman O
with O
COVID O
- O
19 O
; O
treatment O
of O
the O
pregnant O
woman O
with O
COVID O
- O
19 O
; O
management O
and O
route O
of O
termination O
of O
labor O
; O
neonatal O
outcomes O
in O
women O
with O
COVID O
- O
19 O
, O
and O
breastfeeding O
. O

Aerosol O
Barrier O
Hood O
for O
Use O
in O
the O
Management O
of O
Critically O
Ill O
Adults O
With O
COVID O
- O
19 O
. O

No O
patient O
who O
was O
quarantined O
for O
the O
COVID O
- O
19 O
was O
included O
in O
the O
work O
, O
but O
all O
other O
patients O
were O
included O
. O

Nursing O
during O
the O
COVID O
- O
19 O
outbreak O
: O
A O
phenomenological O
study O
. O

Medication O
review O
can O
be O
delivered O
using O
telehealth O
during O
the O
COVID O
- O
19 O
pandemic O
to O
ensure O
ongoing O
provision O
of O
care O
to O
vulnerable O
patient O
populations O
and O
to O
minimise O
risk O
of O
infection O
for O
both O
patients O
and O
health O
professionals O
. O

Although O
MSCs O
- O
based O
treatment O
approaches O
for O
COVID O
- O
19 O
is O
still O
under O
consideration O
with O
limited O
data O
, O
many O
human O
clinical O
trials O
of O
MSC O
' O
s O
has O
been O
initiated O
to O
explore O
their O
potential O
for O
COVID O
19 O
treatment O
. O

Women O
' O
s O
health O
: O
A O
revised O
global O
agenda O
in O
the O
COVID O
- O
19 O
era O
? O

A O
total O
of O
1297 O
patients O
, O
admitted O
between O
18 O
March O
and O
8 O
April O
2020 O
, O
were O
stratified O
according O
to O
their O
risk O
of O
developing O
COVID O
- O
19 O
using O
their O
responses O
to O
a O
questionnaire O
designed O
to O
evaluate O
symptoms O
and O
risk O
conditions O
. O

Adherence O
to O
COVID O
- O
19 O
mitigating O
practices O
is O
presently O
high O
among O
the O
general O
public O
, O
and O
stringent O
lockdown O
measures O
supported O
by O
legal O
and O
policy O
intervention O
have O
facilitated O
this O
. O

The O
CRRF O
offers O
a O
comprehensive O
view O
of O
the O
research O
areas O
relevant O
to O
COVID O
- O
19 O
and O
rehabilitation O
that O
are O
necessary O
to O
inform O
best O
practice O
and O
ensure O
rehabilitation O
services O
and O
health O
systems O
can O
best O
serve O
the O
COVID O
- O
19 O
population O
. O

The O
ongoing O
COVID O
- O
19 O
pandemic O
and O
the O
lockdown O
measures O
have O
forced O
clinicians O
across O
the O
world O
to O
look O
on O
telemedicine O
. O

The O
plausibility O
that O
vaccine O
protection O
against O
symptomatic O
COVID O
- O
19 O
could O
be O
accompanied O
by O
a O
shift O
toward O
more O
SARS O
- O
CoV O
- O
2 O
infections O
that O
are O
asymptomatic O
is O
highlighted O
, O
as O
well O
as O
the O
potential O
implications O
of O
such O
a O
shift O
. O

Responses O
from O
survey O
I O
( O
1520 O
participants O
from O
101 O
countries O
) O
indicate O
that O
COVID O
- O
19 O
is O
impacting O
oncology O
professionals O
; O
in O
particular O
, O
25 O
% O
of O
participants O
indicated O
being O
at O
risk O
of O
distress O
( O
poor O
well O
- O
being O
, O
eWBI O
≥ O
4 O
) O
, O
38 O
% O
reported O
feeling O
burnout O
, O
and O
66 O
% O
reported O
not O
being O
able O
to O
perform O
their O
job O
compared O
with O
the O
pre O
- O
COVID O
- O
19 O
period O
. O

In O
this O
retrospective O
cohort O
review O
, O
we O
included O
all O
AA O
patients O
with O
confirmed O
COVID O
- O
19 O
infection O
admitted O
to O
an O
inner O
- O
city O
teaching O
community O
hospital O
in O
New O
York O
city O
. O

These O
extraordinary O
advances O
provide O
an O
unprecedented O
opportunity O
to O
evaluate O
the O
effects O
of O
mental O
health O
policies O
that O
may O
be O
adopted O
in O
the O
post O
- O
COVID O
- O
19 O
era O
in O
the O
United O
States O
. O

This O
study O
aimed O
to O
assess O
the O
clinical O
outcomes O
of O
critically O
ill O
COVID O
- O
19 O
patients O
using O
Tocilizumab O
treatment O
to O
provide O
recommendations O
for O
the O
treatment O
of O
COVID O
- O
19 O
patients O
with O
severe O
disease O
. O

Participants O
slept O
27 O
minutes O
longer O
( O
95 O
% O
CI O
9 O
- O
51 O
) O
, O
got O
up O
38 O
minutes O
later O
( O
95 O
% O
CI O
25 O
- O
50 O
) O
, O
and O
did O
50 O
fewer O
minutes O
( O
95 O
% O
CI O
- O
69 O
- O
- O
29 O
) O
of O
light O
physical O
activity O
during O
COVID O
- O
19 O
restrictions O
. O

Social O
distancing O
: O
implications O
for O
the O
operating O
room O
in O
the O
face O
of O
COVID O
- O
19 O
. O

Cardiac O
complications O
can O
occur O
in O
patients O
with O
COVID O
- O
19 O
and O
can O
be O
fatal O
in O
severe O
cases O
. O

The O
goal O
of O
our O
investigation O
was O
to O
evaluate O
the O
impact O
of O
the O
COVID O
- O
19 O
lockdown O
on O
the O
concentrations O
of O
the O
main O
air O
pollutants O
in O
the O
urban O
area O
of O
Palermo O
( O
Italy O
) O
. O

Epidemiological O
and O
clinical O
based O
study O
on O
four O
passages O
of O
COVID O
- O
19 O
patients O
: O
intervention O
at O
asymptomatic O
period O
contributes O
to O
early O
recovery O
. O

In O
addition O
, O
the O
level O
of O
ferritin O
was O
higher O
in O
active O
AOSD O
in O
comparison O
with O
severe O
COVID O
- O
19 O
. O

In O
December O
2019 O
, O
a O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
pneumonia O
emerged O
in O
Wuhan O
, O
China O
. O

Dangerous O
liaisons O
? O
As O
the O
COVID O
- O
19 O
wave O
hits O
Africa O
with O
potential O
for O
novel O
transmission O
dynamics O
: O
a O
perspective O
. O

In O
order O
to O
ensure O
the O
timeliness O
and O
reliability O
of O
the O
recommendations O
in O
guidelines O
, O
the O
working O
group O
of O
the O
Rapid O
Advice O
Guidelines O
for O
Management O
of O
Children O
with O
COVID O
- O
19 O
decided O
to O
update O
the O
guideline O
to O
incorporate O
the O
latest O
evidence O
to O
guide O
the O
management O
of O
COVID O
- O
19 O
in O
children O
and O
adolescent O
. O

In O
Sainte O
- O
Anne O
Hospital O
( O
GHU O
PARIS O
Psychiatrie O
& O
Neuroscience O
, O
Paris O
, O
France O
) O
we O
have O
observed O
a O
lower O
incidence O
of O
symptomatic O
forms O
of O
COVID O
- O
19 O
among O
patients O
than O
among O
our O
clinical O
staff O
. O

In O
addition O
, O
stigma O
and O
discrimination O
toward O
sex O
workers O
could O
also O
make O
contact O
tracing O
challenging O
and O
limit O
access O
to O
COVID O
- O
19 O
testing O
among O
this O
vulnerable O
group O
. O

This O
retrospective O
study O
included O
all O
consecutive O
patients O
hospitalized O
with O
COVID O
- O
19 O
who O
underwent O
a O
computed O
tomography O
( O
CT O
) O
angiography O
for O
PE O
clinical O
suspicion O
. O

No O
specific O
data O
exists O
regarding O
management O
of O
patients O
with O
cystic O
fibrosis O
( O
CF O
) O
who O
are O
infected O
with O
COVID O
- O
19 O
. O

These O
novel O
potential O
hypothalamic O
miRNAs O
can O
be O
used O
to O
identify O
new O
therapeutic O
targets O
to O
treat O
neurological O
symptoms O
in O
COVID O
- O
19 O
patients O
via O
regulation O
of O
ACE2 O
and O
TMPRSS2 O
expression O
. O

Unequal O
effects O
of O
the O
COVID O
- O
19 O
pandemic O
on O
scientists O
. O

We O
carried O
out O
proteomic O
profiling O
of O
plasma O
from O
cross O
- O
sectional O
and O
longitudinal O
cohorts O
of O
hospitalized O
patients O
with O
COVID O
- O
19 O
and O
analyzed O
clinical O
data O
from O
our O
health O
system O
database O
of O
more O
than O
3300 O
patients O
. O

All O
these O
outcomes O
are O
accused O
to O
be O
involved O
in O
the O
increasing O
vulnerability O
and O
comorbidity O
in O
COVID O
- O
19 O
- O
infected O
people O
with O
chronic O
diseases O
. O

At O
a O
tertiary O
care O
hospital O
in O
Thailand O
, O
clinical O
pharmacists O
provided O
pharmaceutical O
care O
services O
for O
COVID O
- O
19 O
patients O
via O
telemonitoring O
using O
the O
hospital O
' O
s O
computerized O
physician O
order O
entry O
system O
. O

Patients O
were O
identified O
as O
being O
stable O
, O
unstable O
, O
or O
at O
the O
end O
of O
life O
using O
the O
early O
warning O
parameters O
for O
COVID O
- O
19 O
. O

Macula O
service O
evaluation O
and O
assessing O
priorities O
for O
anti O
- O
VEGF O
treatment O
in O
the O
light O
of O
COVID O
- O
19 O
. O

Flexibility O
in O
individual O
funding O
schemes O
: O
How O
well O
did O
Australia O
' O
s O
National O
Disability O
Insurance O
Scheme O
support O
remote O
learning O
for O
students O
with O
disability O
during O
COVID O
- O
19 O
? O

This O
retrospective O
Double O
- O
Centre O
study O
was O
conducted O
on O
1320 O
COVID O
- O
19 O
patients O
recruited O
at O
Taleghani O
and O
Shohadae O
Tajrish O
Hospitals O
in O
Tehran O
, O
Iran O
. O

The O
positive O
association O
between O
the O
number O
of O
measures O
and O
fear O
and O
worry O
about O
COVID O
- O
19 O
may O
reflect O
increased O
awareness O
about O
COVID O
- O
19 O
among O
employees O
resulted O
from O
taking O
the O
measures O
. O

The O
use O
of O
a O
snorkel O
mask O
is O
an O
important O
, O
viable O
, O
and O
simpler O
NIV O
modality O
for O
the O
management O
of O
patients O
with O
COVID O
- O
19 O
with O
respiratory O
failure O
who O
fail O
to O
use O
a O
reservoir O
mask O
, O
and O
it O
can O
be O
an O
alternative O
before O
the O
use O
of O
a O
mechanical O
ventilator O
. O

Therefore O
, O
in O
this O
scoping O
review O
, O
we O
investigated O
whether O
studies O
on O
pharmacological O
treatment O
in O
COVID O
- O
19 O
were O
performed O
based O
on O
a O
priori O
sex O
- O
specific O
design O
or O
post O
- O
hoc O
sex O
- O
specific O
analyses O
. O

Most O
drugs O
considered O
for O
repurposing O
/ O
repositioning O
in O
the O
therapy O
of O
the O
COVID O
- O
19 O
outbreak O
are O
commercially O
available O
and O
their O
dosage O
and O
toxicity O
in O
humans O
is O
well O
known O
, O
due O
to O
years O
( O
or O
even O
decades O
) O
of O
clinical O
use O
. O

Currently O
, O
there O
is O
no O
vaccine O
or O
specific O
drug O
for O
COVID O
- O
19 O
. O

Of O
the O
350 O
COVID O
- O
19 O
patients O
, O
13 O
. O
7 O
% O
were O
severe O
cases O
. O

COVID O
- O
19 O
presenting O
as O
stroke O
. O

This O
study O
provides O
novel O
insights O
into O
the O
geostatistical O
analysis O
of O
COVID O
- O
19 O
clusters O
and O
hotspots O
that O
might O
assist O
the O
policy O
planner O
to O
predict O
the O
spatiotemporal O
transmission O
dynamics O
and O
formulate O
imperative O
control O
strategies O
of O
SARS O
- O
CoV O
- O
2 O
in O
Bangladesh O
. O

Structural O
analysis O
of O
COVID O
- O
19 O
spike O
protein O
in O
recognizing O
the O
ACE2 O
receptor O
of O
different O
mammalian O
species O
and O
its O
susceptibility O
to O
viral O
infection O
. O

We O
report O
and O
interpret O
preferences O
of O
a O
sample O
of O
the O
Dutch O
adult O
population O
for O
different O
strategies O
to O
end O
the O
so O
- O
called O
' O
intelligent O
lockdown O
' O
which O
their O
government O
had O
put O
in O
place O
in O
response O
to O
the O
COVID O
- O
19 O
pandemic O
. O

Inferring O
the O
age O
- O
and O
setting O
- O
specific O
social O
contact O
mixing O
and O
key O
age O
- O
stratified O
epidemiological O
parameters O
, O
in O
the O
presence O
of O
evolving O
control O
measures O
, O
is O
critical O
to O
inform O
decision O
- O
and O
policy O
- O
making O
for O
the O
current O
COVID O
- O
19 O
pandemic O
. O

COVID O
- O
19 O
and O
the O
ethnicity O
link O
- O
is O
there O
a O
photochemical O
link O
? O

We O
retrospectively O
analysed O
the O
epidemiologic O
, O
clinical O
, O
laboratory O
, O
and O
radiological O
characteristics O
of O
189 O
patients O
with O
confirmed O
COVID O
- O
19 O
who O
were O
admitted O
to O
seven O
hospitals O
in O
four O
Chinese O
provinces O
from O
18 O
January O
2020 O
to O
3 O
February O
2020 O
. O

A O
single O
- O
center O
study O
was O
conducted O
on O
133 O
consecutive O
hypertensive O
subjects O
presenting O
to O
the O
emergency O
department O
with O
acute O
respiratory O
symptoms O
and O
/ O
or O
fever O
who O
were O
diagnosed O
with O
COVID O
- O
19 O
infection O
between O
9 O
and O
31 O
March O
2020 O
. O

The O
progress O
of O
environmental O
research O
on O
COVID O
- O
19 O
will O
guide O
the O
development O
of O
global O
environmental O
strategies O
to O
control O
future O
global O
environmental O
risks O
. O

Low O
physical O
mobility O
during O
the O
second O
half O
of O
March O
and O
during O
April O
likely O
contributed O
to O
the O
quick O
fall O
in O
new O
COVID O
- O
19 O
infections O
since O
mid O
- O
March O
. O

Methods O
This O
cross O
- O
sectional O
study O
analysed O
the O
workload O
at O
the O
Maxillofacial O
and O
Oral O
Surgery O
Department O
( O
Department O
) O
, O
Osijek O
University O
Hospital O
, O
during O
the O
COVID O
- O
19 O
pandemic O
( O
March O
- O
May O
2020 O
) O
and O
four O
subsequent O
months O
. O

This O
review O
describes O
the O
cutaneous O
manifestations O
of O
COVID O
- O
19 O
patients O
from O
diverse O
regions O
with O
the O
aim O
of O
highlighting O
any O
important O
associations O
. O

Stretching O
the O
Analytic O
Frame O
: O
Analytic O
Therapists O
' O
Experiences O
with O
Remote O
Therapy O
During O
COVID O
- O
19 O
. O

COVID O
- O
19 O
pneumonia O
: O
what O
has O
CT O
taught O
us O
? O

Clinical O
management O
of O
sepsis O
resulting O
from O
infections O
including O
COVID O
- O
19 O
. O

Overall O
reduced O
lymphocyte O
especially O
T O
and O
B O
subsets O
closely O
related O
to O
the O
poor O
prognosis O
and O
the O
disease O
severity O
in O
severe O
patients O
with O
COVID O
- O
19 O
and O
diabetes O
mellitus O
. O

SARS O
- O
CoV O
- O
2 O
, O
the O
agent O
of O
the O
COVID O
- O
19 O
pandemic O
, O
has O
80 O
% O
sequence O
homology O
with O
SARS O
- O
CoV O
- O
1 O
and O
96 O
- O
98 O
% O
homology O
with O
coronaviruses O
isolated O
from O
bats O
. O

The O
COVID O
- O
19 O
pandemic O
has O
a O
severe O
and O
immediate O
impact O
on O
unemployment O
and O
reduced O
household O
income O
, O
resulting O
in O
global O
food O
insecurity O
. O

Staff O
experienced O
high O
stress O
levels O
due O
to O
COVID O
- O
19 O
( O
66 O
. O
2 O
% O
, O
labeled O
vulnerable O
) O
and O
33 O
. O
8 O
% O
experienced O
low O
stress O
levels O
( O
labeled O
resilient O
) O
. O

Response O
of O
Cardiac O
Surgery O
Units O
to O
COVID O
- O
19 O
: O
An O
Internationally O
- O
Based O
Quantitative O
Survey O
. O

After O
all O
, O
additional O
COVID O
- O
19 O
lockdowns O
might O
be O
implemented O
in O
the O
future O
. O

The O
pandemic O
of O
COVID O
- O
19 O
and O
its O
implications O
for O
the O
purity O
and O
authenticity O
of O
alcohol O
- O
based O
hand O
sanitizers O
: O
The O
health O
risks O
associated O
with O
falsified O
sanitizers O
and O
recommendations O
for O
regulatory O
and O
public O
health O
bodies O
. O

The O
results O
of O
this O
retrospective O
study O
suggest O
that O
SAA O
is O
a O
good O
marker O
of O
COVID O
- O
19 O
disease O
alone O
and O
/ O
or O
in O
combination O
with O
other O
inflammatory O
biomarkers O
. O

The O
current O
growth O
trends O
of O
the O
SARS O
- O
CoV O
- O
2 O
/ O
COVID O
- O
19 O
outbreak O
globally O
and O
preventive O
measures O
are O
briefly O
discussed O
. O

Self O
- O
Medication O
with O
Antibiotics O
for O
Protection O
against O
COVID O
- O
19 O
: O
The O
Role O
of O
Psychological O
Distress O
, O
Knowledge O
of O
, O
and O
Experiences O
with O
Antibiotics O
. O

The O
majority O
of O
patients O
presents O
with O
mild O
symptoms O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
. O

India O
should O
ramp O
up O
its O
emergency O
medicine O
and O
critical O
care O
infrastructure O
to O
combat O
COVID O
- O
19 O
. O

Cohort O
1 O
, O
patients O
( O
n O
= O
65 O
) O
who O
attended O
the O
emergency O
department O
on O
March O
30 O
, O
2020 O
with O
clinical O
suspicion O
of O
active O
COVID O
- O
19 O
( O
n O
= O
56 O
with O
proven O
/ O
probable O
COVID O
- O
19 O
) O
. O

From O
January O
17 O
to O
February O
9 O
, O
2020 O
, O
38 O
hospitalized O
patients O
with O
COVID O
- O
19 O
pneumonia O
were O
consecutively O
enrolled O
in O
our O
hospitals O
. O

During O
the O
pandemic O
, O
SUD O
, O
a O
significant O
problem O
related O
to O
Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
is O
affecting O
adolescents O
. O

Chest O
CT O
imaging O
features O
and O
clinical O
outcome O
of O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
: O
A O
single O
- O
center O
case O
study O
in O
Ningbo O
, O
China O
. O

Anomalous O
behaviour O
of O
ozone O
under O
COVID O
- O
19 O
and O
explicit O
diagnosis O
of O
O3 O
- O
NOx O
- O
VOCs O
mechanism O
. O

Nutrition O
Support O
in O
the O
ICU O
- O
A O
Refresher O
in O
the O
Era O
of O
COVID O
- O
19 O
. O

The O
unprecedented O
COVID O
- O
19 O
pandemic O
has O
put O
a O
great O
strain O
on O
the O
physical O
and O
mental O
health O
of O
health O
care O
workers O
across O
the O
globe O
. O

Studying O
the O
effect O
of O
lockdown O
using O
epidemiological O
modelling O
of O
COVID O
- O
19 O
and O
a O
quantum O
computational O
approach O
using O
the O
Ising O
spin O
interaction O
. O

Subjective O
Well O
- O
Being O
of O
Chinese O
Sina O
Weibo O
Users O
in O
Residential O
Lockdown O
During O
the O
COVID O
- O
19 O
Pandemic O
: O
Machine O
Learning O
Analysis O
. O

Complex O
Immune O
Dysregulation O
in O
COVID O
- O
19 O
Patients O
with O
Severe O
Respiratory O
Failure O
. O

Twenty O
- O
two O
( O
22 O
/ O
29 O
; O
76 O
% O
) O
had O
close O
contact O
with O
acquaintances O
or O
family O
members O
who O
were O
confirmed O
or O
probable O
COVID O
- O
19 O
cases O
. O

Use O
of O
WhatsApp O
for O
Polyclinic O
Consultation O
of O
Suspected O
Patients O
With O
COVID O
- O
19 O
: O
Retrospective O
Case O
Control O
Study O
. O

Severe O
Acute O
Respiratory O
Syndrome O
( O
SARS O
) O
, O
Middle O
East O
Respiratory O
Syndrome O
( O
MERS O
) O
, O
and O
Coronavirus O
Disease O
2019 O
( O
COVID O
- O
19 O
) O
infections O
are O
the O
three O
epidemiological O
diseases O
caused O
by O
the O
Coronaviridae O
family O
. O

This O
could O
more O
than O
double O
if O
COVID O
- O
19 O
telemedicine O
payment O
policies O
are O
not O
sustained O
. O

Of O
these O
, O
11 O
( O
1 O
% O
) O
were O
confirmed O
and O
73 O
( O
6 O
. O
7 O
% O
) O
suspected O
for O
COVID O
- O
19 O
. O

Of O
294 O
hospitalised O
patients O
with O
COVID O
- O
19 O
, O
88 O
( O
30 O
% O
) O
reported O
musculoskeletal O
complaints O
. O

One O
possible O
limitation O
is O
the O
lack O
of O
awareness O
of O
whether O
or O
not O
this O
treatment O
would O
be O
effective O
for O
other O
stages O
as O
well O
as O
the O
concern O
for O
proper O
hand O
cleansing O
during O
use O
of O
bandages O
, O
given O
the O
current O
COVID O
- O
19 O
pandemic O
situation O
. O

We O
then O
used O
aggregate O
data O
on O
number O
/ O
type O
of O
LTCs O
inform O
a O
Bayesian O
model O
for O
likely O
combinations O
of O
LTCs O
among O
people O
dying O
with O
COVID O
- O
19 O
. O

Radiologists O
rapidly O
adopted O
recommended O
reporting O
terminology O
for O
patients O
with O
suspected O
COVID O
- O
19 O
. O

The O
aim O
of O
our O
study O
was O
to O
collect O
data O
on O
patients O
with O
a O
known O
diagnosis O
of O
COVID O
- O
19 O
who O
underwent O
serial O
testing O
to O
assess O
NPS O
sensitivity O
. O

These O
findings O
suggest O
that O
loneliness O
is O
a O
significant O
public O
health O
concern O
in O
South O
Africa O
in O
the O
time O
of O
COVID O
- O
19 O
. O

Universal O
PPE O
becomes O
cost O
- O
effective O
at O
a O
COVID O
- O
19 O
prevalence O
of O
34 O
. O
3 O
and O
29 O
. O
5 O
% O
and O
at O
a O
PPE O
cost O
of O
$ O
512 O
. O
62 O
and O
$ O
463 O
. O
20 O
for O
spontaneous O
and O
induced O
labor O
, O
respectively O
. O

The O
COVID O
- O
19 O
pandemic O
is O
a O
global O
crisis O
emanating O
both O
from O
a O
virus O
( O
SARS O
- O
CoV O
- O
2 O
) O
and O
from O
the O
drastic O
actions O
to O
contain O
it O
. O

AGILE O
- O
ACCORD O
: O
A O
Randomized O
, O
Multicentre O
, O
Seamless O
, O
Adaptive O
Phase O
I O
/ O
II O
Platform O
Study O
to O
Determine O
the O
Optimal O
Dose O
, O
Safety O
and O
Efficacy O
of O
Multiple O
Candidate O
Agents O
for O
the O
Treatment O
of O
COVID O
- O
19 O
: O
A O
structured O
summary O
of O
a O
study O
protocol O
for O
a O
randomised O
platform O
trial O
. O

To O
identify O
, O
categorize O
, O
and O
analyze O
Magen O
David O
Adom O
( O
MDA O
) O
, O
Israel O
' O
s O
national O
EMS O
, O
pre O
- O
hospital O
activities O
including O
patients O
' O
refusal O
to O
hospital O
transport O
, O
during O
the O
COVID O
- O
19 O
pandemic O
crises O
. O

The O
aims O
of O
our O
study O
were O
to O
evaluate O
disease O
perceptions O
, O
levels O
of O
stress O
, O
emotional O
distress O
, O
and O
coping O
strategies O
among O
medical O
staff O
( O
COVID O
- O
19 O
versus O
non O
- O
COVID O
- O
19 O
departments O
) O
in O
a O
tertiary O
pulmonology O
teaching O
hospital O
in O
the O
first O
month O
after O
the O
outbreak O
of O
COVID O
- O
19 O
. O

This O
survey O
has O
confirmed O
that O
the O
responses O
of O
UK O
IR O
departments O
to O
the O
COVID O
- O
19 O
crisis O
have O
ensured O
vital O
on O
- O
call O
and O
urgent O
services O
have O
continued O
, O
including O
ongoing O
availability O
of O
most O
IR O
sub O
- O
specialties O
. O

We O
describe O
the O
clinical O
features O
and O
management O
of O
CVST O
in O
3 O
women O
with O
COVID O
- O
19 O
who O
developed O
CVST O
days O
to O
months O
after O
initial O
COVID O
- O
19 O
symptoms O
. O

The O
majority O
of O
respondents O
( O
n O
= O
1335 O
, O
96 O
. O
4 O
% O
) O
were O
confident O
about O
their O
doctor O
' O
s O
expertise O
in O
terms O
of O
COVID O
- O
19 O
diagnosis O
and O
treatment O
, O
which O
was O
positively O
associated O
with O
less O
distress O
caused O
by O
the O
outbreak O
( O
B O
= O
- O
7 O
. O
84 O
, O
95 O
% O
CI O
- O
14 O
. O
58 O
to O
- O
1 O
. O
11 O
) O
. O

Background O
: O
The O
current O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
spreading O
globally O
at O
an O
accelerated O
rate O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
: O
latest O
developments O
in O
potential O
treatments O
. O

The O
results O
showed O
that O
the O
perceived O
stress O
level O
among O
medical O
staff O
in O
the O
radiology O
departments O
during O
the O
COVID O
- O
19 O
outbreak O
was O
high O
and O
a O
sense O
of O
tension O
was O
strongly O
present O
. O

This O
study O
characterizes O
suicidal O
ideation O
( O
SI O
) O
and O
suicide O
attempts O
( O
SA O
) O
in O
a O
sample O
of O
adolescents O
psychiatrically O
hospitalized O
during O
COVID O
- O
19 O
. O

Leveraging O
systems O
biology O
for O
predicting O
modulators O
of O
inflammation O
in O
patients O
with O
COVID O
- O
19 O
. O

Panic O
and O
generalized O
anxiety O
during O
the O
COVID O
- O
19 O
pandemic O
among O
Bangladeshi O
people O
: O
An O
online O
pilot O
survey O
early O
in O
the O
outbreak O
. O

Global O
COVID O
- O
19 O
: O
Warnings O
and O
suggestions O
based O
on O
experience O
of O
China O
. O

The O
survey O
included O
four O
general O
questions O
( O
age O
, O
sex O
, O
education O
, O
and O
medical O
/ O
psychiatric O
problem O
) O
and O
four O
COVID O
- O
19 O
specific O
questions O
( O
contracting O
COVID O
- O
19 O
, O
relatives O
with O
COVID O
- O
19 O
, O
wearing O
a O
face O
mask O
, O
and O
frequent O
hand O
washings O
) O
. O

The O
COVID O
- O
19 O
pandemic O
has O
put O
strain O
on O
healthcare O
systems O
and O
the O
availability O
and O
allocation O
of O
healthcare O
manpower O
, O
resources O
and O
infrastructure O
. O

COVID O
- O
19 O
is O
a O
global O
pandemic O
. O

COVID O
- O
19 O
, O
the O
disease O
caused O
by O
the O
SARS O
- O
CoV O
- O
2 O
virus O
, O
can O
progress O
to O
multi O
- O
organ O
failure O
characterized O
by O
respiratory O
insufficiency O
, O
arrhythmias O
, O
thromboembolic O
complications O
and O
shock O
. O

Therefore O
, O
we O
investigated O
whether O
this O
novel O
non O
- O
invasive O
method O
could O
also O
be O
applied O
in O
COVID O
- O
19 O
patients O
. O
∆ O
PL O
and O
Pmus O
were O
derived O
from O
esophageal O
manometry O
in O
COVID O
- O
19 O
patients O
. O

Remdesivir O
in O
COVID O
- O
19 O
: O
relatively O
safe O
but O
turns O
out O
to O
be O
less O
effective O
than O
expected O
. O

Variable O
eosinophil O
counts O
have O
been O
reported O
during O
COVID O
- O
19 O
. O

Conclusions O
Age O
, O
NLR O
score O
and O
RALE O
score O
were O
associated O
with O
mortality O
of O
COVID O
- O
19 O
patients O
in O
the O
hospital O
and O
might O
be O
used O
as O
a O
predictor O
for O
mortality O
of O
COVID O
- O
19 O
patients O
in O
health O
care O
centre O
where O
radiologists O
are O
available O
. O

The O
composition O
ratio O
of O
sigh O
syndrome O
increased O
significantly O
after O
the O
COVID O
- O
19 O
pandemic O
outbreak O
. O

The O
incidence O
of O
pulmonary O
embolism O
and O
VTE O
in O
severe O
COVID O
- O
19 O
patients O
were O
17 O
% O
( O
95 O
% O
CI O
, O
13 O
- O
21 O
% O
) O
and O
42 O
% O
( O
95 O
% O
CI O
, O
25 O
- O
60 O
% O
) O
, O
respectively O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
is O
a O
recently O
recognised O
pandemic O
spreading O
rapidly O
from O
Wuhan O
, O
Hubei O
, O
to O
other O
provinces O
in O
China O
and O
to O
many O
countries O
around O
the O
world O
. O

Gender O
differences O
in O
patients O
with O
COVID O
- O
19 O
: O
a O
narrative O
review O
. O

More O
that O
ACE2 O
? O
NRP1 O
may O
play O
a O
central O
role O
in O
the O
underlying O
pathophysiological O
mechanism O
of O
olfactory O
dysfunction O
in O
COVID O
- O
19 O
and O
its O
association O
with O
enhanced O
survival O
. O

Follow O
- O
up O
was O
finished O
before O
the O
COVID O
- O
19 O
pandemic O
. O

Intensive O
care O
unit O
workers O
are O
at O
high O
risk O
of O
acquiring O
COVID O
- O
19 O
infection O
, O
especially O
when O
performing O
invasive O
techniques O
and O
certain O
procedures O
that O
generate O
aerosols O
( O
< O
5 O
μ O
m O
) O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
first O
appeared O
in O
December O
2019 O
and O
rapidly O
spread O
throughout O
the O
world O
. O

For O
quantitative O
analysis O
, O
the O
total O
daily O
cases O
of O
COVID O
- O
19 O
in O
Wuhan O
were O
obtained O
from O
the O
Chinese O
National O
Health O
Commission O
, O
and O
a O
linear O
regression O
model O
was O
used O
to O
determine O
if O
Weibo O
COVID O
- O
19 O
posts O
were O
predictive O
of O
the O
number O
of O
cases O
reported O
. O

The O
observed O
role O
of O
androgens O
in O
transcription O
of O
transmembrane O
protease O
serine O
- O
2 O
, O
which O
facilitates O
COVID O
- O
19 O
anchoring O
to O
angiotensin O
- O
converting O
enzyme O
2 O
cell O
surface O
receptors O
, O
seems O
to O
suggest O
that O
higher O
testosterone O
levels O
might O
be O
detrimental O
for O
outcomes O
. O

Little O
evidence O
exists O
of O
the O
prevalence O
of O
underlying O
lung O
comorbidities O
among O
COVID O
- O
19 O
patients O
and O
associated O
mortality O
. O

Impact O
of O
COVID O
- O
19 O
State O
of O
Emergency O
restrictions O
on O
presentations O
to O
two O
Victorian O
emergency O
departments O
. O

Higher O
D O
- O
dimer O
, O
higher O
NT O
- O
proBNP O
, O
and O
lower O
lymphocyte O
count O
were O
the O
independent O
risk O
factors O
of O
death O
in O
COVID O
- O
19 O
patients O
. O

Assessment O
of O
ACE O
inhibitors O
/ O
angiotensin O
receptor O
blockers O
in O
COVID O
- O
19 O
patients O
. O

To O
explore O
the O
spreading O
of O
COVID O
- O
19 O
in O
relation O
to O
population O
density O
after O
the O
introduction O
of O
social O
distancing O
measures O
. O

A O
statistical O
framework O
to O
estimate O
diagnostic O
test O
performance O
for O
COVID O
- O
19 O
. O

Of O
these O
, O
7 O
. O
4 O
% O
had O
COVID O
- O
19 O
and O
33 O
. O
8 O
% O
had O
flu O
- O
like O
symptoms O
, O
corresponding O
to O
a O
cumulative O
incidence O
of O
0 O
. O
7 O
and O
3 O
. O
1 O
, O
respectively O
. O

The O
objectives O
are O
to O
answer O
key O
questions O
related O
to O
COVID O
- O
19 O
imaging O
of O
the O
chest O
and O
provide O
guidance O
for O
radiologists O
who O
are O
interpreting O
such O
studies O
during O
this O
pandemic O
. O

Seventy O
- O
two O
percent O
of O
participants O
agreed O
that O
spread O
of O
information O
helped O
to O
contain O
COVID O
- O
19 O
, O
but O
more O
than O
that O
75 O
% O
agreed O
to O
having O
received O
inaccurate O
information O
. O

In O
this O
study O
, O
we O
explored O
the O
impact O
of O
COVID O
- O
19 O
on O
the O
cross O
- O
correlations O
between O
crude O
oil O
and O
agricultural O
futures O
markets O
. O

Half O
of O
patients O
with O
COVID O
- O
19 O
showed O
abnormal O
PR O
interval O
behavior O
( O
paradoxical O
prolongation O
or O
lack O
of O
shortening O
) O
with O
increasing O
HR O
. O

During O
August O
- O
September O
2020 O
, O
the O
Minnesota O
Department O
of O
Health O
( O
MDH O
) O
investigated O
a O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
outbreak O
associated O
with O
the O
rally O
in O
Minnesota O
residents O
. O

The O
impact O
of O
COVID O
- O
19 O
on O
alcohol O
and O
other O
drug O
nurses O
' O
provision O
of O
care O
: O
A O
qualitative O
descriptive O
study O
. O

Emergency O
management O
, O
mitigation O
for O
COVID O
- O
19 O
and O
the O
importance O
of O
preparedness O
for O
future O
outbreaks O
. O

The O
scenario O
of O
1 O
million O
COVID O
- O
19 O
deaths O
is O
similar O
in O
scale O
to O
that O
of O
the O
decades O
- O
long O
HIV O
/ O
AIDS O
and O
opioid O
- O
overdose O
epidemics O
but O
considerably O
smaller O
than O
that O
of O
the O
Spanish O
flu O
of O
1918 O
. O

Using O
the O
flu O
surveillance O
system O
as O
a O
template O
, O
the O
U O
. O
S O
. O
has O
collected O
surveillance O
data O
on O
COVID O
- O
19 O
. O

A O
30 O
- O
year O
- O
old O
man O
with O
no O
significant O
previous O
or O
family O
psychiatric O
history O
became O
severely O
anxious O
about O
his O
health O
after O
a O
positive O
COVID O
- O
19 O
test O
. O

The O
cutoffs O
of O
those O
cardiac O
biomarkers O
for O
effective O
prognosis O
of O
28 O
- O
day O
mortality O
of O
COVID O
- O
19 O
were O
found O
to O
be O
much O
lower O
than O
for O
regular O
heart O
disease O
at O
about O
19 O
% O
- O
50 O
% O
of O
the O
currently O
recommended O
thresholds O
. O

Multiple O
evidence O
revealed O
the O
interdependence O
between O
the O
presence O
of O
cardiovascular O
comorbidities O
and O
a O
severe O
course O
of O
COVID O
- O
19 O
, O
with O
heart O
failure O
( O
HF O
) O
being O
incriminated O
as O
an O
independent O
predictor O
of O
mortality O
. O

As O
the O
COVID O
- O
19 O
pandemic O
has O
had O
a O
profound O
impact O
on O
public O
health O
and O
global O
economies O
in O
2020 O
; O
it O
is O
crucial O
to O
understand O
how O
it O
developed O
and O
spread O
in O
time O
and O
space O
. O

The O
ECQ O
reliably O
assessed O
a O
range O
of O
COVID O
- O
19 O
- O
related O
stresses O
and O
had O
large O
and O
significant O
correlations O
with O
the O
DASS O
- O
21 O
. O

Notably O
, O
in O
COVID O
- O
19 O
patients O
with O
ASA O
1 O
or O
2 O
, O
there O
was O
a O
0 O
% O
mortality O
rate O
in O
the O
postoperative O
period O
. O

The O
conclusion O
of O
our O
study O
will O
provide O
credible O
evidence O
to O
judge O
whether O
exercise O
is O
an O
effective O
intervention O
on O
the O
COVID O
- O
19 O
patients O
therapeutic O
, O
and O
guide O
future O
researches O
. O
PROSPERO O
registration O
number O
: O
CRD42020200883 O
. O

Items O
assessed O
generalized O
anxiety O
( O
GAD O
- O
7 O
) O
, O
COVID O
- O
19 O
- O
related O
fear O
, O
adherent O
/ O
dysfunctional O
safety O
behavior O
, O
and O
the O
subjective O
risk O
perception O
of O
regarding O
symptoms O
, O
having O
a O
severe O
course O
and O
dying O
because O
of O
COVID O
- O
19 O
. O

In O
this O
study O
of O
approximately O
one O
million O
medical O
admissions O
from O
a O
large O
, O
nationally O
representative O
hospitalist O
group O
, O
we O
found O
that O
declines O
in O
non O
- O
COVID O
- O
19 O
admissions O
from O
February O
to O
April O
2020 O
were O
generally O
similar O
across O
patient O
demographic O
subgroups O
and O
exceeded O
20 O
percent O
for O
all O
primary O
admission O
diagnoses O
. O

with O
increased O
mortality O
among O
the O
patients O
with O
COVID O
- O
19 O
. O

Telmisartan O
as O
tentative O
angiotensin O
receptor O
blocker O
therapeutic O
for O
COVID O
- O
19 O
. O

COVID O
- O
19 O
and O
obesity O
are O
two O
pandemic O
diseases O
that O
the O
world O
is O
currently O
facing O
. O

Coronavirus O
disease O
( O
COVID O
- O
19 O
) O
is O
an O
infectious O
disease O
caused O
by O
a O
newly O
discovered O
coronavirus O
. O

With O
the O
emergence O
of O
the O
COVID O
- O
19 O
pandemic O
, O
all O
elective O
surgery O
was O
temporarily O
suspended O
in O
the O
UK O
, O
allowing O
for O
diversion O
of O
resource O
to O
manage O
the O
anticipated O
surge O
of O
critically O
unwell O
patients O
. O

Patients O
were O
recruited O
from O
seven O
specifically O
designated O
hospitals O
for O
patients O
with O
COVID O
- O
19 O
infection O
affiliated O
to O
Shahid O
Beheshti O
University O
of O
Medical O
Sciences O
. O

The O
COVID O
- O
19 O
quarantine O
in O
China O
is O
thought O
to O
have O
reduced O
ambient O
air O
pollution O
. O

Ethics O
and O
practical O
mitigations O
for O
ongoing O
clinical O
trials O
during O
the O
COVID O
- O
19 O
pandemic O
. O

The O
COVID O
- O
19 O
pandemic O
shows O
us O
the O
boundaries O
of O
academic O
searching O
capabilities O
, O
both O
in O
terms O
of O
our O
know O
- O
how O
and O
of O
the O
systems O
we O
have O
. O

A O
medical O
mask O
- O
wearing O
policy O
can O
be O
applied O
safely O
without O
dosimetric O
concerns O
and O
should O
be O
considered O
as O
a O
standard O
practice O
for O
PBT O
centers O
during O
the O
COVID O
- O
19 O
pandemic O
. O

A O
new O
type O
of O
coronavirus O
( O
coronavirus O
disease O
2019 O
; O
COVID O
- O
19 O
) O
, O
which O
emerged O
in O
the O
People O
' O
s O
Republic O
of O
China O
, O
spread O
all O
over O
the O
world O
over O
time O
and O
became O
a O
pandemic O
. O

COVID O
- O
19 O
cases O
* O
among O
educators O
and O
students O
were O
either O
self O
- O
reported O
or O
identified O
by O
local O
public O
health O
officials O
. O

Background O
: O
During O
the O
first O
wave O
of O
the O
COVID O
- O
19 O
pandemic O
, O
many O
non O
- O
urgent O
outpatient O
services O
in O
Italy O
were O
closed O
due O
to O
the O
Government O
- O
enforced O
lockdown O
period O
. O

The O
rate O
of O
use O
of O
COVID O
- O
19 O
- O
directed O
drug O
therapy O
was O
higher O
in O
patients O
with O
vs O
patients O
without O
a O
history O
of O
asthma O
( O
14 O
. O
9 O
% O
vs O
7 O
% O
, O
P O
= O
0 O
. O
037 O
) O
and O
in O
patients O
enrolled O
in O
clinical O
trials O
( O
26 O
. O
9 O
% O
vs O
3 O
. O
2 O
% O
, O
P O
< O
0 O
. O
001 O
) O
. O

Hypertension O
( O
OR O
6 O
. O
550 O
) O
, O
both O
unilateral O
( O
OR O
4 O
. O
764 O
) O
and O
bilateral O
( O
OR O
7 O
. O
916 O
) O
, O
chest O
X O
- O
ray O
abnormalities O
, O
lower O
temperature O
( O
OR O
0 O
. O
535 O
) O
, O
lower O
absolute O
leukocyte O
count O
( O
OR O
0 O
. O
857 O
) O
, O
lower O
AST O
levels O
( O
OR O
0 O
. O
946 O
) O
, O
higher O
LDH O
( O
OR O
1 O
. O
008 O
) O
, O
higher O
ALT O
( O
OR O
1 O
. O
044 O
) O
and O
higher O
ferritin O
( O
OR O
1 O
. O
001 O
) O
were O
predictive O
of O
COVID O
- O
19 O
. O

The O
integration O
of O
emergency O
language O
services O
in O
COVID O
- O
19 O
response O
: O
a O
call O
for O
the O
linguistic O
turn O
in O
public O
health O
. O

There O
are O
currently O
no O
complete O
data O
available O
from O
large O
randomized O
clinical O
trials O
( O
RCTs O
) O
to O
provide O
clinical O
guidance O
on O
the O
use O
, O
dosing O
, O
or O
duration O
to O
validate O
the O
effective O
role O
, O
safety O
profile O
, O
and O
adverse O
effects O
of O
all O
of O
the O
trial O
drugs O
for O
prophylaxis O
or O
treatment O
of O
COVID O
- O
19 O
. O

As O
such O
, O
we O
aimed O
to O
conduct O
a O
comprehensive O
meta O
- O
analysis O
and O
systematic O
review O
to O
collect O
and O
analyze O
current O
evidence O
about O
COVID O
- O
19 O
in O
the O
pediatric O
population O
. O

Vaccinations O
in O
CLL O
: O
implications O
for O
COVID O
- O
19 O
. O

Finally O
, O
clinical O
data O
on O
COVID O
- O
19 O
patients O
demonstrated O
that O
prostate O
diseases O
, O
which O
are O
linked O
to O
elevated O
androgen O
, O
are O
significant O
risk O
factors O
and O
that O
genetic O
variants O
that O
increase O
androgen O
levels O
are O
associated O
with O
higher O
disease O
severity O
. O

The O
purpose O
of O
this O
meta O
- O
analysis O
was O
to O
investigate O
the O
prognosis O
of O
COVID O
- O
19 O
in O
patients O
with O
coronary O
heart O
disease O
. O

The O
current O
review O
presents O
the O
direct O
and O
indirect O
psychological O
impact O
of O
COVID O
- O
19 O
on O
the O
general O
public O
, O
as O
well O
as O
on O
vulnerable O
groups O
, O
including O
the O
elderly O
, O
the O
young O
, O
healthcare O
professionals O
, O
people O
with O
pre O
- O
existing O
mental O
health O
issues O
, O
those O
infected O
by O
COVID O
- O
19 O
, O
homeless O
people O
and O
refugees O
. O

The O
COVID O
- O
19 O
pandemic O
is O
now O
a O
major O
global O
health O
issue O
, O
affecting O
world O
population O
and O
high O
- O
performance O
athlete O
too O
. O

Laryngeal O
and O
Tracheal O
Pressure O
Injuries O
in O
Patients O
With O
COVID O
- O
19 O
- O
Reply O
. O

Challenges O
for O
Drug O
Repurposing O
in O
the O
COVID O
- O
19 O
Pandemic O
Era O
. O

Serum O
ferritin O
levels O
were O
compared O
with O
the O
treatment O
outcomes O
of O
COVID O
- O
19 O
positive O
patients O
who O
were O
treated O
with O
dexamethasone O
and O
vitamin O
C O
. O

Mental O
healthcare O
policies O
in O
South O
Korea O
during O
the O
COVID O
- O
19 O
epidemic O
. O

We O
aimed O
to O
investigate O
factors O
associated O
with O
prolonged O
and O
intermittent O
viral O
RNA O
shedding O
in O
a O
retrospective O
cohort O
of O
symptomatic O
COVID O
- O
19 O
patients O
. O

The O
survey O
consisted O
of O
: O
demographics O
, O
COVID O
- O
19 O
related O
general O
knowledge O
, O
behavioral O
changes O
, O
and O
perceptions O
of O
the O
pandemic O
. O

Will O
the O
extraction O
of O
COVID O
- O
19 O
from O
wastewater O
help O
flatten O
the O
curve O
? O

Withal O
, O
azido O
analog O
of O
2 O
- O
DG O
, O
2 O
- O
azido O
- O
2 O
- O
DG O
can O
produce O
rapid O
catastrophic O
oxidative O
stress O
and O
quell O
the O
cytokine O
storm O
in O
critically O
ill O
COVID O
- O
19 O
patients O
. O

The O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
has O
become O
a O
global O
threat O
. O

Nine O
patients O
developed O
COVID O
- O
19 O
pneumonia O
. O

The O
novel O
coronavirus O
( O
COVID O
- O
19 O
) O
pandemic O
has O
affected O
all O
aspects O
of O
human O
life O
worldwide O
. O

In O
total O
, O
146 O
confirmed O
cases O
( O
85 O
cases O
imported O
and O
61 O
cases O
through O
community O
transmission O
) O
and O
no O
deaths O
due O
to O
COVID O
- O
19 O
had O
been O
reported O
in O
Taizhou O
by O
1 O
June O
2020 O
. O

To O
answer O
these O
questions O
it O
is O
important O
to O
forecast O
regularly O
and O
accurately O
the O
spread O
of O
COVID O
- O
19 O
infections O
. O

Compared O
to O
the O
previous O
coronaviruses O
- O
related O
pandemics O
, O
COVID O
- O
19 O
is O
more O
transmissible O
with O
potential O
systemic O
involvement O
and O
peculiar O
neurological O
manifestations O
, O
such O
as O
Guillan O
- O
Barr O
è O
syndrome O
up O
to O
critical O
illness O
myopathy O
, O
occurring O
in O
the O
intensive O
care O
setting O
. O

Current O
evidence O
suggests O
that O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
severe O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
is O
predominantly O
transmitted O
from O
human O
- O
to O
- O
human O
. O

Mental O
Health O
Conditions O
of O
Italian O
Healthcare O
Professionals O
during O
the O
COVID O
- O
19 O
Disease O
Outbreak O
. O

Research O
should O
examine O
if O
targeting O
these O
factors O
lead O
to O
changes O
in O
COVID O
- O
19 O
behaviours O
over O
time O
. O

In O
response O
to O
the O
impending O
spread O
of O
COVID O
- O
19 O
, O
universities O
worldwide O
abruptly O
stopped O
face O
- O
to O
- O
face O
teaching O
and O
switched O
to O
technology O
- O
mediated O
teaching O
. O

COVID O
- O
19 O
pneumonia O
in O
lung O
transplant O
recipients O
: O
Report O
of O
2 O
cases O
. O

These O
observations O
may O
allude O
to O
a O
potential O
regulatory O
association O
between O
ACE2 O
and O
BNP O
in O
mediating O
myocarditis O
associated O
with O
COVID O
- O
19 O
. O

Cardiovascular O
risk O
factors O
and O
chronic O
cardiovascular O
conditions O
are O
prevalent O
among O
patients O
affected O
by O
COVID O
- O
19 O
and O
associated O
with O
adverse O
outcomes O
. O

We O
present O
this O
Virtual O
Issue O
as O
a O
resource O
for O
the O
eating O
disorder O
community O
to O
showcase O
research O
published O
in O
the O
International O
Journal O
of O
Eating O
Disorders O
that O
provides O
information O
on O
effective O
strategies O
to O
help O
address O
the O
challenges O
arising O
from O
COVID O
- O
19 O
- O
related O
disruptions O
. O

Many O
organizations O
are O
curtailing O
or O
even O
abandoning O
performance O
management O
because O
of O
difficulties O
measuring O
performance O
and O
disruptions O
in O
performance O
- O
based O
pay O
due O
to O
the O
COVID O
- O
19 O
crisis O
. O

Results O
Qualtrics O
results O
demonstrated O
55 O
% O
of O
medical O
students O
( O
n O
= O
55 O
) O
reported O
they O
learned O
new O
information O
about O
the O
COVID O
- O
19 O
pandemic O
from O
the O
perspective O
of O
physicians O
. O

COVID O
- O
19 O
Time O
Capsule O
2 O
: O
DATE O
: O
July O
23 O
, O
2020 O
. O

Fifteen O
individuals O
with O
confirmed O
COVID O
- O
19 O
infection O
were O
included O
and O
interviewed O
individually O
by O
telephone O
. O

Experimental O
results O
show O
that O
the O
proposed O
framework O
can O
achieve O
reasonable O
performances O
when O
evaluated O
on O
a O
collected O
dataset O
( O
3 O
classes O
to O
be O
predicted O
: O
COVID O
- O
19 O
, O
Pneumonia O
, O
and O
Normal O
) O
. O

Effectiveness O
of O
community O
face O
mask O
use O
on O
COVID O
- O
19 O
epidemiological O
trends O
and O
patterns O
in O
Italy O
: O
evidence O
from O
a O
" O
translational O
" O
study O
. O

Health O
system O
should O
act O
immediately O
and O
wisely O
to O
support O
essential O
surgical O
care O
while O
fighting O
against O
COVID O
- O
19 O
. O

Coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
, O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
was O
first O
described O
in O
a O
cluster O
of O
patients O
in O
Wuhan O
, O
China O
, O
in O
December O
of O
2019 O
. O

The O
World O
Health O
Organization O
International O
Clinical O
Trials O
Registry O
and O
clinicaltrials O
. O
gov O
were O
searched O
to O
summarize O
the O
currently O
registered O
randomized O
clinical O
trials O
for O
convalescent O
plasma O
in O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
transformed O
health O
care O
delivery O
, O
including O
rapid O
expansion O
of O
telehealth O
. O

Preparation O
for O
COVID O
- O
19 O
: O
lessons O
from O
simulation O
. O

Conclusions O
: O
The O
COVID O
- O
19 O
pandemic O
is O
spreading O
rapidly O
worldwide O
. O

Coagulopathy O
is O
a O
common O
abnormality O
in O
patients O
with O
COVID O
- O
19 O
. O

The O
risk O
prediction O
nomogram O
incorporating O
age O
, O
C O
- O
reactive O
protein O
, O
and O
D O
- O
dimer O
for O
early O
identification O
of O
patients O
with O
severe O
COVID O
- O
19 O
showed O
favorable O
discrimination O
in O
both O
the O
primary O
( O
area O
under O
the O
curve O
[ O
AUC O
] O
0 O
. O
807 O
) O
and O
validation O
cohorts O
( O
AUC O
0 O
. O
902 O
) O
and O
was O
well O
calibrated O
. O

Two O
chromatographic O
methods O
were O
validated O
for O
the O
determination O
of O
the O
widely O
prescribed O
analgesic O
and O
antipyretic O
drug O
combination O
of O
paracetamol O
( O
PC O
) O
( O
recently O
integrated O
into O
the O
supportive O
treatment O
of O
COVID O
- O
19 O
) O
, O
propyphenazone O
( O
PZ O
) O
and O
caffeine O
( O
CF O
) O
in O
the O
presence O
of O
two O
PC O
impurities O
, O
namely O
4 O
- O
aminophenol O
and O
4 O
- O
nitrophenol O
. O

Trends O
in O
contact O
with O
a O
high O
volume O
national O
digital O
mental O
health O
service O
( O
DMHS O
) O
, O
the O
MindSpot O
Clinic O
, O
provide O
a O
unique O
opportunity O
to O
assess O
the O
mental O
health O
effects O
of O
the O
COVID O
- O
19 O
pandemic O
. O

People O
in O
COVID O
- O
19 O
severely O
affected O
areas O
may O
have O
higher O
scores O
of O
GHQ O
and O
anxiety O
symptoms O
. O

ECCO2R O
combined O
with O
continuous O
blood O
purification O
therapy O
in O
patients O
with O
COVID O
- O
19 O
who O
are O
criti O
- O
cally O
ill O
and O
have O
ARDS O
and O
hypercapnia O
might O
gain O
both O
time O
and O
opportunity O
in O
the O
treatment O
, O
down O
- O
regulate O
the O
ventilator O
parameters O
, O
reduce O
the O
incidence O
of O
VILI O
and O
achieve O
favorable O
therapeutic O
outcomes O
. O

In O
the O
current O
coronavirus O
disease O
2019 O
( O
COVID O
- O
19 O
) O
pandemic O
, O
air O
medical O
transport O
has O
been O
faced O
with O
many O
challenges O
that O
have O
been O
taken O
for O
granted O
in O
the O
past O
. O

The O
health O
crisis O
caused O
by O
COVID O
- O
19 O
pandemic O
has O
led O
to O
a O
restructuring O
of O
urological O
activity O
in O
order O
not O
to O
delay O
priority O
situations O
. O

Systemic O
low O
- O
dose O
corticosteroids O
have O
proven O
clinical O
benefit O
in O
patients O
with O
severe O
COVID O
- O
19 O
. O

A O
statistically O
significant O
trend O
across O
the O
areas O
with O
a O
different O
prevalence O
of O
COVID O
- O
19 O
was O
observed O
related O
to O
the O
number O
of O
signs O
/ O
symptoms O
( O
areas O
z O
= O
6 O
. O
38 O
p O
< O
0 O
. O
01 O
) O
. O

In O
this O
review O
, O
we O
provide O
in O
- O
depth O
analysis O
on O
these O
two O
approaches O
currently O
opted O
all O
around O
the O
world O
to O
treat O
COVID O
- O
19 O
patients O
. O

The O
research O
model O
of O
international O
students O
' O
intention O
to O
wear O
a O
mask O
for O
protection O
against O
COVID O
- O
19 O
was O
acceptable O
. O

Work O
- O
Related O
and O
Personal O
Factors O
Associated O
With O
Mental O
Well O
- O
Being O
During O
the O
COVID O
- O
19 O
Response O
: O
Survey O
of O
Health O
Care O
and O
Other O
Workers O
. O

As O
businesses O
attempt O
to O
reopen O
to O
varying O
degrees O
amid O
the O
current O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
, O
industrial O
hygiene O
( O
IH O
) O
and O
occupational O
and O
environmental O
health O
and O
safety O
( O
OEHS O
) O
professionals O
have O
been O
challenged O
with O
assessing O
and O
managing O
the O
risks O
of O
COVID O
- O
19 O
in O
the O
workplace O
. O

Therefore O
, O
we O
summarize O
current O
evidence O
from O
the O
available O
literature O
and O
, O
on O
behalf O
of O
the O
German O
Society O
of O
Angiology O
( O
DGA O
) O
, O
we O
aim O
to O
provide O
advice O
to O
establish O
an O
improved O
and O
more O
uniform O
strategy O
for O
thromboprophylaxis O
in O
patients O
with O
COVID O
- O
19 O
. O

Pressured O
by O
the O
enormous O
human O
and O
economic O
costs O
of O
the O
COVID O
- O
19 O
pandemic O
, O
certain O
countries O
and O
political O
figures O
have O
advocated O
the O
use O
of O
drugs O
and O
vaccines O
that O
did O
not O
go O
through O
the O
required O
regulatory O
stages O
of O
the O
development O
. O

It O
is O
of O
paramount O
importance O
that O
the O
scientific O
community O
alerts O
the O
healthcare O
professionals O
of O
the O
pieces O
of O
evidence O
that O
can O
herald O
them O
on O
the O
covert O
neurological O
deficits O
in O
progress O
in O
COVID O
- O
19 O
. O

Since O
current O
COVID O
- O
19 O
control O
campaigns O
seek O
to O
educate O
the O
public O
, O
these O
efforts O
' O
impacts O
are O
likely O
to O
be O
limited O
. O

Though O
both O
predictors O
are O
complex O
and O
may O
be O
influenced O
by O
many O
factors O
, O
given O
the O
potential O
return O
of O
COVID O
- O
19 O
threat O
and O
other O
future O
health O
pandemic O
threats O
to O
our O
world O
, O
we O
must O
rethink O
and O
develop O
ways O
to O
reinforce O
them O
. O

Endoscopic O
intervention O
in O
a O
case O
proven O
latterly O
to O
be O
a O
COVID O
- O
19 O
. O

We O
propose O
strategies O
for O
infectious O
diseases O
clinicians O
to O
apply O
risk O
communication O
principles O
and O
frameworks O
to O
improve O
patient O
care O
and O
public O
message O
development O
in O
response O
to O
COVID O
- O
19 O
. O

Using O
a O
pre O
- O
procedure O
COVID O
- O
19 O
huddle O
to O
improve O
operating O
room O
safety O
. O

Conclusions O
Increasing O
age O
and O
disease O
burden O
in O
the O
U O
. O
S O
. O
agricultural O
labor O
force O
puts O
workers O
at O
increased O
risk O
for O
developing O
COVID O
- O
19 O
complications O
. O

Corticosteroids O
appears O
to O
reduce O
the O
inflammation O
and O
temporarily O
improve O
the O
oxygenation O
in O
COVID O
- O
19 O
and O
ARDS O
patients O
. O

Comparative O
Impacts O
of O
ACE O
( O
Angiotensin O
- O
Converting O
Enzyme O
) O
Inhibitors O
Versus O
Angiotensin O
II O
Receptor O
Blockers O
on O
the O
Risk O
of O
COVID O
- O
19 O
Mortality O
. O

Follow O
- O
up O
study O
on O
pulmonary O
function O
and O
radiological O
changes O
in O
critically O
ill O
patients O
with O
COVID O
- O
19 O
. O

Cough O
and O
fever O
were O
commonly O
reported O
in O
COVID O
- O
19 O
and O
less O
frequently O
in O
GCA O
( O
cough O
, O
63 O
% O
for O
COVID O
- O
19 O
vs O
12 O
% O
for O
GCA O
; O
fever O
, O
83 O
% O
for O
COVID O
- O
19 O
vs O
27 O
% O
for O
GCA O
) O
. O

The O
preliminary O
evidence O
available O
suggests O
an O
increasing O
role O
of O
POCUS O
in O
diagnosing O
, O
monitoring O
, O
and O
risk O
- O
stratifying O
COVID O
- O
19 O
patients O
. O

Our O
findings O
, O
that O
such O
effort O
for O
a O
short O
period O
of O
time O
resulted O
in O
a O
significant O
reduction O
in O
air O
pollution O
, O
may O
point O
toward O
reducing O
air O
pollution O
as O
a O
public O
health O
problem O
in O
a O
more O
sustainable O
post O
- O
COVID O
- O
19 O
world O
. O

Management O
of O
primary O
cutaneous O
lymphoma O
patients O
during O
COVID O
- O
19 O
pandemic O
: O
EORTC O
CLTF O
guidelines O
. O

TeleNP O
practices O
before O
the O
COVID O
- O
19 O
pandemic O
and O
early O
on O
during O
the O
global O
outbreak O
were O
queried O
among O
survey O
participants O
, O
along O
with O
examination O
of O
TeleNP O
intentions O
following O
COVID O
- O
19 O
. O
Results O
: O
Multiple O
countries O
were O
represented O
across O
five O
continents O
, O
with O
two O
- O
thirds O
of O
respondents O
being O
from O
the O
United O
States O
. O

Pain O
, O
the O
driving O
force O
behind O
eye O
casualty O
attendance O
during O
the O
COVID O
- O
19 O
lockdown O
. O

Physical O
activity O
( O
PA O
) O
, O
screen O
time O
, O
sleep O
time O
, O
adherence O
to O
the O
Mediterranean O
diet O
( O
KIDMED O
) O
and O
sociodemographic O
information O
were O
longitudinally O
assessed O
before O
( O
N O
= O
291 O
, O
12 O
. O
1 O
± O
2 O
. O
4 O
years O
, O
47 O
. O
8 O
% O
girls O
) O
and O
during O
the O
COVID O
- O
19 O
confinement O
( O
N O
= O
113 O
, O
12 O
. O
0 O
± O
2 O
. O
6 O
years O
, O
48 O
. O
7 O
% O
girls O
) O
by O
online O
questionnaires O
. O

Clostridioides O
difficile O
infection O
in O
the O
COVID O
- O
19 O
era O
: O
old O
and O
new O
problems O
. O

Deeper O
understanding O
of O
the O
gold O
- O
standard O
hierarchical O
organisation O
of O
defence O
mechanisms O
could O
help O
increase O
utilisation O
of O
specific O
therapeutic O
interventions O
for O
enhancing O
changes O
from O
immature O
to O
mature O
defensive O
responses O
to O
stressful O
experiences O
as O
the O
COVID O
- O
19 O
pandemic O
progresses O
. O

Several O
statistical O
, O
dynamic O
, O
and O
mathematical O
models O
of O
the O
COVID O
- O
19 O
outbreak O
including O
the O
SEIR O
model O
have O
been O
developed O
to O
analyze O
the O
infection O
its O
transmission O
dynamics O
. O

Research O
design O
and O
methods O
: O
A O
pooled O
analysis O
was O
performed O
on O
high O
- O
quality O
epidemiological O
studies O
to O
quantify O
the O
prevalence O
( O
% O
) O
of O
comorbidities O
and O
clinical O
signs O
in O
hospitalized O
COVID O
- O
19 O
patients O
. O

The O
study O
aimed O
to O
find O
out O
about O
the O
knowledge O
, O
attitudes O
, O
and O
preventative O
practices O
of O
COVID O
- O
19 O
among O
international O
students O
in O
China O
during O
the O
pandemic O
. O

During O
the O
height O
of O
the O
recent O
outbreak O
of O
coronavirus O
19 O
( O
COVID O
- O
19 O
) O
in O
New O
York O
City O
, O
almost O
all O
the O
hospital O
emergency O
departments O
were O
inundated O
with O
patients O
with O
COVID O
- O
19 O
, O
who O
presented O
with O
typical O
fever O
, O
cough O
, O
and O
dyspnea O
. O

Management O
of O
Cardiovascular O
Disease O
Patients O
With O
Confirmed O
or O
Suspected O
COVID O
- O
19 O
in O
Limited O
Resource O
Settings O
. O

The O
COVID O
- O
19 O
disease O
significantly O
has O
threatened O
the O
human O
lives O
and O
economy O
. O

Treatment O
impact O
on O
COVID O
- O
19 O
evolution O
in O
hemodialysis O
patients O
. O

Our O
model O
uses O
both O
COVID O
- O
19 O
incidence O
and O
mortality O
time O
series O
to O
estimate O
our O
model O
parameters O
. O

This O
case O
highlights O
strengths O
of O
focused O
cardiac O
ultrasound O
in O
critical O
care O
setting O
and O
in O
patients O
with O
COVID O
- O
19 O
when O
access O
to O
other O
imaging O
modalities O
can O
be O
limited O
. O

We O
aimed O
to O
concisely O
summarize O
studies O
examining O
cardiovascular O
outcomes O
in O
COVID O
- O
19 O
patients O
and O
postulate O
on O
how O
PM O
can O
influence O
these O
outcomes O
. O

Coronavirus O
disease O
- O
19 O
( O
COVID O
- O
19 O
) O
is O
a O
new O
type O
of O
epidemic O
pneumonia O
caused O
by O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
. O

The O
intriguing O
commonality O
of O
NETosis O
between O
COVID O
- O
19 O
& O
Periodontal O
disease O
. O

Inter O
- O
OSCTC O
sharing O
of O
successful O
protocols O
and O
systems O
has O
been O
hampered O
by O
evolving O
resource O
constraints O
, O
the O
changing O
science O
of O
testing O
, O
and O
ever O
increasing O
COVID O
- O
19 O
case O
counts O
. O

Foreword O
: O
Research O
in O
times O
of O
pandemic O
COVID O
- O
19 O
. O

These O
results O
suggest O
that O
when O
patients O
with O
mild O
COVID O
- O
19 O
frequently O
aspirate O
periodontopathic O
bacteria O
, O
SARS O
- O
CoV O
- O
2 O
infection O
is O
promoted O
, O
and O
inflammation O
in O
the O
lower O
respiratory O
tract O
may O
become O
severe O
in O
the O
presence O
of O
viral O
pneumonia O
. O

Health O
authorities O
should O
be O
aware O
of O
these O
findings O
, O
in O
order O
to O
adapt O
their O
message O
if O
the O
COVID O
- O
19 O
pandemic O
persists O
or O
recurs O
, O
or O
in O
case O
of O
future O
major O
epidemics O
. O

[ O
Early O
differential O
diagnosis O
between O
COVID O
- O
19 O
and O
mycoplasma O
pneumonia O
with O
chest O
CT O
scan O
] O
. O

Patient O
interviews O
and O
evaluation O
of O
medical O
records O
revealed O
that O
these O
four O
patients O
did O
not O
manifest O
any O
severe O
COVID O
- O
19 O
symptoms O
despite O
their O
substantial O
co O
- O
morbidities O
, O
and O
they O
did O
not O
require O
hospitalization O
. O

Surveying O
Tenants O
of O
Permanent O
Supportive O
Housing O
in O
Skid O
Row O
about O
COVID O
- O
19 O
. O

A O
retrospective O
- O
cohort O
analysis O
was O
conducted O
on O
445 O
COVID O
- O
19 O
patients O
that O
were O
reported O
in O
the O
publicly O
available O
media O
- O
bulletin O
from O
March O
9 O
, O
2020 O
, O
to O
April O
23 O
, O
2020 O
, O
for O
the O
Karnataka O
state O
. O

During O
the O
recent O
and O
ongoing O
coronavirus O
disease O
( O
COVID O
- O
19 O
) O
pandemic O
, O
it O
has O
become O
clear O
that O
the O
gastrointestinal O
system O
and O
the O
gut O
barrier O
may O
be O
affected O
by O
the O
severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
virus O
, O
and O
disruption O
of O
barrier O
functions O
or O
intestinal O
microbial O
dysbiosis O
may O
have O
an O
impact O
on O
the O
progression O
and O
severity O
of O
this O
new O
disease O
. O

Relative O
bradycardia O
in O
COVID O
- O
19 O
might O
be O
associated O
with O
myocardial O
injury O
due O
to O
not O
only O
direct O
viral O
involvement O
but O
also O
systemic O
inflammation O
. O

In O
this O
article O
, O
we O
briefly O
review O
the O
lessons O
and O
tragedies O
in O
the O
evolution O
of O
human O
subject O
research O
regulations O
emphasizing O
the O
need O
for O
the O
proper O
evaluation O
of O
drugs O
and O
vaccines O
for O
COVID O
- O
19 O
. O

To O
quantify O
the O
size O
of O
this O
affected O
population O
, O
we O
compare O
its O
magnitude O
with O
the O
number O
of O
people O
affected O
by O
COVID O
- O
19 O
using O
measures O
of O
susceptibility O
, O
vulnerability O
and O
behavioural O
change O
collected O
in O
the O
same O
questionnaire O
. O

Telemedicine O
for O
management O
of O
patients O
with O
amyotrophic O
lateral O
sclerosis O
through O
COVID O
- O
19 O
tail O
. O

It O
is O
important O
to O
identify O
characteristics O
of O
people O
who O
may O
be O
most O
at O
risk O
of O
COVID O
- O
19 O
to O
inform O
policy O
and O
intervention O
. O

Efforts O
to O
mitigate O
the O
economic O
impact O
of O
the O
COVID O
- O
19 O
pandemic O
: O
potential O
entry O
points O
for O
neglected O
tropical O
diseases O
. O

Anosmia O
and O
ageusia O
seem O
to O
be O
part O
of O
important O
symptoms O
and O
clues O
for O
the O
diagnosis O
of O
COVID O
- O
19 O
, O
particularly O
in O
the O
early O
stage O
of O
the O
disease O
. O

Although O
the O
possibility O
of O
vertical O
transmission O
in O
infected O
pregnant O
women O
is O
rare O
, O
four O
neonates O
' O
test O
results O
for O
COVID O
- O
19 O
infection O
were O
positive O
in O
this O
review O
. O

Given O
the O
novelty O
of O
COVID O
- O
19 O
and O
the O
lack O
of O
specific O
anti O
- O
virus O
therapies O
, O
the O
current O
management O
is O
essentially O
supportive O
. O

Thus O
, O
the O
need O
to O
develop O
an O
effective O
strategy O
for O
monitoring O
, O
restricting O
, O
but O
especially O
for O
predicting O
the O
evolution O
of O
COVID O
- O
19 O
is O
urgent O
, O
especially O
in O
middle O
- O
class O
countries O
such O
as O
Romania O
. O

Patients O
( O
aged O
≥ O
18 O
years O
) O
hospitalized O
with O
COVID O
- O
19 O
at O
13 O
hospitals O
in O
metropolitan O
New O
York O
between O
March O
1 O
, O
2020 O
, O
and O
April O
27 O
, O
2020 O
, O
followed O
up O
until O
hospital O
discharge O
. O

Severe O
acute O
respiratory O
syndrome O
coronavirus O
2 O
( O
SARS O
- O
CoV O
- O
2 O
) O
, O
at O
the O
origin O
of O
the O
worldwide O
COVID O
- O
19 O
pandemic O
, O
is O
characterized O
by O
a O
dramatic O
cytokine O
storm O
in O
some O
critical O
patients O
with O
COVID O
- O
19 O
. O

The O
COVID O
- O
19 O
pandemic O
has O
placed O
unprecedented O
strain O
on O
the O
American O
healthcare O
system O
. O

Cardiovascular O
disease O
, O
hypertension O
, O
and O
renal O
disease O
were O
premorbid O
risk O
factors O
present O
before O
SARS O
- O
CoV O
- O
2 O
PCR O
testing O
associated O
with O
COVID O
- O
19 O
susceptibility O
. O

Social O
Bots O
' O
Sentiment O
Engagement O
in O
Health O
Emergencies O
: O
A O
Topic O
- O
Based O
Analysis O
of O
the O
COVID O
- O
19 O
Pandemic O
Discussions O
on O
Twitter O
. O

Four O
medical O
staff O
cases O
of O
Chlamydia O
psittaci O
pneumonia O
in O
a O
COVID O
- O
19 O
screening O
ward O
, O
as O
well O
as O
the O
experience O
in O
dealing O
with O
such O
a O
nosocomial O
infection O
event O
, O
were O
described O
. O

Recently O
, O
a O
severe O
multisystem O
inflammatory O
syndrome O
in O
children O
( O
MIS O
- O
C O
) O
, O
with O
active O
or O
recent O
COVID O
- O
19 O
infection O
, O
has O
been O
increasingly O
reported O
. O

Limited O
data O
is O
available O
in O
patients O
with O
COVID O
- O
19 O
and O
metabolic O
dysfunction O
associated O
fatty O
liver O
disease O
( O
MAFLD O
) O
. O
The O
aim O
of O
this O
review O
is O
to O
analyse O
the O
effect O
of O
MAFLD O
on O
severity O
of O
COVID O
- O
19 O
. O

COVID O
- O
19 O
outbreaks O
in O
meat O
and O
other O
food O
processing O
plants O
raise O
concern O
for O
potential O
of O
foodborne O
spread O
. O

This O
would O
be O
a O
valuable O
diagnostic O
tool O
not O
only O
for O
mass O
screening O
of O
current O
COVID O
- O
19 O
pandemic O
but O
also O
in O
viral O
pandemic O
outbreaks O
of O
future O
. O

Managing O
the O
COVID O
- O
19 O
pandemic O
: O
innovations O
, O
adaptations O
and O
leadership O
. O

The O
bacterial O
diversity O
was O
lower O
in O
COVID O
- O
19 O
patients O
than O
healthy O
controls O
and O
decreased O
gradually O
from O
community O
type O
I O
to O
III O
/ O
IV O
. O

